Biomarker identification

ABSTRACT

Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected of suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.

RELATED APPLICATION

This application claims priority to Australian Provisional ApplicationNo. 2013902243 entitled “Biomarker Identification”, filed on 20 Jun.2013, the subject matter of which is hereby incorporated herein byreference in its entirety.

FIELD OF THE INVENTION

The present invention relates to a method and apparatus for identifyingbiomarkers and in particular for identifying biomarkers for use inmaking clinical assessments, such as early diagnostic, diagnostic,disease stage, disease severity, disease subtype, response to therapy orprognostic assessments. In one particular example, the techniques areapplied to allow assessments of patients suffering from, suspected ofsuffering from, or with clinical signs of SIRS (Systemic InflammatoryResponse Syndrome) being either infection-negative SIRS (inSIRS) orinfection-positive SIRS (ipSIRS).

DESCRIPTION OF THE PRIOR ART

The reference in this specification to any prior publication (orinformation derived from it), or to any matter which is known, is not,and should not be taken as an acknowledgement or admission or any formof suggestion that the prior publication (or information derived fromit) or known matter forms part of the common general knowledge in thefield of endeavour to which this specification relates.

The analysis of gene expression products for diagnostic purposes isknown. Such analysis requires identification of one or more genes thatcan be used to generate a signature for use in distinguishing betweendifferent conditions. However, such identification can require theanalysis of many gene expression products, which can be mathematicallycomplex, computationally expensive and hence difficult. Much of thebiomarker discovery process is devoted to identifying a subset of thedata that may have relevant import, from which a signature is derivedusing a combination of these values to produce a model for diagnostic orprognostic use.

WO2004044236 describes a method of determining the status of a subject.In particular, this is achieved by obtaining subject data includingrespective values for each of a number of parameters, the parametervalues being indicative of the current biological status of the subject.The subject data are compared to predetermined data that includes valuesfor at least some of the parameters and an indication of the condition.The status of the subject, and in particular, the presence and/orabsence of the one or more conditions, can then be determined inaccordance with the results of the comparison.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides apparatus for identifyingbiomarkers, the apparatus including an electronic processing devicethat:

uses reference data from a plurality of individuals to define a numberof groups of individuals, the reference data including measurements ofthe activity of a plurality of reference biomarkers;

uses a plurality of analysis techniques to identify a number ofpotential biomarkers from the plurality of reference biomarkers that arepotentially useful for distinguishing the groups of individuals,allowing the potential biomarkers to be used in generating signaturesfor use in clinical assessments.

Suitably, the electronic processing device, for each analysis technique:

using the analysis technique, identifies a number of referencebiomarkers that best distinguish the groups of individuals;

determines if the predictive performance of the identified referencebiomarkers exceeds a predetermined threshold; and,

in response to a successful determination, determines the identifiedreference biomarkers to be potential biomarkers.

In some embodiments, the number of reference biomarkers is at least oneof:

less than 10;

more than 1;

between 2 and 8; and,

5.

In some embodiments, the predetermined threshold is at least one of:

at least 90%;

at least 85%; and,

at least 80%.

Suitably, the electronic processing device:

adds potential biomarkers to a potential biomarker collection; and,

removes the potential biomarkers from a reference biomarker collection.

Suitably, for each of a plurality of analysis techniques the electronicprocessing device repeatedly identifies reference biomarkers aspotential biomarkers until the predictive performance of the identifiedreference biomarkers falls below the predetermined threshold.

The electronic processing device may iteratively identify potentialbiomarkers.

In some embodiments, the electronic processing device uses a number ofiterations including at least one of:

at least 100;

at least 500;

at least 1000;

at least 2000; and,

at least 5000.

The electronic processing device may repeatedly determine potentialbiomarkers until a predetermined number of potential biomarkers areidentified.

Suitably, the predetermined number of potential biomarkers includes atleast one of:

at least 100;

less than 500;

about 200.

In some embodiments, the analysis techniques include at least one of:

regression techniques;

correlation analysis; and,

a combination of regression and correlation techniques.

Suitably, the analysis techniques include:

sparse PLS;

random forest; and,

support vector machines.

In some embodiments, the electronic processing device:

removes a validation subgroup from the reference data prior todetermining the potential biomarkers;

determines the potential biomarkers using the reference data without thevalidation subgroup; and,

uses the validation subgroup to validate at least one of:

-   -   the potential biomarkers; and,    -   signatures including a number of the potential biomarkers.

In some embodiments, the processing system determines the number ofgroups by classifying the individuals using at least one of:

an indication of a presence, absence, degree, or stage, or progressionof a condition;

phenotypic traits associated with the individuals;

genetic information associated with the individuals;

biomarkers associated with the individuals.

Suitably, the processing system determines groups at least in part usinginput commands from a user.

The reference data may include time series data indicative of theprogression of a condition.

In some embodiments, the time series data is indicative of whether acondition that is at least one of:

improving;

worsening; and,

static.

The reference data may include for each of the individuals an indicationof at least one of:

an activity of each of the reference biomarkers;

a degree of a condition;

a stage of a condition;

a presence of a condition;

an absence of a condition;

an indication of a condition progression;

phenotypic information;

genetic information; and,

a SOFA score.

In some embodiments, the electronic processing device identifies anumber of potential biomarkers for use as signature biomarkers, thesignature biomarkers being used in generating the signatures.

Suitably, the electronic processing device:

determines a clinical assessment; and,

identifies the signature biomarkers for the clinical assessment.

Suitably, the electronic processing device:

determines second groups of individuals relevant to the clinicalassessment;

using a second analysis technique, identifies a number of the potentialbiomarkers that best distinguish the second groups of individuals;

determines if the predictive performance of the identified potentialbiomarkers exceeds a predetermined threshold; and,

in response to a successful determination, determines the identifiedpotential biomarkers to be signature biomarkers.

In some embodiments, the electronic processing device, in response to anunsuccessful determination:

modifies parameters of the second analysis technique; and,

uses the second analysis technique to identify alternative potentialbiomarkers.

In some embodiments, the electronic processing device:

determines if the identified potential biomarkers are to be excluded;and,

in response to a successful determination:

removes the potential biomarkers from a potential biomarker database;and,

uses the second analysis technique to identify alternative potentialbiomarkers for use as signature biomarkers.

Suitably, the second analysis technique includes at least one of:

ordinal regression and,

support vector machines.

In some embodiments, the signatures are indicative of:

activities of each of a number of signature biomarkers; and,

at least one of:

a SOFA score; and,

a presence, absence, degree, or stage, or progression of a condition.

The signatures may be indicative of a presence, absence, degree, orstage or progression of at least one of:

infection-negative SIRS; and,

infection-positive SIRS.

In some embodiments, activities of at least some of the potentialbiomarkers are indicative of at least one of:

a presence, absence, degree, or stage, or progression of SIRS;

a healthy diagnosis;

a presence, absence, degree, or stage, or progression of infectionpositive SIRS; and,

a presence, absence, degree, or stage, or progression of infectionnegative SIRS.

Suitably, an activity of biomarkers are indicative of a level orabundance of a molecule selected from one or more of:

A nucleic acid molecule;

A proteinaceous molecule;

An amino acid

A carbohydrate;

A lipid;

A steroid;

An inorganic molecule;

An ion;

A drug;

A chemical;

A metabolite;

A toxin;

A nutrient;

A gas;

A cell;

A pathogenic organism; and,

A non pathogenic organism.

In another aspect, the present invention provides a method fordetermining the likelihood of the presence or absence of a conditionselected from a healthy condition (e.g., a normal condition or one inwhich inSIRS and ipSIRS are absent), SIRS generally (i.e., notdistinguishing between inSIRS or ipSIRS), inSIRS or ipSIRS, or to assessthe likelihood of the presence, absence or risk of development of astage of ipSIRS (e.g., a stage of ipSIRS with a particular severity),the method comprising: (1) correlating a reference Inflammatory ResponseSyndrome (IRS) biomarker profile with the presence or absence of acondition selected from a healthy condition, SIRS, inSIRS, ipSIRS, or aparticular stage of ipSIRS, wherein the reference IRS biomarker profileevaluates at least one IRS biomarker; (2) obtaining an IRS biomarkerprofile of a sample from a subject, wherein the sample IRS biomarkerprofile evaluates for an individual IRS biomarker in the reference IRSbiomarker profile a corresponding IRS biomarker; and (3) determining alikelihood of the subject having or not having the condition based onthe sample IRS biomarker profile and the reference IRS biomarkerprofile, wherein an individual IRS biomarker is an expression product ofan IRS biomarker gene selected from the group consisting of: TLR5;CD177; VNN1; UBE2J1; IMP3; RNASE2//LOC643332; CLEC4D; C3AR1; GPR56;ARG1; FCGR1A//FCGR1B//FCGR1C; C11orf82; FAR2; GNLY; GALNT3; OMG;SLC37A3; BMX//HNRPDL; STOM; TDRD9; KREMEN1; FAIM3; CLEC4E; IL18R1;ACER3; ERLIN1; TGFBR1; FKBP5//LOC285847; GPR84; C7orf53; PLB1; DSE;PTGDR; CAMK4; DNAJC13; TNFAIP6;FOXD4L3//FOXD4L6//FOXD4//FOXD4L1//FOXD4L2//FOXD4L4//FOXD4L5;MMP9//LOC100128028; GSR; KLRF1; SH2D1B; ANKRD34B; SGMS2; B3GNT5//MCF2L2;GK3P//GK; PFKFB2; PICALM; METTL7B; HIST1H4C; C9orf72; HIST1H3I; SLC15A2;TLR10; ADM; CD274; CRIP1; LRRN3; HLA-DPB1; VAMP2; SMPDL3A; IFI16; JKAMP;MRPL41; SLC1A3; OLFM4; CASS4; TCN1; WSB2; CLU; ODZ1; KPNA5; PLAC8; CD63;HPSE; C1orf161; DDAH2; KLRK1//KLRC4; ATP13A3; ITK; PMAIP1; LOC284757;GOT2; PDGFC; B3GAT3; HIST1H4E; HPGD; FGFBP2; LRRC70//IPO11;TMEM144//LOC285505; CDS2; BPI; ECHDC3; CCR3; HSPC159; OLAH;PPP2R5A//SNORA16B; TMTC1; EAF2//HCG11//LOC647979; RCBTB2//LOC100131993;SEC24A//SAR1B; SH3PXD2B; HMGB2; KLRD1; CHI3L1; FRMD3; SLC39A9; GIMAP7;ANAPC11; EXOSC4; gene for IL-1beta-regulated neutrophil survival proteinas set forth in GenBank Accession No. AF234262; INSIG1; FOLR3//FOLR2;RUNX2; PRR13//PCBP2; HIST1H4L; LGALS1; CCR1; TPST1; HLA-DRA; CD163;FFAR2; PHOSPHO1; PPIF; MTHFS; DNAJC9//FAM149B1//RPL26; LCN2; EIF2AK2;LGALS2; SIAE; AP3B2; ABCA13; gene for transcript set forth in GenBankAccession No. AK098012; EFCAB2; HIST1H2AA; HINT1; HIST1H3J; CDA; SAP30;AGTRAP; SUCNR1; MTRR; PLA2G7; AIG1; PCOLCE2; GAB2; HS2ST1//UBA2;HIST1H3A; C22orf37; HLA-DPA1; VOPP1//LOC100128019; SLC39A8; MKI67;SLC11A1; AREG; ABCA1; DAAM2//LOC100131657; LTF; TREML1; GSTO1; PTGER2;CEACAM8; CLEC4A; PMS2CL//PMS2; REIN; PDE3B; SULF2; NEK6//LOC100129034;CENPK; TRAF3; GPR65; IRF4; MACF1; AMFR; RPL17//SNORD58B; IRS2; JUP;CD24; GALNT2; HSP90AB1//HSP90AB3P//HSP90AB2P; GLT25D1; OR9A2; HDHD1A;ACTA2; ACPL2; LRRFIP1; KCNMA1; OCR1; ITGA4//CERKL;EIF1AX//SCARNA9L//EIF1AP1; SFRS9; DPH3; ERGIC1; CD300A; NF-E4; MINPP1;TRIM21; ZNF28; NPCDR1; gene for protein FLJ21394 as set forth in GenBankAccession No. BC0013935; gene for transcript set forth in GenBankAccession No. AK000992; ICAM1; TAF13; P4HA1//RPL17; C15orf54; KLHL5;HAL; DLEU2//DLEU2L; ANKRD28; LY6G5B//CSNK2B;KIAA1257//ACAD9//LOC100132731; MGST3; KIAA0746; HSPB1//HSPBL2; CCR4;TYMS; RRP12//LOC644215; CCDC125; HIST1H2BM; PDK4; ABCG1; IL1B; THBS1;ITGA2B; LHFP; LAIR1//LAIR2; HIST1H3B; ZRANB1; TIMM10; FSD1L//GARNL1;HIST1H2AJ//HIST1H2AI; PTGS1; gene for transcript set forth in GenBankAccession No. BC008667; UBE2F//C20orf194//SCLY; HIST1H3C; FAM118A;CCRL2; E2F6; MPZL3; SRXN1; CD151; HIST1H3H; FSD1L; RFESD//SPATA9; TPX2;S100B; ZNF587//ZNF417; PYHIN1; KIAA1324; CEACAM6//CEACAM5; APOLD1;FABP2; KDM6B//TMEM88;IGK@//IGKC//IGKV1-5//IGKV3D-11//IGKV3-20//IGKV3D-15//LOC440871//LOC652493//LOC100291464//LOC652694//IGKV3-15//LOC650405//LOC100291682;MYL9; HIST1H2BJ; TAAR1; CLC; CYP4F3//CYP4F2; CEP97; SON; IRF1; SYNE2;MME; LASS4; DEFA4//DEFA8P; C7orf58; DYNLL1; gene for transcript setforth in GenBank Accession No. AY461701; MPO; CPM; TSHZ2; PLIN2;FAM118B; B4GALT3; RASA4//RASA4P//RASA4B//POLR2J4//LOC100132214;CTSL1//CTSLL3; NP; ATF7; SPARC; PLB1; C4orf3; POLE2; TNFRSF17; FBXL13;PLEKHA3; TMEM62//SPCS2//LOC653566; RBP7; PLEKHF2; RGS2;ATP6V0D1//LOC100132855; RPIA; CAMK1D; IL1RL1; CMTM5; AIF1; CFD; MPZL2;LOC100128751; IGJ; CDC26; PPP1R2//PPP1R2P3; IL5RA; ARL17P1//ARL17;ATP5L//ATP5L2; TAS2R31; HIST2H2BF//HIST2H3D; CALM2//C2orf61; SPATA6;IGLV6-57; C1orf128; KRTAP15-1; IF144;IGL@//IGLV1-44//LOC96610//IGLV2-23//IGLC1//IGLV2-18//IGLV5-45//IGLV3-25//IGLV3-12//IGLV1-36//IGLV3-27//IGLV7-46//IGLV4-3//IGLV3-16//IGLV3-19//IGLV7-43//IGLV3-22//IGLV5-37//IGLV10-54//IGLV8-61//LOC651536;gene for transcript set forth in GenBank Accession No. BC034024; SDHC;NFXL1; GLDC; DCTN5; and KIAA0101//CSNK1G1

In some embodiments, the method determines the likelihood that SIRS or ahealthy condition is present or absent in the subject, and wherein themethod comprises: 1) providing a correlation of a reference IRSbiomarker profile with the presence or absence of SIRS or the healthycondition, wherein the reference biomarker profile evaluates at leastone IRS biomarker selected from CD177, CLEC4D, BMX, VNN1, GPR84, ARG1,IL18R1, ERLIN1, IMP3, TLR5, UBE2J1, GPR56, FCGR1A, SLC1A3, SLC37A3,FAIM3, C3AR1, RNASE2, TNFAIP6, GNLY, OMG, FAR2, OLAH, CAMK4, METTL7B,B3GNT5, CLEC4E, MMP9, KREMEN1, GALNT3, PTGDR, TDRD9, GK3P, FKBP5, STOM,SMPDL3A, PFKFB2, ANKRD34B, SGMS2, DNAJC13, LRRN3, SH2D1B, C1orf161,HIST1H4C, IFI16, ACER3, PLB1, C9orf72, HMGB2, KLRK1, C7orf53, GOT2,TCN1, DSE, CCR3, CRIP1, ITK, KLRF1, TGFBR1, GSR, HIST1H4E, HPGD, FRMD3,ABCA13, C11orf82, PPP2R5A, BPI, CASS4, AP3B2, ODZ1, TMTC1, ADM, FGFBP2,HSPC159, HLA-DRA, HIST1H3I, TMEM144, MRPL41, FOLR3, PICALM, SH3PXD2B,DDAH2, HLA-DPB1, KPNA5, PHOSPHO1, TPST1, EIF2AK2, OR9A2, OLFM4, CD163,CDA, CHI3L1, MTHFS, CLU, ANAPC11, JUP, PMAIP1, GIMAP7, KLRD1, CCR1,CD274, EFCAB2, SUCNR1, KCNMA1, LGALS2, SLC11A1, FOXD4L3, VAMP2, ITGA4,LHFP, PRR13, FFAR2, B3GAT3, EAF2, HPSE, CLC, TLR10, CCR4, HIST1H3A,CENPK, DPH3, HLA-DPA1, ATP13A3, DNAJC9, S100B, HIST1H3J, 110, RPL17,C15orf54, LRRC70, IL5RA, PLA2G7, ECHDC3, HINT1, LCN2, PPIF, SLC15A2,PMS2CL, HIST1H2AA, CEACAM8, HSP90AB1, ABCG1, PDGFC, NPCDR1, PDK4, GAB2,WSB2, FAM118A, JKAMP, TREML1, PYHIN1, IRF4, ABCA1, DAAM2, ACPL2, RCBTB2,SAP30, THBS1, PCOLCE2, GPR65, NF-E4, LTF, LASS4, B4GALT3, REIN, TIMM10,IL1B, CLEC4A, SEC24A, RUNX2, LRRFIP1, CFD, EIF1AX, ZRANB1, SULF2,EXOSC4, CCDC125, LOC284757, ANKRD28, HIST1H2AJ, CD63, PLIN2, SON,HIST1H4L, KRTAP15-1, DLEU2, MYL9, FABP2, CD24, MACF1, GSTO1, RRP12,AIG1, RASA4, FBXL13, PDE3B, CCRL2, C1orf128, E2F6, IL1RL1, CEACAM6,CYP4F3, 199, TAAR1, TSHZ2, PLB1, UBE2F; (2) obtaining a sample IRSbiomarker profile from the subject, which evaluates for an individualIRS biomarker in the reference IRS biomarker profile a corresponding IRSbiomarker, and (3) determining a likelihood of the subject having or nothaving the healthy condition or SIRS based on the sample IRS biomarkerprofile and the reference IRS biomarker profile.

Suitably, the method determines the likelihood that inSIRS, ipSIRS or ahealthy condition is present or absent in the subject, wherein themethod comprises: 1) providing a correlation of a reference IRSbiomarker profile with the likelihood of having or not having inSIRS,ipSIRS or the healthy condition, wherein the reference biomarker profileevaluates at least one IRS biomarker selected from PLAC8, 132, INSIG1,CDS2, VOPP1, SLC39A9, B3GAT3, CD300A, OCR1, PTGER2, LGALS1, HIST1H4L,AMFR, SIAE, SLC39A8, TGFBR1, GAB2, MRPL41, TYMS, HIST1H3B, MPZL3,KIAA1257, OMG, HIST1H2BM, TDRD9, C22orf37, GALNT3, SYNE2, MGST3,HIST1H3I, LOC284757, TRAF3, HIST1H3C, STOM, C3AR1, KIAA0101, TNFRSF17,HAL, UBE2J1, GLT25D1, CD151, HSPB1, IMP3, PICALM, ACER3, IGL@,HIST1H2BJ, CASS4, KREMEN1, IRS2, APOLD1, RBP7, DNAJC13, ERGIC1, FSD1L,TLR5, TMEM62, SDHC, C9orf72, NP, KIAA0746, PMAIP1, DSE, SMPDL3A, DNAJC9,HIST1H3H, CDC26, CRIP1, FAR2, FRMD3, RGS2, METTL7B, CLEC4E, MME, ABCA13,PRR13, HIST1H4C, RRP12, GLDC, ECHDC3, IRF1, C7orf53, IGK@, RNASE2,FCGR1A, SAP30, PMS2CL, SLC11A1, AREG, PLB1, PPIF, GSR, NFXL1, AP3B2,DCTN5, RPL17, IGLV6-57, KLRF1, CHI3L1, ANKRD34B, OLFM4, CPM, CCDC125,GPR56, PPP1R2, 110, ACPL2, HIST1H3A, C7orf58, IRF4, ANAPC11, HIST1H3J,KLRD1, GPR84, ZRANB1, KDM6B, TPST1, HINT1, DAAM2, PTGDR, FKBP5,HSP90AB1, HPGD, IFI16, CD177, TAS2R31, CD163, B4GALT3, EIF1AX, CYP4F3,HIST1H2AA, LASS4 (where if a gene name is not provided then a SEQ ID NO.is provided).; (2) obtaining a sample IRS biomarker profile from thesubject, which evaluates for an individual IRS biomarker in thereference IRS biomarker profile a corresponding IRS biomarker; and (3)determining a likelihood of the subject having or not having inSIRS,ipSIRS or a healthy condition the condition based on the sample IRSbiomarker profile and the reference IRS biomarker profile.

In some embodiments, the method determines the likelihood that inSIRS oripSIRS is present or absent in the subject, wherein the methodcomprises: 1) providing a correlation of a reference IRS biomarkerprofile with the likelihood of having or not having inSIRS or ipSIRS,wherein the reference biomarker profile evaluates at least one IRSbiomarker selected from C11orf82, PLACE, 132, INSIG1, CDS2, VOPP1,SLC39A9, FOXD4L3, WSB2, CD63, CD274, B3GAT3, CD300A, OCR1, JKAMP, TLR10,PTGER2, PDGFC, LGALS1, HIST1H4L, AGTRAP, AMFR, SIAE, 200, SLC15A2,SLC39A8, TGFBR1, DDAH2, HPSE, SUCNR1, MTRR, GAB2, P4HA1, HS2ST1, MRPL41,TYMS, RUNX2, GSTO1, LRRC70, HIST1H3B, RCBTB2, MPZL3, KIAA1257, AIG1,NEK6, OMG, HIST1H2BM, TDRD9, GALNT3, ATP13A3, C22orf37, SYNE2, ADM,MGST3, PDE3B, HIST1H3I, LOC284757, TRAF3, HIST1H3C, STOM, KLHL5, EXOSC4,C3AR1, KIAA0101, TNFRSF17, HAL, UBE2J1, GLT25D1, CD151, TPX2, PCOLCE2,HSPB1, EAF2, IMP3, PICALM, ACER3, IGL@, HIST1H2BJ, CASS4, ACTA2, PTGS1,KREMEN1, IRS2, TAF13, FSD1L, APOLD1, RBP7, DNAJC13, SEC24A, ERGIC1,FSD1L, TLR5, MKI67, TMEM62, CLEC4A, SDHC, C9orf72, NP, CLU, ABCA1,KIAA0746, PMAIP1, DSE, CMTM5, SMPDL3A, DNAJC9, HDHD1A, HIST1H3H, CDC26,ICAM1, LOC100128751, FAR2, CRIP1, MPZL2, FRMD3, CTSL1, METTL7B, RGS2,CLEC4E, MME, ABCA13, PRR13, HIST1H4C, RRP12, GLDC, ECHDC3, ITGA2B,C7orf53, IRF1, 268, IGK@, RNASE2, FCGR1A, UBE2F, SAP30, LAIR1, PMS2CL,SLC11A1, PLB1, AREG, PPIF, GSR, NFXL1, AP3B2, DCTN5, RPL17, PLA2G7,GALNT2, IGLV6-57, KLRF1, CHI3L1, ANKRD34B, OLFM4, 199, CPM, CCDC125,SULF2, LTF, GPR56, MACF1, PPP1R2, DYNLL1, LCN2, FFAR2, SFRS9, IGJ,FAM118B, 110, ACPL2, HIST1H3A, C7orf58, ANAPC11, HIST1H3J, IRF4, MPO,TREML1, KLRD1, GPR84, CCRL2, CAMK1D, CCR1, ZRANB1, KDM6B, TPST1, HINT1,DAAM2, PTGDR, FKBP5, CD24, HSP90AB1, HPGD, CEACAM8, DEFA4, IL1B, IFI16,CD177, KIAA1324, SRXN1, TAS2R31, CEACAM6, CD163, B4GALT3, ANKRD28,TAAR1, EIF1AX, CYP4F3, 314, HIST1H2AA, LY6G5B, LASS4 (where if a genename is not provided then a SEQ ID NO. is provided); (2) obtaining asample IRS biomarker profile from the subject, which evaluates for anindividual IRS biomarker in the reference IRS biomarker profile acorresponding IRS biomarker; and (3) determining a likelihood of thesubject having or not having inSIRS or ipSIRS based on the sample IRSbiomarker profile and the reference IRS biomarker profile.

Suitably, the method determines the likelihood that a stage of ipSIRSselected from mild sepsis, severe sepsis and septic shock is present orabsent the subject, wherein the method comprises: 1) providing acorrelation of a reference IRS biomarker profile with the likelihood ofhaving or not having the stage of ipSIRS, wherein the referencebiomarker IRS biomarker profile evaluates at least one IRS biomarkerselected from PLEKHA3, PLEKHF2, 232, SFRS9, ZNF587, KPNA5, LOC284757,GPR65, VAMP2, SLC1A3, ITK, ATF7, ZNF28, AIF1, MINPP1, GIMAP7, MKI67,IRF4, TSHZ2, HLA-DPB1, EFCAB2, POLE2, FAIM3, 110, CAMK4, TRIM21, IF144,CENPK, ATP5L, GPR56, HLA-DPA1, C4orf3, GSR, GNLY, RFESD, BPI, HIST1H2AA,NF-E4, CALM2, EIF1AX, E2F6, ARL17P1, TLR5, SH3PXD2B, FAM118A, RETN,PMAIP1, DNAJC9, PCOLCE2, TPX2, BMX, LRRFIP1, DLEU2, JKAMP, JUP, ABCG1,SLC39A9, B3GNT5, ACER3, LRRC70, NPCDR1, TYMS, HLA-DRA, TDRD9, FSD1L,FAR2, C7orf53, PPP1R2, SGMS2, EXOSC4, TGFBR1, CD24, TCN1, TAF13, AP3B2,CD63, SLC15A2, IL18R1, ATP6V0D1, SON, HSP90AB1, CEACAM8, SMPDL3A, IMPS,SEC24A, PICALM, 199, CEACAM6, CYP4F3, OLAH, ECHDC3, ODZ1, KIAA0746,KIAA1324, HINT1, VNN1, C22orf37, FSD1L, FOLR3, IL1RL1, OMG, MTHFS,OLFM4, S100B, ITGA4, KLRD1, SLC39A8, KLHL5, KLRK1, MPO, PPIF, GOT2,LRRN3, HIST1H2AJ, CLU, LCN2, 132, CEP97, KLRF1, FBXL13, HIST1H3B,ANKRD34B, RPIA, HPGD, HIST2H2BF, GK3P (where if a gene name is notprovided then a SEQ ID NO. is provided); (2) obtaining a sample IRSbiomarker profile from the subject, which evaluates for an individualIRS biomarker in the reference IRS biomarker profile a corresponding IRSbiomarker; and (3) determining a likelihood of the subject having or nothaving the stage of ipSIRS based on the sample IRS biomarker profile andthe reference IRS biomarker profile.

In illustrative examples, an individual IRS biomarker is selected fromthe group consisting of: (a) a polynucleotide expression productcomprising a nucleotide sequence that shares at least 70% (or at least71% to at least 99% and all integer percentages in between) sequenceidentity with the sequence set forth in any one of SEQ ID NO: 1-319, ora complement thereof; (b) a polynucleotide expression product comprisinga nucleotide sequence that encodes a polypeptide comprising the aminoacid sequence set forth in any one of SEQ ID NO: 320-619; (c) apolynucleotide expression product comprising a nucleotide sequence thatencodes a polypeptide that shares at least 70% (or at least 71% to atleast 99% and all integer percentages in between) sequence similarity oridentity with at least a portion of the sequence set forth in SEQ ID NO:320-619; (d) a polynucleotide expression product comprising a nucleotidesequence that hybridizes to the sequence of (a), (b), (c) or acomplement thereof, under medium or high stringency conditions; (e) apolypeptide expression product comprising the amino acid sequence setforth in any one of SEQ ID NO: 320-619; and (f) a polypeptide expressionproduct comprising an amino acid sequence that shares at least 70% (orat least 71% to at least 99% and all integer percentages in between)sequence similarity or identity with the sequence set forth in any oneof SEQ ID NO: 320-619.

Evaluation of IRS markers suitably includes determining the levels ofindividual IRS markers, which correlate with the presence or absence ofa condition, as defined above.

In some embodiments, the method of determining the likelihood of thepresence or absence of a condition, as broadly described above,comprises comparing the level of a first IRS biomarker in the sample IRSbiomarker profile with the level of a second IRS biomarker in the sampleIRS biomarker profile to provide a ratio and determining a likelihood ofthe presence or absence of the condition based on that ratio. Inillustrative examples of this type, the determination is carried out inthe absence of comparing the level of the first or second IRS biomarkersin the sample IRS biomarker profile to the level of a corresponding IRSbiomarker in the reference IRS biomarker profile. Representative IRSbiomarkers that are useful for these embodiments are suitably selectedfrom those listed in Example 6 and Tables 16-21.

In a related aspect, the present invention provides a kit comprising oneor more reagents and/or devices for use in performing the method ofdetermining the likelihood of the presence or absence of a condition asbroadly described above.

Another aspect of the present invention provides a method for treating,preventing or inhibiting the development of inSIRS, ipSIRS or aparticular stage of ipSIRS in a subject, the method comprising: (1)correlating a reference IRS biomarker profile with the presence orabsence of a condition selected from a healthy condition, SIRS, inSIRS,ipSIRS, or a particular stage of ipSIRS, wherein the reference IRSbiomarker profile evaluates at least one IRS biomarker; (2) obtaining anIRS biomarker profile of a sample from a subject, wherein the sample IRSbiomarker profile evaluates for an individual IRS biomarker in thereference IRS biomarker profile a corresponding IRS biomarker; (3)determining a likelihood of the subject having or not having thecondition based on the sample IRS biomarker profile and the referenceIRS biomarker profile, and administering to the subject, on the basisthat the subject has an increased likelihood of having inSIRS, aneffective amount of an agent that treats or ameliorates the symptoms orreverses or inhibits the development of inSIRS, or administering to thesubject, on the basis that the subject has an increased likelihood ofhaving ipSIRS or a particular stage of ipSIRS, an effective amount of anagent that treats or ameliorates the symptoms or reverses or inhibitsthe development of ipSIRS or the particular stage of ipSIRS.

Yet another aspect of the present invention provides a method ofmonitoring the efficacy of a particular treatment regimen in a subjecttowards a desired health state (e.g., healthy condition), the methodcomprising: (1) providing a correlation of a reference IRS biomarkerprofile with the likelihood of having a healthy condition; (2) obtaininga corresponding IRS biomarker profile of a subject having inSIRS, ipSIRSor a particular stage of ipSIRS after treatment with a treatmentregimen, wherein a similarity of the subject's IRS biomarker profileafter treatment to the reference IRS biomarker profile indicates thelikelihood that the treatment regimen is effective for changing thehealth status of the subject to the desired health state.

Still another aspect of the present invention provides a method ofcorrelating a reference IRS biomarker profile with an effectivetreatment regimen for a condition selected from inSIRS, ipSIRS or aparticular stage of ipSIRS, wherein the reference IRS biomarker profileevaluates at least one IRS biomarker, the method comprising: (a)determining a sample IRS biomarker profile from a subject with thecondition prior to treatment, wherein the sample IRS biomarker profileevaluates for an individual IRS biomarker in the reference IRS biomarkerprofile a corresponding IRS biomarker; and correlating the sample IRSbiomarker profile with a treatment regimen that is effective fortreating the condition.

In another aspect, the present invention provides a method ofdetermining whether a treatment regimen is effective for treating asubject with a condition selected from inSIRS, ipSIRS or a particularstage of ipSIRS, the method comprising: (a) correlating a referencebiomarker profile prior to treatment with an effective treatment regimenfor the condition, wherein the reference IRS biomarker profile evaluatesat least one IRS biomarker; and (b) obtaining a sample IRS biomarkerprofile from the subject after treatment, wherein the sample IRSbiomarker profile evaluates for an individual IRS biomarker in thereference IRS biomarker profile a corresponding IRS biomarker, andwherein the sample IRS biomarker profile after treatment indicateswhether the treatment regimen is effective for treating the condition inthe subject.

In a further aspect, the present invention provides a method ofcorrelating an IRS biomarker profile with a positive or negativeresponse to a treatment regimen, the method comprising: (a) obtaining anIRS biomarker profile from a subject with a condition selected frominSIRS, ipSIRS or a particular stage of ipSIRS following commencement ofthe treatment regimen, wherein the IRS biomarker profile evaluates atleast one IRS biomarker; and (b) correlating the IRS biomarker profilefrom the subject with a positive or negative response to the treatmentregimen.

Another aspect of the present invention provides a method of determininga positive or negative response to a treatment regimen by a subject witha condition selected from inSIRS, ipSIRS or a particular stage ofipSIRS, the method comprising: (a) correlating a reference IRS biomarkerprofile with a positive or negative response to the treatment regimen,wherein the reference IRS biomarker profile evaluates at least one(e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) IRS biomarker; and (b)determining a sample IRS biomarker profile from the subject, wherein thesubject's sample IRS biomarker profile evaluates for an individual IRSbiomarker in the reference IRS biomarker profile a corresponding IRSbiomarker and indicates whether the subject is responding to thetreatment regimen.

In some embodiments, the method of determining a positive or negativeresponse to a treatment regimen further comprises: determining a firstsample IRS biomarker profile from the subject prior to commencing thetreatment regimen, wherein the first sample IRS biomarker profileevaluates at least one IRS biomarker; and comparing the first sample IRSbiomarker profile with a second sample IRS biomarker profile from thesubject after commencement of the treatment regimen, wherein the secondsample IRS biomarker profile evaluates for an individual IRS biomarkerin the first sample IRS biomarker profile a corresponding IRS biomarker.

BRIEF DESCRIPTION OF THE DRAWINGS

An example of the present invention will now be described with referenceto the accompanying drawings, in which:—

FIG. 1 is a schematic diagram of an example of flow chart of a processfor identifying biomarkers for use in a clinical assessment;

FIG. 2 is a schematic diagram of an example of a distributed computerarchitecture;

FIG. 3 is a schematic diagram of an example of a base station processingsystem;

FIG. 4 is a schematic diagram of an example of an computer system;

FIGS. 5A and 5B are a flowchart of a second example of a process foridentifying biomarkers for use in a clinical assessment.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

An example process for performing biomarker identification will now bedescribed with reference to FIG. 1. For the purpose of this example, itis assumed that the process is performed at least in part using anelectronic processing device, such as a processor of a computer system,as will be described in more detail below.

Furthermore, for the purpose of explanation, different terms will beused to identify biomarkers at different stages of the process. Forexample, the term “reference biomarkers” is used to refer to biomarkerswhose activity has been quantified for a sample population of referenceindividuals having different conditions, stages of different conditions,subtypes of different conditions or with different prognoses. Thedifferent reference biomarkers measured for the individuals may bereferred to as a reference biomarker collection. The term “referencedata” refers to data measured for the individuals in the samplepopulation, and may include quantification of the activity of thebiomarkers measured for each individual, information regarding anyconditions of the individuals, and optionally any other information ofinterest. The number of reference biomarkers will vary, but is typicallymore than 1000 biomarkers.

The term “potential biomarkers” refers to a subset of the referencebiomarkers that have been identified as being potentially useful indistinguishing between different groups of individuals, such asindividuals suffering from different conditions, or having differentstages or prognoses. The number of potential biomarkers will vary, butis typically about 200. The different potential biomarkers may bereferred to as a potential biomarker collection.

The term “remaining reference biomarkers” refers to reference biomarkersremaining in the reference biomarker collection, once potentialbiomarkers have been removed.

The term “signature biomarkers” is used to refer to a subset of thepotential biomarkers that have been identified as being potentiallyuseful in defining signatures that can be used in performing a clinicalassessment, such as to rule in or rule out a specific condition,different stages or severity of conditions, subtypes of differentconditions or different prognoses. The number of signature biomarkerswill vary, but is typically of the order of 10 or less, with thedifferent signature biomarkers identified being referred to as asignature biomarker collection.

It will be appreciated that the above described terms and associateddefinitions are used for the purpose of explanation only and are notintended to be limiting.

In this example, at step 100, the process involves using reference datafrom a plurality of individuals to define a number of groups ofindividuals. The individuals are taken from a reference population,typically including individuals having a range of different conditions,or stages of different conditions, or subtypes of different conditionsor with different prognoses.

The reference data typically includes measurements of a plurality ofreference biomarkers, the measurements including information regardingthe activity, such as the level or abundance, of any expression productor measurable molecule, as will be described in more detail below. Thereference data may also include other additional relevant informationsuch as clinical data regarding one or more conditions suffered by eachindividual. This can include information regarding a presence, absence,degree, stage, severity or progression of a condition, phenotypicinformation, such as details of phenotypic traits, genetic orgenetically regulated information, amino acid or nucleotide relatedgenomics information, results of other tests including imaging,biochemical and hematological assays, other physiological scores such asa SOFA (Sequential Organ Failure Assessment) score, or the like and thisis not intended to be limiting, as will be apparent from the descriptionbelow.

At step 110, a plurality of analysis techniques, such as statisticalanalysis or machine learning techniques, are used to identify a numberof potential biomarkers from the plurality of reference biomarkers thatare potentially useful for distinguishing the groups of individuals,allowing the potential biomarkers to be used in selecting signaturebiomarkers for use in generating signatures for use in clinicalassessments.

The analysis techniques are typically applied in an iterative fashion,with each iteration being used to identify a subset of referencebiomarkers that might prove suitable for use as potential biomarkers. Inone example, as each iteration is performed, the predictive performanceof the reference biomarkers in distinguishing the groups is assessed,with reference biomarkers being identified for use as potentialbiomarkers only in the event that they exceed a predetermined predictiveperformance threshold, such as at least 90%, at least 85% or moretypically, at least 80%. This threshold may be implemented as accuracyin the case of classification or a measure of correlation in the case ofcontinuous outcomes.

Once reference biomarkers are identified for use as potentialbiomarkers, they can be removed from the reference biomarker collection,allowing the next iteration to be performed on the remaining referencebiomarkers. The number of iterations will depend on the analysistechniques and associated parameters used, and can include at least 100,at least 500, at least 1000, at least 2000 and even at least 5000.

The process uses a plurality of different analysis techniques, such asclassification, regression and/or machine learning techniques, allowinga variety of potential biomarkers to be identified. This is performed aseach analysis technique typically operates slightly differently and as aresult will often identify different potential biomarkers, so using theplurality of different analysis techniques ensures that as manypotentially useful biomarkers as possible are captured for use aspotential biomarkers.

The analysis techniques may be performed until the predictiveperformance of the remaining reference biomarkers in the referencebiomarker collection falls below the predetermined threshold and eachtechnique has been used, or may be repeated until a predetermined numberof potential biomarkers, such as at least 100, less than 500 or moretypically about 200, are identified.

Following identification of potential biomarkers, at step 120, a subsetof the potential biomarkers can be optionally identified for use assignature biomarkers, to allow signatures for use in specific clinicalassessments to be determined. This can be achieved in any suitablemanner, but in one example, this involves a further process ofidentifying specific groups relevant to the clinical assessment, andthen performing a further regression or other similar statisticalanalysis to select those potential biomarkers that can be used assignature biomarkers.

Accordingly, in one example, the above described process is used toidentify a subset of measured reference biomarkers that can act aspotential biomarkers, before a more in depth analysis is performed toidentify a subset of potential biomarkers for use as signaturebiomarkers that can be used in specific clinical assessments. As aresult, the above process can act as a coarse filter, allowing arelatively large number of potential biomarkers to be identified thatcan be used in distinguishing the different groups of individuals.

By way of example, many patients suffer from a condition called SystemicInflammatory Response Syndrome (SIRS) (M S Rangel-Frausto, D Pittet, MCostigan, T Hwang, C S Davis, and R P Wenzel, “The Natural History ofthe Systemic Inflammatory Response Syndrome (SIRS). a ProspectiveStudy,” JAMA the Journal of the American Medical Association 273, no. 2(Jan. 11, 1995): 117-123.). SIRS is an overwhelming whole body reactionthat may have an infectious or non-infectious aetiology, whereas sepsisis SIRS that occurs during infection. Both are defined by a number ofnon-specific host response parameters including changes in heart andrespiratory rate, body temperature and white cell counts (Mitchell MLevy et al., “2001 SCCM/ESICM/ACCP/ATS/SIS International SepsisDefinitions Conference,” Critical Care Medicine 31, no. 4 (April 2003):1250-1256, doi:10.1097/01.CCM.0000050454.01978.3B.; K Reinhart, M Bauer,N C Riedemann, and C S Hartog, “New Approaches to Sepsis: MolecularDiagnostics and Biomarkers,” Clinical Microbiology Reviews 25, no. 4(Oct. 3, 2012): 609-634, doi:10.1128/CMR.00016-12.) To differentiatethese conditions they are referred herein to as SIRS (both conditions),infection-negative SIRS (SIRS without infection, hereafter referred toas “inSIRS”) and infection-positive SIRS (sepsis, SIRS with a known orsuspected infection, hereafter referred to as “ipSIRS”). The causes ofSIRS are multiple and varied and can include, but are not limited to,trauma, burns, pancreatitis, endotoxemia, surgery, adverse drugreactions, and infections (local and systemic). Using two patientpopulations of healthy individuals and individuals having SIRS, a coarsefilter can be used to identify which reference biomarkers candistinguish these two groups of individuals, thereby allowing potentialbiomarkers to be identified. A coarse filter could also be used toidentify which reference biomarkers can separate inSIRS patients fromipSIRS patients, both groups of patients having SIRS in common, but eachgroup of patients differing in whether a clinician has determined thepresence of an infection or not.

Following this, more specific and computationally intensive analysescould be performed to identify a subset of potential biomarkers for useas signature biomarkers to answer more specific clinical questions suchas: for patients with ipSIRS which biomarkers can separate out thosewith severe sepsis or septic shock, or provide a prognosis or indicationof likely progression to another stage of disease, or for patients withinSIRS which biomarkers can separate those with pancreatitis from thosefollowing surgery.

Thus, if it is desired to make clinical assessments relating to SIRS,and in particular, inSIRS and ipSIRS, a suite of biomarkers can bequantified for individuals suffering either one of these conditions, aswell as healthy individuals and used as reference biomarkers. These datacan be used to define first groups of individuals having one of the twoconditions or both, as well as of healthy individuals. Potentialbiomarkers can be ascertained that may be used to distinguish thesegroups. For example, the first stage could be used to determinebiomarkers that differentiate healthy individuals and individuals havingSIRS.

Following this, signature biomarkers for specific clinical assessmentswithin these groups, such as distinguishing inSIRS from ipSIRS (rule inand rule out ipSIRS), can be determined. In this case, second groups aredefined that relate to individuals having or not havinginfection-positive or inSIRS, and then signature biomarkers aredetermined from the potential biomarkers.

It can be complex and computationally difficult to select a limitednumber of clinically useful and manageable biomarkers from a large dataset in a single stage. Thus, using a single stage identificationprocess, potentially useful biomarkers can be easily overlooked oromitted, so that the resulting signature biomarkers are not necessarilythe best suited for use in a specific clinical assessment. A particularbenefit of the described approach is that by separating the process intomultiple stages, the chances of overlooking or omitting the discovery ofnew and clinically useful biomarkers is greatly reduced.

The multi-stage approach allows coarse filtering to be used first so asto limit the number of measured reference biomarkers to a moremanageable number of potential biomarkers, so that more specific, andcomputationally intensive, techniques can be used to identify signaturebiomarkers for use in specific clinical assessments. The coarse analysistherefore allows a collection of potential biomarkers to be establishedthat will be relevant to a range of different but related clinicalassessments. A more focussed analysis can then be performed to identifyspecific signature biomarkers, which is less computationally intensivethan attempting to do this for a greater number of biomarkers, and alsohelps ensure the best biomarkers for the clinical assessment areidentified by excluding the noise introduced by many uninformativebiomarkers which have been removed from consideration.

The above approach can therefore allow a large number of measuredreference biomarkers, typically several thousand, to be used as a basisfor the analysis, thereby reducing the likelihood of new and clinicallyrelevant biomarkers being excluded from the resulting potentialbiomarkers, and ultimately signature biomarkers, hence improving theability of the signatures to be clinically useful in assessments.

In one example, the process is performed at least in part using aprocessing system, such as a suitably programmed computer system. Thiscan be performed on a stand-alone computer, with the microprocessorexecuting applications software allowing the above-described method tobe performed. Alternatively, the process can be performed by one or moreprocessing systems operating as part of a distributed architecture, anexample of which will now be described with reference to FIG. 2.

In this example, a base station 201 is coupled via a communicationsnetwork, such as the Internet 202, and/or a number of local areanetworks (LANs) 204, to a number of computer systems 203. It will beappreciated that the configuration of the networks 202, 204 are for thepurpose of example only, and in practice the base station 201, computersystems 203 can communicate via any appropriate mechanism, such as viawired or wireless connections, including, but not limited to mobilenetworks, private networks, such as an 802.11 networks, the Internet,LANs, WANs, or the like, as well as via direct or point-to-pointconnections, such as Bluetooth, or the like.

In one example, the base station 201 includes a processing system 210coupled to a database 211. The base station 201 is adapted to be used inanalysing reference data, selecting potential biomarkers, and optionallygenerating signatures for use in clinical assessments. The referencedata may be stored in the database 211 and may be received from thecomputer systems 203, or other remote devices. The base station 201 mayalso be adapted to assist in performing clinical assessments bycomparing individual data relating to a patient or other individual andthen comparing this to the signatures to allow a clinical assessment tobe made. The computer systems 203 are therefore adapted to communicatewith the base station 201, allowing data to be transferred there betweenand/or to control the operation of the base station 201.

Whilst the base station 201 is a shown as a single entity, it will beappreciated that the base station 201 can be distributed over a numberof geographically separate locations, for example by using processingsystems 210 and/or databases 211 that are provided as part of a cloudbased environment.

However, the above-described arrangement is not essential and othersuitable configurations could be used. For example, the process foridentifying biomarkers, as well as any subsequent clinical assessment ofindividual data could be performed on a stand-alone computer system.

An example of a suitable processing system 210 is shown in FIG. 3. Inthis example, the processing system 210 includes at least onemicroprocessor 300, a memory 301, an input/output device 302, such as akeyboard and/or display, and an external interface 303, interconnectedvia a bus 304 as shown. In this example the external interface 303 canbe utilised for connecting the processing system 210 to peripheraldevices, such as the communications networks 202, 204, databases 211,other storage devices, or the like. Although a single external interface303 is shown, this is for the purpose of example only, and in practicemultiple interfaces using various methods (e.g., Ethernet, serial, USB,wireless or the like) may be provided.

In use, the microprocessor 300 executes instructions in the form ofapplications software stored in the memory 301 to allow the biomarkeridentification process to be performed, as well as to perform any otherrequired processes, such as communicating with the computer systems 203.The applications software may include one or more software modules, andmay be executed in a suitable execution environment, such as anoperating system environment, or the like.

Accordingly, it will be appreciated that the processing system 300 maybe formed from any suitable processing system, such as a suitablyprogrammed computer system, PC, web server, network server, or the like.In one particular example, the processing system 100 is a standardprocessing system such as a 32-bit or 64-bit Intel Architecture basedprocessing system, which executes software applications stored onnon-volatile (e.g., hard disk) storage, although this is not essential.However, it will also be understood that the processing system could beany electronic processing device such as a microprocessor, microchipprocessor, logic gate configuration, firmware optionally associated withimplementing logic such as an FPGA (Field Programmable Gate Array), orany other electronic device, system or arrangement.

As shown in FIG. 4, in one example, the computer system 203 includes atleast one microprocessor 400, a memory 401, an input/output device 402,such as a keyboard and/or display, and an external interface 403,interconnected via a bus 404 as shown. In this example the externalinterface 403 can be utilised for connecting the computer system 203 toperipheral devices, such as the communications networks 202, 204,databases 211, other storage devices, or the like. Although a singleexternal interface 403 is shown, this is for the purpose of exampleonly, and in practice multiple interfaces using various methods (eg.Ethernet, serial, USB, wireless or the like) may be provided.

In use, the microprocessor 400 executes instructions in the form ofapplications software stored in the memory 401 to allow communicationwith the base station 201, for example to allow data to be suppliedthereto and allowing results of any clinical assessment to be displayedto an operator. The computer system 203 may also be used to allow theoperation of the base station 201 to be controlled, for example to allowthe biomarker identification process to be performed remotely.

Accordingly, it will be appreciated that the computer systems 203 may beformed from any suitable processing system, such as a suitablyprogrammed PC, Internet terminal, lap-top, hand-held PC, smart phone,PDA, web server, or the like. Thus, in one example, the processingsystem 100 is a standard processing system such as a 32-bit or 64-bitIntel Architecture based processing system, which executes softwareapplications stored on non-volatile (e.g., hard disk) storage, althoughthis is not essential. However, it will also be understood that thecomputer systems 203 can be any electronic processing device such as amicroprocessor, microchip processor, logic gate configuration, firmwareoptionally associated with implementing logic such as an FPGA (FieldProgrammable Gate Array), or any other electronic device, system orarrangement.

Examples of the biomarker identification process, and subsequent use ina clinical assessment will now be described in further detail. For thepurpose of these examples, it is assumed that reference data, includingthe reference biomarker collection, any potential biomarkers, signaturebiomarkers or signatures can be stored in the database 211, and that thebiomarker identification process is performed using the processingsystem 210 under control of one of the computer systems 203. Thus, it isassumed that the processing system 210 of the base station 201 hostsapplications software for performing the biomarker identificationprocess, with actions performed by the processing system 210 beingperformed by the processor 300 in accordance with instructions stored asapplications software in the memory 301 and/or input commands receivedfrom a user via the I/O device 302, or commands received from thecomputer system 203.

It will also be assumed that the user interacts with applicationsoftware executed by the processing system 210 via a GUI, or the likepresented on the computer system 203. Actions performed by the computersystem 203 are performed by the processor 401 in accordance withinstructions stored as applications software in the memory 402 and/orinput commands received from a user via the I/O device 403. The basestation 201 is typically a server which communicates with the computersystem 203 via a LAN, or the like, depending on the particular networkinfrastructure available.

However, it will be appreciated that the above-described configurationassumed for the purpose of the following examples is not essential, andnumerous other configurations may be used. It will also be appreciatedthat the partitioning of functionality between the computer system 203,and the base station 201 may vary, depending on the particularimplementation.

A second example of a process for determining biomarkers will now bedescribed with reference to FIGS. 5A and 5B.

In this example, at step 500 reference data is acquired for a pluralityof individuals with the reference data including at least data regardinga plurality of reference biomarkers, measured for each individual.

The reference data may be acquired in any appropriate manner buttypically this involves obtaining gene expression product data from aplurality of individuals, selected to include individuals diagnosed withone or more conditions of interest, as well as healthy individuals. Theterms “expression” or “gene expression” refer to production of RNAmessage or translation of RNA message into proteins or polypeptides, orboth. Detection of either types of gene expression in use of any of themethods described herein is encompassed by the present invention. Theconditions are typically medical, veterinary or other health statusconditions and may include any illness, disease, stages of disease,disease subtypes, severities of disease, diseases of varying prognosesor the like.

In order to achieve this, gene expression product data are collected,for example by obtaining a biological sample, such as a peripheral bloodsample, and then performing a quantification process, such as a nucleicacid amplification process, including PCR (Polymerase Chain Reaction) orthe like, in order to assess the activity, and in particular, level orabundance of a number of reference biomarkers. Quantified valuesindicative of the relative activity are then stored as part of thereference data.

Example reference biomarkers will be described in more detail below butit will be appreciated that these could include expression products suchas nucleic acid or proteinaceous molecules, as well as other moleculesrelevant in making a clinical assessment. The number of biomarkersmeasured for use as reference biomarkers will vary depending upon thepreferred implementation, but typically include a large number such as,1000, 5000, 10000 or above, although this is not intended to belimiting.

The individuals also typically undergo a clinical assessment allowingany conditions to be clinically identified, and with an indication ofany assessment or condition forming part of the reference data. Whilstany conditions can be assessed, in one example the process is utilizedspecifically to identify conditions such as SIRS, including inSIRS andipSIRS or sepsis. It will be appreciated from the following, however,that this can be applied to a range of different conditions, andreference to SIRS or sepsis is not intended to be limiting.

Additionally, the reference data may include details of one or morephenotypic traits of the individuals and/or their relatives. Phenotypictraits can include information such as the gender, ethnicity, age, orthe like. Additionally, in the case of the technology being applied toindividuals other than humans, this can also include information such asdesignation of a species, breed or the like.

Accordingly, in one example the reference data can include for each ofthe reference individuals an indication of the activity of a pluralityof reference biomarkers, a presence, absence degree, stage, orprogression of a condition, phenotypic information such as phenotypictraits, genetic information and a physiological score such as a SOFAscore.

The reference data is typically collected from individuals presenting ata medical centre with clinical signs relating to relevant any conditionsof interest, and may involve follow-on consultations in order to confirmclinical assessments, as well as to identify changes in biomarkers,and/or clinical signs, and/or severity of clinical signs, over a periodof time. In this latter case, the reference data can include time seriesdata indicative of the progression of a condition, and/or the activityof the reference biomarkers, so that the reference data for anindividual can be used to determine if the condition of the individualis improving, worsening or static. It will also be appreciated that thereference biomarkers are preferably substantially similar for theindividuals within the sample population, so that comparisons ofmeasured activities between individuals can be made.

It will be appreciated that once collected, the reference data can bestored in the database 211 allowing this to be subsequently retrieved bythe processing system 210 for subsequent analysis. The processing system210 also typically stores an indication of an identity of each of thereference biomarkers as a reference biomarker collection.

At step 505, the processing system 210 optionally removes a validationsubgroup of individuals from the reference data prior to determining thepotential biomarkers. This is performed to allow the processing system210 to determine the potential biomarkers using the reference datawithout the validation subgroup so that the validation subgroup can besubsequently used to validate the potential biomarkers or signaturesincluding a number of the potential biomarkers. Thus, data from thevalidation subgroup is used to validate the efficacy of the potential orsignature biomarkers in identifying the presence, absence, degree,stage, severity, prognosis or progression of any one or more of theconditions to ensure the potential or signature biomarkers areeffective, as will be described in more detail below.

In one example, this is achieved by having the processing system 210flag individuals within the validation subgroup or alternatively storethese in either an alternative location within the database 211 or analternative database to the reference data. The validation subgroup ofindividuals is typically selected randomly and may optionally beselected to include individuals having different phenotypic traits. Whena validation subgroup of individuals is removed, the remainingindividuals will simply be referred to as reference data for easethroughout the remaining description.

At step 510, the individuals remaining within the reference data (ieexcluding the validation subgroup) are classified into groups. Thegroups may be defined in any appropriate manner and may be defined basedon any one or more of an indication of a presence, absence, degree,stage, severity, prognosis or progression of a condition, phenotypictraits, other tests or assays, genetic information or measured activityof the reference biomarkers associated with the individuals.

For example, a first selection of groups may be to identify one or moregroups of individuals suffering from SIRS, one or more groups ofindividuals suffering ipSIRS, one or more groups of individualssuffering inSIRS, and one or more groups of healthy individuals. Furthergroups may also be defined for individuals suffering from otherconditions. Additionally, further subdivision may be performed based onphenotypic traits, so groups could be defined based on gender, ethnicityor the like so that a plurality of groups of individuals suffering froma condition are defined, with each group relating to a differentphenotypic trait.

It will also be appreciated, however, that identification of differentgroups can be performed in other manners, for example on the basis ofparticular activities of biomarkers within the biological samples of thereference individuals, and accordingly, reference to conditions is notintended to be limiting and other information may be used as required.

The manner in which classification into groups is performed may varydepending on the preferred implementation. In one example, this can beperformed automatically by the processing system 210, for example, usingunsupervised methods such as Principal Components Analysis (PCA), orsupervised methods such as k-means or Self Organising Map (SOM).Alternatively, this may be performed manually by an operator by allowingthe operator to review reference data presented on a Graphical UserInterface (GUI), and define respective groups using appropriate inputcommands.

Once the groups have been defined, analysis techniques are utilized inorder to identify reference biomarkers that can be utilized topotentially distinguish the groups. The analysis technique typicallyexamines the activity of the reference biomarkers for individuals withinand across the groups, to identify reference biomarkers whose activitiesdiffer between and hence can distinguish groups. A range of differentanalysis techniques can be utilized including, for example, regressionor correlation analysis techniques. Examples of the techniques used caninclude established methods for parametized model building such asPartial Least Squares, Random Forest or Support Vector Machines, usuallycoupled to a feature reduction technique for the selection of thespecific subset of the biomarkers to be used in a signature.

Such techniques are known and described in a number of publications. Forexample, the use of Partial Least Squares is described in “Partial leastsquares: a versatile tool for the analysis of high-dimensional genomicdata” by Boulesteix, Anne-Laure and Strimmer, Korbinian, from Briefingsin Bioinformatics 2007 vol 8. no. 1, pg 32-44. Support Vector machinesare described in “LIBSVM: a library for support vector machines” byChang, C. C. and Lin, C. J. from ACM Transactions on Intelligent Systemsand Technology (TIST), 2011 vol 2, no. 3, pg 27. Standard Random Forestin R language is described in “Classification and Regression by randomForest” by Liaw, A. and Wiener, M., in R news 2002, vol 2, no. 3, pg18-22.

The analysis techniques are implemented by the processing system 210,using applications software, which allows the processing system 210 toperform multiple ones of the analysis techniques in sequence. This isadvantageous as the different analysis techniques typically havedifferent biases and can therefore be used to identify differentpotential biomarkers that can distinguish the groups, thereby reducingthe risk of clinically relevant biomarkers being overlooked.

At step 515 a next analysis technique is selected by the processingsystem 210, with this being implemented at step 520 to identify the bestN reference biomarkers for distinguishing the groups, where the variableN is a predetermined or algorithmically derived number of biomarkerswhose value may vary depending on the analysis technique used and thepreferred implementation, but is typically a relatively small numbercompared to the overall number of biomarkers, such as less than 10, morethan 1, between 2 and 8 and 5. This process typically involves apredictive model to assess the ability of activities of particular onesof the reference biomarkers to distinguish between different groups. Forexample this can examine the manner in which the activity of referencebiomarkers differ between groups, and/or are relatively similar within agroup. This can be performed iteratively for different combinations ofreference biomarkers until a best N of the reference biomarkers areidentified.

At step 525, the processing system 210 determines the predictiveperformance of the identified best N reference biomarkers, when used inthe model, for in distinguishing the relevant groups. The predictiveperformance is typically a parameter determined as part of thecombination of analysis technique and chosen embodying model, as will beappreciated by persons skilled in the art. For example, receiveroperating characteristic (ROC) analysis may be used to determine optimalassay parameters to achieve a specific level of accuracy, specificity,positive predictive value, negative predictive value, and/or falsediscovery rate.

Optionally, a cross-validation approach may be used whereby steps 520and 525 are repeated M times to produce a distribution of M predictiveperformance measures, and N×M selected reference biomarkers. It will beappreciated that there may be none, some, or complete overlap in thesets of selected reference biomarkers for the M iterations. The union(unique set) of selected reference biomarkers from all M iterations isthe set U.

At step 530, the predictive performance is compared to a predeterminedthreshold, which is typically selected dependent upon the preferredimplementation, but may be a relatively low value such as 80%. In thecase of cross-validation, in which steps 520 and 525 are repeated Mtimes, the predictive performance at step 530 is some property of the Mpredictive performance measurements such as the mean, median or maximum.

By example, ruling in ipSIRS might have a lower threshold than rulingout ipSIRS since the clinical risk of treating someone with inSIRS withantibiotics might be considered to be less than not treating someonewith ipSIRS with antibiotics. Thus, it can be appreciated that thethreshold set is influenced by a variety of factors including clinicalutility, patient welfare, disease prevalence, and econometrics of testuse to name a few examples.

At step 535, if it is determined that the predictive performance isabove the threshold, the identified N reference biomarkers are added toa list or collection of potential biomarkers, an indication of which istypically stored in the database 211. In the case of a cross-validationapproach, where the set of unique selected biomarkers (U) may be largerthan the number to be selected as potential biomarkers (N), the N mostfrequently selected biomarkers during the M iterations are identified asthe N reference biomarkers and are then removed from the referencebiomarker collection before further analysis is performed. The processthen returns to step 520 allowing the same analysis technique to beperformed and the next N reference biomarkers identified.

It will therefore be appreciated that this is an iterative techniquethat allows reference biomarkers capable of distinguishing the groups tobe progressively identified with the ability of an additional Nreference biomarkers to act as potential biomarkers being assessed,within each iteration. This process performs a relatively coarsefiltering of reference biomarkers allowing groups of referencebiomarkers with predictive performance above the threshold to beprogressively removed from the reference biomarker collection and addedto the potential biomarker collection.

During this process, if it is determined that the predictive performanceof the N identified reference biomarkers is below the threshold, thenthe process moves to step 540 when it is determined by the processingsystem 210 if all analysis techniques have been used. If not, theprocess returns to step 515 allowing a next analysis technique to beselected.

Thus, it will be appreciated that the iterative process is repeated fora number of different analysis techniques allowing biases between thetechniques to identify different potential biomarkers. Accordingly, thisprocess progressively identifies reference biomarkers useful aspotential biomarkers utilizing a coarse identification process that canbe performed relatively rapidly, and optionally in parallel, over alarge number of reference biomarkers.

At this stage, the potential biomarkers may be utilized in an attempt toclassify the validation subgroup of individuals. In particular, thedifferent activities of the identified potential biomarkers forindividuals within each group are utilized to attempt to classifyindividuals in the validation subgroup into the groups defined at step510. In the event that classification of the validation subgroup issuccessful, potential biomarkers may be retained, whereas if avalidation is unsuccessful potential biomarkers may optionally beremoved from the potential biomarker collection.

In one example, the above-described process is performed over severalthousand different reference biomarkers allowing a collection of severalhundred potential biomarkers to be identified. However, the potentialbiomarkers may not be ideal for answering specific clinical assessmentquestions, such as ruling in a condition, ruling out a condition, ordetermining a stage of progression or likely outcome of a condition ortreatment.

Accordingly, once the potential biomarkers have been identified, morerefined processes are used to allow the processing system 210 toidentify a number of potential biomarkers for use as signaturebiomarkers, in turn allowing signatures to be developed for performingspecific clinical assessments.

In this regard, it will be appreciated that typically clinicians willwant to perform a specific clinical assessment based on a preliminarydiagnosis made using clinical signs, present in a subject presented tothem. Accordingly, a clinician could potentially only need to answer thequestion of whether the subject has ipSIRS, or does not have ipSIRS. Asthe cost, speed and ability to perform a diagnostic test will typicallybe heavily dependent on the number of biomarkers assessed as part of thetest, it is preferable to be able to identify a minimal number ofbiomarkers that are able to answer the specific clinical assessment ofinterest. To address this, the process can use more refined analysis ofthe potential biomarkers to identify those that are most useful inperforming a particular clinical assessment, and hence can be used assignature biomarkers.

Accordingly, at step 545 a next clinical assessment is determined. Thiscan be achieved in any manner, but usually involves having the userdefine the clinical assessment using appropriate input commands. As partof this, at step 550, the processing system 210 is used to identifysecond groups that are relevant to the clinical assessment, for example,by having the user identify criteria, such as the relevant conditionsassociated with each group, or the stage of progression for theindividuals within the groups. This could include, for example, defininggroups of individuals having ipSIRS and those not having ipSIRS, orthose having mild, major, worsening or improving ipSIRS. Whilst it willbe appreciated that the second groups may be the same as the firstgroups previously defined at step 510, more typically the second groupsare more appropriately targeted based on the particular clinicalassessment.

At step 555, the processing system 210 uses a second analysis techniqueto identify a number of the potential biomarkers that best distinguishthe second groups of individuals. In particular, this will attempt toidentify potential biomarkers whose level of activity for theindividuals within the groups, can be used to distinguish the groups.The nature of the analysis technique will vary depending upon thepreferred implementation and can include analysis techniques similar tothose outlined above. Alternatively, different analysis techniques canbe used such as ordinal classification, which differs from regularclassification in that the known order of classes is used withoutassumptions as to their relative similarity to impose extra constraintsin the model leading to more accurate clarification of borderline cases.Such ordinal classification is described in “Support vector ordinalregression” by Chu, W. and Keerthi, S. S., in Neural Computation 2007,vol 19, no. 3, pg 792-815.

An ordinal SVM for classification consists of the same fundamentalelements of any SVM technique that would be familiar to anyone skilledin the art. Namely, the objective is to describe a number of maximallyseparating hyper-planes in the transformed hyperspace defined by thekernel function. An ordinal classifier differs from a regular SVMclassifier in that it imposes an ordinal structure through the use ofthe cost function. This is implemented by adding to cost functions acomponent which penalizes incorrect ranks during execution, as described“Support vector ordinal regression” by Chu et al. (2007, supra).

Typically, the analysis techniques are implemented to identify a limitedoverall number of potential biomarkers that can be used as signaturebiomarkers, and may therefore use more stringent criteria than theanalysis techniques used in steps 515 to 530 above. Alternatively, theanalysis techniques may not be limited in the number of potentialbiomarkers identified, and can instead identify more or less potentialbiomarkers than the predetermined number N, above. Additionally, forthis reason, only a single analysis technique is typically required atthis stage, although this is not essential and multiple second analysistechniques could be used.

At step 560, the processing system 210 determines if the predictiveperformance of the identified potential biomarkers exceeds a secondpredetermined threshold.

Optionally, a cross-validation approach may be used whereby steps 550and 560 are repeated M times to produce a distribution of M predictiveperformance measures, and N×M selected reference biomarkers. It will beappreciated that there may be none, some, or complete overlap in thesets of selected reference biomarkers for the M iterations. The union(unique set) of selected reference biomarkers from all M iterations isthe set U.

Optionally, a consensus approach may be used, whereby steps 555 and 560are repeated multiple times, and the predictive performance measure issome measure of the consensus of the iterations, such as the averagevalue.

At step 565, if it is determined that the predictive performance is notabove the second predetermined threshold, the processing system 210modifies parameters associated with the analysis technique at step 570and the process returns to step 555 allowing the same or alternativepotential biomarkers to be assessed. This process is repeated until asuccessful determination occurs when a limited number of potentialbiomarkers are identified which provide a predictive performance abovethe threshold, in which case the process moves on to step 575.

It will be appreciated that as this is attempting to identify a limitednumber of biomarkers that provide better predictive performance, thesecond predetermined threshold is typically set to be higher that thefirst predetermined threshold used at step 530, and as a result of this,the second analysis technique may be computationally more expensive.Despite this, as the process is only being performed on the basis of thepotential biomarkers and not the entire set of reference biomarkers,this can typically be performed relatively easily.

At step 575, the processing system 210 determines if the identifiedpotential biomarkers are to be excluded. This may occur for any one of anumber of reasons. For example, a limited number of say five biomarkersmay be identified which are capable of providing the required clinicalassessment outcome. However, it may not be possible to use some of thesebiomarkers for legal or technical reasons, in which case the biomarkersmay be excluded. In this case, the excluded biomarkers are removed fromthe potential biomarker database at step 580 and the process returns tostep 555 allowing the analysis to be performed.

It will be appreciated that whilst such excluded biomarkers may beremoved from the reference data at an earlier point in the process, theability to identify excluded biomarkers may be difficult. For example,performing a freedom-to-operate assessment of potential biomarkers canbe an expensive process. It is therefore unfeasible to do this to theentire collection of biomarkers within the reference database or even tothe entire collection of potential biomarkers. Accordingly, thisassessment is only typically made once a potential biomarker has beenidentified at step 555 to 565 as providing a predictive performanceabove the threshold.

In the event that none of the potential biomarkers are excluded, theidentified potential biomarkers are used as signature biomarkers, and anindication of the signature biomarkers is typically stored in asignature biomarker collection in the database 211. The measuredactivities from the reference individuals for the signature biomarkerscan then be used to generate signatures for use in performing theclinical assessment at step 585. The signatures will typically defineactivities or ranges of activities of the signature biomarkers that areindicative of the presence, absence, degree, stage, or progression of acondition. This allows the signatures to be used in performingdiagnostic and/or prognostic assessment of subjects.

For example, an indication of the activity of the signature biomarkerscan be obtained from a sample taken from a test subject, and used toderive a signature indicative of the health status of the test subject.This can then be compared to the signatures derived from the referencedata to assess the likely heath status of the subject.

Following this, at step 590 the process moves on to determine whetherall clinical assessments have been addressed and if not, returns to step545 allowing a next clinical assessment to be selected. Otherwise, theprocess ends at step 595.

Accordingly, it will be appreciated that the above-described methodologyutilizes a staged approach in order to generate potential biomarkers andoptionally, further signature biomarkers, for use in performing clinicalassessments.

The process utilizes an initial coarse filtering based on a plurality ofanalysis techniques in order to identify a limited number of potentialbiomarkers. The limited number of potential biomarkers, which istypically in the region of less than 500, are selected from a largerdatabase of biomarkers as being those most capable of distinguishingbetween different conditions, and/or different stages or progressions ofa condition.

Following this, in a further stage, specific clinical assessments areidentified with additional analysis techniques being used to selectparticular biomarkers from the database of potential biomarkers with theparticular biomarkers being capable of being use in answering thespecific clinical assessments.

A specific example of the above-described process will now be describedwith reference to distinguishing between inSIRS and ipSIRS.

A number of patients clinically identified as having infection negativeSIRS and infection positive SIRS had peripheral blood samples taken(N=141). These samples were run on microarray. The microarray data wasthen normalised and quality control (QC) filtered as per therecommendation of the manufacturer to produce a list of samples with acorresponding clinical diagnosis of SIRS with or without an infection(N=141), and a list of reference biomarkers that passed QC (N=15,989).

The process of building and testing a model will now be described. Inthis example, 10% of the samples are randomly selected to act as thetesting/validation set and are put aside. The remaining 90% of thesamples are the training set, used to identify the potential biomarkers.

A feature selection algorithm coupled to a machine learning model isthen applied to the training set, In this example a Recursive FeatureSelection Support Vector Machine, described for example in “RecursiveSVM feature selection and sample classification for mass-spectrometryand microarray data”, by Xuegong Zhang, Xin Lu, Qian Shi, Xiu-qin Xu,Hon-chiu E Leung, Lyndsay N Harris, James D Iglehart, Alexander Miron,Jun S Liu and Wing H Wong from BMC Bioinformatics 2006, 7:197, was usedto build a model with exactly 10 genes as the input.

Assuming no technical or biological noise and ignoring sample sizeconsiderations, these genes best describe the inherent variabilitybetween inSIRS and ipSIRS samples when using an SVM model, and thereforeprovide the best available separation signature.

For each sample in the testing set, the model is used to predict eitherinSIRS or ipSIRS. If the prediction matches the clinical record for thissample, it is declared a correct prediction. The performance of themodel in this case is measured by accuracy, which can be expressed asthe percentage of correct predictions for the testing set.

Optionally, the building and testing step may be repeated with adifferent random testing and training set. This could be performed anynumber of times depending on the preferred implementation, and in oneexample is performed 100 times. If the accuracy of the model was notsignificantly better than the last 2 iterations (1 way ANOVAp-value >0.95), then the selection of biomarkers was terminated.

If the accuracy remained significantly better than either of the last 2iterations (as described above), then the 10 genes that were selected inthe model (or most frequently appear if repeated runs were used) arethen added to the collection of potentially useful biomarkers, and wereremoved from subsequent iterations.

The biomarker identification process described above and elsewhereherein has been used to identify 319 biomarker genes (hereafter referredto as “inflammatory response syndrome (IRS) biomarker genes”), which aresurrogate markers that are useful for assisting in distinguishing: (1)between SIRS affected subjects (i.e., subject having inSIRS or ipSIRS)and healthy subjects or subjects not affected by SIRS; (2) betweensubjects with inSIRS and subjects with ipSIRS; and/or (3) betweensubjects with different stages of ipSIRS (e.g., sepsis, severe sepsisand septic shock). Based on this identification, the present inventorshave developed various methods and kits, which take advantage of thesebiomarkers to determine the likelihood of the presence or absence of acondition selected from a healthy condition (e.g., a normal condition orone in which inSIRS and inSIRS are absent), SIRS generally (i.e., notdistinguishing between inSIRS or ipSIRS), inSIRS or ipSIRS, or to assessthe likelihood of the presence, absence or risk of development of astage of ipSIRS (e.g., a stage of ipSIRS with a particular severity,illustrative examples of which include mild sepsis, severe sepsis andseptic shock). In advantageous embodiments, the methods and kits involvemonitoring the expression of IRS biomarker genes in blood cells (e.g.,immune cells such as leukocytes), which may be reflected in changingpatterns of RNA levels or protein production that correlate with thepresence of active disease or response to disease.

As used herein, the term SIRS (“systemic inflammatory responsesyndrome”) refers to a clinical response arising from a non-specificinsult with two or more of the following measurable clinicalcharacteristics; a body temperature greater than 38° C. or less than 36°C., a heart rate greater than 90 beats per minute, a respiratory rategreater than 20 per minute, a white blood cell count (total leukocytes)greater than 12,000 per mm³ or less than 4,000 per mm³, or a bandneutrophil percentage greater than 10%. From an immunologicalperspective, it may be seen as representing a systemic response toinsult (e.g., major surgery) or systemic inflammation. As used herein,“inSIRS” includes the clinical response noted above but in the absenceof a systemic infectious process. By contrast, “ipSIRS” includes theclinical response noted above but in the presence of a presumed orconfirmed systemic infectious process. Confirmation of infectiousprocess can be determined using microbiological culture or isolation ofthe infectious agent. From an immunological perspective, ipSIRS may beseen as a systemic response to microorganisms be it local, peripheral ora systemic infection.

The terms “surrogate marker” and “biomarker” are used interchangeablyherein to refer to a parameter whose measurement (e.g., level, presenceor absence) provides information as to the state of a subject. Invarious exemplary embodiments, a plurality of biomarkers is used toassess a condition (e.g., healthy condition, SIRS, inSIRS, ipSIRS, or aparticular stage of ipSIRS). Measurements of the biomarkers may be usedalone or combined with other data obtained regarding a subject in orderto determine the state of the subject biomarker. In some embodiments,the biomarkers are “differentially present” in a sample taken from asubject of one phenotypic status (e.g., having a specified condition) ascompared with another phenotypic status (e.g., not having thecondition). A biomarker may be determined to be “differentially present”in a variety of ways, for example, between different phenotypic statusesif the presence or absence or mean or median level or concentration ofthe biomarker in the different groups is calculated to be statisticallysignificant. Common tests for statistical significance include, amongothers, t-test, ANOVA, Kruskal-Wallis, Wilcoxon, Mann-Whitney and oddsratio.

In some embodiments, the methods and kits involve: (1) correlating areference IRS biomarker profile with the presence or absence of acondition selected from a healthy condition, SIRS, inSIRS, ipSIRS, or aparticular stage of ipSIRS, wherein the reference IRS biomarker profileevaluates at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 etc.) IRSbiomarker; (2) obtaining an IRS biomarker profile of a sample (i.e., “asample IRS biomarker profile”) from a subject, wherein the sample IRSbiomarker profile evaluates for an individual IRS biomarker in thereference IRS biomarker profile a corresponding IRS biomarker; and (3)determining a likelihood of the subject having or not having thecondition based on the sample IRS biomarker profile and the referenceIRS biomarker profile.

As used herein, the term “profile” includes any set of data thatrepresents the distinctive features or characteristics associated with acondition of interest, such as with a particular prediction, diagnosisand/or prognosis of a specified condition as taught herein. The termgenerally encompasses quantification of one or more biomarkers interalia nucleic acid profiles, such as for example gene expression profiles(sets of gene expression data that represents the mRNA levels of one ormore genes associated with a condition of interest), as well as protein,polypeptide or peptide profiles, such as for example protein expressionprofiles (sets of protein expression data that represents the levels ofone or more proteins associated with a condition of interest), and anycombinations thereof.

Biomarker profiles may be created in a number of ways and may be thecombination of measurable biomarkers or aspects of biomarkers usingmethods such as ratios, or other more complex association methods oralgorithms (e.g., rule-based methods), as discussed for example in moredetail below. A biomarker profile comprises at least two measurements,where the measurements can correspond to the same or differentbiomarkers. Thus, for example, distinct reference profiles may representthe prediction of a risk (e.g., an abnormally elevated risk) of having aspecified condition as compared the prediction of no or normal risk ofhaving that condition. In another example, distinct reference profilesmay represent predictions of differing degrees of risk of having aspecified condition.

The terms “subject,” “individual” and “patient” are used interchangeablyherein to refer to any subject, particularly a vertebrate subject, andeven more particularly a mammalian subject. Suitable vertebrate animalsthat fall within the scope of the invention include, but are notrestricted to, any member of the subphylum Chordata including primates,rodents (e.g., mice rats, guinea pigs), lagomorphs (e.g., rabbits,hares), bovines (e.g., cattle), ovines (e.g., sheep), caprines (e.g.,goats), porcines (e.g., pigs), equines (e.g., horses), canines (e.g.,dogs), felines (e.g., cats), avians (e.g., chickens, turkeys, ducks,geese, companion birds such as canaries, budgerigars etc), marinemammals (e.g., dolphins, whales), reptiles (snakes, frogs, lizards,etc.), and fish. A preferred subject is a primate (e.g., a human, ape,monkey, chimpanzee).

IRS biomarkers are suitably expression products of IRS biomarker genes,including polynucleotide and polypeptide expression products. The term“gene” as used herein refers to any and all discrete coding regions ofthe cell's genome, as well as associated non-coding and regulatoryregions. The term “gene” is also intended to mean the open reading frameencoding specific polypeptides, introns, and adjacent 5′ and 3′non-coding nucleotide sequences involved in the regulation ofexpression. In this regard, the gene may further comprise controlsignals such as promoters, enhancers, termination and/or polyadenylationsignals that are naturally associated with a given gene, or heterologouscontrol signals. The DNA sequences may be cDNA or genomic DNA or afragment thereof. The gene may be introduced into an appropriate vectorfor extrachromosomal maintenance or for integration into the host.

As used herein, polynucleotide expression products of IRS biomarkergenes are referred to herein as “IRS biomarker polynucleotides.”Polypeptide expression products of the IRS biomarker genes are referredto herein as “IRS biomarker polypeptides.”

Suitably, individual IRS biomarker genes are selected from the groupconsisting of: TLR5; CD177; VNN1; UBE2J1; IMP3; RNASE2//LOC643332;CLEC4D; C3AR1; GPR56; ARG1; FCGR1A//FCGR1B//FCGR1C; C11orf82; FAR2;GNLY; GALNT3; OMG; SLC37A3; BMX//HNRPDL; STOM; TDRD9; KREMEN1; FAIM3;CLEC4E; IL18R1; ACER3; ERLIN1; TGFBR1; FKBP5//LOC285847; GPR84; C7orf53;PLB1; DSE; PTGDR; CAMK4; DNAJC13; TNFAIP6;FOXD4L3//FOXD4L6//FOXD4//FOXD4L1//FOXD4L2//FOXD4L4//FOXD4L5;MMP9//LOC100128028; GSR; KLRF1; SH2D1B; ANKRD34B; SGMS2; B3GNT5//MCF2L2;GK3P//GK; PFKFB2; PICALM; METTL7B; HIST1H4C; C9orf72; HIST1H3I; SLC15A2;TLR10; ADM; CD274; CRIP1; LRRN3; HLA-DPB1; VAMP2; SMPDL3A; IF116; JKAMP;MRPL41; SLC1A3; OLFM4; CASS4; TCN1; WSB2; CLU; ODZ1; KPNA5; PLAC8; CD63;HPSE; C1orf161; DDAH2; KLRK1//KLRC4; ATP13A3; ITK; PMAIP1; LOC284757;GOT2; PDGFC; B3GAT3; HIST1H4E; HPGD; FGFBP2; LRRC70//IPO11;TMEM144//LOC285505; CDS2; BPI; ECHDC3; CCR3; HSPC159; OLAH;PPP2R5A//SNORA16B; TMTC1; EAF2//HCG11//LOC647979; RCBTB2//LOC100131993;SEC24A//SAR1B; SH3PXD2B; HMGB2; KLRD1; CHI3L1; FRMD3; SLC39A9; GIMAP7;ANAPC11; EXOSC4; gene for IL-1beta-regulated neutrophil survival proteinas set forth in GenBank Accession No. AF234262; INSIG1; FOLR3//FOLR2;RUNX2; PRR13//PCBP2; HIST1H4L; LGALS1; CCR1; TPST1; HLA-DRA; CD163;FFAR2; PHOSPHO1; PPIF; MTHFS; DNAJC9//FAM149B1//RPL26; LCN2; EIF2AK2;LGALS2; SIAE; AP3B2; ABCA13; gene for transcript set forth in GenBankAccession No. AK098012; EFCAB2; HIST1H2AA; HINT1; HIST1H3J; CDA; SAP30;AGTRAP; SUCNR1; MTRR; PLA2G7; AIG1; PCOLCE2; GAB2; HS2ST1//UBA2;HIST1H3A; C22orf37; HLA-DPA1; VOPP1//LOC100128019; SLC39A8; MKI67;SLC11A1; AREG; ABCA1; DAAM2//LOC100131657; LTF; TREML1; GSTO1; PTGER2;CEACAM8; CLEC4A; PMS2CL//PMS2; REIN; PDE3B; SULF2; NEK6//LOC100129034;CENPK; TRAF3; GPR65; IRF4; MACF1; AMFR; RPL17//SNORD58B; IRS2; JUP;CD24; GALNT2; HSP90AB1//HSP90AB3P//HSP90AB2P; GLT25D1; OR9A2; HDHD1A;ACTA2; ACPL2; LRRFIP1; KCNMA1; OCR1; ITGA4//CERKL;EIF1AX//SCARNA9L//EIF1AP1; SFRS9; DPH3; ERGIC1; CD300A; NF-E4; MINPP1;TRIM21; ZNF28; NPCDR1; gene for protein FLJ21394 as set forth in GenBankAccession No. BC013935; gene for transcript set forth in GenBankAccession No. AK000992; ICAM1; TAF13; P4HA1//RPL17; C15orf54; KLHL5;HAL; DLEU2//DLEU2L; ANKRD28; LY6G5B//CSNK2B;KIAA1257//ACAD9//LOC100132731; MGST3; KIAA0746; HSPB1//HSPBL2; CCR4;TYMS; RRP12//LOC644215; CCDC125; HIST1H2BM; PDK4; ABCG1; IL1B; THBS1;ITGA2B; LHFP; LAIR1//LAIR2; HIST1H3B; ZRANB1; TIMM10; FSD1L//GARNL1;HIST1H2AJ//HIST1H2AI; PTGS1; gene for transcript set forth in GenBankAccession No. BC008667; UBE2F//C20orf194//SCLY; HIST1H3C; FAM118A;CCRL2; E2F6; MPZL3; SRXN1; CD151; HIST1H3H; FSD1L; RFESD//SPATA9; TPX2;S100B; ZNF587//ZNF417; PYHIN1; KIAA1324; CEACAM6//CEACAM5; APOLD1;FABP2; KDM6B//TMEM88;IGK@//IGKC//IGKV1-5//IGKV3D-11//IGKV3-20//IGKV3D-15//LOC440871//LOC652493//LOC100291464//LOC652694//IGKV3-15//LOC650405//LOC100291682;MYL9; HIST1H2BJ; TAAR1; CLC; CYP4F3//CYP4F2; CEP97; SON; IRF1; SYNE2;MME; LASS4; DEFA4//DEFA8P; C7orf58; DYNLL1; gene for transcript setforth in GenBank Accession No. AY461701; MPO; CPM; TSHZ2; PLIN2;FAM118B; B4GALT3; RASA4//RASA4P/RASA4B//POLR2J4//LOC100132214;CTSL1//CTSLL3; NP; ATF7; SPARC; PLB1; C4orf3; POLE2; TNFRSF17; FBXL13;PLEKHA3; TMEM62//SPCS2//LOC653566; RBP7; PLEKHF2; RGS2;ATP6V0D1//LOC100132855; RPIA; CAMK1D; IL1RL1; CMTM5; AIF1; CFD; MPZL2;LOC100128751; IGJ; CDC26; PPP1R2//PPP1R2P3; IL5RA; ARL17P1//ARL17;ATP5L//ATP5L2; TAS2R31; HIST2H2BF//HIST2H3D; CALM2//C2orf61; SPATA6;IGLV6-57; C1orf128; KRTAP15-1; IF144;IGL@//IGLV1-44//LOC96610//IGLV2-23//IGLC1//IGLV2-18//IGLV5-45//IGLV3-25//IGLV3-12//IGLV1-36//IGLV3-27//IGLV7-46//IGLV4-3//IGLV3-16//IGLV3-19//IGLV7-43//IGLV3-22//IGLV5-37//IGLV10-54//IGLV8-61//LOC651536;gene for transcript set forth in GenBank Accession No. BC034024; SDHC;NFXL1; GLDC; DCTN5; and KIAA0101//CSNK1G1.

As used herein, the term “likelihood” is used as a measure of whethersubjects with a particular IRS biomarker profile actually have acondition (or not) based on a given mathematical model. An increasedlikelihood for example may be relative or absolute and may be expressedqualitatively or quantitatively. For instance, an increased risk may beexpressed as simply determining the subject's level of a given IRSbiomarker and placing the test subject in an “increased risk” category,based upon previous population studies. Alternatively, a numericalexpression of the test subject's increased risk may be determined basedupon IRS biomarker level analysis.

As used herein, the term “probability” refers strictly to theprobability of class membership for a sample as determined by a givenmathematical model and is construed to be equivalent likelihood in thiscontext.

In some embodiments, likelihood is assessed by comparing the level orabundance of individual IRS biomarkers to one or more preselected orthreshold levels. Thresholds may be selected that provide an acceptableability to predict diagnosis, prognostic risk, treatment success, etc.In illustrative examples, receiver operating characteristic (ROC) curvesare calculated by plotting the value of a variable versus its relativefrequency in two populations in which a first population has a firstcondition or risk and a second population has a second condition or risk(called arbitrarily, for example, “healthy condition” and “SIRS,”“healthy condition” and “inSIRS,” “healthy condition” and “ipSIRS,”“inSIRS” and “ipSIRS,” “mild sepsis” and “severe sepsis,” “severesepsis” and “septic shock,” “mild sepsis” and “septic shock,” or “lowrisk” and “high risk”).

For any particular IRS biomarker, a distribution of IRS biomarker levelsfor subjects with and without a disease will likely overlap. Under suchconditions, a test does not absolutely distinguish a first condition anda second condition with 100% accuracy, and the area of overlap indicateswhere the test cannot distinguish the first condition and the secondcondition. A threshold is selected, above which (or below which,depending on how an IRS biomarker changes with a specified condition orprognosis) the test is considered to be “positive” and below which thetest is considered to be “negative.” The area under the ROC curve (AUC)provides the C-statistic, which is a measure of the probability that theperceived measurement will allow correct identification of a condition(see, e.g., Hanley et al., Radiology 143: 29-36 (1982).

Alternatively, or in addition, thresholds may be established byobtaining an earlier biomarker result from the same patient, to whichlater results may be compared. In these embodiments, the individual ineffect acts as their own “control group.” In biomarkers that increasewith condition severity or prognostic risk, an increase over time in thesame patient can indicate a worsening of the condition or a failure of atreatment regimen, while a decrease over time can indicate remission ofthe condition or success of a treatment regimen.

In some embodiments, a positive likelihood ratio, negative likelihoodratio, odds ratio, and/or AUC or receiver operating characteristic (ROC)values are used as a measure of a method's ability to predict risk or todiagnose a disease or condition. As used herein, the term “likelihoodratio” is the probability that a given test result would be observed ina subject with a condition of interest divided by the probability thatthat same result would be observed in a patient without the condition ofinterest. Thus, a positive likelihood ratio is the probability of apositive result observed in subjects with the specified conditiondivided by the probability of a positive results in subjects without thespecified condition. A negative likelihood ratio is the probability of anegative result in subjects without the specified condition divided bythe probability of a negative result in subjects with specifiedcondition. The term “odds ratio,” as used herein, refers to the ratio ofthe odds of an event occurring in one group (e.g., a healthy conditiongroup) to the odds of it occurring in another group (e.g., a SIRS group,an inSIRS group, an ipSIRS group, or a group with particular stage ofipSIRS), or to a data-based estimate of that ratio. The term “area underthe curve” or “AUC” refers to the area under the curve of a receiveroperating characteristic (ROC) curve, both of which are well known inthe art. AUC measures are useful for comparing the accuracy of aclassifier across the complete data range. Classifiers with a greaterAUC have a greater capacity to classify unknowns correctly between twogroups of interest (e.g., a healthy condition IRS biomarker profile anda SIRS, inSIRS, ipSIRS, or ipSIRS stage IRS biomarker profile). ROCcurves are useful for plotting the performance of a particular feature(e.g., any of the IRS biomarkers described herein and/or any item ofadditional biomedical information) in distinguishing or discriminatingbetween two populations (e.g., cases having a condition and controlswithout the condition). Typically, the feature data across the entirepopulation (e.g., the cases and controls) are sorted in ascending orderbased on the value of a single feature. Then, for each value for thatfeature, the true positive and false positive rates for the data arecalculated. The sensitivity is determined by counting the number ofcases above the value for that feature and then dividing by the totalnumber of cases. The specificity is determined by counting the number ofcontrols below the value for that feature and then dividing by the totalnumber of controls. Although this definition refers to scenarios inwhich a feature is elevated in cases compared to controls, thisdefinition also applies to scenarios in which a feature is lower incases compared to the controls (in such a scenario, samples below thevalue for that feature would be counted). ROC curves can be generatedfor a single feature as well as for other single outputs, for example, acombination of two or more features can be mathematically combined(e.g., added, subtracted, multiplied, etc.) to produce a single value,and this single value can be plotted in a ROC curve. Additionally, anycombination of multiple features, in which the combination derives asingle output value, can be plotted in a ROC curve. These combinationsof features may comprise a test. The ROC curve is the plot of thesensitivity of a test against the specificity of the test, wheresensitivity is traditionally presented on the vertical axis andspecificity is traditionally presented on the horizontal axis. Thus,“AUC ROC values” are equal to the probability that a classifier willrank a randomly chosen positive instance higher than a randomly chosennegative one. An AUC ROC value may be thought of as equivalent to theMann-Whitney U test, which tests for the median difference betweenscores obtained in the two groups considered if the groups are ofcontinuous data, or to the Wilcoxon test of ranks.

In some embodiments, at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,or more) IRS biomarker or a panel if IRS biomarkers is selected todiscriminate between subjects with a first condition and subjects with asecond condition with at least about 50%, 55% 60%, 65%, 70%, 75%, 80%,85%, 90%, 95% accuracy or having a C-statistic of at least about 0.50,0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95.

In the case of a positive likelihood ratio, a value of 1 indicates thata positive result is equally likely among subjects in both the“condition” and “control” groups; a value greater than 1 indicates thata positive result is more likely in the condition group; and a valueless than 1 indicates that a positive result is more likely in thecontrol group. In this context, “condition” is meant to refer to a grouphaving one characteristic (e.g., the presence of a healthy condition,SIRS, inSIRS, ipSIRS, or a particular stage of ipSIRS) and “control”group lacking the same characteristic. In the case of a negativelikelihood ratio, a value of 1 indicates that a negative result isequally likely among subjects in both the “condition” and “control”groups; a value greater than 1 indicates that a negative result is morelikely in the “condition” group; and a value less than 1 indicates thata negative result is more likely in the “control” group. In the case ofan odds ratio, a value of 1 indicates that a positive result is equallylikely among subjects in both the condition” and “control” groups; avalue greater than 1 indicates that a positive result is more likely inthe “condition” group; and a value less than 1 indicates that a positiveresult is more likely in the “control” group. In the case of an AUC ROCvalue, this is computed by numerical integration of the ROC curve. Therange of this value can be 0.5 to 1.0. A value of 0.5 indicates that aclassifier (e.g., a IRS biomarker profile) is no better than a 50%chance to classify unknowns correctly between two groups of interest,while 1.0 indicates the relatively best diagnostic accuracy. In certainembodiments, IRS biomarkers and/or IRS biomarker panels are selected toexhibit a positive or negative likelihood ratio of at least about 1.5 ormore or about 0.67 or less, at least about 2 or more or about 0.5 orless, at least about 5 or more or about 0.2 or less, at least about 10or more or about 0.1 or less, or at least about 20 or more or about 0.05or less.

In certain embodiments, IRS biomarkers and/or IRS biomarker panels areselected to exhibit an odds ratio of at least about 2 or more or about0.5 or less, at least about 3 or more or about 0.33 or less, at leastabout 4 or more or about 0.25 or less, at least about 5 or more or about0.2 or less, or at least about 10 or more or about 0.1 or less.

In certain embodiments, IRS biomarkers and/or IRS biomarker panels areselected to exhibit an AUC ROC value of greater than 0.5, preferably atleast 0.6, more preferably 0.7, still more preferably at least 0.8, evenmore preferably at least 0.9, and most preferably at least 0.95.

In some cases, multiple thresholds may be determined in so-called“tertile,” “quartile,” or “quintile” analyses. In these methods, the“diseased” and “control groups” (or “high risk” and “low risk”) groupsare considered together as a single population, and are divided into 3,4, or 5 (or more) “bins” having equal numbers of individuals. Theboundary between two of these “bins” may be considered “thresholds.” Arisk (of a particular diagnosis or prognosis for example) can beassigned based on which “bin” a test subject falls into.

In other embodiments, particular thresholds for the IRS biomarker(s)measured are not relied upon to determine if the biomarker level(s)obtained from a subject are correlated to a particular diagnosis orprognosis. For example, a temporal change in the biomarker(s) can beused to rule in or out one or more particular diagnoses and/orprognoses. Alternatively, IRS biomarker(s) are correlated to acondition, disease, prognosis, etc., by the presence or absence of oneor more IRS biomarkers in a particular assay format. In the case of IRSbiomarker panels, the present invention may utilize an evaluation of theentire profile of IRS biomarkers to provide a single result value (e.g.,a “panel response” value expressed either as a numeric score or as apercentage risk). In such embodiments, an increase, decrease, or otherchange (e.g., slope over time) in a certain subset of IRS biomarkers maybe sufficient to indicate a particular condition or future outcome inone patient, while an increase, decrease, or other change in a differentsubset of IRS biomarkers may be sufficient to indicate the same or adifferent condition or outcome in another patient.

In certain embodiments, a panel of IRS biomarkers is selected to assistin distinguishing a pair of groups (i.e., assist in assessing whether asubject has an increased likelihood of being in one group or the othergroup of the pair) selected from “healthy condition” and “SIRS,”“healthy condition” and “inSIRS,” “healthy condition” and “ipSIRS,”“inSIRS” and “ipSIRS,” “mild sepsis” and “severe sepsis,” “severesepsis” and “septic shock,” “mild sepsis” and “septic shock,” or “lowrisk” and “high risk” with at least about 70%, 80%, 85%, 90% or 95%sensitivity, suitably in combination with at least about 70% 80%, 85%,90% or 95% specificity. In some embodiments, both the sensitivity andspecificity are at least about 75%, 80%, 85%, 90% or 95%.

The phrases “assessing the likelihood” and “determining the likelihood,”as used herein, refer to methods by which the skilled artisan canpredict the presence or absence of a condition (e.g., a conditionselected from healthy condition, SIRS, inSIRS, ipSIRS, or a particularstage of ipSIRS) in a patient. The skilled artisan will understand thatthis phrase includes within its scope an increased probability that acondition is present or absence in a patient; that is, that a conditionis more likely to be present or absent in a subject. For example, theprobability that an individual identified as having a specifiedcondition actually has the condition may be expressed as a “positivepredictive value” or “PPV.” Positive predictive value can be calculatedas the number of true positives divided by the sum of the true positivesand false positives. PPV is determined by the characteristics of thepredictive methods of the present invention as well as the prevalence ofthe condition in the population analysed. The statistical algorithms canbe selected such that the positive predictive value in a populationhaving a condition prevalence is in the range of 70% to 99% and can be,for example, at least 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%,84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, or 99%.

In other examples, the probability that an individual identified as nothaving a specified condition actually does not have that condition maybe expressed as a “negative predictive value” or “NPV.” Negativepredictive value can be calculated as the number of true negativesdivided by the sum of the true negatives and false negatives. Negativepredictive value is determined by the characteristics of the diagnosticor prognostic method, system, or code as well as the prevalence of thedisease in the population analysed. The statistical methods and modelscan be selected such that the negative predictive value in a populationhaving a condition prevalence is in the range of about 70% to about 99%and can be, for example, at least about 70%, 75%, 76%, 77%, 78%, 79%,80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,94%, 95%, 96%, 97%, 98%, or 99%.

In some embodiments, a subject is determined as having a significantlikelihood of having or not having a specified condition. By“significant likelihood” is meant that the subject has a reasonableprobability (0.6, 0.7, 0.8, 0.9 or more) of having, or not having, aspecified condition.

The IRS biomarker analysis of the present invention permits thegeneration of high-density data sets that can be evaluated usinginformatics approaches. High data density informatics analytical methodsare known and software is available to those in the art, e.g., clusteranalysis (Pirouette, Informetrix), class prediction (SIMCA-P, Umetrics),principal components analysis of a computationally modeled dataset(SIMCA-P, Umetrics), 2D cluster analysis (GeneLinker Platinum, ImprovedOutcomes Software), and metabolic pathway analysis(biotech.icmb.utexas.edu). The choice of software packages offersspecific tools for questions of interest (Kennedy et al., Solving DataMining Problems Through Pattern Recognition. Indianapolis: Prentice HallPTR, 1997; Golub et al., (2999) Science 286:531-7; Eriksson et al.,Multi and Megavariate Analysis Principles and Applications: Umetrics,Umea, 2001). In general, any suitable mathematic analyses can be used toevaluate at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, et.) IRSbiomarker in an IRS biomarker profile with respect to a conditionselected from healthy condition, SIRS, inSIRS, ipSIRS, or a particularstage of ipSIRS. For example, methods such as multivariate analysis ofvariance, multivariate regression, and/or multiple regression can beused to determine relationships between dependent variables (e.g.,clinical measures) and independent variables (e.g., levels of IRSbiomarkers). Clustering, including both hierarchical andnon-hierarchical methods, as well as non-metric Dimensional Scaling canbe used to determine associations or relationships among variables andamong changes in those variables.

In addition, principal component analysis is a common way of reducingthe dimension of studies, and can be used to interpret thevariance-covariance structure of a data set. Principal components may beused in such applications as multiple regression and cluster analysis.Factor analysis is used to describe the covariance by constructing“hidden” variables from the observed variables. Factor analysis may beconsidered an extension of principal component analysis, where principalcomponent analysis is used as parameter estimation along with themaximum likelihood method. Furthermore, simple hypothesis such asequality of two vectors of means can be tested using Hotelling's Tsquared statistic.

In some embodiments, the data sets corresponding to IRS biomarkerprofiles are used to create a diagnostic or predictive rule or modelbased on the application of a statistical and machine learningalgorithm. Such an algorithm uses relationships between an IRS biomarkerprofile and a condition selected from healthy condition, SIRS, inSIRS,ipSIRS, or a particular stage of ipSIRS observed in control subjects ortypically cohorts of control subjects (sometimes referred to as trainingdata), which provides combined control or reference IRS biomarkerprofiles for comparison with IRS biomarker profiles of a subject. Thedata are used to infer relationships that are then used to predict thestatus of a subject, including the presence or absence of one of theconditions referred to above.

Practitioners skilled in the art of data analysis recognize that manydifferent forms of inferring relationships in the training data may beused without materially changing the present invention. The datapresented in the Tables and Examples herein has been used to generateillustrative minimal combinations of IRS biomarkers (models) thatdifferentiate between two conditions selected from healthy condition,SIRS, inSIRS, ipSIRS, or a particular stage of ipSIRS using featureselection based on AUC maximisation in combination with support vectormachine classification. Tables 1-15 provide illustrative lists of IRSbiomarkers ranked according to their p value and FIGS. 1-331 illustratethe ability of each IRS biomarker to distinguish between at least two ofthe conditions. Illustrative models comprising at least about 2 IRSbiomarkers were able to discriminate between two control groups asdefined above with significantly improved positive predictive valuescompared to conventional methodologies.

The term “correlating” generally refers to determining a relationshipbetween one type of data with another or with a state. In variousembodiments, correlating an IRS biomarker profile with the presence orabsence of a condition (e.g., a condition selected from a healthycondition, SIRS, inSIRS, ipSIRS, or a particular stage of ipSIRS)comprises determining the presence, absence or amount of at least oneIRS biomarker in a subject that suffers from that condition; or inpersons known to be free of that condition. In specific embodiments, aprofile of IRS biomarker levels, absences or presences is correlated toa global probability or a particular outcome, using receiver operatingcharacteristic (ROC) curves.

Thus, in some embodiments, evaluation of IRS biomarkers includesdetermining the levels of individual IRS biomarkers, which correlatewith the presence or absence of a condition, as defined above. Incertain embodiments, the techniques used for detection of IRS biomarkerswill include internal or external standards to permit quantitative orsemi-quantitative determination of those biomarkers, to thereby enable avalid comparison of the level of the IRS biomarkers in a biologicalsample with the corresponding IRS biomarkers in a reference sample orsamples. Such standards can be determined by the skilled practitionerusing standard protocols. In specific examples, absolute values for thelevel or functional activity of individual expression products aredetermined.

In semi-quantitative methods, a threshold or cut-off value is suitablydetermined, and is optionally a predetermined value. In particularembodiments, the threshold value is predetermined in the sense that itis fixed, for example, based on previous experience with the assayand/or a population of affected and/or unaffected subjects.Alternatively, the predetermined value can also indicate that the methodof arriving at the threshold is predetermined or fixed even if theparticular value varies among assays or may even be determined for everyassay run.

In some embodiments, the level of an IRS biomarker is normalized againsta housekeeping biomarker. The term “housekeeping biomarker” refers to abiomarker or group of biomarkers (e.g., polynucleotides and/orpolypeptides), which are typically found at a constant level in the celltype(s) being analysed and across the conditions being assessed. In someembodiments, the housekeeping biomarker is a “housekeeping gene.” A“housekeeping gene” refers herein to a gene or group of genes whichencode proteins whose activities are essential for the maintenance ofcell function and which are typically found at a constant level in thecell type(s) being analysed and across the conditions being assessed.

Generally, the levels of individual IRS biomarkers in an IRS biomarkerprofile are derived from a biological sample. The term “biologicalsample” as used herein refers to a sample that may be extracted,untreated, treated, diluted or concentrated from an animal. Thebiological sample is suitably a biological fluid such as whole blood,serum, plasma, saliva, urine, sweat, ascitic fluid, peritoneal fluid,synovial fluid, amniotic fluid, cerebrospinal fluid, tissue biopsy, andthe like. In certain embodiments, the biological sample contains blood,especially peripheral blood, or a fraction or extract thereof.Typically, the biological sample comprises blood cells such as mature,immature or developing leukocytes, including lymphocytes,polymorphonuclear leukocytes, neutrophils, monocytes, reticulocytes,basophils, coelomocytes, hemocytes, eosinophils, megakaryocytes,macrophages, dendritic cells natural killer cells, or fraction of suchcells (e.g., a nucleic acid or protein fraction). In specificembodiments, the biological sample comprises leukocytes includingperipheral blood mononuclear cells (PBMC).

The term “nucleic acid” or “polynucleotide” refers to a polymer,typically a heteropolymer, of nucleotides or the sequence of thesenucleotides from the 5′ to 3′ end of a nucleic acid molecule andincludes DNA or RNA molecules, illustrative examples of which includeRNA, mRNA, siRNA, miRNA, hpRNA, cRNA, cDNA or DNA. The term encompassesa polymeric form of nucleotides that is linear or branched, single ordouble stranded, or a hybrid thereof. The term also encompasses RNA/DNAhybrids. Nucleic acid sequences provided herein are presented herein inthe 5′ to 3′ direction, from left to right and are represented using thestandard code for representing the nucleotide characters as set forth inthe U.S. sequence rules, 37 CFR 1.821-1.825 and the World IntellectualProperty Organization (WIPO) Standard ST.25.

“Protein,” “polypeptide” and “peptide” are used interchangeably hereinto refer to a polymer of amino acid residues and to variants andsynthetic analogues of the same.

Suitably, the levels of individual IRS biomarkers in a reference IRSbiomarker profile are derived from IRS biomarker samples obtained fromone or more control subjects having that condition (e.g., “healthycontrol subjects,” “SIRS control subjects,” “inSIRS control subjects,”“ipSIRS control subjects,” “control subjects with a particular stage ofipSIRS,” illustrative examples of which include “mild sepsis controlsubjects,” “severe sepsis control subjects,” and “septic shock controlsubjects,” etc.), which are also referred to herein as control groups(e.g., “healthy control group,” “SIRS control group,” “inSIRS controlgroup,” “ipSIRS control group,” “ipSIRS stage group,” illustrativeexamples of which include “mild sepsis control group,” “severe sepsiscontrol group,” and “septic shock control group,” etc.). By “obtained”is meant to come into possession. Biological or reference samples soobtained include, for example, nucleic acid extracts or polypeptideextracts isolated or derived from a particular source. For instance, theextract may be isolated directly from a biological fluid or tissue of asubject.

As used herein the terms “level” and “amount” are used interchangeablyherein to refer to a quantitative amount (e.g., weight or moles), asemi-quantitative amount, a relative amount (e.g., weight % or mole %within class or a ratio), a concentration, and the like. Thus, theseterms encompasses absolute or relative amounts or concentrations of IRSbiomarkers in a sample, including ratios of levels of IRS biomarkers,and odds ratios of levels or ratios of odds ratios. IRS biomarker levelsin cohorts of subjects may be represented as mean levels and standarddeviations as shown in the Tables and Figures herein.

In some embodiments, the level of at least one (e.g., 1, 2, 3, 4, 5, 6,7, 8, 9, 10 etc.) IRS biomarker of the subject's sample IRS biomarkerprofile is compared to the level of a corresponding IRS biomarker in thereference IRS biomarker profile. By “corresponding IRS biomarker” ismeant an IRS biomarker that is structurally and/or functionally similarto a reference IRS biomarker. Representative corresponding IRSbiomarkers include expression products of allelic variants (same locus),homologs (different locus), and orthologs (different organism) ofreference IRS biomarker genes. Nucleic acid variants of reference IRSbiomarker genes and encoded IRS biomarker polynucleotide expressionproducts can contain nucleotide substitutions, deletions, inversionsand/or insertions. Variation can occur in either or both the coding andnon-coding regions. The variations can produce both conservative andnon-conservative amino acid substitutions (as compared in the encodedproduct). For nucleotide sequences, conservative variants include thosesequences that, because of the degeneracy of the genetic code, encodethe amino acid sequence of a reference IRS polypeptide.

Generally, variants of a particular IRS biomarker gene or polynucleotidewill have at least about 40%, 45%, 50%, 51%, 52%, 53%, 54%, 55%, 56%,57%, 58%, 59% 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69% 70%, 71%,72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%,86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% ormore sequence identity to that particular nucleotide sequence asdetermined by sequence alignment programs known in the art using defaultparameters. In some embodiments, the IRS biomarker gene orpolynucleotide displays at least about 40%, 45%, 50%, 51%, 52%, 53%,54%, 55%, 56%, 57%, 58%, 59% 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%,68%, 69% 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%,82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, 99% or more sequence identity to a nucleotide sequenceselected from any one of SEQ ID NO: 1-319.

Corresponding IRS biomarkers also include amino acid sequence thatdisplays substantial sequence similarity or identity to the amino acidsequence of a reference IRS biomarker polypeptide. In general, an aminoacid sequence that corresponds to a reference amino acid sequence willdisplay at least about 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61,62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79,80, 81, 82, 83, 84, 85, 86, 97, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98, 99% or even up to 100% sequence similarity or identity to areference amino acid sequence selected from any one of SEQ ID NO:320-619.

In some embodiments, calculations of sequence similarity or sequenceidentity between sequences are performed as follows:

To determine the percent identity of two amino acid sequences, or of twonucleic acid sequences, the sequences are aligned for optimal comparisonpurposes (e.g., gaps can be introduced in one or both of a first and asecond amino acid or nucleic acid sequence for optimal alignment andnon-homologous sequences can be disregarded for comparison purposes). Insome embodiments, the length of a reference sequence aligned forcomparison purposes is at least 30%, usually at least 40%, more usuallyat least 50%, 60%, and even more usually at least 70%, 80%, 90%, 100% ofthe length of the reference sequence. The amino acid residues ornucleotides at corresponding amino acid positions or nucleotidepositions are then compared. When a position in the first sequence isoccupied by the same amino acid residue or nucleotide at thecorresponding position in the second sequence, then the molecules areidentical at that position. For amino acid sequence comparison, when aposition in the first sequence is occupied by the same or similar aminoacid residue (i.e., conservative substitution) at the correspondingposition in the second sequence, then the molecules are similar at thatposition.

The percent identity between the two sequences is a function of thenumber of identical amino acid residues shared by the sequences atindividual positions, taking into account the number of gaps, and thelength of each gap, which need to be introduced for optimal alignment ofthe two sequences. By contrast, the percent similarity between the twosequences is a function of the number of identical and similar aminoacid residues shared by the sequences at individual positions, takinginto account the number of gaps, and the length of each gap, which needto be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity orpercent similarity between sequences can be accomplished using amathematical algorithm. In certain embodiments, the percent identity orsimilarity between amino acid sequences is determined using theNeedleman and Wunsch, (1970, J. Mol. Biol. 48: 444-453) algorithm whichhas been incorporated into the GAP program in the GCG software package(available at http://www.gcg.com), using either a Blossum 62 matrix or aPAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and alength weight of 1, 2, 3, 4, 5, or 6. In specific embodiments, thepercent identity between nucleotide sequences is determined using theGAP program in the GCG software package (available athttp://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. Annon-limiting set of parameters (and the one that should be used unlessotherwise specified) includes a Blossum 62 scoring matrix with a gappenalty of 12, a gap extend penalty of 4, and a frameshift gap penaltyof 5.

In some embodiments, the percent identity or similarity between aminoacid or nucleotide sequences can be determined using the algorithm of E.Meyers and W. Miller (1989, Cabios, 4: 11-17) which has beenincorporated into the ALIGN program (version 2.0), using a PAM120 weightresidue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences described herein can be used as a“query sequence” to perform a search against public databases to, forexample, identify other family members or related sequences. Suchsearches can be performed using the NBLAST and XBLAST programs (version2.0) of Altschul, et al., (1990, J. Mol. Biol, 215: 403-10). BLASTnucleotide searches can be performed with the NBLAST program, score=100,wordlength=12 to obtain nucleotide sequences homologous to 53010 nucleicacid molecules of the invention. BLAST protein searches can be performedwith the XBLAST program, score=50, wordlength=3 to obtain amino acidsequences homologous to 53010 protein molecules of the invention. Toobtain gapped alignments for comparison purposes, Gapped BLAST can beutilized as described in Altschul et al., (1997, Nucleic Acids Res, 25:3389-3402). When utilizing BLAST and Gapped BLAST programs, the defaultparameters of the respective programs (e.g., XBLAST and NBLAST) can beused.

Corresponding IRS biomarker polynucleotides also include nucleic acidsequences that hybridize to reference IRS biomarker polynucleotides, orto their complements, under stringency conditions described below. Asused herein, the term “hybridizes under low stringency, mediumstringency, high stringency, or very high stringency conditions”describes conditions for hybridization and washing. “Hybridization” isused herein to denote the pairing of complementary nucleotide sequencesto produce a DNA-DNA hybrid or a DNA-RNA hybrid. Complementary basesequences are those sequences that are related by the base-pairingrules. In DNA, A pairs with T and C pairs with G. In RNA, U pairs with Aand C pairs with G. In this regard, the terms “match” and “mismatch” asused herein refer to the hybridization potential of paired nucleotidesin complementary nucleic acid strands. Matched nucleotides hybridizeefficiently, such as the classical A-T and G-C base pair mentionedabove. Mismatches are other combinations of nucleotides that do nothybridize efficiently.

Guidance for performing hybridization reactions can be found in Ausubelet al., (1998, supra), Sections 6.3.1-6.3.6. Aqueous and non-aqueousmethods are described in that reference and either can be used.Reference herein to low stringency conditions include and encompass fromat least about 1% v/v to at least about 15% v/v formamide and from atleast about 1 M to at least about 2 M salt for hybridization at 42° C.,and at least about 1 M to at least about 2 M salt for washing at 42° C.Low stringency conditions also may include 1% Bovine Serum Albumin(BSA), 1 mM EDTA, 0.5 M NaHPO₄ (pH 7.2), 7% SDS for hybridization at 65°C., and (i) 2×SSC, 0.1% SDS; or (ii) 0.5% BSA, 1 mM EDTA, 40 mM NaHPO₄(pH 7.2), 5% SDS for washing at room temperature. One embodiment of lowstringency conditions includes hybridization in 6× sodiumchloride/sodium citrate (SSC) at about 45□□C, followed by two washes in0.2×SSC, 0.1% SDS at least at 50° C. (the temperature of the washes canbe increased to 55° C. for low stringency conditions). Medium stringencyconditions include and encompass from at least about 16% v/v to at leastabout 30% v/v formamide and from at least about 0.5 M to at least about0.9 M salt for hybridization at 42° C., and at least about 0.1 M to atleast about 0.2 M salt for washing at 55° C. Medium stringencyconditions also may include 1% Bovine Serum Albumin (BSA), 1 mM EDTA,0.5 M NaHPO₄ (pH 7.2), 7% SDS for hybridization at 65° C., and (i)2×SSC, 0.1% SDS; or (ii) 0.5% BSA, 1 mM EDTA, 40 mM NaHPO₄ (pH 7.2), 5%SDS for washing at 60-65° C. One embodiment of medium stringencyconditions includes hybridizing in 6×SSC at about 45□□C, followed by oneor more washes in 0.2×SSC, 0.1% SDS at 60° C. High stringency conditionsinclude and encompass from at least about 31% v/v to at least about 50%v/v formamide and from about 0.01 M to about 0.15 M salt forhybridization at 42° C., and about 0.01 M to about 0.02 M salt forwashing at 55° C. High stringency conditions also may include 1% BSA, 1mM EDTA, 0.5 M NaHPO₄ (pH 7.2), 7% SDS for hybridization at 65° C., and(i) 0.2×SSC, 0.1% SDS; or (ii) 0.5% BSA, 1 mM EDTA, 40 mM NaHPO₄ (pH7.2), 1% SDS for washing at a temperature in excess of 65° C. Oneembodiment of high stringency conditions includes hybridizing in 6×SSCat about 45□□C, followed by one or more washes in 0.2×SSC, 0.1% SDS at65° C.

In certain embodiments, a corresponding IRS biomarker polynucleotide isone that hybridizes to a disclosed nucleotide sequence under very highstringency conditions. One embodiment of very high stringency conditionsincludes hybridizing 0.5 M sodium phosphate, 7% SDS at 65° C., followedby one or more washes at 0.2×SSC, 1% SDS at 65° C.

Other stringency conditions are well known in the art and a skilledaddressee will recognize that various factors can be manipulated tooptimize the specificity of the hybridization. Optimization of thestringency of the final washes can serve to ensure a high degree ofhybridization. For detailed examples, see Ausubel et al., supra at pages2.10.1 to 2.10.16 and Sambrook et al. (1989, supra) at sections 1.101 to1.104.

Thus, in some embodiments, IRS biomarker levels in control groups asbroadly defined above and elsewhere herein are used to generate aprofile of IRS biomarker levels reflecting difference between levels intwo control groups as described above and elsewhere herein. Thus, aparticular IRS biomarker may be more abundant or less abundant in onecontrol group as compared to another control group. The data may berepresented as an overall signature score or the profile may berepresented as a barcode or other graphical representation to facilitateanalysis or diagnosis or determination of likelihood. The IRS biomarkerlevels from a test subject may be represented in the same way and thesimilarity with the signature score or level of “fit” to a signaturebarcode or other graphical representation may be determined. In otherembodiments, the levels of a particular IRS biomarker are analysed and adownward or an upward trend in IRS biomarker level determined.

In some embodiments, the individual level of an IRS biomarker in a firstcontrol group (e.g., a control group selected from healthy conditioncontrol group, SIRS control group, inSIRS control group, ipSIRS controlgroup, or ipSIRS stage control group) is at least 101%, 102%, 103%,104%, 105%, 106%, 107% 108%, 109%, 110%, 120%, 130%, 140%, 150%, 160%,170%, 180%, 190%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900% or1000% (i.e. an increased or higher level), or no more than about 99%,98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 80%, 70%, 60%, 50%, 40%,30%, 20%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.01%, 0.001% or 0.0001%(i.e. a decreased or lower level) of the level of a corresponding IRSbiomarker in a second control group (e.g., a control group selected fromhealthy condition control group, SIRS control group, inSIRS controlgroup, ipSIRS control group, or ipSIRS stage control group, illustrativeexamples of which include “mild sepsis control group, severe sepsiscontrol group, and septic shock control group, which is different fromthe first control group).

An IRS biomarker profile provides a compositional analysis (e.g.,concentration or mole percentage (%) of the IRS biomarker) in which twoor more, three or more, four or more, five or more, six or more, sevenor more, eight or more, nine or more, ten or more, twelve or more,fifteen or more, twenty or more, fifty or more, one-hundred or more or agreater number of IRS biomarkers are evaluated.

The IRS biomarker profile can be quantitative, semi-quantitative and/orqualitative. For example, the IRS biomarker profile can evaluate thepresence or absence of an IRS biomarker, can evaluate the presence of anIRS biomarker(s) above or below a particular threshold, and/or canevaluate the relative or absolute amount of an IRS biomarker(s). Inparticular embodiments, a ratio among two, three, four or more IRSbiomarkers is determined (see Example 6 and Tables 16-21 for examples ofthe use of 2-gene ratios in separating various inSIRS and ipSIRSconditions). Changes or perturbations in IRS biomarker ratios can beadvantageous in indicating where there are blocks (or releases of suchblocks) or other alterations in cellular pathways associated with an IRScondition, response to treatment, development of side effects, and thelike.

IRS biomarkers may be quantified or detected using any suitabletechnique including nucleic acid- and protein-based assays.

In illustrative nucleic acid-based assays, nucleic acid is isolated fromcells contained in the biological sample according to standardmethodologies (Sambrook, et al., 1989, supra; and Ausubel et al., 1994,supra). The nucleic acid is typically fractionated (e.g., poly A⁺ RNA)or whole cell RNA. Where RNA is used as the subject of detection, it maybe desired to convert the RNA to a complementary DNA. In someembodiments, the nucleic acid is amplified by a template-dependentnucleic acid amplification technique. A number of template dependentprocesses are available to amplify the IRS biomarker sequences presentin a given template sample. An exemplary nucleic acid amplificationtechnique is the polymerase chain reaction (referred to as PCR), whichis described in detail in U.S. Pat. Nos. 4,683,195, 4,683,202 and4,800,159, Ausubel et al. (supra), and in Innis et al., (“PCRProtocols”, Academic Press, Inc., San Diego Calif., 1990). Briefly, inPCR, two primer sequences are prepared that are complementary to regionson opposite complementary strands of the biomarker sequence. An excessof deoxynucleotide triphosphates are added to a reaction mixture alongwith a DNA polymerase, e.g., Taq polymerase. If a cognate IRS biomarkersequence is present in a sample, the primers will bind to the biomarkerand the polymerase will cause the primers to be extended along thebiomarker sequence by adding on nucleotides. By raising and lowering thetemperature of the reaction mixture, the extended primers willdissociate from the biomarker to form reaction products, excess primerswill bind to the biomarker and to the reaction products and the processis repeated. A reverse transcriptase PCR amplification procedure may beperformed in order to quantify the amount of mRNA amplified. Methods ofreverse transcribing RNA into cDNA are well known and described inSambrook et al., 1989, supra. Alternative methods for reversetranscription utilize thermostable, RNA-dependent DNA polymerases. Thesemethods are described in WO 90/07641. Polymerase chain reactionmethodologies are well known in the art.

In certain advantageous embodiments, the template-dependentamplification involves quantification of transcripts in real-time. Forexample, RNA or DNA may be quantified using the Real-Time PCR technique(Higuchi, 1992, et al., Biotechnology 10: 413-417). By determining theconcentration of the amplified products of the target DNA in PCRreactions that have completed the same number of cycles and are in theirlinear ranges, it is possible to determine the relative concentrationsof the specific target sequence in the original DNA mixture. If the DNAmixtures are cDNAs synthesized from RNAs isolated from different tissuesor cells, the relative abundance of the specific mRNA from which thetarget sequence was derived can be determined for the respective tissuesor cells. This direct proportionality between the concentration of thePCR products and the relative mRNA abundance is only true in the linearrange of the PCR reaction. The final concentration of the target DNA inthe plateau portion of the curve is determined by the availability ofreagents in the reaction mix and is independent of the originalconcentration of target DNA. In specific embodiments, multiplexed,tandem PCR (MT-PCR) is employed, which uses a two-step process for geneexpression profiling from small quantities of RNA or DNA, as describedfor example in US Pat. Appl. Pub. No. 20070190540. In the first step,RNA is converted into cDNA and amplified using multiplexed gene specificprimers. In the second step each individual gene is quantitated by realtime PCR.

In certain embodiments, target nucleic acids are quantified usingblotting techniques, which are well known to those of skill in the art.Southern blotting involves the use of DNA as a target, whereas Northernblotting involves the use of RNA as a target. Each provides differenttypes of information, although cDNA blotting is analogous, in manyaspects, to blotting or RNA species. Briefly, a probe is used to targeta DNA or RNA species that has been immobilized on a suitable matrix,often a filter of nitrocellulose. The different species should bespatially separated to facilitate analysis. This often is accomplishedby gel electrophoresis of nucleic acid species followed by “blotting” onto the filter. Subsequently, the blotted target is incubated with aprobe (usually labelled) under conditions that promote denaturation andrehybridisation. Because the probe is designed to base pair with thetarget, the probe will bind a portion of the target sequence underrenaturing conditions. Unbound probe is then removed, and detection isaccomplished as described above. Following detection/quantification, onemay compare the results seen in a given subject with a control reactionor a statistically significant reference group or population of controlsubjects as defined herein. In this way, it is possible to correlate theamount of a IRS biomarker nucleic acid detected with the progression orseverity of the disease.

Also contemplated are biochip-based technologies such as those describedby Hacia et al. (1996, Nature Genetics 14: 441-447) and Shoemaker et al.(1996, Nature Genetics 14: 450-456). Briefly, these techniques involvequantitative methods for analysing large numbers of genes rapidly andaccurately. By tagging genes with oligonucleotides or using fixed probearrays, one can employ biochip technology to segregate target moleculesas high-density arrays and screen these molecules on the basis ofhybridization. See also Pease et al. (1994, Proc. Natl. Acad. Sci.U.S.A. 91: 5022-5026); Fodor et al. (1991, Science 251: 767-773).Briefly, nucleic acid probes to IRS biomarker polynucleotides are madeand attached to biochips to be used in screening and diagnostic methods,as outlined herein. The nucleic acid probes attached to the biochip aredesigned to be substantially complementary to specific expressed IRSbiomarker nucleic acids, i.e., the target sequence (either the targetsequence of the sample or to other probe sequences, for example insandwich assays), such that hybridization of the target sequence and theprobes of the present invention occur. This complementarity need not beperfect; there may be any number of base pair mismatches, which willinterfere with hybridization between the target sequence and the nucleicacid probes of the present invention. However, if the number ofmismatches is so great that no hybridization can occur under even theleast stringent of hybridization conditions, the sequence is not acomplementary target sequence. In certain embodiments, more than oneprobe per sequence is used, with either overlapping probes or probes todifferent sections of the target being used. That is, two, three, fouror more probes, with three being desirable, are used to build in aredundancy for a particular target. The probes can be overlapping (i.e.have some sequence in common), or separate.

In an illustrative biochip analysis, oligonucleotide probes on thebiochip are exposed to or contacted with a nucleic acid sample suspectedof containing one or more IRS biomarker polynucleotides under conditionsfavouring specific hybridization. Sample extracts of DNA or RNA, eithersingle or double-stranded, may be prepared from fluid suspensions ofbiological materials, or by grinding biological materials, or followinga cell lysis step which includes, but is not limited to, lysis effectedby treatment with SDS (or other detergents), osmotic shock, guanidiniumisothiocyanate and lysozyme. Suitable DNA, which may be used in themethod of the invention, includes cDNA. Such DNA may be prepared by anyone of a number of commonly used protocols as for example described inAusubel, et al., 1994, supra, and Sambrook, et al., et al., 1989, supra.

Suitable RNA, which may be used in the method of the invention, includesmessenger RNA, complementary RNA transcribed from DNA (cRNA) or genomicor subgenomic RNA. Such RNA may be prepared using standard protocols asfor example described in the relevant sections of Ausubel, et al. 1994,supra and Sambrook, et al. 1989, supra).

cDNA may be fragmented, for example, by sonication or by treatment withrestriction endonucleases. Suitably, cDNA is fragmented such thatresultant DNA fragments are of a length greater than the length of theimmobilized oligonucleotide probe(s) but small enough to allow rapidaccess thereto under suitable hybridization conditions. Alternatively,fragments of cDNA may be selected and amplified using a suitablenucleotide amplification technique, as described for example above,involving appropriate random or specific primers.

Usually the target IRS biomarker polynucleotides are detectably labelledso that their hybridization to individual probes can be determined. Thetarget polynucleotides are typically detectably labelled with a reportermolecule illustrative examples of which include chromogens, catalysts,enzymes, fluorochromes, chemiluminescent molecules, bioluminescentmolecules, lanthanide ions (e.g., Eu³⁴), a radioisotope and a directvisual label. In the case of a direct visual label, use may be made of acolloidal metallic or non-metallic particle, a dye particle, an enzymeor a substrate, an organic polymer, a latex particle, a liposome, orother vesicle containing a signal producing substance and the like.Illustrative labels of this type include large colloids, for example,metal colloids such as those from gold, selenium, silver, tin andtitanium oxide. In some embodiments in which an enzyme is used as adirect visual label, biotinylated bases are incorporated into a targetpolynucleotide.

The hybrid-forming step can be performed under suitable conditions forhybridizing oligonucleotide probes to test nucleic acid including DNA orRNA. In this regard, reference may be made, for example, to NUCLEIC ACIDHYBRIDIZATION, A PRACTICAL APPROACH (Homes and Higgins, eds.) (IRLpress, Washington D.C., 1985). In general, whether hybridization takesplace is influenced by the length of the oligonucleotide probe and thepolynucleotide sequence under test, the pH, the temperature, theconcentration of mono- and divalent cations, the proportion of G and Cnucleotides in the hybrid-forming region, the viscosity of the mediumand the possible presence of denaturants. Such variables also influencethe time required for hybridization. The preferred conditions willtherefore depend upon the particular application. Such empiricalconditions, however, can be routinely determined without undueexperimentation.

After the hybrid-forming step, the probes are washed to remove anyunbound nucleic acid with a hybridization buffer. This washing stepleaves only bound target polynucleotides. The probes are then examinedto identify which probes have hybridized to a target polynucleotide.

The hybridization reactions are then detected to determine which of theprobes has hybridized to a corresponding target sequence. Depending onthe nature of the reporter molecule associated with a targetpolynucleotide, a signal may be instrumentally detected by irradiating afluorescent label with light and detecting fluorescence in afluorimeter; by providing for an enzyme system to produce a dye whichcould be detected using a spectrophotometer; or detection of a dyeparticle or a coloured colloidal metallic or non metallic particle usinga reflectometer; in the case of using a radioactive label orchemiluminescent molecule employing a radiation counter orautoradiography. Accordingly, a detection means may be adapted to detector scan light associated with the label which light may includefluorescent, luminescent, focussed beam or laser light. In such a case,a charge couple device (CCD) or a photocell can be used to scan foremission of light from a probe:target polynucleotide hybrid from eachlocation in the micro-array and record the data directly in a digitalcomputer. In some cases, electronic detection of the signal may not benecessary. For example, with enzymatically generated colour spotsassociated with nucleic acid array format, visual examination of thearray will allow interpretation of the pattern on the array. In the caseof a nucleic acid array, the detection means is suitably interfaced withpattern recognition software to convert the pattern of signals from thearray into a plain language genetic profile. In certain embodiments,oligonucleotide probes specific for different IRS biomarkerpolynucleotides are in the form of a nucleic acid array and detection ofa signal generated from a reporter molecule on the array is performedusing a ‘chip reader’. A detection system that can be used by a ‘chipreader’ is described for example by Pirrung et al (U.S. Pat. No.5,143,854). The chip reader will typically also incorporate some signalprocessing to determine whether the signal at a particular arrayposition or feature is a true positive or maybe a spurious signal.Exemplary chip readers are described for example by Fodor et al (U.S.Pat. No. 5,925,525). Alternatively, when the array is made using amixture of individually addressable kinds of labelled microbeads, thereaction may be detected using flow cytometry.

In other embodiments, IRS biomarker protein levels are assayed usingprotein-based assays known in the art. For example, when an IRSbiomarker protein is an enzyme, the protein can be quantified based uponits catalytic activity or based upon the number of molecules of theprotein contained in a sample. Antibody-based techniques may be employedincluding, for example, immunoassays, such as the enzyme-linkedimmunosorbent assay (ELISA) and the radioimmunoassay (RIA).

In specific embodiments, protein-capture arrays that permit simultaneousdetection and/or quantification of a large number of proteins areemployed. For example, low-density protein arrays on filter membranes,such as the universal protein array system (Ge, 2000 Nucleic Acids Res.28(2):e3) allow imaging of arrayed antigens using standard ELISAtechniques and a scanning charge-coupled device (CCD) detector.Immuno-sensor arrays have also been developed that enable thesimultaneous detection of clinical analytes. It is now possible usingprotein arrays, to profile protein expression in bodily fluids, such asin sera of healthy or diseased subjects, as well as in subjects pre- andpost-drug treatment.

Exemplary protein capture arrays include arrays comprising spatiallyaddressed antigen-binding molecules, commonly referred to as antibodyarrays, which can facilitate extensive parallel analysis of numerousproteins defining a proteome or subproteome. Antibody arrays have beenshown to have the required properties of specificity and acceptablebackground, and some are available commercially (e.g., BD Biosciences,Clontech, BioRad and Sigma). Various methods for the preparation ofantibody arrays have been reported (see, e.g., Lopez et al., 2003 J.Chromatogr. B 787:19-27; Cahill, 2000 Trends in Biotechnology 7:47-51;U.S. Pat. App. Pub. 2002/0055186; U.S. Pat. App. Pub. 2003/0003599; PCTpublication WO 03/062444; PCT publication WO 03/077851; PCT publicationWO 02/59601; PCT publication WO 02/39120; PCT publication WO 01/79849;PCT publication WO 99/39210). The antigen-binding molecules of sucharrays may recognise at least a subset of proteins expressed by a cellor population of cells, illustrative examples of which include growthfactor receptors, hormone receptors, neurotransmitter receptors,catecholamine receptors, amino acid derivative receptors, cytokinereceptors, extracellular matrix receptors, antibodies, lectins,cytokines, serpins, proteases, kinases, phosphatases, ras-like GTPases,hydrolases, steroid hormone receptors, transcription factors, heat-shocktranscription factors, DNA-binding proteins, zinc-finger proteins,leucine-zipper proteins, homeodomain proteins, intracellular signaltransduction modulators and effectors, apoptosis-related factors, DNAsynthesis factors, DNA repair factors, DNA recombination factors andcell-surface antigens.

Individual spatially distinct protein-capture agents are typicallyattached to a support surface, which is generally planar or contoured.Common physical supports include glass slides, silicon, microwells,nitrocellulose or PVDF membranes, and magnetic and other microbeads.

Particles in suspension can also be used as the basis of arrays,providing they are coded for identification; systems include colourcoding for microbeads (e.g., available from Luminex, Bio-Rad andNanomics Biosystems) and semiconductor nanocrystals (e.g., QDots™,available from Quantum Dots), and barcoding for beads (UltraPlex™,available from Smartbeads) and multimetal microrods (Nanobarcodes™particles, available from Surromed). Beads can also be assembled intoplanar arrays on semiconductor chips (e.g., available from LEAPStechnology and BioArray Solutions). Where particles are used, individualprotein-capture agents are typically attached to an individual particleto provide the spatial definition or separation of the array. Theparticles may then be assayed separately, but in parallel, in acompartmentalized way, for example in the wells of a microtiter plate orin separate test tubes.

In operation, a protein sample, which is optionally fragmented to formpeptide fragments (see, e.g., U.S. Pat. App. Pub. 2002/0055186), isdelivered to a protein-capture array under conditions suitable forprotein or peptide binding, and the array is washed to remove unbound ornon-specifically bound components of the sample from the array. Next,the presence or amount of protein or peptide bound to each feature ofthe array is detected using a suitable detection system. The amount ofprotein bound to a feature of the array may be determined relative tothe amount of a second protein bound to a second feature of the array.In certain embodiments, the amount of the second protein in the sampleis already known or known to be invariant.

For analysing differential expression of proteins between two cells orcell populations, a protein sample of a first cell or population ofcells is delivered to the array under conditions suitable for proteinbinding. In an analogous manner, a protein sample of a second cell orpopulation of cells to a second array is delivered to a second arraythat is identical to the first array. Both arrays are then washed toremove unbound or non-specifically bound components of the sample fromthe arrays. In a final step, the amounts of protein remaining bound tothe features of the first array are compared to the amounts of proteinremaining bound to the corresponding features of the second array. Todetermine the differential protein expression pattern of the two cellsor populations of cells, the amount of protein bound to individualfeatures of the first array is subtracted from the amount of proteinbound to the corresponding features of the second array.

All the essential materials and reagents required for detecting andquantifying IRS biomarker expression products may be assembled togetherin a kit, which is encompassed by the present invention. The kits mayalso optionally include appropriate reagents for detection of labels,positive and negative controls, washing solutions, blotting membranes,microtiter plates dilution buffers and the like. For example, a nucleicacid-based detection kit may include (i) an IRS biomarker polynucleotide(which may be used as a positive control), (ii) a primer or probe thatspecifically hybridizes to an IRS biomarker polynucleotide. Alsoincluded may be enzymes suitable for amplifying nucleic acids includingvarious polymerases (Reverse Transcriptase, Taq, Sequenase™, DNA ligaseetc. depending on the nucleic acid amplification technique employed),deoxynucleotides and buffers to provide the necessary reaction mixturefor amplification. Such kits also generally will comprise, in suitablemeans, distinct containers for each individual reagent and enzyme aswell as for each primer or probe. Alternatively, a protein-baseddetection kit may include (i) an IRS biomarker polypeptide (which may beused as a positive control), (ii) an antibody that binds specifically toan IRS biomarker polypeptide. The kit can also feature various devices(e.g., one or more) and reagents (e.g., one or more) for performing oneof the assays described herein; and/or printed instructions for usingthe kit to quantify the expression of an IRS biomarker gene.

In some embodiments, the methods and kits comprise or enable: comparingthe level of at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 etc.) IRSbiomarker in the subject's sample IRS profile to the level of acorresponding IRS biomarker in a reference IRS biomarker profile from atleast one control subject or group selected from a healthy controlsubject or group (hereafter referred to as a “reference healthy IRSbiomarker profile”), a SIRS control subject or group (hereafter referredto as a “reference SIRS IRS biomarker profile”), an inSIRS controlsubject or group (hereafter referred to as a “reference inSIRS IRSbiomarker profile”), an ipSIRS control subject or group (hereafterreferred to as a “reference ipSIRS IRS biomarker profile”) and a controlsubject or group with a particular stage of ipSIRS (hereafter referredto as a “reference ipSIRS stage IRS biomarker profile”), wherein asimilarity between the level of the at least one IRS biomarker in thesample IRS biomarker profile and the level of the corresponding IRSbiomarker in the reference healthy IRS biomarker profile identifies thatthe subject has an IRS biomarker profile that correlates with thepresence of a healthy condition, or alternatively the absence of inSIRS,ipSIRS, or a particular stage of ipSIRS, wherein a similarity betweenthe level of the at least one IRS biomarker in the sample IRS biomarkerprofile and the level of the corresponding IRS biomarker in the SIRS IRSbiomarker profile identifies that the subject has an IRS biomarkerprofile that correlates with the presence of inSIRS or ipSIRS, oralternatively the absence of a healthy condition, wherein a similaritybetween the level of the at least one IRS biomarker in the sample IRSbiomarker profile and the level of the corresponding IRS biomarker inthe inSIRS IRS biomarker profile identifies that the subject has an IRSbiomarker profile that correlates with the presence of inSIRS, oralternatively the absence of a healthy condition, ipSIRS, or aparticular stage of ipSIRS, wherein a similarity between the level ofthe at least one IRS biomarker in the sample IRS biomarker profile andthe level of the corresponding IRS biomarker in the ipSIRS IRS biomarkerprofile identifies that the subject has an IRS biomarker profile thatcorrelates with the presence of ipSIRS, or alternatively the absence ofa healthy condition or inSIRS, and wherein a similarity between thelevel of the at least one IRS biomarker in the sample IRS biomarkerprofile and the level of the corresponding IRS biomarker in the ipSIRSstage IRS biomarker profile identifies that the subject has an IRSbiomarker profile that correlates with the presence of a particularstage of ipSIRS, or alternatively the absence of a healthy condition orinSIRS.

A subset of the instantly disclosed IRS biomarkers has been identifiedas being useful for assisting in distinguishing between healthy subjectsand unhealthy subjects that have SIRS (i.e., sick subjects with eitherinSIRS or ipSIRS). Thus, in some embodiments, the methods and kitsinvolve determining the likelihood that SIRS or a healthy condition(e.g., a normal condition or a condition in which SIRS is absent) ispresent or absent in a subject. These methods and kits generallycomprise or involve: 1) providing a correlation of a reference IRSbiomarker profile with the presence or absence of SIRS or the healthycondition, wherein the reference biomarker profile evaluates at leastone (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 etc.) IRS biomarker selectedfrom CD177, CLEC4D, BMX, VNN1, GPR84, ARG1, IL18R1, ERLIN1, IMP3, TLR5,UBE2J1, GPR56, FCGR1A, SLC1A3, SLC37A3, FAIM3, C3AR1, RNASE2, TNFAIP6,GNLY, OMG, FAR2, OLAH, CAMK4, METTL7B, B3GNT5, CLEC4E, MMP9, KREMEN1,GALNT3, PTGDR, TDRD9, GK3P, FKBP5, STOM, SMPDL3A, PFKFB2, ANKRD34B,SGMS2, DNAJC13, LRRN3, SH2D1B, C1orf161, HIST1H4C, IFI16, ACER3, PLB1,C9orf72, HMGB2, KLRK1, C7orf53, GOT2, TCN1, DSE, CCR3, CRIP1, ITK,KLRF1, TGFBR1, GSR, HIST1H4E, HPGD, FRMD3, ABCA13, C11orf82, PPP2R5A,BPI, CASS4, AP3B2, ODZ1, TMTC1, ADM, FGFBP2, HSPC159, HLA-DRA, HIST1H3I,TMEM144, MRPL41, FOLR3, PICALM, SH3PXD2B, DDAH2, HLA-DPB1, KPNA5,PHOSPHO1, TPST1, EIF2AK2, OR9A2, OLFM4, CD163, CDA, CHI3L1, MTHFS, CLU,ANAPC11, JUP, PMAIP1, GIMAP7, KLRD1, CCR1, CD274, EFCAB2, SUCNR1,KCNMA1, LGALS2, SLC11A1, FOXD4L3, VAMP2, ITGA4, LHFP, PRR13, FFAR2,B3GAT3, EAF2, HPSE, CLC, TLR10, CCR4, HIST1H3A, CENPK, DPH3, HLA-DPA1,ATP13A3, DNAJC9, S100B, HIST1H3J, 110, RPL17, C15orf54, LRRC70, IL5RA,PLA2G7, ECHDC3, HINT1, LCN2, PPIF, SLC15A2, PMS2CL, HIST1H2AA, CEACAM8,HSP90AB1, ABCG1, PDGFC, NPCDR1, PDK4, GAB2, WSB2, FAM118A, JKAMP,TREML1, PYHIN1, IRF4, ABCA1, DAAM2, ACPL2, RCBTB2, SAP30, THBS1,PCOLCE2, GPR65, NF-E4, LTF, LASS4, B4GALT3, RETN, TIMM10, IL1B, CLEC4A,SEC24A, RUNX2, LRRFIP1, CFD, EIF1AX, ZRANB1, SULF2, EXOSC4, CCDC125,LOC284757, ANKRD28, HIST1H2AJ, CD63, PLIN2, SON, HIST1H4L, KRTAP15-1,DLEU2, MYL9, FABP2, CD24, MACF1, GSTO1, RRP12, AIG1, RASA4, FBXL13,PDE3B, CCRL2, C1orf128, E2F6, IL1RL1, CEACAM6, CYP4F3, 199, TAAR1,TSHZ2, PLB1, UBE2F (where if a gene name is not provided then a SEQ IDNO. is provided); (2) obtaining a sample IRS biomarker profile from thesubject, which evaluates for an individual IRS biomarker in thereference IRS biomarker profile a corresponding IRS biomarker, and (3)determining a likelihood of the subject having or not having the healthycondition or SIRS based on the sample IRS biomarker profile and thereference IRS biomarker profile.

In illustrative examples of this type, a reference healthy condition IRSbiomarker profile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8,9, 10 etc.) IRS biomarker that is downregulated or underexpressedrelative to a reference SIRS IRS biomarker profile, illustrativeexamples of which include: GNLY, GPR56, KLRF1, HIST1H2AJ, HIST1H4C,KLRK1, CHI3L1, SH2D1B, PTGDR, CAMK4, FAIM3, CRIP1, CLC, HLA-DPB1,FGFBP2, HIST1H3J, IMP3, ITK, HIST1H3I, LRRN3, KLRD1, PHOSPHO1, CCR3,HIST1H4E, MRPL41, HIST1H3A, HLA-DRA, GIMAP7, KPNA5, CENPK, HLA-DPA1,HINT1, HIST1H4L, GOT2, DNAJC9, PLA2G7, CASS4, CFD, ITGA4, HSP90AB1,IL5RA, PMAIP1, LGALS2, SULF2, C1orf128, RPL17, EIF1AX, PYHIN1, S100B,PMS2CL, CCR4, C15orf54, VAMP2, ANAPC11, B3GAT3, E2F6, NPCDR1, FAM118A,PPIF, 199, JUP, B4GALT3, TIMM10, RUNX2, RASA4, SON, ABCG1, TSHZ2, IRF4,PDE3B, RRP12, LASS4 (where if a gene name is not provided then a SEQ IDNO. is provided). is provided).

In other illustrative examples, a reference healthy condition IRSbiomarker profile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8,9, 10 etc.) IRS biomarker that is upregulated or overexpressed relativeto a reference SIRS IRS biomarker profile, non-limiting examples ofwhich include: CD177, ARG1, VNN1, CLEC4D, GPR84, IL18R1, OLFM4, FCGR1A,RNASE2, TLR5, TNFAIP6, PFKFB2, C3AR1, TCN1, BMX, FKBP5, TDRD9, OLAH,ERLIN1, LCN2, MMP9, BPI, CEACAM8, CLEC4E, HPGD, CD274, GK3P, KREMEN1,ANKRD34B, SLC37A3, CD163, TMTC1, PLB1, UBE2J1, TPST1, B3GNT5, SMPDL3A,FAR2, ACER3, ODZ1, HMGB2, LTF, SGMS2, EIF2AK2, TMEM144, GALNT3, DNAJC13,IFI16, C11orf82, ABCA13, CD24, METTL7B, FOLR3, C7orf53, SLC1A3, DAAM2,HSPC159, OMG, CCR1, TREML1, STOM, CEACAM6, FOXD4L3, C9orf72, GSR, DSE,THBS1, SH3PXD2B, PDGFC, KCNMA1, PICALM, TLR10, PDK4, ADM, CLU, C1orf161,NF-E4, HPSE, FFAR2, PPP2R5A, CDA, NA, ATP13A3, ABCA1, TGFBR1, OR9A2,EFCAB2, EAF2, AP3B2, SLC15A2, ECHDC3, MTHFS, IL1B, WSB2, SUCNR1, DDAH2,CLEC4A, MACF1, MYL9, IL1RL1, EXOSC4, FBXL13, LOC284757, PRR13, DPH3,SLC11A1, FRMD3, ACPL2, PLB1, RETN, RCBTB2, CD63, CYP4F3, SEC24A, ZRANB1,CCDC125, PCOLCE2, JKAMP, LRRFIP1, GPR65, ANKRD28, LRRC70, AIG1, UBE2F,GAB2, CCRL2, SAP30, DLEU2, HIST1H2AA, GSTO1, PLIN2, LHFP, KRTAP15-1,TAAR1, FABP2 (where if a gene name is not provided then a SEQ ID NO. isprovided).

In still other illustrative examples, a reference healthy condition IRSbiomarker profile comprises: (1) at least one IRS biomarker that isdownregulated or underexpressed relative to a reference SIRS IRSbiomarker profile, as broadly described above and (2) at least one IRSbiomarker that is upregulated or overexpressed relative to a referenceSIRS IRS biomarker profile, as broadly described above.

The term “upregulated,” “overexpressed” and the like refer to an upwarddeviation in the level of expression of an IRS biomarker as compared toa baseline expression level of a corresponding IRS biomarker in acontrol sample.

The term “downregulated,” “underexpressed” and the like refer to adownward deviation in the level of expression of an IRS biomarker ascompared to a baseline expression level of a corresponding IRS biomarkerin a control sample.

Another subset of the instantly disclosed IRS biomarkers has beenidentified as being useful for assisting in distinguishing betweenhealthy subjects, inSIRS affected subjects and subjects having ipSIRS.Accordingly, in some embodiments, the methods and kits are useful fordetermining the likelihood that inSIRS, ipSIRS or a healthy condition(e.g., a normal condition or a condition in which SIRS is absent) ispresent or absent in a subject. These methods and kits generallycomprise or involve: 1) providing a correlation of a reference IRSbiomarker profile with the likelihood of having or not having inSIRS,ipSIRS or the healthy condition, wherein the reference biomarker profileevaluates at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 etc.) IRSbiomarker selected from PLAC8, 132, INSIG1, CDS2, VOPP1, SLC39A9,B3GAT3, CD300A, OCR1, PTGER2, LGALS1, HIST1H4L, AMFR, SIAE, SLC39A8,TGFBR1, GAB2, MRPL41, TYMS, HIST1H3B, MPZL3, KIAA1257, OMG, HIST1H2BM,TDRD9, C22orf37, GALNT3, SYNE2, MGST3, HIST1H3I, LOC284757, TRAF3,HIST1H3C, STOM, C3AR1, KIAA0101, TNFRSF17, HAL, UBE2J1, GLT25D1, CD151,HSPB1, IMP3, PICALM, ACER3, IGL@, HIST1H2BJ, CASS4, KREMEN1, IRS2,APOLD1, RBP7, DNAJC13, ERGIC1, FSD1L, TLR5, TMEM62, SDHC, C9orf72, NP,KIAA0746, PMAIP1, DSE, SMPDL3A, DNAJC9, HIST1H3H, CDC26, CRIP1, FAR2,FRMD3, RGS2, METTL7B, CLEC4E, MME, ABCA13, PRR13, HIST1H4C, RRP12, GLDC,ECHDC3, IRF1, C7orf53, IGK@, RNASE2, FCGR1A, SAP30, PMS2CL, SLC11A1,AREG, PLB1, PPIF, GSR, NFXL1, AP3B2, DCTN5, RPL17, IGLV6-57, KLRF1,CHI3L1, ANKRD34B, OLFM4, CPM, CCDC125, GPR56, PPP1R2, 110, ACPL2,HIST1H3A, C7orf58, IRF4, ANAPC11, HIST1H33, KLRD1, GPR84, ZRANB1, KDM6B,TPST1, HINT1, DAAM2, PTGDR, FKBP5, HSP90AB1, HPGD, IFI16, CD177,TAS2R31, CD163, B4GALT3, EIF1AX, CYP4F3, HIST1H2AA, LASS4 (where if agene name is not provided then a SEQ ID NO. is provided).; (2) obtaininga sample IRS biomarker profile from the subject, which evaluates for anindividual IRS biomarker in the reference IRS biomarker profile acorresponding IRS biomarker; and (3) determining a likelihood of thesubject having or not having inSIRS, ipSIRS or a healthy condition thecondition based on the sample IRS biomarker profile and the referenceIRS biomarker profile.

In illustrative examples of this type, a reference healthy condition IRSbiomarker profile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8,9, 10 etc.) IRS biomarker that is downregulated or underexpressedrelative to a reference inSIRS IRS biomarker profile, representativeexamples of which include: CD177, CLEC4E, FKBP5, CD163, TPST1, DAAM2,GPR84, FCGR1A, IFI16, RNASE2, TLR5, ECHDC3, OCR1, MME, LOC284757, 110,C3AR1, HAL, PRR13, ACPL2, SLC11A1, CYP4F3, SAP30, OLFM4, ZRANB1, GAB2,CCDC125, KREMEN1, UBE2J1, AREG, FAR2, CPM, PLB1, ERGIC1, RGS2, 132,HPGD, ANKRD34B, TDRD9, DNAJC13, GALNT3, IRS2, HIST1H2AA, RBP7, KDM6B,ACER3, MPZL3, KIAA1257, C7orf53, C9orf72, STOM, METTL7B, SMPDL3A, GSR,SYNE2, OMG, DSE, PICALM, ABCA13, PPP1R2, TGFBR1, AP3B2, FRMD3 (where ifa gene name is not provided then a SEQ ID NO. is provided).

In other illustrative examples, a reference healthy condition IRSbiomarker profile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8,9, 10 etc.) IRS biomarker that is upregulated or overexpressed, relativeto a reference inSIRS IRS biomarker profile, illustrative examples ofwhich include: SIAE, FSD1L, GLDC, HSPB1, HIST1H2BJ, CDS2, CASS4, DCTN5,SLC39A9, CDC26, LGALS1, CD151, NP, TYMS, IGLV6-57, TMEM62, CD300A,LASS4, GLT25D1, IRF1, AMFR, IGL@, NFXL1, SLC39A8, APOLD1, TNFRSF17,KIAA0101, C22orf37, VOPP1, KLRD1, TRAF3, RRP12, PTGER2, KIAA0746, MGST3,CHI3L1, TAS2R31, SDHC, IRF4, INSIG1, PPIF, B4GALT3, ANAPC11, PLAC8,HIST1H2BM, KLRF1, B3GAT3, C7orf58, PMS2CL, PTGDR, RPL17, EIF1AX, PMAIP1,HIST1H3B, IGK@, HINT1, HSP90AB1, GPR56, HIST1H3H, HIST1H3A, IMP3,DNAJC9, MRPL41, HIST1H3J, HIST1H3C, HIST1H3I, HIST1H4L, CRIP1, HIST1H4C(where if a gene name is not provided then a SEQ ID NO. is provided).

In still other illustrative examples, a reference healthy condition IRSbiomarker profile comprises: (1) at least one IRS biomarker that isdownregulated or underexpressed relative to a reference inSIRS IRSbiomarker profile, as broadly described above and (2) at least one IRSbiomarker that is upregulated or overexpressed relative to a referenceinSIRS IRS biomarker profile, as broadly described above.

In other illustrative examples, a reference inSIRS IRS biomarker profilecomprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 etc.) IRSbiomarker that is downregulated or underexpressed relative to areference ipSIRS IRS biomarker profile, representative examples of whichinclude: OLFM4, PLAC8, HIST1H4L, HIST1H3C, TDRD9, IGK@, HIST1H3B,HIST1H2BM, HPGD, GPR84, TLR5, SMPDL3A, CD177, HIST1H3I, C3AR1, DNAJC9,ABCA13, ANKRD34B, RNASE2, FCGR1A, HIST1H3H, KIAA0746, ACER3, SDHC,CRIP1, IGLV6-57, PLB1, MRPL41, HIST1H4C, SLC39A8, NP, NFXL1, PTGER2,TYMS, LGALS1, C7orf58, CD151, KREMEN1, AMFR, METTL7B, TNFRSF17,HSP90AB1, VOPP1, GLT25D1, GALNT3, OMG, SIAE, FAR2, C7orf53, DNAJC13,HIST1H2BJ, KIAA0101, HSPB1, UBE2J1, HIST1H3J, CDS2, MGST3, PICALM,HINT1, SLC39A9, STOM, TRAF3, INSIG1, AP3B2, B3GAT3, CD300A, TGFBR1,HIST1H3A, PMAIP1, DSE, TMEM62, IGL@, IRF4, GSR, IRF1, EIF1AX, C9orf72,PMS2CL, C22orf37, FRMD3, IMP3, RPL17, FSD1L, APOLD1, B4GALT3, DCTN5,PPIF, CDC26, TAS2R31, RRP12, ANAPC11, GLDC, LASS4 (where if a gene nameis not provided then a SEQ ID NO. is provided).

In yet other illustrative examples, a reference inSIRS IRS biomarkerprofile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10etc.) IRS biomarker that is upregulated or overexpressed, relative to areference ipSIRS IRS biomarker profile, non-limiting examples of whichinclude: HIST1H2AA, IFI16, PPP1R2, CCDC125, ZRANB1, SLC11A1, GPR56, 110,KDM6B, GAB2, CYP4F3, RGS2, KIAA1257, CPM, ACPL2, PRR13, ERGIC1, PTGDR,IRS2, MPZL3, AREG, SAP30, RBP7, CASS4, FKBP5, SYNE2, KLRD1, 132, KLRF1,LOC284757, HAL, TPST1, ECHDC3, CD163, CLEC4E, DAAM2, CHI3L1, MME, OCR1(where if a gene name is not provided then a SEQ ID NO. is provided).

In still other illustrative examples, a reference inSIRS IRS biomarkerprofile comprises: (1) at least one IRS biomarker that is downregulatedor underexpressed relative to a reference ipSIRS IRS biomarker profile,as broadly described above and (2) at least one IRS biomarker that isupregulated or overexpressed relative to a reference ipSIRS IRSbiomarker profile, as broadly described above.

In other illustrative examples, a reference ipSIRS IRS biomarker profilecomprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 etc.) IRSbiomarker that is downregulated or underexpressed relative to areference healthy condition IRS biomarker profile, representativeexamples of which include: GNLY, GPR56, CHI3L1, KLRF1, KLRK1, PTGDR,SH2D1B, HIST1H2AJ, FAIM3, HLA-DPB1, CAMK4, FGFBP2, KLRD1, CLC, PHOSPHO1,HIST1H4C, ITK, LRRN3, CCR3, CRIP1, IMP3, HIST1H3J, HIST1H4E, HLA-DRA,PLA2G7, GIMAP7, HLA-DPA1, CASS4, HIST1H3I, KPNA5, CENPK, SULF2,KIAA1324, HIST1H3A, CFD, C1orf128, RPIA, MRPL41, GOT2, IL5RA, PYHIN1,ITGA4, HINT1, 200, VAMP2, C15orf54, LGALS2, 199, S100B, HSP90AB1,DNAJC9, PMAIP1, CCR4, RPL17, RUNX2, NPCDR1, JUP, PMS2CL, ANAPC11, PDE3B,RASA4, CAMK1D, LY6G5B, 268, FAM118A, PPIF, B4GALT3, B3GAT3, ABCG1, IRF4,LASS4 (where if a gene name is not provided then a SEQ ID NO. isprovided).

In yet other illustrative examples, a reference ipSIRS IRS biomarkerprofile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10etc.) IRS biomarker that is upregulated or overexpressed relative to areference healthy condition IRS biomarker profile, illustrative examplesof which include: ATP6V0D1, SAP30, GAB2, KRTAP15-1, NEK6, HDHD1A,SLC39A8, HIST1H2AA, FABP2, CDS2, SRXN1, KLHL5, ACPL2, HS2ST1, HIST1H2BJ,PLIN2, ICAM1, HSPB1, PRR13, P4HA1, SLC11A1, ECHDC3, TAF13, LGALS1,TAAR1, TPX2, DLEU2, TRIM21, AGTRAP, PTGS1, LHFP, CEP97, ACTA2, SIAE,GPR65, IL1RL1, MTHFS, FAM118B, MKI67, LRRFIP1, CCRL2, GALNT2, GSTO1,LRRC70, MTRR, ANKRD28, DPH3, 110, AIG1, UBE2F, LAIR1, PCOLCE2, PLB1,CDA, JKAMP, FRMD3, ITGA2B, SEC24A, REIN, THBS1, MYL9, SPARC, RCBTB2,PLAC8, PDK4, PPP2R5A, SH3PXD2B, DAAM2, NF-E4, DDAH2, MACF1, CD63,CLEC4A, MPO, SUCNR1, EXOSC4, EFCAB2, IL1B, OR9A2, AP3B2, DYNLL1, WSB2,SLC15A2, EAF2, C1orf161, TGFBR1, ABCA1, FFAR2, SLC1A3, ATP13A3, CLU,ADM, IFI16, KCNMA1, C9orf72, GSR, DSE, PICALM, EIF2AK2, HPSE, TLR10,HSPC159, TPST1, ODZ1, STOM, HMGB2, PDGFC, CCR1, OMG, CD163, SGMS2,TREML1, FOXD4L3, C7orf53, CEACAM6, FOLR3, METTL7B, TMEM144, DNAJC13,GALNT3, B3GNT5, CLEC4E, SLC37A3, ABCA13, CD24, C11orf82, FAR2, UBE2J1,GK3P, DEFA4, LTF, ACER3, TMTC1, SMPDL3A, FKBP5, ERLIN1, PLB1, MMP9,KREMEN1, ANKRD34B, OLAH, BMX, PFKFB2, HPGD, BPI, CD274, CEACAM8, TDRD9,LCN2, TNFAIP6, C3AR1, TCN1, IL18R1, CLEC4D, TLR5, RNASE2, FCGR1A, GPR84,OLFM4, VNN1, ARG1, CD177 (where if a gene name is not provided then aSEQ ID NO. is provided).

In yet other illustrative examples, a reference ipSIRS IRS biomarkerprofile comprises: (1) at least one IRS biomarker that is downregulatedor underexpressed relative to a reference healthy condition IRSbiomarker profile, as broadly described above and (2) at least one IRSbiomarker that is upregulated or overexpressed, relative to a referencehealthy condition IRS biomarker profile, as broadly described above.

Yet another subset of the disclosed IRS biomarkers has been identifiedas being useful for assisting in distinguishing between inSIRS affectedsubjects and ipSIRS affected subjects. Accordingly, in some embodiments,the methods and kits are useful for determining the likelihood thatinSIRS or ipSIRS is present or absent in a subject. These methods andkits generally comprise or involve: 1) providing a correlation of areference IRS biomarker profile with the likelihood of having or nothaving inSIRS or ipSIRS, wherein the reference biomarker profileevaluates at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 etc.) IRSbiomarker selected from C11orf82, PLAC8, 132, INSIG1, CDS2, VOPP1,SLC39A9, FOXD4L3, WSB2, CD63, CD274, B3GAT3, CD300A, OCR1, JKAMP, TLR10,PTGER2, PDGFC, LGALS1, HIST1H4L, AGTRAP, AMFR, SIAE, 200, SLC15A2,SLC39A8, TGFBR1, DDAH2, HPSE, SUCNR1, MTRR, GAB2, P4HA1, HS2ST1, MRPL41,TYMS, RUNX2, GSTO1, LRRC70, HIST1H3B, RCBTB2, MPZL3, KIAA1257, AIG1,NEK6, OMG, HIST1H2BM, TDRD9, GALNT3, ATP13A3, C22orf37, SYNE2, ADM,MGST3, PDE3B, HIST1H3I, LOC284757, TRAF3, HIST1H3C, STOM, KLHL5, EXOSC4,C3AR1, KIAA0101, TNFRSF17, HAL, UBE2J1, GLT25D1, CD151, TPX2, PCOLCE2,HSPB1, EAF2, IMP3, PICALM, ACER3, IGL@, HIST1H2BJ, CASS4, ACTA2, PTGS1,KREMEN1, IRS2, TAF13, FSD1L, APOLD1, RBP7, DNAJC13, SEC24A, ERGIC1,FSD1L, TLR5, MKI67, TMEM62, CLEC4A, SDHC, C9orf72, NP, CLU, ABCA1,KIAA0746, PMAIP1, DSE, CMTM5, SMPDL3A, DNAJC9, HDHD1A, HIST1H3H, CDC26,ICAM1, LOC100128751, FAR2, CRIP1, MPZL2, FRMD3, CTSL1, METTL7B, RGS2,CLEC4E, MME, ABCA13, PRR13, HIST1H4C, RRP12, GLDC, ECHDC3, ITGA2B,C7orf53, IRF1, 268, IGK@, RNASE2, FCGR1A, UBE2F, SAP30, LAIR1, PMS2CL,SLC11A1, PLB1, AREG, PPIF, GSR, NFXL1, AP3B2, DCTN5, RPL17, PLA2G7,GALNT2, IGLV6-57, KLRF1, CHI3L1, ANKRD34B, OLFM4, 199, CPM, CCDC125,SULF2, LTF, GPR56, MACF1, PPP1R2, DYNLL1, LCN2, FFAR2, SFRS9, IGJ,FAM118B, 110, ACPL2, HIST1H3A, C7orf58, ANAPC11, HIST1H3J, IRF4, MPO,TREML1, KLRD1, GPR84, CCRL2, CAMK1D, CCR1, ZRANB1, KDM6B, TPST1, HINT1,DAAM2, PTGDR, FKBP5, CD24, HSP90AB1, HPGD, CEACAM8, DEFA4, IL1B, IFI16,CD177, KIAA1324, SRXN1, TAS2R31, CEACAM6, CD163, B4GALT3, ANKRD28,TAAR1, EIF1AX, CYP4F3, 314, HIST1H2AA, LY6G5B, LASS4 (where if a genename is not provided then a SEQ ID NO. is provided); (2) obtaining asample IRS biomarker profile from the subject, which evaluates for anindividual IRS biomarker in the reference IRS biomarker profile acorresponding IRS biomarker; and (3) determining a likelihood of thesubject having or not having inSIRS or ipSIRS based on the sample IRSbiomarker profile and the reference IRS biomarker profile.

In illustrative examples of thus type, a reference inSIRS IRS biomarkerprofile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10etc.) IRS biomarker that is downregulated or underexpressed relative toa reference ipSIRS IRS biomarker profile, non-limiting examples of whichinclude: OLFM4, CD274, PLACE, LCN2, IGJ, HIST1H4L, HIST1H3C, DEFA4,TDRD9, IGK@, HIST1H3B, CEACAM8, C11orf82, HIST1H2BM, LTF, HPGD, FOXD4L3,PDGFC, CD24, GPR84, CEACAM6, TLR5, SMPDL3A, CD177, HIST1H3I, C3AR1,TLR10, DNAJC9, ABCA13, ANKRD34B, RNASE2, FCGR1A, HPSE, HIST1H3H,KIAA0746, ACER3, SDHC, MTRR, WSB2, CRIP1, IGLV6-57, ATP13A3, CD63,TREML1, PLB1, MRPL41, HIST1H4C, SLC39A8, NP, NFXL1, MPO, ITGA2B, LAIR1,PTGER2, EXOSC4, TYMS, LGALS1, C7orf58, SLC15A2, CD151, ADM, KREMEN1,RCBTB2, PTGS1, AMFR, ABCA1, METTL7B, TNFRSF17, DYNLL1, HSP90AB1, CLU,MKI67, VOPP1, UBE2F, P4HA1, GLT25D1, IL1B, SUCNR1, GALNT3, AIG1, CCR1,OMG, MACF1, CLEC4A, SIAE, FAR2, C7orf53, DNAJC13, HIST1H2BJ, JKAMP,KIAA0101, GSTO1, HSPB1, DDAH2, ICAM1, UBE2J1, KLHL5, HIST1H3J, EAF2,CDS2, MGST3, FFAR2, TPX2, PICALM, HINT1, SLC39A9, SEC24A, STOM, TRAF3,INSIG1, AP3B2, PCOLCE2, B3GAT3, TAF13, CD300A, TGFBR1, HIST1H3A, PMAIP1,AGTRAP, FAM118B, DSE, NEK6, CMTM5, GALNT2, TMEM62, HS2ST1, IGL@, ACTA2,LRRC70, IRF4, GSR, IRF1, EIF1AX, C9orf72, PMS2CL, ANKRD28, CTSL1,C22orf37, FRMD3, HDHD1A, CCRL2, IMP3, RPL17, FSD1L, APOLD1, B4GALT3,FSD1L, DCTN5, PPIF, CDC26, TAS2R31, RRP12, SFRS9, TAAR1, ANAPC11, SRXN1,GLDC, LASS4 (where if a gene name is not provided then a SEQ ID NO. isprovided).

In other illustrative examples, a reference inSIRS IRS biomarker profilecomprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 etc.) IRSbiomarker that is upregulated or overexpressed, relative to a referenceipSIRS IRS biomarker profile, representative examples of which include:HIST1H2AA, LY6G5B, 268, IFI16, PPP1R2, CCDC125, ZRANB1, LOC100128751,SLC11A1, GPR56, RUNX2, 110, KDM6B, GAB2, 199, CYP4F3, RGS2, PDE3B,KIAA1257, CAMK1D, CPM, ACPL2, PRR13, ERGIC1, PTGDR, IRS2, MPZL3, MPZL2,AREG, SAP30, RBP7, CASS4, FKBP5, SYNE2, SULF2, KLRD1, 132, KLRF1, 314,LOC284757, HAL, TPST1, ECHDC3, CD163, KIAA1324, PLA2G7, CLEC4E, DAAM2,200, CHI3L1, MME, OCR1 (where if a gene name is not provided then a SEQID NO. is provided).

In still other illustrative examples, an inSIRS IRS biomarker profilecomprises: (1) at least one IRS biomarker that is downregulated orunderexpressed relative to a reference ipSIRS IRS biomarker profile, asbroadly described above and (2) at least one IRS biomarker that isupregulated or overexpressed relative to a reference ipSIRS IRSbiomarker profile, as broadly described above.

Still another subset of the disclosed IRS biomarkers has been identifiedas being useful for assisting in distinguishing between subjects withdifferent stages of ipSIRS selected from mild sepsis, severe sepsis andseptic shock. Accordingly, in some embodiments, the methods and kits areuseful for determining the likelihood that a stage of ipSIRS selectedfrom mild sepsis, severe sepsis and septic shock is present or absent ina subject. These methods and kits generally comprise or involve: 1)providing a correlation of a reference IRS biomarker profile with thelikelihood of having or not having the stage of ipSIRS, wherein thereference biomarker IRS biomarker profile evaluates at least one (e.g.,1, 2, 3, 4, 5, 6, 7, 8, 9, 10 etc.) IRS biomarker selected from PLEKHA3,PLEKHF2, 232, SFRS9, ZNF587, KPNA5, LOC284757, GPR65, VAMP2, SLC1A3,ITK, ATF7, ZNF28, AIF1, MINPP1, GIMAP7, MKI67, IRF4, TSHZ2, HLA-DPB1,EFCAB2, POLE2, FAIM3, 110, CAMK4, TRIM21, IF144, CENPK, ATP5L, GPR56,HLA-DPA1, C4orf3, GSR, GNLY, RFESD, BPI, HIST1H2AA, NF-E4, CALM2,EIF1AX, E2F6, ARL17P1, TLR5, SH3PXD2B, FAM118A, RETN, PMAIP1, DNAJC9,PCOLCE2, TPX2, BMX, LRRFIP1, DLEU2, JKAMP, JUP, ABCG1, SLC39A9, B3GNT5,ACER3, LRRC70, NPCDR1, TYMS, HLA-DRA, TDRD9, FSD1L, FAR2, C7orf53,PPP1R2, SGMS2, EXOSC4, TGFBR1, CD24, TCN1, TAF13, AP3B2, CD63, SLC15A2,IL18R1, ATP6V0D1, SON, HSP90AB1, CEACAM8, SMPDL3A, IMP3, SEC24A, PICALM,199, CEACAM6, CYP4F3, OLAH, ECHDC3, ODZ1, KIAA0746, KIAA1324, HINT1,VNN1, C22orf37, FSD1L, FOLR3, IL1RL1, OMG, MTHFS, OLFM4, S100B, ITGA4,KLRD1, SLC39A8, KLHL5, KLRK1, MPO, PPIF, GOT2, LRRN3, HIST1H2AJ, CLU,LCN2, 132, CEP97, KLRF1, FBXL13, HIST1H3B, ANKRD34B, RPIA, HPGD,HIST2H2BF, GK3P (where if a gene name is not provided then a SEQ ID NO.is provided); (2) obtaining a sample IRS biomarker profile from thesubject, which evaluates for an individual IRS biomarker in thereference IRS biomarker profile a corresponding IRS biomarker; and (3)determining a likelihood of the subject having or not having the stageof ipSIRS based on the sample IRS biomarker profile and the referenceIRS biomarker profile.

In illustrative examples of this type, a reference mild sepsis IRSbiomarker profile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8,9, 10 etc.) IRS biomarker that is downregulated or underexpressedrelative to a reference severe sepsis IRS biomarker profile,illustrative examples of which include: OLFM4, CEACAM8, TCN1, BPI, LCN2,CD24, CEACAM6, NF-E4, HIST1H3B, MKI67, OLAH, TYMS, DNAJC9, MPO,LOC284757, ODZ1, HSP90AB1, VNN1, ANKRD34B, FBXL13, TSHZ2, KIAA0746,FOLR3, GSR, IRF4, LRRN3, TPX2, SFRS9, C7orf53, CYP4F3, IL1RL1, TDRD9,IL18R1, BMX, NPCDR1, GOT2, ATF7, CEP97, ITK, SEC24A, KIAA1324, FAM118A,132, SMPDL3A, CD63, ABCG1, TLR5, CAMK4, CLU, SLC39A9, GK3P, LRRFIP1,AP3B2, SLC15A2, PICALM, HIST1H2AA, SGMS2, OMG, REIN, FAIM3, EXOSC4,SH3PXD2B, FAR2, 199, C4orf3, PCOLCE2 (where if a gene name is notprovided then a SEQ ID NO. is provided).

In other illustrative examples, a reference mild sepsis IRS biomarkerprofile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10etc.) IRS biomarker that is upregulated or overexpressed, relative to areference severe sepsis IRS biomarker profile, non-limiting examples ofwhich include: JUP, SLC1A3, ECHDC3, IMP3, SLC39A8, MTHFS, TGFBR1, FSD1L,HIST2H2BF, HPGD, FSD1L, PPP1R2, B3GNT5, C22orf37, ACER3, GIMAP7,ATP6V0D1, KLHL5, PPIF, KLRK1, HINT1, GPR56, LRRC70, S100B, 110, SON,ZNF587, JKAMP, ITGA4, HLA-DRA, ZNF28, TRIM21, TAF13, HLA-DPA1, ARL17P1,KLRF1, PMAIP1, RPIA, ATP5L, VAMP2, E2F6, KLRD1, EIF1AX, PLEKHA3, GPR65,CENPK, CALM2, GNLY, DLEU2, HLA-DPB1, AIF1, KPNA5, EFCAB2, PLEKHF2, 232,RFESD, MINPP1, HIST1H2AJ, POLE2, IF144 (where if a gene name is notprovided then a SEQ ID NO. is provided).

In still other illustrative examples, a reference mild sepsis IRSbiomarker profile comprises: (1) at least one IRS biomarker that isdownregulated or underexpressed relative to a reference severe sepsisIRS biomarker profile, as broadly described above and (2) at least oneIRS biomarker that is upregulated or overexpressed relative to areference severe sepsis IRS biomarker profile, as broadly describedabove.

In other illustrative examples, a reference severe sepsis IRS biomarkerprofile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10etc.) IRS biomarker that is downregulated or underexpressed relative toa reference septic shock IRS biomarker profile, non-limiting examples ofwhich include: HPGD, SLC1A3, B3GNT5, SMPDL3A, ACER3, REIN, IL18R1,FSD1L, SH3PXD2B, SLC39A8, EXOSC4, FSD1L, AP3B2, ECHDC3, GPR65, TDRD9,BMX, PCOLCE2, PLEKHF2, SGMS2, RPIA, GK3P, FAR2, LRRC70, TGFBR1, MTHFS,C4orf3, TLR5, OLAH, TAF13, JKAMP, POLE2, PICALM, RFESD, ANKRD34B, OMG,VNN1, EIF1AX, KLHL5, SON, LRRFIP1, HIST1H2AJ, AIF1, SLC15A2, CALM2,CD63, HIST1H2AA, MINPP1, S100B, DLEU2, PLEKHA3, ODZ1, FOLR3, 232,EFCAB2, SEC24A, E2F6, SLC39A9, ZNF28, KLRF1, ATP6V0D1, IL1RL1, PPIF(where if a gene name is not provided then a SEQ ID NO. is provided).

In yet other illustrative examples, a reference severe sepsis IRSbiomarker profile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8,9, 10 etc.) IRS biomarker that is upregulated or overexpressed, relativeto a reference septic shock IRS biomarker profile, representativeexamples of which include: LCN2, CENPK, C22orf37, PMAIP1, KPNA5, ATP5L,TCN1, 132, CD24, ITGA4, KLRD1, SFRS9, TRIM21, VAMP2, GSR, LOC284757,PPP1R2, HINT1, 110, IMP3, C7orf53, ATF7, KIAA0746, GNLY, HLA-DRA, IF144,ZNF587, CEP97, GPR56, OLFM4, CLU, KLRK1, GOT2, JUP, HLA-DPA1, NPCDR1,TPX2, HIST2H2BF, HLA-DPB1, FAM118A, ABCG1, MKI67, MPO, LRRN3, FBXL13,ARL17P1, CEACAM8, TSHZ2, 199, BPI, HSP90AB1, CYP4F3, TYMS, GIMAP7,DNAJC9, NF-E4, IRF4, HIST1H3B, CAMK4, FAIM3, CEACAM6, ITK, KIAA1324(where if a gene name is not provided then a SEQ ID NO. is provided).

In still other illustrative examples, a reference severe sepsis IRSbiomarker profile comprises: (1) at least one IRS biomarker that isdownregulated or underexpressed relative to a reference septic shock IRSbiomarker profile, as broadly described above and (2) at least one IRSbiomarker that is upregulated or overexpressed relative to a referenceseptic shock IRS biomarker profile, as broadly described above.

In other illustrative examples, a reference septic shock IRS biomarkerprofile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10etc.) IRS biomarker that is downregulated or underexpressed relative toa reference mild sepsis IRS biomarker profile, representative examplesof which include: IF144, HLA-DPB1, ARL17P1, HIST1H2AJ, MINPP1, GNLY,GIMAP7, HLA-DPA1, POLE2, 232, KPNA5, GPR56, HLA-DRA, ZNF587, KLRK1,RFESD, VAMP2, CENPK, KIAA1324, KLRD1, EFCAB2, ATP5L, 110, ITK, FAIM3,TRIM21, PMAIP1, HIST2H2BF, HINT1, DLEU2, AIF1, E2F6, ITGA4, KLRF1,CALM2, PLEKHA3, PPP1R2, CAMK4, 199, ZNF28, PLEKHF2, JUP, EIF1AX, PPIF,IMP3, C22orf37, ATP6V0D1, S100B, SON, GPR65, ABCG1, TAF13, FAM118A,RPIA, KLHL5, JKAMP, IRF4, CLU, CYP4F3, LRRC70 (where if a gene name isnot provided then a SEQ ID NO. is provided).

In yet other illustrative examples, a reference septic shock IRSbiomarker profile comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8,9, 10 etc.) IRS biomarker that is upregulated or overexpressed, relativeto a reference mild sepsis IRS biomarker profile, illustrative examplesof which include: GOT2, NPCDR1, CEP97, LRRN3, DNAJC9, TSHZ2, HSP90AB1,TYMS, HIST1H3B, ATF7, FBXL13, TPX2, TGFBR1, MPO, 132, NF-E4, MTHFS,CEACAM6, C7orf53, FSD1L, FSD1L, SLC39A9, MKI67, KIAA0746, HIST1H2AA,ACER3, ECHDC3, SLC15A2, SLC39A8, SEC24A, SFRS9, LRRFIP1, OMG, GSR,C4orf3, CD63, PICALM, LOC284757, FAR2, PCOLCE2, IL1RL1, B3GNT5, SGMS2,TLR5, EXOSC4, SH3PXD2B, GK3P, AP3B2, FOLR3, BPI, RETN, ODZ1, CEACAM8,BMX, HPGD, VNN1, ANKRD34B, SLC1A3, TDRD9, SMPDL3A, CD24, IL18R1, OLAH,LCN2, TCN1, OLFM4 (where if a gene name is not provided then a SEQ IDNO. is provided).

In yet other illustrative examples, a reference septic shock IRSbiomarker profile comprises: (1) at least one IRS biomarker that isdownregulated or underexpressed relative to a reference mild sepsis IRSbiomarker profile, as broadly described above and (2) at least one IRSbiomarker that is upregulated or overexpressed relative to a referencemild sepsis IRS biomarker profile, as broadly described above.

In some embodiments, individual IRS biomarkers as broadly describedabove and elsewhere herein are selected from the group consisting of:(a) a polynucleotide expression product comprising a nucleotide sequencethat shares at least 70% (or at least 71% to at least 99% and allinteger percentages in between) sequence identity with the sequence setforth in any one of SEQ ID NO: 1-319, or a complement thereof; (b) apolynucleotide expression product comprising a nucleotide sequence thatencodes a polypeptide comprising the amino acid sequence set forth inany one of SEQ ID NO: 320-619; (c) a polynucleotide expression productcomprising a nucleotide sequence that encodes a polypeptide that sharesat least 70% (or at least 71% to at least 99% and all integerpercentages in between) sequence similarity or identity with at least aportion of the sequence set forth in SEQ ID NO: 320-619; (d) apolynucleotide expression product comprising a nucleotide sequence thathybridizes to the sequence of (a), (b), (c) or a complement thereof,under medium or high stringency conditions; (e) a polypeptide expressionproduct comprising the amino acid sequence set forth in any one of SEQID NO: 320-619; and (f) a polypeptide expression product comprising anamino acid sequence that shares at least 70% (or at least 71% to atleast 99% and all integer percentages in between) sequence similarity oridentity with the sequence set forth in any one of SEQ ID NO: 320-619.

In some embodiments, the methods and kits comprise or involve: (1)measuring in the biological sample the level of an expression product ofat least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) IRS biomarkergene and (2) comparing the measured level or functional activity of eachexpression product to the level or functional activity of acorresponding expression product in a reference sample.

The present invention also extends to the management of inSIRS, ipSIRSor particular stages of ipSIRS, or prevention of further progression ofinSIRS, ipSIRS or particular stages of ipSIRS (e.g., mild sepsis, severesepsis and septic shock), or assessment of the efficacy of therapies insubjects following positive diagnosis for the presence of inSIRS, ipSIRSor particular stage of ipSIRS (e.g., mild sepsis, severe sepsis andseptic shock) in a subject. The management of inSIRS or ipSIRSconditions is generally highly intensive and can include identificationand amelioration of the underlying cause and aggressive use oftherapeutic compounds such as, vasoactive compounds, antibiotics,steroids, antibodies to endotoxin, anti tumour necrosis factor agents,recombinant protein C. In addition, palliative therapies as describedfor example in Cohen and Glauser (1991, Lancet 338: 736-739) aimed atrestoring and protecting organ function can be used such as intravenousfluids and oxygen and tight glycemic control. Therapies for ipSIRS arereviewed in Healy (2002, Ann. Pharmacother. 36(4): 648-54) and Brindley(2005, CJEM. 7(4): 227) and Jenkins (2006, 1 Hosp Med. 1(5): 285-295).

Typically, the therapeutic agents will be administered in pharmaceutical(or veterinary) compositions together with a pharmaceutically acceptablecarrier and in an effective amount to achieve their intended purpose.The dose of active compounds administered to a subject should besufficient to achieve a beneficial response in the subject over timesuch as a reduction in, or relief from, the symptoms of inSIRS, ipSIRSor particular stages of ipSIRS. The quantity of the pharmaceuticallyactive compounds(s) to be administered may depend on the subject to betreated inclusive of the age, sex, weight and general health conditionthereof. In this regard, precise amounts of the active compound(s) foradministration will depend on the judgment of the practitioner. Indetermining the effective amount of the active compound(s) to beadministered in the treatment or prevention of inSIRS, ipSIRS orparticular stages of ipSIRS, the medical practitioner or veterinarianmay evaluate severity of any symptom associated with the presence ofinSIRS, ipSIRS or particular stages of ipSIRS including, inflammation,blood pressure anomaly, tachycardia, tachypnea fever, chills, vomiting,diarrhea, skin rash, headaches, confusion, muscle aches, seizures. Inany event, those of skill in the art may readily determine suitabledosages of the therapeutic agents and suitable treatment regimenswithout undue experimentation.

The therapeutic agents may be administered in concert with adjunctive(palliative) therapies to increase oxygen supply to major organs,increase blood flow to major organs and/or to reduce the inflammatoryresponse. Illustrative examples of such adjunctive therapies include nonsteroidal-anti inflammatory drugs (NSAIDs), intravenous saline andoxygen.

Thus, the present invention contemplates the use of the methods and kitsdescribed above and elsewhere herein in methods for treating, preventingor inhibiting the development of inSIRS, ipSIRS or a particular stage ofipSIRS (e.g., mild sepsis, severe sepsis and septic shock) in a subject.These methods generally comprise (1) correlating a reference IRSbiomarker profile with the presence or absence of a condition selectedfrom a healthy condition, SIRS, inSIRS, ipSIRS, or a particular stage ofipSIRS, wherein the reference IRS biomarker profile evaluates at leastone (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 etc.) IRS biomarker; (2)obtaining an IRS biomarker profile of a sample (i.e., “a sample IRSbiomarker profile”) from a subject, wherein the sample IRS biomarkerprofile evaluates for an individual IRS biomarker in the reference IRSbiomarker profile a corresponding IRS biomarker; (3) determining alikelihood of the subject having or not having the condition based onthe sample IRS biomarker profile and the reference IRS biomarkerprofile, and administering to the subject, on the basis that the subjecthas an increased likelihood of having inSIRS, an effective amount of anagent that treats or ameliorates the symptoms or reverses or inhibitsthe development of inSIRS, or administering to the subject, on the basisthat the subject has an increased likelihood of having ipSIRS or aparticular stage of ipSIRS, an effective amount of an agent that treatsor ameliorates the symptoms or reverses or inhibits the development ofipSIRS or the particular stage of ipSIRS.

In some embodiments the methods and kits of the present invention areused for monitoring, treatment and management of conditions that canlead to inSIRS or ipSIRS, illustrative examples of which includeretained placenta, meningitis, endometriosis, shock, toxic shock (i.e.,sequelae to tampon use), gastroenteritis, appendicitis, ulcerativecolitis, Crohn's disease, inflammatory bowel disease, acid gut syndrome,liver failure and cirrhosis, failure of colostrum transfer in neonates,ischemia (in any organ), bacteraemia, infections within body cavitiessuch as the peritoneal, pericardial, thecal, and pleural cavities,burns, severe wounds, excessive exercise or stress, haemodialysis,conditions involving intolerable pain (e.g., pancreatitis, kidneystones), surgical operations, and non-healing lesions. In theseembodiments, the methods or kits of the present invention are typicallyused at a frequency that is effective to monitor the early developmentof inSIRS, ipSIRS or particular stages of ipSIRS, to thereby enableearly therapeutic intervention and treatment of that condition. Inillustrative examples, the diagnostic methods or kits are used at leastat 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22, 23 or 24 hour intervals or at least 1, 2, 3, 4, 5 or 6 dayintervals, or at least weekly, fortnightly or monthly. Accordingly, thepresent invention encompasses the use of the methods and kits of thepresent invention for early diagnosis of inSIRS, ipSIRS or particularstages of ipSIRS.

The term “early diagnosis” as used herein with “early detection” refersto specific screening/monitoring processes that allow detection andevaluation of inSIRS, ipSIRS or particular stages of ipSIRS at an earlypoint in disease development and/or progression. For example, since bothinSIRS and ipSIRS patients present with similar clinical signs, earlydetection of ipSIRS can be achieved through a plurality of evaluationsof patients with inSIRS to detect a transition to ipSIRS.

The present invention can be practiced in the field of predictivemedicine for the purposes of diagnosis or monitoring the presence ordevelopment of a condition selected from inSIRS, ipSIRS or a particularstage of ipSIRS in a subject, and/or monitoring response to therapyefficacy.

The IRS biomarker profile further enables determination of endpoints inpharmacotranslational studies. For example, clinical trials can takemany months or even years to establish the pharmacological parametersfor a medicament to be used in treating or preventing inSIRS, ipSIRS ora particular stage of ipSIRS (e.g., mild sepsis, severe sepsis andseptic shock). However, these parameters may be associated with an IRSbiomarker profile associated with a health state (e.g., a healthycondition). Hence, the clinical trial can be expedited by selecting atreatment regimen (e.g., medicament and pharmaceutical parameters),which results in an IRS biomarker profile associated with the desiredhealth state (e.g., healthy condition). This may be determined forexample by (1) providing a correlation of a reference IRS biomarkerprofile with the likelihood of having the healthy condition; (2)obtaining a corresponding IRS biomarker profile of a subject havinginSIRS, ipSIRS or a particular stage of ipSIRS after treatment with atreatment regimen, wherein a similarity of the subject's IRS biomarkerprofile after treatment to the reference IRS biomarker profile indicatesthe likelihood that the treatment regimen is effective for changing thehealth status of the subject to the desired health state (e.g., healthycondition). This aspect of the present invention advantageously providesmethods of monitoring the efficacy of a particular treatment regimen ina subject (for example, in the context of a clinical trial) alreadydiagnosed with a condition selected from inSIRS, ipSIRS or a particularstage of ipSIRS. These methods take advantage of IRS biomarkers thatcorrelate with treatment efficacy, for example, to determine whether theIRS biomarker profile of a subject undergoing treatment partially orcompletely normalizes during the course of or following therapy orotherwise shows changes associated with responsiveness to the therapy.

The IRS biomarker profile further enables stratification of patientsprior to enrolment in pharmacotranslational studies. For example, aclinical trial can be expedited by selecting a priori patients with aparticular IRS biomarker profile that would most benefit from aparticular treatment regimen (e.g., medicament and pharmaceuticalparameters). For instance, patient enrolment into a clinical trialtesting the efficacy of a new antibiotic would best include patientswith an IRS biomarker profile that indicated that they had ipSIRS ratherthan inSIRS, and as such the selected patients would most likely benefitfrom the new therapy. Further, and by example, patient enrolment into aclinical trial testing the efficacy of a new inotrope would best includepatients with an IRS biomarker profile that indicated that they had theshock stage of ipSIRS rather than inSIRS or other stage of ipSIRS, andas such the selected patients would most likely benefit from the newtherapy.

As used herein, the term “treatment regimen” refers to prophylacticand/or therapeutic (i.e., after onset of a specified condition)treatments, unless the context specifically indicates otherwise. Theterm “treatment regimen” encompasses natural substances andpharmaceutical agents (i.e., “drugs”) as well as any other treatmentregimen including but not limited to dietary treatments, physicaltherapy or exercise regimens, surgical interventions, and combinationsthereof.

Thus, the invention provides methods of correlating a reference IRSbiomarker profile with an effective treatment regimen for a conditionselected from inSIRS, ipSIRS or a particular stage of ipSIRS (e.g., mildsepsis, severe sepsis and septic shock), wherein the reference IRSbiomarker profile evaluates at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8,9, 10, etc.) IRS biomarker. These methods generally comprise: (a)determining a sample IRS biomarker profile from a subject with thecondition prior to treatment (i.e., baseline), wherein the sample IRSbiomarker profile evaluates for an individual IRS biomarker in thereference IRS biomarker profile a corresponding IRS biomarker; andcorrelating the sample IRS biomarker profile with a treatment regimenthat is effective for treating that condition.

The invention further provides methods of determining whether atreatment regimen is effective for treating a subject with a conditionselected from inSIRS, ipSIRS or a particular stage of ipSIRS (e.g., mildsepsis, severe sepsis and septic shock). These methods generallycomprise: (a) correlating a reference biomarker profile prior totreatment (i.e., baseline) with an effective treatment regimen for thecondition, wherein the reference IRS biomarker profile evaluates atleast one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) IRS biomarker; and(b) obtaining a sample IRS biomarker profile from the subject aftertreatment, wherein the sample IRS biomarker profile evaluates for anindividual IRS biomarker in the reference IRS biomarker profile acorresponding IRS biomarker, and wherein the sample IRS biomarkerprofile after treatment indicates whether the treatment regimen iseffective for treating the condition in the subject.

The invention can also be practiced to evaluate whether a subject isresponding (i.e., a positive response) or not responding (i.e., anegative response) to a treatment regimen. This aspect of the inventionprovides methods of correlating an IRS biomarker profile with a positiveand/or negative response to a treatment regimen. These methods generallycomprise: (a) obtaining an IRS biomarker profile from a subject with acondition selected from inSIRS, ipSIRS or a particular stage of ipSIRS(e.g., mild sepsis, severe sepsis and septic shock) followingcommencement of the treatment regimen, wherein the IRS biomarker profileevaluates at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) IRSbiomarker; and (b) correlating the IRS biomarker profile from thesubject with a positive and/or negative response to the treatmentregimen.

The invention also provides methods of determining a positive and/ornegative response to a treatment regimen by a subject with a conditionselected from inSIRS, ipSIRS or a particular stage of ipSIRS (e.g., mildsepsis, severe sepsis and septic shock). These methods generallycomprise: (a) correlating a reference IRS biomarker profile with apositive and/or negative response to the treatment regimen, wherein thereference IRS biomarker profile evaluates at least one (e.g., 1, 2, 3,4, 5, 6, 7, 8, 9, 10, etc.) IRS biomarker; and (b) determining a sampleIRS biomarker profile from the subject, wherein the subject's sample IRSbiomarker profile evaluates for an individual IRS biomarker in thereference IRS biomarker profile a corresponding IRS biomarker andindicates whether the subject is responding to the treatment regimen.

In some embodiments, the methods further comprise determining a firstsample IRS biomarker profile from the subject prior to commencing thetreatment regimen (i.e., a baseline profile), wherein the first sampleIRS biomarker profile evaluates at least one (e.g., 1, 2, 3, 4, 5, 6, 7,8, 9, 10, etc.) IRS biomarker; and comparing the first sample IRSbiomarker profile with a second sample IRS biomarker profile from thesubject after commencement of the treatment regimen, wherein the secondsample IRS biomarker profile evaluates for an individual IRS biomarkerin the first sample IRS biomarker profile a corresponding IRS biomarker.

This aspect of the invention can be practiced to identify responders ornon-responders relatively early in the treatment process, i.e., beforeclinical manifestations of efficacy. In this way, the treatment regimencan optionally be discontinued, a different treatment protocol can beimplemented and/or supplemental therapy can be administered. Thus, insome embodiments, a sample IRS biomarker profile is obtained withinabout 2 hours, 4 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10weeks, 12 weeks, 4 months, six months or longer of commencing therapy.

In order that the invention may be readily understood and put intopractical effect, particular preferred embodiments will now be describedby way of the following non-limiting examples.

EXAMPLES Example 1 Monitoring Severity of ipSIRS in Patients inIntensive Care

Patients admitted to intensive care (ICU) often have ipSIRS, or developipSIRS during their ICU stay. The ultimate aim of intensive care is toensure the patient survives and is discharged to a general ward in theminimum time. Patients in intensive care with diagnosed ipSIRS areusually administered a number of therapeutic compounds—many of whichhave opposing actions on the immune system and many of which could becounterproductive depending on the severity of ipSIRS (mild sepsis,severe sepsis, septic shock). Monitoring intensive care patients on aregular basis with biomarkers of the present invention will allowmedical practitioners to determine the stage of ipSIRS and hence choiceof therapies and patient management procedures, and ultimately responseto therapy. Information provided by these biomarkers disclosed herein(“the IRS biomarkers”) will therefore allow medical practitioners totailor and modify therapies to ensure patients survive and spend lesstime in intensive care. Less time in intensive care leads toconsiderable savings in medical expenses including through lessoccupancy time and appropriate use and timing of medications. Practicalexamples of the use of the IRS biomarkers in Tables 1-6 are described.

Tables 1, 2 and 3 list those top 10 IRS biomarkers (by example) inascending order of p value (less than 0.05) when comparing the clinicalgroups of mild sepsis, severe sepsis and septic shock (severe versusmild, shock versus mild and shock versus severe—the appropriate columnis filled grey for each group in respective tables). In this and thefollowing examples significance is defined when a p value is less than0.05. P values were determined by adjusted t-test (Benjamini & Hochberg,1995) in the case of healthy vs. other and inSIRS vs. ipSIRS, and byTukey's Honestly Significant Difference for analysis of variance (ANOVA)for the mild/severe/shock comparisons. For the groups severe versusmild, shock versus mild and shock versus severe there were 72, 120 and47 biomarkers respectively with a p value less than 0.05.

Tables 4, 5 and 6 list those top 10 biomarkers (by example) indescending order of Area Under Curve (AUC) value when comparing theclinical groups of mild sepsis, severe sepsis and septic shock (severeversus mild, shock versus mild and shock versus severe—the appropriatecolumn is filled grey for each group in respective tables). For thegroups severe versus mild, shock versus mild and shock versus severethere were 34, 17 and 2 biomarkers respectively with an AUC greater than0.8 (a nominal cut-off above which would be considered to be good).

In each of Tables 1-6 a SEQ ID NO. is provided for each IRS biomarker(IRS biomarker polynucleotides range from SEQ ID NO. 1-319, IRSbiomarker polypeptides range from SEQ ID No. 320-619), along with adatabase identification tag (e.g. NM_), a gene name (Gene Name) if thereis one, and either; mean expression values for healthy (HC), inSIRS,mild sepsis, severe sepsis and septic shock, and p values for HC vs. allother groups, inSIRS vs. ipSIRS, mild sepsis versus severe sepsis, mildsepsis versus septic shock and septic shock versus severe sepsis, or AUCvalues for HC vs. Sick, HC vs. inSIRS, HC vs. ipSIRS, inSIRS vs. ipSIRS,Mild Sepsis versus Severe Sepsis, Mild Sepsis versus Septic Shock andSeptic Shock versus Severe Sepsis. Such biomarkers have clinical utilityin determining ipSIRS severity based on these groups. By example, inTable 1, Severe versus Mild p Value, it can be seen that the genePLEKHA3 has a significant p value for both Severe versus Mild and Shockversus Mild and therefore has utility in separating mild sepsis fromboth severe sepsis and septic shock. In Table 2, Severe versus Mild AreaUnder Curve, it can be seen that the gene PLEKHA3 has an AUC of 0.8748and therefore has most utility in separating mild sepsis from severesepsis. It can be seen that the p value for PLEKHA3 for separatingseptic shock from severe sepsis is not significant (>0.05) and thereforethis biomarker has no utility in separating these two groups. From thecolumns in the table containing mean expression data it can be seen thatPLEKHA3 is down-regulated in both severe sepsis (6.689) and septic shock(6.825) compared to mild sepsis (7.281) (also see FIG. 1).

Further and by example in Table 3, Shock vs. Mild p Value, it can beseen that the biomarker VAMP2 has utility in separating mild sepsis fromseptic shock but also from severe sepsis. VAMP2 does not have utility inseparating septic shock from severe sepsis (p=0.708038) but does havefurther utility in separating healthy from other groups. From the meanexpression columns it can also be seen that the expression level ofVAMP2 is downregulated in both severe sepsis (8.454) and septic shock(8.353) compared to mild sepsis (9.016) (see also FIG. 2). In Table 4,Shock vs. Mild Area Under Curve, it can be seen that VAMP2 has an AUC of0.8342. Further and by example in Table 5, Shock versus Severe p Value,it can be seen that the biomarker ITK has utility in separating Shockversus Severe Sepsis and Mild Sepsis, and healthy from other groups butno utility in separating Severe Sepsis and Mild Sepsis. From the meanexpression values for ITK it can be seen that it is comparativelydownregulated in Septic Shock compared to both Severe and Mild Sepsis(see also FIG. 3). In Table 6, Shock versus Severe Area Under Curve, itcan be seen that ITK has an AUC of 0.8054.

TABLE 1 Severe versus Mild p Value SEQ pval. pval. pval pval pval IDDatabase Gene HC inSIRS Mild Severe Shock HC.vs. inSIRS. Severe.vs.Shock.vs Shock.vs. Number ID Name Mean Mean Mean Mean Mean Othervs.ipSIRS Mild Mild Severe 285 NM_019091 PLEKHA3 7.058 6.910 7.281 6.6896.825 1.000000 1.000000 0.000001 0.000011 0.409707 587 NM_019091 PLEKHA37.058 6.910 7.281 6.689 6.825 1.000000 1.000000 0.000001 0.0000110.409707 232 gi|14250459 NA 6.389 5.970 6.875 5.976 6.059 1.0000000.638753 0.000001 0.000000 0.869569 gi|14250459 NA 6.389 5.970 6.8755.976 6.059 1.000000 0.638753 0.000001 0.000000 0.869569 195 NM_004897MINPP1 8.212 7.697 8.228 7.151 7.317 0.006705 1.000000 0.000005 0.0000080.707929 504 NM_004897 MINPP1 8.212 7.697 8.228 7.151 7.317 0.0067051.000000 0.000005 0.000008 0.707929 288 NM_024613 PLEKHF2 7.432 7.6608.044 7.255 7.671 0.789194 1.000000 0.000012 0.023331 0.029137 590 NM024613 PLEKHF2 7.432 7.660 8.044 7.255 7.671 0.789194 1.000000 0.0000120.023331 0.029137 190 NM_176818 SFRS9 9.739 9.666 9.715 10.226 10.1281.000000 0.000618 0.000018 0.000064 0.627141 499 NM_176818 SFRS9 9.7399.666 9.715 10.226 10.128 1.000000 0.000618 0.000018 0.000064 0.627141207 NR_002612 DLEU2 6.549 6.894 7.347 6.699 6.850 0.000171 1.0000000.000019 0.000152 0.504529 NR_002612 DLEU2 6.549 6.894 7.347 6.699 6.8500.000171 1.000000 0.000019 0.000152 0.504529 197 NM_006969 ZNF28 4.9364.511 5.008 4.554 4.612 0.021118 0.027741 0.000020 0.000018 0.814925 506NM_006969 ZNF28 4.936 4.511 5.008 4.554 4.612 0.021118 0.027741 0.0000200.000018 0.814925 71 NM_002269 KPNA5 6.822 5.908 6.451 5.758 5.7120.000000 1.000000 0.000021 0.000000 0.945115 387 NM_002269 KPNA5 6.8225.908 6.451 5.758 5.712 0.000000 1.000000 0.000021 0.000000 0.945115 278NM_001130 ATF7 5.212 5.212 5.253 5.605 5.372 1.000000 0.438013 0.0000330.171523 0.007397 059 580 NM_001130 ATF7 5.212 5.212 5.253 5.605 5.3721.000000 0.438013 0.000033 0.171523 0.007397 059 81 NR_046099 LOC2847576.913 8.028 6.894 7.534 7.376 0.000001 0.000004 0.000039 0.0003640.493398 NR_046099 LOC284757 6.913 8.028 6.894 7.534 7.376 0.0000010.000004 0.000039 0.000364 0.493398

TABLE 2 Severe versus Mild Area Under Curve (AUC) SEQ HC vs. HC vs. HCvs. inSIRS vs. ID Database Gene Sick SIRS ipSIRS ipSIRS Mild vs. Mildvs. Severe vs. Number ID Name AUC AUC AUC AUC Severe AUC Shock AUC ShockAUC 195 NM_004897 MINPP1 0.689217443 0.699775533 0.685388685 0.5321345320.88707483 0.779591837 0.488435374 504 NM_004897 MINPP1 0.6892174430.699775533 0.685388685 0.532134532 0.88707483 0.779591837 0.488435374285 NM_019091 PLEKHA3 0.584378734 0.644781145 0.562474562 0.5417915420.874829932 0.794285714 0.619047619 587 NM_019091 PLEKHA3 0.5843787340.644781145 0.562474562 0.541791542 0.874829932 0.794285714 0.619047619282 NM_002692 POLE2 0.675029869 0.693602694 0.668294668 0.5011655010.854421769 0.707755102 0.563265306 584 NM_002692 POLE2 0.6750298690.693602694 0.668294668 0.501165501 0.854421769 0.707755102 0.563265306288 NM_024613 PLEKHF2 0.654868578 0.667227834 0.65038665 0.5387945390.850340136 0.692244898 0.718367347 590 NM_024613 PLEKHF2 0.6548685780.667227834 0.65038665 0.538794539 0.850340136 0.692244898 0.718367347190 NM_176818 SFRS9 0.597520908 0.557800224 0.653846154 0.7489177490.840816327 0.79755102 0.587755102 499 NM_176818 SFRS9 0.5975209080.557800224 0.653846154 0.748917749 0.840816327 0.79755102 0.587755102170 NM_003608 GPR65 0.765681004 0.735690236 0.776556777 0.60039960.839455782 0.615510204 0.740136054 480 NM 003608 GPR65 0.7656810040.735690236 0.776556777 0.6003996 0.839455782 0.615510204 0.740136054232 gi|14250459 NA 0.571983274 0.7003367 0.525437525 0.6613386610.838095238 0.83755102 0.559183673 gi|14250459 NA 0.571983274 0.70033670.525437525 0.661338661 0.838095238 0.83755102 0.559183673 197 NM_006969ZNF28 0.689964158 0.837261504 0.636548637 0.670662671 0.83673469410.796734694 0.536054422 506 NM_006969 ZNF28 0.689964158 0.8372615040.636548637 0.670662671 0.836734694 0.796734694 0.536054422 81 NR_046099LOC284757 0.738948626 0.939393939 0.666259666 0.835497835 0.8340136050.749387755 0.613605442 NR_046099 LOC284757 0.738948626 0.9393939390.666259666 0.835497835 0.834013605 0.749387755 0.613605442 71 NM_002269KPNA5 0.85483871 0.895061728 0.84025234 0.564768565 0.8312925170.844897959 0.530612245 387 NM_002269 KPNA5 0.85483871 0.8950617280.84025234 0.564768565 0.831292517 0.844897959 0.530612245

TABLE 3 Shock vs. Mild p Value SEQ pval. pval. pval pval pval IDDatabase Gene HC inSIRS Mild Severe Shock HC.vs. inSIRS. Severe.vs.Shock.vs. Shock.vs. Number ID Name Mean Mean Mean Mean Mean Othervs.IpSIRS Mild Mild Severe 59 NM_014232 VAMP2 9.213 8.896 9.016 8.4548.353 0.000000 0.297018 0.000084 0.000000 0.708038 376 NM_014232 VAMP29.213 8.896 9.016 8.454 8.353 0.000000 0.297018 0.000084 0.0000000.708038 71 NM_002269 KPNA5 6.822 5.908 6.451 5.758 5.712 0.0000001.000000 0.000021 0.000000 0.945115 387 NM_002269 KPNA5 6.822 5.9086.451 5.758 5.712 0.000000 1.000000 0.000021 0.000000 0.945115 232gi|14250459 NA 6.389 5.970 6.875 5.976 6.059 1.000000 0.638753 0.0000010.000000 0.869569 gi|14250459 NA 6.389 5.970 6.875 5.976 6.059 1.0000000.638753 0.000001 0.000000 0.869569 246 NM_032828 ZNF587 8.514 8.8168.783 8.381 8.101 1.000000 0.003242 0.018153 0.000001 0.136854 549 NM032828 ZNF587 8.514 8.816 8.783 8.381 8.101 1.000000 0.003242 0.0181530.000001 0.136854 195 NM_004897 MINPP1 8.212 7.697 8.228 7.151 7.3170.006705 1.000000 0.000005 0.000008 0.707929 504 NM_004897 MINPP1 8.2127.697 8.228 7.151 7.317 0.006705 1.000000 0.000005 0.000008 0.707929 107NM_153236 GIMAP7 9.533 8.865 8.974 8.682 8.112 0.000000 1.0000000.310769 0.000008 0.014285 420 NM_153236 GIMAP7 9.533 8.865 8.974 8.6828.112 0.000000 1.000000 0.310769 0.000008 0.014285 285 NM_019091 PLEKHA37.058 6.910 7.281 6.689 6.825 1.000000 1.000000 0.000001 0.0000110.409707 587 NM_019091 PLEKHA3 7.058 6.910 7.281 6.689 6.825 1.0000001.000000 0.000001 0.000011 0.409707 58 NM_002121 HLA-DPB1 11.414 10.66510.623 9.971 9.578 0.000000 0.067333 0.026428 0.000013 0.253098 375NM_002121 HLA-DPB1 11.414 10.665 10.623 9.971 9.578 0.000000 0.0673330.026428 0.000013 0.253098 304 NR_033759 ATP5L 7.242 7.337 7.379 6.8246.772 1.000000 0.748516 0.000612 0.000014 0.929559 NR_033759 ATP5L 7.2427.337 7.379 6.824 6.772 1.000000 0.748516 0.000612 0.000014 0.929559 197NM_006969 ZNF28 4.936 4.511 5.008 4.554 4.612 0.021118 0.027741 0.0000200.000018 0.814925 506 NM_006969 ZNF28 4.936 4.511 5.008 4.554 4.6120.021118 0.027741 0.000020 0.000018 0.814925

TABLE 4 Shock vs. Mild Area Under Curve (AUC) SEQ ID HC vs. Sick HC vs.SIRS HC vs. inSIRS vs. Mild vs. Mild vs. Severe vs. Number Database IDGene Name AUC AUC ipSIRS AUC ipSIRS AUC Severe AUC Shock AUC Shock AUC71 NM_002269 KPNA5 0.85483871 0.895061728 0.84025234 0.5647685650.831292517 0.844897959 0.530612245 387 NM_002269 KPNA5 0.854838710.895061728 0.84025234 0.564768565 0.831292517 0.844897959 0.530612245246 NM_032828 ZNF587 0.506571087 0.632435466 0.539072039 0.689643690.723809524 0.84244898 0.644897959 549 NM_032828 ZNF587 0.5065710870.632435466 0.539072039 0.68964369 0.723809524 0.84244898 0.644897959232 gi|14250459 NA 0.571983274 0.7003367 0.525437525 0.6613386610.838095238 0.83755102 0.559183673 gi|14250459 NA 0.571983274 0.70033670.525437525 0.661338661 0.838095238 0.83755102 0.559183673 59 NM_014232VAMP2 0.814366786 0.78338945 0.825600326 0.636363636 0.8108843540.834285714 0.54829932 376 NM_014232 VAMP2 0.814366786 0.783389450.825600326 0.636363636 0.810884354 0.834285714 0.54829932 107 NM_153236GIMAP7 0.829898447 0.80359147 0.839438339 0.603063603 0.6176870750.826938776 0.710204082 420 NM_153236 GIMAP7 0.829898447 0.803591470.839438339 0.603063603 0.617687075 0.826938776 0.710204082 58 NM_002121HLA-DPB1 0.857228196 0.814814815 0.872608873 0.682317682 0.6938775510.809795918 0.628571429 375 NM_002121 HLA-DPB1 0.857228196 0.8148148150.872608873 0.682317682 0.693877551 0.809795918 0.628571429 110gi|13182974 NA 0.796893668 0.92704826 0.74969475 0.743589744 0.6816326530.808163265 0.617687075 423 gi|13182974 NA 0.796893668 0.927048260.74969475 0.743589744 0.681632653 0.808163265 0.617687075 64 NM_004172SLC1A3 0.954599761 0.985409652 0.943426943 0.636030636 0.5578231290.806530612 0.823129252 381 NM_004172 SLC1A3 0.954599761 0.9854096520.943426943 0.636030636 0.557823129 0.806530612 0.823129252 190NM_176818 SFRS9 0.597520908 0.557800224 0.653846154 0.7489177490.840816327 0.79755102 0.587755102 499 NM_176818 SFRS9 0.5975209080.557800224 0.653846154 0.748917749 0.840816327 0.79755102 0.587755102197 NM_006969 ZNF28 0.689964158 0.837261504 0.636548637 0.6706626710.836734694 0.796734694 0.536054422 506 NM_006969 ZNF28 0.6899641580.837261504 0.636548637 0.670662671 0.836734694 0.796734694 0.536054422

TABLE 5 Shock versus Severe p Value pval pval pval SEQ ID Gene inSIRSMild Severe Shock pval.HC.vs. pval.inSIRS.vs. Severe.vs. Shock.vs.Shock.vs. Number Database ID Name HC Mean Mean Mean Mean Mean OtherSepsis Mild Mild Severe 79 NM_005546 ITK 9.271 8.099 8.227 8.536 7.6350.000000 1.000000 0.276607 0.002832 0.000063 395 NM_005546 ITK 9.2718.099 8.227 8.536 7.635 0.000000 1.000000 0.276607 0.002832 0.000063 34NM_001744 CAMK4 8.155 6.723 6.902 7.152 6.470 0.000000 1.000000 0.3059820.011176 0.000339 352 NM_001744 CAMK4 8.155 6.723 6.902 7.152 6.4700.000000 1.000000 0.305982 0.011176 0.000339 64 NM_004172 SLC1A3 5.8496.892 6.472 6.447 7.373 0.000000 1.000000 0.993673 0.000056 0.000352 381NM_004172 SLC1A3 5.849 6.892 6.472 6.447 7.373 0.000000 1.0000000.993673 0.000056 0.000352 171 NR_046000 IRF4 8.200 7.491 7.843 8.3817.762 0.000105 0.000070 0.002770 0.825556 0.000501 NR_046000 IRF4 8.2007.491 7.843 8.381 7.762 0.000105 0.000070 0.002770 0.825556 0.000501 271NM_173485 TSHZ2 7.382 6.972 6.846 7.429 6.929 0.004682 1.000000 0.0000510.739871 0.000534 574 NM_173485 TSHZ2 7.382 6.972 6.846 7.429 6.9290.004682 1.000000 0.000051 0.739871 0.000534 22 NM_005449 FAIM3 10.2599.101 9.036 9.174 8.464 0.000000 1.000000 0.732360 0.001453 0.000582 340NM_005449 FAIM3 10.259 9.101 9.036 9.174 8.464 0.000000 1.0000000.732360 0.001453 0.000582 44 NM_032047 B3GNT5 6.871 8.033 8.009 7.7448.548 0.000000 1.000000 0.438680 0.013149 0.000955 362 NM_032047 B3GNT56.871 8.033 8.009 7.744 8.548 0.000000 1.000000 0.438680 0.0131490.000955 229 NM_207647 FSD1L 4.605 4.402 4.801 4.565 5.099 1.0000000.000000 0.235142 0.050177 0.001077 534 NM_207647 FSD1L 4.605 4.4024.801 4.565 5.099 1.000000 0.000000 0.235142 0.050177 0.001077 198gi|21538810 NPCDR1 5.404 5.022 4.784 5.166 4.817 0.000001 1.0000000.000589 0.919120 0.001847 507 gi|21538810 NPCDR1 5.404 5.022 4.7845.166 4.817 0.000001 1.000000 0.000589 0.919120 0.001847 220 NM_207627ABCG1 8.318 7.923 7.960 8.214 7.791 0.000000 1.000000 0.112606 0.2709610.003184 526 NM_207627 ABCG1 8.318 7.923 7.960 8.214 7.791 0.0000001.000000 0.112606 0.270961 0.003184

TABLE 6 Shock versus Severe Area Under Curve (AUC) SEQ ID HC vs. Sick HCvs. SIRS HC vs. inSIRS vs. Mild vs. Mild vs. Severe vs. Number DatabaseID Gene Name AUC AUC ipSIRS AUC ipSIRS AUC Severe AUC Shock AUC ShockAUC 64 NM_004172 SLC1A3 0.954599761 0.985409652 0.943426943 0.6360306360.557823129 0.806530612 0.823129252 381 NM_004172 SLC1A3 0.9545997610.985409652 0.943426943 0.636030636 0.557823129 0.806530612 0.82312925279 NM_005546 ITK 0.888888889 0.873737374 0.894383394 0.5208125210.646258503 0.735510204 0.805442177 395 NM_005546 ITK 0.8888888890.873737374 0.894383394 0.520812521 0.646258503 0.735510204 0.80544217722 NM_005449 FAIM3 0.951612903 0.930415264 0.959299959 0.5960705960.57414966 0.749387755 0.793197279 340 NM_005449 FAIM3 0.9516129030.930415264 0.959299959 0.596070596 0.57414966 0.749387755 0.793197279171 NR_046000 IRF4 0.776433692 0.946127946 0.714896215 0.7412587410.759183673 0.604897959 0.782312925 NR_046000 IRF4 0.7764336920.946127946 0.714896215 0.741258741 0.759183673 0.604897959 0.78231292534 NM_001744 CAMK4 0.939217443 0.921436588 0.945665446 0.559773560.594557823 0.725714286 0.776870748 352 NM_001744 CAMK4 0.9392174430.921436588 0.945665446 0.55977356 0.594557823 0.725714286 0.776870748271 NM_173485 TSHZ2 0.705197133 0.733445567 0.694953195 0.5434565430.828571429 0.528979592 0.776870748 574 NM_173485 TSHZ2 0.7051971330.733445567 0.694953195 0.543456543 0.828571429 0.528979592 0.77687074888 NM_181506 LRRC70 0.795997611 0.49382716 0.901098901 0.8578088580.736054422 0.515102041 0.76462585 402 NM_181506 LRRC70 0.7959976110.49382716 0.901098901 0.857808858 0.736054422 0.515102041 0.76462585176 NM_002230 JUP 0.830346476 0.75308642 0.858363858 0.5730935730.500680272 0.765714286 0.760544218 485 NM_002230 JUP 0.8303464760.75308642 0.858363858 0.573093573 0.500680272 0.765714286 0.76054421844 NM_032047 B3GNT5 0.9369773 0.948933782 0.932641433 0.5487845490.565986395 0.692244898 0.759183673 362 NM_032047 B3GNT5 0.93697730.948933782 0.932641433 0.548784549 0.565986395 0.692244898 0.759183673235 NM_003531 HIST1H3C 0.781212664 0.881593715 0.744810745 0.6723276720.643537415 0.651428571 0.752380952 539 NM_003531 HIST1H3C 0.7812126640.881593715 0.744810745 0.672327672 0.643537415 0.651428571 0.752380952

Example 2 Differentiating inSIRS and ipSIRS in Post-Surgical and MedicalPatients

Surgical and medical patients often develop inSIRS post-surgery,post-procedural or as part of a co-morbidity or co-morbidities. Suchinpatients have a higher incidence of inSIRS and a higher risk ofdeveloping ipSIRS. Medical care in such patients therefore involvesmonitoring for signs of inSIRS and ipSIRS, differentiating between thesetwo conditions, and determining at the earliest possible time when apatient transitions from inSIRS to ipSIRS. The treatment and managementof inSIRS and ipSIRS patients is different, since inSIRS patients can beput on mild anti-inflammatory drugs or anti-pyretics and ipSIRS patientsmust be started on antibiotics as soon as possible for best outcomes.Monitoring post-surgical and medical patients on a regular basis withbiomarkers of the present invention will allow nursing and medicalpractitioners to differentiate inSIRS and ipSIRS at an early stage andhence make informed decisions on choice of therapies and patientmanagement procedures, and ultimately response to therapy. Informationprovided by these biomarkers will therefore allow medical practitionersto tailor and modify therapies to ensure patients recover quickly fromsurgery and do not develop ipSIRS. Less time in hospital and lesscomplications leads to considerable savings in medical expensesincluding through less occupancy time and appropriate use and timing ofmedications. Practical examples of the use of the biomarkers in Tables 7and 8 are described.

Table 7 lists the top 10 biomarkers (of 216) in order of ascending pvalue when comparing the two clinical groups of inSIRS and ipSIRS. A SEQID NO. is provided for each IRS biomarker (IRS biomarker polynucleotidesrange from SEQ ID NO. 1-319, IRS biomarker polypeptides range from SEQID No. 320-619), along with a database identification tag (e.g. NM_), agene name (Gene Name) if there is one, mean expression values forhealthy (HC), inSIRS, mild sepsis, severe sepsis and septic shock, and pvalues for HC vs. all other groups, inSIRS vs. ipSIRS, mild sepsisversus severe sepsis, mild sepsis versus septic shock and septic shockversus severe sepsis. All biomarkers have clinical utility indistinguishing inSIRS and ipSIRS and for distinguishing inSIRS andipSIRS as early as possible. Seven (7) of these biomarkers are alsouseful in distinguishing healthy control from sick although this has noclinical utility for post-surgical or medical patients. Some of thesebiomarkers also have limited utility in determining ipSIRS severity asindicated by respective p values less than 0.05. By example, in Table 7,inSIRS vs. ipSIRS p Value, it can be seen that the gene C11orf82 has asignificant p value for both inSIRS versus ipSIRS and Healthy versusother groups and therefore has utility in separating healthy and inSIRSpatients from septic patients. From the columns in the table containingmean expression data it can be seen that C11orf82 is down-regulated inboth inSIRS (5.888) and healthy controls (5.776) compared to septicpatients of all classes (mild (6.889), severe (7.153) and shock (7.293))(7.281) (also see FIG. 4).

Table 8 lists the top 10 biomarkers (of 104 with an AUC >0.8) in orderof descending AUC when comparing the two clinical groups of inSIRS andipSIRS and it can be seen that C11orf82, PLAC8 and INSIG1 have AUCs of0.9477, 0.9210 and 0.9120, respectively (see also FIGS. 4, 5 and 6).

TABLE 7 inSIRS VERSUS ipSIRS p Value pval pval HC pval pval Shock SEQ IDGene HC inSIRS Mild Severe Shock vs. pval inSIRS Severe Shock vs. NumberDatabase ID Name Mean Mean Mean Mean Mean Other vs. ipSIRS vs. Mild vs.Mild Severe 12 NM_145018 C11orf82 5.776 5.888 6.889 7.153 7.293 0.0000000.000000 0.322762 0.032568 0.722429 330 NM_145018 C11orf82 5.776 5.8886.889 7.153 7.293 0.000000 0.000000 0.322762 0.032568 0.722429 83NR_036641 PDGFC 6.098 6.117 6.987 7.044 7.466 0.000000 0.000000 0.9706370.064634 0.196970 NR_036641 PDGFC 6.098 6.117 6.987 7.044 7.466 0.0000000.000000 0.970637 0.064634 0.196970 106 NM_018375 SLC39A9 8.038 7.7198.121 8.368 8.428 1.000000 0.000000 0.034062 0.001276 0.808136 419NM_018375 SLC39A9 8.038 7.719 8.121 8.368 8.428 1.000000 0.0000000.034062 0.001276 0.808136 150 NM_030796 VOPP1 9.302 8.771 9.510 9.3189.517 1.000000 0.000000 0.298375 0.997162 0.269787 461 NM_030796 VOPP19.302 8.771 9.510 9.318 9.517 1.000000 0.000000 0.298375 0.9971620.269787 73 NM_001257400 CD63 9.235 9.126 9.718 9.990 10.159 0.0000000.000000 0.156468 0.002260 0.485665 389 NM_001257400 CD63 9.235 9.1269.718 9.990 10.159 0.000000 0.000000 0.156468 0.002260 0.485665 55NM_014143 CD274 5.508 5.656 7.557 7.211 7.237 0.000000 0.000000 0.5366620.490374 0.996684 372 NM_014143 CD274 5.508 5.656 7.557 7.211 7.2370.000000 0.000000 0.536662 0.490374 0.996684 111 NM_198336 INSIG1 8.0817.370 8.062 7.867 7.913 0.001237 0.000000 0.123875 0.197540 0.883915 424NM_198336 INSIG1 8.081 7.370 8.062 7.867 7.913 0.001237 0.0000000.123875 0.197540 0.883915 76 ENST00000443533 DDAH2 8.067 8.170 8.6308.707 9.015 0.000000 0.000000 0.868573 0.011535 0.108528 392ENST00000443533 DDAH2 8.067 8.170 8.630 8.707 9.015 0.000000 0.0000000.868573 0.011535 0.108528 115 NM_003546 HIST1H4L 9.807 7.908 9.4669.602 9.065 0.000032 0.000000 0.878290 0.231084 0.140998 428 NM_003546HIST1H4L 9.807 7.908 9.466 9.602 9.065 0.000032 0.000000 0.8782900.231084 0.140998 226 NM_003537 HIST1H3B 8.783 7.684 8.739 9.501 8.8521.000000 0.000000 0.042709 0.908040 0.098544 532 NM_003537 HIST1H3B8.783 7.684 8.739 9.501 8.852 1.000000 0.000000 0.042709 0.9080400.098544

TABLE 8 inSIRS versus ipSIRS Area Under Curve (AUC) SEQ ID HC vs. SickHC vs. SIRS HC vs. inSIRS vs. Mild vs. Mild vs. Severe vs. NumberDatabase ID Gene Name AUC AUC ipSIRS AUC ipSIRS AUC Severe AUC Shock AUCShock AUC 12 NM_145018 C11orf82 0.873058542 0.580246914 0.9792429790.947718948 0.619047619 0.650612245 0.555102041 330 NM_145018 C11orf820.873058542 0.580246914 0.979242979 0.947718948 0.619047619 0.6506122450.555102041 72 NM_001130715 PLAC8 0.635902031 0.828282828 0.8042328040.921078921 0.506122449 0.653061224 0.642176871 388 NM_001130715 PLAC80.635902031 0.828282828 0.804232804 0.921078921 0.506122449 0.6530612240.642176871 132 gi|21757933 NA 0.533004779 0.867564534 0.5883190880.912753913 0.708843537 0.631020408 0.540136054 445 gi|21757933 NA0.533004779 0.867564534 0.588319088 0.912753913 0.708843537 0.6310204080.540136054 111 NM_198336 INSIG1 0.695191159 0.957351291 0.60012210.912087912 0.666666667 0.631836735 0.518367347 424 NM_198336 INSIG10.695191159 0.957351291 0.6001221 0.912087912 0.666666667 0.6318367350.518367347 90 gi|21749325 CDS2 0.669354839 0.730078563 0.8142043140.907092907 0.586394558 0.56244898 0.504761905 gi|21749325 CDS20.669354839 0.730078563 0.814204314 0.907092907 0.586394558 0.562448980.504761905 150 NM_030796 VOPP1 0.53875448 0.937710438 0.6059218560.906759907 0.63537415 0.544489796 0.66122449 461 NM_030796 VOPP10.53875448 0.937710438 0.605921856 0.906759907 0.63537415 0.5444897960.66122449 106 NM_018375 SLC39A9 0.559587814 0.775533109 0.6811151810.901098901 0.730612245 0.735510204 0.557823129 419 NM_018375 SLC39A90.559587814 0.775533109 0.681115181 0.901098901 0.730612245 0.7355102040.557823129 37 NM_199135 FOXD4L3 0.815860215 0.49382716 0.9281644280.900765901 0.597278912 0.608163265 0.48707483 355 NM_199135 FOXD4L30.815860215 0.49382716 0.928164428 0.900765901 0.597278912 0.6081632650.48707483 68 NM_018639 WSB2 0.782108722 0.581369248 0.9139194140.9004329 0.555102041 0.533877551 0.530612245 384 NM_018639 WSB20.782108722 0.581369248 0.913919414 0.9004329 0.555102041 0.5338775510.530612245 73 NM_001257400 CD63 0.73655914 0.612233446 0.8630443630.897768898 0.644897959 0.72244898 0.613605442 389 NM_001257400 CD630.73655914 0.612233446 0.863044363 0.897768898 0.644897959 0.722448980.613605442

Example 3 Differentiating Both inSIRS and ipSIRS in Emergency DepartmentPatients and Determining Degree of Illness

Patients presenting to emergency departments often have a fever, whichis one (of four) of the clinical signs of inSIRS. Such patients need tobe assessed to determine if they have either inSIRS or ipSIRS. Furtherit is important to determine how sick they are to be able to make ajudgement call on whether to admit the patient or not. As mentionedabove, the treatment and management of pyretic, inSIRS and septicpatients are different. By way of example, a patient with a feverwithout other inSIRS clinical signs and no obvious source of infectionmay be sent home, or provided with other non-hospital services, withoutfurther hospital treatment. However, a patient with a fever may haveearly ipSIRS and not admitting such a patient may put their life atrisk. Because these biomarkers can differentiate inSIRS and ipSIRS anddetermine how sick a patient is they will allow medical practitioners totriage emergency department patients quickly and effectively. Accuratetriage decision-making insures that patients requiring hospitaltreatment are given it, and those that don't are provided with otherappropriate services. Practical examples of the use of the biomarkers inTables 9 and 10 are described.

Table 9 lists 30 significant biomarkers when comparing the groups ofhealthy and sick (sick consisting of those patients with either inSIRSor ipSIRS) and inSIRS versus ipSIRS. A SEQ ID NO. is provided for eachIRS biomarker (IRS biomarker polynucleotides range from SEQ ID NO.1-319, IRS biomarker polypeptides range from SEQ ID No. 320-619), alongwith a database identification tag (e.g. NM_), a gene name (Gene Name)if there is one, mean expression values for healthy (HC), inSIRS, mildsepsis, severe sepsis and septic shock, and p values for HC vs. allother groups, inSIRS vs. ipSIRS, mild sepsis versus severe sepsis, mildsepsis versus septic shock and septic shock versus severe sepsis. Suchbiomarkers have clinical utility in distinguishing healthy from sickpatients and inSIRS from ipSIRS patients. By example, in Table 5,Healthy versus inSIRS versus ipSIRS, it can be seen that the gene FCGR1Ahas a significant p value for both inSIRS versus ipSIRS and Healthyversus other groups and therefore has utility in separating healthy andinSIRS and ipSIRS patients. From the columns in the table containingmean expression data it can be seen that FCGR1A is up-regulated ininSIRS (9.281) compared to healthy controls (7.871) but more so inipSIRS patients (9.985-10.308). Such a upward gradient in geneexpression can be used to determine the degree of illness in patientspresenting to an emergency department allowing clinicians to riskstratify and triage with greater certainty (see also FIG. 7).

Table 10 lists 10 significant biomarkers when comparing the groups ofhealthy and sick (sick consisting of those patients with either inSIRSor ipSIRS) and inSIRS versus ipSIRS. A SEQ ID NO. is provided for eachIRS biomarker (IRS biomarker polynucleotides range from SEQ ID NO.1-319, IRS biomarker polypeptides range from SEQ ID No. 320-619), alongwith a database identification tag (e.g. NM_), a gene name (Gene Name)if there is one, mean expression values for healthy (HC), inSIRS, mildsepsis, severe sepsis and septic shock, and p values for HC vs. allother groups, inSIRS vs. ipSIRS, mild sepsis versus severe sepsis, mildsepsis versus septic shock and septic shock versus severe sepsis. Suchbiomarkers have clinical utility in distinguishing healthy from sickpatients and inSIRS from ipSIRS patients. By example, in Table 10,Healthy versus inSIRS versus ipSIRS, it can be seen that the gene CHI3L1has a significant p value for both inSIRS versus ipSIRS and Healthyversus other groups and therefore has utility in separating healthy andinSIRS and septic patients. From the columns in the table containingmean expression data it can be seen that CHI3L1 is down-regulated ininSIRS (9.876) compared to healthy controls (10.47) but more so inipSIRS patients (8.64-9.035). Such a downward gradient in geneexpression can be used to determine the degree of illness in patientspresenting to an emergency department allowing clinicians to riskstratify and triage with greater certainty (see also FIG. 8).

TABLE 9 Healthy versus inSIRS versus ipSIRS p Value pval pval pval pvalSEQ ID inSIRS Mild Severe Shock pval HC inSIRS vs. Severe vs. Shock vs.Shock vs. Number Database ID Gene Name HC Mean Mean Mean Mean Mean vs.Other ipSIRS Mild Mild Severe 79 NR_045213 FCGR1A 7.871 9.281 10.3089.985 10.273 0.000000 0.001046 0.284201 0.980298 0.366022 395 NR_045213FCGR1A 7.871 9.281 10.308 9.985 10.273 0.000000 0.001046 0.2842010.980298 0.366022 34 NM_153046 TDRD9 4.986 5.567 6.483 6.937 7.3850.000000 0.000000 0.248195 0.001153 0.259068 352 NM_153046 TDRD9 4.9865.567 6.483 6.937 7.385 0.000000 0.000000 0.248195 0.001153 0.259068 64NM_020370 GPR84 6.712 8.157 9.030 8.980 9.583 0.000000 0.001894 0.9895730.184680 0.221197 381 NM_020370 GPR84 6.712 8.157 9.030 8.980 9.5830.000000 0.001894 0.989573 0.184680 0.221197 171 NM_018367 ACER3 7.3177.845 8.701 8.417 9.050 0.000000 0.000000 0.362961 0.132905 0.008450NM_018367 ACER3 7.317 7.845 8.701 8.417 9.050 0.000000 0.000000 0.3629610.132905 0.008450 271 NM_000860 HPGD 5.621 6.238 7.085 6.908 7.9460.000000 0.000025 0.895298 0.035905 0.027021 574 NM_000860 HPGD 5.6216.238 7.085 6.908 7.946 0.000000 0.000025 0.895298 0.035905 0.027021 22NM_006418 OLFM4 6.365 7.209 8.023 9.641 9.322 0.000000 0.000069 0.0031500.006691 0.784808 340 NM_006418 OLFM4 6.365 7.209 8.023 9.641 9.3220.000000 0.000069 0.003150 0.006691 0.784808 44 NM_004054 C3AR1 8.4299.449 10.261 10.439 10.593 0.000000 0.000016 0.650271 0.142678 0.725241362 NM_004054 C3AR1 8.429 9.449 10.261 10.439 10.593 0.000000 0.0000160.650271 0.142678 0.725241 229 NM_002934 RNASE2 9.164 10.500 11.24311.670 11.388 0.000000 0.002979 0.095954 0.690976 0.351809 534 NM_002934RNASE2 9.164 10.500 11.243 11.670 11.388 0.000000 0.002979 0.0959540.690976 0.351809 198 NM_032045 KREMEN1 8.626 9.409 10.143 10.189 10.0550.000000 0.000079 0.962640 0.837239 0.731337 507 NM_032045 KREMEN1 8.6269.409 10.143 10.189 10.055 0.000000 0.000079 0.962640 0.837239 0.731337220 NM_003268 TLR5 7.747 9.010 9.726 9.979 10.311 0.000000 0.0002250.275728 0.000244 0.110996 526 NM_003268 TLR5 7.747 9.010 9.726 9.97910.311 0.000000 0.000225 0.275728 0.000244 0.110996 281 NM_153021 PLB18.205 8.887 9.574 9.463 10.019 0.000000 0.000133 0.872838 0.0593980.037699 583 NM_153021 PLB1 8.205 8.887 9.574 9.463 10.019 0.0000000.000133 0.872838 0.059398 0.037699 214 NM_004482 GALNT3 5.685 6.2516.916 6.728 7.075 0.000000 0.000000 0.407446 0.422801 0.051201 520NM_004482 GALNT3 5.685 6.251 6.916 6.728 7.075 0.000000 0.0000000.407446 0.422801 0.051201 27 NM_001816 CEACAM8 7.336 7.874 8.503 9.7759.287 0.000000 0.001298 0.011921 0.098854 0.501991 345 NM_001816 CEACAM87.336 7.874 8.503 9.775 9.287 0.000000 0.001298 0.011921 0.0988540.501991 242 NM_007115 TNFAIP6 7.738 9.246 9.829 9.631 9.738 0.0000001.000000 0.712067 0.908467 0.905260 545 NM_007115 TNFAIP6 7.738 9.2469.829 9.631 9.738 0.000000 1.000000 0.712067 0.908467 0.905260 170NM_016021 UBE2J1 8.792 9.555 10.118 10.044 10.335 0.000000 0.0000150.817659 0.104460 0.049488 480 NM_016021 UBE2J1 8.792 9.555 10.11810.044 10.335 0.000000 0.000015 0.817659 0.104460 0.049488 278 NM_015268DNAJC13 7.507 8.083 8.596 8.693 8.878 0.000000 0.000000 0.8337180.133216 0.512817 580 NM_015268 DNAJC13 7.507 8.083 8.596 8.693 8.8780.000000 0.000000 0.833718 0.133216 0.512817

TABLE 10 Healthy versus inSIRS versus ipSIRS p Value SEQ ID pval pvalpval pval Num- HC inSIRS Mild Severe Shock pval HC inSIRS Severe vs.Shock Shock vs. ber Database ID Gene Name Mean Mean Mean Mean Mean vs.Other vs. ipSIRS Mild vs. Mild Severe 104 NM_001276 CHI3L1 10.470 9.8768.640 9.035 8.726 0.000000 0.000056 0.485576 0.954853 0.641602 417NM_001276 CHI3L1 10.470 9.876 8.640 9.035 8.726 0.000000 0.0000560.485576 0.954853 0.641602 122 NM_001143804 PHOSPHO1 11.398 10.82610.374 9.837 10.185 0.000000 0.048380 0.088690 0.661703 0.354179 435NM_001143804 PHOSPHO1 11.398 10.826 10.374 9.837 10.185 0.0000000.048380 0.088690 0.661703 0.354179 40 NM_016523 KLRF1 6.343 5.438 5.0224.504 4.543 0.000000 0.007278 0.033428 0.021421 0.979558 358 NM_016523KLRF1 6.343 5.438 5.022 4.504 4.543 0.000000 0.007278 0.033428 0.0214210.979558 33 NM_000953 PTGDR 9.310 8.373 8.028 7.790 7.577 0.0000000.007043 0.500548 0.040553 0.570947 351 NM_000953 PTGDR 9.310 8.3738.028 7.790 7.577 0.000000 0.007043 0.500548 0.040553 0.570947 103ENST00000381907 KLRD1 8.651 8.097 7.766 7.201 7.123 0.000000 0.0118380.056985 0.008125 0.944270 416 ENST00000381907 KLRD1 8.651 8.097 7.7667.201 7.123 0.000000 0.011838 0.056985 0.008125 0.944270

Example 4 Differentiating Healthy from Sick Patients and DeterminingDegree of Illness

Patients presenting to medical clinics often have any one of the fourclinical signs of inSIRS (increased heart rate, increased respiratoryrate, abnormal white blood cell count, fever or hypothermia). Manydifferent clinical conditions can present with one of the four clinicalsigns of inSIRS and such patients need to be assessed to determine ifthey have either inSIRS or ipSIRS and to exclude other differentialdiagnoses. By way of example, a patient with colic might also presentwith clinical signs of increased heart rate. Differential diagnosescould be (but not limited to) appendicitis, urolithiasis, cholecystitis,pancreatitis, enterocolitis. In each of these conditions it would beimportant to determine if there was a systemic inflammatory response(inSIRS) or whether an infection was contributing to the condition. Thetreatment and management of patients with and without systemicinflammation and/or infection are different. Because these biomarkerscan differentiate healthy from sick (inSIRS and ipSIRS), and determinethe degree of systemic involvement, the use of them will allow medicalpractitioners to determine the next medical procedure(s) to perform tosatisfactorily resolve the patient issue. Practical examples of the useof the biomarkers in Tables 11, 12, 13 and 14 are described.

Table 11 lists 20 significant biomarkers (of 150) when comparing thegroups of healthy and sick (sick consisting of those patients witheither inSIRS or ipSIRS). A SEQ ID NO. is provided for each IRSbiomarker (IRS biomarker polynucleotides range from SEQ ID NO. 1-319,IRS biomarker polypeptides range from SEQ ID No. 320-619), along with adatabase identification tag (e.g. NM_), a gene name (Gene Name) if thereis one, mean expression values for healthy (HC), inSIRS, mild sepsis,severe sepsis and septic shock, and p values for HC vs. all othergroups, inSIRS vs. ipSIRS, mild sepsis versus severe sepsis, mild sepsisversus septic shock and septic shock versus severe sepsis. Suchbiomarkers have clinical utility in distinguishing healthy from sickpatients and determining the level of systemic inflammation and/orinfection. For example, in Table 11, Healthy versus Sick, it can be seenthat the gene CD177 has a significant p value for healthy control versusother groups and therefore has utility in separating healthy and sickpatients. From the columns in the table containing mean expression datait can be seen that CD177 is up-regulated in inSIRS (10.809) compared tohealthy controls (8.091) but more so in ipSIRS patients (11.267-12.088).Such up-regulated differences in gene expression can be used todetermine the degree of systemic inflammation and infection in patientspresenting to clinics allowing clinicians to more easily determine thenext medical procedure(s) to perform to satisfactorily resolve thepatient issue (see also FIG. 9).

Further, and by example, in Table 11, Healthy versus Sick, it can beseen that the gene GNLY has a significant p value for healthy controlversus other groups and therefore has utility in separating healthy andsick patients. From the columns in the table containing mean expressiondata it can be seen that GNLY is down-regulated in inSIRS (9.428)compared to healthy controls (10.653) but more so in septic patients(9.305-8.408). GNLY has an AUC of 0.9445 (not shown) for separatinghealthy and sick patients. Such down-regulated differences in geneexpression can be used to determine the degree of systemic inflammationand infection in patients presenting to clinics allowing clinicians tomore easily determine the next medical procedure(s) to perform tosatisfactorily resolve the patient issue (see also FIG. 10).

Table 12 lists the top 10 biomarkers (of 118 with an AUC of at least0.8) for separating healthy from sick patients (sick being thosepatients with either inSIRS or ipSIRS) by decreasing value of Area UnderCurve (AUC). It can be seen that the highest AUC is for CD177 forseparating healthy from sick (0.9929) (see also FIG. 9).

Table 13 lists the top 10 biomarkers (of 152 with an AUC of at least0.8) for separating healthy from inSIRS patients by decreasing value ofArea Under Curve (AUC). It can be seen that the highest AUC is for BMXfor separating healthy from inSIRS (1). That is, this biomarker alonecan perfectly separate these two groups (see also FIG. 11).

Table 14 lists the top 10 biomarkers (of 140 with an AUC of at least0.8) for separating healthy from ipSIRS patients by decreasing value ofArea Under Curve (AUC). It can be seen that the highest AUC is for TLR5for separating healthy from ipSIRS (0.9945) (see also FIG. 12).

TABLE 11 Healthy versus Sick p Value pval SIRS pval pval pval SEQ ID Gene HC SIRS Mild Severe Shock pval HC vs. Severe Shock vs. Shock vs.Number Database ID Name Mean Mean Mean Mean Mean vs. Other ipSIRS vs.Mild Mild Severe 2 NM_020406 CD177 8.091 10.809 11.267 12.088 12.0440.000000 0.087061 0.048910 0.027926 0.991139 321 NM_020406 CD177 8.09110.809 11.267 12.088 12.044 0.000000 0.087061 0.048910 0.027926 0.99113910 NM_001244438 ARG1 5.410 9.054 7.895 8.254 8.919 0.000000 1.0000000.628534 0.008931 0.209877 329 NM_001244438 ARG1 5.410 9.054 7.895 8.2548.919 0.000000 1.000000 0.628534 0.008931 0.209877 3 NM_004666 VNN17.736 10.013 10.007 10.629 10.876 0.000000 1.000000 0.087388 0.0024020.671136 322 NM_004666 VNN1 7.736 10.013 10.007 10.629 10.876 0.0000001.000000 0.087388 0.002402 0.671136 7 NM_080387 CLEC4D 7.187 9.915 9.2389.152 9.828 0.000000 0.383427 0.945300 0.034026 0.035853 326 NM_080387CLEC4D 7.187 9.915 9.238 9.152 9.828 0.000000 0.383427 0.945300 0.0340260.035853 29 NM_020370 GPR84 6.712 8.157 9.030 8.980 9.583 0.0000000.001894 0.989573 0.184680 0.221197 347 NM_020370 GPR84 6.712 8.1579.030 8.980 9.583 0.000000 0.001894 0.989573 0.184680 0.221197 24NM_003855 IL18R1 5.516 8.101 7.098 7.538 8.097 0.000000 1.0000000.373616 0.001873 0.205385 342 NM_003855 IL18R1 5.516 8.101 7.098 7.5388.097 0.000000 1.000000 0.373616 0.001873 0.205385 65 NM_006418 OLFM46.365 7.209 8.023 9.641 9.322 0.000000 0.000068 0.003150 0.0066910.784808 382 NM_006418 OLFM4 6.365 7.209 8.023 9.641 9.322 0.0000000.000068 0.003150 0.006691 0.784808 11 NR_045213 FCGR1A 7.871 9.28110.308 9.985 10.273 0.000000 0.001046 0.284201 0.980298 0.366022NR_045213 FCGR1A 7.871 9.281 10.308 9.985 10.273 0.000000 0.0010460.284201 0.980298 0.366022 6 NM_002934 RNASE2 9.164 10.500 11.243 11.67011.388 0.000000 0.002979 0.095954 0.690976 0.351809 325 NM_002934 RNASE29.164 10.500 11.243 11.670 11.388 0.000000 0.002979 0.095954 0.6909760.351809 14 NM_006433 GNLY 10.653 9.428 9.305 8.659 8.408 0.0000000.020098 0.014566 0.000045 0.511511 332 NM_006433 GNLY 10.653 9.4289.305 8.659 8.408 0.000000 0.020098 0.014566 0.000045 0.511511

TABLE 12 Healthy versus Sick Area Under Curve (AUC) SEQ HC vs. Sick HCvs. HC vs. SIRS vs. Mild vs. Mild vs. Severe vs. ID Number Database IDGene Name AUC inSIRS AUC ipSIRS AUC ipSIRS AUC Severe AUC Shock AUCShock AUC 2 NM_020406 CD177 0.992980884 0.991582492 0.9934879930.718281718 0.668027211 0.675102041 0.540136054 321 NM_020406 CD1770.992980884 0.991582492 0.993487993 0.718281718 0.668027211 0.6751020410.540136054 7 NM_080387 CLEC4D 0.981780167 0.998877666 0.9755799760.64968365 0.52244898 0.671020408 0.691156463 326 NM_080387 CLEC4D0.981780167 0.998877666 0.975579976 0.64968365 0.52244898 0.6710204080.691156463 18 NM_203281 BMX 0.979988053 1 0.972730973 0.560439560.639455782 0.749387755 0.644897959 336 NM_203281 BMX 0.979988053 10.972730973 0.56043956 0.639455782 0.749387755 0.644897959 3 NM_004666VNN1 0.979241338 0.996632997 0.972934473 0.663003663 0.6489795920.710204082 0.575510204 322 NM_004666 VNN1 0.979241338 0.9966329970.972934473 0.663003663 0.648979592 0.710204082 0.575510204 29 NM_020370GPR84 0.974313023 0.92704826 0.991452991 0.738927739 0.4965986390.608163265 0.623129252 347 NM_020370 GPR84 0.974313023 0.927048260.991452991 0.738927739 0.496598639 0.608163265 0.623129252 10NM_001244438 ARG1 0.970878136 0.999438833 0.960520961 0.6443556440.561904762 0.683265306 0.662585034 329 NM_001244438 ARG1 0.9708781360.999438833 0.960520961 0.644355644 0.561904762 0.683265306 0.66258503424 NM_003855 IL18R1 0.966845878 0.989337823 0.958689459 0.629703630.62585034 0.715102041 0.639455782 342 NM_003855 IL18R1 0.9668458780.989337823 0.958689459 0.62970363 0.62585034 0.715102041 0.639455782 26NM_006459 ERLIN1 0.964755078 0.994949495 0.953805454 0.6949716950.561904762 0.639183673 0.594557823 344 NM_006459 ERLIN1 0.9647550780.994949495 0.953805454 0.694971695 0.561904762 0.639183673 0.5945578235 NM_018285 IMP3 0.96385902 0.997755331 0.951566952 0.8175158180.610884354 0.742040816 0.614965986 324 NM_018285 IMP3 0.963859020.997755331 0.951566952 0.817515818 0.610884354 0.742040816 0.6149659861 NM_003268 TLR5 0.962365591 0.873737374 0.994505495 0.8085248090.606802721 0.768979592 0.672108844 320 NM_003268 TLR5 0.9623655910.873737374 0.994505495 0.808524809 0.606802721 0.768979592 0.672108844

TABLE 13 Healthy versus inSIRS Area Under Curve (AUC) SEQ ID HC vs. SickHC vs. inSIRS HC vs. ipSIRS SIRS vs. Mild vs. Mild vs. Severe vs. NumberDatabase ID Gene Name AUC AUC AUC ipSIRS AUC Severe AUC Shock AUC ShockAUC 18 NM_203281 BMX 0.979988053 1 0.972730973 0.56043956 0.6394557820.749387755 0.644897959 336 NM_203281 BMX 0.979988053 1 0.9727309730.56043956 0.639455782 0.749387755 0.644897959 10 NM_001244438 ARG10.970878136 0.999438833 0.960520961 0.644355644 0.561904762 0.6832653060.662585034 329 NM_001244438 ARG1 0.970878136 0.999438833 0.9605209610.644355644 0.561904762 0.683265306 0.662585034 7 NM_080387 CLEC4D0.981780167 0.998877666 0.975579976 0.64968365 0.52244898 0.6710204080.691156463 326 NM_080387 CLEC4D 0.981780167 0.998877666 0.9755799760.64968365 0.52244898 0.671020408 0.691156463 5 NM_018285 IMP30.96385902 0.997755331 0.951566952 0.817515818 0.610884354 0.7420408160.614965986 324 NM_018285 IMP3 0.96385902 0.997755331 0.9515669520.817515818 0.610884354 0.742040816 0.614965986 3 NM_004666 VNN10.979241338 0.996632997 0.972934473 0.663003663 0.648979592 0.7102040820.575510204 322 NM_004666 VNN1 0.979241338 0.996632997 0.9729344730.663003663 0.648979592 0.710204082 0.575510204 26 NM_006459 ERLIN10.964755078 0.994949495 0.953805454 0.694971695 0.561904762 0.6391836730.594557823 344 NM_006459 ERLIN1 0.964755078 0.994949495 0.9538054540.694971695 0.561904762 0.639183673 0.594557823 17 NM_207113 SLC37A30.954301075 0.99382716 0.93996744 0.582417582 0.619047619 0.6530612240.551020408 335 NM_207113 SLC37A3 0.954301075 0.99382716 0.939967440.582417582 0.619047619 0.653061224 0.551020408 38 NM_004994 MMP90.935782557 0.993265993 0.914936915 0.625374625 0.653061224 0.6538775510.48707483 356 NM_004994 MMP9 0.935782557 0.993265993 0.9149369150.625374625 0.653061224 0.653877551 0.48707483 120 NM_004244 CD1630.842293907 0.993265993 0.787545788 0.716949717 0.481632653 0.6636734690.648979592 433 NM_004244 CD163 0.842293907 0.993265993 0.7875457880.716949717 0.481632653 0.663673469 0.648979592 46 NM_006212 PFKFB20.922341697 0.992704826 0.896825397 0.678654679 0.51292517 0.6791836730.68707483 363 NM_006212 PFKFB2 0.922341697 0.992704826 0.8968253970.678654679 0.51292517 0.679183673 0.68707483

TABLE 14 Healthy versus ipSIRS Area Under Curve (AUC) SEQ ID HC vs. SickHC vs. HC vs. SIRS vs. Mild vs. Mild vs. Severe vs. Number Database IDGene Name AUC inSIRS AUC ipSIRS AUC ipSIRS AUC Severe AUC Shock AUCShock AUC 1 NM_003268 TLR5 0.962365591 0.873737374 0.9945054950.808524809 0.606802721 0.768979592 0.672108844 320 NM_003268 TLR50.962365591 0.873737374 0.994505495 0.808524809 0.606802721 0.7689795920.672108844 2 NM_020406 CD177 0.992980884 0.991582492 0.9934879930.718281718 0.668027211 0.675102041 0.540136054 321 NM_020406 CD1770.992980884 0.991582492 0.993487993 0.718281718 0.668027211 0.6751020410.540136054 29 NM_020370 GPR84 0.974313023 0.92704826 0.9914529910.738927739 0.496598639 0.608163265 0.623129252 347 NM_020370 GPR840.974313023 0.92704826 0.991452991 0.738927739 0.496598639 0.6081632650.623129252 20 NM_153046 TDRD9 0.929062127 0.758136925 0.9910459910.844488844 0.640816327 0.734693878 0.636734694 338 NM_153046 TDRD90.929062127 0.758136925 0.991045991 0.844488844 0.640816327 0.7346938780.636734694 4 NM_016021 UBE2J1 0.959677419 0.888327722 0.9855514860.826173826 0.468027211 0.644897959 0.682993197 323 NM_016021 UBE2J10.959677419 0.888327722 0.985551486 0.826173826 0.468027211 0.6448979590.682993197 11 NR_045213 FCGR1A 0.954749104 0.87037037 0.9853479850.77988678 0.612244898 0.492244898 0.621768707 NR_045213 FCGR1A0.954749104 0.87037037 0.985347985 0.77988678 0.612244898 0.4922448980.621768707 6 NM_002934 RNASE2 0.94937276 0.854657688 0.9837199840.780552781 0.67755102 0.564081633 0.643537415 325 NM_002934 RNASE20.94937276 0.854657688 0.983719984 0.780552781 0.67755102 0.5640816330.643537415 8 NM_004054 C3AR1 0.950119474 0.868125701 0.979853480.832833833 0.529251701 0.609795918 0.582312925 327 NM_004054 C3AR10.950119474 0.868125701 0.97985348 0.832833833 0.529251701 0.6097959180.582312925 12 NM_145018 C11orf82 0.873058542 0.580246914 0.9792429790.947718948 0.619047619 0.650612245 0.555102041 330 NM_145018 C11orf820.873058542 0.580246914 0.979242979 0.947718948 0.619047619 0.6506122450.555102041 13 NM_018099 FAR2 0.942502987 0.843434343 0.9784289780.794205794 0.561904762 0.746122449 0.693877551 331 NM_018099 FAR20.942502987 0.843434343 0.978428978 0.794205794 0.561904762 0.7461224490.693877551

Example 5 Differential Expression of IRS Biomarkersmarkers BetweenHealthy, inSIRS, Mild Sepsis, Severe Sepsis and Septic Shock

Presented below in FIGS. 13 to 331 are “Box and Whisker” plots for eachof the 319 biomarkers where the bottom and top of the box are the firstand third quartiles, and the band inside the box is the second quartile(the median) (of gene expression). Biomarkers are presented in order ofascending adjusted p value when comparing “All Classes” (i.e., healthycontrol, referred to as “Healthy” in FIGS. 13-331; inSIRS, referred toas “SIRS” in FIGS. 13-331; mild sepsis referred to as “Mild” in FIGS.13-331; severe sepsis, referred to as “Severe” in FIGS. 13-331; andseptic shock, referred to as “Shock” in FIGS. 13-331)—varying from6.49E-48 to 1.00, and according to the following table (Table 15).Appropriate choice and use of such markers can be used to selectpatients for inclusion in, or exclusion from, clinical trials. Further,such markers can be used to determine the efficacy of treatment,therapies or management regimens in patients by determining whether apatient has transitioned from one condition to another and bydetermining the stage or degree of a particular condition. For example,an exemplary clinical trial design testing for the efficacy of aninotrope may include only those patients with shock ipSIRS that are mostlikely to best respond to such a drug. In addition, and followinginclusion of such patients and treatment with the inotrope, suchpatients could be monitored to determine if, when, how quickly and towhat degree they respond to the inotrope by their transition from shockipSIRS to other degrees of ipSIRS, inSIRS or health. Similarly, a modelclinical trial design testing for the efficacy of an antibiotic, orcombination of antibiotics, may include only those patients with ipSIRS,and not inSIRS, that are most likely to best respond to such a drug. Inaddition, and following inclusion of such patients and treatment withthe antibiotic(s), such patients could be monitored to determine if,when, how quickly and to what degree they respond to the antibiotic(s)by their transition from ipSIRS to inSIRS or health. Similarly, anexemplary clinical trial design testing for the efficacy of an immunemodulating drug (e.g. a steroid) may include only those patients withknown stages of ipSIRS, for example those recovering from ipSIRS orthose in the early stages of ipSIRS. Following inclusion of suchpatients and treatment with the immune modulating drug, such patientscould be monitored to determine if, when, how quickly and to what degreethey respond to the immune modulating drug by their transition fromipSIRS to inSIRS or health. The biomarker response and outcome (e.g.reduced length of hospital stay, reduced mortality) of patients invarious stages of ipSIRS (early, late) treated with an immune modulatingdrug may also indicate when such a drug is best administered for maximumbenefit.

TABLE 15 Healthy versus inSIRS versus ipSIRS versus Mild versus Severeversus Shock p Value and Area Under Curve (AUC) SEQ ID HC inSIRS MildSevere Number Database ID Gene Name Mean Mean Mean Mean 1 NM_003268 TLR57.747 9.010 9.726 9.979 2 NM_020406 CD177 8.091 10.809 11.267 12.088 3NM_004666 VNN1 7.736 10.013 10.007 10.629 4 NM_016021 UBE2J1 8.792 9.55510.118 10.044 5 NM_018285 IMP3 7.951 6.465 7.032 6.934 6 NM_002934RNASE2 9.164 10.500 11.243 11.670 7 NM_080387 CLEC4D 7.187 9.915 9.2389.152 8 NM_004054 C3AR1 8.429 9.449 10.261 10.439 9 NM_001145772 GPR569.741 8.456 8.297 7.926 10 NM_001244438 ARG1 5.410 9.054 7.895 8.254 11NR_045213 FCGR1A 7.871 9.281 10.308 9.985 12 NM_145018 C11orf82 5.7765.888 6.889 7.153 13 NM_018099 FAR2 8.164 8.881 9.322 9.439 14 NM_006433GNLY 10.653 9.428 9.305 8.659 15 NM_004482 GALNT3 5.685 6.251 6.9166.728 16 NM_002544 OMG 4.756 5.187 5.644 5.799 17 NM_207113 SLC37A38.600 10.048 9.633 9.916 18 NM_203281 BMX 4.804 6.547 6.012 6.397 19NM_004099 STOM 9.914 10.377 10.824 10.894 20 NM_153046 TDRD9 4.986 5.5676.483 6.937 21 NM_032045 KREMEN1 8.626 9.409 10.143 10.189 22 NM_005449FAIM3 10.259 9.101 9.036 9.174 23 NM_014358 CLEC4E 8.446 10.547 9.4919.618 24 NM_003855 IL18R1 5.516 8.101 7.098 7.538 25 NM_018367 ACER37.317 7.845 8.701 8.417 26 NM_006459 ERLIN1 7.136 9.162 8.418 8.526 27NM_004612 TGFBR1 9.328 9.614 10.165 9.999 28 NM_001145775 FKBP5 9.00611.106 10.185 10.457 29 NM_020370 GPR84 6.712 8.157 9.030 8.980 30NM_182597 C7orf53 6.397 6.878 7.266 7.760 31 NM_153021 PLB1 8.205 8.8879.574 9.463 32 NM_013352 DSE 7.272 7.680 8.183 8.109 33 NM_000953 PTGDR9.310 8.373 8.028 7.790 34 NM_001744 CAMK4 8.155 6.723 6.902 7.152 35NM_015268 DNAJC13 7.507 8.083 8.596 8.693 36 NM_007115 TNFAIP6 7.7389.246 9.829 9.631 37 NM_199135 FOXD4L3 6.441 6.501 7.402 7.610 38NM_004994 MMP9 10.179 12.012 11.383 11.801 39 NM_000637 GSR 8.866 9.3229.492 10.037 40 NM_016523 KLRF1 6.343 5.438 5.022 4.504 41 NM_053282SH2D1B 8.067 6.992 6.896 6.451 42 NM_001004441 ANKRD34B 4.809 5.4155.855 6.471 43 NM_001136258 SGMS2 6.693 7.708 7.553 7.712 44 NM_032047B3GNT5 6.871 8.033 8.009 7.744 45 NR_026575 GK3P 4.227 5.729 5.316 5.55246 NM_006212 PFKFB2 7.955 10.444 9.336 9.326 47 NM_007166 PICALM 9.0799.433 9.822 9.993 48 NM_152637 METTL7B 6.693 7.153 7.628 7.927 49NM_003542 HIST1H4C 11.803 9.795 10.815 10.617 50 NM_145005 C9orf72 8.2628.742 9.312 9.073 51 NM_003533 HIST1H3I 10.878 9.003 10.144 10.141 52NM_021082 SLC15A2 7.246 7.309 7.861 8.034 53 NM_030956 TLR10 6.794 6.8427.713 7.823 54 NM_001124 ADM 8.676 8.896 9.739 9.441 55 NM_014143 CD2745.508 5.656 7.557 7.211 56 NM_001311 CRIP1 8.880 6.932 7.984 7.844 57NM_001099660 LRRN3 7.163 5.997 5.841 6.367 58 NM_002121 HLA-DPB1 11.41410.665 10.623 9.971 59 NM_014232 VAMP2 9.213 8.896 9.016 8.454 60NM_006714 SMPDL3A 6.243 6.701 7.288 7.563 61 NM_005531 IFI16 8.97310.323 9.950 9.942 62 NM_016475 JKAMP 8.440 8.442 9.231 8.827 63ENST00000371443 MRPL41 8.037 6.496 7.288 7.313 64 NM_004172 SLC1A3 5.8496.892 6.472 6.447 65 NM_006418 OLFM4 6.365 7.209 8.023 9.641 66NM_001164116 CASS4 8.124 7.848 7.410 7.217 67 ENST00000533734 TCN1 6.0156.936 7.241 8.481 68 NM_018639 WSB2 8.870 8.808 9.618 9.714 69ENST00000405140 CLU 9.016 9.264 9.889 10.137 70 NM_001163278 ODZ1 6.0887.677 6.668 7.303 71 NM_002269 KPNA5 6.822 5.908 6.451 5.758 72NM_001130715 PLAC8 10.873 10.024 11.434 11.500 73 NM_001257400 CD639.235 9.126 9.718 9.990 74 NM_006665 HPSE 8.103 8.173 9.127 9.174 75NM_152367 C1orf161 5.851 6.354 6.479 6.738 76 ENST00000443533 DDAH28.067 8.170 8.630 8.707 77 NM_001199805 KLRK1 8.677 7.641 7.492 7.142 78NM_024524 ATP13A3 7.668 7.763 8.429 8.547 79 NM_005546 ITK 9.271 8.0998.227 8.536 80 NM_021127 PMAIP1 6.940 5.860 6.770 6.251 81 NR_046099LOC284757 6.913 8.028 6.894 7.534 82 NM_002080 GOT2 6.854 5.823 6.0176.378 83 NR_036641 PDGFC 6.098 6.117 6.987 7.044 84 NM_012200 B3GAT37.939 7.030 7.516 7.658 85 NM_003545 HIST1H4E 10.534 9.717 9.907 9.36286 NM_000860 HPGD 5.621 6.238 7.085 6.908 87 NM_031950 FGFBP2 8.0907.266 7.130 6.722 88 NM_181506 LRRC70 3.455 3.495 4.144 3.763 89NM_018342 TMEM144 5.697 6.377 6.781 7.043 90 gi|21749325 CDS2 10.2359.988 10.651 10.561 91 NM_001725 BPI 7.724 8.603 8.894 10.119 92ENST00000379215 ECHDC3 7.486 8.705 7.801 7.715 93 NM_001837 CCR3 7.0786.226 6.015 6.079 94 NM_014181 HSPC159 9.120 9.779 9.933 10.248 95NM_018324 OLAH 4.483 6.220 5.483 6.162 96 NM_006243 PPP2R5A 8.141 9.0008.646 8.931 97 NM_001193451 TMTC1 6.316 7.153 7.497 7.783 98NM_001023570 EAF2 8.389 8.607 9.323 9.016 99 NM_001268 RCBTB2 8.6468.621 9.321 9.357 100 NM_021982 SEC24A 7.847 7.914 8.266 8.571 101NM_001017995 SH3PXD2B 5.800 6.949 6.262 6.384 102 NM_001130688 HMGB27.782 9.225 8.769 8.869 103 ENST00000381907 KLRD1 8.651 8.097 7.7667.201 104 NM_001276 CHI3L1 10.470 9.876 8.640 9.035 105 NM_174938 FRMD36.218 6.408 6.959 6.889 106 NM_018375 SLC39A9 8.038 7.719 8.121 8.368107 NM_153236 GIMAP7 9.533 8.865 8.974 8.682 108 NM_016476 ANAPC11 6.7165.940 6.219 6.214 109 NM_019037 EXOSC4 8.216 8.199 8.716 8.845 110gi|13182974 NA 7.793 8.895 8.712 8.321 111 NM_198336 INSIG1 8.081 7.3708.062 7.867 112 ENST00000542161 FOLR3 7.767 8.283 8.505 9.059 113NM_001024630 RUNX2 9.359 9.363 8.874 8.973 114 NM_018457 PRR13 8.9199.881 9.380 9.204 115 NM_003546 HIST1H4L 9.807 7.908 9.466 9.602 116NM_002305 LGALS1 10.393 10.059 10.730 10.741 117 NM_001295 CCR1 9.0369.458 10.071 10.000 118 NM_003596 TPST1 8.526 10.334 9.295 9.600 119NM_019111 HLA-DRA 11.467 10.758 10.870 10.441 120 NM_004244 CD163 6.8238.730 7.652 7.643 121 NM_005306 FFAR2 9.559 9.849 10.479 10.309 122NM_001143804 PHOSPHO1 11.398 10.826 10.374 9.837 123 NM_005729 PPIF9.131 8.392 8.994 8.669 124 NM_001199760 MTHFS 8.177 9.060 8.644 8.530125 NM_015190 DNAJC9 7.382 5.889 6.594 7.251 126 NM_005564 LCN2 7.7298.168 8.921 10.113 127 ENST00000233057 EIF2AK2 7.237 8.670 8.347 8.159128 NM_006498 LGALS2 6.920 6.085 6.594 6.235 129 NM_001199922 SIAE 6.7216.530 7.174 7.284 130 NM_004644 AP3B2 5.979 6.181 6.485 6.665 131NM_152701 ABCA13 5.814 6.131 6.688 7.350 132 gi|21757933 NA 7.336 7.9637.065 7.340 133 NR_026586 EFCAB2 4.462 4.942 5.648 4.939 134 NM_170745HIST1H2AA 6.310 6.872 6.483 6.652 135 NR_024610 HINT1 7.948 6.705 7.5917.235 136 NM_003535 HIST1H3J 8.323 6.703 7.484 7.314 137 NM_001785 CDA10.407 11.415 11.045 11.032 138 NM_003864 SAP30 9.022 9.883 9.258 9.251139 NM_001040196 AGTRAP 10.055 9.933 10.594 10.356 140 NM_033050 SUCNR13.660 3.734 4.329 4.517 141 NM_002454 MTRR 8.163 7.862 8.523 8.796 142NM_001168357 PLA2G7 6.797 6.685 5.928 5.753 143 NM_016108 AIG1 6.2986.237 6.932 6.735 144 NM_013363 PCOLCE2 5.863 5.909 6.292 6.366 145NM_080491 GAB2 9.471 10.280 9.787 9.810 146 NM_012262 HS2ST1 7.018 6.8747.363 7.378 147 NM_003529 HIST1H3A 7.822 6.477 7.240 7.007 148gi|21757754 C22orf37 8.047 7.525 8.170 7.898 149 ENST00000443117HLA-DPA1 11.917 11.327 11.426 10.930 150 NM_030796 VOPP1 9.302 8.7719.510 9.318 151 NM_001135147 SLC39A8 7.820 7.364 8.061 7.951 152NM_002417 MKI67 5.979 5.822 6.140 6.894 153 NM_000578 SLC11A1 10.81211.719 11.333 11.110 154 NM_001657 AREG 6.075 6.806 6.139 6.126 155NM_005502 ABCA1 7.734 7.909 8.601 8.816 156 NM_001201427 DAAM2 6.5918.217 7.135 7.167 157 NM_002343 LTF 8.098 8.330 8.923 9.937 158NM_178174 TREML1 8.869 9.169 9.868 10.187 159 NM_004832 GSTO1 7.1137.036 7.593 7.598 160 NM_000956 PTGER2 8.918 8.348 9.019 8.983 161NM_001816 CEACAM8 7.336 7.874 8.503 9.775 162 NM_016184 CLEC4A 8.2108.289 9.043 8.708 163 NR_002217 PMS2CL 7.598 6.664 7.289 7.057 164NM_001193374 RETN 7.747 7.886 8.097 8.248 165 NM_000922 PDE3B 8.1428.242 7.627 7.734 166 NM_018837 SULF2 9.831 9.704 9.064 9.248 167NM_001145001 NEK6 9.503 9.287 9.835 9.710 168 NM_022145 CENPK 7.0736.142 6.664 6.040 169 NM_145725 TRAF3 8.046 7.482 8.145 8.152 170NM_003608 GPR65 9.085 9.452 9.834 9.216 171 NR_046000 IRF4 8.200 7.4917.843 8.381 172 gi|42521648 MACF1 6.473 6.545 7.013 7.187 173 NM_001144AMFR 9.420 8.994 9.671 9.823 174 NM_000985 RPL17 6.122 5.182 5.758 5.556175 NM_003749 IRS2 8.965 9.531 8.841 8.998 176 NM_002230 JUP 8.165 7.8037.812 7.804 177 NM_013230 CD24 5.563 5.793 6.173 7.205 178 NM_004481GALNT2 8.541 8.534 8.896 8.980 179 NM_007355 HSP90AB1 9.881 8.635 9.0859.720 180 NM_024656 GLT25D1 9.757 9.336 9.948 9.861 181 NM_001001658OR9A2 4.207 4.662 4.825 4.991 182 NM_001178135 HDHD1A 8.039 7.927 8.2968.300 183 NM_001141945 ACTA2 6.977 6.906 7.430 7.434 184 NM_152282 ACPL26.821 7.762 7.139 7.253 185 NM_001137550 LRRFIP1 6.512 6.814 6.827 7.037186 NM_001161352 KCNMA1 5.664 6.042 6.492 6.317 187 gi|12584148 OCR18.817 9.952 8.387 8.844 188 NM_000885 ITGA4 8.779 7.932 8.394 7.981 189NM_001412 EIF1AX 7.439 6.463 7.251 6.667 190 NM_176818 SFRS9 9.739 9.6669.715 10.226 191 NM_206831 DPH3 6.211 6.602 6.923 6.606 192 NM_001031711ERGIC1 9.539 10.203 9.742 9.565 193 NM_007261 CD300A 9.890 9.479 10.05810.054 194 NM_001085386 NF-E4 7.348 8.202 7.715 8.545 195 NM_004897MINPP1 8.212 7.697 8.228 7.151 196 NM_003141 TRIM21 8.072 8.151 8.8408.371 197 NM_006969 ZNF28 4.936 4.511 5.008 4.554 198 gi|21538810 NPCDR15.404 5.022 4.784 5.166 199 gi|15530286 NA 9.276 9.224 8.804 8.909 200gi|7021995 NA 7.607 8.002 6.917 7.075 201 NM_000201 ICAM1 8.842 8.6259.470 9.156 202 NM_005645 TAF13 5.332 5.173 5.949 5.474 203 NM_000917P4HA1 6.365 6.096 6.773 6.664 204 NM_207445 C15orf54 4.953 4.588 4.3944.290 205 NM_002108 HAL 7.142 6.909 7.654 7.331 206 NM_015998 KLHL59.003 9.971 9.113 9.407 207 NR_002612 DLEU2 6.549 6.894 7.347 6.699 208NM_015199 ANKRD28 7.286 7.393 7.898 7.722 209 ENST00000375864 LY6G5B9.037 8.992 8.780 8.654 210 ENST00000344062 KIAA1257 6.868 7.365 6.8826.874 211 NM_004528 MGST3 9.104 8.519 9.273 9.098 212 NM_015187 KIAA07468.174 7.591 8.170 8.747 213 NM_001540 HSPB1 9.140 8.923 9.664 9.580 214NM_005508 CCR4 7.105 6.356 6.598 6.829 215 NM_001071 TYMS 6.084 5.6956.186 6.854 216 ENST00000536831 RRP12 8.946 8.381 8.821 8.752 217NM_176816 CCDC125 7.600 8.401 7.883 8.048 218 NM_003521 HIST1H2BM 10.1049.242 10.213 10.837 219 NM_002612 PDK4 7.445 8.411 8.080 8.035 220NM_207627 ABCG1 8.318 7.923 7.960 8.214 221 NM_000576 IL1B 9.070 9.17210.021 9.550 222 NM_003246 THBS1 8.599 9.860 8.993 9.423 223 NM_000419ITGA2B 8.899 8.768 9.482 9.747 224 NM_005780 LHFP 6.216 6.391 6.5236.665 225 NM_002287 LAIR1 9.265 9.118 9.815 9.654 226 NM_003537 HIST1H3B8.783 7.684 8.739 9.501 227 gi|29387167 ZRANB1 8.205 9.041 8.641 8.455228 ENST00000525158 TIMM10 7.454 6.704 7.473 7.175 229 NM_207647 FSD1L4.605 4.402 4.801 4.565 230 NM_021066 HIST1H2AJ 5.699 4.152 4.990 3.871231 ENST00000362012 PTGS1 8.883 8.605 9.293 9.429 232 gi|14250459 NA6.389 5.970 6.875 5.976 233 NM_080678 UBE2F 7.698 7.618 8.235 8.225 234NM_001104595 FAM118A 8.366 7.706 7.946 8.222 235 NM_003531 HIST1H3C9.254 7.630 9.025 9.427 236 NM_003965 CCRL2 6.401 6.488 6.982 6.754 237NR_003094 E2F6 4.235 3.673 4.143 3.579 238 NM_198275 MPZL3 10.241 10.75410.209 10.039 239 NM_080725 SRXN1 9.497 9.560 9.732 9.815 240 NM_004357CD151 9.083 8.712 9.309 9.522 241 NM_003536 HIST1H3H 9.933 8.623 9.6889.538 242 NM_031919 FSD1L 2.752 2.614 2.977 2.804 243 NM_001131065 RFESD6.745 6.242 6.502 5.562 244 NM_012112 TPX2 5.722 5.535 5.917 6.431 245NM_006272 S100B 5.289 4.661 4.917 4.533 246 NM_032828 ZNF587 8.514 8.8168.783 8.381 247 NM_152501 PYHIN1 8.390 8.040 7.744 7.890 248 NM_020775KIAA1324 9.383 9.433 8.708 9.010 249 NM_002483 CEACAM6 5.249 5.373 5.9596.957 250 NM_001130415 APOLD1 7.318 6.858 7.205 7.363 251 NM_000134FABP2 4.244 4.518 4.396 4.549 252 NM_001080424 KDM6B 9.854 10.383 10.1479.749 253 ENST00000390265 IGK@ 10.393 9.201 10.307 11.107 254 NM_006097MYL9 9.235 9.445 10.021 9.931 255 NM_021058 HIST1H2BJ 5.949 5.710 6.3306.446 256 NM_138327 TAAR1 5.009 5.081 5.282 5.490 257 NM_001828 CLC10.866 9.692 9.618 9.860 258 NM_001199208 CYP4F3 9.187 10.093 9.4029.895 259 NM_024548 CEP97 6.566 6.717 6.887 7.228 260 NM_138927 SON8.449 7.921 8.330 7.930 261 NM_002198 IRF1 10.490 10.067 10.764 10.511262 NM_182914 SYNE2 7.764 8.208 7.453 7.752 263 NM_000902 MME 9.62510.744 9.401 10.054 264 NM_024552 LASS4 8.222 7.808 7.961 8.050 265NM_001925 DEFA4 7.421 7.383 8.289 9.454 266 NM_024913 C7orf58 7.7276.800 7.706 7.617 267 ENST00000549649 DYNLL1 7.250 7.328 8.200 7.946 268gi|38532374 NA 5.269 5.274 4.828 4.979 269 NM_000250 MPO 7.605 7.5658.053 8.694 270 NM_001874 CPM 5.874 6.569 5.926 5.965 271 NM_173485TSHZ2 7.382 6.972 6.846 7.429 272 NR_038064 PLIN2 8.210 8.534 8.4708.589 273 NM_024556 FAM118B 7.287 7.256 7.846 7.892 274 NM_001199873B4GALT3 9.539 8.790 9.278 9.265 275 NM_006989 RASA4 8.298 8.139 7.7968.031 276 NM_001257971 CTSL1 6.074 5.925 6.577 6.106 277 NM_000270 NP9.487 9.103 9.780 10.001 278 NM_001130059 ATF7 5.212 5.212 5.253 5.605279 NM_003118 SPARC 9.083 9.207 9.737 9.964 280 NM_153021 PLB1 6.8677.077 7.318 7.615 281 NM_001170330 C4orf3 7.478 7.240 7.324 7.402 282NM_002692 POLE2 7.205 6.613 7.184 6.047 283 NM_001192 TNFRSF17 4.4744.005 4.587 5.008 284 NM_145032 FBXL13 6.474 6.987 6.791 7.387 285NM_019091 PLEKHA3 7.058 6.910 7.281 6.689 286 NM_024956 TMEM62 7.5997.189 7.875 7.664 287 NM_052960 RBP7 7.270 7.808 7.218 7.267 288NM_024613 PLEKHF2 7.432 7.660 8.044 7.255 289 NM_002923 RGS2 11.58412.239 11.737 11.649 290 NM_004691 ATP6V0D1 11.562 11.584 11.951 11.656291 NM_144563 RPIA 9.444 9.221 8.913 8.388 292 NM_020397 CAMK1D 9.0019.118 8.603 8.572 293 NM_016232 IL1RL1 5.573 6.273 5.757 6.219 294NM_138460 CMTM5 7.473 7.266 7.853 7.851 295 NM_004847 AIF1 8.167 8.3108.735 8.045 296 NM_001928 CFD 10.389 9.779 9.631 9.496 297 NM_144765MPZL2 7.015 7.320 6.845 6.660 298 gi|27884043 LOC100128751 8.552 8.8778.333 8.552 299 NM_144646 IGJ 8.646 7.900 8.962 10.005 300 NM_139286CDC26 7.968 7.634 8.113 7.886 301 NM_006241 PPP1R2 7.446 7.738 7.5467.286 302 NM_000564 IL5RA 6.871 6.298 6.092 6.455 303 NM_001113738ARL17P1 8.846 8.829 8.802 8.293 304 NR_033759 ATP5L 7.242 7.337 7.3796.824 305 NM_176885 TAS2R31 6.228 5.589 5.847 6.020 306 NM_001024599HIST2H2BF 8.854 9.615 9.386 9.211 307 NM_001743 CALM2 8.475 9.041 9.0038.357 308 NM_019073 SPATA6 6.797 7.301 7.095 6.806 309 ENST00000390285IGLV6-57 5.779 5.379 6.029 6.575 310 NM_020362 C1orf128 9.258 9.0268.605 8.315 311 NM_181623 KRTAP15-1 6.250 6.690 6.548 6.617 312NM_006417 IFI44 6.559 6.924 8.107 6.674 313 NM_001178126 IGL@ 7.0526.606 7.027 7.343 314 gi|21707823 NA 4.903 5.476 4.955 4.639 315NM_003001 SDHC 7.530 6.874 7.879 7.593 316 NM_152995 NFXL1 7.326 6.8767.694 7.644 317 NM_000170 GLDC 5.599 5.395 5.679 5.770 318 NM_001199743DCTN5 8.646 8.336 8.737 8.794 319 NM_014736 KIAA0101 4.443 3.951 4.5374.749 pval pval SEQ ID Shock pval HC inSIRS vs pval pval Shock vs NumberMean vs Other Sepsis Severe vs Mild Shock vs Mild Severe 1 10.3110.000000 0.000225 0.275728 0.000244 0.110996 2 12.044 0.000000 0.0870610.048910 0.027926 0.991139 3 10.876 0.000000 1.000000 0.087388 0.0024020.671136 4 10.335 0.000000 0.000015 0.817659 0.104460 0.049488 5 6.7230.000000 0.000000 0.645365 0.004479 0.136619 6 11.388 0.000000 0.0029790.095954 0.690976 0.351809 7 9.828 0.000000 0.383427 0.945300 0.0340260.035853 8 10.593 0.000000 0.000016 0.650271 0.142678 0.725241 9 7.6110.000000 0.009068 0.118387 0.000147 0.212773 10 8.919 0.000000 1.0000000.628534 0.008931 0.209877 11 10.273 0.000000 0.001046 0.284201 0.9802980.366022 12 7.293 0.000000 0.000000 0.322762 0.032568 0.722429 13 9.8130.000000 0.000434 0.708180 0.000658 0.034215 14 8.408 0.000000 0.0200980.014566 0.000045 0.511511 15 7.075 0.000000 0.000000 0.407446 0.4228010.051201 16 6.063 0.000000 0.000000 0.486295 0.001484 0.125031 17 9.9900.000000 1.000000 0.200617 0.035680 0.892137 18 6.839 0.000000 1.0000000.251812 0.000431 0.163472 19 11.148 0.000000 0.000000 0.861884 0.0173910.144729 20 7.385 0.000000 0.000000 0.248195 0.001153 0.259068 21 10.0550.000000 0.000079 0.962640 0.837239 0.731337 22 8.464 0.000000 1.0000000.732360 0.001453 0.000582 23 9.945 0.000000 0.000082 0.796454 0.0246900.225126 24 8.097 0.000000 1.000000 0.373616 0.001873 0.205385 25 9.0500.000000 0.000000 0.362961 0.132905 0.008450 26 8.855 0.000000 0.4314360.880592 0.070482 0.316561 27 10.368 0.000000 0.000000 0.333550 0.1152810.005971 28 10.750 0.000000 0.035769 0.441852 0.011707 0.389198 29 9.5830.000000 0.001894 0.989573 0.184680 0.221197 30 7.532 0.000000 0.0000800.007994 0.141534 0.338948 31 10.019 0.000000 0.000133 0.872838 0.0593980.037699 32 8.384 0.000000 0.000062 0.830987 0.170622 0.085371 33 7.5770.000000 0.007043 0.500548 0.040553 0.570947 34 6.470 0.000000 1.0000000.305982 0.011176 0.000339 35 8.878 0.000000 0.000000 0.833718 0.1332160.512817 36 9.738 0.000000 1.000000 0.712067 0.908467 0.905260 37 7.6490.000000 0.000000 0.417434 0.196375 0.968937 38 11.830 0.000000 1.0000000.196819 0.086637 0.992129 39 9.928 0.000000 0.000039 0.000432 0.0012070.709854 40 4.543 0.000000 0.007278 0.033428 0.021421 0.979558 41 6.4500.000000 0.652812 0.064249 0.026676 0.999993 42 6.738 0.000000 0.0000000.074815 0.001252 0.606835 43 8.128 0.000000 1.000000 0.670176 0.0017690.073073 44 8.548 0.000000 1.000000 0.438680 0.013149 0.000955 45 5.9370.000000 1.000000 0.493837 0.002433 0.158402 46 10.196 0.000000 0.0690410.999591 0.014557 0.037351 47 10.284 0.000000 0.000000 0.500534 0.0019580.138243 48 8.037 0.000000 0.000000 0.315445 0.060594 0.854279 49 10.3230.000000 0.000004 0.695152 0.055254 0.448113 50 9.243 0.000000 0.0000390.180477 0.821921 0.417016 51 9.669 0.000000 0.000000 0.999875 0.0291470.070614 52 8.227 0.000000 0.000000 0.350572 0.002949 0.273300 53 7.9000.000000 0.000000 0.798408 0.423055 0.895083 54 9.674 0.000000 0.0000010.091052 0.855508 0.225820 55 7.237 0.000000 0.000000 0.536662 0.4903740.996684 56 7.526 0.000000 0.002476 0.799183 0.046887 0.320589 57 5.9060.000000 1.000000 0.002710 0.877917 0.009767 58 9.578 0.000000 0.0673330.026428 0.000013 0.253098 59 8.353 0.000000 0.297018 0.000084 0.0000000.708038 60 8.227 0.000000 0.000000 0.609142 0.000879 0.060210 61 9.8600.000000 0.020087 0.998663 0.799026 0.869508 62 9.150 0.000000 0.0000000.000984 0.661905 0.010409 63 7.279 0.000000 0.000000 0.986016 0.9977760.974877 64 7.373 0.000000 1.000000 0.993673 0.000056 0.000352 65 9.3220.000000 0.000068 0.003150 0.006691 0.784808 66 7.047 0.000000 0.0000000.428924 0.022397 0.521806 67 8.420 0.000000 0.000290 0.005182 0.0019320.986095 68 9.657 0.000000 0.000000 0.761189 0.939475 0.910197 69 9.8130.000000 0.000063 0.216377 0.819582 0.075588 70 7.416 0.000000 0.2456520.024855 0.001421 0.884318 71 5.712 0.000000 1.000000 0.000021 0.0000000.945115 72 11.772 1.000000 0.000000 0.950268 0.172935 0.420732 7310.159 0.000000 0.000000 0.156468 0.002260 0.485665 74 8.937 0.0000000.000000 0.958822 0.401504 0.346256 75 6.845 0.000000 0.417891 0.1962670.015651 0.756446 76 9.015 0.000000 0.000000 0.868573 0.011535 0.10852877 6.815 0.000000 1.000000 0.344640 0.006675 0.394595 78 8.804 0.0000000.000000 0.777976 0.039725 0.310273 79 7.635 0.000000 1.000000 0.2766070.002832 0.000063 80 6.214 0.000000 0.000000 0.002936 0.000187 0.96828781 7.376 0.000001 0.000004 0.000039 0.000364 0.493398 82 6.047 0.0000000.490985 0.040847 0.969911 0.066504 83 7.466 0.000000 0.000000 0.9706370.064634 0.196970 84 7.632 0.000000 0.000000 0.387020 0.434149 0.96627585 9.307 0.000000 1.000000 0.026325 0.003375 0.962707 86 7.946 0.0000000.000024 0.895298 0.035905 0.027021 87 6.520 0.000000 0.976589 0.2228690.013639 0.687542 88 4.135 0.000000 0.000000 0.020091 0.996732 0.02401289 6.824 0.000000 0.914921 0.404820 0.968067 0.529328 90 10.570 0.0418440.000000 0.584395 0.561379 0.994393 91 9.589 0.000000 0.026705 0.0011450.046592 0.253799 92 8.165 0.000000 0.001975 0.857762 0.030361 0.01876393 5.783 0.000000 1.000000 0.937302 0.322103 0.253166 94 10.249 0.0000001.000000 0.218914 0.132537 0.999989 95 6.492 0.000000 1.000000 0.1256880.003063 0.604976 96 8.952 0.000000 1.000000 0.109345 0.035683 0.98834297 7.961 0.000000 0.543009 0.580949 0.154696 0.809916 98 9.301 0.0000000.000012 0.105531 0.985106 0.141523 99 9.340 0.000000 0.000001 0.9613970.985058 0.991536 100 8.641 0.000000 0.000000 0.094884 0.010201 0.880791101 6.870 0.000000 1.000000 0.786615 0.000756 0.026622 102 8.9100.000000 1.000000 0.894388 0.745151 0.981575 103 7.123 0.000000 0.0118380.056985 0.008125 0.944270 104 8.726 0.000000 0.000056 0.485576 0.9548530.641602 105 6.703 0.000000 0.000000 0.872556 0.096505 0.389383 1068.428 1.000000 0.000000 0.034062 0.001276 0.808136 107 8.112 0.0000001.000000 0.310769 0.000008 0.014285 108 6.368 0.000000 0.016248 0.9988080.245788 0.323554 109 9.307 0.000000 0.000000 0.796042 0.002754 0.059157110 8.114 0.000000 0.003518 0.039103 0.000094 0.391472 111 7.9130.001237 0.000000 0.123875 0.197540 0.883915 112 9.163 0.000000 0.0398070.074391 0.008772 0.909407 113 8.703 0.000000 0.000000 0.683914 0.2237310.064525 114 9.375 0.000000 0.000085 0.390820 0.998964 0.411767 1159.065 0.000032 0.000000 0.878290 0.231084 0.140998 116 10.938 0.2468940.000000 0.995433 0.137821 0.261564 117 10.253 0.000000 0.0096810.937695 0.574455 0.448234 118 9.760 0.000000 0.055822 0.518907 0.1361900.833502 119 10.188 0.000000 1.000000 0.091925 0.000575 0.429491 1208.413 0.000000 0.092636 0.999632 0.037288 0.077812 121 10.573 0.0000000.002329 0.564897 0.791331 0.256398 122 10.185 0.000000 0.0483800.088690 0.661703 0.354179 123 8.682 0.000000 0.001262 0.016029 0.0066150.993122 124 8.897 0.000000 0.406481 0.678016 0.086391 0.022355 1256.665 0.000000 0.000027 0.007512 0.921502 0.019348 126 10.092 0.0000000.000002 0.028722 0.011016 0.998889 127 8.071 0.000000 0.263528 0.7092450.379350 0.929139 128 6.142 0.000000 0.375827 0.045528 0.001960 0.806041129 7.068 0.000300 0.000000 0.666202 0.603123 0.213378 130 7.1160.000000 0.000003 0.646507 0.001477 0.071475 131 7.182 0.000000 0.0000000.066387 0.130673 0.834277 132 7.275 1.000000 0.000000 0.034322 0.0714920.818353 133 5.021 0.000000 1.000000 0.000756 0.000575 0.898330 1346.820 0.000002 0.020011 0.118625 0.000044 0.124349 135 7.052 0.0000000.041290 0.142709 0.003549 0.590766 136 7.135 0.000000 0.000274 0.7158620.160141 0.691744 137 11.020 0.000000 0.043371 0.996584 0.9824750.996794 138 9.295 0.000000 0.001328 0.998061 0.924872 0.921435 13910.502 0.000787 0.000000 0.083006 0.602023 0.382046 140 4.334 0.0000000.000000 0.487465 0.999396 0.504866 141 8.849 0.122045 0.000000 0.2168370.057755 0.942570 142 5.816 0.000000 0.011194 0.534519 0.708535 0.921793143 7.005 0.000001 0.000000 0.470358 0.871019 0.246707 144 6.7850.000000 0.000000 0.925694 0.013235 0.089534 145 9.689 0.000000 0.0000000.982341 0.635805 0.599323 146 7.465 0.001571 0.000000 0.990909 0.5565640.723490 147 6.871 0.000000 0.000513 0.477800 0.090217 0.776827 1487.869 0.152851 0.000000 0.021435 0.002302 0.954990 149 10.582 0.0000001.000000 0.125876 0.000597 0.352649 150 9.517 1.000000 0.000000 0.2983750.997162 0.269787 151 8.434 1.000000 0.000000 0.788039 0.031226 0.013434152 6.463 0.105108 0.000000 0.000163 0.097385 0.045251 153 11.2140.000000 0.000048 0.338648 0.659426 0.788341 154 6.310 0.001304 0.0237710.980680 0.018616 0.030209 155 8.449 0.000000 0.000000 0.574359 0.6926240.204976 156 7.607 0.000000 0.072069 0.992564 0.124949 0.254325 1579.639 0.000000 0.000019 0.012909 0.052398 0.670808 158 9.876 0.0000000.000638 0.449927 0.999311 0.468015 159 7.768 0.000017 0.000000 0.9992470.345252 0.470840 160 9.315 1.000000 0.000000 0.970366 0.070654 0.081972161 9.287 0.000000 0.001298 0.011921 0.098854 0.501991 162 9.0510.000001 0.000030 0.153416 0.998827 0.141809 163 7.040 0.000000 0.0004400.281314 0.146553 0.993528 164 8.835 0.000000 0.000109 0.767125 0.0005260.022922 165 7.730 0.000586 0.000010 0.567468 0.494918 0.999337 1668.696 0.000000 0.000000 0.721156 0.183689 0.059640 167 9.943 0.1530830.000000 0.541334 0.546065 0.125355 168 6.012 0.000000 1.000000 0.0038710.000401 0.988210 169 7.882 1.000000 0.000003 0.997488 0.011707 0.028412170 9.665 0.000000 1.000000 0.000115 0.360571 0.006354 171 7.7620.000105 0.000070 0.002770 0.825556 0.000501 172 7.377 0.000009 0.0004810.609788 0.061186 0.553735 173 9.635 1.000000 0.000000 0.543847 0.9548650.395265 174 5.513 0.000000 0.000708 0.298432 0.096378 0.944801 1759.024 1.000000 0.000068 0.322209 0.133169 0.969809 176 7.467 0.0000001.000000 0.997835 0.006010 0.023849 177 7.139 0.000000 0.044339 0.0087140.004161 0.979397 178 9.333 0.000001 0.000000 0.887956 0.017521 0.130219179 9.186 0.000000 0.052850 0.015572 0.861439 0.050094 180 10.2011.000000 0.000001 0.826970 0.124352 0.061226 181 5.108 0.000000 1.0000000.671976 0.216358 0.816042 182 8.508 0.156481 0.000026 0.999441 0.1014040.187976 183 7.417 0.000137 0.000000 0.999465 0.993242 0.991119 1847.209 0.000000 0.038264 0.736975 0.857652 0.955277 185 7.241 0.0000151.000000 0.216163 0.000656 0.232230 186 7.025 0.000000 0.031350 0.8044760.075606 0.033982 187 8.270 1.000000 0.000000 0.273663 0.890199 0.131897188 7.906 0.000000 1.000000 0.064191 0.007047 0.909442 189 6.9070.000022 0.033776 0.002586 0.056446 0.338019 190 10.128 1.0000000.000618 0.000018 0.000064 0.627141 191 6.842 0.000000 1.000000 0.0523190.764333 0.189405 192 9.579 0.014810 0.000006 0.364984 0.320097 0.993728193 10.025 1.000000 0.000000 0.999363 0.929522 0.957280 194 7.9340.000000 1.000000 0.002063 0.535657 0.030775 195 7.317 0.006705 1.0000000.000005 0.000008 0.707929 196 8.271 0.002474 0.019577 0.006536 0.0000920.782377 197 4.612 0.021118 0.027741 0.000020 0.000018 0.814925 1984.817 0.000001 1.000000 0.000589 0.919120 0.001847 199 8.390 0.0013920.000629 0.821276 0.021614 0.011283 200 6.999 0.480277 0.000000 0.7216940.889525 0.926763 201 9.088 0.069361 0.000002 0.113961 0.015602 0.900519202 5.798 0.054434 0.000001 0.004467 0.457202 0.072895 203 6.8731.000000 0.000000 0.752172 0.731181 0.358637 204 4.370 0.000000 0.8914180.669439 0.972296 0.787051 205 7.571 0.894890 0.000000 0.049449 0.7585720.184215 206 9.083 0.009758 0.000000 0.315312 0.984513 0.248776 2076.850 0.000171 1.000000 0.000019 0.000152 0.504529 208 7.941 0.0000010.046283 0.544926 0.951892 0.391621 209 8.383 0.014059 0.001656 0.6423770.004351 0.135693 210 6.689 1.000000 0.000000 0.997049 0.129430 0.242441211 9.003 1.000000 0.000001 0.377410 0.050613 0.751799 212 8.5021.000000 0.000002 0.015387 0.148674 0.453449 213 9.371 0.267148 0.0000000.845749 0.072845 0.359260 214 6.321 0.000000 1.000000 0.321399 0.1202020.005850 215 6.291 1.000000 0.000000 0.003309 0.816061 0.015734 2168.721 0.000127 0.000063 0.794423 0.522969 0.952728 217 7.988 0.0000290.000070 0.517640 0.700053 0.915690 218 10.261 1.000000 0.0000000.055178 0.976895 0.083087 219 8.318 0.000000 1.000000 0.982556 0.5217420.501879 220 7.791 0.000000 1.000000 0.112606 0.270961 0.003184 2219.930 0.000002 0.124840 0.077098 0.874756 0.185371 222 9.387 0.0000001.000000 0.179953 0.147689 0.987631 223 9.378 0.011285 0.000003 0.4033900.825144 0.174155 224 6.778 0.000000 0.003992 0.475817 0.046096 0.625105225 10.179 0.001517 0.000113 0.773401 0.179212 0.071167 226 8.8521.000000 0.000000 0.042709 0.908040 0.098544 227 8.619 0.000016 0.0017230.476723 0.985358 0.563742 228 6.921 0.000333 0.000431 0.308861 0.0063450.426642 229 5.099 1.000000 0.000000 0.235142 0.050177 0.001077 2304.070 0.000128 1.000000 0.008735 0.013543 0.852098 231 9.247 1.0000000.000001 0.723148 0.952752 0.562936 232 6.059 1.000000 0.638753 0.0000010.000000 0.869569 233 8.425 0.009739 0.003879 0.998629 0.495878 0.558822234 7.802 0.000086 0.879292 0.116376 0.451548 0.008324 235 8.7490.908521 0.000000 0.439119 0.594489 0.101186 236 7.040 0.000011 0.0010070.386796 0.919567 0.226387 237 3.647 0.002951 1.000000 0.000262 0.0002080.874090 238 10.276 1.000000 0.000000 0.418422 0.832036 0.186944 23910.069 0.084230 0.126068 0.777086 0.005812 0.101705 240 9.473 1.0000000.000001 0.408420 0.488688 0.954477 241 9.310 0.018867 0.000017 0.8118220.177187 0.617435 242 3.257 0.713444 0.000000 0.455516 0.068219 0.006227243 5.837 0.011176 1.000000 0.000486 0.005152 0.486482 244 6.0631.000000 0.000000 0.009609 0.587740 0.085624 245 4.692 0.000031 1.0000000.034824 0.206071 0.549376 246 8.101 1.000000 0.003242 0.018153 0.0000010.136854 247 7.473 0.000001 1.000000 0.732308 0.247163 0.086327 2488.061 0.053345 0.004214 0.630998 0.065841 0.013683 249 6.219 0.0000140.000574 0.023214 0.699643 0.121152 250 7.253 0.906687 0.000002 0.2636620.846643 0.520142 251 4.826 0.000004 1.000000 0.578201 0.004767 0.174039252 9.701 1.000000 0.000332 0.072707 0.013999 0.962410 253 10.2281.000000 0.000007 0.087003 0.967489 0.053514 254 9.763 0.000001 0.0174140.905037 0.337602 0.704183 255 6.237 1.000000 0.000001 0.744162 0.7799760.389990 256 5.498 0.000172 0.002470 0.224230 0.119996 0.998003 2579.296 0.000000 1.000000 0.790640 0.575586 0.284504 258 9.361 0.0019980.007361 0.085034 0.976056 0.056129 259 6.933 0.000121 1.000000 0.0353140.917808 0.079681 260 8.146 0.000817 1.000000 0.003077 0.175728 0.168438261 10.387 1.000000 0.000000 0.154204 0.005202 0.633454 262 7.3221.000000 0.000000 0.184100 0.642671 0.032921 263 8.937 1.000000 0.0000000.270540 0.411394 0.024808 264 8.099 0.000006 0.005941 0.629532 0.2321350.868727 265 8.658 0.001307 0.000125 0.042189 0.642870 0.220174 2667.307 0.136406 0.003979 0.899378 0.062794 0.276354 267 7.948 0.0894090.021345 0.534724 0.441022 0.999958 268 4.814 0.188367 0.002418 0.3077600.984538 0.242328 269 8.262 0.003309 0.000013 0.050366 0.644219 0.248933270 6.153 0.263893 0.011698 0.965100 0.195596 0.424691 271 6.9290.004682 1.000000 0.000051 0.739871 0.000534 272 8.747 0.000009 1.0000000.661459 0.056585 0.485502 273 7.670 0.002863 0.002878 0.963051 0.4894330.425727 274 9.060 0.000004 0.006105 0.996920 0.309691 0.456795 2757.741 0.000237 0.794307 0.149393 0.868630 0.057952 276 6.472 0.5561740.000261 0.038526 0.798163 0.134791 277 9.866 1.000000 0.000006 0.5570460.887942 0.802758 278 5.372 1.000000 0.438013 0.000033 0.171523 0.007397279 9.620 0.000424 0.113905 0.627252 0.847118 0.345974 280 7.5390.001516 1.000000 0.250568 0.355397 0.913465 281 7.760 1.000000 0.2454600.750146 0.000037 0.004098 282 6.359 0.156285 1.000000 0.000226 0.0022510.494438 283 4.554 1.000000 0.000000 0.122703 0.982429 0.088234 2846.914 0.000011 1.000000 0.027018 0.806772 0.098170 285 6.825 1.0000001.000000 0.000001 0.000011 0.409707 286 7.625 1.000000 0.002245 0.2541010.080350 0.953292 287 7.088 1.000000 0.000005 0.953122 0.639431 0.530295288 7.671 0.789194 1.000000 0.000012 0.023331 0.029137 289 11.7030.162049 0.000001 0.862749 0.969968 0.947024 290 11.692 0.0640671.000000 0.011327 0.010003 0.932084 291 8.784 0.001733 0.264252 0.0979180.824211 0.261542 292 8.527 0.163494 0.002054 0.980872 0.858346 0.960862293 6.253 0.000028 1.000000 0.065034 0.016357 0.984841 294 7.7161.000000 0.000000 0.999922 0.538365 0.635314 295 8.239 1.000000 1.0000000.000120 0.001571 0.448676 296 9.702 0.000005 1.000000 0.830277 0.9342250.650508 297 6.644 1.000000 0.000023 0.471520 0.309485 0.994504 2988.283 1.000000 0.001039 0.155603 0.877005 0.063053 299 9.230 1.0000000.000100 0.078833 0.793766 0.239952 300 8.065 1.000000 0.000005 0.0959360.867921 0.226701 301 7.113 1.000000 0.001735 0.115620 0.000618 0.379268302 5.954 0.000000 1.000000 0.186587 0.721925 0.044203 303 7.8101.000000 1.000000 0.160174 0.000219 0.191966 304 6.772 1.000000 0.7485160.000612 0.000014 0.929559 305 6.056 0.010741 0.032666 0.488873 0.2534340.969967 306 8.840 0.014281 0.064555 0.679691 0.009289 0.184703 3078.540 1.000000 1.000000 0.000906 0.007024 0.542344 308 7.221 0.0005721.000000 0.238268 0.690136 0.055163 309 6.026 1.000000 0.000002 0.1380730.999915 0.135136 310 8.523 0.000049 0.377958 0.469588 0.921733 0.676477311 6.488 0.001154 1.000000 0.779960 0.773039 0.418346 312 6.4081.000000 1.000000 0.007884 0.000183 0.836520 313 7.023 1.000000 0.0000000.162844 0.999656 0.156176 314 4.576 1.000000 0.188292 0.144998 0.0264710.921677 315 7.764 1.000000 0.000026 0.453417 0.841420 0.752519 3167.620 1.000000 0.000002 0.977232 0.934372 0.994545 317 5.666 1.0000000.000010 0.537664 0.982363 0.443725 318 8.672 1.000000 0.000532 0.8659680.779044 0.519467 319 4.419 1.000000 0.000000 0.416052 0.694594 0.124264

Example 6 Ratios of IRS Biomarkersmarkers Between Healthy, inSIRS, MildSepsis, Severe Sepsis and Septic Shock

Examples of the use of 2-gene ratios as a more informative predictor ofclinical condition than either of the two component genes are presentedin Tables 16, 17, 18, 19, 20 and 21. These tables show instances of theprediction of Healthy and inSIRS (Table 16), Healthy vs. ipSIRS (Table17), inSIRS and ipSIRS (Table 18), Mild Sepsis vs.Vs Severe Sepsis(Table 19), Mild Sepsis Vs Septic Shock (Table 20), and Severe Sepsisvs.Vs Septic Shock (Table 21) using 2 genes and their ratios. Columnsfrom left to right are: name of the first component gene (Gene 1 Name),the corresponding Area Under Curve for this gene (Gene 1 AUC), thesecond component gene (Gene 2 Name), the corresponding AUC for this gene(Gene 2 AUC), the AUC for this ratio (Ratio AUC), the statisticalsignificance using Delong's method (DeLong E R, DeLong D M,Clarke-Pearson DL: Comparing the Areas under Two or More CorrelatedReceiver Operating Characteristic Curves: A Non parametric Approach.Biometrics 1988, 44:837-845) that the ratio is a better predictor thanGene 1 (Ratio Signif to Gene 1), the statistical significance usingDelong's method that the ratio is a better predictor than Gene2 (RatioSignif to Gene 2). These tables show results for which the ratio AUC isshown to be superior to both of the component genes, and the improvementstatistically significant over both genes. Examples of less significantratios, or cases where the ratio is statistically superior to only oneof the component genes are not listed in these tables. Such ratios canalso be used in clinical trials in a similar fashion to that describedin Example 5.

TABLE 16 Ratios Healthy Versus inSIRS Gene 1 Name Gene 1 AUC Gene 2 NameGene 2 AUC Ratio AUC Ratio Signif to Gene 1 Ratio Signif to Gene 2 TLR50.874 HLA-DPB1 0.815 0.953 0.008 0.004 TLR5 0.874 PLAC8 0.828 0.9790.003 0.004 TLR5 0.874 CDS2 0.73 0.933 0.003 0.003 TLR5 0.874 SLC39A90.776 0.946 0.003 0.002 TLR5 0.874 LGALS1 0.722 0.941 0.015 0 TLR5 0.874DNAJC9_FAM149B1 0.944 0.994 0.003 0.037 TLR5 0.874 LGALS2 0.922 0.9830.003 0.019 TLR5 0.874 HINT1 0.9 0.949 0.048 0.036 TLR5 0.874HS2ST1_UBA2 0.668 0.938 0.006 0 TLR5 0.874 HLA-DPA1 0.796 0.948 0.0050.003 TLR5 0.874 PTGER2 0.881 0.957 0.007 0.038 TLR5 0.874 TRAF3 0.870.966 0.011 0.015 TLR5 0.874 RPL17_SNORD58B 0.917 0.964 0.02 0.029 TLR50.874 JUP 0.753 0.938 0.02 0.007 TLR5 0.874 HSP90AB1_HSP90A 0.924 0.9910.003 0.021 TLR5 0.874 ITGA4_CERKL 0.88 0.957 0.018 0.026 TLR5 0.874EIF1AX_SCARNA9L 0.871 0.942 0.039 0.032 TLR5 0.874 CD300A 0.841 0.9550.003 0.02 TLR5 0.874 P4HA1_RPL17 0.664 0.947 0.027 0 TLR5 0.874 MGST30.857 0.969 0.002 0.011 TLR5 0.874 KIAA0746 0.776 0.949 0.026 0.001 TLR50.874 HSPB1_HSPBL2 0.705 0.915 0.05 0.001 TLR5 0.874 CD151 0.718 0.9380.047 0 TLR5 0.874 IGK@_IGKC_IGKV 0.855 0.946 0.01 0.02 TLR5 0.874 SON0.856 0.942 0.02 0.045 TLR5 0.874 IRF1 0.82 0.961 0.003 0.008 TLR5 0.874C7orf58 0.831 0.996 0.003 0 TLR5 0.874 NP 0.726 0.957 0.021 0 TLR5 0.874AIF1 0.618 0.941 0.019 0 TLR5 0.874 CDC26 0.799 0.949 0.009 0.003 TLR50.874 TAS2R31 0.833 0.946 0.038 0.002 TLR5 0.874 NFXL1 0.728 0.945 0.0170 TLR5 0.874 DCTN5 0.722 0.929 0.034 0 UBE2J1 0.888 FAIM3 0.93 0.9810.007 0.023 UBE2J1 0.888 SH2D1B 0.894 0.953 0.034 0.02 UBE2J1 0.888LRRN3 0.928 0.962 0.029 0.023 UBE2J1 0.888 HLA-DPB1 0.815 0.974 0.015 0UBE2J1 0.888 PLAC8 0.828 0.997 0.002 0.001 UBE2J1 0.888 GOT2 0.966 0.990.004 0.044 UBE2J1 0.888 CDS2 0.73 0.958 0.005 0 UBE2J1 0.888 SLC39A90.776 0.981 0.002 0 UBE2J1 0.888 GIMAP7 0.804 0.967 0.034 0 UBE2J1 0.888INSIG1 0.957 0.997 0.002 0.032 UBE2J1 0.888 LGALS1 0.722 0.946 0.046 0UBE2J1 0.888 DNAJC9_FAM149B1 0.944 0.992 0.005 0.017 UBE2J1 0.888 LGALS20.922 0.979 0.004 0.015 UBE2J1 0.888 HS2ST1_UBA2 0.668 0.956 0.032 0UBE2J1 0.888 HLA-DPA1 0.796 0.971 0.015 0 UBE2J1 0.888 PTGER2 0.8810.978 0.007 0.002 UBE2J1 0.888 PMS2CL_PMS2 0.942 0.992 0.003 0.017UBE2J1 0.888 NEK6_LOC1001290 0.671 0.948 0.047 0 UBE2J1 0.888 TRAF3 0.870.981 0.011 0.003 UBE2J1 0.888 IRF4 0.946 0.993 0.002 0.041 UBE2J1 0.888AMFR 0.867 0.947 0.049 0.025 UBE2J1 0.888 HSP90AB1_HSP90A 0.924 0.9960.003 0.009 UBE2J1 0.888 ITGA4_CERKL 0.88 0.987 0.005 0.002 UBE2J1 0.888EIF1AX_SCARNA9L 0.871 0.971 0.023 0.001 UBE2J1 0.888 CD300A 0.841 0.9640.002 0.005 UBE2J1 0.888 MGST3 0.857 0.98 0.007 0.001 UBE2J1 0.888KIAA0746 0.776 0.964 0.05 0 UBE2J1 0.888 CCR4 0.871 0.971 0.018 0.004UBE2J1 0.888 RRP12_LOC644215 0.904 0.976 0.006 0.015 UBE2J1 0.888 TIMM100.949 0.992 0.002 0.031 UBE2J1 0.888 FAM118A 0.882 0.976 0.009 0.01UBE2J1 0.888 IGK@_IGKC_IGKV 0.855 0.962 0.039 0.002 UBE2J1 0.888 SON0.856 0.967 0.023 0.006 UBE2J1 0.888 IRF1 0.82 0.965 0.004 0.002 UBE2J10.888 C7orf58 0.831 0.988 0.007 0 UBE2J1 0.888 B4GALT3 0.917 0.975 0.0060.041 UBE2J1 0.888 CDC26 0.799 0.956 0.029 0 UBE2J1 0.888 DCTN5 0.7220.955 0.042 0 RNASE2_LOC64333 0.855 HLA-DPB1 0.815 0.955 0.009 0.004RNASE2_LOC64333 0.855 PLAC8 0.828 0.969 0.003 0.009 RNASE2_LOC643330.855 ITK 0.874 0.94 0.034 0.047 RNASE2_LOC64333 0.855 CDS2 0.73 0.9120.01 0.008 RNASE2_LOC64333 0.855 CCR3 0.869 0.95 0.008 0.047RNASE2_LOC64333 0.855 SLC39A9 0.776 0.944 0.003 0.003 RNASE2_LOC643330.855 GIMAP7 0.804 0.951 0.009 0.003 RNASE2_LOC64333 0.855 LGALS1 0.7220.952 0.003 0.001 RNASE2_LOC64333 0.855 HLA-DRA 0.855 0.97 0.005 0.012RNASE2_LOC64333 0.855 SIAE 0.737 0.921 0.018 0.01 RNASE2_LOC64333 0.855HIST1H3J 0.898 0.949 0.007 0.021 RNASE2_LOC64333 0.855 MTRR 0.674 0.9460.018 0 RNASE2_LOC64333 0.855 HIST1H3A 0.908 0.961 0.009 0.015RNASE2_LOC64333 0.855 HLA-DPA1 0.796 0.951 0.005 0.004 RNASE2_LOC643330.855 SLC39A8 0.825 0.954 0.007 0.021 RNASE2_LOC64333 0.855 PTGER2 0.8810.954 0.005 0.035 RNASE2_LOC64333 0.855 NEK6_LOC1001290 0.671 0.921 0.020.001 RNASE2_LOC64333 0.855 TRAF3 0.87 0.97 0.003 0.033 RNASE2_LOC643330.855 JUP 0.753 0.931 0.025 0.011 RNASE2_LOC64333 0.855 GALNT2 0.5280.898 0.017 0 RNASE2_LOC64333 0.855 HSP90AB1_HSP90A 0.924 0.988 0.0020.036 RNASE2_LOC64333 0.855 GLT25D1 0.77 0.956 0.005 0.004RNASE2_LOC64333 0.855 ITGA4_CERKL 0.88 0.958 0.007 0.03 RNASE2_LOC643330.855 EIF1AX_SCARNA9L 0.871 0.958 0.009 0.011 RNASE2_LOC64333 0.855ZNF28 0.837 0.921 0.023 0.026 RNASE2_LOC64333 0.855 ICAM1 0.675 0.9310.013 0 RNASE2_LOC64333 0.855 P4HA1_RPL17 0.664 0.935 0.034 0RNASE2_LOC64333 0.855 KLHL5 0.657 0.924 0.034 0 RNASE2_LOC64333 0.855MGST3 0.857 0.97 0.002 0.01 RNASE2_LOC64333 0.855 KIAA0746 0.776 0.9450.018 0.001 RNASE2_LOC64333 0.855 HSPB1_HSPBL2 0.705 0.913 0.009 0.004RNASE2_LOC64333 0.855 CCR4 0.871 0.947 0.012 0.047 RNASE2_LOC64333 0.855HIST1H3B 0.89 0.948 0.013 0.045 RNASE2_LOC64333 0.855 FSD1L_GARNL1 0.7790.929 0.013 0.008 RNASE2_LOC64333 0.855 CD151 0.718 0.923 0.039 0RNASE2_LOC64333 0.855 HIST1H3H 0.861 0.919 0.05 0.021 RNASE2_LOC643330.855 IGK@_IGKC_IGKV 0.855 0.948 0.013 0.015 RNASE2_LOC64333 0.855 IRF10.82 0.926 0.012 0.03 RNASE2_LOC64333 0.855 C7orf58 0.831 0.978 0.0060.001 RNASE2_LOC64333 0.855 CTSL1_CTSLL3 0.676 0.912 0.042 0RNASE2_LOC64333 0.855 NP 0.726 0.941 0.017 0 RNASE2_LOC64333 0.855TMEM62_SPCS2_L 0.78 0.937 0.036 0.002 RNASE2_LOC64333 0.855 TAS2R310.833 0.945 0.026 0.002 RNASE2_LOC64333 0.855 DCTN5 0.722 0.925 0.021 0C3AR1 0.868 GPR56 0.943 0.98 0.009 0.032 C3AR1 0.868 CAMK4 0.921 0.970.038 0.034 C3AR1 0.868 SH2D1B 0.894 0.974 0.014 0.003 C3AR1 0.868HLA-DPB1 0.815 0.935 0.025 0.023 C3AR1 0.868 VAMP2 0.783 0.929 0.0290.01 C3AR1 0.868 PLAC8 0.828 0.969 0.004 0.018 C3AR1 0.868 ITK 0.8740.961 0.049 0.008 C3AR1 0.868 SLC39A9 0.776 0.953 0.008 0.004 C3AR10.868 GIMAP7 0.804 0.957 0.013 0.002 C3AR1 0.868 LGALS1 0.722 0.9280.019 0.004 C3AR1 0.868 DNAJC9_FAM149B1 0.944 0.997 0.006 0.026 C3AR10.868 SIAE 0.737 0.927 0.042 0.007 C3AR1 0.868 HINT1 0.9 0.965 0.0380.01 C3AR1 0.868 HLA-DPA1 0.796 0.931 0.025 0.014 C3AR1 0.868 PTGER20.881 0.962 0.006 0.044 C3AR1 0.868 PMS2CL_PMS2 0.942 0.992 0.005 0.036C3AR1 0.868 RPL17_SNORD58B 0.917 0.965 0.033 0.015 C3AR1 0.868 GALNT20.528 0.91 0.024 0 C3AR1 0.868 GLT25D1 0.77 0.937 0.01 0.021 C3AR1 0.868ITGA4_CERKL 0.88 0.967 0.014 0.021 C3AR1 0.868 EIF1AX_SCARNA9L 0.8710.956 0.035 0.008 C3AR1 0.868 P4HA1_RPL17 0.664 0.942 0.044 0 C3AR10.868 KIAA0746 0.776 0.948 0.038 0.001 C3AR1 0.868 FSD1L_GARNL1 0.7790.928 0.024 0.013 C3AR1 0.868 IGK@_IGKC_IGKV 0.855 0.951 0.035 0.025C3AR1 0.868 SON 0.856 0.961 0.025 0.012 C3AR1 0.868 C7orf58 0.831 0.9580.019 0.003 C3AR1 0.868 NP 0.726 0.942 0.016 0.001 C3AR1 0.868 CDC260.799 0.934 0.018 0.02 C3AR1 0.868 TAS2R31 0.833 0.947 0.046 0.003 C3AR10.868 DCTN5 0.722 0.94 0.017 0.001 GPR56 0.943 TGFBR1 0.734 0.984 0.0070 GPR56 0.943 DNAJC13 0.819 0.985 0.03 0 GPR56 0.943 ANKRD34B 0.9040.987 0.037 0.002 GPR56 0.943 SGMS2 0.938 0.996 0.013 0.013 GPR56 0.943B3GNT5_MCF2L2 0.949 0.987 0.018 0.026 GPR56 0.943 SMPDL3A 0.797 0.9810.027 0 GPR56 0.943 LOC284757 0.939 0.996 0.013 0.048 GPR56 0.943PPP2R5A_SNORA16 0.953 0.997 0.009 0.029 GPR56 0.943 FRMD3 0.755 0.980.011 0 GPR56 0.943 EIF2AK2 0.964 0.999 0.011 0.034 GPR56 0.943 NA 0.8680.977 0.043 0.002 GPR56 0.943 HIST1H2AA 0.903 0.978 0.028 0.012 GPR560.943 CDA 0.945 0.978 0.03 0.045 GPR56 0.943 SAP30 0.911 0.983 0.0290.021 GPR56 0.943 ACPL2 0.906 0.99 0.018 0.011 GPR56 0.943 HAL 0.9420.99 0.018 0.018 GPR56 0.943 KIAA1257_ACAD9/ 0.851 0.981 0.031 0.001GPR56 0.943 CCDC125 0.917 0.995 0.011 0.009 GPR56 0.943 PDK4 0.863 0.9870.041 0.001 GPR56 0.943 ZRANB1 0.897 0.99 0.023 0.002 GPR56 0.943 MPZL30.892 0.975 0.017 0.007 GPR56 0.943 CYP4F3_CYP4F2 0.901 0.995 0.0240.007 GPR56 0.943 SYNE2 0.748 0.997 0.013 0 GPR56 0.943 MME 0.894 0.9860.043 0.007 GPR56 0.943 RBP7 0.848 0.974 0.035 0.002 GPR56 0.943 RGS20.915 0.979 0.01 0.02 FCGR1A_FCGR1B_(—) 0.87 HLA-DPB1 0.815 0.952 0.0020.008 FCGR1A_FCGR1B_(—) 0.87 VAMP2 0.783 0.895 0.029 0.038FCGR1A_FCGR1B_(—) 0.87 CASS4 0.738 0.91 0.024 0.003 FCGR1A_FCGR1B_(—)0.87 PLAC8 0.828 0.971 0.002 0.009 FCGR1A_FCGR1B_(—) 0.87 ITK 0.8740.949 0.013 0.041 FCGR1A_FCGR1B_(—) 0.87 CDS2 0.73 0.916 0.004 0.008FCGR1A_FCGR1B_(—) 0.87 SLC39A9 0.776 0.932 0.002 0.007 FCGR1A_FCGR1B_(—)0.87 GIMAP7 0.804 0.956 0.004 0.002 FCGR1A_FCGR1B_(—) 0.87 LGALS1 0.7220.933 0.009 0.001 FCGR1A_FCGR1B_(—) 0.87 FFAR2 0.637 0.934 0.014 0FCGR1A_FCGR1B_(—) 0.87 LGALS2 0.922 0.986 0.002 0.017 FCGR1A_FCGR1B_(—)0.87 MTRR 0.674 0.947 0.006 0 FCGR1A_FCGR1B_(—) 0.87 HS2ST1_UBA2 0.6680.922 0.015 0 FCGR1A_FCGR1B_(—) 0.87 HLA-DPA1 0.796 0.932 0.002 0.018FCGR1A_FCGR1B_(—) 0.87 SLC39A8 0.825 0.95 0.001 0.041 FCGR1A_FCGR1B_(—)0.87 NEK6_LOC1001290 0.671 0.907 0.035 0.001 FCGR1A_FCGR1B_(—) 0.87 JUP0.753 0.936 0.012 0.011 FCGR1A_FCGR1B_(—) 0.87 GALNT2 0.528 0.897 0.0260 FCGR1A_FCGR1B_(—) 0.87 GLT25D1 0.77 0.933 0.024 0.004FCGR1A_FCGR1B_(—) 0.87 HDHD1A 0.602 0.914 0.028 0 FCGR1A_FCGR1B_(—) 0.87EIF1AX_SCARNA9L 0.871 0.965 0.003 0.017 FCGR1A_FCGR1B_(—) 0.87 SFRS90.558 0.901 0.039 0 FCGR1A_FCGR1B_(—) 0.87 ZNF28 0.837 0.922 0.029 0.048FCGR1A_FCGR1B_(—) 0.87 ICAM1 0.675 0.96 0.002 0 FCGR1A_FCGR1B_(—) 0.87P4HA1_RPL17 0.664 0.942 0.006 0 FCGR1A_FCGR1B_(—) 0.87 KLHL5 0.657 0.9330.022 0 FCGR1A_FCGR1B_(—) 0.87 MGST3 0.857 0.97 0.002 0.009FCGR1A_FCGR1B_(—) 0.87 KIAA0746 0.776 0.952 0.012 0.001FCGR1A_FCGR1B_(—) 0.87 HSPB1_HSPBL2 0.705 0.91 0.018 0.003FCGR1A_FCGR1B_(—) 0.87 CCR4 0.871 0.964 0.002 0.036 FCGR1A_FCGR1B_(—)0.87 IL1B 0.576 0.977 0.012 0 FCGR1A_FCGR1B_(—) 0.87 FSD1L_GARNL1 0.7790.908 0.044 0.01 FCGR1A_FCGR1B_(—) 0.87 NA 0.7 0.95 0.02 0FCGR1A_FCGR1B_(—) 0.87 IGK@_IGKC_IGKV 0.855 0.941 0.01 0.028FCGR1A_FCGR1B_(—) 0.87 IRF1 0.82 0.95 0.001 0.021 FCGR1A_FCGR1B_(—) 0.87C7orf58 0.831 0.983 0.003 0.001 FCGR1A_FCGR1B_(—) 0.87 NP 0.726 0.9320.033 0.001 FCGR1A_FCGR1B_(—) 0.87 PLEKHA3 0.645 0.919 0.025 0FCGR1A_FCGR1B_(—) 0.87 CDC26 0.799 0.919 0.02 0.024 FCGR1A_FCGR1B_(—)0.87 TAS2R31 0.833 0.961 0.003 0.003 FCGR1A_FCGR1B_(—) 0.87 IGLV6-570.761 0.914 0.044 0.002 FCGR1A_FCGR1B_(—) 0.87 NFXL1 0.728 0.929 0.019 0FCGR1A_FCGR1B_(—) 0.87 DCTN5 0.722 0.932 0.005 0.001 C11orf82 0.58C7orf58 0.831 0.911 0 0.023 FAR2 0.843 PTGDR 0.896 0.953 0.014 0.035FAR2 0.843 SH2D1B 0.894 0.961 0.007 0.006 FAR2 0.843 VAMP2 0.783 0.9360.005 0.006 FAR2 0.843 SLC39A9 0.776 0.921 0.013 0.004 FAR2 0.843NEK6_LOC1001290 0.671 0.893 0.046 0.001 FAR2 0.843 GLT25D1 0.77 0.9120.016 0.027 FAR2 0.843 ITGA4_CERKL 0.88 0.955 0.011 0.013 FAR2 0.843EIF1AX_SCARNA9L 0.871 0.939 0.028 0.01 FAR2 0.843 CD300A 0.841 0.9460.001 0.02 FAR2 0.843 ZNF28 0.837 0.934 0.021 0.006 FAR2 0.843 ABCG10.85 0.952 0.001 0.037 FAR2 0.843 HIST1H3B 0.89 0.946 0.016 0.037 FAR20.843 FSD1L_GARNL1 0.779 0.921 0.006 0.007 FAR2 0.843 APOLD1 0.871 0.9560.003 0.021 FAR2 0.843 IGK@_IGKC_IGKV 0.855 0.926 0.031 0.024 FAR2 0.843SON 0.856 0.948 0.009 0.024 FAR2 0.843 IRF1 0.82 0.921 0.006 0.044 FAR20.843 TNFRSF17 0.875 0.935 0.021 0.048 FAR2 0.843 CDC26 0.799 0.9350.003 0.008 GNLY 0.914 GALNT3 0.837 0.97 0.036 0.001 GNLY 0.914 STOM0.825 0.952 0.02 0.003 GNLY 0.914 TGFBR1 0.734 0.958 0.01 0 GNLY 0.914DNAJC13 0.819 0.961 0.03 0.001 GNLY 0.914 ANKRD34B 0.904 0.964 0.0190.035 GNLY 0.914 SGMS2 0.938 0.989 0.006 0.028 GNLY 0.914 C9orf72 0.7960.959 0.028 0.001 GNLY 0.914 SMPDL3A 0.797 0.977 0.007 0.001 GNLY 0.914PPP2R5A_SNORA16 0.953 0.993 0.005 0.044 GNLY 0.914 FRMD3 0.755 0.9550.018 0 GNLY 0.914 NA 0.927 0.99 0.01 0.012 GNLY 0.914 EIF2AK2 0.9640.997 0.005 0.048 GNLY 0.914 NA 0.868 0.967 0.027 0.003 GNLY 0.914 ACPL20.906 0.978 0.014 0.029 GNLY 0.914 OCR1 0.896 0.977 0.046 0.009 GNLY0.914 CCDC125 0.917 0.988 0.004 0.017 GNLY 0.914 ZRANB1 0.897 0.9890.008 0.004 GNLY 0.914 CYP4F3_CYP4F2 0.901 0.981 0.045 0.007 GNLY 0.914SYNE2 0.748 0.973 0.019 0 GNLY 0.914 RBP7 0.848 0.976 0.013 0.002 GALNT30.837 FAIM3 0.93 0.983 0 0.032 GALNT3 0.837 PTGDR 0.896 0.964 0.0020.024 GALNT3 0.837 CAMK4 0.921 0.98 0.001 0.033 GALNT3 0.837 SH2D1B0.894 0.976 0.001 0.003 GALNT3 0.837 TLR10 0.521 0.942 0.031 0 GALNT30.837 CRIP1 0.943 0.957 0.004 0.05 GALNT3 0.837 LRRN3 0.928 0.974 0.0010.017 GALNT3 0.837 HLA-DPB1 0.815 0.934 0.005 0.007 GALNT3 0.837 CASS40.738 0.92 0.008 0.001 GALNT3 0.837 KPNA5 0.895 0.98 0.001 0.005 GALNT30.837 PLAC8 0.828 0.985 0.001 0.001 GALNT3 0.837 KLRK1_KLRC4 0.865 0.9480.018 0.006 GALNT3 0.837 ITK 0.874 0.969 0.003 0.006 GALNT3 0.837 FGFBP20.814 0.937 0.015 0.001 GALNT3 0.837 CDS2 0.73 0.925 0 0.004 GALNT30.837 CCR3 0.869 0.937 0.014 0.003 GALNT3 0.837 CHI3L1 0.722 0.911 0.030.001 GALNT3 0.837 SLC39A9 0.776 0.958 0 0 GALNT3 0.837 GIMAP7 0.8040.982 0 0 GALNT3 0.837 LGALS1 0.722 0.901 0.009 0.003 GALNT3 0.837DNAJC9_FAM149B1 0.944 0.989 0 0.024 GALNT3 0.837 LGALS2 0.922 0.972 00.046 GALNT3 0.837 SIAE 0.737 0.927 0.002 0.003 GALNT3 0.837 HINT1 0.90.965 0.002 0.017 GALNT3 0.837 MTRR 0.674 0.954 0.003 0 GALNT3 0.837AIG1 0.56 0.921 0.023 0 GALNT3 0.837 HS2ST1_UBA2 0.668 0.973 0 0 GALNT30.837 HLA-DPA1 0.796 0.939 0.003 0.002 GALNT3 0.837 PTGER2 0.881 0.969 00.016 GALNT3 0.837 PMS2CL_PMS2 0.942 0.994 0 0.028 GALNT3 0.837NEK6_LOC1001290 0.671 0.899 0.039 0 GALNT3 0.837 CENPK 0.834 0.942 0.0230.001 GALNT3 0.837 TRAF3 0.87 0.971 0.002 0.004 GALNT3 0.837RPL17_SNORD58B 0.917 0.978 0.001 0.01 GALNT3 0.837 HSP90AB1_HSP90A 0.9240.988 0 0.009 GALNT3 0.837 GLT25D1 0.77 0.905 0.02 0.009 GALNT3 0.837ITGA4_CERKL 0.88 0.993 0 0.004 GALNT3 0.837 EIF1AX_SCARNA9L 0.871 0.9760.001 0.002 GALNT3 0.837 CD300A 0.841 0.946 0 0.03 GALNT3 0.837 ZNF280.837 0.946 0.003 0.005 GALNT3 0.837 P4HA1_RPL17 0.664 0.956 0.006 0GALNT3 0.837 KLHL5 0.657 0.971 0.001 0 GALNT3 0.837 MGST3 0.857 0.9640.001 0.002 GALNT3 0.837 KIAA0746 0.776 0.949 0.012 0 GALNT3 0.837 CCR40.871 0.99 0 0.002 GALNT3 0.837 FSD1L_GARNL1 0.779 0.916 0.009 0.003GALNT3 0.837 FAM118A 0.882 0.965 0 0.042 GALNT3 0.837 CD151 0.718 0.9010.048 0.001 GALNT3 0.837 HIST1H3H 0.861 0.914 0.047 0.029 GALNT3 0.837PYHIN1 0.686 0.926 0.044 0 GALNT3 0.837 IGK@_IGKC_IGKV 0.855 0.964 0.0020.002 GALNT3 0.837 IRF1 0.82 0.953 0 0.01 GALNT3 0.837 C7orf58 0.8310.987 0.001 0 GALNT3 0.837 B4GALT3 0.917 0.99 0 0.035 GALNT3 0.837 NP0.726 0.976 0 0 GALNT3 0.837 C4orf3 0.723 0.891 0.032 0.002 GALNT3 0.837TNFRSF17 0.875 0.944 0.005 0.024 GALNT3 0.837 CDC26 0.799 0.938 0.0010.005 GALNT3 0.837 TAS2R31 0.833 0.96 0.003 0.001 GALNT3 0.837 NFXL10.728 0.942 0.014 0 GALNT3 0.837 DCTN5 0.722 0.925 0.014 0 OMG 0.851SH2D1B 0.894 0.951 0.005 0.03 OMG 0.851 LRRN3 0.928 0.955 0.015 0.047OMG 0.851 CDS2 0.73 0.895 0.044 0.004 OMG 0.851 HIST1H4L 0.961 0.996 00.042 OMG 0.851 LGALS1 0.722 0.91 0.013 0.001 OMG 0.851 LGALS2 0.9220.972 0.001 0.036 OMG 0.851 HIST1H3J 0.898 0.961 0.005 0.006 OMG 0.851HS2ST1_UBA2 0.668 0.897 0.047 0.001 OMG 0.851 HIST1H3A 0.908 0.971 0.0060.004 OMG 0.851 RPL17_SNORD58B 0.917 0.971 0.002 0.035 OMG 0.851 GLT25D10.77 0.913 0.032 0.014 OMG 0.851 ITGA4_CERKL 0.88 0.946 0.005 0.031 OMG0.851 EIF1AX_SCARNA9L 0.871 0.94 0.022 0.017 OMG 0.851 ZNF28 0.837 0.9570.005 0.002 OMG 0.851 MGST3 0.857 0.921 0.011 0.039 OMG 0.851 HIST1H3B0.89 0.969 0.004 0.01 OMG 0.851 FSD1L_GARNL1 0.779 0.924 0.018 0.004 OMG0.851 HIST1H3H 0.861 0.958 0.014 0.001 OMG 0.851 APOLD1 0.871 0.9640.001 0.016 OMG 0.851 IRF1 0.82 0.909 0.026 0.047 OMG 0.851 CDC26 0.7990.947 0.003 0.003 STOM 0.825 CAMK4 0.921 0.94 0.014 0.046 STOM 0.825SH2D1B 0.894 0.938 0.016 0.004 STOM 0.825 KPNA5 0.895 0.929 0.028 0.013STOM 0.825 PLAC8 0.828 0.912 0.048 0.014 STOM 0.825 HIST1H4E 0.915 0.9750 0.04 STOM 0.825 CCR3 0.869 0.906 0.037 0.017 STOM 0.825 HIST1H4L 0.9610.992 0 0.018 STOM 0.825 HINT1 0.9 0.934 0.015 0.043 STOM 0.825 HIST1H3J0.898 0.962 0.004 0.002 STOM 0.825 HIST1H3A 0.908 0.962 0.003 0.004 STOM0.825 PTGER2 0.881 0.939 0.002 0.032 STOM 0.825 AMFR 0.867 0.966 0 0.013STOM 0.825 RPL17_SNORD58B 0.917 0.957 0.007 0.03 STOM 0.825EIF1AX_SCARNA9L 0.871 0.92 0.03 0.011 STOM 0.825 CD300A 0.841 0.9090.009 0.039 STOM 0.825 ZNF28 0.837 0.923 0.026 0.005 STOM 0.825 MGST30.857 0.939 0.003 0.012 STOM 0.825 TYMS 0.863 0.961 0.001 0.005 STOM0.825 HIST1H2BM 0.891 0.969 0.001 0.01 STOM 0.825 HIST1H3B 0.89 0.960.003 0.004 STOM 0.825 FAM118A 0.882 0.963 0.002 0.008 STOM 0.825HIST1H3H 0.861 0.944 0.017 0 STOM 0.825 APOLD1 0.871 0.949 0.001 0.015STOM 0.825 IGK@_IGKC_IGKV 0.855 0.912 0.044 0.008 STOM 0.825 SON 0.8560.921 0.045 0.011 STOM 0.825 IRF1 0.82 0.911 0.016 0.025 STOM 0.825B4GALT3 0.917 0.986 0 0.021 STOM 0.825 TNFRSF17 0.875 0.918 0.03 0.032STOM 0.825 CDC26 0.799 0.919 0.004 0.007 TDRD9 0.758 PLAC8 0.828 0.9370.001 0.046 TDRD9 0.758 GIMAP7 0.804 0.891 0.015 0.05 TDRD9 0.758 LGALS10.722 0.898 0.003 0.018 TDRD9 0.758 HS2ST1_UBA2 0.668 0.836 0.022 0.03TDRD9 0.758 NEK6_LOC1001290 0.671 0.821 0.041 0.049 TDRD9 0.758 GLT25D10.77 0.932 0.002 0.002 TDRD9 0.758 P4HA1_RPL17 0.664 0.845 0.045 0.003TDRD9 0.758 C15orf54 0.72 0.859 0.037 0.002 TDRD9 0.758 KIAA0746 0.7760.9 0.006 0.014 TDRD9 0.758 LAIR1_LAIR2 0.607 0.87 0.018 0 TDRD9 0.758E2F6 0.787 0.882 0.039 0.003 TDRD9 0.758 CD151 0.718 0.9 0.014 0.001TDRD9 0.758 FSD1L 0.674 0.847 0.04 0.003 TDRD9 0.758 C7orf58 0.831 0.9570.002 0.002 TDRD9 0.758 CTSL1_CTSLL3 0.676 0.863 0.04 0.007 TDRD9 0.758NP 0.726 0.863 0.048 0.03 TDRD9 0.758 IGLV6-57 0.761 0.864 0.016 0.033KREMEN1 0.848 PLAC8 0.828 0.947 0.004 0.029 KREMEN1 0.848 CDS2 0.730.902 0.006 0.012 KREMEN1 0.848 SLC39A9 0.776 0.894 0.021 0.017 KREMEN10.848 LGALS2 0.922 0.987 0.002 0.012 KREMEN1 0.848 HIST1H3J 0.898 0.9390.028 0.04 KREMEN1 0.848 CD300A 0.841 0.939 0.002 0.04 KREMEN1 0.848MGST3 0.857 0.945 0.008 0.027 KREMEN1 0.848 IGK@_IGKC_IGKV 0.855 0.9280.035 0.01 KREMEN1 0.848 IRF1 0.82 0.951 0.003 0.007 KREMEN1 0.848C7orf58 0.831 0.96 0.014 0.001 KREMEN1 0.848 TNFRSF17 0.875 0.947 0.0090.014 KREMEN1 0.848 CDC26 0.799 0.913 0.004 0.033 FAIM3 0.93 DNAJC130.819 0.989 0.04 0 FAIM3 0.93 GSR 0.799 0.973 0.045 0 FAIM3 0.93 SGMS20.938 0.99 0.036 0.012 FAIM3 0.93 METTL7B 0.898 0.954 0.05 0.023 FAIM30.93 C9orf72 0.796 0.976 0.038 0 FAIM3 0.93 SMPDL3A 0.797 0.992 0.019 0FAIM3 0.93 NA 0.927 0.997 0.03 0.013 FAIM3 0.93 EIF2AK2 0.964 0.9980.027 0.038 FAIM3 0.93 NA 0.868 0.992 0.02 0.001 FAIM3 0.93 CCDC1250.917 1 0.025 0.006 FAIM3 0.93 MPZL3 0.892 0.966 0.017 0.018 FAIM3 0.93SYNE2 0.748 0.994 0.038 0 FAIM3 0.93 RBP7 0.848 0.969 0.045 0.003 FAIM30.93 RGS2 0.915 0.975 0.02 0.03 FAIM3 0.93 PPP1R2_PPP1R2P3 0.702 0.9930.041 0 ACER3 0.746 HLA-DPB1 0.815 0.934 0 0.009 ACER3 0.746 PLAC8 0.8280.968 0 0.007 ACER3 0.746 SLC39A9 0.776 0.918 0 0.003 ACER3 0.746 GIMAP70.804 0.921 0.002 0.005 ACER3 0.746 LGALS1 0.722 0.923 0 0.002 ACER30.746 HLA-DRA 0.855 0.942 0.002 0.008 ACER3 0.746 SIAE 0.737 0.888 0.0030.027 ACER3 0.746 AGTRAP 0.611 0.809 0.024 0.005 ACER3 0.746 MTRR 0.6740.91 0.005 0 ACER3 0.746 AIG1 0.56 0.856 0.016 0 ACER3 0.746 HS2ST1_UBA20.668 0.838 0.016 0.018 ACER3 0.746 HIST1H3A 0.908 0.946 0 0.032 ACER30.746 HLA-DPA1 0.796 0.93 0 0.009 ACER3 0.746 SLC39A8 0.825 0.934 0.0010.018 ACER3 0.746 PTGER2 0.881 0.959 0 0.015 ACER3 0.746 NEK6_LOC10012900.671 0.858 0.007 0.01 ACER3 0.746 TRAF3 0.87 0.953 0 0.048 ACER3 0.746RPL17_SNORD58B 0.917 0.955 0 0.045 ACER3 0.746 JUP 0.753 0.888 0.0090.035 ACER3 0.746 GALNT2 0.528 0.817 0.025 0.001 ACER3 0.746HSP90AB1_HSP90A 0.924 0.984 0 0.029 ACER3 0.746 GLT25D1 0.77 0.952 00.003 ACER3 0.746 HDHD1A 0.602 0.855 0.024 0 ACER3 0.746 ITGA4_CERKL0.88 0.956 0 0.022 ACER3 0.746 EIF1AX_SCARNA9L 0.871 0.944 0.001 0.015ACER3 0.746 ICAM1 0.675 0.865 0.011 0.004 ACER3 0.746 P4HA1_RPL17 0.6640.919 0.005 0 ACER3 0.746 C15orf54 0.72 0.844 0.041 0.002 ACER3 0.746KLHL5 0.657 0.865 0.022 0.001 ACER3 0.746 MGST3 0.857 0.97 0 0.005 ACER30.746 KIAA0746 0.776 0.923 0.002 0.002 ACER3 0.746 HSPB1_HSPBL2 0.7050.866 0.002 0.017 ACER3 0.746 FSD1L_GARNL1 0.779 0.902 0.001 0.015 ACER30.746 NA 0.7 0.886 0.042 0 ACER3 0.746 E2F6 0.787 0.863 0.05 0.002 ACER30.746 CD151 0.718 0.878 0.012 0.002 ACER3 0.746 SON 0.856 0.946 0 0.027ACER3 0.746 C7orf58 0.831 0.97 0 0.001 ACER3 0.746 NP 0.726 0.915 0.0030.001 ACER3 0.746 C4orf3 0.723 0.842 0.024 0.039 ACER3 0.746TMEM62_SPCS2_L 0.78 0.903 0.024 0.001 ACER3 0.746 TAS2R31 0.833 0.9250.002 0.002 ACER3 0.746 IGLV6-57 0.761 0.846 0.019 0.048 ACER3 0.746SDHC 0.736 0.877 0.045 0 ACER3 0.746 NFXL1 0.728 0.865 0.021 0.002 ACER30.746 DCTN5 0.722 0.893 0.005 0.001 ACER3 0.746 KIAA0101_CSNK1G 0.7360.851 0.027 0.002 TGFBR1 0.734 PTGDR 0.896 0.956 0.001 0.005 TGFBR10.734 SH2D1B 0.894 0.952 0 0.001 TGFBR1 0.734 LRRN3 0.928 0.95 0 0.043TGFBR1 0.734 HLA-DPB1 0.815 0.888 0.005 0.024 TGFBR1 0.734 VAMP2 0.7830.891 0.002 0.013 TGFBR1 0.734 CASS4 0.738 0.861 0.022 0.001 TGFBR10.734 KPNA5 0.895 0.935 0.002 0.016 TGFBR1 0.734 PLAC8 0.828 0.928 0.0020.002 TGFBR1 0.734 KLRK1_KLRC4 0.865 0.908 0.015 0.023 TGFBR1 0.734 ITK0.874 0.925 0.002 0.006 TGFBR1 0.734 FGFBP2 0.814 0.878 0.034 0.001TGFBR1 0.734 CDS2 0.73 0.902 0.001 0.001 TGFBR1 0.734 SLC39A9 0.7760.949 0 0 TGFBR1 0.734 GIMAP7 0.804 0.91 0.004 0 TGFBR1 0.734 ANAPC110.943 0.974 0 0.037 TGFBR1 0.734 INSIG1 0.957 0.992 0 0.048 TGFBR1 0.734HIST1H4L 0.961 0.98 0 0.042 TGFBR1 0.734 LGALS1 0.722 0.848 0.022 0.008TGFBR1 0.734 DNAJC9_FAM149B1 0.944 0.985 0 0.013 TGFBR1 0.734 SIAE 0.7370.868 0.033 0.008 TGFBR1 0.734 HINT1 0.9 0.935 0.001 0.019 TGFBR1 0.734HLA-DPA1 0.796 0.886 0.003 0.021 TGFBR1 0.734 VOPP1_LOC100128 0.9380.985 0 0.029 TGFBR1 0.734 SLC39A8 0.825 0.899 0.014 0.008 TGFBR1 0.734PTGER2 0.881 0.97 0 0.005 TGFBR1 0.734 PMS2CL_PMS2 0.942 0.984 0 0.02TGFBR1 0.734 NEK6_LOC1001290 0.671 0.868 0.005 0.001 TGFBR1 0.734 CENPK0.834 0.879 0.035 0.009 TGFBR1 0.734 TRAF3 0.87 0.922 0.002 0.035 TGFBR10.734 AMFR 0.867 0.959 0 0.011 TGFBR1 0.734 RPL17_SNORD58B 0.917 0.953 00.008 TGFBR1 0.734 HSP90AB1_HSP90A 0.924 0.971 0 0.011 TGFBR1 0.734GLT25D1 0.77 0.873 0.006 0.026 TGFBR1 0.734 ITGA4_CERKL 0.88 0.966 00.003 TGFBR1 0.734 EIF1AX_SCARNA9L 0.871 0.937 0.001 0.002 TGFBR1 0.734CD300A 0.841 0.935 0 0.013 TGFBR1 0.734 ZNF28 0.837 0.918 0.002 0.002TGFBR1 0.734 MGST3 0.857 0.94 0 0.007 TGFBR1 0.734 CCR4 0.871 0.9140.006 0.007 TGFBR1 0.734 FSD1L_GARNL1 0.779 0.918 0.001 0.001 TGFBR10.734 FAM118A 0.882 0.958 0 0.009 TGFBR1 0.734 S100B 0.841 0.89 0.0220.011 TGFBR1 0.734 IGK@_IGKC_IGKV 0.855 0.906 0.003 0.009 TGFBR1 0.734SON 0.856 0.953 0 0.003 TGFBR1 0.734 IRF1 0.82 0.941 0 0.005 TGFBR10.734 C7orf58 0.831 0.894 0.01 0.005 TGFBR1 0.734 B4GALT3 0.917 0.97 00.05 TGFBR1 0.734 NP 0.726 0.884 0.021 0 TGFBR1 0.734 TNFRSF17 0.8750.924 0 0.022 TGFBR1 0.734 TMEM62_SPCS2_L 0.78 0.909 0.004 0 TGFBR10.734 CDC26 0.799 0.926 0 0.004 TGFBR1 0.734 TAS2R31 0.833 0.907 0.007 0TGFBR1 0.734 DCTN5 0.722 0.851 0.046 0.002 GPR84 0.927 PLAC8 0.828 0.9710.038 0.01 GPR84 0.927 HIST1H4E 0.915 0.989 0.045 0.033 GPR84 0.927SLC39A8 0.825 0.971 0.039 0.012 GPR84 0.927 TRAF3 0.87 0.975 0.032 0.035GPR84 0.927 RRP12_LOC644215 0.904 0.987 0.044 0.021 GPR84 0.927 IRF10.82 0.982 0.038 0.001 GPR84 0.927 CTSL1_CTSLL3 0.676 0.966 0.05 0C7orf53 0.786 SH2D1B 0.894 0.943 0.002 0.009 C7orf53 0.786 HLA-DPB10.815 0.901 0.005 0.046 C7orf53 0.786 CASS4 0.738 0.898 0.004 0.006C7orf53 0.786 PLAC8 0.828 0.93 0.002 0.022 C7orf53 0.786 CDS2 0.73 0.8830 0.038 C7orf53 0.786 CHI3L1 0.722 0.902 0.006 0.002 C7orf53 0.786SLC39A9 0.776 0.896 0.002 0.02 C7orf53 0.786 GIMAP7 0.804 0.905 0.0150.004 C7orf53 0.786 LGALS1 0.722 0.852 0.015 0.034 C7orf53 0.786 SIAE0.737 0.864 0.019 0.05 C7orf53 0.786 HS2ST1_UBA2 0.668 0.882 0.008 0.003C7orf53 0.786 HLA-DPA1 0.796 0.895 0.006 0.038 C7orf53 0.786NEK6_LOC1001290 0.671 0.863 0.029 0.004 C7orf53 0.786 GLT25D1 0.77 0.8770.014 0.045 C7orf53 0.786 ITGA4_CERKL 0.88 0.94 0.001 0.043 C7orf530.786 ICAM1 0.675 0.855 0.04 0.004 C7orf53 0.786 KIAA0746 0.776 0.8920.04 0.001 C7orf53 0.786 CCR4 0.871 0.932 0.002 0.031 C7orf53 0.786FSD1L_GARNL1 0.779 0.868 0.025 0.05 C7orf53 0.786 E2F6 0.787 0.893 0.0420.001 C7orf53 0.786 S100B 0.841 0.905 0.034 0.018 C7orf53 0.786IGK@_IGKC_IGKV 0.855 0.92 0.003 0.034 C7orf53 0.786 C7orf58 0.831 0.9710.001 0 C7orf53 0.786 NP 0.726 0.909 0.003 0.002 C7orf53 0.786 TAS2R310.833 0.904 0.009 0.017 PLB1 0.783 HLA-DPB1 0.815 0.938 0.002 0.006 PLB10.783 PLAC8 0.828 0.975 0 0.004 PLB1 0.783 CDS2 0.73 0.864 0.011 0.049PLB1 0.783 CCR3 0.869 0.921 0.012 0.03 PLB1 0.783 SLC39A9 0.776 0.9090.002 0.009 PLB1 0.783 GIMAP7 0.804 0.906 0.017 0.016 PLB1 0.783 LGALS10.722 0.906 0.003 0.004 PLB1 0.783 HLA-DRA 0.855 0.936 0.019 0.007 PLB10.783 SIAE 0.737 0.87 0.038 0.03 PLB1 0.783 MTRR 0.674 0.896 0.041 0PLB1 0.783 HLA-DPA1 0.796 0.923 0.002 0.014 PLB1 0.783 PTGER2 0.8810.951 0.001 0.027 PLB1 0.783 NEK6_LOC1001290 0.671 0.877 0.01 0.004 PLB10.783 TRAF3 0.87 0.954 0.002 0.024 PLB1 0.783 JUP 0.753 0.895 0.0490.025 PLB1 0.783 GALNT2 0.528 0.849 0.004 0 PLB1 0.783 HSP90AB1_HSP90A0.924 0.992 0 0.014 PLB1 0.783 GLT25D1 0.77 0.936 0.001 0.005 PLB1 0.783EIF1AX_SCARNA9L 0.871 0.938 0.005 0.021 PLB1 0.783 MGST3 0.857 0.956 00.014 PLB1 0.783 KIAA0746 0.776 0.923 0.008 0.002 PLB1 0.783HSPB1_HSPBL2 0.705 0.868 0.029 0.01 PLB1 0.783 CCR4 0.871 0.936 0.0060.023 PLB1 0.783 FSD1L_GARNL1 0.779 0.877 0.015 0.044 PLB1 0.783 CD1510.718 0.875 0.047 0.001 PLB1 0.783 IGK@_IGKC_IGKV 0.855 0.923 0.0020.039 PLB1 0.783 C7orf58 0.831 0.963 0.002 0.001 PLB1 0.783 NP 0.7260.901 0.016 0.001 PLB1 0.783 CDC26 0.799 0.894 0.004 0.035 PLB1 0.783TAS2R31 0.833 0.919 0.014 0.003 PLB1 0.783 IGLV6-57 0.761 0.87 0.0160.018 PLB1 0.783 NFXL1 0.728 0.879 0.048 0.001 PLB1 0.783 DCTN5 0.7220.896 0.011 0.001 DSE 0.747 HLA-DPB1 0.815 0.915 0.001 0.023 DSE 0.747KPNA5 0.895 0.933 0.002 0.049 DSE 0.747 PLAC8 0.828 0.978 0 0.003 DSE0.747 ITK 0.874 0.934 0.001 0.011 DSE 0.747 FGFBP2 0.814 0.873 0.0270.035 DSE 0.747 SLC39A9 0.776 0.899 0 0.019 DSE 0.747 GIMAP7 0.804 0.9420.001 0.001 DSE 0.747 LGALS1 0.722 0.891 0 0.013 DSE 0.747 HLA-DRA 0.8550.932 0.001 0.006 DSE 0.747 HINT1 0.9 0.944 0.001 0.039 DSE 0.747 MTRR0.674 0.885 0.018 0 DSE 0.747 HS2ST1_UBA2 0.668 0.847 0.021 0.009 DSE0.747 HLA-DPA1 0.796 0.919 0 0.013 DSE 0.747 SLC39A8 0.825 0.933 0.0020.007 DSE 0.747 NEK6_LOC1001290 0.671 0.815 0.049 0.028 DSE 0.747 CENPK0.834 0.886 0.029 0.01 DSE 0.747 TRAF3 0.87 0.966 0 0.017 DSE 0.747RPL17_SNORD58B 0.917 0.95 0.001 0.038 DSE 0.747 JUP 0.753 0.877 0.0170.045 DSE 0.747 HSP90AB1_HSP90A 0.924 0.994 0 0.015 DSE 0.747 GLT25D10.77 0.877 0.004 0.036 DSE 0.747 ITGA4_CERKL 0.88 0.944 0 0.032 DSE0.747 EIF1AX_SCARNA9L 0.871 0.943 0 0.021 DSE 0.747 ICAM1 0.675 0.8720.004 0.003 DSE 0.747 P4HA1_RPL17 0.664 0.861 0.05 0 DSE 0.747 KLHL50.657 0.896 0.014 0 DSE 0.747 MGST3 0.857 0.975 0 0.004 DSE 0.747KIAA0746 0.776 0.928 0.002 0.001 DSE 0.747 HSPB1_HSPBL2 0.705 0.8420.014 0.033 DSE 0.747 CCR4 0.871 0.941 0.001 0.019 DSE 0.747 LAIR1_LAIR20.607 0.874 0.016 0 DSE 0.747 CD151 0.718 0.852 0.048 0.005 DSE 0.747IGK@_IGKC_IGKV 0.855 0.928 0 0.024 DSE 0.747 C7orf58 0.831 0.957 0 0.001DSE 0.747 NP 0.726 0.893 0.016 0.001 DSE 0.747 TAS2R31 0.833 0.915 0.0040.004 DSE 0.747 IGLV6-57 0.761 0.856 0.012 0.021 DSE 0.747 DCTN5 0.7220.884 0.006 0.002 PTGDR 0.896 DNAJC13 0.819 0.955 0.011 0.004 PTGDR0.896 GSR 0.799 0.942 0.035 0.002 PTGDR 0.896 PICALM 0.723 0.954 0.038 0PTGDR 0.896 C9orf72 0.796 0.952 0.018 0.002 PTGDR 0.896 SMPDL3A 0.7970.953 0.012 0.007 PTGDR 0.896 NA 0.868 0.952 0.023 0.025 PTGDR 0.896DAAM2_LOC100131 0.903 0.96 0.034 0.044 PTGDR 0.896 IRS2 0.817 0.937 0.050.024 PTGDR 0.896 ACPL2 0.906 0.983 0.006 0.027 PTGDR 0.896 OCR1 0.8960.987 0.013 0.01 PTGDR 0.896 NF-E4 0.861 0.961 0.044 0.006 PTGDR 0.896KIAA1257_ACAD9/ 0.851 0.95 0.019 0.017 PTGDR 0.896 PDK4 0.863 0.9660.028 0.005 PTGDR 0.896 ZRANB1 0.897 0.978 0.007 0.011 PTGDR 0.896CYP4F3_CYP4F2 0.901 0.98 0.008 0.025 PTGDR 0.896 SYNE2 0.748 0.985 0.0030 PTGDR 0.896 MME 0.894 0.979 0.01 0.017 PTGDR 0.896 RBP7 0.848 0.9690.005 0.006 PTGDR 0.896 PPP1R2_PPP1R2P3 0.702 0.944 0.044 0 PTGDR 0.896CALM2_C2orf61 0.749 0.962 0.026 0 CAMK4 0.921 TNFAIP6 0.911 0.989 0.050.021 CAMK4 0.921 ANKRD34B 0.904 0.969 0.033 0.044 CAMK4 0.921 C9orf720.796 0.96 0.026 0.002 CAMK4 0.921 SMPDL3A 0.797 0.985 0.038 0.001 CAMK40.921 NA 0.927 0.989 0.035 0.036 CAMK4 0.921 NA 0.868 0.97 0.033 0.011CAMK4 0.921 GPR65 0.736 0.96 0.025 0 CAMK4 0.921 OCR1 0.896 0.987 0.0360.021 CAMK4 0.921 CCDC125 0.917 0.991 0.032 0.015 CAMK4 0.921 ZRANB10.897 0.983 0.033 0.012 CAMK4 0.921 CYP4F3_CYP4F2 0.901 0.98 0.032 0.05CAMK4 0.921 SYNE2 0.748 0.979 0.043 0 CAMK4 0.921 RBP7 0.848 0.959 0.0450.016 CAMK4 0.921 PPP1R2_PPP1R2P3 0.702 0.987 0.032 0 DNAJC13 0.819SH2D1B 0.894 0.978 0.001 0.002 DNAJC13 0.819 LRRN3 0.928 0.966 0.0010.027 DNAJC13 0.819 HLA-DPB1 0.815 0.945 0.003 0.001 DNAJC13 0.819 VAMP20.783 0.9 0.012 0.019 DNAJC13 0.819 CASS4 0.738 0.902 0.015 0.002DNAJC13 0.819 KPNA5 0.895 0.965 0.002 0.007 DNAJC13 0.819 PLAC8 0.8280.977 0.001 0.001 DNAJC13 0.819 KLRK1_KLRC4 0.865 0.938 0.022 0.009DNAJC13 0.819 ITK 0.874 0.962 0.003 0.008 DNAJC13 0.819 FGFBP2 0.8140.918 0.038 0 DNAJC13 0.819 CDS2 0.73 0.909 0.001 0.005 DNAJC13 0.819CCR3 0.869 0.935 0.007 0.029 DNAJC13 0.819 SEC24A_SAR1B 0.478 0.9050.036 0 DNAJC13 0.819 SLC39A9 0.776 0.988 0 0 DNAJC13 0.819 GIMAP7 0.8040.968 0.001 0 DNAJC13 0.819 LGALS1 0.722 0.885 0.032 0.006 DNAJC13 0.819HLA-DRA 0.855 0.948 0.005 0.018 DNAJC13 0.819 DNAJC9_FAM149B1 0.9440.987 0 0.016 DNAJC13 0.819 SIAE 0.737 0.92 0.016 0.003 DNAJC13 0.819HINT1 0.9 0.947 0.007 0.013 DNAJC13 0.819 MTRR 0.674 0.957 0.004 0DNAJC13 0.819 HS2ST1_UBA2 0.668 0.905 0.019 0 DNAJC13 0.819 HLA-DPA10.796 0.951 0.001 0.001 DNAJC13 0.819 SLC39A8 0.825 0.918 0.027 0.017DNAJC13 0.819 PTGER2 0.881 0.977 0 0.003 DNAJC13 0.819 PMS2CL_PMS2 0.9420.998 0 0.016 DNAJC13 0.819 NEK6_LOC1001290 0.671 0.903 0.008 0 DNAJC130.819 TRAF3 0.87 0.95 0.003 0.018 DNAJC13 0.819 RPL17_SNORD58B 0.9170.965 0.003 0.007 DNAJC13 0.819 HSP90AB1_HSP90A 0.924 0.979 0 0.02DNAJC13 0.819 GLT25D1 0.77 0.922 0.003 0.011 DNAJC13 0.819 ITGA4_CERKL0.88 0.994 0 0.003 DNAJC13 0.819 EIF1AX_SCARNA9L 0.871 0.958 0.005 0.001DNAJC13 0.819 ZNF28 0.837 0.933 0.008 0.004 DNAJC13 0.819 P4HA1_RPL170.664 0.952 0.007 0 DNAJC13 0.819 KLHL5 0.657 0.934 0.007 0 DNAJC130.819 MGST3 0.857 0.957 0 0.006 DNAJC13 0.819 KIAA0746 0.776 0.974 0.0020 DNAJC13 0.819 CCR4 0.871 0.964 0.001 0.008 DNAJC13 0.819 FSD1L_GARNL10.779 0.93 0.003 0.003 DNAJC13 0.819 FAM118A 0.882 0.965 0.001 0.023DNAJC13 0.819 IGK@_IGKC_IGKV 0.855 0.966 0.001 0.002 DNAJC13 0.819 SON0.856 0.953 0.008 0.004 DNAJC13 0.819 IRF1 0.82 0.94 0 0.022 DNAJC130.819 C7orf58 0.831 0.965 0.002 0.001 DNAJC13 0.819 B4GALT3 0.917 0.98 00.044 DNAJC13 0.819 NP 0.726 0.939 0.01 0 DNAJC13 0.819 TNFRSF17 0.8750.943 0.003 0.029 DNAJC13 0.819 TMEM62_SPCS2_L 0.78 0.946 0.024 0DNAJC13 0.819 CDC26 0.799 0.926 0.001 0.009 DNAJC13 0.819 TAS2R31 0.8330.942 0.011 0 DNAJC13 0.819 DCTN5 0.722 0.937 0.004 0 TNFAIP6 0.911SH2D1B 0.894 0.988 0.026 0.002 TNFAIP6 0.911 LRRN3 0.928 0.992 0.0190.019 TNFAIP6 0.911 HLA-DPB1 0.815 0.952 0.014 0.011 TNFAIP6 0.911 CASS40.738 0.953 0.019 0 TNFAIP6 0.911 KPNA5 0.895 0.982 0.044 0.008 TNFAIP60.911 PLAC8 0.828 0.969 0.012 0.01 TNFAIP6 0.911 ITK 0.874 0.978 0.0250.013 TNFAIP6 0.911 SLC39A9 0.776 0.946 0.013 0.002 TNFAIP6 0.911 GIMAP70.804 0.978 0.034 0 TNFAIP6 0.911 LGALS2 0.922 0.985 0.006 0.031 TNFAIP60.911 HLA-DPA1 0.796 0.944 0.016 0.008 TNFAIP6 0.911 SLC39A8 0.825 0.9690.007 0.012 TNFAIP6 0.911 TRAF3 0.87 0.965 0.01 0.042 TNFAIP6 0.911 JUP0.753 0.943 0.047 0.008 TNFAIP6 0.911 HSP90AB1_HSP90A 0.924 0.991 0.0120.026 TNFAIP6 0.911 EIF1AX_SCARNA9L 0.871 0.962 0.014 0.021 TNFAIP60.911 CD300A 0.841 0.952 0.006 0.024 TNFAIP6 0.911 ICAM1 0.675 0.9460.01 0 TNFAIP6 0.911 MGST3 0.857 0.963 0.011 0.018 TNFAIP6 0.911KIAA0746 0.776 0.966 0.033 0 TNFAIP6 0.911 IGK@_IGKC_IGKV 0.855 0.9830.027 0.002 TNFAIP6 0.911 IRF1 0.82 0.963 0.003 0.009 TNFAIP6 0.911C7orf58 0.831 0.981 0.044 0 TNFAIP6 0.911 TNFRSF17 0.875 0.975 0.0220.009 TNFAIP6 0.911 CDC26 0.799 0.94 0.036 0.007 GSR 0.799 SH2D1B 0.8940.938 0.005 0.014 GSR 0.799 HLA-DPB1 0.815 0.93 0.004 0.003 GSR 0.799VAMP2 0.783 0.907 0.001 0.013 GSR 0.799 CASS4 0.738 0.897 0.015 0.001GSR 0.799 KPNA5 0.895 0.928 0.007 0.037 GSR 0.799 PLAC8 0.828 0.962 00.002 GSR 0.799 KLRK1_KLRC4 0.865 0.907 0.027 0.041 GSR 0.799 ITK 0.8740.937 0.008 0.012 GSR 0.799 CDS2 0.73 0.89 0.004 0.004 GSR 0.799 SLC39A90.776 0.988 0 0 GSR 0.799 GIMAP7 0.804 0.935 0.004 0.001 GSR 0.799HLA-DRA 0.855 0.952 0.004 0.003 GSR 0.799 DNAJC9_FAM149B1 0.944 0.984 00.018 GSR 0.799 HLA-DPA1 0.796 0.925 0.002 0.003 GSR 0.799 PTGER2 0.8810.952 0 0.025 GSR 0.799 PMS2CL_PMS2 0.942 0.985 0 0.033 GSR 0.799NEK6_LOC1001290 0.671 0.88 0.037 0 GSR 0.799 TRAF3 0.87 0.966 0 0.007GSR 0.799 RPL17_SNORD58B 0.917 0.942 0.005 0.047 GSR 0.799HSP90AB1_HSP90A 0.924 0.994 0 0.006 GSR 0.799 GLT25D1 0.77 0.89 0.0350.016 GSR 0.799 ITGA4_CERKL 0.88 0.955 0 0.013 GSR 0.799 EIF1AX_SCARNA9L0.871 0.925 0.006 0.015 GSR 0.799 CD300A 0.841 0.927 0 0.032 GSR 0.799ZNF28 0.837 0.893 0.024 0.032 GSR 0.799 MGST3 0.857 0.957 0.001 0.002GSR 0.799 KIAA0746 0.776 0.915 0.031 0 GSR 0.799 CCR4 0.871 0.921 0.0110.026 GSR 0.799 FSD1L_GARNL1 0.779 0.908 0.005 0.004 GSR 0.799 FAM118A0.882 0.978 0 0.006 GSR 0.799 IGK@_IGKC_IGKV 0.855 0.94 0.005 0.003 GSR0.799 SON 0.856 0.941 0.006 0.009 GSR 0.799 IRF1 0.82 0.947 0 0.005 GSR0.799 C7orf58 0.831 0.914 0.031 0.002 GSR 0.799 TNFRSF17 0.875 0.9510.002 0.005 GSR 0.799 CDC26 0.799 0.892 0.007 0.022 GSR 0.799 TAS2R310.833 0.905 0.031 0.002 GSR 0.799 DCTN5 0.722 0.92 0.008 0 KLRF1 0.8PICALM 0.723 0.865 0.002 0.041 KLRF1 0.8 EAF2_HCG11_LOC 0.613 0.847 0.030.001 KLRF1 0.8 PDE3B 0.567 0.831 0.017 0.003 KLRF1 0.8 LRRFIP1 0.6780.847 0.04 0.012 KLRF1 0.8 DPH3 0.749 0.885 0 0.039 KLRF1 0.8 NA 0.6820.888 0.005 0.002 KLRF1 0.8 DLEU2_DLEU2L 0.711 0.898 0.001 0.005 KLRF10.8 ZNF587_ZNF417 0.632 0.848 0.014 0.003 KLRF1 0.8 CEP97 0.554 0.8590.033 0 KLRF1 0.8 SYNE2 0.748 0.908 0 0.022 KLRF1 0.8 PLEKHF2 0.6670.866 0.004 0.009 KLRF1 0.8 IL1RL1 0.738 0.879 0.026 0.013 KLRF1 0.8MPZL2 0.699 0.838 0.033 0.042 KLRF1 0.8 PPP1R2_PPP1R2P3 0.702 0.8610.003 0.028 KLRF1 0.8 ATP5L_ATP5L2 0.547 0.859 0.023 0 KLRF1 0.8CALM2_C2orf61 0.749 0.885 0.001 0.043 SH2D1B 0.894 ANKRD34B 0.904 0.9640.004 0.046 SH2D1B 0.894 SGMS2 0.938 0.989 0.003 0.027 SH2D1B 0.894GK3P_GK 0.961 0.99 0.005 0.031 SH2D1B 0.894 PICALM 0.723 0.951 0.016 0SH2D1B 0.894 C9orf72 0.796 0.955 0.003 0.002 SH2D1B 0.894 SMPDL3A 0.7970.965 0.003 0.002 SH2D1B 0.894 TCN1 0.855 0.964 0.019 0.002 SH2D1B 0.894HPGD 0.823 0.947 0.013 0.009 SH2D1B 0.894 FRMD3 0.755 0.944 0.006 0.001SH2D1B 0.894 NA 0.927 0.998 0.002 0.013 SH2D1B 0.894 RUNX2 0.507 0.9260.021 0 SH2D1B 0.894 TPST1 0.92 0.974 0.026 0.036 SH2D1B 0.894 EIF2AK20.964 1 0.002 0.032 SH2D1B 0.894 NA 0.868 0.962 0.002 0.019 SH2D1B 0.894AREG 0.849 0.951 0.05 0.003 SH2D1B 0.894 DAAM2_LOC100131 0.903 0.9670.014 0.021 SH2D1B 0.894 GPR65 0.736 0.947 0.009 0 SH2D1B 0.894 IRS20.817 0.938 0.044 0.011 SH2D1B 0.894 ACPL2 0.906 0.979 0.002 0.036SH2D1B 0.894 OCR1 0.896 0.994 0.002 0.012 SH2D1B 0.894 DPH3 0.749 0.950.021 0 SH2D1B 0.894 NF-E4 0.861 0.974 0.003 0.008 SH2D1B 0.894KIAA1257_ACAD9/ 0.851 0.965 0.003 0.005 SH2D1B 0.894 CCDC125 0.917 0.990.002 0.017 SH2D1B 0.894 PDK4 0.863 0.971 0.005 0.004 SH2D1B 0.894 THBS10.849 0.953 0.022 0.005 SH2D1B 0.894 ZRANB1 0.897 0.973 0.002 0.017SH2D1B 0.894 ZNF587_ZNF417 0.632 0.942 0.021 0 SH2D1B 0.894CYP4F3_CYP4F2 0.901 0.978 0.001 0.045 SH2D1B 0.894 SYNE2 0.748 0.9810.002 0 SH2D1B 0.894 MME 0.894 0.994 0.002 0.009 SH2D1B 0.894 PLIN20.706 0.942 0.014 0 SH2D1B 0.894 FBXL13 0.795 0.971 0.006 0 SH2D1B 0.894RBP7 0.848 0.963 0.002 0.01 SH2D1B 0.894 PPP1R2_PPP1R2P3 0.702 0.9490.02 0 SH2D1B 0.894 HIST2H2BF_HIST2 0.855 0.938 0.032 0.041 SH2D1B 0.894CALM2_C2orf61 0.749 0.966 0.016 0 SH2D1B 0.894 SPATA6 0.812 0.954 0.0130.005 ANKRD34B 0.904 HLA-DPB1 0.815 0.953 0.047 0.001 ANKRD34B 0.904PLAC8 0.828 0.962 0.034 0.003 ANKRD34B 0.904 HIST1H4E 0.915 0.971 0.0070.05 ANKRD34B 0.904 CCR3 0.869 0.976 0.014 0.005 ANKRD34B 0.904 ANAPC110.943 0.984 0.004 0.027 ANKRD34B 0.904 HLA-DRA 0.855 0.965 0.013 0.015ANKRD34B 0.904 DNAJC9_FAM149B1 0.944 0.985 0.006 0.03 ANKRD34B 0.904LGALS2 0.922 0.977 0.004 0.018 ANKRD34B 0.904 SIAE 0.737 0.951 0.039 0ANKRD34B 0.904 HIST1H3A 0.908 0.964 0.019 0.017 ANKRD34B 0.904 C22orf370.924 0.985 0.002 0.026 ANKRD34B 0.904 HLA-DPA1 0.796 0.957 0.041 0ANKRD34B 0.904 PTGER2 0.881 0.971 0.01 0.005 ANKRD34B 0.904 PMS2CL_PMS20.942 0.988 0.002 0.032 ANKRD34B 0.904 NEK6_LOC1001290 0.671 0.949 0.0380 ANKRD34B 0.904 IRF4 0.946 0.99 0.002 0.048 ANKRD34B 0.904 AMFR 0.8670.965 0.003 0.021 ANKRD34B 0.904 HSP90AB1_HSP90A 0.924 0.971 0.018 0.021ANKRD34B 0.904 GLT25D1 0.77 0.951 0.037 0.001 ANKRD34B 0.904 ITGA4_CERKL0.88 0.98 0.01 0.004 ANKRD34B 0.904 CD300A 0.841 0.965 0.008 0.002ANKRD34B 0.904 MGST3 0.857 0.955 0.025 0.002 ANKRD34B 0.904 CCR4 0.8710.97 0.038 0.003 ANKRD34B 0.904 TYMS 0.863 0.969 0.007 0.006 ANKRD34B0.904 RRP12_LOC644215 0.904 0.973 0.003 0.021 ANKRD34B 0.904 HIST1H2BM0.891 0.971 0.015 0.009 ANKRD34B 0.904 ABCG1 0.85 0.964 0.007 0.007ANKRD34B 0.904 HIST1H3B 0.89 0.973 0.015 0.008 ANKRD34B 0.904 FAM118A0.882 0.969 0.011 0.016 ANKRD34B 0.904 APOLD1 0.871 0.973 0.006 0.006ANKRD34B 0.904 IRF1 0.82 0.955 0.022 0.003 ANKRD34B 0.904 B4GALT3 0.9170.981 0.003 0.043 ANKRD34B 0.904 CDC26 0.799 0.956 0.015 0 SGMS2 0.938LRRN3 0.928 0.981 0.031 0.014 SGMS2 0.938 VAMP2 0.783 0.981 0.022 0SGMS2 0.938 PLAC8 0.828 0.985 0.026 0.001 SGMS2 0.938 GOT2 0.966 0.9940.019 0.042 SGMS2 0.938 SLC39A9 0.776 0.99 0.012 0 SGMS2 0.938 ANAPC110.943 0.984 0.025 0.02 SGMS2 0.938 INSIG1 0.957 0.995 0.009 0.046 SGMS20.938 HIST1H4L 0.961 0.988 0.038 0.047 SGMS2 0.938 HLA-DRA 0.855 0.990.011 0.004 SGMS2 0.938 DNAJC9_FAM149B1 0.944 0.992 0.022 0.021 SGMS20.938 LGALS2 0.922 0.98 0.02 0.015 SGMS2 0.938 C22orf37 0.924 0.9730.038 0.03 SGMS2 0.938 HLA-DPA1 0.796 0.983 0.035 0 SGMS2 0.938VOPP1_LOC100128 0.938 0.979 0.015 0.05 SGMS2 0.938 PTGER2 0.881 0.9880.018 0.003 SGMS2 0.938 PMS2CL_PMS2 0.942 0.998 0.009 0.017 SGMS2 0.938IRF4 0.946 0.994 0.01 0.035 SGMS2 0.938 GALNT2 0.528 0.971 0.034 0 SGMS20.938 HSP90AB1_HSP90A 0.924 0.998 0.01 0.009 SGMS2 0.938 GLT25D1 0.770.985 0.018 0 SGMS2 0.938 ITGA4_CERKL 0.88 0.991 0.019 0.002 SGMS2 0.938MGST3 0.857 0.98 0.035 0.001 SGMS2 0.938 RRP12_LOC644215 0.904 0.9790.027 0.016 SGMS2 0.938 ABCG1 0.85 0.981 0.026 0.003 SGMS2 0.938 TIMM100.949 0.987 0.021 0.029 SGMS2 0.938 FSD1L_GARNL1 0.779 0.986 0.018 0SGMS2 0.938 IGK@_IGKC_IGKV 0.855 0.987 0.029 0.001 SGMS2 0.938 IRF1 0.820.974 0.046 0 SGMS2 0.938 B4GALT3 0.917 0.989 0.03 0.01 SGMS2 0.938TNFRSF17 0.875 0.99 0.024 0.001 SGMS2 0.938 DCTN5 0.722 0.985 0.017 0B3GNT5_MCF2L2 0.949 MRPL41 0.976 0.999 0.012 0.05 B3GNT5_MCF2L2 0.949PLAC8 0.828 0.992 0.022 0.001 B3GNT5_MCF2L2 0.949 GOT2 0.966 0.989 0.0330.044 B3GNT5_MCF2L2 0.949 HIST1H4E 0.915 0.998 0.01 0.015 B3GNT5_MCF2L20.949 CDS2 0.73 0.979 0.021 0 B3GNT5_MCF2L2 0.949 SLC39A9 0.776 0.9820.041 0 B3GNT5_MCF2L2 0.949 ANAPC11 0.943 0.994 0.017 0.011B3GNT5_MCF2L2 0.949 INSIG1 0.957 0.999 0.011 0.028 B3GNT5_MCF2L2 0.949HIST1H4L 0.961 0.992 0.028 0.032 B3GNT5_MCF2L2 0.949 LGALS1 0.722 0.9830.039 0 B3GNT5_MCF2L2 0.949 PPIF 0.934 0.998 0.01 0.05 B3GNT5_MCF2L20.949 DNAJC9_FAM149B1 0.944 0.997 0.013 0.027 B3GNT5_MCF2L2 0.949 LGALS20.922 0.995 0.02 0.004 B3GNT5_MCF2L2 0.949 HS2ST1_UBA2 0.668 0.979 0.0490 B3GNT5_MCF2L2 0.949 C22orf37 0.924 0.993 0.019 0.011 B3GNT5_MCF2L20.949 VOPP1_LOC100128 0.938 0.991 0.011 0.026 B3GNT5_MCF2L2 0.949SLC39A8 0.825 0.985 0.044 0.002 B3GNT5_MCF2L2 0.949 PTGER2 0.881 0.9860.02 0.002 B3GNT5_MCF2L2 0.949 PMS2CL_PMS2 0.942 0.998 0.011 0.016B3GNT5_MCF2L2 0.949 HSP90AB1_HSP90A 0.924 0.996 0.013 0.013B3GNT5_MCF2L2 0.949 CD300A 0.841 0.987 0.019 0.001 B3GNT5_MCF2L2 0.949ICAM1 0.675 0.981 0.043 0 B3GNT5_MCF2L2 0.949 MGST3 0.857 0.997 0.0130.001 B3GNT5_MCF2L2 0.949 RRP12_LOC644215 0.904 0.984 0.024 0.014B3GNT5_MCF2L2 0.949 TIMM10 0.949 0.995 0.011 0.027 B3GNT5_MCF2L2 0.949FAM118A 0.882 0.987 0.024 0.009 B3GNT5_MCF2L2 0.949 APOLD1 0.871 0.9840.034 0.002 B3GNT5_MCF2L2 0.949 IRF1 0.82 0.997 0.012 0 B3GNT5_MCF2L20.949 LASS4 0.924 0.982 0.019 0.038 B3GNT5_MCF2L2 0.949 B4GALT3 0.9170.987 0.018 0.026 B3GNT5_MCF2L2 0.949 CDC26 0.799 0.984 0.02 0 GK3P_GK0.961 HIST1H4E 0.915 0.984 0.028 0.047 GK3P_GK 0.961 DNAJC9_FAM149B10.944 0.997 0.03 0.03 GK3P_GK 0.961 LGALS2 0.922 0.99 0.032 0.013GK3P_GK 0.961 HIST1H3A 0.908 0.989 0.033 0.006 GK3P_GK 0.961 C22orf370.924 0.982 0.03 0.046 GK3P_GK 0.961 PMS2CL_PMS2 0.942 0.993 0.025 0.036GK3P_GK 0.961 AMFR 0.867 0.977 0.03 0.017 GK3P_GK 0.961 HSP90AB1_HSP90A0.924 0.99 0.034 0.025 GK3P_GK 0.961 CD300A 0.841 0.982 0.031 0.001GK3P_GK 0.961 MGST3 0.857 0.98 0.048 0.003 GK3P_GK 0.961 TYMS 0.8630.976 0.043 0.004 GK3P_GK 0.961 RRP12_LOC644215 0.904 0.993 0.033 0.011GK3P_GK 0.961 HIST1H3B 0.89 0.983 0.038 0.009 GK3P_GK 0.961 FAM118A0.882 0.984 0.038 0.017 GK3P_GK 0.961 IRF1 0.82 0.985 0.023 0.001 PICALM0.723 MRPL41 0.976 1 0 0.048 PICALM 0.723 CASS4 0.738 0.863 0.002 0.012PICALM 0.723 PLAC8 0.828 0.907 0.001 0.015 PICALM 0.723 KLRK1_KLRC40.865 0.914 0.002 0.038 PICALM 0.723 ITK 0.874 0.917 0.001 0.022 PICALM0.723 FGFBP2 0.814 0.89 0.006 0.004 PICALM 0.723 CDS2 0.73 0.857 0.0010.037 PICALM 0.723 CHI3L1 0.722 0.861 0.013 0.005 PICALM 0.723 SLC39A90.776 0.917 0 0.002 PICALM 0.723 GIMAP7 0.804 0.906 0.001 0.004 PICALM0.723 PHOSPHO1 0.721 0.821 0.039 0.025 PICALM 0.723 DNAJC9_FAM149B10.944 0.983 0 0.028 PICALM 0.723 HS2ST1_UBA2 0.668 0.851 0.016 0.003PICALM 0.723 SLC39A8 0.825 0.886 0.01 0.026 PICALM 0.723 PTGER2 0.8810.955 0 0.041 PICALM 0.723 NEK6_LOC1001290 0.671 0.814 0.043 0.019PICALM 0.723 CENPK 0.834 0.898 0.007 0.009 PICALM 0.723 RPL17_SNORD58B0.917 0.968 0 0.009 PICALM 0.723 EIF1AX_SCARNA9L 0.871 0.929 0 0.029PICALM 0.723 CD300A 0.841 0.931 0 0.028 PICALM 0.723 ZNF28 0.837 0.915 00.026 PICALM 0.723 MGST3 0.857 0.937 0 0.012 PICALM 0.723 KIAA0746 0.7760.85 0.04 0.006 PICALM 0.723 FSD1L_GARNL1 0.779 0.865 0.002 0.047 PICALM0.723 E2F6 0.787 0.851 0.041 0.004 PICALM 0.723 S100B 0.841 0.893 0.0120.007 PICALM 0.723 IRF1 0.82 0.923 0 0.032 PICALM 0.723 C7orf58 0.8310.915 0.002 0.002 PICALM 0.723 NP 0.726 0.871 0.011 0.001 PICALM 0.723C4orf3 0.723 0.827 0.036 0.025 PICALM 0.723 PLEKHA3 0.645 0.829 0.0380.001 PICALM 0.723 TMEM62_SPCS2_L 0.78 0.868 0.017 0.002 PICALM 0.723CDC26 0.799 0.938 0 0.007 PICALM 0.723 TAS2R31 0.833 0.916 0.001 0.002PICALM 0.723 IGLV6-57 0.761 0.831 0.027 0.041 PICALM 0.723 NFXL1 0.7280.858 0.031 0 PICALM 0.723 DCTN5 0.722 0.852 0.014 0.008 PICALM 0.723KIAA0101_CSNK1G 0.736 0.841 0.037 0.003 METTL7B 0.898 HIST1H4E 0.9150.973 0.02 0.01 METTL7B 0.898 HIST1H4L 0.961 0.99 0.006 0.017 METTL7B0.898 PPIF 0.934 0.966 0.029 0.047 METTL7B 0.898 LGALS2 0.922 0.9920.003 0.007 METTL7B 0.898 C22orf37 0.924 0.98 0.005 0.023 METTL7B 0.898HSP90AB1_HSP90A 0.924 0.97 0.009 0.046 METTL7B 0.898 MGST3 0.857 0.9570.028 0.005 METTL7B 0.898 TYMS 0.863 0.971 0.015 0.001 METTL7B 0.898RRP12_LOC644215 0.904 0.965 0.016 0.031 METTL7B 0.898 TIMM10 0.949 0.9830.004 0.048 METTL7B 0.898 FAM118A 0.882 0.956 0.036 0.025 METTL7B 0.898LASS4 0.924 0.973 0.004 0.036 METTL7B 0.898 B4GALT3 0.917 0.979 0.0080.02 C9orf72 0.796 LRRN3 0.928 0.965 0.001 0.012 C9orf72 0.796 HLA-DPB10.815 0.934 0.002 0.002 C9orf72 0.796 MRPL41 0.976 0.999 0 0.049 C9orf720.796 CASS4 0.738 0.915 0.004 0 C9orf72 0.796 KPNA5 0.895 0.951 0.0050.003 C9orf72 0.796 PLAC8 0.828 0.969 0.001 0 C9orf72 0.796 KLRK1_KLRC40.865 0.92 0.032 0.009 C9orf72 0.796 ITK 0.874 0.943 0.007 0.003 C9orf720.796 CDS2 0.73 0.937 0 0.001 C9orf72 0.796 SLC39A9 0.776 0.969 0 0C9orf72 0.796 GIMAP7 0.804 0.961 0.002 0 C9orf72 0.796 INSIG1 0.9570.996 0 0.026 C9orf72 0.796 HIST1H4L 0.961 0.986 0 0.025 C9orf72 0.796LGALS1 0.722 0.891 0.01 0.003 C9orf72 0.796 HLA-DRA 0.855 0.936 0.0080.004 C9orf72 0.796 DNAJC9_FAM149B1 0.944 0.988 0 0.025 C9orf72 0.796LGALS2 0.922 0.969 0 0.032 C9orf72 0.796 HINT1 0.9 0.955 0.002 0.013C9orf72 0.796 MTRR 0.674 0.911 0.05 0 C9orf72 0.796 HS2ST1_UBA2 0.6680.914 0.006 0 C9orf72 0.796 HLA-DPA1 0.796 0.942 0.001 0.001 C9orf720.796 SLC39A8 0.825 0.923 0.03 0.002 C9orf72 0.796 PTGER2 0.881 0.967 00.017 C9orf72 0.796 PMS2CL_PMS2 0.942 0.988 0 0.014 C9orf72 0.796NEK6_LOC1001290 0.671 0.887 0.016 0 C9orf72 0.796 TRAF3 0.87 0.967 00.008 C9orf72 0.796 RPL17_SNORD58B 0.917 0.962 0.001 0.015 C9orf72 0.796HSP90AB1_HSP90A 0.924 0.977 0 0.011 C9orf72 0.796 GLT25D1 0.77 0.8940.013 0.01 C9orf72 0.796 ITGA4_CERKL 0.88 0.984 0 0.003 C9orf72 0.796EIF1AX_SCARNA9L 0.871 0.954 0.002 0.002 C9orf72 0.796 CD300A 0.841 0.9340 0.038 C9orf72 0.796 ZNF28 0.837 0.922 0.007 0.01 C9orf72 0.796P4HA1_RPL17 0.664 0.924 0.02 0 C9orf72 0.796 KLHL5 0.657 0.916 0.04 0C9orf72 0.796 MGST3 0.857 0.979 0 0 C9orf72 0.796 KIAA0746 0.776 0.9150.04 0 C9orf72 0.796 CCR4 0.871 0.951 0.004 0.001 C9orf72 0.796FSD1L_GARNL1 0.779 0.9 0.011 0.003 C9orf72 0.796 FAM118A 0.882 0.957 00.042 C9orf72 0.796 IGK@_IGKC_IGKV 0.855 0.935 0.006 0.003 C9orf72 0.796SON 0.856 0.938 0.002 0.021 C9orf72 0.796 IRF1 0.82 0.941 0 0.012C9orf72 0.796 C7orf58 0.831 0.96 0.002 0 C9orf72 0.796 NP 0.726 0.9250.012 0 C9orf72 0.796 TNFRSF17 0.875 0.931 0.003 0.029 C9orf72 0.796CDC26 0.799 0.921 0 0.008 C9orf72 0.796 TAS2R31 0.833 0.923 0.012 0.001C9orf72 0.796 DCTN5 0.722 0.927 0.008 0 SLC15A2 0.534 C7orf58 0.8310.932 0 0.004 TLR10 0.521 C7orf58 0.831 0.9 0 0.029 LRRN3 0.928 SMPDL3A0.797 0.971 0.044 0.001 LRRN3 0.928 NA 0.927 0.989 0.007 0.035 LRRN30.928 NA 0.868 0.976 0.008 0.005 LRRN3 0.928 GPR65 0.736 0.961 0.022 0LRRN3 0.928 ACPL2 0.906 0.972 0.043 0.031 LRRN3 0.928 OCR1 0.896 0.9810.013 0.028 LRRN3 0.928 CCDC125 0.917 0.982 0.014 0.028 LRRN3 0.928ZRANB1 0.897 0.98 0.009 0.011 LRRN3 0.928 CYP4F3_CYP4F2 0.901 0.98 0.0060.047 LRRN3 0.928 MME 0.894 0.98 0.031 0.015 LRRN3 0.928 PLIN2 0.7060.956 0.038 0 HLA-DPB1 0.815 SMPDL3A 0.797 0.941 0.002 0.004 HLA-DPB10.815 TCN1 0.855 0.915 0.02 0.02 HLA-DPB1 0.815 HPGD 0.823 0.947 0.0020.011 HLA-DPB1 0.815 FRMD3 0.755 0.881 0.021 0.017 HLA-DPB1 0.815 NA0.927 0.97 0.001 0.041 HLA-DPB1 0.815 NA 0.868 0.957 0 0.014 HLA-DPB10.815 OR9A2 0.823 0.894 0.038 0.027 HLA-DPB1 0.815 PDK4 0.863 0.9740.001 0.001 HLA-DPB1 0.815 SYNE2 0.748 0.898 0.037 0.001 HLA-DPB1 0.815PLIN2 0.706 0.908 0.018 0.001 HLA-DPB1 0.815 HIST2H2BF_HIST2 0.855 0.9130.027 0.048 VAMP2 0.783 TCN1 0.855 0.921 0.017 0.004 VAMP2 0.783LOC284757 0.939 0.978 0 0.02 VAMP2 0.783 HPGD 0.823 0.905 0.02 0.029VAMP2 0.783 HSPC159 0.809 0.883 0.039 0.018 VAMP2 0.783 FRMD3 0.7550.903 0.006 0.002 VAMP2 0.783 NA 0.927 0.951 0.001 0.045 VAMP2 0.783TPST1 0.92 0.955 0.003 0.037 VAMP2 0.783 EIF2AK2 0.964 0.994 0 0.049VAMP2 0.783 NA 0.868 0.92 0.003 0.021 VAMP2 0.783 CDA 0.945 0.98 0 0.039VAMP2 0.783 SAP30 0.911 0.961 0 0.029 VAMP2 0.783 AREG 0.849 0.903 0.010.037 VAMP2 0.783 DAAM2_LOC100131 0.903 0.956 0.001 0.021 VAMP2 0.783IRS2 0.817 0.932 0.002 0.006 VAMP2 0.783 ACPL2 0.906 0.981 0 0.013 VAMP20.783 OCR1 0.896 0.935 0.006 0.023 VAMP2 0.783 ERGIC1 0.886 0.965 0.0010.013 VAMP2 0.783 NF-E4 0.861 0.928 0.014 0.002 VAMP2 0.783 HAL 0.9420.984 0 0.021 VAMP2 0.783 KIAA1257_ACAD9/ 0.851 0.93 0.007 0.002 VAMP20.783 CCDC125 0.917 0.98 0 0.009 VAMP2 0.783 PDK4 0.863 0.903 0.017 0.03VAMP2 0.783 THBS1 0.849 0.923 0.009 0.007 VAMP2 0.783 ZRANB1 0.897 0.9490 0.023 VAMP2 0.783 MPZL3 0.892 0.939 0 0.042 VAMP2 0.783 CYP4F3_CYP4F20.901 0.955 0.003 0.014 VAMP2 0.783 SYNE2 0.748 0.896 0.037 0 VAMP20.783 MME 0.894 0.945 0.004 0.006 VAMP2 0.783 CPM 0.854 0.901 0.0290.036 VAMP2 0.783 RBP7 0.848 0.946 0.001 0.005 VAMP2 0.783HIST2H2BF_HIST2 0.855 0.902 0.047 0.004 VAMP2 0.783 SPATA6 0.812 0.9010.027 0.018 SMPDL3A 0.797 CASS4 0.738 0.884 0.042 0.001 SMPDL3A 0.797KPNA5 0.895 0.966 0.004 0.007 SMPDL3A 0.797 PLAC8 0.828 0.985 0 0.002SMPDL3A 0.797 KLRK1_KLRC4 0.865 0.937 0.03 0.003 SMPDL3A 0.797 ITK 0.8740.968 0.003 0.006 SMPDL3A 0.797 FGFBP2 0.814 0.925 0.034 0 SMPDL3A 0.797CCR3 0.869 0.92 0.011 0.023 SMPDL3A 0.797 SLC39A9 0.776 0.935 0.0020.001 SMPDL3A 0.797 GIMAP7 0.804 0.99 0 0 SMPDL3A 0.797 LGALS1 0.7220.921 0.002 0.001 SMPDL3A 0.797 HLA-DRA 0.855 0.924 0.017 0.009 SMPDL3A0.797 DNAJC9_FAM149B1 0.944 0.991 0 0.03 SMPDL3A 0.797 LGALS2 0.9220.973 0 0.042 SMPDL3A 0.797 HINT1 0.9 0.975 0.002 0.009 SMPDL3A 0.797MTRR 0.674 0.948 0.006 0 SMPDL3A 0.797 HS2ST1_UBA2 0.668 0.897 0.046 0SMPDL3A 0.797 HIST1H3A 0.908 0.941 0.004 0.047 SMPDL3A 0.797 HLA-DPA10.796 0.929 0.004 0.003 SMPDL3A 0.797 SLC39A8 0.825 0.985 0 0.003SMPDL3A 0.797 PTGER2 0.881 0.964 0.001 0.012 SMPDL3A 0.797 PMS2CL_PMS20.942 0.994 0 0.017 SMPDL3A 0.797 TRAF3 0.87 0.976 0.001 0.011 SMPDL3A0.797 RPL17_SNORD58B 0.917 0.962 0.004 0.008 SMPDL3A 0.797HSP90AB1_HSP90A 0.924 0.996 0 0.012 SMPDL3A 0.797 GLT25D1 0.77 0.8930.03 0.009 SMPDL3A 0.797 ITGA4_CERKL 0.88 0.978 0.001 0.005 SMPDL3A0.797 EIF1AX_SCARNA9L 0.871 0.949 0.004 0.007 SMPDL3A 0.797 ZNF28 0.8370.909 0.023 0.018 SMPDL3A 0.797 ICAM1 0.675 0.877 0.007 0.004 SMPDL3A0.797 KLHL5 0.657 0.923 0.027 0 SMPDL3A 0.797 MGST3 0.857 0.982 0 0.001SMPDL3A 0.797 KIAA0746 0.776 0.968 0.002 0 SMPDL3A 0.797 HSPB1_HSPBL20.705 0.881 0.006 0.007 SMPDL3A 0.797 CCR4 0.871 0.974 0.001 0.007SMPDL3A 0.797 FAM118A 0.882 0.969 0.001 0.019 SMPDL3A 0.797 CD151 0.7180.893 0.039 0 SMPDL3A 0.797 HIST1H3H 0.861 0.897 0.044 0.046 SMPDL3A0.797 IGK@_IGKC_IGKV 0.855 0.954 0.006 0.002 SMPDL3A 0.797 SON 0.8560.93 0.01 0.022 SMPDL3A 0.797 IRF1 0.82 0.93 0.001 0.012 SMPDL3A 0.797C7orf58 0.831 0.933 0.01 0.008 SMPDL3A 0.797 NP 0.726 0.921 0.032 0SMPDL3A 0.797 TNFRSF17 0.875 0.932 0.009 0.043 SMPDL3A 0.797 CDC26 0.7990.901 0.006 0.021 SMPDL3A 0.797 TAS2R31 0.833 0.94 0.01 0 SMPDL3A 0.797DCTN5 0.722 0.911 0.019 0 JKAMP 0.493 RPL17_SNORD58B 0.917 0.947 0 0.024MRPL41 0.976 PPP2R5A_SNORA16 0.953 0.999 0.05 0.02 MRPL41 0.976 MTHFS0.933 0.999 0.048 0.019 MRPL41 0.976 EIF2AK2 0.964 0.999 0.049 0.035MRPL41 0.976 ACPL2 0.906 0.999 0.049 0.007 MRPL41 0.976 CCDC125 0.9170.996 0.05 0.008 MRPL41 0.976 RBP7 0.848 1 0.048 0 OLFM4 0.715 LTF 0.5930.776 0.025 0.003 OLFM4 0.715 DEFA4_DEFA8P 0.481 0.81 0.048 0 OLFM40.715 MPO 0.508 0.775 0.008 0 CASS4 0.738 LOC284757 0.939 0.971 0 0.033CASS4 0.738 HSPC159 0.809 0.879 0.022 0.01 CASS4 0.738 NA 0.927 0.987 00.005 CASS4 0.738 PRR13_PCBP2 0.947 0.987 0 0.041 CASS4 0.738 NA 0.8680.93 0 0.048 CASS4 0.738 GPR65 0.736 0.858 0.016 0.008 CASS4 0.738 OR9A20.823 0.877 0.005 0.043 CASS4 0.738 OCR1 0.896 0.951 0 0.006 CASS4 0.738NF-E4 0.861 0.942 0.001 0.001 CASS4 0.738 KIAA1257_ACAD9/ 0.851 0.983 00 CASS4 0.738 CCDC125 0.917 0.974 0 0.025 CASS4 0.738 PDK4 0.863 0.9090.002 0.04 CASS4 0.738 THBS1 0.849 0.92 0.001 0.007 CASS4 0.738 ZRANB10.897 0.977 0 0.002 CASS4 0.738 ZNF587_ZNF417 0.632 0.883 0.018 0 CASS40.738 CYP4F3_CYP4F2 0.901 0.958 0 0.026 CASS4 0.738 SYNE2 0.748 0.8890.01 0 CASS4 0.738 MME 0.894 0.951 0 0.013 CASS4 0.738 FBXL13 0.795 0.890.012 0.003 CASS4 0.738 HIST2H2BF_HIST2 0.855 0.924 0.001 0.014 CASS40.738 SPATA6 0.812 0.891 0.003 0.045 TCN1 0.855 KPNA5 0.895 0.965 0.0030.033 TCN1 0.855 KLRK1_KLRC4 0.865 0.949 0.028 0.011 TCN1 0.855 ITK0.874 0.952 0.008 0.034 TCN1 0.855 FGFBP2 0.814 0.932 0.032 0.004 TCN10.855 CCR3 0.869 0.963 0.001 0.025 TCN1 0.855 SLC39A9 0.776 0.906 0.0020.02 TCN1 0.855 GIMAP7 0.804 0.923 0.004 0.015 TCN1 0.855 LGALS1 0.7220.889 0.024 0.007 TCN1 0.855 PHOSPHO1 0.721 0.948 0.002 0.001 TCN1 0.855DNAJC9_FAM149B1 0.944 0.994 0 0.042 TCN1 0.855 HINT1 0.9 0.969 0.0020.04 TCN1 0.855 HIST1H3J 0.898 0.973 0.003 0.007 TCN1 0.855 HIST1H3A0.908 0.972 0.001 0.03 TCN1 0.855 HLA-DPA1 0.796 0.893 0.025 0.037 TCN10.855 SLC39A8 0.825 0.938 0.001 0.049 TCN1 0.855 MKI67 0.621 0.914 0.0130 TCN1 0.855 NEK6_LOC1001290 0.671 0.887 0.033 0.001 TCN1 0.855 CENPK0.834 0.946 0.031 0.002 TCN1 0.855 RPL17_SNORD58B 0.917 0.973 0.0010.045 TCN1 0.855 EIF1AX_SCARNA9L 0.871 0.961 0.002 0.015 TCN1 0.855ZNF28 0.837 0.948 0.002 0.014 TCN1 0.855 KIAA0746 0.776 0.912 0.03 0.007TCN1 0.855 CCR4 0.871 0.945 0.005 0.049 TCN1 0.855 HIST1H3B 0.89 0.9770.001 0.015 TCN1 0.855 FSD1L_GARNL1 0.779 0.929 0.001 0.01 TCN1 0.855HIST1H3C 0.863 0.956 0.015 0.001 TCN1 0.855 HIST1H3H 0.861 0.955 0.0060.005 TCN1 0.855 TPX2 0.635 0.901 0.022 0 TCN1 0.855 IGK@_IGKC_IGKV0.855 0.925 0.036 0.024 TCN1 0.855 CLC 0.782 0.958 0.006 0.002 TCN10.855 SON 0.856 0.953 0.001 0.041 TCN1 0.855 C7orf58 0.831 0.906 0.0490.026 TCN1 0.855 MPO 0.508 0.912 0.024 0 TCN1 0.855 NP 0.726 0.921 0.0040.002 TCN1 0.855 C4orf3 0.723 0.889 0.045 0.008 TCN1 0.855 CDC26 0.7990.922 0.003 0.022 TCN1 0.855 TAS2R31 0.833 0.951 0.007 0.003 TCN1 0.855IGLV6-57 0.761 0.909 0.046 0.003 CLU 0.664 ITGA2B 0.58 0.806 0.039 0.001CLU 0.664 PTGS1 0.675 0.89 0 0.002 CLU 0.664 E2F6 0.787 0.842 0.01 0.042CLU 0.664 KIAA0101_CSNK1G 0.736 0.82 0.008 0.024 KPNA5 0.895 HPGD 0.8230.95 0.024 0.016 KPNA5 0.895 NA 0.927 0.99 0.008 0.023 KPNA5 0.895 NA0.868 0.944 0.023 0.044 KPNA5 0.895 GPR65 0.736 0.962 0.003 0 KPNA50.895 OCR1 0.896 0.979 0.009 0.032 KPNA5 0.895 DPH3 0.749 0.948 0.014 0KPNA5 0.895 NF-E4 0.861 0.957 0.042 0.014 KPNA5 0.895 NA 0.682 0.9560.041 0 KPNA5 0.895 KIAA1257_ACAD9/ 0.851 0.945 0.026 0.02 KPNA5 0.895CCDC125 0.917 0.98 0.005 0.042 KPNA5 0.895 PDK4 0.863 0.961 0.02 0.007KPNA5 0.895 ZRANB1 0.897 0.984 0.007 0.008 KPNA5 0.895 SYNE2 0.748 0.970.006 0 KPNA5 0.895 MME 0.894 0.983 0.014 0.011 KPNA5 0.895 RBP7 0.8480.955 0.007 0.024 KPNA5 0.895 PPP1R2_PPP1R2P3 0.702 0.957 0.016 0 PLAC80.828 HPGD 0.823 0.946 0.007 0.008 PLAC8 0.828 HSPC159 0.809 0.917 0.0480.003 PLAC8 0.828 TMTC1 0.809 0.942 0.027 0.001 PLAC8 0.828 SH3PXD2B 0.90.948 0.03 0.032 PLAC8 0.828 FRMD3 0.755 0.891 0.04 0.016 PLAC8 0.828 NA0.927 0.989 0.002 0.012 PLAC8 0.828 MTHFS 0.933 0.995 0.001 0.031 PLAC80.828 EIF2AK2 0.964 0.997 0.001 0.035 PLAC8 0.828 NA 0.868 0.952 0.0070.012 PLAC8 0.828 GPR65 0.736 0.953 0.002 0 PLAC8 0.828 OR9A2 0.8230.916 0.01 0.018 PLAC8 0.828 PDK4 0.863 0.983 0.003 0.001 PLAC8 0.828PLIN2 0.706 0.926 0.014 0 PLAC8 0.828 PPP1R2_PPP1R2P3 0.702 0.916 0.0250 CD63 0.612 PDK4 0.863 0.903 0 0.03 HPSE 0.462 C7orf58 0.831 0.928 00.017 C1orf161 0.842 CDS2 0.73 0.903 0.037 0.006 C1orf161 0.842 HIST1H3A0.908 0.961 0.022 0.007 C1orf161 0.842 CD300A 0.841 0.942 0.01 0.016C1orf161 0.842 HIST1H2BM 0.891 0.956 0.013 0.041 C1orf161 0.842 HIST1H3B0.89 0.956 0.02 0.017 C1orf161 0.842 APOLD1 0.871 0.966 0.008 0.008C1orf161 0.842 CDC26 0.799 0.908 0.04 0.037 DDAH2 0.681 LGALS1 0.7220.82 0.049 0.025 DDAH2 0.681 C22orf37 0.924 0.957 0 0.048 DDAH2 0.681GLT25D1 0.77 0.878 0.008 0.007 DDAH2 0.681 CD300A 0.841 0.902 0 0.043DDAH2 0.681 MGST3 0.857 0.926 0 0.029 DDAH2 0.681 S100B 0.841 0.8640.019 0.032 DDAH2 0.681 IRF1 0.82 0.903 0.001 0.006 KLRK1_KLRC4 0.865AREG 0.849 0.951 0.018 0.014 KLRK1_KLRC4 0.865 GPR65 0.736 0.932 0.0060.003 KLRK1_KLRC4 0.865 OCR1 0.896 0.971 0.01 0.036 KLRK1_KLRC4 0.865DPH3 0.749 0.929 0.02 0.001 KLRK1_KLRC4 0.865 NF-E4 0.861 0.945 0.0230.038 KLRK1_KLRC4 0.865 PDK4 0.863 0.942 0.01 0.048 KLRK1_KLRC4 0.865ZRANB1 0.897 0.968 0.003 0.043 KLRK1_KLRC4 0.865 SYNE2 0.748 0.962 0.0020.001 KLRK1_KLRC4 0.865 MME 0.894 0.973 0.005 0.042 KLRK1_KLRC4 0.865PPP1R2_PPP1R2P3 0.702 0.931 0.02 0 KLRK1_KLRC4 0.865 CALM2_C2orf61 0.7490.935 0.018 0.002 ATP13A3 0.545 MTRR 0.674 0.814 0 0.032 ATP13A3 0.545KIAA0746 0.776 0.896 0 0.007 ATP13A3 0.545 C7orf58 0.831 0.906 0 0.04ITK 0.874 HPGD 0.823 0.936 0.018 0.04 ITK 0.874 FRMD3 0.755 0.913 0.0450.009 ITK 0.874 NA 0.927 0.987 0.005 0.036 ITK 0.874 NA 0.868 0.9660.002 0.02 ITK 0.874 GPR65 0.736 0.948 0.004 0.001 ITK 0.874 LRRFIP10.678 0.944 0.021 0 ITK 0.874 OCR1 0.896 0.977 0.008 0.025 ITK 0.874KIAA1257_ACAD9/ 0.851 0.933 0.04 0.043 ITK 0.874 CCDC125 0.917 0.990.004 0.018 ITK 0.874 PDK4 0.863 0.955 0.011 0.019 ITK 0.874 ZRANB10.897 0.978 0.005 0.016 ITK 0.874 ZNF587_ZNF417 0.632 0.941 0.03 0 ITK0.874 CYP4F3_CYP4F2 0.901 0.976 0.005 0.05 ITK 0.874 SYNE2 0.748 0.9730.005 0 ITK 0.874 MME 0.894 0.974 0.014 0.017 ITK 0.874 PLIN2 0.7060.936 0.01 0.001 ITK 0.874 RBP7 0.848 0.935 0.013 0.046 ITK 0.874PPP1R2_PPP1R2P3 0.702 0.975 0.005 0 LOC284757 0.939 SLC39A9 0.776 0.9750.026 0 LOC284757 0.939 HLA-DRA 0.855 0.979 0.04 0.011 LOC284757 0.939DNAJC9_FAM149B1 0.944 0.988 0.047 0.035 LOC284757 0.939 PMS2CL_PMS20.942 0.988 0.033 0.044 LOC284757 0.939 TRAF3 0.87 0.975 0.027 0.022LOC284757 0.939 MGST3 0.857 0.967 0.05 0.009 LOC284757 0.939 ABCG1 0.850.986 0.018 0.005 GOT2 0.966 PRR13_PCBP2 0.947 0.988 0.044 0.049 GOT20.966 HAL 0.942 0.988 0.033 0.025 GOT2 0.966 MPZL3 0.892 0.979 0.04 0.01B3GAT3 0.973 PPP2R5A_SNORA16 0.953 1 0.046 0.019 B3GAT3 0.973 MTHFS0.933 0.999 0.046 0.018 B3GAT3 0.973 CDA 0.945 1 0.046 0.022 HIST1H4E0.915 PPP2R5A_SNORA16 0.953 0.993 0.022 0.018 HIST1H4E 0.915 PRR13_PCBP20.947 0.986 0.023 0.025 HIST1H4E 0.915 MTHFS 0.933 0.995 0.018 0.016HIST1H4E 0.915 CDA 0.945 0.994 0.014 0.021 HIST1H4E 0.915 SAP30 0.9110.971 0.037 0.039 HIST1H4E 0.915 HAL 0.942 0.978 0.035 0.034 HIST1H4E0.915 MPZL3 0.892 0.986 0.012 0.005 HIST1H4E 0.915 RBP7 0.848 0.9810.046 0 HIST1H4E 0.915 RGS2 0.915 0.987 0.013 0.011 HPGD 0.823 CDS2 0.730.888 0.039 0.006 HPGD 0.823 CCR3 0.869 0.941 0.024 0.004 HPGD 0.823SLC39A9 0.776 0.915 0.015 0.004 HPGD 0.823 GIMAP7 0.804 0.918 0.0490.002 HPGD 0.823 LGALS2 0.922 0.973 0.001 0.036 HPGD 0.823 SIAE 0.7370.92 0.034 0.003 HPGD 0.823 HINT1 0.9 0.947 0.015 0.041 HPGD 0.823HIST1H3J 0.898 0.936 0.009 0.037 HPGD 0.823 HIST1H3A 0.908 0.95 0.0070.018 HPGD 0.823 HLA-DPA1 0.796 0.955 0.005 0 HPGD 0.823 PTGER2 0.8810.973 0.001 0.02 HPGD 0.823 PMS2CL_PMS2 0.942 0.987 0.001 0.019 HPGD0.823 TRAF3 0.87 0.935 0.012 0.048 HPGD 0.823 RPL17_SNORD58B 0.917 0.9650.005 0.034 HPGD 0.823 GLT25D1 0.77 0.928 0.011 0.008 HPGD 0.823ITGA4_CERKL 0.88 0.987 0.002 0.002 HPGD 0.823 EIF1AX_SCARNA9L 0.8710.944 0.014 0.002 HPGD 0.823 ZNF28 0.837 0.924 0.029 0.01 HPGD 0.823MGST3 0.857 0.933 0.007 0.032 HPGD 0.823 CCR4 0.871 0.944 0.026 0.004HPGD 0.823 FSD1L_GARNL1 0.779 0.909 0.028 0.003 HPGD 0.823 HIST1H3H0.861 0.923 0.031 0.004 HPGD 0.823 S100B 0.841 0.923 0.018 0.006 HPGD0.823 IGK@_IGKC_IGKV 0.855 0.932 0.03 0.01 HPGD 0.823 SON 0.856 0.9250.019 0.018 HPGD 0.823 C7orf58 0.831 0.95 0.012 0.003 HPGD 0.823 CDC260.799 0.915 0.03 0.004 HPGD 0.823 TAS2R31 0.833 0.922 0.043 0.002 FGFBP20.814 TMTC1 0.809 0.894 0.035 0.035 FGFBP2 0.814 AREG 0.849 0.92 0.0050.037 FGFBP2 0.814 GPR65 0.736 0.884 0.008 0.015 FGFBP2 0.814 DPH3 0.7490.897 0.007 0.005 FGFBP2 0.814 NF-E4 0.861 0.939 0.002 0.031 FGFBP20.814 SYNE2 0.748 0.947 0 0 FGFBP2 0.814 MME 0.894 0.965 0 0.05 FGFBP20.814 FBXL13 0.795 0.914 0.013 0.008 FGFBP2 0.814 PPP1R2_PPP1R2P3 0.7020.886 0.049 0.002 FGFBP2 0.814 CALM2_C2orf61 0.749 0.898 0.005 0.012TMEM144_LOC2855 0.747 MTRR 0.674 0.879 0.002 0.006 TMEM144_LOC2855 0.747HDHD1A 0.602 0.816 0.006 0.017 TMEM144_LOC2855 0.747 NPCDR1 0.726 0.8620.013 0.016 TMEM144_LOC2855 0.747 ICAM1 0.675 0.842 0.01 0.03TMEM144_LOC2855 0.747 TAF13 0.617 0.846 0.025 0.002 TMEM144_LOC28550.747 P4HA1_RPL17 0.664 0.877 0.003 0.003 TMEM144_LOC2855 0.747 C15orf540.72 0.837 0.015 0.028 TMEM144_LOC2855 0.747 KLHL5 0.657 0.858 0.0070.011 TMEM144_LOC2855 0.747 KIAA0746 0.776 0.91 0 0.024 TMEM144_LOC28550.747 NA 0.7 0.885 0.011 0.001 TMEM144_LOC2855 0.747 E2F6 0.787 0.8710.018 0.02 TMEM144_LOC2855 0.747 CD151 0.718 0.859 0.007 0.038TMEM144_LOC2855 0.747 FSD1L 0.674 0.838 0.036 0.008 TMEM144_LOC28550.747 C7orf58 0.831 0.996 0 0 TMEM144_LOC2855 0.747 NP 0.726 0.874 0.0010.043 TMEM144_LOC2855 0.747 IGJ 0.698 0.827 0.037 0.018 TMEM144_LOC28550.747 SDHC 0.736 0.888 0.014 0.002 TMEM144_LOC2855 0.747 NFXL1 0.7280.869 0.003 0.018 CDS2 0.73 HSPC159 0.809 0.878 0.036 0.007 CDS2 0.73FRMD3 0.755 0.866 0.006 0.012 CDS2 0.73 NA 0.927 0.959 0 0.041 CDS2 0.73MTHFS 0.933 0.979 0 0.01 CDS2 0.73 OR9A2 0.823 0.873 0.015 0.028 CDS20.73 KIAA1257_ACAD9/ 0.851 0.907 0.001 0.037 CDS2 0.73 PDK4 0.863 0.9180.003 0.005 CDS2 0.73 ZRANB1 0.897 0.942 0 0.024 CDS2 0.73 SYNE2 0.7480.848 0.045 0.003 CDS2 0.73 FBXL13 0.795 0.854 0.041 0.027 CDS2 0.73HIST2H2BF_HIST2 0.855 0.928 0.003 0.003 CDS2 0.73 SPATA6 0.812 0.8820.015 0.037 BPI 0.817 LGALS1 0.722 0.86 0.029 0.029 BPI 0.817 PHOSPHO10.721 0.885 0.022 0.013 BPI 0.817 HIST1H3J 0.898 0.955 0.001 0.031 BPI0.817 NEK6_LOC1001290 0.671 0.852 0.037 0.01 BPI 0.817 ICAM1 0.675 0.8610.04 0.005 BPI 0.817 PTGS1 0.675 0.861 0.047 0.004 BPI 0.817 HIST1H3C0.863 0.933 0.007 0.018 BPI 0.817 CLC 0.782 0.896 0.015 0.049 BPI 0.817MPO 0.508 0.914 0.001 0 BPI 0.817 NP 0.726 0.857 0.042 0.037 BPI 0.817TAS2R31 0.833 0.906 0.015 0.05 BPI 0.817 KIAA0101_CSNK1G 0.736 0.8860.045 0.003 CCR3 0.869 TMTC1 0.809 0.949 0.036 0.001 CCR3 0.869 FRMD30.755 0.909 0.025 0.008 CCR3 0.869 NA 0.868 0.944 0.005 0.047 CCR3 0.869SAP30 0.911 0.955 0.017 0.021 CCR3 0.869 AREG 0.849 0.965 0.021 0.002CCR3 0.869 DAAM2_LOC100131 0.903 0.961 0.016 0.037 CCR3 0.869 IRS2 0.8170.939 0.019 0.013 CCR3 0.869 OR9A2 0.823 0.932 0.01 0.014 CCR3 0.869ACPL2 0.906 0.963 0.014 0.035 CCR3 0.869 NF-E4 0.861 0.933 0.018 0.047CCR3 0.869 KIAA1257_ACAD9/ 0.851 0.942 0.02 0.012 CCR3 0.869 CCDC1250.917 0.973 0.003 0.048 CCR3 0.869 PDK4 0.863 0.945 0.025 0.011 CCR30.869 RBP7 0.848 0.935 0.007 0.048 HSPC159 0.809 SLC39A9 0.776 0.8870.003 0.045 HSPC159 0.809 GIMAP7 0.804 0.884 0.037 0.031 HSPC159 0.809PHOSPHO1 0.721 0.896 0.047 0.002 HSPC159 0.809 SIAE 0.737 0.91 0.0020.013 HSPC159 0.809 ITGA4_CERKL 0.88 0.961 0.001 0.013 HSPC159 0.809EIF1AX_SCARNA9L 0.871 0.925 0.027 0.007 HSPC159 0.809 ZNF28 0.837 0.9260.009 0.015 HSPC159 0.809 FSD1L_GARNL1 0.779 0.888 0.014 0.042 HSPC1590.809 PTGS1 0.675 0.925 0.008 0 HSPC159 0.809 HIST1H3C 0.863 0.92 0.050.004 HSPC159 0.809 HIST1H3H 0.861 0.933 0.018 0.005 HSPC159 0.809C7orf58 0.831 0.937 0.016 0.004 HSPC159 0.809 NP 0.726 0.893 0.011 0.004PPP2R5A_SNORA16 0.953 SLC39A9 0.776 0.996 0.024 0 PPP2R5A_SNORA16 0.953ANAPC11 0.943 0.996 0.033 0.009 PPP2R5A_SNORA16 0.953 INSIG1 0.957 0.9990.018 0.028 PPP2R5A_SNORA16 0.953 HIST1H4L 0.961 0.996 0.034 0.028PPP2R5A_SNORA16 0.953 C22orf37 0.924 0.993 0.026 0.011 PPP2R5A_SNORA160.953 VOPP1_LOC100128 0.938 0.992 0.026 0.016 PPP2R5A_SNORA16 0.953PTGER2 0.881 0.99 0.046 0.002 PPP2R5A_SNORA16 0.953 PMS2CL_PMS2 0.942 10.019 0.015 PPP2R5A_SNORA16 0.953 IRF4 0.946 0.997 0.023 0.028PPP2R5A_SNORA16 0.953 AMFR 0.867 0.987 0.05 0.004 PPP2R5A_SNORA16 0.953HSP90AB1_HSP90A 0.924 0.996 0.027 0.01 PPP2R5A_SNORA16 0.953 ITGA4_CERKL0.88 1 0.019 0.002 PPP2R5A_SNORA16 0.953 RRP12_LOC644215 0.904 0.990.047 0.006 PPP2R5A_SNORA16 0.953 TIMM10 0.949 0.989 0.03 0.031PPP2R5A_SNORA16 0.953 FAM118A 0.882 0.99 0.048 0.005 PPP2R5A_SNORA160.953 IRF1 0.82 0.996 0.027 0 PPP2R5A_SNORA16 0.953 B4GALT3 0.917 0.9990.019 0.013 PPP2R5A_SNORA16 0.953 CDC26 0.799 0.989 0.027 0 TMTC1 0.809GIMAP7 0.804 0.911 0.007 0.011 TMTC1 0.809 LGALS1 0.722 0.896 0.0020.009 TMTC1 0.809 DNAJC9_FAM149B1 0.944 0.983 0 0.042 TMTC1 0.809 HINT10.9 0.949 0.003 0.049 TMTC1 0.809 HLA-DPA1 0.796 0.898 0.006 0.035 TMTC10.809 NEK6_LOC1001290 0.671 0.855 0.033 0.007 TMTC1 0.809 GLT25D1 0.770.922 0 0.03 TMTC1 0.809 ITGA4_CERKL 0.88 0.946 0.001 0.048 TMTC1 0.809ZNF28 0.837 0.916 0.005 0.034 TMTC1 0.809 KIAA0746 0.776 0.903 0.0220.005 TMTC1 0.809 HIST1H3C 0.863 0.922 0.008 0.014 TMTC1 0.809 CD1510.718 0.885 0.01 0.005 TMTC1 0.809 HIST1H3H 0.861 0.928 0.003 0.013TMTC1 0.809 C7orf58 0.831 0.916 0.009 0.015 TMTC1 0.809 CTSL1_CTSLL30.676 0.879 0.047 0.003 TMTC1 0.809 NP 0.726 0.874 0.041 0.011 TMTC10.809 TMEM62_SPCS2_L 0.78 0.911 0.004 0.022 TMTC1 0.809 CDC26 0.7990.897 0.005 0.048 TMTC1 0.809 TAS2R31 0.833 0.906 0.019 0.013EAF2_HCG11_LOC 0.613 DNAJC9_FAM149B1 0.944 0.979 0 0.046 EAF2_HCG11_LOC0.613 MTRR 0.674 0.861 0 0.002 EAF2_HCG11_LOC 0.613 P4HA1_RPL17 0.6640.857 0 0 EAF2_HCG11_LOC 0.613 KLHL5 0.657 0.8 0.003 0.022EAF2_HCG11_LOC 0.613 KIAA0746 0.776 0.899 0 0.006 EAF2_HCG11_LOC 0.613NA 0.7 0.792 0.019 0.015 EAF2_HCG11_LOC 0.613 C7orf58 0.831 0.935 00.002 EAF2_HCG11_LOC 0.613 TMEM62_SPCS2_L 0.78 0.866 0 0.026EAF2_HCG11_LOC 0.613 SDHC 0.736 0.801 0.006 0.033 RCBTB2_LOC10013 0.506PDK4 0.863 0.933 0 0.038 RCBTB2_LOC10013 0.506 C7orf58 0.831 0.9 0 0.006SEC24A_SAR1B 0.478 GIMAP7 0.804 0.889 0 0.043 SEC24A_SAR1B 0.478 MTRR0.674 0.791 0 0.015 SEC24A_SAR1B 0.478 PMS2CL_PMS2 0.942 0.997 0 0.018SEC24A_SAR1B 0.478 P4HA1_RPL17 0.664 0.763 0.001 0.028 SEC24A_SAR1B0.478 KIAA0746 0.776 0.861 0 0.024 SEC24A_SAR1B 0.478 E2F6 0.787 0.823 00.038 SEC24A_SAR1B 0.478 SDHC 0.736 0.823 0 0.002 SH3PXD2B 0.9 LGALS20.922 0.976 0.019 0.048 SH3PXD2B 0.9 GALNT2 0.528 0.93 0.025 0 SH3PXD2B0.9 GLT25D1 0.77 0.961 0.017 0.006 KLRD1 0.731 CCR1 0.693 0.808 0.0470.012 KLRD1 0.731 PDE3B 0.567 0.799 0.035 0.007 KLRD1 0.731 NA 0.6820.84 0.018 0.006 KLRD1 0.731 DLEU2_DLEU2L 0.711 0.86 0.001 0.017 KLRD10.731 ZNF587_ZNF417 0.632 0.828 0.009 0.005 KLRD1 0.731 SYNE2 0.7480.904 0 0.019 KLRD1 0.731 PLEKHF2 0.667 0.808 0.041 0.041 KLRD1 0.731LOC100128751 0.686 0.814 0.03 0.05 CHI3L1 0.722 OCR1 0.896 0.966 0 0.045CHI3L1 0.722 DPH3 0.749 0.833 0.032 0.041 CHI3L1 0.722 NF-E4 0.861 0.970 0.006 CHI3L1 0.722 DLEU2_DLEU2L 0.711 0.82 0.032 0.022 CHI3L1 0.722THBS1 0.849 0.916 0.001 0.038 CHI3L1 0.722 ZNF587_ZNF417 0.632 0.8160.03 0.002 CHI3L1 0.722 SYNE2 0.748 0.888 0.003 0.004 CHI3L1 0.722FBXL13 0.795 0.9 0.002 0.025 CHI3L1 0.722 HIST2H2BF_HIST2 0.855 0.932 00.047 FRMD3 0.755 SLC39A9 0.776 0.884 0.007 0.009 FRMD3 0.755 LGALS10.722 0.83 0.05 0.014 FRMD3 0.755 HINT1 0.9 0.926 0.003 0.048 FRMD30.755 HIST1H3J 0.898 0.93 0.002 0.027 FRMD3 0.755 HLA-DPA1 0.796 0.8830.009 0.012 FRMD3 0.755 AMFR 0.867 0.96 0 0.006 FRMD3 0.755RPL17_SNORD58B 0.917 0.952 0.001 0.022 FRMD3 0.755 ITGA4_CERKL 0.880.951 0 0.01 FRMD3 0.755 EIF1AX_SCARNA9L 0.871 0.907 0.003 0.026 FRMD30.755 ZNF28 0.837 0.913 0.005 0.007 FRMD3 0.755 HIST1H3B 0.89 0.9340.002 0.019 FRMD3 0.755 FSD1L_GARNL1 0.779 0.877 0.028 0.005 FRMD3 0.755HIST1H3C 0.863 0.891 0.027 0.011 FRMD3 0.755 HIST1H3H 0.861 0.897 0.0170.01 FRMD3 0.755 S100B 0.841 0.877 0.019 0.041 FRMD3 0.755IGK@_IGKC_IGKV 0.855 0.909 0.006 0.028 FRMD3 0.755 SON 0.856 0.926 0.0010.015 FRMD3 0.755 TNFRSF17 0.875 0.922 0.003 0.041 FRMD3 0.755 CDC260.799 0.904 0.001 0.012 SLC39A9 0.776 NA 0.927 0.973 0 0.023 SLC39A90.776 EIF2AK2 0.964 0.997 0 0.037 SLC39A9 0.776 NA 0.868 0.944 0.0010.008 SLC39A9 0.776 GPR65 0.736 0.898 0.011 0 SLC39A9 0.776 OR9A2 0.8230.883 0.02 0.027 SLC39A9 0.776 ACPL2 0.906 0.97 0 0.039 SLC39A9 0.776ERGIC1 0.886 0.949 0 0.029 SLC39A9 0.776 NF-E4 0.861 0.919 0.008 0.007SLC39A9 0.776 HAL 0.942 0.982 0 0.05 SLC39A9 0.776 KIAA1257_ACAD9/ 0.8510.951 0 0.001 SLC39A9 0.776 CCDC125 0.917 0.984 0 0.006 SLC39A9 0.776PDK4 0.863 0.971 0 0 SLC39A9 0.776 THBS1 0.849 0.905 0.008 0.019 SLC39A90.776 ZRANB1 0.897 0.965 0 0.003 SLC39A9 0.776 MPZL3 0.892 0.956 0 0.046SLC39A9 0.776 ZNF587_ZNF417 0.632 0.906 0.019 0 SLC39A9 0.776CYP4F3_CYP4F2 0.901 0.956 0.001 0.022 SLC39A9 0.776 SYNE2 0.748 0.9210.011 0 SLC39A9 0.776 MME 0.894 0.931 0.005 0.017 SLC39A9 0.776 CPM0.854 0.915 0.005 0.025 SLC39A9 0.776 FBXL13 0.795 0.888 0.048 0.001SLC39A9 0.776 HIST2H2BF_HIST2 0.855 0.928 0.006 0.007 SLC39A9 0.776SPATA6 0.812 0.921 0.006 0.003 GIMAP7 0.804 NA 0.927 0.996 0 0.016GIMAP7 0.804 NA 0.868 0.973 0 0.006 GIMAP7 0.804 GPR65 0.736 0.947 0 0GIMAP7 0.804 OR9A2 0.823 0.896 0.012 0.023 GIMAP7 0.804 LRRFIP1 0.6780.914 0.012 0 GIMAP7 0.804 CCDC125 0.917 0.991 0 0.015 GIMAP7 0.804 PDK40.863 0.968 0 0.003 GIMAP7 0.804 ZRANB1 0.897 0.968 0 0.015 GIMAP7 0.804CYP4F3_CYP4F2 0.901 0.955 0.003 0.04 GIMAP7 0.804 SYNE2 0.748 0.9390.001 0 GIMAP7 0.804 MME 0.894 0.956 0.003 0.017 GIMAP7 0.804 PLIN20.706 0.899 0.021 0.001 GIMAP7 0.804 FBXL13 0.795 0.898 0.046 0.007GIMAP7 0.804 PPP1R2_PPP1R2P3 0.702 0.945 0.001 0 ANAPC11 0.943 NA 0.9270.992 0.026 0.007 ANAPC11 0.943 SAP30 0.911 0.979 0.046 0.026 ANAPC110.943 ERGIC1 0.886 0.98 0.048 0.011 ANAPC11 0.943 HAL 0.942 0.984 0.0240.033 ANAPC11 0.943 CCDC125 0.917 0.981 0.041 0.013 ANAPC11 0.943 MPZL30.892 0.974 0.024 0.008 ANAPC11 0.943 RGS2 0.915 0.975 0.023 0.023 NA0.927 DNAJC9_FAM149B1 0.944 0.988 0.016 0.04 NA 0.927 LGALS2 0.922 0.9790.032 0.015 NA 0.927 MTRR 0.674 0.974 0.021 0 NA 0.927 HLA-DPA1 0.7960.979 0.012 0 NA 0.927 PTGER2 0.881 0.97 0.017 0.021 NA 0.927PMS2CL_PMS2 0.942 0.997 0.01 0.021 NA 0.927 TRAF3 0.87 0.989 0.013 0.006NA 0.927 AMFR 0.867 0.963 0.029 0.026 NA 0.927 RPL17_SNORD58B 0.9170.988 0.039 0.007 NA 0.927 HSP90AB1_HSP90A 0.924 0.996 0.014 0.013 NA0.927 ITGA4_CERKL 0.88 0.99 0.006 0.007 NA 0.927 CD300A 0.841 0.954 0.040.007 NA 0.927 P4HA1_RPL17 0.664 0.97 0.048 0 NA 0.927 KLHL5 0.657 0.9810.042 0 NA 0.927 MGST3 0.857 0.975 0.028 0.002 NA 0.927 KIAA0746 0.7760.993 0.019 0 NA 0.927 CCR4 0.871 0.989 0.028 0.003 NA 0.927 ABCG1 0.850.965 0.039 0.003 NA 0.927 FAM118A 0.882 0.974 0.022 0.02 NA 0.927IGK@_IGKC_IGKV 0.855 0.992 0.025 0.001 NA 0.927 IRF1 0.82 0.965 0.0160.003 NA 0.927 C7orf58 0.831 0.989 0.037 0 NA 0.927 B4GALT3 0.917 0.9840.008 0.039 NA 0.927 TNFRSF17 0.875 0.984 0.043 0.001 NA 0.927 DCTN50.722 0.975 0.015 0 INSIG1 0.957 PRR13_PCBP2 0.947 0.993 0.04 0.015INSIG1 0.957 MTHFS 0.933 0.999 0.024 0.019 INSIG1 0.957 EIF2AK2 0.9640.999 0.028 0.033 INSIG1 0.957 CDA 0.945 0.996 0.042 0.015 INSIG1 0.957GAB2 0.969 0.996 0.033 0.045 INSIG1 0.957 HAL 0.942 0.994 0.037 0.011INSIG1 0.957 MPZL3 0.892 0.993 0.027 0.003 INSIG1 0.957 RGS2 0.915 0.9970.023 0.003 FOLR3_FOLR2 0.78 HIST1H3J 0.898 0.943 0.001 0.05 FOLR3_FOLR20.78 HIST1H3A 0.908 0.962 0.001 0.015 FOLR3_FOLR2 0.78 GLT25D1 0.770.926 0.002 0.012 FOLR3_FOLR2 0.78 HIST1H3B 0.89 0.943 0.001 0.05FOLR3_FOLR2 0.78 HIST1H3C 0.863 0.915 0.013 0.02 FOLR3_FOLR2 0.78HIST1H3H 0.861 0.92 0.006 0.023 PRR13_PCBP2 0.947 LGALS2 0.922 0.9890.035 0.003 PRR13_PCBP2 0.947 C22orf37 0.924 0.985 0.024 0.021PRR13_PCBP2 0.947 VOPP1_LOC100128 0.938 0.981 0.028 0.017 PRR13_PCBP20.947 PMS2CL_PMS2 0.942 0.992 0.019 0.019 PRR13_PCBP2 0.947 IRF4 0.9460.994 0.015 0.032 PRR13_PCBP2 0.947 HSP90AB1_HSP90A 0.924 0.988 0.050.007 PRR13_PCBP2 0.947 CD300A 0.841 0.985 0.038 0 PRR13_PCBP2 0.947RRP12_LOC644215 0.904 0.989 0.025 0.008 PRR13_PCBP2 0.947 TIMM10 0.9490.993 0.017 0.022 PRR13_PCBP2 0.947 IRF1 0.82 0.985 0.042 0 PRR13_PCBP20.947 LASS4 0.924 0.979 0.018 0.041 PRR13_PCBP2 0.947 B4GALT3 0.9170.991 0.024 0.014 PRR13_PCBP2 0.947 CDC26 0.799 0.982 0.035 0PRR13_PCBP2 0.947 IGL@_IGLV1-44_(—) 0.953 0.992 0.018 0.033 HIST1H4L0.961 SAP30 0.911 0.988 0.018 0.036 HIST1H4L 0.961 IRS2 0.817 0.9850.023 0.002 HIST1H4L 0.961 ERGIC1 0.886 0.98 0.048 0.026 HIST1H4L 0.961MPZL3 0.892 0.979 0.027 0.012 HIST1H4L 0.961 MYL9 0.641 0.992 0.038 0HIST1H4L 0.961 RBP7 0.848 0.992 0.038 0 HIST1H4L 0.961 RGS2 0.915 0.9850.017 0.022 LGALS1 0.722 RETN 0.694 0.851 0.014 0.011 LGALS1 0.722 GPR650.736 0.853 0.015 0.011 LGALS1 0.722 OR9A2 0.823 0.888 0.004 0.028LGALS1 0.722 KCNMA1 0.707 0.825 0.037 0.007 LGALS1 0.722 PDK4 0.8630.948 0 0.003 LGALS1 0.722 LHFP 0.731 0.814 0.032 0.039 LGALS1 0.722FABP2 0.744 0.832 0.05 0.023 LGALS1 0.722 RBP7 0.848 0.902 0.002 0.039CCR1 0.693 MTRR 0.674 0.854 0.005 0.012 CCR1 0.693 P4HA1_RPL17 0.6640.824 0.017 0.012 CCR1 0.693 KLHL5 0.657 0.808 0.019 0.044 CCR1 0.693LAIR1_LAIR2 0.607 0.802 0.043 0.014 CCR1 0.693 PYHIN1 0.686 0.805 0.0210.022 CCR1 0.693 C7orf58 0.831 0.939 0 0.004 CCR1 0.693 SDHC 0.736 0.8340.04 0.008 CCR1 0.693 NFXL1 0.728 0.827 0.013 0.039 TPST1 0.92 PHOSPHO10.721 0.985 0.047 0 TPST1 0.92 HIST1H3J 0.898 0.979 0.046 0.008 TPST10.92 HIST1H3A 0.908 0.979 0.039 0.018 TPST1 0.92 TYMS 0.863 0.957 0.0370.042 TPST1 0.92 ABCG1 0.85 0.966 0.043 0.018 TPST1 0.92 HIST1H3B 0.890.981 0.037 0.013 TPST1 0.92 TNFRSF17 0.875 0.964 0.036 0.035 HLA-DRA0.855 NA 0.868 0.946 0.009 0.04 HLA-DRA 0.855 GPR65 0.736 0.911 0.0220.001 HLA-DRA 0.855 ACPL2 0.906 0.96 0.031 0.01 HLA-DRA 0.855KIAA1257_ACAD9/ 0.851 0.937 0.042 0.011 HLA-DRA 0.855 PDK4 0.863 0.9850.005 0.001 HLA-DRA 0.855 PLIN2 0.706 0.965 0.024 0 FFAR2 0.637LAIR1_LAIR2 0.607 0.759 0.021 0.029 FFAR2 0.637 C7orf58 0.831 0.905 00.045 PHOSPHO1 0.721 ABCA13 0.743 0.895 0.003 0.005 PHOSPHO1 0.721DAAM2_LOC100131 0.903 0.986 0 0.016 PHOSPHO1 0.721 IRS2 0.817 0.96 00.015 PHOSPHO1 0.721 DPH3 0.749 0.886 0.004 0.003 PHOSPHO1 0.721 NF-E40.861 0.926 0.001 0.049 PHOSPHO1 0.721 DLEU2_DLEU2L 0.711 0.819 0.0440.02 PHOSPHO1 0.721 THBS1 0.849 0.952 0 0.003 PHOSPHO1 0.721 MYL9 0.6410.832 0.023 0.008 PHOSPHO1 0.721 FBXL13 0.795 0.898 0.005 0.019 PHOSPHO10.721 RBP7 0.848 0.942 0 0.018 PHOSPHO1 0.721 CALM2_C2orf61 0.749 0.8950.004 0.001 PPIF 0.934 MTHFS 0.933 0.997 0.048 0.021 MTHFS 0.933DNAJC9_FAM149B1 0.944 0.992 0.032 0.023 MTHFS 0.933 LGALS2 0.922 0.9940.031 0.003 MTHFS 0.933 C22orf37 0.924 0.979 0.033 0.042 MTHFS 0.933PTGER2 0.881 0.979 0.043 0.004 MTHFS 0.933 PMS2CL_PMS2 0.942 0.994 0.0280.012 MTHFS 0.933 HSP90AB1_HSP90A 0.924 0.996 0.026 0.01 MTHFS 0.933CD300A 0.841 0.97 0.029 0.002 MTHFS 0.933 MGST3 0.857 0.996 0.021 0.001MTHFS 0.933 RRP12_LOC644215 0.904 0.989 0.022 0.011 MTHFS 0.933 TIMM100.949 0.993 0.022 0.027 MTHFS 0.933 FAM118A 0.882 0.982 0.049 0.009MTHFS 0.933 IRF1 0.82 0.988 0.031 0 MTHFS 0.933 B4GALT3 0.917 0.984 0.030.029 MTHFS 0.933 ATP6V0D1_LOC100 0.567 0.969 0.01 0 MTHFS 0.933 CDC260.799 0.972 0.031 0 DNAJC9_FAM149B1 0.944 EIF2AK2 0.964 0.997 0.0230.044 DNAJC9_FAM149B1 0.944 NA 0.868 0.98 0.035 0.002 DNAJC9_FAM149B10.944 HIST1H2AA 0.903 0.974 0.035 0.018 DNAJC9_FAM149B1 0.944 GPR650.736 0.975 0.048 0 DNAJC9_FAM149B1 0.944 ACPL2 0.906 0.988 0.024 0.022DNAJC9_FAM149B1 0.944 LRRFIP1 0.678 0.983 0.041 0 DNAJC9_FAM149B1 0.944TRIM21 0.538 0.974 0.049 0 DNAJC9_FAM149B1 0.944 HAL 0.942 0.989 0.0210.037 DNAJC9_FAM149B1 0.944 CCDC125 0.917 0.991 0.016 0.016DNAJC9_FAM149B1 0.944 PDK4 0.863 0.996 0.02 0.001 DNAJC9_FAM149B1 0.944ZRANB1 0.897 0.988 0.018 0.006 DNAJC9_FAM149B1 0.944 MPZL3 0.892 0.9740.03 0.024 DNAJC9_FAM149B1 0.944 CYP4F3_CYP4F2 0.901 0.991 0.027 0.017DNAJC9_FAM149B1 0.944 SYNE2 0.748 0.986 0.023 0 DNAJC9_FAM149B1 0.944RBP7 0.848 0.984 0.036 0.001 DNAJC9_FAM149B1 0.944 RGS2 0.915 0.98 0.0190.025 DNAJC9_FAM149B1 0.944 PPP1R2_PPP1R2P3 0.702 0.981 0.047 0DNAJC9_FAM149B1 0.944 HIST2H2BF_HIST2 0.855 0.992 0.03 0.002 LCN2 0.653HIST1H2AJ_HIST1 0.77 0.82 0.033 0.005 LCN2 0.653 HIST1H3C 0.863 0.924 00.048 LCN2 0.653 MPO 0.508 0.74 0.012 0.001 EIF2AK2 0.964 LGALS2 0.9220.99 0.048 0.006 EIF2AK2 0.964 VOPP1_LOC100128 0.938 0.993 0.03 0.019EIF2AK2 0.964 PTGER2 0.881 0.997 0.037 0.002 EIF2AK2 0.964 PMS2CL_PMS20.942 1 0.032 0.015 EIF2AK2 0.964 TRAF3 0.87 0.995 0.048 0.004 EIF2AK20.964 IRF4 0.946 1 0.032 0.023 EIF2AK2 0.964 HSP90AB1_HSP90A 0.924 0.9990.031 0.01 EIF2AK2 0.964 ITGA4_CERKL 0.88 0.998 0.037 0.002 EIF2AK20.964 CD300A 0.841 0.997 0.035 0 EIF2AK2 0.964 TRIM21 0.538 0.993 0.0420 EIF2AK2 0.964 KIAA0746 0.776 0.996 0.044 0 EIF2AK2 0.964 TIMM10 0.9490.997 0.034 0.019 EIF2AK2 0.964 IGK@_IGKC_IGKV 0.855 0.994 0.043 0.001EIF2AK2 0.964 IRF1 0.82 0.999 0.032 0 EIF2AK2 0.964 B4GALT3 0.917 10.032 0.012 EIF2AK2 0.964 DCTN5 0.722 0.99 0.035 0 LGALS2 0.922HIST1H2AA 0.903 0.977 0.013 0.009 LGALS2 0.922 ACPL2 0.906 0.961 0.0450.041 LGALS2 0.922 ERGIC1 0.886 0.961 0.021 0.037 LGALS2 0.922 CCDC1250.917 0.974 0.009 0.027 LGALS2 0.922 ZRANB1 0.897 0.971 0.016 0.007LGALS2 0.922 MPZL3 0.892 0.974 0.003 0.02 LGALS2 0.922 KDM6B_TMEM880.869 0.971 0.019 0.019 LGALS2 0.922 RBP7 0.848 0.958 0.048 0.001 LGALS20.922 RGS2 0.915 0.978 0.004 0.03 SIAE 0.737 GPR65 0.736 0.844 0.0480.032 SIAE 0.737 PDK4 0.863 0.924 0.005 0.024 AP3B2 0.756 HIST1H3J 0.8980.926 0.005 0.01 AP3B2 0.756 HIST1H3A 0.908 0.944 0.002 0.002 AP3B20.756 GLT25D1 0.77 0.875 0.036 0.027 AP3B2 0.756 HIST1H2BM 0.891 0.9280.004 0.018 AP3B2 0.756 HIST1H3B 0.89 0.924 0.006 0.006 AP3B2 0.756HIST1H3C 0.863 0.895 0.03 0.006 AP3B2 0.756 HIST1H3H 0.861 0.903 0.0210.005 AP3B2 0.756 APOLD1 0.871 0.924 0.003 0.012 AP3B2 0.756 C7orf580.831 0.886 0.028 0.05 AP3B2 0.756 CDC26 0.799 0.859 0.04 0.05 ABCA130.743 HIST1H3J 0.898 0.962 0 0.002 ABCA13 0.743 AGTRAP 0.611 0.811 0.0490.003 ABCA13 0.743 HIST1H3A 0.908 0.97 0 0.006 ABCA13 0.743 CENPK 0.8340.879 0.029 0.036 ABCA13 0.743 HIST1H3B 0.89 0.978 0 0.004 ABCA13 0.743HIST1H3C 0.863 0.933 0.003 0.002 ABCA13 0.743 HIST1H3H 0.861 0.934 0.0010.004 ABCA13 0.743 TPX2 0.635 0.833 0.035 0.002 ABCA13 0.743 MPO 0.5080.853 0.028 0 ABCA13 0.743 KIAA0101_CSNK1G 0.736 0.875 0.018 0.001 NA0.868 HINT1 0.9 0.956 0.025 0.013 NA 0.868 HLA-DPA1 0.796 0.951 0.0090.001 NA 0.868 PMS2CL_PMS2 0.942 0.984 0.001 0.039 NA 0.868 SULF2 0.5910.931 0.033 0 NA 0.868 TRAF3 0.87 0.993 0.001 0.004 NA 0.868 IRF4 0.9460.996 0.001 0.035 NA 0.868 RPL17_SNORD58B 0.917 0.947 0.047 0.02 NA0.868 HSP90AB1_HSP90A 0.924 0.996 0.001 0.01 NA 0.868 ITGA4_CERKL 0.880.981 0.002 0.002 NA 0.868 CD300A 0.841 0.928 0.011 0.023 NA 0.868 MGST30.857 0.941 0.014 0.023 NA 0.868 KIAA0746 0.776 0.969 0.011 0 NA 0.868CCR4 0.871 0.965 0.015 0.001 NA 0.868 ABCG1 0.85 0.947 0.005 0.018 NA0.868 FAM118A 0.882 0.947 0.025 0.025 NA 0.868 IGK@_IGKC_IGKV 0.8550.957 0.03 0.001 NA 0.868 IRF1 0.82 0.932 0.013 0.008 NA 0.868 TNFRSF170.875 0.958 0.024 0.002 NA 0.868 DCTN5 0.722 0.947 0.041 0 EFCAB2 0.773AIG1 0.56 0.829 0.029 0.001 EFCAB2 0.773 HS2ST1_UBA2 0.668 0.829 0.0120.048 EFCAB2 0.773 NEK6_LOC1001290 0.671 0.832 0.021 0.04 EFCAB2 0.773MINPP1 0.7 0.857 0.038 0.005 EFCAB2 0.773 C15orf54 0.72 0.875 0.0040.007 EFCAB2 0.773 PTGS1 0.675 0.855 0.011 0.012 EFCAB2 0.773 E2F6 0.7870.882 0.021 0.012 EFCAB2 0.773 CD151 0.718 0.843 0.036 0.031 EFCAB20.773 TPX2 0.635 0.823 0.037 0.009 EFCAB2 0.773 HIST1H2BJ 0.703 0.8540.042 0.022 EFCAB2 0.773 C7orf58 0.831 0.937 0.003 0.004 EFCAB2 0.773 NP0.726 0.862 0.008 0.043 EFCAB2 0.773 SDHC 0.736 0.899 0.014 0.001 EFCAB20.773 NFXL1 0.728 0.865 0.048 0.006 EFCAB2 0.773 KIAA0101_CSNK1G 0.7360.872 0.009 0.01 HIST1H2AA 0.903 C22orf37 0.924 0.978 0.006 0.015HIST1H2AA 0.903 IRF4 0.946 0.98 0.01 0.047 HIST1H2AA 0.903HSP90AB1_HSP90A 0.924 0.964 0.032 0.043 HIST1H2AA 0.903 TYMS 0.863 0.9590.041 0.002 HIST1H2AA 0.903 RRP12_LOC644215 0.904 0.959 0.029 0.03 HINT10.9 GPR65 0.736 0.95 0.035 0 HINT1 0.9 OCR1 0.896 0.978 0.008 0.042HINT1 0.9 KIAA1257_ACAD9/ 0.851 0.932 0.049 0.04 HINT1 0.9 PDK4 0.8630.978 0.014 0.002 HINT1 0.9 ZRANB1 0.897 0.963 0.014 0.035 HINT1 0.9CYP4F3_CYP4F2 0.901 0.978 0.008 0.046 HINT1 0.9 SYNE2 0.748 0.962 0.0060 HINT1 0.9 MME 0.894 0.971 0.018 0.034 HINT1 0.9 PLIN2 0.706 0.9380.049 0 HINT1 0.9 RBP7 0.848 0.963 0.005 0.013 HINT1 0.9 PPP1R2_PPP1R2P30.702 0.953 0.033 0 HIST1H3J 0.898 PCOLCE2 0.567 0.925 0.008 0 HIST1H3J0.898 AREG 0.849 0.961 0.003 0.007 HIST1H3J 0.898 DAAM2_LOC100131 0.9030.977 0.003 0.023 HIST1H3J 0.898 IRS2 0.817 0.955 0.005 0.009 HIST1H3J0.898 OR9A2 0.823 0.943 0.03 0.004 HIST1H3J 0.898 KCNMA1 0.707 0.930.032 0 HIST1H3J 0.898 DPH3 0.749 0.951 0.045 0 HIST1H3J 0.898 NF-E40.861 0.957 0.027 0.01 HIST1H3J 0.898 THBS1 0.849 0.956 0.026 0.003HIST1H3J 0.898 LHFP 0.731 0.928 0.044 0.001 HIST1H3J 0.898 ZRANB1 0.8970.964 0.023 0.018 HIST1H3J 0.898 FABP2 0.744 0.928 0.026 0.001 HIST1H3J0.898 MYL9 0.641 0.952 0.01 0 HIST1H3J 0.898 RBP7 0.848 0.973 0.0020.004 HIST1H3J 0.898 HIST2H2BF_HIST2 0.855 0.939 0.048 0.028 HIST1H3J0.898 CALM2_C2orf61 0.749 0.953 0.041 0 CDA 0.945 C22orf37 0.924 0.9860.05 0.015 CDA 0.945 VOPP1_LOC100128 0.938 0.985 0.014 0.025 CDA 0.945PMS2CL_PMS2 0.942 0.998 0.022 0.017 CDA 0.945 HSP90AB1_HSP90A 0.9240.997 0.02 0.011 CDA 0.945 MGST3 0.857 0.989 0.031 0.001 CDA 0.945RRP12_LOC644215 0.904 0.996 0.022 0.006 CDA 0.945 TIMM10 0.949 0.9860.031 0.033 CDA 0.945 IRF1 0.82 0.994 0.033 0 CDA 0.945 LASS4 0.9240.993 0.018 0.019 CDA 0.945 B4GALT3 0.917 0.992 0.031 0.012 CDA 0.945CDC26 0.799 0.981 0.04 0 SAP30 0.911 C22orf37 0.924 0.976 0.017 0.035SAP30 0.911 TYMS 0.863 0.972 0.047 0.001 SAP30 0.911 ABCG1 0.85 0.9780.014 0.005 SAP30 0.911 TIMM10 0.949 0.98 0.036 0.034 SAP30 0.911B4GALT3 0.917 0.976 0.036 0.02 AGTRAP 0.611 HIST1H3A 0.908 0.93 0 0.03AGTRAP 0.611 RBP7 0.848 0.926 0 0.007 MTRR 0.674 LRRFIP1 0.678 0.8480.002 0.004 MTRR 0.674 DLEU2_DLEU2L 0.711 0.813 0.005 0.045 MTRR 0.674PDK4 0.863 0.953 0 0.017 MTRR 0.674 ZNF587_ZNF417 0.632 0.807 0.0090.007 MTRR 0.674 PLEKHF2 0.667 0.807 0.018 0.021 MTRR 0.674 IL1RL1 0.7380.842 0.006 0.026 MTRR 0.674 AIF1 0.618 0.788 0.027 0.024 MTRR 0.674PPP1R2_PPP1R2P3 0.702 0.836 0.003 0.032 PCOLCE2 0.567 HIST1H3A 0.9080.936 0 0.025 PCOLCE2 0.567 HIST1H2BM 0.891 0.924 0 0.023 PCOLCE2 0.567HIST1H3B 0.89 0.916 0 0.012 PCOLCE2 0.567 HIST1H3C 0.863 0.894 0 0.011PCOLCE2 0.567 HIST1H3H 0.861 0.898 0 0.011 PCOLCE2 0.567 CMTM5 0.6710.738 0.05 0.033 HS2ST1_UBA2 0.668 KCNMA1 0.707 0.808 0.019 0.039HS2ST1_UBA2 0.668 DLEU2_DLEU2L 0.711 0.806 0.04 0.017 HS2ST1_UBA2 0.668PDK4 0.863 0.914 0 0.049 HS2ST1_UBA2 0.668 SYNE2 0.748 0.848 0.005 0.033HS2ST1_UBA2 0.668 FBXL13 0.795 0.857 0.005 0.033 HIST1H3A 0.908 AREG0.849 0.967 0.005 0.005 HIST1H3A 0.908 DAAM2_LOC100131 0.903 0.98 0.0040.027 HIST1H3A 0.908 IRS2 0.817 0.961 0.003 0.007 HIST1H3A 0.908 ACPL20.906 0.967 0.014 0.043 HIST1H3A 0.908 DPH3 0.749 0.958 0.039 0 HIST1H3A0.908 NF-E4 0.861 0.959 0.019 0.01 HIST1H3A 0.908 DLEU2_DLEU2L 0.7110.965 0.032 0 HIST1H3A 0.908 PDK4 0.863 0.949 0.035 0.02 HIST1H3A 0.908THBS1 0.849 0.966 0.036 0.001 HIST1H3A 0.908 LHFP 0.731 0.94 0.028 0HIST1H3A 0.908 ZRANB1 0.897 0.961 0.028 0.024 HIST1H3A 0.908 FABP2 0.7440.943 0.041 0 HIST1H3A 0.908 MYL9 0.641 0.946 0.046 0 HIST1H3A 0.908RBP7 0.848 0.966 0.006 0.007 HIST1H3A 0.908 HIST2H2BF_HIST2 0.855 0.9550.048 0.009 C22orf37 0.924 ERGIC1 0.886 0.978 0.047 0.008 C22orf37 0.924HAL 0.942 0.988 0.024 0.01 C22orf37 0.924 CCDC125 0.917 0.984 0.0330.006 C22orf37 0.924 MPZL3 0.892 0.973 0.007 0.014 C22orf37 0.924 RGS20.915 0.975 0.028 0.011 HLA-DPA1 0.796 GPR65 0.736 0.9 0.031 0 HLA-DPA10.796 OR9A2 0.823 0.889 0.028 0.029 HLA-DPA1 0.796 KIAA1257_ACAD9/ 0.8510.914 0.002 0.035 HLA-DPA1 0.796 PDK4 0.863 0.966 0.001 0.001 HLA-DPA10.796 THBS1 0.849 0.895 0.022 0.047 HLA-DPA1 0.796 PLIN2 0.706 0.8920.04 0.001 HLA-DPA1 0.796 HIST2H2BF_HIST2 0.855 0.912 0.019 0.029VOPP1_LOC100128 0.938 HAL 0.942 0.98 0.033 0.012 VOPP1_LOC100128 0.938MPZL3 0.892 0.981 0.021 0.005 VOPP1_LOC100128 0.938 RGS2 0.915 0.9850.019 0.006 SLC39A8 0.825 GPR65 0.736 0.917 0.007 0.005 SLC39A8 0.825PDK4 0.863 0.935 0.01 0.036 SLC39A8 0.825 SPATA6 0.812 0.894 0.013 0.035MKI67 0.621 HIST1H3C 0.863 0.897 0 0.021 AREG 0.849 GLT25D1 0.77 0.9180.024 0.011 AREG 0.849 CD300A 0.841 0.905 0.039 0.025 AREG 0.849 ZNF280.837 0.915 0.041 0.023 AREG 0.849 HIST1H2BM 0.891 0.947 0.009 0.045AREG 0.849 HIST1H3B 0.89 0.949 0.017 0.006 AREG 0.849 HIST1H3C 0.8630.942 0.032 0.001 AREG 0.849 HIST1H3H 0.861 0.951 0.017 0.001 AREG 0.849APOLD1 0.871 0.937 0.016 0.033 AREG 0.849 CLC 0.782 0.937 0.026 0.002AREG 0.849 CDC26 0.799 0.912 0.036 0.011 DAAM2_LOC100131 0.903 GLT25D10.77 0.965 0.033 0.002 DAAM2_LOC100131 0.903 CD300A 0.841 0.958 0.0320.003 DAAM2_LOC100131 0.903 TYMS 0.863 0.965 0.012 0.014 DAAM2_LOC1001310.903 RRP12_LOC644215 0.904 0.969 0.022 0.048 DAAM2_LOC100131 0.903HIST1H2BM 0.891 0.971 0.021 0.026 DAAM2_LOC100131 0.903 ABCG1 0.85 0.9770.022 0.006 DAAM2_LOC100131 0.903 HIST1H3B 0.89 0.986 0.018 0.004DAAM2_LOC100131 0.903 APOLD1 0.871 0.971 0.019 0.008 DAAM2_LOC1001310.903 SON 0.856 0.955 0.036 0.022 DAAM2_LOC100131 0.903 IRF1 0.82 0.9460.014 0.008 DAAM2_LOC100131 0.903 TNFRSF17 0.875 0.968 0.019 0.012DAAM2_LOC100131 0.903 CDC26 0.799 0.965 0.023 0.001 DAAM2_LOC1001310.903 GLDC 0.714 0.966 0.042 0 TREML1 0.634 CENPK 0.834 0.88 0 0.049TREML1 0.634 MINPP1 0.7 0.795 0.017 0.044 TREML1 0.634 ITGA2B 0.58 0.8270 0.002 TREML1 0.634 HIST1H2AJ_HIST1 0.77 0.803 0.039 0.01 TREML1 0.634PTGS1 0.675 0.909 0 0.001 TREML1 0.634 HIST1H3C 0.863 0.916 0 0.017TREML1 0.634 E2F6 0.787 0.856 0.001 0.033 TREML1 0.634 HIST1H3H 0.8610.936 0 0.015 TREML1 0.634 HIST1H2BJ 0.703 0.838 0.001 0.03 TREML1 0.634RPIA 0.601 0.761 0.049 0.022 TREML1 0.634 CMTM5 0.671 0.828 0 0.045TREML1 0.634 SDHC 0.736 0.814 0.005 0.044 TREML1 0.634 KIAA0101_CSNK1G0.736 0.836 0.001 0.02 PTGER2 0.881 GPR65 0.736 0.96 0.032 0 PTGER20.881 ACPL2 0.906 0.969 0.012 0.032 PTGER2 0.881 HAL 0.942 0.976 0.0060.039 PTGER2 0.881 CCDC125 0.917 0.968 0.011 0.021 PTGER2 0.881 PDK40.863 0.976 0.011 0.001 PTGER2 0.881 ZRANB1 0.897 0.973 0.012 0.003PTGER2 0.881 MPZL3 0.892 0.962 0.002 0.05 PTGER2 0.881 RBP7 0.848 0.9420.05 0.006 PTGER2 0.881 RGS2 0.915 0.974 0.003 0.021 CEACAM8 0.647HIST1H2AJ_HIST1 0.77 0.823 0.019 0.006 CEACAM8 0.647 DEFA4_DEFA8P 0.4810.824 0.004 0 CEACAM8 0.647 MPO 0.508 0.732 0 0 PMS2CL_PMS2 0.942 ACPL20.906 0.999 0.017 0.007 PMS2CL_PMS2 0.942 ERGIC1 0.886 0.98 0.043 0.012PMS2CL_PMS2 0.942 HAL 0.942 0.992 0.015 0.019 PMS2CL_PMS2 0.942 CCDC1250.917 0.996 0.016 0.008 PMS2CL_PMS2 0.942 PDK4 0.863 0.991 0.041 0.001PMS2CL_PMS2 0.942 ZRANB1 0.897 0.995 0.022 0.002 PMS2CL_PMS2 0.942 MPZL30.892 0.983 0.015 0.007 PMS2CL_PMS2 0.942 SYNE2 0.748 0.983 0.037 0PMS2CL_PMS2 0.942 RBP7 0.848 0.984 0.047 0.001 PMS2CL_PMS2 0.942 RGS20.915 0.99 0.016 0.007 RETN 0.694 GLT25D1 0.77 0.842 0.031 0.044 PDE3B0.567 TAS2R31 0.833 0.891 0 0.03 SULF2 0.591 ZNF587_ZNF417 0.632 0.7590.017 0.005 NEK6_LOC1001290 0.671 OR9A2 0.823 0.878 0.001 0.045NEK6_LOC1001290 0.671 KCNMA1 0.707 0.815 0.013 0.013 NEK6_LOC10012900.671 PDK4 0.863 0.924 0 0.004 NEK6_LOC1001290 0.671 FABP2 0.744 0.8230.033 0.023 CENPK 0.834 GPR65 0.736 0.895 0.006 0.015 CENPK 0.834 DPH30.749 0.907 0.008 0.006 CENPK 0.834 NA 0.682 0.925 0.013 0 CENPK 0.834DLEU2_DLEU2L 0.711 0.92 0.022 0 CENPK 0.834 LHFP 0.731 0.86 0.048 0.036CENPK 0.834 MYL9 0.641 0.869 0.027 0.002 CENPK 0.834 SYNE2 0.748 0.9260.001 0.005 CENPK 0.834 FBXL13 0.795 0.912 0.019 0.015 CENPK 0.834CALM2_C2orf61 0.749 0.914 0.011 0.004 TRAF3 0.87 GPR65 0.736 0.966 0.0120 TRAF3 0.87 CCDC125 0.917 0.983 0.004 0.023 TRAF3 0.87 PDK4 0.863 0.9670.017 0.003 TRAF3 0.87 ZRANB1 0.897 0.97 0.005 0.02 GPR65 0.736HSP90AB1_HSP90A 0.924 0.975 0 0.021 GPR65 0.736 GLT25D1 0.77 0.866 0.010.016 GPR65 0.736 ITGA4_CERKL 0.88 0.969 0 0.015 GPR65 0.736EIF1AX_SCARNA9L 0.871 0.935 0 0.008 GPR65 0.736 ZNF28 0.837 0.916 00.019 GPR65 0.736 MGST3 0.857 0.934 0 0.022 GPR65 0.736 KIAA0746 0.7760.891 0.012 0.001 GPR65 0.736 HSPB1_HSPBL2 0.705 0.823 0.047 0.048 GPR650.736 CCR4 0.871 0.936 0.001 0.008 GPR65 0.736 FSD1L_GARNL1 0.779 0.8540.014 0.036 GPR65 0.736 CD151 0.718 0.843 0.044 0.004 GPR65 0.736IGK@_IGKC_IGKV 0.855 0.906 0.002 0.042 GPR65 0.736 C7orf58 0.831 0.9140.006 0.001 GPR65 0.736 NP 0.726 0.895 0.008 0.001 GPR65 0.736TMEM62_SPCS2_L 0.78 0.872 0.026 0.005 GPR65 0.736 TAS2R31 0.833 0.9020.005 0.005 GPR65 0.736 IGLV6-57 0.761 0.839 0.044 0.014 GPR65 0.736DCTN5 0.722 0.858 0.016 0.003 IRF4 0.946 HAL 0.942 0.989 0.036 0.016IRF4 0.946 CCDC125 0.917 0.995 0.02 0.008 IRF4 0.946 RGS2 0.915 0.990.045 0.003 AMFR 0.867 ACPL2 0.906 0.979 0.014 0.011 AMFR 0.867 ZRANB10.897 0.971 0.022 0.002 RPL17_SNORD58B 0.917 ACPL2 0.906 0.981 0.0130.029 RPL17_SNORD58B 0.917 OCR1 0.896 0.979 0.021 0.026 RPL17_SNORD58B0.917 NF-E4 0.861 0.977 0.034 0.003 RPL17_SNORD58B 0.917 KIAA1257_ACAD9/0.851 0.958 0.029 0.01 RPL17_SNORD58B 0.917 PDK4 0.863 0.978 0.022 0.003RPL17_SNORD58B 0.917 ZRANB1 0.897 0.969 0.041 0.024 RPL17_SNORD58B 0.917CYP4F3_CYP4F2 0.901 0.979 0.012 0.031 RPL17_SNORD58B 0.917 SYNE2 0.7480.967 0.01 0 RPL17_SNORD58B 0.917 MME 0.894 0.969 0.027 0.038RPL17_SNORD58B 0.917 FBXL13 0.795 0.966 0.044 0 RPL17_SNORD58B 0.917RBP7 0.848 0.971 0.007 0.007 RPL17_SNORD58B 0.917 CALM2_C2orf61 0.7490.998 0.013 0 IRS2 0.817 GLT25D1 0.77 0.925 0.02 0.007 IRS2 0.817 ZNF280.837 0.915 0.046 0.007 IRS2 0.817 TYMS 0.863 0.933 0.007 0.04 IRS20.817 HIST1H2BM 0.891 0.947 0.008 0.039 IRS2 0.817 ABCG1 0.85 0.9620.001 0.017 IRS2 0.817 HIST1H3B 0.89 0.958 0.01 0.002 IRS2 0.817HIST1H3H 0.861 0.937 0.039 0.001 IRS2 0.817 APOLD1 0.871 0.949 0.0120.004 IRS2 0.817 B4GALT3 0.917 0.963 0.005 0.025 IRS2 0.817 CDC26 0.7990.919 0.033 0.002 GALNT2 0.528 PDK4 0.863 0.911 0 0.002 HSP90AB1_HSP90A0.924 ACPL2 0.906 0.979 0.019 0.019 HSP90AB1_HSP90A 0.924 CCDC125 0.9170.994 0.008 0.009 HSP90AB1_HSP90A 0.924 PDK4 0.863 0.993 0.016 0.001HSP90AB1_HSP90A 0.924 ZRANB1 0.897 0.985 0.009 0.004 HSP90AB1_HSP90A0.924 MPZL3 0.892 0.979 0.009 0.015 HSP90AB1_HSP90A 0.924 PLIN2 0.7060.987 0.007 0 HSP90AB1_HSP90A 0.924 RGS2 0.915 0.973 0.006 0.046 GLT25D10.77 OR9A2 0.823 0.909 0.011 0.016 GLT25D1 0.77 KCNMA1 0.707 0.867 0.040.002 GLT25D1 0.77 PDK4 0.863 0.96 0.004 0 GLT25D1 0.77 THBS1 0.8490.918 0.026 0.002 GLT25D1 0.77 LHFP 0.731 0.839 0.044 0.021 GLT25D1 0.77CPM 0.854 0.92 0.022 0.014 GLT25D1 0.77 ATP6V0D1_LOC100 0.567 0.8510.006 0 GLT25D1 0.77 HIST2H2BF_HIST2 0.855 0.925 0.009 0.018 GLT25D10.77 SPATA6 0.812 0.916 0.025 0.004 OR9A2 0.823 EIF1AX_SCARNA9L 0.8710.933 0.006 0.039 OR9A2 0.823 ZNF28 0.837 0.904 0.025 0.016 OR9A2 0.823HIST1H3C 0.863 0.918 0.041 0.018 OR9A2 0.823 HIST1H3H 0.861 0.923 0.0180.007 OR9A2 0.823 S100B 0.841 0.919 0.019 0.033 OR9A2 0.823IGK@_IGKC_IGKV 0.855 0.914 0.009 0.046 OR9A2 0.823 C7orf58 0.831 0.9420.011 0.001 OR9A2 0.823 C4orf3 0.723 0.9 0.033 0.002 OR9A2 0.823 CDC260.799 0.901 0.004 0.025 OR9A2 0.823 TAS2R31 0.833 0.919 0.011 0.01 OR9A20.823 GLDC 0.714 0.882 0.045 0 ACPL2 0.906 CD300A 0.841 0.964 0.0280.001 ACPL2 0.906 MGST3 0.857 0.964 0.045 0.003 ACPL2 0.906 TYMS 0.8630.965 0.013 0.01 ACPL2 0.906 RRP12_LOC644215 0.904 0.976 0.01 0.035ACPL2 0.906 HIST1H2BM 0.891 0.975 0.012 0.023 ACPL2 0.906 ABCG1 0.850.979 0.007 0.005 ACPL2 0.906 HIST1H3B 0.89 0.985 0.011 0.006 ACPL20.906 FSD1L_GARNL1 0.779 0.956 0.012 0.001 ACPL2 0.906 APOLD1 0.8710.966 0.036 0.007 ACPL2 0.906 SON 0.856 0.973 0.044 0.003 ACPL2 0.906IRF1 0.82 0.979 0.014 0.001 ACPL2 0.906 B4GALT3 0.917 0.988 0.009 0.035ACPL2 0.906 TNFRSF17 0.875 0.978 0.021 0.004 ACPL2 0.906 CDC26 0.7990.983 0.01 0 LRRFIP1 0.678 ITGA4_CERKL 0.88 0.955 0 0.033 LRRFIP1 0.678SFRS9 0.558 0.746 0.047 0.033 LRRFIP1 0.678 NPCDR1 0.726 0.817 0.0250.023 LRRFIP1 0.678 P4HA1_RPL17 0.664 0.857 0.005 0 LRRFIP1 0.678 KLHL50.657 0.799 0.019 0.032 LRRFIP1 0.678 KIAA0746 0.776 0.9 0 0.004 LRRFIP10.678 E2F6 0.787 0.85 0.004 0.028 LRRFIP1 0.678 PYHIN1 0.686 0.803 0.0390.016 LRRFIP1 0.678 C7orf58 0.831 0.925 0 0.002 LRRFIP1 0.678TMEM62_SPCS2_L 0.78 0.884 0 0.048 LRRFIP1 0.678 TAS2R31 0.833 0.9 00.046 LRRFIP1 0.678 SDHC 0.736 0.822 0.022 0.023 LRRFIP1 0.678 NFXL10.728 0.834 0.004 0.029 KCNMA1 0.707 KIAA0746 0.776 0.843 0.006 0.033KCNMA1 0.707 HIST1H3C 0.863 0.897 0.002 0.032 KCNMA1 0.707 E2F6 0.7870.839 0.027 0.023 KCNMA1 0.707 CD151 0.718 0.832 0.027 0.006 KCNMA10.707 HIST1H3H 0.861 0.912 0.001 0.013 KCNMA1 0.707 C7orf58 0.831 0.9090 0.023 KCNMA1 0.707 NP 0.726 0.809 0.03 0.049 KCNMA1 0.707 C4orf3 0.7230.832 0.011 0.018 KCNMA1 0.707 IGLV6-57 0.761 0.868 0.003 0.005 KCNMA10.707 NFXL1 0.728 0.805 0.038 0.029 KCNMA1 0.707 GLDC 0.714 0.825 0.0240.007 KCNMA1 0.707 DCTN5 0.722 0.792 0.042 0.047 OCR1 0.896 ITGA4_CERKL0.88 0.964 0.006 0.044 OCR1 0.896 CCR4 0.871 0.978 0.029 0.004 OCR10.896 ABCG1 0.85 0.949 0.021 0.012 OCR1 0.896 IGK@_IGKC_IGKV 0.855 0.9570.049 0.005 OCR1 0.896 TNFRSF17 0.875 0.967 0.023 0.01 OCR1 0.896 CDC260.799 0.932 0.042 0.009 ITGA4_CERKL 0.88 KIAA1257_ACAD9/ 0.851 0.9440.029 0.007 ITGA4_CERKL 0.88 CCDC125 0.917 0.995 0.002 0.007 ITGA4_CERKL0.88 PDK4 0.863 0.985 0.006 0.001 ITGA4_CERKL 0.88 ZRANB1 0.897 0.9830.005 0.002 ITGA4_CERKL 0.88 ZNF587_ZNF417 0.632 0.957 0.025 0ITGA4_CERKL 0.88 CYP4F3_CYP4F2 0.901 0.965 0.05 0.014 ITGA4_CERKL 0.88SYNE2 0.748 0.986 0.005 0 ITGA4_CERKL 0.88 MME 0.894 0.965 0.038 0.006ITGA4_CERKL 0.88 PLIN2 0.706 0.953 0.024 0 ITGA4_CERKL 0.88 RBP7 0.8480.94 0.036 0.012 ITGA4_CERKL 0.88 SPATA6 0.812 0.942 0.038 0.006EIF1AX_SCARNA9L 0.871 DPH3 0.749 0.928 0.019 0.001 EIF1AX_SCARNA9L 0.871KIAA1257_ACAD9/ 0.851 0.935 0.004 0.034 EIF1AX_SCARNA9L 0.871 PDK4 0.8630.943 0.006 0.026 EIF1AX_SCARNA9L 0.871 THBS1 0.849 0.923 0.022 0.032EIF1AX_SCARNA9L 0.871 MYL9 0.641 0.908 0.036 0 EIF1AX_SCARNA9L 0.871SYNE2 0.748 0.934 0.006 0.001 EIF1AX_SCARNA9L 0.871 MME 0.894 0.96 0.0090.028 EIF1AX_SCARNA9L 0.871 RBP7 0.848 0.951 0.008 0.013 EIF1AX_SCARNA9L0.871 PLEKHF2 0.667 0.93 0.044 0 EIF1AX_SCARNA9L 0.871 CALM2_C2orf610.749 0.935 0.019 0 EIF1AX_SCARNA9L 0.871 SPATA6 0.812 0.926 0.013 0.019DPH3 0.749 ZNF28 0.837 0.932 0 0.026 DPH3 0.749 CCR4 0.871 0.913 0.0010.048 DPH3 0.749 HIST1H3B 0.89 0.957 0 0.034 DPH3 0.749 HIST1H3C 0.8630.921 0.002 0.014 DPH3 0.749 HIST1H3H 0.861 0.947 0 0.01 DPH3 0.749S100B 0.841 0.9 0.011 0.03 DPH3 0.749 NP 0.726 0.84 0.023 0.042 DPH30.749 TAS2R31 0.833 0.909 0.001 0.015 DPH3 0.749 KIAA0101_CSNK1G 0.7360.869 0.02 0.001 ERGIC1 0.886 CD300A 0.841 0.969 0.018 0.001 ERGIC10.886 TYMS 0.863 0.954 0.028 0.009 ERGIC1 0.886 RRP12_LOC644215 0.9040.981 0.013 0.012 ERGIC1 0.886 ABCG1 0.85 0.974 0.016 0.005 ERGIC1 0.886IRF1 0.82 0.967 0.011 0.001 ERGIC1 0.886 B4GALT3 0.917 0.976 0.015 0.044ERGIC1 0.886 CDC26 0.799 0.969 0.04 0 CD300A 0.841 HAL 0.942 0.992 00.019 CD300A 0.841 KIAA1257_ACAD9/ 0.851 0.941 0.019 0.002 CD300A 0.841CCDC125 0.917 0.969 0.001 0.018 CD300A 0.841 PDK4 0.863 0.941 0.0280.001 CD300A 0.841 ZRANB1 0.897 0.945 0.01 0.01 CD300A 0.841 MPZL3 0.8920.972 0 0.018 CD300A 0.841 KDM6B_TMEM88 0.869 0.967 0.004 0.014 CD300A0.841 CYP4F3_CYP4F2 0.901 0.948 0.011 0.046 CD300A 0.841 MME 0.894 0.9440.015 0.023 CD300A 0.841 RBP7 0.848 0.928 0.026 0.005 CD300A 0.841HIST2H2BF_HIST2 0.855 0.962 0.015 0.001 NF-E4 0.861 ZNF28 0.837 0.9490.01 0.006 NF-E4 0.861 CCR4 0.871 0.938 0.031 0.04 NF-E4 0.861 ABCG10.85 0.953 0.004 0.013 NF-E4 0.861 HIST1H3B 0.89 0.957 0.004 0.042 NF-E40.861 HIST1H3H 0.861 0.938 0.037 0.004 NF-E4 0.861 IRF1 0.82 0.929 0.0010.044 NF-E4 0.861 C7orf58 0.831 0.931 0.047 0.005 NF-E4 0.861 TNFRSF170.875 0.941 0.019 0.04 NF-E4 0.861 CDC26 0.799 0.938 0.001 0.012 NF-E40.861 TAS2R31 0.833 0.939 0.039 0.002 NF-E4 0.861 DCTN5 0.722 0.91 0.0390.001 MINPP1 0.7 DLEU2_DLEU2L 0.711 0.829 0.002 0.047 ZNF28 0.837DLEU2_DLEU2L 0.711 0.935 0.02 0 ZNF28 0.837 KIAA1257_ACAD9/ 0.851 0.9230.011 0.045 ZNF28 0.837 PDK4 0.863 0.939 0.009 0.012 ZNF28 0.837 THBS10.849 0.918 0.027 0.016 ZNF28 0.837 LHFP 0.731 0.887 0.029 0.004 ZNF280.837 ZRANB1 0.897 0.951 0.004 0.037 ZNF28 0.837 SYNE2 0.748 0.91 0.0430.001 ZNF28 0.837 MME 0.894 0.956 0.004 0.036 ZNF28 0.837 CPM 0.8540.916 0.027 0.047 ZNF28 0.837 RBP7 0.848 0.957 0.001 0.008 ZNF28 0.837CALM2_C2orf61 0.749 0.934 0.017 0 ZNF28 0.837 SPATA6 0.812 0.922 0.0070.02 NPCDR1 0.726 ZNF587_ZNF417 0.632 0.82 0.004 0.007 NA 0.682 PYHIN10.686 0.805 0.025 0.036 NA 0.682 SDHC 0.736 0.821 0.027 0.015 NA 0.682KIAA0101_CSNK1G 0.736 0.833 0.005 0.032 ICAM1 0.675 ATP6V0D1_LOC1000.567 0.788 0.003 0.01 P4HA1_RPL17 0.664 DLEU2_DLEU2L 0.711 0.822 0.0020.039 P4HA1_RPL17 0.664 PDK4 0.863 0.953 0 0.014 P4HA1_RPL17 0.664ZNF587_ZNF417 0.632 0.816 0.002 0.005 P4HA1_RPL17 0.664 PLEKHF2 0.6670.816 0.003 0.021 P4HA1_RPL17 0.664 IL1RL1 0.738 0.834 0.004 0.03C15orf54 0.72 DLEU2_DLEU2L 0.711 0.819 0.015 0.034 KLHL5 0.657ZNF587_ZNF417 0.632 0.787 0.006 0.016 HAL 0.942 ABCG1 0.85 0.99 0.0180.002 HAL 0.942 TIMM10 0.949 0.986 0.03 0.028 HAL 0.942 IRF1 0.82 0.9860.016 0 HAL 0.942 LASS4 0.924 0.982 0.01 0.045 HAL 0.942 B4GALT3 0.9170.989 0.019 0.02 HAL 0.942 CDC26 0.799 0.99 0.02 0 DLEU2_DLEU2L 0.711KIAA0746 0.776 0.85 0.007 0.046 DLEU2_DLEU2L 0.711 FSD1L_GARNL1 0.7790.879 0 0.043 DLEU2_DLEU2L 0.711 NA 0.7 0.865 0.023 0 DLEU2_DLEU2L 0.711HIST1H3C 0.863 0.918 0.001 0.035 DLEU2_DLEU2L 0.711 E2F6 0.787 0.8560.01 0.014 DLEU2_DLEU2L 0.711 HIST1H3H 0.861 0.934 0 0.023 DLEU2_DLEU2L0.711 C7orf58 0.831 0.9 0.001 0.017 DLEU2_DLEU2L 0.711 NP 0.726 0.8510.004 0.024 DLEU2_DLEU2L 0.711 PLEKHA3 0.645 0.868 0.002 0 DLEU2_DLEU2L0.711 TMEM62_SPCS2_L 0.78 0.865 0.006 0.049 DLEU2_DLEU2L 0.711 SDHC0.736 0.869 0.015 0 DLEU2_DLEU2L 0.711 NFXL1 0.728 0.825 0.019 0.021DLEU2_DLEU2L 0.711 KIAA0101_CSNK1G 0.736 0.863 0.003 0.005KIAA1257_ACAD9/ 0.851 ABCG1 0.85 0.963 0.001 0.01 KIAA1257_ACAD9/ 0.851HIST1H3B 0.89 0.943 0.017 0.048 KIAA1257_ACAD9/ 0.851 IGK@_IGKC_IGKV0.855 0.924 0.045 0.014 KIAA1257_ACAD9/ 0.851 SON 0.856 0.936 0.0450.014 KIAA1257_ACAD9/ 0.851 IRF1 0.82 0.941 0.001 0.016 KIAA1257_ACAD9/0.851 TNFRSF17 0.875 0.944 0.015 0.013 KIAA1257_ACAD9/ 0.851 CDC26 0.7990.941 0.003 0.004 MGST3 0.857 CCDC125 0.917 0.963 0.003 0.048 MGST30.857 PDK4 0.863 0.974 0.006 0.001 MGST3 0.857 ZRANB1 0.897 0.952 0.0070.021 MGST3 0.857 KDM6B_TMEM88 0.869 0.953 0.01 0.027 MGST3 0.857CYP4F3_CYP4F2 0.901 0.951 0.032 0.027 MGST3 0.857 RBP7 0.848 0.956 0.0050.004 KIAA0746 0.776 PDK4 0.863 0.963 0 0.007 KIAA0746 0.776ZNF587_ZNF417 0.632 0.893 0.001 0 KIAA0746 0.776 SYNE2 0.748 0.911 0.0020.004 KIAA0746 0.776 PLIN2 0.706 0.892 0.001 0.008 KIAA0746 0.776PLEKHF2 0.667 0.871 0.014 0.001 KIAA0746 0.776 IL1RL1 0.738 0.88 0.0340.003 KIAA0746 0.776 MPZL2 0.699 0.867 0.023 0.004 KIAA0746 0.776LOC100128751 0.686 0.864 0.02 0.006 KIAA0746 0.776 PPP1R2_PPP1R2P3 0.7020.903 0.002 0.001 HSPB1_HSPBL2 0.705 PDK4 0.863 0.905 0.001 0.03 CCR40.871 PDK4 0.863 0.966 0.012 0.004 CCR4 0.871 ZRANB1 0.897 0.97 0.0030.027 CCR4 0.871 ZNF587_ZNF417 0.632 0.931 0.033 0 CCR4 0.871 SYNE20.748 0.948 0.013 0 CCR4 0.871 MME 0.894 0.967 0.009 0.037 CCR4 0.871RBP7 0.848 0.929 0.018 0.047 CCR4 0.871 PPP1R2_PPP1R2P3 0.702 0.9390.035 0 TYMS 0.863 ZRANB1 0.897 0.961 0.005 0.01 TYMS 0.863CYP4F3_CYP4F2 0.901 0.947 0.049 0.031 TYMS 0.863 MME 0.894 0.954 0.0260.02 TYMS 0.863 CPM 0.854 0.934 0.049 0.013 TYMS 0.863 RBP7 0.848 0.9730.007 0 RRP12_LOC644215 0.904 CCDC125 0.917 0.967 0.019 0.028RRP12_LOC644215 0.904 MPZL3 0.892 0.983 0.005 0.009 RRP12_LOC6442150.904 KDM6B_TMEM88 0.869 0.976 0.017 0.015 RRP12_LOC644215 0.904 RGS20.915 0.971 0.011 0.044 CCDC125 0.917 ABCG1 0.85 0.987 0.009 0.001CCDC125 0.917 FAM118A 0.882 0.974 0.03 0.008 CCDC125 0.917 IRF1 0.820.987 0.007 0 CCDC125 0.917 B4GALT3 0.917 0.99 0.008 0.016 CCDC125 0.917TNFRSF17 0.875 0.981 0.032 0.002 CCDC125 0.917 CDC26 0.799 0.959 0.034 0CCDC125 0.917 DCTN5 0.722 0.969 0.039 0 HIST1H2BM 0.891 ZRANB1 0.8970.976 0.014 0.006 HIST1H2BM 0.891 MME 0.894 0.963 0.03 0.027 HIST1H2BM0.891 RBP7 0.848 0.966 0.03 0.001 PDK4 0.863 LAIR1_LAIR2 0.607 0.9320.033 0 PDK4 0.863 HIST1H3B 0.89 0.946 0.015 0.039 PDK4 0.863FSD1L_GARNL1 0.779 0.941 0.002 0.003 PDK4 0.863 CD151 0.718 0.932 0.0360 PDK4 0.863 IGK@_IGKC_IGKV 0.855 0.955 0.009 0.006 PDK4 0.863 SON 0.8560.948 0.008 0.018 PDK4 0.863 IRF1 0.82 0.941 0.001 0.018 PDK4 0.863C7orf58 0.831 0.97 0.009 0 PDK4 0.863 CTSL1_CTSLL3 0.676 0.929 0.038 0PDK4 0.863 NP 0.726 0.947 0.014 0 PDK4 0.863 TNFRSF17 0.875 0.938 0.0180.049 PDK4 0.863 TMEM62_SPCS2_L 0.78 0.966 0.015 0 PDK4 0.863 CDC260.799 0.942 0.004 0.002 PDK4 0.863 TAS2R31 0.833 0.952 0.016 0.001 PDK40.863 NFXL1 0.728 0.946 0.039 0 PDK4 0.863 DCTN5 0.722 0.955 0.004 0ABCG1 0.85 ZRANB1 0.897 0.944 0.018 0.019 ABCG1 0.85 CYP4F3_CYP4F2 0.9010.965 0.008 0.026 ABCG1 0.85 MME 0.894 0.969 0.006 0.013 ABCG1 0.85 RBP70.848 0.963 0.009 0.001 THBS1 0.849 HIST1H3B 0.89 0.96 0.002 0.028 THBS10.849 FSD1L_GARNL1 0.779 0.909 0.008 0.015 THBS1 0.849 PTGS1 0.675 0.930.012 0 THBS1 0.849 HIST1H3C 0.863 0.936 0.023 0.011 THBS1 0.849HIST1H3H 0.861 0.941 0.011 0.012 THBS1 0.849 IGK@_IGKC_IGKV 0.855 0.9280.021 0.028 THBS1 0.849 SON 0.856 0.926 0.031 0.042 THBS1 0.849 C4orf30.723 0.911 0.027 0.001 THBS1 0.849 CDC26 0.799 0.919 0.005 0.015 THBS10.849 DCTN5 0.722 0.894 0.03 0.002 ITGA2B 0.58 MYL9 0.641 0.819 0 0.023LHFP 0.731 HIST1H3B 0.89 0.929 0 0.02 LHFP 0.731 HIST1H3C 0.863 0.9030.005 0.009 LHFP 0.731 HIST1H3H 0.861 0.907 0.003 0.012 LHFP 0.731APOLD1 0.871 0.937 0 0.009 LHFP 0.731 IGLV6-57 0.761 0.864 0.036 0LAIR1_LAIR2 0.607 PLIN2 0.706 0.827 0.002 0.037 HIST1H3B 0.89 ZRANB10.897 0.959 0.024 0.037 HIST1H3B 0.89 MYL9 0.641 0.948 0.029 0 HIST1H3B0.89 CPM 0.854 0.946 0.026 0.018 HIST1H3B 0.89 RBP7 0.848 0.97 0.0030.004 HIST1H3B 0.89 CALM2_C2orf61 0.749 0.959 0.022 0 HIST1H3B 0.89SPATA6 0.812 0.939 0.043 0.011 ZRANB1 0.897 FAM118A 0.882 0.975 0.0120.007 ZRANB1 0.897 IRF1 0.82 0.954 0.011 0.004 ZRANB1 0.897 B4GALT30.917 0.982 0.002 0.046 ZRANB1 0.897 NP 0.726 0.955 0.036 0 ZRANB1 0.897TNFRSF17 0.875 0.959 0.028 0.006 ZRANB1 0.897 CDC26 0.799 0.95 0.0160.001 TIMM10 0.949 MPZL3 0.892 0.983 0.03 0.006 TIMM10 0.949 RBP7 0.8480.985 0.045 0.001 TIMM10 0.949 RGS2 0.915 0.981 0.04 0.008 FSD1L_GARNL10.779 CPM 0.854 0.909 0.014 0.033 FSD1L_GARNL1 0.779 HIST2H2BF_HIST20.855 0.917 0.005 0.041 FSD1L_GARNL1 0.779 SPATA6 0.812 0.913 0.0130.004 HIST1H2AJ_HIST1 0.77 NA 0.627 0.824 0.021 0.005 PTGS1 0.675 MYL90.641 0.933 0 0 PTGS1 0.675 SPARC 0.574 0.854 0.018 0 NA 0.7ZNF587_ZNF417 0.632 0.771 0.017 0.046 NA 0.7 PLEKHF2 0.667 0.873 0 0.005HIST1H3C 0.863 MYL9 0.641 0.918 0.005 0 HIST1H3C 0.863 CALM2_C2orf610.749 0.922 0.015 0.004 E2F6 0.787 ZNF587_ZNF417 0.632 0.838 0.024 0.002E2F6 0.787 IL1RL1 0.738 0.859 0.016 0.019 E2F6 0.787 MPZL2 0.699 0.8440.021 0.015 E2F6 0.787 CALM2_C2orf61 0.749 0.896 0 0.013 MPZL3 0.892LASS4 0.924 0.987 0.004 0.015 MPZL3 0.892 B4GALT3 0.917 0.96 0.044 0.019SRXN1 0.513 HIST1H3H 0.861 0.918 0 0.013 SRXN1 0.513 POLE2 0.694 0.7430.013 0.035 CD151 0.718 ATP6V0D1_LOC100 0.567 0.77 0.048 0.024 HIST1H3H0.861 MYL9 0.641 0.944 0.002 0 HIST1H3H 0.861 RBP7 0.848 0.948 0.0010.029 HIST1H3H 0.861 CALM2_C2orf61 0.749 0.93 0.015 0.001 HIST1H3H 0.861SPATA6 0.812 0.923 0.002 0.045 FSD1L 0.674 IL1RL1 0.738 0.82 0.016 0.041S100B 0.841 SYNE2 0.748 0.898 0.035 0.014 S100B 0.841 LOC100128751 0.6860.898 0.04 0 S100B 0.841 CALM2_C2orf61 0.749 0.895 0.026 0.017ZNF587_ZNF417 0.632 PYHIN1 0.686 0.804 0.015 0.009 ZNF587_ZNF417 0.632IGK@_IGKC_IGKV 0.855 0.915 0 0.027 ZNF587_ZNF417 0.632 TSHZ2 0.733 0.8190.007 0.021 ZNF587_ZNF417 0.632 TMEM62_SPCS2_L 0.78 0.873 0 0.018ZNF587_ZNF417 0.632 NFXL1 0.728 0.841 0.001 0.005 ZNF587_ZNF417 0.632DCTN5 0.722 0.875 0 0.006 PYHIN1 0.686 SYNE2 0.748 0.956 0 0 PYHIN10.686 PPP1R2_PPP1R2P3 0.702 0.847 0.001 0.03 APOLD1 0.871 RBP7 0.8480.948 0.033 0.001 FABP2 0.744 TAS2R31 0.833 0.88 0.01 0.05 FABP2 0.744IGLV6-57 0.761 0.866 0.018 0.004 KDM6B_TMEM88 0.869 IRF1 0.82 0.956 0.030.001 IGK@_IGKC_IGKV 0.855 SYNE2 0.748 0.923 0.036 0 IGK@_IGKC_IGKV0.855 MME 0.894 0.944 0.018 0.046 IGK@_IGKC_IGKV 0.855 PLIN2 0.706 0.9110.039 0.001 IGK@_IGKC_IGKV 0.855 LOC100128751 0.686 0.916 0.044 0IGK@_IGKC_IGKV 0.855 HIST2H2BF_HIST2 0.855 0.934 0.029 0.017 MYL9 0.641HIST1H2BJ 0.703 0.815 0.02 0.005 MYL9 0.641 CMTM5 0.671 0.872 0.0010.001 MYL9 0.641 SDHC 0.736 0.793 0.039 0.031 MYL9 0.641 KIAA0101_CSNK1G0.736 0.82 0.01 0.008 CLC 0.782 PLIN2 0.706 0.901 0.003 0.013 CLC 0.782IL1RL1 0.738 0.93 0.015 0 CYP4F3_CYP4F2 0.901 IRF1 0.82 0.96 0.019 0.009CYP4F3_CYP4F2 0.901 CDC26 0.799 0.952 0.026 0.004 SON 0.856 SYNE2 0.7480.938 0.009 0.001 SON 0.856 RBP7 0.848 0.966 0.007 0.006 IRF1 0.82 MME0.894 0.947 0.017 0.008 IRF1 0.82 RBP7 0.848 0.944 0.007 0.002 IRF1 0.82RGS2 0.915 0.975 0 0.03 IRF1 0.82 HIST2H2BF_HIST2 0.855 0.951 0.0190.001 SYNE2 0.748 C7orf58 0.831 0.912 0.003 0.017 SYNE2 0.748 NP 0.7260.883 0.008 0.004 SYNE2 0.748 TMEM62_SPCS2_L 0.78 0.919 0.002 0 SYNE20.748 TAS2R31 0.833 0.938 0.001 0 SYNE2 0.748 NFXL1 0.728 0.881 0.0090.001 SYNE2 0.748 DCTN5 0.722 0.893 0.002 0.004 MME 0.894 TNFRSF17 0.8750.96 0.007 0.029 MME 0.894 CDC26 0.799 0.939 0.014 0.007 C7orf58 0.831FBXL13 0.795 0.897 0.045 0.019 C7orf58 0.831 PLEKHF2 0.667 0.895 0.046 0C7orf58 0.831 IL1RL1 0.738 0.898 0.042 0.003 C7orf58 0.831 AIF1 0.6180.918 0.004 0 C7orf58 0.831 PPP1R2_PPP1R2P3 0.702 0.898 0.016 0.002C7orf58 0.831 HIST2H2BF_HIST2 0.855 0.961 0 0.022 C7orf58 0.831 SPATA60.812 0.92 0.001 0.049 CPM 0.854 CDC26 0.799 0.931 0.01 0.01 TSHZ2 0.733LOC100128751 0.686 0.824 0.036 0.042 TSHZ2 0.733 PPP1R2_PPP1R2P3 0.7020.83 0.045 0.044 PLIN2 0.706 NP 0.726 0.836 0.009 0.04 PLIN2 0.706TMEM62_SPCS2_L 0.78 0.918 0.003 0.003 PLIN2 0.706 DCTN5 0.722 0.8610.005 0.011 B4GALT3 0.917 RBP7 0.848 0.981 0.045 0.001 B4GALT3 0.917RGS2 0.915 0.987 0.009 0.012 NP 0.726 FBXL13 0.795 0.857 0.009 0.05TNFRSF17 0.875 RBP7 0.848 0.934 0.013 0.048 FBXL13 0.795 TAS2R31 0.8330.92 0.003 0.019 FBXL13 0.795 DCTN5 0.722 0.859 0.032 0.018 PLEKHA30.645 PLEKHF2 0.667 0.781 0.045 0.029 TMEM62_SPCS2_L 0.78 PLEKHF2 0.6670.859 0.042 0.002 TMEM62_SPCS2_L 0.78 PPP1R2_PPP1R2P3 0.702 0.877 0.0150.002 TMEM62_SPCS2_L 0.78 CALM2_C2orf61 0.749 0.889 0.02 0.014 RBP70.848 CDC26 0.799 0.964 0.001 0.001 RBP7 0.848 TAS2R31 0.833 0.936 0.0460.001 PLEKHF2 0.667 SDHC 0.736 0.842 0.021 0.001 PLEKHF2 0.667 NFXL10.728 0.814 0.012 0.027 RGS2 0.915 CDC26 0.799 0.975 0.019 0 IL1RL10.738 IL5RA 0.782 0.975 0 0.002 IL1RL1 0.738 TAS2R31 0.833 0.928 0 0.019IL1RL1 0.738 KIAA0101_CSNK1G 0.736 0.829 0.029 0.03 AIF1 0.618 SDHC0.736 0.801 0.023 0.017 MPZL2 0.699 NFXL1 0.728 0.814 0.034 0.029 MPZL20.699 DCTN5 0.722 0.845 0.002 0.028 CDC26 0.799 HIST2H2BF_HIST2 0.8550.94 0.012 0.001 CDC26 0.799 SPATA6 0.812 0.923 0.012 0.004PPP1R2_PPP1R2P3 0.702 NFXL1 0.728 0.835 0.03 0.009 TAS2R31 0.833HIST2H2BF_HIST2 0.855 0.926 0.012 0.019 TAS2R31 0.833 CALM2_C2orf610.749 0.896 0.037 0.003 CALM2_C2orf61 0.749 IGLV6-57 0.761 0.852 0.010.034 CALM2_C2orf61 0.749 SDHC 0.736 0.879 0.05 0 CALM2_C2orf61 0.749KIAA0101_CSNK1G 0.736 0.903 0.003 0

TABLE 17 Ratios Healthy Versus ipSIRS Ratio Signif Ratio Signif Gene 1Name Gene 1 AUC Gene 2 Name Gene 2 AUC Ratio AUC to Gene 1 to Gene 2VNN1 0.933 GNLY 0.917 0.986 0.042 0.019 VNN1 0.933 PTGDR 0.919 0.9910.043 0.013 VNN1 0.933 SH2D1B 0.867 0.986 0.046 0.005 VNN1 0.933HIST1H4C 0.859 0.976 0.041 0.008 VNN1 0.933 VAMP2 0.673 0.963 0.029 0VNN1 0.933 MRPL41 0.811 0.985 0.039 0 VNN1 0.933 CASS4 0.877 0.981 0.0370.006 VNN1 0.933 ITK 0.899 0.991 0.034 0.004 VNN1 0.933 B3GAT3 0.7830.975 0.05 0 VNN1 0.933 HIST1H4E 0.83 0.978 0.027 0.002 VNN1 0.933CHI3L1 0.909 0.985 0.043 0.047 VNN1 0.933 RUNX2 0.848 0.982 0.023 0.004VNN1 0.933 DNAJC9_FAM149B1 0.811 0.99 0.048 0 VNN1 0.933 PDE3B 0.850.978 0.031 0.005 VNN1 0.933 IRF4 0.781 0.97 0.031 0.001 VNN1 0.933LY6G5B_CSNK2B 0.661 0.979 0.029 0 VNN1 0.933 KIAA0746 0.544 0.985 0.0440 VNN1 0.933 CCR4 0.784 0.972 0.05 0 VNN1 0.933 MME 0.507 0.98 0.05 0VNN1 0.933 TSHZ2 0.801 0.973 0.035 0.001 VNN1 0.933 RASA4_RASA4P_R 0.7790.969 0.045 0 VNN1 0.933 RGS2 0.605 0.975 0.034 0 IMP3 0.942 OMG 0.960.997 0.019 0.031 IMP3 0.942 SLC37A3 0.885 0.99 0.05 0.007 IMP3 0.942IL18R1 0.933 0.993 0.026 0.013 IMP3 0.942 ERLIN1 0.937 0.989 0.04 0.023IMP3 0.942 C7orf53 0.921 0.99 0.024 0.008 IMP3 0.942 DSE 0.936 0.9940.02 0.038 IMP3 0.942 DNAJC13 0.948 0.998 0.021 0.038 IMP3 0.942 GSR0.831 0.981 0.045 0 IMP3 0.942 B3GNT5_MCF2L2 0.956 0.997 0.018 0.026IMP3 0.942 PICALM 0.879 0.992 0.021 0.003 IMP3 0.942 METTL7B 0.943 0.990.022 0.035 IMP3 0.942 IFI16 0.912 0.984 0.033 0.011 IMP3 0.942 JKAMP0.93 1 0.021 0.008 IMP3 0.942 WSB2 0.911 0.995 0.024 0.003 IMP3 0.942CLU 0.894 0.979 0.041 0.006 IMP3 0.942 CD63 0.757 0.999 0.022 0 IMP30.942 HPSE 0.939 0.997 0.023 0.007 IMP3 0.942 DDAH2 0.886 0.984 0.0160.017 IMP3 0.942 ATP13A3 0.841 0.985 0.039 0.004 IMP3 0.942 LRRC70_IPO110.923 0.995 0.023 0.009 IMP3 0.942 CDS2 0.869 0.982 0.022 0.007 IMP30.942 OLAH 0.885 0.981 0.036 0.008 IMP3 0.942 EAF2_HCG11_LOC 0.917 0.9860.032 0.029 IMP3 0.942 EXOSC4 0.731 0.977 0.031 0 IMP3 0.942 FOLR3_FOLR20.848 0.992 0.046 0 IMP3 0.942 LGALS1 0.736 0.99 0.028 0 IMP3 0.942 SIAE0.814 0.984 0.03 0 IMP3 0.942 EFCAB2 0.96 0.989 0.04 0.03 IMP3 0.942AGTRAP 0.856 0.989 0.025 0.001 IMP3 0.942 SUCNR1 0.922 0.996 0.029 0.005IMP3 0.942 AIG1 0.842 0.986 0.042 0.001 IMP3 0.942 HS2ST1_UBA2 0.7580.977 0.035 0 IMP3 0.942 VOPP1_LOC100128 0.618 0.98 0.037 0 IMP3 0.942CLEC4A 0.87 0.985 0.044 0.002 IMP3 0.942 TRIM21 0.874 0.989 0.026 0.004IMP3 0.942 MGST3 0.602 0.988 0.038 0 IMP3 0.942 ATP6V0D1_LOC100 0.8560.978 0.016 0.008 IMP3 0.942 CALM2_C2orf61 0.733 0.99 0.026 0 CLEC4D0.976 CASS4 0.877 0.996 0.048 0.001 GPR56 0.933 FAR2 0.963 0.998 0.0070.042 GPR56 0.933 CLEC4E 0.883 0.982 0.03 0.003 GPR56 0.933 IL18R1 0.9330.98 0.048 0.014 GPR56 0.933 ERLIN1 0.937 0.996 0.007 0.031 GPR56 0.933C7orf53 0.921 0.984 0.018 0.012 GPR56 0.933 DSE 0.936 0.972 0.043 0.037GPR56 0.933 DNAJC13 0.948 0.981 0.034 0.033 GPR56 0.933 FOXD4L3_FOXD4L60.892 0.981 0.041 0.004 GPR56 0.933 GSR 0.831 0.977 0.021 0.001 GPR560.933 PICALM 0.879 0.968 0.03 0.012 GPR56 0.933 IFI16 0.912 0.983 0.0110.012 GPR56 0.933 JKAMP 0.93 0.984 0.004 0.043 GPR56 0.933 WSB2 0.9110.978 0.007 0.019 GPR56 0.933 CLU 0.894 0.975 0.02 0.006 GPR56 0.933HPSE 0.939 0.986 0.007 0.023 GPR56 0.933 LRRC70_IPO11 0.923 0.975 0.0350.025 GPR56 0.933 CDS2 0.869 0.97 0.011 0.016 GPR56 0.933 OLAH 0.8850.976 0.023 0.01 GPR56 0.933 RCBTB2_LOC10013 0.905 0.972 0.038 0.016GPR56 0.933 SIAE 0.814 0.968 0.049 0 GPR56 0.933 AP3B2 0.887 0.961 0.0440.028 GPR56 0.933 SUCNR1 0.922 0.976 0.022 0.023 GPR56 0.933 ACTA2 0.7830.977 0.042 0 GPR56 0.933 KCNMA1 0.897 0.975 0.02 0.03 GPR56 0.933TRIM21 0.874 0.986 0.011 0.006 GPR56 0.933 ICAM1 0.821 0.971 0.028 0.002GPR56 0.933 ATP6V0D1_LOC100 0.856 0.968 0.005 0.019 ARG1 0.922 HIST1H4C0.859 0.968 0.043 0.021 ARG1 0.922 VAMP2 0.673 0.944 0.049 0 ARG1 0.922MRPL41 0.811 0.978 0.046 0.001 ARG1 0.922 HIST1H4E 0.83 0.963 0.04 0.01ARG1 0.922 RUNX2 0.848 0.961 0.04 0.026 ARG1 0.922 HIST1H3A 0.715 0.9670.043 0 ARG1 0.922 IRF4 0.781 0.952 0.05 0.006 ARG1 0.922 IRS2 0.6480.954 0.048 0 FAR2 0.963 CAMK4 0.953 0.998 0.041 0.04 FAR2 0.963 CASS40.877 0.998 0.037 0 FAR2 0.963 RUNX2 0.848 0.996 0.043 0 FAR2 0.963PDE3B 0.85 0.997 0.041 0 GNLY 0.917 SLC37A3 0.885 0.983 0.02 0.01 GNLY0.917 CLEC4E 0.883 0.977 0.03 0.003 GNLY 0.917 IL18R1 0.933 0.981 0.0180.027 GNLY 0.917 ERLIN1 0.937 0.978 0.041 0.01 GNLY 0.917 C7orf53 0.9210.983 0.01 0.009 GNLY 0.917 DSE 0.936 0.983 0.019 0.017 GNLY 0.917DNAJC13 0.948 0.986 0.02 0.015 GNLY 0.917 FOXD4L3_FOXD4L6 0.892 0.9770.042 0.004 GNLY 0.917 B3GNT5_MCF2L2 0.956 0.992 0.004 0.029 GNLY 0.917PICALM 0.879 0.974 0.015 0.007 GNLY 0.917 TLR10 0.905 0.974 0.023 0.007GNLY 0.917 IFI16 0.912 0.984 0.008 0.005 GNLY 0.917 JKAMP 0.93 0.9930.004 0.013 GNLY 0.917 WSB2 0.911 0.987 0.004 0.007 GNLY 0.917 CLU 0.8940.975 0.01 0.007 GNLY 0.917 HPSE 0.939 0.993 0.006 0.008 GNLY 0.917LRRC70_IPO11 0.923 0.988 0.007 0.01 GNLY 0.917 CDS2 0.869 0.959 0.0090.029 GNLY 0.917 OLAH 0.885 0.974 0.008 0.01 GNLY 0.917 EAF2_HCG11_LOC0.917 0.975 0.046 0.02 GNLY 0.917 RCBTB2_LOC10013 0.905 0.967 0.0240.016 GNLY 0.917 FOLR3_FOLR2 0.848 0.98 0.014 0.001 GNLY 0.917 SIAE0.814 0.972 0.023 0 GNLY 0.917 AP3B2 0.887 0.947 0.046 0.048 GNLY 0.917ABCA13 0.868 0.976 0.032 0.001 GNLY 0.917 CDA 0.804 0.97 0.04 0 GNLY0.917 SAP30 0.728 0.952 0.011 0 GNLY 0.917 AGTRAP 0.856 0.969 0.0040.005 GNLY 0.917 SUCNR1 0.922 0.987 0.012 0.008 GNLY 0.917 KCNMA1 0.8970.964 0.015 0.044 GNLY 0.917 TRIM21 0.874 0.972 0.026 0.007 GNLY 0.917DLEU2_DLEU2L 0.874 0.966 0.036 0.002 GNLY 0.917 ANKRD28 0.8 0.977 0.0390 GNLY 0.917 ATP6V0D1_LOC100 0.856 0.953 0.021 0.029 OMG 0.96 PTGDR0.919 0.998 0.026 0.01 OMG 0.96 CAMK4 0.953 0.997 0.034 0.042 OMG 0.96LRRN3 0.947 0.998 0.023 0.033 OMG 0.96 PDE3B 0.85 0.997 0.028 0.001SLC37A3 0.885 PTGDR 0.919 0.979 0.022 0.021 SLC37A3 0.885 VAMP2 0.6730.941 0.018 0 SLC37A3 0.885 MRPL41 0.811 0.958 0.046 0.001 SLC37A3 0.885CASS4 0.877 0.972 0.01 0.013 SLC37A3 0.885 ITK 0.899 0.985 0.011 0.004SLC37A3 0.885 GOT2 0.905 0.975 0.01 0.034 SLC37A3 0.885 B3GAT3 0.7830.961 0.021 0 SLC37A3 0.885 HIST1H4E 0.83 0.968 0.014 0.002 SLC37A30.885 ANAPC11 0.818 0.954 0.035 0.002 SLC37A3 0.885 RUNX2 0.848 0.9690.01 0.007 SLC37A3 0.885 PMS2CL_PMS2 0.685 0.948 0.043 0 SLC37A3 0.885PDE3B 0.85 0.975 0.008 0.007 SLC37A3 0.885 SFRS9 0.527 0.942 0.027 0SLC37A3 0.885 NPCDR1 0.86 0.954 0.035 0.006 SLC37A3 0.885 LY6G5B_CSNK2B0.661 0.965 0.014 0 SLC37A3 0.885 CCR4 0.784 0.945 0.043 0.001 SLC37A30.885 LASS4 0.794 0.951 0.021 0.009 SLC37A3 0.885 TSHZ2 0.801 0.9550.023 0.002 SLC37A3 0.885 CAMK1D 0.702 0.949 0.03 0 BMX_HNRPDL 0.947GOT2 0.905 0.988 0.05 0.018 BMX_HNRPDL 0.947 ABCG1 0.789 0.965 0.0450.003 FAIM3 0.938 C7orf53 0.921 0.98 0.044 0.047 FAIM3 0.938 SLC15A20.824 0.992 0.046 0 FAIM3 0.938 IFI16 0.912 0.977 0.037 0.05 FAIM3 0.938WSB2 0.911 0.985 0.045 0.02 FAIM3 0.938 HPSE 0.939 0.989 0.042 0.04FAIM3 0.938 HS2ST1_UBA2 0.758 0.969 0.025 0.001 FAIM3 0.938 KLHL5 0.8260.972 0.043 0.002 CLEC4E 0.883 PTGDR 0.919 0.963 0.022 0.032 CLEC4E0.883 KLRF1 0.872 0.959 0.048 0 CLEC4E 0.883 CASS4 0.877 0.976 0.0010.008 CLEC4E 0.883 ITK 0.899 0.98 0.005 0.003 CLEC4E 0.883 GOT2 0.9050.96 0.018 0.038 CLEC4E 0.883 HIST1H4E 0.83 0.942 0.022 0.007 CLEC4E0.883 CCR3 0.905 0.953 0.02 0.04 CLEC4E 0.883 CHI3L1 0.909 0.987 0.0060.019 CLEC4E 0.883 GIMAP7 0.755 0.946 0.033 0 CLEC4E 0.883 RUNX2 0.8480.969 0.003 0.005 CLEC4E 0.883 PHOSPHO1 0.85 0.947 0.009 0.025 CLEC4E0.883 PDE3B 0.85 0.979 0.002 0.004 CLEC4E 0.883 SULF2 0.819 0.948 0.0410.003 CLEC4E 0.883 IRS2 0.648 0.946 0.009 0 CLEC4E 0.883 NPCDR1 0.860.946 0.031 0.004 CLEC4E 0.883 CCR4 0.784 0.949 0.028 0 CLEC4E 0.883ABCG1 0.789 0.937 0.026 0.008 CLEC4E 0.883 LASS4 0.794 0.919 0.036 0.031CLEC4E 0.883 TSHZ2 0.801 0.965 0.005 0.001 CLEC4E 0.883 CAMK1D 0.7020.947 0.023 0 IL18R1 0.933 LRRN3 0.947 0.997 0.01 0.036 IL18R1 0.933VAMP2 0.673 0.962 0.036 0 IL18R1 0.933 CASS4 0.877 0.979 0.008 0.003IL18R1 0.933 ITK 0.899 0.995 0.013 0.002 IL18R1 0.933 B3GAT3 0.783 0.9840.017 0 IL18R1 0.933 HIST1H4E 0.83 0.967 0.042 0.002 IL18R1 0.933 GIMAP70.755 0.974 0.017 0 IL18R1 0.933 RUNX2 0.848 0.972 0.037 0.002 IL18R10.933 PMS2CL_PMS2 0.685 0.979 0.027 0 IL18R1 0.933 PDE3B 0.85 0.9880.007 0.002 IL18R1 0.933 IRS2 0.648 0.958 0.034 0 IL18R1 0.933KIAA1257_ACAD9/ 0.496 0.976 0.016 0 IL18R1 0.933 CCR4 0.784 0.976 0.0130 IL18R1 0.933 RRP12_LOC644215 0.632 0.957 0.047 0 IL18R1 0.933 ABCG10.789 0.965 0.016 0.003 IL18R1 0.933 TSHZ2 0.801 0.975 0.026 0 ERLIN10.937 LRRN3 0.947 0.995 0.017 0.049 ERLIN1 0.937 CASS4 0.877 0.992 0.0280.001 ERLIN1 0.937 ITK 0.899 0.991 0.028 0.003 ERLIN1 0.937 B3GAT3 0.7830.979 0.036 0 ERLIN1 0.937 RUNX2 0.848 0.963 0.044 0.008 ERLIN1 0.937PDE3B 0.85 0.987 0.016 0.002 ERLIN1 0.937 LASS4 0.794 0.957 0.05 0.005ERLIN1 0.937 TSHZ2 0.801 0.98 0.012 0 FKBP5_LOC285847 0.841 KLRF1 0.8720.935 0.022 0.005 FKBP5_LOC285847 0.841 SH2D1B 0.867 0.928 0.041 0.029FKBP5_LOC285847 0.841 VAMP2 0.673 0.894 0.028 0.001 FKBP5_LOC2858470.841 KLRK1_KLRC4 0.857 0.914 0.045 0.042 FKBP5_LOC285847 0.841 ITK0.899 0.967 0.002 0.021 FKBP5_LOC285847 0.841 B3GAT3 0.783 0.908 0.0240.012 FKBP5_LOC285847 0.841 GIMAP7 0.755 0.911 0.016 0.003FKBP5_LOC285847 0.841 NA 0.696 0.902 0.039 0.001 FKBP5_LOC285847 0.841PLA2G7 0.834 0.923 0.046 0.011 FKBP5_LOC285847 0.841 PMS2CL_PMS2 0.6850.902 0.029 0 FKBP5_LOC285847 0.841 PDE3B 0.85 0.957 0.001 0.017FKBP5_LOC285847 0.841 SULF2 0.819 0.913 0.043 0.036 FKBP5_LOC2858470.841 IRS2 0.648 0.903 0.012 0.001 FKBP5_LOC285847 0.841 NPCDR1 0.860.941 0.003 0.012 FKBP5_LOC285847 0.841 LY6G5B_CSNK2B 0.661 0.915 0.0130 FKBP5_LOC285847 0.841 CCR4 0.784 0.909 0.016 0.008 FKBP5_LOC2858470.841 ABCG1 0.789 0.915 0.003 0.042 FKBP5_LOC285847 0.841 FAM118A 0.7590.901 0.021 0.01 FKBP5_LOC285847 0.841 PYHIN1 0.807 0.922 0.033 0.006FKBP5_LOC285847 0.841 NA 0.746 0.915 0.048 0 FKBP5_LOC285847 0.841 TSHZ20.801 0.944 0.002 0.004 FKBP5_LOC285847 0.841 RASA4_RASA4P_R 0.779 0.8940.049 0.008 FKBP5_LOC285847 0.841 CAMK1D 0.702 0.921 0.007 0FKBP5_LOC285847 0.841 CFD 0.767 0.911 0.048 0.003 C7orf53 0.921 PTGDR0.919 0.979 0.04 0.006 C7orf53 0.921 CAMK4 0.953 0.997 0.006 0.045C7orf53 0.921 LRRN3 0.947 0.992 0.005 0.045 C7orf53 0.921 CASS4 0.8770.999 0.004 0 C7orf53 0.921 ITK 0.899 0.987 0.014 0.002 C7orf53 0.921GOT2 0.905 0.976 0.039 0.008 C7orf53 0.921 HIST1H4E 0.83 0.967 0.040.001 C7orf53 0.921 CCR3 0.905 0.967 0.042 0.006 C7orf53 0.921 CHI3L10.909 0.978 0.023 0.026 C7orf53 0.921 RUNX2 0.848 0.994 0.007 0 C7orf530.921 PDE3B 0.85 0.996 0.005 0.001 C7orf53 0.921 NPCDR1 0.86 0.969 0.0370.001 C7orf53 0.921 LY6G5B_CSNK2B 0.661 0.973 0.044 0 C7orf53 0.921KIAA1257_ACAD9/ 0.496 0.98 0.022 0 C7orf53 0.921 CCR4 0.784 0.976 0.0330 C7orf53 0.921 ABCG1 0.789 0.965 0.028 0.001 C7orf53 0.921 TSHZ2 0.8010.974 0.035 0 C7orf53 0.921 CAMK1D 0.702 0.978 0.033 0 PLB1 0.938 RUNX20.848 0.989 0.034 0.002 PLB1 0.938 PDE3B 0.85 0.975 0.046 0.005 DSE0.936 CAMK4 0.953 0.999 0.031 0.04 DSE 0.936 LRRN3 0.947 0.993 0.0450.033 DSE 0.936 CASS4 0.877 0.974 0.013 0.008 DSE 0.936 RUNX2 0.8480.974 0.019 0.004 DSE 0.936 PDE3B 0.85 0.974 0.019 0.006 DSE 0.936LY6G5B_CSNK2B 0.661 0.972 0.039 0 PTGDR 0.919 FOXD4L3_FOXD4L6 0.8920.991 0.019 0.006 PTGDR 0.919 SGMS2 0.859 0.971 0.038 0.005 PTGDR 0.919PICALM 0.879 0.983 0.006 0.008 PTGDR 0.919 TLR10 0.905 0.972 0.021 0.022PTGDR 0.919 JKAMP 0.93 0.986 0.004 0.047 PTGDR 0.919 WSB2 0.911 0.9830.004 0.02 PTGDR 0.919 CLU 0.894 0.961 0.012 0.03 PTGDR 0.919 HPSE 0.9390.987 0.014 0.026 PTGDR 0.919 PDGFC 0.837 0.969 0.018 0.013 PTGDR 0.919HPGD 0.871 0.96 0.041 0.047 PTGDR 0.919 CDS2 0.869 0.954 0.022 0.049PTGDR 0.919 HSPC159 0.823 0.97 0.016 0.001 PTGDR 0.919 PPP2R5A_SNORA160.775 0.958 0.032 0 PTGDR 0.919 EAF2_HCG11_LOC 0.917 0.974 0.039 0.046PTGDR 0.919 RCBTB2_LOC10013 0.905 0.981 0.022 0.011 PTGDR 0.919 HMGB20.849 0.972 0.016 0.01 PTGDR 0.919 SIAE 0.814 0.956 0.031 0.002 PTGDR0.919 ABCA13 0.868 0.96 0.034 0.009 PTGDR 0.919 AGTRAP 0.856 0.949 0.0210.015 PTGDR 0.919 SUCNR1 0.922 0.979 0.007 0.034 PTGDR 0.919 TREML10.793 0.958 0.043 0.002 PTGDR 0.919 NEK6_LOC1001290 0.765 0.943 0.0290.002 PTGDR 0.919 ANKRD28 0.8 0.968 0.009 0.001 CAMK4 0.953 DNAJC130.948 1 0.04 0.036 CAMK4 0.953 TNFAIP6 0.971 0.997 0.042 0.041 CAMK40.953 B3GNT5_MCF2L2 0.956 0.997 0.043 0.019 CAMK4 0.953 PICALM 0.8790.999 0.043 0.001 CAMK4 0.953 C9orf72 0.958 0.999 0.044 0.039 CAMK40.953 SLC15A2 0.824 0.987 0.025 0 CAMK4 0.953 TLR10 0.905 1 0.04 0.003CAMK4 0.953 IFI16 0.912 0.992 0.039 0.005 CAMK4 0.953 JKAMP 0.93 0.9980.038 0.009 CAMK4 0.953 WSB2 0.911 0.986 0.021 0.01 CAMK4 0.953 HPSE0.939 0.992 0.026 0.018 CAMK4 0.953 DDAH2 0.886 0.974 0.045 0.034 CAMK40.953 LRRC70_IPO11 0.923 0.994 0.048 0.011 CAMK4 0.953 TMEM144_LOC28550.92 0.999 0.042 0.016 CAMK4 0.953 EAF2_HCG11_LOC 0.917 0.998 0.0430.018 CAMK4 0.953 RCBTB2_LOC10013 0.905 0.994 0.037 0.005 CAMK4 0.953SLC39A9 0.551 0.975 0.037 0 CAMK4 0.953 LGALS1 0.736 0.977 0.022 0 CAMK40.953 SIAE 0.814 0.979 0.044 0 CAMK4 0.953 EFCAB2 0.96 0.999 0.044 0.023CAMK4 0.953 AGTRAP 0.856 0.973 0.049 0.003 CAMK4 0.953 SUCNR1 0.9220.993 0.04 0.009 CAMK4 0.953 MTRR 0.703 0.99 0.028 0 CAMK4 0.953 AIG10.842 0.993 0.042 0.001 CAMK4 0.953 HS2ST1_UBA2 0.758 0.995 0.047 0CAMK4 0.953 NEK6_LOC1001290 0.765 0.972 0.027 0 CAMK4 0.953 GPR65 0.8860.992 0.03 0.007 CAMK4 0.953 LRRFIP1 0.673 0.995 0.039 0 CAMK4 0.953SFRS9 0.527 0.981 0.025 0 CAMK4 0.953 TAF13 0.854 0.995 0.044 0.001CAMK4 0.953 KLHL5 0.826 0.997 0.035 0 CAMK4 0.953 ANKRD28 0.8 0.9980.043 0 CAMK4 0.953 MGST3 0.602 0.986 0.038 0 CAMK4 0.953 CEP97 0.6950.987 0.031 0 CAMK4 0.953 FAM118B 0.737 0.992 0.031 0 CAMK4 0.953TMEM62_SPCS2_L 0.645 0.984 0.05 0 CAMK4 0.953 AIF1 0.816 0.993 0.05 0DNAJC13 0.948 CASS4 0.877 0.982 0.028 0.003 DNAJC13 0.948 ITK 0.899 10.036 0.002 DNAJC13 0.948 GOT2 0.905 0.998 0.038 0.007 DNAJC13 0.948HIST1H4E 0.83 0.981 0.041 0.001 DNAJC13 0.948 SLC39A9 0.551 0.978 0.02 0DNAJC13 0.948 GIMAP7 0.755 0.997 0.042 0 DNAJC13 0.948 RUNX2 0.848 0.9750.04 0.003 DNAJC13 0.948 LY6G5B_CSNK2B 0.661 0.979 0.03 0 DNAJC13 0.948TSHZ2 0.801 0.99 0.043 0 TNFAIP6 0.971 LRRN3 0.947 0.998 0.035 0.03TNFAIP6 0.971 HLA-DPB1 0.765 0.995 0.039 0 TNFAIP6 0.971 CASS4 0.8770.998 0.031 0 TNFAIP6 0.971 GIMAP7 0.755 0.992 0.05 0 TNFAIP6 0.971RUNX2 0.848 0.993 0.038 0.001 TNFAIP6 0.971 HLA-DPA1 0.65 0.995 0.036 0TNFAIP6 0.971 PDE3B 0.85 0.997 0.035 0.001 FOXD4L3_FOXD4L6 0.892 SH2D1B0.867 0.973 0.034 0.002 FOXD4L3_FOXD4L6 0.892 KLRK1_KLRC4 0.857 0.970.029 0.003 FOXD4L3_FOXD4L6 0.892 ITK 0.899 0.97 0.005 0.031FOXD4L3_FOXD4L6 0.892 HIST1H4E 0.83 0.937 0.027 0.02 FOXD4L3_FOXD4L60.892 CCR3 0.905 0.97 0.005 0.034 FOXD4L3_FOXD4L6 0.892 CHI3L1 0.9090.987 0.005 0.039 FOXD4L3_FOXD4L6 0.892 GIMAP7 0.755 0.951 0.011 0FOXD4L3_FOXD4L6 0.892 ANAPC11 0.818 0.948 0.015 0.007 FOXD4L3_FOXD4L60.892 RUNX2 0.848 0.966 0.003 0.015 FOXD4L3_FOXD4L6 0.892 HLA-DRA 0.7680.929 0.023 0.002 FOXD4L3_FOXD4L6 0.892 PDE3B 0.85 0.977 0.003 0.006FOXD4L3_FOXD4L6 0.892 ITGA4_CERKL 0.694 0.946 0.041 0 FOXD4L3_FOXD4L60.892 NPCDR1 0.86 0.948 0.021 0.017 FOXD4L3_FOXD4L6 0.892 CCR4 0.7840.939 0.037 0.001 FOXD4L3_FOXD4L6 0.892 ABCG1 0.789 0.946 0.021 0.007FOXD4L3_FOXD4L6 0.892 PYHIN1 0.807 0.952 0.038 0.002 FOXD4L3_FOXD4L60.892 TSHZ2 0.801 0.952 0.013 0.002 FOXD4L3_FOXD4L6 0.892 RASA4_RASA4P_R0.779 0.943 0.018 0.001 FOXD4L3_FOXD4L6 0.892 CAMK1D 0.702 0.937 0.045 0MMP9_LOC1001280 0.887 CASS4 0.877 0.962 0.034 0.03 MMP9_LOC1001280 0.887ITK 0.899 0.959 0.041 0.031 MMP9_LOC1001280 0.887 HIST1H4E 0.83 0.9560.008 0.014 MMP9_LOC1001280 0.887 PHOSPHO1 0.85 0.957 0.049 0.025MMP9_LOC1001280 0.887 RRP12_LOC644215 0.632 0.928 0.049 0MMP9_LOC1001280 0.887 LASS4 0.794 0.935 0.022 0.027 GSR 0.831 KLRF10.872 0.927 0.031 0.005 GSR 0.831 SH2D1B 0.867 0.935 0.016 0.031 GSR0.831 MRPL41 0.811 0.926 0.031 0.002 GSR 0.831 CASS4 0.877 0.981 0 0.002GSR 0.831 KLRK1_KLRC4 0.857 0.943 0.01 0.009 GSR 0.831 ITK 0.899 0.9850.001 0.002 GSR 0.831 GOT2 0.905 0.988 0 0.008 GSR 0.831 B3GAT3 0.7830.925 0.012 0.002 GSR 0.831 CCR3 0.905 0.95 0.005 0.037 GSR 0.831SLC39A9 0.551 0.916 0.025 0 GSR 0.831 GIMAP7 0.755 0.921 0.012 0.001 GSR0.831 ANAPC11 0.818 0.908 0.028 0.026 GSR 0.831 RUNX2 0.848 0.95 0 0.022GSR 0.831 HLA-DRA 0.768 0.893 0.046 0.013 GSR 0.831 PDE3B 0.85 0.9490.009 0.003 GSR 0.831 SULF2 0.819 0.957 0.007 0.001 GSR 0.831 IRF4 0.7810.933 0.01 0.002 GSR 0.831 HSP90AB1_HSP90A 0.799 0.933 0.023 0.002 GSR0.831 NPCDR1 0.86 0.939 0.01 0.003 GSR 0.831 LY6G5B_CSNK2B 0.661 0.9520.004 0 GSR 0.831 CCR4 0.784 0.91 0.044 0.003 GSR 0.831 FAM118A 0.7590.94 0.01 0 GSR 0.831 PYHIN1 0.807 0.949 0.006 0.001 GSR 0.831 TSHZ20.801 0.962 0 0.001 GSR 0.831 RASA4_RASA4P_R 0.779 0.917 0.034 0.001 GSR0.831 CAMK1D 0.702 0.941 0.005 0 KLRF1 0.872 ANKRD34B 0.846 0.95 0.0040.013 KLRF1 0.872 SGMS2 0.859 0.957 0.001 0.032 KLRF1 0.872 GK3P_GK0.877 0.952 0.006 0.012 KLRF1 0.872 SLC15A2 0.824 0.933 0.001 0.013KLRF1 0.872 OLFM4 0.806 0.935 0.034 0.003 KLRF1 0.872 TCN1 0.816 0.9530.002 0.004 KLRF1 0.872 ATP13A3 0.841 0.951 0.001 0.035 KLRF1 0.872TMEM144_LOC2855 0.92 0.976 0.001 0.045 KLRF1 0.872 BPI 0.83 0.932 0.0040.015 KLRF1 0.872 HSPC159 0.823 0.944 0.002 0.015 KLRF1 0.872PPP2R5A_SNORA16 0.775 0.937 0.001 0.003 KLRF1 0.872 TMTC1 0.826 0.9460.004 0.01 KLRF1 0.872 SEC24A_SAR1B 0.761 0.917 0.006 0.004 KLRF1 0.872HMGB2 0.849 0.951 0.001 0.031 KLRF1 0.872 NA 0.866 0.958 0.001 0.02KLRF1 0.872 LGALS1 0.736 0.901 0.018 0.011 KLRF1 0.872 CD163 0.735 0.9270.009 0.002 KLRF1 0.872 MTHFS 0.757 0.916 0.015 0.003 KLRF1 0.872 LCN20.752 0.921 0.026 0.001 KLRF1 0.872 EIF2AK2 0.857 0.948 0.008 0.013KLRF1 0.872 SIAE 0.814 0.92 0.006 0.026 KLRF1 0.872 CDA 0.804 0.9120.018 0.029 KLRF1 0.872 SAP30 0.728 0.903 0.005 0.011 KLRF1 0.872 MTRR0.703 0.912 0.048 0 KLRF1 0.872 AIG1 0.842 0.928 0.001 0.048 KLRF1 0.872HS2ST1_UBA2 0.758 0.904 0.043 0.01 KLRF1 0.872 TREML1 0.793 0.932 0.0060.01 KLRF1 0.872 GSTO1 0.793 0.928 0.001 0.015 KLRF1 0.872 MACF1 0.7420.919 0.037 0 KLRF1 0.872 AMFR 0.69 0.903 0.017 0.003 KLRF1 0.872 OR9A20.813 0.926 0.005 0.01 KLRF1 0.872 HDHD1A 0.63 0.915 0.006 0 KLRF1 0.872ACTA2 0.783 0.922 0.01 0.013 KLRF1 0.872 DPH3 0.86 0.943 0.003 0.022KLRF1 0.872 ZNF28 0.558 0.911 0.033 0 KLRF1 0.872 TAF13 0.854 0.95 0.0040.02 KLRF1 0.872 P4HA1_RPL17 0.715 0.931 0.01 0 KLRF1 0.872 KLHL5 0.8260.932 0.005 0.019 KLRF1 0.872 DLEU2_DLEU2L 0.874 0.958 0.001 0.022 KLRF10.872 ANKRD28 0.8 0.942 0.001 0.006 KLRF1 0.872 HSPB1_HSPBL2 0.778 0.9110.01 0.014 KLRF1 0.872 CCDC125 0.632 0.912 0.041 0 KLRF1 0.872 LHFP0.759 0.903 0.015 0.005 KLRF1 0.872 ZRANB1 0.724 0.941 0.001 0 KLRF10.872 FSD1L_GARNL1 0.66 0.906 0.034 0 KLRF1 0.872 UBE2F_C20orf194 0.7620.924 0.007 0.002 KLRF1 0.872 MYL9 0.771 0.921 0.013 0.009 KLRF1 0.872CYP4F3_CYP4F2 0.593 0.925 0.005 0 KLRF1 0.872 CEP97 0.695 0.923 0.01 0KLRF1 0.872 DYNLL1 0.776 0.947 0.003 0 KLRF1 0.872 PLIN2 0.671 0.9150.003 0 KLRF1 0.872 FAM118B 0.737 0.941 0.001 0.001 KLRF1 0.872 NP 0.6330.901 0.038 0 KLRF1 0.872 SPARC 0.703 0.932 0.008 0 KLRF1 0.872 PLEKHA30.658 0.921 0.006 0 KLRF1 0.872 TMEM62_SPCS2_L 0.645 0.929 0.003 0 KLRF10.872 PLEKHF2 0.822 0.941 0.004 0.011 KLRF1 0.872 CMTM5 0.694 0.9060.035 0.001 KLRF1 0.872 AIF1 0.816 0.933 0.001 0.022 KLRF1 0.872HIST2H2BF_HIST2 0.754 0.916 0.031 0.002 KLRF1 0.872 CALM2_C2orf61 0.7330.934 0.003 0 KLRF1 0.872 SPATA6 0.642 0.917 0.01 0 KLRF1 0.872 DCTN50.557 0.903 0.05 0 SH2D1B 0.867 ANKRD34B 0.846 0.938 0.018 0.033 SH2D1B0.867 SGMS2 0.859 0.974 0.003 0.008 SH2D1B 0.867 GK3P_GK 0.877 0.9470.025 0.018 SH2D1B 0.867 SLC15A2 0.824 0.966 0.002 0.002 SH2D1B 0.867TCN1 0.816 0.959 0.028 0.001 SH2D1B 0.867 PLAC8 0.767 0.922 0.027 0.008SH2D1B 0.867 ATP13A3 0.841 0.96 0.005 0.02 SH2D1B 0.867 HSPC159 0.8230.938 0.008 0.023 SH2D1B 0.867 PPP2R5A_SNORA16 0.775 0.939 0.008 0.003SH2D1B 0.867 SEC24A_SAR1B 0.761 0.921 0.018 0.006 SH2D1B 0.867 HMGB20.849 0.962 0.016 0.012 SH2D1B 0.867 SLC39A9 0.551 0.908 0.042 0 SH2D1B0.867 NA 0.866 0.948 0.006 0.03 SH2D1B 0.867 LGALS1 0.736 0.914 0.0210.007 SH2D1B 0.867 EIF2AK2 0.857 0.948 0.005 0.028 SH2D1B 0.867 ABCA130.868 0.959 0.017 0.01 SH2D1B 0.867 CDA 0.804 0.928 0.023 0.015 SH2D1B0.867 SAP30 0.728 0.903 0.009 0.013 SH2D1B 0.867 SUCNR1 0.922 0.9850.003 0.022 SH2D1B 0.867 MTRR 0.703 0.928 0.002 0.001 SH2D1B 0.867 AIG10.842 0.961 0.006 0.008 SH2D1B 0.867 HS2ST1_UBA2 0.758 0.91 0.03 0.015SH2D1B 0.867 GSTO1 0.793 0.944 0.006 0.008 SH2D1B 0.867 MACF1 0.742 0.930.022 0.001 SH2D1B 0.867 AMFR 0.69 0.897 0.046 0.006 SH2D1B 0.867 HDHD1A0.63 0.93 0.016 0 SH2D1B 0.867 DPH3 0.86 0.948 0.011 0.026 SH2D1B 0.867TAF13 0.854 0.972 0.001 0.01 SH2D1B 0.867 P4HA1_RPL17 0.715 0.941 0.0110 SH2D1B 0.867 KLHL5 0.826 0.946 0.003 0.022 SH2D1B 0.867 DLEU2_DLEU2L0.874 0.954 0.003 0.041 SH2D1B 0.867 ANKRD28 0.8 0.948 0.004 0.005SH2D1B 0.867 MGST3 0.602 0.932 0.019 0 SH2D1B 0.867 HSPB1_HSPBL2 0.7780.917 0.008 0.014 SH2D1B 0.867 ZRANB1 0.724 0.913 0.019 0.002 SH2D1B0.867 UBE2F_C20orf194 0.762 0.943 0.01 0.001 SH2D1B 0.867 CCRL2 0.7860.935 0.033 0.004 SH2D1B 0.867 MYL9 0.771 0.917 0.021 0.013 SH2D1B 0.867CEP97 0.695 0.943 0.025 0 SH2D1B 0.867 DYNLL1 0.776 0.956 0.013 0 SH2D1B0.867 PLIN2 0.671 0.934 0.012 0 SH2D1B 0.867 FAM118B 0.737 0.951 0.0030.001 SH2D1B 0.867 CTSL1_CTSLL3 0.715 0.939 0.041 0 SH2D1B 0.867 PLEKHA30.658 0.919 0.027 0 SH2D1B 0.867 TMEM62_SPCS2_L 0.645 0.929 0.006 0SH2D1B 0.867 PLEKHF2 0.822 0.957 0.004 0.006 SH2D1B 0.867 AIF1 0.8160.941 0.008 0.021 SH2D1B 0.867 HIST2H2BF_HIST2 0.754 0.918 0.022 0.004SH2D1B 0.867 CALM2_C2orf61 0.733 0.957 0.005 0 SH2D1B 0.867 DCTN5 0.5570.916 0.019 0 ANKRD34B 0.846 HIST1H4C 0.859 0.944 0.006 0.026 ANKRD34B0.846 HIST1H3I 0.787 0.921 0.022 0.003 ANKRD34B 0.846 MRPL41 0.811 0.9520.01 0 ANKRD34B 0.846 KLRK1_KLRC4 0.857 0.952 0.005 0.017 ANKRD34B 0.846B3GAT3 0.783 0.911 0.006 0.015 ANKRD34B 0.846 HIST1H4E 0.83 0.934 0.0020.028 ANKRD34B 0.846 FGFBP2 0.812 0.938 0.019 0.003 ANKRD34B 0.846 KLRD10.784 0.932 0.021 0.002 ANKRD34B 0.846 GIMAP7 0.755 0.908 0.027 0.006ANKRD34B 0.846 ANAPC11 0.818 0.924 0.008 0.028 ANKRD34B 0.846DNAJC9_FAM149B1 0.811 0.952 0.013 0.001 ANKRD34B 0.846 PLA2G7 0.8340.938 0.024 0.006 ANKRD34B 0.846 SULF2 0.819 0.923 0.015 0.014 ANKRD34B0.846 IRF4 0.781 0.914 0.006 0.023 ANKRD34B 0.846 HSP90AB1_HSP90A 0.7990.921 0.043 0.015 ANKRD34B 0.846 NPCDR1 0.86 0.921 0.008 0.034 ANKRD34B0.846 CCR4 0.784 0.917 0.02 0.005 ANKRD34B 0.846 PYHIN1 0.807 0.9310.006 0.015 ANKRD34B 0.846 TSHZ2 0.801 0.938 0.002 0.006 SGMS2 0.859CRIP1 0.83 0.95 0.041 0.001 SGMS2 0.859 MRPL41 0.811 0.957 0.018 0 SGMS20.859 CASS4 0.877 0.962 0.001 0.027 SGMS2 0.859 KLRK1_KLRC4 0.857 0.9510.022 0.009 SGMS2 0.859 ITK 0.899 0.984 0.001 0.01 SGMS2 0.859 GOT20.905 0.976 0.002 0.036 SGMS2 0.859 B3GAT3 0.783 0.936 0.018 0.003 SGMS20.859 HIST1H4E 0.83 0.938 0.004 0.021 SGMS2 0.859 CHI3L1 0.909 0.990.002 0.028 SGMS2 0.859 SLC39A9 0.551 0.91 0.043 0 SGMS2 0.859 GIMAP70.755 0.959 0.004 0 SGMS2 0.859 ANAPC11 0.818 0.943 0.033 0.002 SGMS20.859 RUNX2 0.848 0.965 0.003 0.007 SGMS2 0.859 DNAJC9_FAM149B1 0.8110.959 0.046 0 SGMS2 0.859 PLA2G7 0.834 0.955 0.026 0.001 SGMS2 0.859PDE3B 0.85 0.976 0.003 0.003 SGMS2 0.859 SULF2 0.819 0.978 0.003 0.001SGMS2 0.859 IRF4 0.781 0.923 0.047 0.01 SGMS2 0.859 HSP90AB1_HSP90A0.799 0.929 0.045 0.014 SGMS2 0.859 NPCDR1 0.86 0.942 0.014 0.013 SGMS20.859 LY6G5B_CSNK2B 0.661 0.933 0.005 0 SGMS2 0.859 CCR4 0.784 0.9690.003 0 SGMS2 0.859 FAM118A 0.759 0.931 0.002 0.005 SGMS2 0.859 PYHIN10.807 0.948 0.017 0.003 SGMS2 0.859 CLC 0.81 0.943 0.048 0.003 SGMS20.859 TSHZ2 0.801 0.971 0.002 0.001 SGMS2 0.859 RASA4_RASA4P_R 0.7790.928 0.031 0.002 SGMS2 0.859 CAMK1D 0.702 0.938 0.013 0 SGMS2 0.859IL5RA 0.832 0.939 0.05 0.004 B3GNT5_MCF2L2 0.956 LRRN3 0.947 0.999 0.0180.028 B3GNT5_MCF2L2 0.956 VAMP2 0.673 0.985 0.016 0 B3GNT5_MCF2L2 0.956CASS4 0.877 0.998 0.014 0 B3GNT5_MCF2L2 0.956 RUNX2 0.848 0.986 0.0230.001 B3GNT5_MCF2L2 0.956 PDE3B 0.85 0.998 0.015 0.001 GK3P_GK 0.877CRIP1 0.83 0.932 0.037 0.015 GK3P_GK 0.877 VAMP2 0.673 0.911 0.015 0.001GK3P_GK 0.877 MRPL41 0.811 0.951 0.006 0.001 GK3P_GK 0.877 CASS4 0.8770.953 0.002 0.047 GK3P_GK 0.877 B3GAT3 0.783 0.935 0.003 0.005 GK3P_GK0.877 HIST1H4E 0.83 0.928 0.006 0.035 GK3P_GK 0.877 CCR3 0.905 0.9590.002 0.043 GK3P_GK 0.877 CHI3L1 0.909 0.96 0.012 0.048 GK3P_GK 0.877GIMAP7 0.755 0.924 0.009 0.001 GK3P_GK 0.877 ANAPC11 0.818 0.93 0.0130.008 GK3P_GK 0.877 HLA-DRA 0.768 0.907 0.047 0.007 GK3P_GK 0.877DNAJC9_FAM149B1 0.811 0.943 0.034 0.003 GK3P_GK 0.877 NA 0.696 0.9310.013 0 GK3P_GK 0.877 PLA2G7 0.834 0.944 0.02 0.004 GK3P_GK 0.877PMS2CL_PMS2 0.685 0.915 0.02 0 GK3P_GK 0.877 PDE3B 0.85 0.949 0.0010.041 GK3P_GK 0.877 SULF2 0.819 0.922 0.038 0.031 GK3P_GK 0.877HSP90AB1_HSP90A 0.799 0.925 0.038 0.011 GK3P_GK 0.877 NPCDR1 0.86 0.9420.009 0.017 GK3P_GK 0.877 LY6G5B_CSNK2B 0.661 0.931 0.013 0 GK3P_GK0.877 CCR4 0.784 0.938 0.002 0.003 GK3P_GK 0.877 ABCG1 0.789 0.91 0.0330.041 GK3P_GK 0.877 FAM118A 0.759 0.913 0.041 0.004 GK3P_GK 0.877 CLC0.81 0.933 0.019 0.014 GK3P_GK 0.877 TSHZ2 0.801 0.94 0.004 0.005GK3P_GK 0.877 RASA4_RASA4P_R 0.779 0.921 0.021 0.003 GK3P_GK 0.877CAMK1D 0.702 0.927 0.009 0 GK3P_GK 0.877 CFD 0.767 0.951 0.003 0.001GK3P_GK 0.877 IL5RA 0.832 0.935 0.017 0.016 PFKFB2 0.874 MRPL41 0.8110.954 0.025 0.002 PFKFB2 0.874 ITK 0.899 0.962 0.015 0.047 PFKFB2 0.874B3GAT3 0.783 0.954 0.019 0.001 PFKFB2 0.874 HIST1H4E 0.83 0.937 0.0230.025 PFKFB2 0.874 DNAJC9_FAM149B1 0.811 0.961 0.04 0.001 PFKFB2 0.874PMS2CL_PMS2 0.685 0.935 0.035 0 PFKFB2 0.874 PDE3B 0.85 0.948 0.0130.045 PFKFB2 0.874 IRF4 0.781 0.929 0.024 0.014 PFKFB2 0.874 IRS2 0.6480.925 0.039 0 PFKFB2 0.874 HSP90AB1_HSP90A 0.799 0.954 0.044 0.003PFKFB2 0.874 ABCG1 0.789 0.927 0.017 0.033 PFKFB2 0.874 FAM118A 0.7590.935 0.032 0.001 PFKFB2 0.874 TSHZ2 0.801 0.946 0.019 0.005 PFKFB20.874 CAMK1D 0.702 0.93 0.05 0 PICALM 0.879 LRRN3 0.947 0.993 0.0020.033 PICALM 0.879 VAMP2 0.673 0.952 0.015 0 PICALM 0.879 CASS4 0.8770.989 0.002 0.001 PICALM 0.879 ITK 0.899 0.983 0.004 0.002 PICALM 0.879GOT2 0.905 0.976 0.013 0.005 PICALM 0.879 B3GAT3 0.783 0.953 0.047 0PICALM 0.879 HIST1H4E 0.83 0.962 0.019 0 PICALM 0.879 CCR3 0.905 0.9670.01 0.009 PICALM 0.879 CHI3L1 0.909 0.975 0.006 0.039 PICALM 0.879GIMAP7 0.755 0.958 0.018 0 PICALM 0.879 ANAPC11 0.818 0.96 0.033 0PICALM 0.879 RUNX2 0.848 0.989 0.002 0.001 PICALM 0.879 PDE3B 0.85 0.9890.002 0.001 PICALM 0.879 LY6G5B_CSNK2B 0.661 0.948 0.039 0 PICALM 0.879CCR4 0.784 0.972 0.014 0 PICALM 0.879 TSHZ2 0.801 0.947 0.048 0 METTL7B0.943 GOT2 0.905 0.983 0.047 0.014 METTL7B 0.943 HIST1H4E 0.83 0.9780.043 0.001 HIST1H4C 0.859 JKAMP 0.93 0.982 0.001 0.036 HIST1H4C 0.859CD63 0.757 0.953 0.005 0.001 HIST1H4C 0.859 ATP13A3 0.841 0.928 0.0440.045 HIST1H4C 0.859 HSPC159 0.823 0.937 0.036 0.006 HIST1H4C 0.859PPP2R5A_SNORA16 0.775 0.925 0.038 0.002 HIST1H4C 0.859 TMTC1 0.826 0.9230.032 0.018 HIST1H4C 0.859 HMGB2 0.849 0.95 0.029 0.007 HIST1H4C 0.859EXOSC4 0.731 0.935 0.009 0.001 HIST1H4C 0.859 FOLR3_FOLR2 0.848 0.9590.012 0.001 HIST1H4C 0.859 LGALS1 0.736 0.929 0.034 0.001 HIST1H4C 0.859SIAE 0.814 0.942 0.003 0.008 HIST1H4C 0.859 ABCA13 0.868 0.985 0.003 0HIST1H4C 0.859 CDA 0.804 0.927 0.037 0.007 HIST1H4C 0.859 SAP30 0.7280.895 0.029 0.008 HIST1H4C 0.859 AGTRAP 0.856 0.955 0.001 0.039 HIST1H4C0.859 SUCNR1 0.922 0.996 0.001 0.006 HIST1H4C 0.859 AIG1 0.842 0.9450.025 0.004 HIST1H4C 0.859 PCOLCE2 0.709 0.937 0.009 0 HIST1H4C 0.859VOPP1_LOC100128 0.618 0.907 0.037 0 HIST1H4C 0.859 SLC39A8 0.698 0.9330.02 0 HIST1H4C 0.859 SLC11A1 0.785 0.917 0.025 0.017 HIST1H4C 0.859TREML1 0.793 0.952 0.012 0.002 HIST1H4C 0.859 GSTO1 0.793 0.926 0.0460.005 HIST1H4C 0.859 CLEC4A 0.87 0.933 0.027 0.043 HIST1H4C 0.859NEK6_LOC1001290 0.765 0.906 0.024 0.011 HIST1H4C 0.859 AMFR 0.69 0.9080.046 0.002 HIST1H4C 0.859 DPH3 0.86 0.966 0.001 0.006 HIST1H4C 0.859TAF13 0.854 0.952 0.048 0.003 HIST1H4C 0.859 DLEU2_DLEU2L 0.874 0.9550.003 0.016 HIST1H4C 0.859 ANKRD28 0.8 0.932 0.036 0.005 HIST1H4C 0.859HSPB1_HSPBL2 0.778 0.915 0.046 0.006 HIST1H4C 0.859 LHFP 0.759 0.9070.027 0.005 HIST1H4C 0.859 UBE2F_C20orf194 0.762 0.952 0.014 0 HIST1H4C0.859 MYL9 0.771 0.95 0.003 0.002 HIST1H4C 0.859 CMTM5 0.694 0.947 0.0070 HIST1H4C 0.859 CALM2_C2orf61 0.733 0.94 0.031 0 C9orf72 0.958 LRRN30.947 0.998 0.05 0.026 C9orf72 0.958 CASS4 0.877 0.998 0.043 0 C9orf720.958 GIMAP7 0.755 0.989 0.041 0 C9orf72 0.958 RUNX2 0.848 0.995 0.0440.001 C9orf72 0.958 PDE3B 0.85 0.999 0.04 0.001 HIST1H3I 0.787 TCN10.816 0.899 0.044 0.006 HIST1H3I 0.787 CD63 0.757 0.901 0.002 0.015HIST1H3I 0.787 BPI 0.83 0.913 0.025 0.002 HIST1H3I 0.787 PPP2R5A_SNORA160.775 0.878 0.015 0.043 HIST1H3I 0.787 SEC24A_SAR1B 0.761 0.866 0.0330.039 HIST1H3I 0.787 HMGB2 0.849 0.917 0.01 0.047 HIST1H3I 0.787 EXOSC40.731 0.888 0.007 0.017 HIST1H3I 0.787 FOLR3_FOLR2 0.848 0.924 0.0030.018 HIST1H3I 0.787 LGALS1 0.736 0.87 0.017 0.033 HIST1H3I 0.787 ABCA130.868 0.952 0.001 0.007 HIST1H3I 0.787 SUCNR1 0.922 0.981 0 0.025HIST1H3I 0.787 PCOLCE2 0.709 0.886 0.003 0.005 HIST1H3I 0.787VOPP1_LOC100128 0.618 0.844 0.02 0.003 HIST1H3I 0.787 SLC39A8 0.6980.875 0.005 0.009 HIST1H3I 0.787 TREML1 0.793 0.892 0.035 0.025 HIST1H3I0.787 RETN 0.663 0.858 0.043 0.002 HIST1H3I 0.787 DPH3 0.86 0.936 00.044 HIST1H3I 0.787 TAF13 0.854 0.932 0.003 0.026 HIST1H3I 0.787HSPB1_HSPBL2 0.778 0.884 0.005 0.044 HIST1H3I 0.787 LHFP 0.759 0.8660.005 0.047 HIST1H3I 0.787 UBE2F_C20orf194 0.762 0.903 0.014 0.003HIST1H3I 0.787 MYL9 0.771 0.912 0.003 0.011 HIST1H3I 0.787 CTSL1_CTSLL30.715 0.874 0.045 0.003 HIST1H3I 0.787 PLEKHA3 0.658 0.857 0.039 0.002HIST1H3I 0.787 CMTM5 0.694 0.877 0.045 0.002 SLC15A2 0.824 LRRN3 0.9470.979 0 0.023 SLC15A2 0.824 HLA-DPB1 0.765 0.917 0.011 0 SLC15A2 0.824VAMP2 0.673 0.905 0.01 0 SLC15A2 0.824 MRPL41 0.811 0.926 0.015 0.002SLC15A2 0.824 CASS4 0.877 0.959 0 0.017 SLC15A2 0.824 KLRK1_KLRC4 0.8570.95 0.004 0.004 SLC15A2 0.824 ITK 0.899 0.998 0 0.002 SLC15A2 0.824GOT2 0.905 0.979 0 0.018 SLC15A2 0.824 B3GAT3 0.783 0.931 0.004 0.002SLC15A2 0.824 FGFBP2 0.812 0.907 0.044 0.006 SLC15A2 0.824 CCR3 0.9050.957 0.001 0.021 SLC15A2 0.824 SLC39A9 0.551 0.902 0.022 0 SLC15A20.824 GIMAP7 0.755 0.946 0.001 0 SLC15A2 0.824 ANAPC11 0.818 0.914 0.0070.018 SLC15A2 0.824 RUNX2 0.848 0.946 0.001 0.01 SLC15A2 0.824 HLA-DRA0.768 0.926 0.006 0.001 SLC15A2 0.824 DNAJC9_FAM149B1 0.811 0.947 0.0140 SLC15A2 0.824 NA 0.696 0.924 0.008 0 SLC15A2 0.824 PLA2G7 0.834 0.9340.018 0.001 SLC15A2 0.824 PDE3B 0.85 0.941 0.006 0.007 SLC15A2 0.824SULF2 0.819 0.92 0.012 0.008 SLC15A2 0.824 IRF4 0.781 0.966 0.001 0SLC15A2 0.824 HSP90AB1_HSP90A 0.799 0.942 0.006 0.002 SLC15A2 0.824ITGA4_CERKL 0.694 0.933 0.012 0 SLC15A2 0.824 NPCDR1 0.86 0.956 0.0020.001 SLC15A2 0.824 LY6G5B_CSNK2B 0.661 0.948 0.001 0 SLC15A2 0.824 CCR40.784 0.949 0.002 0 SLC15A2 0.824 ABCG1 0.789 0.913 0.008 0.015 SLC15A20.824 FAM118A 0.759 0.923 0.008 0 SLC15A2 0.824 PYHIN1 0.807 0.965 0.0020 SLC15A2 0.824 CLC 0.81 0.929 0.014 0.005 SLC15A2 0.824 SYNE2 0.6780.945 0.006 0 SLC15A2 0.824 NA 0.746 0.92 0.022 0 SLC15A2 0.824 TSHZ20.801 0.953 0.001 0.001 SLC15A2 0.824 RASA4_RASA4P_R 0.779 0.93 0.0030.001 SLC15A2 0.824 CAMK1D 0.702 0.919 0.013 0 SLC15A2 0.824LOC100128751 0.651 0.903 0.038 0 SLC15A2 0.824 IL5RA 0.832 0.922 0.0310.002 TLR10 0.905 VAMP2 0.673 0.952 0.011 0 TLR10 0.905 CASS4 0.8770.983 0.004 0.002 TLR10 0.905 ITK 0.899 0.983 0.006 0.004 TLR10 0.905GOT2 0.905 0.971 0.022 0.017 TLR10 0.905 HIST1H4E 0.83 0.958 0.018 0.003TLR10 0.905 CCR3 0.905 0.965 0.025 0.01 TLR10 0.905 CHI3L1 0.909 0.9680.033 0.035 TLR10 0.905 GIMAP7 0.755 0.964 0.018 0 TLR10 0.905 ANAPC110.818 0.966 0.034 0 TLR10 0.905 RUNX2 0.848 0.972 0.005 0.005 TLR100.905 PDE3B 0.85 0.984 0.002 0.002 TLR10 0.905 NPCDR1 0.86 0.96 0.0340.002 TLR10 0.905 LY6G5B_CSNK2B 0.661 0.969 0.011 0 TLR10 0.905 CCR40.784 0.979 0.003 0 TLR10 0.905 TSHZ2 0.801 0.962 0.017 0 TLR10 0.905RASA4_RASA4P_R 0.779 0.949 0.042 0 TLR10 0.905 CAMK1D 0.702 0.969 0.0150 ADM 0.963 PPIF 0.614 0.989 0.035 0 CD274 0.966 CCR4 0.784 0.984 0.0490 CRIP1 0.83 CD63 0.757 0.917 0.003 0.012 CRIP1 0.83 PPP2R5A_SNORA160.775 0.899 0.015 0.023 CRIP1 0.83 SEC24A_SAR1B 0.761 0.892 0.007 0.027CRIP1 0.83 SH3PXD2B 0.734 0.885 0.019 0.005 CRIP1 0.83 HMGB2 0.849 0.9570.002 0.023 CRIP1 0.83 EXOSC4 0.731 0.888 0.018 0.017 CRIP1 0.83 LGALS10.736 0.908 0.003 0.016 CRIP1 0.83 MTHFS 0.757 0.893 0.013 0.029 CRIP10.83 ABCA13 0.868 0.952 0.008 0.006 CRIP1 0.83 SAP30 0.728 0.868 0.010.035 CRIP1 0.83 SUCNR1 0.922 0.986 0 0.02 CRIP1 0.83 AIG1 0.842 0.940.005 0.016 CRIP1 0.83 PCOLCE2 0.709 0.871 0.035 0.011 CRIP1 0.83SLC11A1 0.785 0.904 0.006 0.048 CRIP1 0.83 TREML1 0.793 0.901 0.0490.043 CRIP1 0.83 GSTO1 0.793 0.919 0.011 0.017 CRIP1 0.83NEK6_LOC1001290 0.765 0.899 0.009 0.027 CRIP1 0.83 AMFR 0.69 0.878 0.020.017 CRIP1 0.83 OR9A2 0.813 0.915 0.01 0.026 CRIP1 0.83 TAF13 0.8540.921 0.032 0.045 CRIP1 0.83 ANKRD28 0.8 0.911 0.003 0.04 CRIP1 0.83MGST3 0.602 0.894 0.046 0 CRIP1 0.83 LHFP 0.759 0.86 0.038 0.045 CRIP10.83 UBE2F_C20orf194 0.762 0.916 0.013 0.004 CRIP1 0.83 MYL9 0.771 0.9050.007 0.024 CRIP1 0.83 CEP97 0.695 0.895 0.033 0.001 CRIP1 0.83 DYNLL10.776 0.949 0.006 0 CRIP1 0.83 FAM118B 0.737 0.903 0.02 0.005 CRIP1 0.83CDC26 0.619 0.88 0.049 0 CRIP1 0.83 CALM2_C2orf61 0.733 0.931 0.0020.001 LRRN3 0.947 IFI16 0.912 0.989 0.016 0.01 LRRN3 0.947 JKAMP 0.930.996 0.025 0.013 LRRN3 0.947 SLC1A3 0.896 0.975 0.047 0.014 LRRN3 0.947WSB2 0.911 0.975 0.026 0.029 LRRN3 0.947 HPSE 0.939 0.988 0.013 0.035LRRN3 0.947 DDAH2 0.886 0.976 0.02 0.041 LRRN3 0.947 LRRC70_IPO11 0.9230.994 0.042 0.013 LRRN3 0.947 TMEM144_LOC2855 0.92 0.997 0.035 0.018LRRN3 0.947 PPP2R5A_SNORA16 0.775 0.988 0.047 0 LRRN3 0.947EAF2_HCG11_LOC 0.917 0.996 0.02 0.024 LRRN3 0.947 RCBTB2_LOC10013 0.9050.988 0.018 0.015 LRRN3 0.947 SEC24A_SAR1B 0.761 0.979 0.021 0 LRRN30.947 EXOSC4 0.731 0.974 0.046 0 LRRN3 0.947 NA 0.866 0.994 0.039 0.001LRRN3 0.947 LGALS1 0.736 0.969 0.041 0 LRRN3 0.947 CCR1 0.897 0.9760.042 0.011 LRRN3 0.947 FFAR2 0.868 0.976 0.036 0.003 LRRN3 0.947EIF2AK2 0.857 0.99 0.025 0.001 LRRN3 0.947 SIAE 0.814 0.976 0.03 0.001LRRN3 0.947 EFCAB2 0.96 0.999 0.03 0.022 LRRN3 0.947 AGTRAP 0.856 0.9740.019 0.005 LRRN3 0.947 SUCNR1 0.922 0.993 0.017 0.012 LRRN3 0.947 MTRR0.703 0.978 0.04 0 LRRN3 0.947 AIG1 0.842 0.986 0.024 0.001 LRRN3 0.947GSTO1 0.793 0.978 0.023 0.001 LRRN3 0.947 CLEC4A 0.87 0.988 0.023 0.004LRRN3 0.947 GPR65 0.886 0.984 0.021 0.013 LRRN3 0.947 MACF1 0.742 0.9830.048 0 LRRN3 0.947 HDHD1A 0.63 0.985 0.043 0 LRRN3 0.947 TRIM21 0.8740.977 0.027 0.009 LRRN3 0.947 TAF13 0.854 0.989 0.034 0.002 LRRN3 0.947P4HA1_RPL17 0.715 0.984 0.03 0 LRRN3 0.947 KLHL5 0.826 0.985 0.029 0.001LRRN3 0.947 MGST3 0.602 0.977 0.03 0 LRRN3 0.947 FAM118B 0.737 0.9820.036 0 LRRN3 0.947 TMEM62_SPCS2_L 0.645 0.978 0.033 0 LRRN3 0.947 AIF10.816 0.987 0.022 0.001 HLA-DPB1 0.765 IFI16 0.912 0.975 0 0.025HLA-DPB1 0.765 PLAC8 0.767 0.864 0.05 0.043 HLA-DPB1 0.765PPP2R5A_SNORA16 0.775 0.868 0.019 0.029 HLA-DPB1 0.765 SEC24A_SAR1B0.761 0.895 0 0.017 HLA-DPB1 0.765 NA 0.866 0.931 0.001 0.036 HLA-DPB10.765 FFAR2 0.868 0.936 0 0.026 HLA-DPB1 0.765 EIF2AK2 0.857 0.947 0.0010.007 HLA-DPB1 0.765 AIG1 0.842 0.912 0.002 0.047 HLA-DPB1 0.765 GAB20.729 0.849 0.016 0.035 HLA-DPB1 0.765 GSTO1 0.793 0.899 0.001 0.041HLA-DPB1 0.765 CLEC4A 0.87 0.946 0 0.034 HLA-DPB1 0.765 TRAF3 0.5940.856 0.037 0 HLA-DPB1 0.765 MACF1 0.742 0.859 0.029 0.007 HLA-DPB10.765 TRIM21 0.874 0.978 0 0.011 HLA-DPB1 0.765 ICAM1 0.821 0.943 0 0.01HLA-DPB1 0.765 TAF13 0.854 0.907 0.004 0.032 HLA-DPB1 0.765 P4HA1_RPL170.715 0.884 0.024 0 HLA-DPB1 0.765 KLHL5 0.826 0.922 0 0.018 HLA-DPB10.765 HSPB1_HSPBL2 0.778 0.888 0.005 0.023 HLA-DPB1 0.765 LAIR1_LAIR20.749 0.855 0.025 0.04 HLA-DPB1 0.765 UBE2F_C20orf194 0.762 0.862 0.0210.02 HLA-DPB1 0.765 CCRL2 0.786 0.916 0.006 0.004 HLA-DPB1 0.765 IRF10.651 0.876 0.008 0.001 HLA-DPB1 0.765 DYNLL1 0.776 0.89 0.008 0.003HLA-DPB1 0.765 FAM118B 0.737 0.872 0.048 0.003 HLA-DPB1 0.765CTSL1_CTSLL3 0.715 0.886 0.006 0.002 HLA-DPB1 0.765 TMEM62_SPCS2_L 0.6450.861 0.035 0 HLA-DPB1 0.765 PLEKHF2 0.822 0.905 0.005 0.028 HLA-DPB10.765 AIF1 0.816 0.915 0.001 0.027 HLA-DPB1 0.765 CALM2_C2orf61 0.7330.862 0.024 0.004 VAMP2 0.673 JKAMP 0.93 0.977 0 0.023 VAMP2 0.673 OLFM40.806 0.837 0.04 0.027 VAMP2 0.673 TCN1 0.816 0.875 0.004 0.021 VAMP20.673 WSB2 0.911 0.978 0 0.016 VAMP2 0.673 PLAC8 0.767 0.857 0.001 0.019VAMP2 0.673 CD63 0.757 0.915 0 0.003 VAMP2 0.673 PDGFC 0.837 0.913 0.0010.037 VAMP2 0.673 HPGD 0.871 0.921 0.001 0.046 VAMP2 0.673 LRRC70_IPO110.923 0.954 0 0.039 VAMP2 0.673 BPI 0.83 0.876 0.002 0.032 VAMP2 0.673PPP2R5A_SNORA16 0.775 0.854 0.004 0.022 VAMP2 0.673 TMTC1 0.826 0.8590.01 0.038 VAMP2 0.673 SEC24A_SAR1B 0.761 0.865 0 0.022 VAMP2 0.673HMGB2 0.849 0.921 0.001 0.005 VAMP2 0.673 EXOSC4 0.731 0.851 0.003 0.009VAMP2 0.673 FOLR3_FOLR2 0.848 0.929 0 0.002 VAMP2 0.673 PRR13_PCBP2 0.770.861 0.004 0.02 VAMP2 0.673 LGALS1 0.736 0.833 0.006 0.047 VAMP2 0.673FFAR2 0.868 0.926 0 0.011 VAMP2 0.673 MTHFS 0.757 0.885 0.001 0.002VAMP2 0.673 SIAE 0.814 0.919 0 0.026 VAMP2 0.673 ABCA13 0.868 0.916 00.036 VAMP2 0.673 CDA 0.804 0.907 0 0.007 VAMP2 0.673 MTRR 0.703 0.8070.022 0.007 VAMP2 0.673 AIG1 0.842 0.924 0 0.012 VAMP2 0.673 PCOLCE20.709 0.803 0.008 0.022 VAMP2 0.673 GAB2 0.729 0.823 0.021 0.042 VAMP20.673 HS2ST1_UBA2 0.758 0.892 0 0.007 VAMP2 0.673 VOPP1_LOC100128 0.6180.806 0.033 0.004 VAMP2 0.673 SLC11A1 0.785 0.892 0.001 0.019 VAMP20.673 ABCA1 0.866 0.922 0 0.018 VAMP2 0.673 GSTO1 0.793 0.891 0 0.019VAMP2 0.673 CLEC4A 0.87 0.932 0 0.003 VAMP2 0.673 NEK6_LOC1001290 0.7650.892 0 0.011 VAMP2 0.673 MACF1 0.742 0.837 0.02 0.002 VAMP2 0.673GALNT2 0.651 0.802 0.01 0.026 VAMP2 0.673 OR9A2 0.813 0.871 0.004 0.032VAMP2 0.673 DPH3 0.86 0.92 0 0.017 VAMP2 0.673 TRIM21 0.874 0.944 00.042 VAMP2 0.673 ICAM1 0.821 0.916 0 0.024 VAMP2 0.673 TAF13 0.8540.914 0 0.005 VAMP2 0.673 P4HA1_RPL17 0.715 0.819 0.033 0.001 VAMP20.673 KLHL5 0.826 0.91 0 0.004 VAMP2 0.673 ANKRD28 0.8 0.906 0 0.02VAMP2 0.673 LAIR1_LAIR2 0.749 0.878 0.002 0.002 VAMP2 0.673UBE2F_C20orf194 0.762 0.863 0.007 0.002 VAMP2 0.673 KDM6B_TMEM88 0.7110.852 0.003 0.014 VAMP2 0.673 DYNLL1 0.776 0.829 0.024 0.028 VAMP2 0.673FAM118B 0.737 0.828 0.02 0.031 VAMP2 0.673 PLEKHF2 0.822 0.897 0.0010.008 VAMP2 0.673 AIF1 0.816 0.888 0.001 0.016 VAMP2 0.673 CALM2_C2orf610.733 0.838 0.019 0.002 IFI16 0.912 CASS4 0.877 0.989 0.005 0.001 IFI160.912 ITK 0.899 0.99 0.006 0.002 IFI16 0.912 GOT2 0.905 0.974 0.0490.003 IFI16 0.912 CCR3 0.905 0.97 0.037 0.005 IFI16 0.912 CHI3L1 0.9090.974 0.034 0.017 IFI16 0.912 GIMAP7 0.755 0.979 0.005 0 IFI16 0.912RUNX2 0.848 0.963 0.017 0.002 IFI16 0.912 HLA-DRA 0.768 0.976 0.012 0IFI16 0.912 NPCDR1 0.86 0.97 0.038 0 IFI16 0.912 TSHZ2 0.801 0.962 0.0460 JKAMP 0.93 MRPL41 0.811 0.981 0.041 0 JKAMP 0.93 CASS4 0.877 0.9880.016 0.001 JKAMP 0.93 ITK 0.899 0.987 0.026 0.002 JKAMP 0.93 GOT2 0.9050.986 0.021 0.007 JKAMP 0.93 B3GAT3 0.783 0.985 0.008 0 JKAMP 0.93HIST1H4E 0.83 0.999 0.009 0 JKAMP 0.93 ANAPC11 0.818 0.979 0.022 0 JKAMP0.93 RUNX2 0.848 0.979 0.023 0.001 JKAMP 0.93 PDE3B 0.85 0.999 0.009 0MRPL41 0.811 TCN1 0.816 0.933 0.014 0.002 MRPL41 0.811 CD63 0.757 0.9580 0.001 MRPL41 0.811 BPI 0.83 0.924 0.024 0.003 MRPL41 0.811 HSPC1590.823 0.922 0.001 0.035 MRPL41 0.811 PPP2R5A_SNORA16 0.775 0.927 0.0010.004 MRPL41 0.811 TMTC1 0.826 0.9 0.042 0.014 MRPL41 0.811 SEC24A_SAR1B0.761 0.926 0 0.004 MRPL41 0.811 SH3PXD2B 0.734 0.866 0.026 0.016 MRPL410.811 HMGB2 0.849 0.984 0 0.003 MRPL41 0.811 EXOSC4 0.731 0.916 0.0010.004 MRPL41 0.811 INSIG1 0.509 0.872 0.012 0 MRPL41 0.811 FOLR3_FOLR20.848 0.962 0 0.003 MRPL41 0.811 PRR13_PCBP2 0.77 0.889 0.017 0.024MRPL41 0.811 LGALS1 0.736 0.916 0 0.007 MRPL41 0.811 MTHFS 0.757 0.9230.001 0.006 MRPL41 0.811 EIF2AK2 0.857 0.935 0.002 0.04 MRPL41 0.811SIAE 0.814 0.935 0 0.024 MRPL41 0.811 ABCA13 0.868 0.962 0.001 0.001MRPL41 0.811 CDA 0.804 0.938 0 0.011 MRPL41 0.811 SAP30 0.728 0.8530.023 0.045 MRPL41 0.811 SUCNR1 0.922 0.986 0 0.012 MRPL41 0.811 AIG10.842 0.97 0 0.002 MRPL41 0.811 HS2ST1_UBA2 0.758 0.908 0 0.015 MRPL410.811 C22orf37 0.582 0.88 0.018 0 MRPL41 0.811 VOPP1_LOC100128 0.6180.892 0.003 0 MRPL41 0.811 SLC39A8 0.698 0.898 0.007 0.002 MRPL41 0.811SLC11A1 0.785 0.915 0 0.033 MRPL41 0.811 TREML1 0.793 0.918 0.006 0.013MRPL41 0.811 GSTO1 0.793 0.949 0.001 0.003 MRPL41 0.811 CLEC4A 0.870.952 0.001 0.028 MRPL41 0.811 NEK6_LOC1001290 0.765 0.906 0.001 0.021MRPL41 0.811 MACF1 0.742 0.907 0.016 0.001 MRPL41 0.811 AMFR 0.69 0.8870.002 0.01 MRPL41 0.811 OR9A2 0.813 0.908 0.01 0.016 MRPL41 0.811 HDHD1A0.63 0.901 0.01 0 MRPL41 0.811 ACPL2 0.651 0.898 0.026 0 MRPL41 0.811DPH3 0.86 0.958 0 0.014 MRPL41 0.811 TAF13 0.854 0.958 0.003 0.001MRPL41 0.811 P4HA1_RPL17 0.715 0.897 0.046 0 MRPL41 0.811 KLHL5 0.8260.92 0.002 0.038 MRPL41 0.811 ANKRD28 0.8 0.938 0 0.01 MRPL41 0.811MGST3 0.602 0.916 0.005 0 MRPL41 0.811 HSPB1_HSPBL2 0.778 0.884 0.0080.04 MRPL41 0.811 LHFP 0.759 0.86 0.019 0.045 MRPL41 0.811 LAIR1_LAIR20.749 0.904 0.014 0.004 MRPL41 0.811 PTGS1 0.68 0.889 0.012 0.001 MRPL410.811 UBE2F_C20orf194 0.762 0.958 0 0 MRPL41 0.811 SRXN1 0.612 0.890.028 0 MRPL41 0.811 KDM6B_TMEM88 0.711 0.86 0.032 0.019 MRPL41 0.811MYL9 0.771 0.916 0.001 0.011 MRPL41 0.811 HIST1H2BJ 0.697 0.905 0.031 0MRPL41 0.811 CEP97 0.695 0.933 0.002 0 MRPL41 0.811 DYNLL1 0.776 0.950.002 0 MRPL41 0.811 FAM118B 0.737 0.914 0.004 0.002 MRPL41 0.811CTSL1_CTSLL3 0.715 0.919 0.016 0 MRPL41 0.811 NP 0.633 0.888 0.015 0MRPL41 0.811 PLEKHA3 0.658 0.906 0.005 0 MRPL41 0.811 TMEM62_SPCS2_L0.645 0.895 0.019 0 MRPL41 0.811 PLEKHF2 0.822 0.934 0.004 0.006 MRPL410.811 CMTM5 0.694 0.889 0.019 0.001 MRPL41 0.811 AIF1 0.816 0.931 0.0010.018 MRPL41 0.811 CDC26 0.619 0.904 0.004 0 MRPL41 0.811 CALM2_C2orf610.733 0.959 0 0 OLFM4 0.806 KLRD1 0.784 0.901 0.005 0.024 OLFM4 0.806HIST1H3J 0.722 0.883 0.029 0.002 OLFM4 0.806 HIST1H3A 0.715 0.887 0.0060.005 OLFM4 0.806 PMS2CL_PMS2 0.685 0.852 0.028 0.012 OLFM4 0.806 NA0.763 0.877 0.009 0.035 OLFM4 0.806 B4GALT3 0.659 0.859 0.008 0.012OLFM4 0.806 CFD 0.767 0.889 0.012 0.027 OLFM4 0.806 IGL@_IGLV1-44_(—)0.657 0.846 0.043 0.027 CASS4 0.877 WSB2 0.911 0.984 0.001 0.005 CASS40.877 CLU 0.894 0.97 0.001 0.007 CASS4 0.877 HPSE 0.939 0.997 0 0.009CASS4 0.877 C1orf161 0.888 0.963 0.016 0.009 CASS4 0.877 HPGD 0.8710.968 0.018 0.01 CASS4 0.877 LRRC70_IPO11 0.923 0.974 0.002 0.021 CASS40.877 TMEM144_LOC2855 0.92 0.966 0.023 0.017 CASS4 0.877 CDS2 0.8690.977 0.001 0.006 CASS4 0.877 OLAH 0.885 0.97 0.006 0.005 CASS4 0.877PPP2R5A_SNORA16 0.775 0.96 0.016 0 CASS4 0.877 EAF2_HCG11_LOC 0.917 0.970.011 0.013 CASS4 0.877 RCBTB2_LOC10013 0.905 0.989 0.001 0.004 CASS40.877 SEC24A_SAR1B 0.761 0.95 0.018 0 CASS4 0.877 HMGB2 0.849 0.963 0.020.003 CASS4 0.877 NA 0.866 0.977 0.008 0.001 CASS4 0.877 PRR13_PCBP20.77 0.967 0.012 0 CASS4 0.877 CCR1 0.897 0.977 0.001 0.011 CASS4 0.877FFAR2 0.868 0.978 0.003 0.001 CASS4 0.877 MTHFS 0.757 0.979 0.003 0CASS4 0.877 EIF2AK2 0.857 0.95 0.04 0.004 CASS4 0.877 SIAE 0.814 0.9520.006 0.001 CASS4 0.877 ABCA13 0.868 0.967 0.013 0.001 CASS4 0.877 CDA0.804 0.961 0.017 0 CASS4 0.877 AGTRAP 0.856 0.937 0.024 0.012 CASS40.877 SUCNR1 0.922 0.969 0.004 0.021 CASS4 0.877 AIG1 0.842 0.961 0.0140.001 CASS4 0.877 GAB2 0.729 0.981 0.002 0 CASS4 0.877 HS2ST1_UBA2 0.7580.943 0.027 0 CASS4 0.877 SLC11A1 0.785 0.969 0.003 0.001 CASS4 0.877ABCA1 0.866 0.963 0.023 0.002 CASS4 0.877 CLEC4A 0.87 0.963 0.028 0.003CASS4 0.877 NEK6_LOC1001290 0.765 0.965 0.002 0 CASS4 0.877 GPR65 0.8860.952 0.044 0.007 CASS4 0.877 ACTA2 0.783 0.943 0.041 0.001 CASS4 0.877KCNMA1 0.897 0.959 0.006 0.042 CASS4 0.877 DPH3 0.86 0.967 0.013 0.001CASS4 0.877 TRIM21 0.874 0.993 0.001 0.003 CASS4 0.877 ICAM1 0.821 0.9590.004 0.002 CASS4 0.877 KLHL5 0.826 0.955 0.042 0 CASS4 0.877DLEU2_DLEU2L 0.874 0.969 0.005 0.001 CASS4 0.877 ANKRD28 0.8 0.97 0.0070 CASS4 0.877 IL1B 0.871 0.98 0.002 0.005 CASS4 0.877 KDM6B_TMEM88 0.7110.959 0.004 0 CASS4 0.877 ATP6V0D1_LOC100 0.856 0.957 0.001 0.025 CASS40.877 AIF1 0.816 0.956 0.043 0.001 TCN1 0.816 KPNA5 0.705 0.881 0.0430.002 TCN1 0.816 KLRK1_KLRC4 0.857 0.943 0.003 0.025 TCN1 0.816 B3GAT30.783 0.896 0.004 0.042 TCN1 0.816 FGFBP2 0.812 0.937 0.006 0.004 TCN10.816 KLRD1 0.784 0.918 0.02 0.003 TCN1 0.816 CHI3L1 0.909 0.985 0 0.024TCN1 0.816 GIMAP7 0.755 0.88 0.027 0.022 TCN1 0.816 DNAJC9_FAM149B10.811 0.94 0.004 0.006 TCN1 0.816 PLA2G7 0.834 0.914 0.011 0.043 TCN10.816 HSP90AB1_HSP90A 0.799 0.91 0.011 0.043 TCN1 0.816 NA 0.763 0.9030.014 0.003 TCN1 0.816 C15orf54 0.821 0.914 0.017 0.014 TCN1 0.816 CCR40.784 0.915 0.01 0.007 TCN1 0.816 FAM118A 0.759 0.893 0.017 0.016 TCN10.816 PYHIN1 0.807 0.914 0.007 0.032 TCN1 0.816 CLC 0.81 0.939 0.0020.017 TCN1 0.816 B4GALT3 0.659 0.88 0.017 0.002 TCN1 0.816RASA4_RASA4P_R 0.779 0.901 0.003 0.015 TCN1 0.816 CAMK1D 0.702 0.8650.02 0.012 TCN1 0.816 IL5RA 0.832 0.917 0.004 0.047 TCN1 0.816 C1orf1280.751 0.896 0.047 0.004 TCN1 0.816 IGL@_IGLV1-44_(—) 0.657 0.871 0.040.007 WSB2 0.911 ITK 0.899 0.987 0.007 0.002 WSB2 0.911 GOT2 0.905 0.9930.005 0.008 WSB2 0.911 B3GAT3 0.783 0.979 0.022 0 WSB2 0.911 HIST1H4E0.83 0.968 0.039 0 WSB2 0.911 CCR3 0.905 0.968 0.045 0.003 WSB2 0.911CHI3L1 0.909 0.981 0.019 0.024 WSB2 0.911 RUNX2 0.848 0.977 0.017 0 WSB20.911 HLA-DRA 0.768 0.968 0.049 0 CLU 0.894 ITK 0.899 0.956 0.042 0.004CLU 0.894 GOT2 0.905 0.968 0.03 0.004 CLU 0.894 HIST1H4E 0.83 0.9610.016 0.001 CLU 0.894 CCR3 0.905 0.966 0.022 0.005 CLU 0.894 CHI3L10.909 0.985 0.006 0.019 CLU 0.894 RUNX2 0.848 0.97 0.005 0.003 CLU 0.894PHOSPHO1 0.85 0.984 0.004 0.002 CLU 0.894 SULF2 0.819 0.966 0.016 0.001CLU 0.894 LASS4 0.794 0.959 0.002 0.004 CLU 0.894 TSHZ2 0.801 0.9540.045 0 KPNA5 0.705 PPP2R5A_SNORA16 0.775 0.888 0 0.036 KPNA5 0.705 NA0.866 0.934 0 0.033 KPNA5 0.705 MTRR 0.703 0.814 0.013 0.049 KPNA5 0.705HDHD1A 0.63 0.816 0.009 0.006 KPNA5 0.705 LRRFIP1 0.673 0.802 0.0430.009 KPNA5 0.705 DPH3 0.86 0.935 0 0.045 KPNA5 0.705 TAF13 0.854 0.9430 0.021 KPNA5 0.705 P4HA1_RPL17 0.715 0.866 0.002 0.003 KPNA5 0.705DLEU2_DLEU2L 0.874 0.956 0 0.017 KPNA5 0.705 MGST3 0.602 0.805 0.0060.01 KPNA5 0.705 FSD1L_GARNL1 0.66 0.829 0.019 0.006 KPNA5 0.705 NA0.705 0.867 0.01 0 KPNA5 0.705 UBE2F_C20orf194 0.762 0.879 0 0.023 KPNA50.705 CEP97 0.695 0.841 0.005 0.017 KPNA5 0.705 DYNLL1 0.776 0.896 0.0010.001 KPNA5 0.705 FAM118B 0.737 0.842 0.004 0.047 KPNA5 0.705 PLEKHA30.658 0.873 0 0.001 KPNA5 0.705 TMEM62_SPCS2_L 0.645 0.843 0 0.007 KPNA50.705 PLEKHF2 0.822 0.961 0 0.002 KPNA5 0.705 CMTM5 0.694 0.797 0.0360.044 KPNA5 0.705 CDC26 0.619 0.786 0.025 0.018 KPNA5 0.705CALM2_C2orf61 0.733 0.913 0 0 PLAC8 0.767 ITK 0.899 0.971 0 0.005 PLAC80.767 B3GAT3 0.783 0.901 0.003 0.036 PLAC8 0.767 GIMAP7 0.755 0.8770.021 0.008 PLAC8 0.767 HLA-DRA 0.768 0.891 0.015 0.021 PLAC8 0.767PLA2G7 0.834 0.9 0.024 0.01 PLAC8 0.767 C15orf54 0.821 0.887 0.007 0.034PLAC8 0.767 LY6G5B_CSNK2B 0.661 0.851 0.037 0.001 PLAC8 0.767 CLC 0.810.89 0.026 0.02 CD63 0.757 GOT2 0.905 0.962 0 0.041 CD63 0.757 B3GAT30.783 0.961 0 0 CD63 0.757 HIST1H4E 0.83 0.957 0.001 0.001 CD63 0.757FGFBP2 0.812 0.879 0.045 0.006 CD63 0.757 ANAPC11 0.818 0.925 0.0030.004 CD63 0.757 RUNX2 0.848 0.921 0.002 0.029 CD63 0.757 PDE3B 0.850.917 0.008 0.016 CD63 0.757 JUP 0.804 0.885 0.013 0.039 CD63 0.757NPCDR1 0.86 0.905 0.004 0.043 CD63 0.757 C15orf54 0.821 0.879 0.0480.009 CD63 0.757 CCR4 0.784 0.879 0.022 0.009 CD63 0.757 LASS4 0.7940.92 0.003 0.016 CD63 0.757 TSHZ2 0.801 0.883 0.025 0.015 CD63 0.757RASA4_RASA4P_R 0.779 0.861 0.027 0.016 HPSE 0.939 ITK 0.899 0.997 0.0080.002 HPSE 0.939 GOT2 0.905 0.996 0.011 0.006 HPSE 0.939 HIST1H4E 0.830.979 0.029 0 HPSE 0.939 CHI3L1 0.909 0.998 0.009 0.016 HPSE 0.939GIMAP7 0.755 0.994 0.01 0 HPSE 0.939 RUNX2 0.848 0.984 0.025 0 HPSE0.939 LY6G5B_CSNK2B 0.661 0.985 0.028 0 HPSE 0.939 CCR4 0.784 0.9920.015 0 HPSE 0.939 PYHIN1 0.807 0.989 0.029 0 C1orf161 0.888 CCR3 0.9050.954 0.038 0.038 C1orf161 0.888 RUNX2 0.848 0.967 0.02 0.005 C1orf1610.888 PHOSPHO1 0.85 0.954 0.035 0.017 C1orf161 0.888 PDE3B 0.85 0.9590.019 0.011 C1orf161 0.888 ABCG1 0.789 0.95 0.008 0.008 KLRK1_KLRC40.857 ATP13A3 0.841 0.965 0.001 0.022 KLRK1_KLRC4 0.857 HSPC159 0.8230.94 0.008 0.007 KLRK1_KLRC4 0.857 PPP2R5A_SNORA16 0.775 0.947 0.0020.003 KLRK1_KLRC4 0.857 TMTC1 0.826 0.934 0.012 0.013 KLRK1_KLRC4 0.857HMGB2 0.849 0.951 0.007 0.024 KLRK1_KLRC4 0.857 NA 0.866 0.95 0.0030.034 KLRK1_KLRC4 0.857 FOLR3_FOLR2 0.848 0.942 0.017 0.009 KLRK1_KLRC40.857 LGALS1 0.736 0.905 0.02 0.009 KLRK1_KLRC4 0.857 MTHFS 0.757 0.9070.021 0.007 KLRK1_KLRC4 0.857 EIF2AK2 0.857 0.946 0.018 0.009KLRK1_KLRC4 0.857 SIAE 0.814 0.932 0.004 0.017 KLRK1_KLRC4 0.857 CDA0.804 0.917 0.033 0.015 KLRK1_KLRC4 0.857 SAP30 0.728 0.89 0.009 0.011KLRK1_KLRC4 0.857 AIG1 0.842 0.93 0.021 0.04 KLRK1_KLRC4 0.857HS2ST1_UBA2 0.758 0.902 0.017 0.017 KLRK1_KLRC4 0.857 SLC11A1 0.7850.896 0.022 0.039 KLRK1_KLRC4 0.857 TREML1 0.793 0.919 0.038 0.011KLRK1_KLRC4 0.857 GSTO1 0.793 0.934 0.004 0.017 KLRK1_KLRC4 0.857NEK6_LOC1001290 0.765 0.886 0.025 0.039 KLRK1_KLRC4 0.857 DPH3 0.860.942 0.002 0.034 KLRK1_KLRC4 0.857 TAF13 0.854 0.953 0.015 0.016KLRK1_KLRC4 0.857 KLHL5 0.826 0.921 0.015 0.043 KLRK1_KLRC4 0.857DLEU2_DLEU2L 0.874 0.954 0.003 0.023 KLRK1_KLRC4 0.857 ANKRD28 0.8 0.9450.005 0.006 KLRK1_KLRC4 0.857 HSPB1_HSPBL2 0.778 0.918 0.012 0.006KLRK1_KLRC4 0.857 LHFP 0.759 0.903 0.012 0.007 KLRK1_KLRC4 0.857 ZRANB10.724 0.923 0.014 0 KLRK1_KLRC4 0.857 UBE2F_C20orf194 0.762 0.916 0.0130.002 KLRK1_KLRC4 0.857 MYL9 0.771 0.912 0.023 0.011 KLRK1_KLRC4 0.857CEP97 0.695 0.929 0.031 0 KLRK1_KLRC4 0.857 DYNLL1 0.776 0.95 0.017 0KLRK1_KLRC4 0.857 FAM118B 0.737 0.933 0.024 0 KLRK1_KLRC4 0.857 PLEKHA30.658 0.913 0.014 0 KLRK1_KLRC4 0.857 TMEM62_SPCS2_L 0.645 0.94 0.007 0KLRK1_KLRC4 0.857 PLEKHF2 0.822 0.939 0.005 0.015 KLRK1_KLRC4 0.857CALM2_C2orf61 0.733 0.914 0.01 0.001 ATP13A3 0.841 ITK 0.899 0.978 0.0040.044 ATP13A3 0.841 B3GAT3 0.783 0.94 0.018 0.002 ATP13A3 0.841 HIST1H4E0.83 0.937 0.009 0.03 ATP13A3 0.841 GIMAP7 0.755 0.92 0.026 0.009ATP13A3 0.841 ANAPC11 0.818 0.941 0.012 0.01 ATP13A3 0.841 RUNX2 0.8480.945 0.007 0.032 ATP13A3 0.841 PDE3B 0.85 0.961 0.01 0.017 ATP13A30.841 NPCDR1 0.86 0.937 0.024 0.026 ATP13A3 0.841 CCR4 0.784 0.947 0.010.002 ATP13A3 0.841 ABCG1 0.789 0.909 0.017 0.039 ATP13A3 0.841 PYHIN10.807 0.941 0.021 0.006 ATP13A3 0.841 TSHZ2 0.801 0.94 0.004 0.016ATP13A3 0.841 RASA4_RASA4P_R 0.779 0.903 0.039 0.02 ITK 0.899 PDGFC0.837 0.961 0.01 0.011 ITK 0.899 HPGD 0.871 0.955 0.033 0.034 ITK 0.899TMEM144_LOC2855 0.92 0.983 0.005 0.039 ITK 0.899 PPP2R5A_SNORA16 0.7750.977 0.006 0 ITK 0.899 EAF2_HCG11_LOC 0.917 0.992 0.004 0.021 ITK 0.899RCBTB2_LOC10013 0.905 0.973 0.011 0.024 ITK 0.899 SEC24A_SAR1B 0.7610.977 0.005 0 ITK 0.899 HMGB2 0.849 0.976 0.008 0.004 ITK 0.899 SLC39A90.551 0.969 0.006 0 ITK 0.899 NA 0.866 0.978 0.009 0.002 ITK 0.899 FFAR20.868 0.957 0.021 0.004 ITK 0.899 MTHFS 0.757 0.962 0.009 0 ITK 0.899EIF2AK2 0.857 0.98 0.009 0.001 ITK 0.899 SIAE 0.814 0.961 0.006 0.001ITK 0.899 ABCA13 0.868 0.953 0.046 0.004 ITK 0.899 CDA 0.804 0.96 0.0150.001 ITK 0.899 SUCNR1 0.922 0.976 0.004 0.03 ITK 0.899 MTRR 0.703 0.9930.002 0 ITK 0.899 AIG1 0.842 0.976 0.004 0.001 ITK 0.899 HS2ST1_UBA20.758 0.948 0.01 0.001 ITK 0.899 GSTO1 0.793 0.966 0.019 0 ITK 0.899CLEC4A 0.87 0.978 0.008 0.003 ITK 0.899 TRAF3 0.594 0.966 0.007 0 ITK0.899 GPR65 0.886 0.974 0.004 0.02 ITK 0.899 MACF1 0.742 0.978 0.023 0ITK 0.899 GALNT2 0.651 0.932 0.045 0 ITK 0.899 HDHD1A 0.63 0.961 0.016 0ITK 0.899 ACTA2 0.783 0.953 0.015 0.001 ITK 0.899 LRRFIP1 0.673 0.9810.009 0 ITK 0.899 SFRS9 0.527 0.959 0.021 0 ITK 0.899 DPH3 0.86 0.9610.021 0.003 ITK 0.899 TRIM21 0.874 0.985 0.002 0.005 ITK 0.899 ICAM10.821 0.944 0.015 0.007 ITK 0.899 TAF13 0.854 0.974 0.01 0.002 ITK 0.899P4HA1_RPL17 0.715 0.984 0.007 0 ITK 0.899 KLHL5 0.826 0.984 0.003 0 ITK0.899 DLEU2_DLEU2L 0.874 0.959 0.033 0.003 ITK 0.899 ANKRD28 0.8 0.9750.011 0 ITK 0.899 CCDC125 0.632 0.968 0.018 0 ITK 0.899 LAIR1_LAIR20.749 0.979 0.006 0 ITK 0.899 CEP97 0.695 0.967 0.015 0 ITK 0.899 DYNLL10.776 0.97 0.035 0 ITK 0.899 PLIN2 0.671 0.971 0.009 0 ITK 0.899 FAM118B0.737 0.989 0.003 0 ITK 0.899 NP 0.633 0.956 0.041 0 ITK 0.899TMEM62_SPCS2_L 0.645 0.977 0.011 0 ITK 0.899 PLEKHF2 0.822 0.958 0.0420.001 ITK 0.899 AIF1 0.816 0.961 0.022 0.001 ITK 0.899 DCTN5 0.557 0.9880.004 0 PMAIP1 0.622 NA 0.705 0.808 0.009 0.026 GOT2 0.905 LRRC70_IPO110.923 0.972 0.024 0.042 GOT2 0.905 PPP2R5A_SNORA16 0.775 0.96 0.048 0GOT2 0.905 EAF2_HCG11_LOC 0.917 0.978 0.018 0.04 GOT2 0.905RCBTB2_LOC10013 0.905 0.968 0.007 0.037 GOT2 0.905 SEC24A_SAR1B 0.7610.965 0.014 0 GOT2 0.905 FOLR3_FOLR2 0.848 0.964 0.046 0.002 GOT2 0.905CCR1 0.897 0.963 0.024 0.024 GOT2 0.905 FFAR2 0.868 0.961 0.02 0.007GOT2 0.905 EIF2AK2 0.857 0.975 0.021 0.003 GOT2 0.905 SIAE 0.814 0.9670.013 0.001 GOT2 0.905 AGTRAP 0.856 0.949 0.04 0.023 GOT2 0.905 SUCNR10.922 0.992 0.011 0.008 GOT2 0.905 AIG1 0.842 0.979 0.028 0.001 GOT20.905 GSTO1 0.793 0.985 0.012 0 GOT2 0.905 CLEC4A 0.87 0.978 0.009 0.006GOT2 0.905 ACTA2 0.783 0.948 0.032 0.002 GOT2 0.905 TRIM21 0.874 0.9890.005 0.005 GOT2 0.905 ICAM1 0.821 0.956 0.018 0.007 GOT2 0.905 TAF130.854 0.972 0.049 0.001 GOT2 0.905 KLHL5 0.826 0.961 0.024 0.002 GOT20.905 DLEU2_DLEU2L 0.874 0.948 0.037 0.018 GOT2 0.905 ANKRD28 0.8 0.9670.038 0.001 GOT2 0.905 LAIR1_LAIR2 0.749 0.968 0.041 0 GOT2 0.905 AIF10.816 0.958 0.02 0.004 GOT2 0.905 CALM2_C2orf61 0.733 0.961 0.047 0PDGFC 0.837 B3GAT3 0.783 0.958 0.01 0 PDGFC 0.837 HIST1H4E 0.83 0.9480.02 0.002 PDGFC 0.837 RUNX2 0.848 0.966 0.004 0.008 PDGFC 0.837PMS2CL_PMS2 0.685 0.924 0.027 0 PDGFC 0.837 PDE3B 0.85 0.945 0.01 0.034PDGFC 0.837 NPCDR1 0.86 0.925 0.035 0.041 PDGFC 0.837 CCR4 0.784 0.9350.028 0.001 PDGFC 0.837 FAM118A 0.759 0.907 0.05 0.009 PDGFC 0.837 TSHZ20.801 0.929 0.026 0.009 B3GAT3 0.783 HPGD 0.871 0.945 0 0.047 B3GAT30.783 LRRC70_IPO11 0.923 0.96 0 0.04 B3GAT3 0.783 BPI 0.83 0.901 0.0310.004 B3GAT3 0.783 PPP2R5A_SNORA16 0.775 0.9 0.011 0.006 B3GAT3 0.783SEC24A_SAR1B 0.761 0.944 0.001 0 B3GAT3 0.783 HMGB2 0.849 0.967 0 0.004B3GAT3 0.783 EXOSC4 0.731 0.93 0 0.001 B3GAT3 0.783 FOLR3_FOLR2 0.8480.957 0 0.003 B3GAT3 0.783 PRR13_PCBP2 0.77 0.889 0.029 0.006 B3GAT30.783 LGALS1 0.736 0.912 0.002 0.003 B3GAT3 0.783 FFAR2 0.868 0.95 00.008 B3GAT3 0.783 MTHFS 0.757 0.926 0.001 0.001 B3GAT3 0.783 EIF2AK20.857 0.914 0.013 0.013 B3GAT3 0.783 SIAE 0.814 0.947 0 0.006 B3GAT30.783 ABCA13 0.868 0.934 0.002 0.02 B3GAT3 0.783 CDA 0.804 0.942 0 0.003B3GAT3 0.783 AGTRAP 0.856 0.952 0 0.025 B3GAT3 0.783 AIG1 0.842 0.963 00.001 B3GAT3 0.783 PCOLCE2 0.709 0.872 0.033 0.001 B3GAT3 0.783HS2ST1_UBA2 0.758 0.92 0.001 0.003 B3GAT3 0.783 VOPP1_LOC100128 0.6180.865 0.028 0 B3GAT3 0.783 SLC11A1 0.785 0.894 0.003 0.049 B3GAT3 0.783GSTO1 0.793 0.934 0.002 0.001 B3GAT3 0.783 CLEC4A 0.87 0.952 0.001 0.006B3GAT3 0.783 NEK6_LOC1001290 0.765 0.906 0.002 0.01 B3GAT3 0.783 GALNT20.651 0.889 0.012 0 B3GAT3 0.783 GLT25D1 0.607 0.876 0.035 0 B3GAT30.783 OR9A2 0.813 0.882 0.029 0.03 B3GAT3 0.783 ACTA2 0.783 0.897 0.0240.008 B3GAT3 0.783 DPH3 0.86 0.944 0.001 0.014 B3GAT3 0.783 TRIM21 0.8740.968 0 0.012 B3GAT3 0.783 ICAM1 0.821 0.94 0 0.012 B3GAT3 0.783 TAF130.854 0.944 0.005 0.001 B3GAT3 0.783 KLHL5 0.826 0.923 0.003 0.009B3GAT3 0.783 ANKRD28 0.8 0.93 0.002 0.004 B3GAT3 0.783 IL1B 0.871 0.9290.003 0.041 B3GAT3 0.783 LAIR1_LAIR2 0.749 0.906 0.014 0.001 B3GAT30.783 UBE2F_C20orf194 0.762 0.924 0.011 0 B3GAT3 0.783 CCRL2 0.786 0.8810.048 0.02 B3GAT3 0.783 KDM6B_TMEM88 0.711 0.857 0.04 0.014 B3GAT3 0.783MYL9 0.771 0.87 0.014 0.035 B3GAT3 0.783 IRF1 0.651 0.872 0.04 0 B3GAT30.783 FAM118B 0.737 0.888 0.046 0.001 B3GAT3 0.783 CTSL1_CTSLL3 0.7150.916 0.011 0 B3GAT3 0.783 PLEKHA3 0.658 0.869 0.043 0 B3GAT3 0.783PLEKHF2 0.822 0.917 0.007 0.009 B3GAT3 0.783 AIF1 0.816 0.939 0.0010.002 B3GAT3 0.783 CALM2_C2orf61 0.733 0.913 0.008 0 HIST1H4E 0.83 HPGD0.871 0.948 0.003 0.042 HIST1H4E 0.83 LRRC70_IPO11 0.923 0.975 0 0.042HIST1H4E 0.83 ECHDC3 0.629 0.892 0.042 0 HIST1H4E 0.83 HSPC159 0.8230.936 0.031 0.001 HIST1H4E 0.83 OLAH 0.885 0.968 0 0.025 HIST1H4E 0.83PPP2R5A_SNORA16 0.775 0.953 0.005 0 HIST1H4E 0.83 HMGB2 0.849 0.9590.008 0.003 HIST1H4E 0.83 EXOSC4 0.731 0.957 0 0 HIST1H4E 0.83 NA 0.8660.926 0.024 0.011 HIST1H4E 0.83 FOLR3_FOLR2 0.848 0.967 0.002 0.001HIST1H4E 0.83 LGALS1 0.736 0.946 0.002 0 HIST1H4E 0.83 MTHFS 0.757 0.9210.006 0.001 HIST1H4E 0.83 SIAE 0.814 0.979 0 0 HIST1H4E 0.83 ABCA130.868 0.971 0.003 0.001 HIST1H4E 0.83 EFCAB2 0.96 0.987 0 0.04 HIST1H4E0.83 CDA 0.804 0.955 0.002 0.001 HIST1H4E 0.83 SAP30 0.728 0.902 0.0080.003 HIST1H4E 0.83 AGTRAP 0.856 0.98 0 0.004 HIST1H4E 0.83 SUCNR1 0.9220.988 0.001 0.004 HIST1H4E 0.83 AIG1 0.842 0.951 0.01 0.001 HIST1H4E0.83 PCOLCE2 0.709 0.914 0.018 0 HIST1H4E 0.83 HS2ST1_UBA2 0.758 0.920.005 0.002 HIST1H4E 0.83 C22orf37 0.582 0.916 0.011 0 HIST1H4E 0.83VOPP1_LOC100128 0.618 0.906 0.023 0 HIST1H4E 0.83 SLC39A8 0.698 0.9340.021 0 HIST1H4E 0.83 SLC11A1 0.785 0.945 0.001 0.004 HIST1H4E 0.83GSTO1 0.793 0.925 0.023 0.003 HIST1H4E 0.83 CLEC4A 0.87 0.935 0.008 0.03HIST1H4E 0.83 NEK6_LOC1001290 0.765 0.919 0.001 0.005 HIST1H4E 0.83 AMFR0.69 0.9 0.034 0.001 HIST1H4E 0.83 OR9A2 0.813 0.914 0.044 0.003HIST1H4E 0.83 DPH3 0.86 0.965 0.001 0.002 HIST1H4E 0.83 TRIM21 0.8740.926 0.02 0.044 HIST1H4E 0.83 ICAM1 0.821 0.914 0.014 0.02 HIST1H4E0.83 TAF13 0.854 0.957 0.018 0.001 HIST1H4E 0.83 KLHL5 0.826 0.916 0.0370.014 HIST1H4E 0.83 DLEU2_DLEU2L 0.874 0.956 0.002 0.006 HIST1H4E 0.83ANKRD28 0.8 0.945 0.005 0.002 HIST1H4E 0.83 HSPB1_HSPBL2 0.778 0.9210.019 0.002 HIST1H4E 0.83 LHFP 0.759 0.897 0.01 0.005 HIST1H4E 0.83UBE2F_C20orf194 0.762 0.936 0.038 0 HIST1H4E 0.83 MYL9 0.771 0.948 0.0030.001 HIST1H4E 0.83 PLEKHA3 0.658 0.916 0.036 0 HIST1H4E 0.83 PLEKHF20.822 0.941 0.035 0 HIST1H4E 0.83 CMTM5 0.694 0.924 0.041 0 HIST1H4E0.83 AIF1 0.816 0.915 0.036 0.013 HIST1H4E 0.83 CDC26 0.619 0.908 0.0410 HIST1H4E 0.83 CALM2_C2orf61 0.733 0.938 0.021 0 HPGD 0.871 RUNX2 0.8480.95 0.009 0.029 HPGD 0.871 PDE3B 0.85 0.957 0.005 0.04 HPGD 0.871NPCDR1 0.86 0.94 0.048 0.014 HPGD 0.871 C15orf54 0.821 0.941 0.027 0.005HPGD 0.871 ABCG1 0.789 0.936 0.02 0.021 HPGD 0.871 LASS4 0.794 0.9350.033 0.017 HPGD 0.871 TSHZ2 0.801 0.935 0.035 0.01 FGFBP2 0.812 BPI0.83 0.913 0.018 0.017 FGFBP2 0.812 HSPC159 0.823 0.915 0.003 0.047FGFBP2 0.812 PPP2R5A_SNORA16 0.775 0.9 0.001 0.03 FGFBP2 0.812 TMTC10.826 0.917 0.004 0.038 FGFBP2 0.812 EXOSC4 0.731 0.865 0.032 0.018FGFBP2 0.812 PCOLCE2 0.709 0.86 0.022 0.009 FGFBP2 0.812 TREML1 0.7930.914 0.005 0.023 FGFBP2 0.812 AMFR 0.69 0.867 0.006 0.021 FGFBP2 0.812ANKRD28 0.8 0.913 0.002 0.037 FGFBP2 0.812 HSPB1_HSPBL2 0.778 0.8760.014 0.049 FGFBP2 0.812 LHFP 0.759 0.871 0.005 0.042 FGFBP2 0.812ZRANB1 0.724 0.877 0.025 0.007 FGFBP2 0.812 PTGS1 0.68 0.871 0.031 0.002FGFBP2 0.812 UBE2F_C20orf194 0.762 0.895 0.005 0.01 FGFBP2 0.812 MYL90.771 0.905 0.004 0.019 FGFBP2 0.812 HIST1H2BJ 0.697 0.887 0.035 0.002FGFBP2 0.812 CEP97 0.695 0.882 0.031 0.002 FGFBP2 0.812 DYNLL1 0.7760.901 0.031 0.002 FGFBP2 0.812 FAM118B 0.737 0.885 0.039 0.007 FGFBP20.812 SPARC 0.703 0.889 0.026 0.001 FGFBP2 0.812 PLEKHA3 0.658 0.8660.034 0.002 FGFBP2 0.812 CMTM5 0.694 0.868 0.047 0.004 FGFBP2 0.812CALM2_C2orf61 0.733 0.865 0.028 0.019 LRRC70_IPO11 0.923 RUNX2 0.8480.965 0.022 0.005 LRRC70_IPO11 0.923 PHOSPHO1 0.85 0.965 0.018 0.009LRRC70_IPO11 0.923 PDE3B 0.85 0.987 0.021 0.001 LRRC70_IPO11 0.923 ABCG10.789 0.979 0.015 0.001 TMEM144_LOC2855 0.92 CCR3 0.905 0.986 0.0360.005 TMEM144_LOC2855 0.92 GIMAP7 0.755 0.99 0.02 0 TMEM144_LOC2855 0.92RUNX2 0.848 0.963 0.035 0.009 TMEM144_LOC2855 0.92 HLA-DRA 0.768 0.9750.047 0 TMEM144_LOC2855 0.92 PLA2G7 0.834 0.985 0.047 0.001TMEM144_LOC2855 0.92 PMS2CL_PMS2 0.685 0.952 0.043 0 TMEM144_LOC28550.92 PDE3B 0.85 0.968 0.021 0.011 TMEM144_LOC2855 0.92 CCR4 0.784 0.990.014 0 TMEM144_LOC2855 0.92 ABCG1 0.789 0.962 0.021 0.001TMEM144_LOC2855 0.92 FAM118A 0.759 0.949 0.033 0.001 TMEM144_LOC28550.92 TSHZ2 0.801 0.967 0.029 0.001 TMEM144_LOC2855 0.92 CFD 0.767 0.9630.042 0 CDS2 0.869 CHI3L1 0.909 0.965 0.042 0.01 CDS2 0.869 RUNX2 0.8480.979 0.005 0.001 BPI 0.83 DNAJC9_FAM149B1 0.811 0.914 0.014 0.022 BPI0.83 IRS2 0.648 0.879 0.047 0.002 BPI 0.83 NA 0.763 0.897 0.023 0.004BPI 0.83 CCR4 0.784 0.894 0.029 0.024 BPI 0.83 RRP12_LOC644215 0.6320.869 0.038 0.001 BPI 0.83 CLC 0.81 0.926 0.006 0.021 BPI 0.83 B4GALT30.659 0.898 0.004 0.001 BPI 0.83 RASA4_RASA4P_R 0.779 0.897 0.012 0.017ECHDC3 0.629 PHOSPHO1 0.85 0.941 0 0.033 ECHDC3 0.629 HIST1H3J 0.7220.784 0.034 0.012 ECHDC3 0.629 HIST1H3A 0.715 0.796 0.022 0.011 ECHDC30.629 IRS2 0.648 0.871 0 0.005 ECHDC3 0.629 S100B 0.72 0.799 0.018 0.005ECHDC3 0.629 C4orf3 0.629 0.744 0.031 0.049 ECHDC3 0.629 TAS2R31 0.6850.751 0.028 0.046 CCR3 0.905 RCBTB2_LOC10013 0.905 0.974 0.005 0.02 CCR30.905 SEC24A_SAR1B 0.761 0.943 0.024 0 CCR3 0.905 NA 0.866 0.968 0.0150.004 CCR3 0.905 CCR1 0.897 0.978 0.005 0.015 CCR3 0.905 FFAR2 0.8680.975 0.005 0.003 CCR3 0.905 EIF2AK2 0.857 0.967 0.022 0.002 CCR3 0.905SIAE 0.814 0.946 0.029 0.002 CCR3 0.905 AGTRAP 0.856 0.948 0.015 0.021CCR3 0.905 SUCNR1 0.922 0.978 0.004 0.033 CCR3 0.905 AIG1 0.842 0.9540.028 0.004 CCR3 0.905 GAB2 0.729 0.948 0.045 0 CCR3 0.905 ABCA1 0.8660.976 0.012 0.009 CCR3 0.905 GSTO1 0.793 0.956 0.014 0.002 CCR3 0.905CLEC4A 0.87 0.988 0.003 0.004 CCR3 0.905 GPR65 0.886 0.982 0.004 0.012CCR3 0.905 KCNMA1 0.897 0.963 0.029 0.019 CCR3 0.905 DPH3 0.86 0.9560.026 0.003 CCR3 0.905 TRIM21 0.874 0.979 0.004 0.009 CCR3 0.905 ICAM10.821 0.976 0.002 0.002 CCR3 0.905 TAF13 0.854 0.967 0.02 0.004 CCR30.905 KLHL5 0.826 0.958 0.016 0.001 CCR3 0.905 DLEU2_DLEU2L 0.874 0.9740.01 0.002 CCR3 0.905 ANKRD28 0.8 0.953 0.02 0.002 CCR3 0.905 IL1B 0.8710.979 0.003 0.013 CCR3 0.905 UBE2F_C20orf194 0.762 0.949 0.039 0 CCR30.905 PLEKHF2 0.822 0.967 0.027 0.001 CCR3 0.905 AIF1 0.816 0.966 0.0050.002 CCR3 0.905 CALM2_C2orf61 0.733 0.948 0.047 0 HSPC159 0.823 KLRD10.784 0.91 0.043 0.001 HSPC159 0.823 CHI3L1 0.909 0.989 0.001 0.027HSPC159 0.823 ANAPC11 0.818 0.928 0.005 0.012 HSPC159 0.823 RUNX2 0.8480.963 0 0.016 HSPC159 0.823 PHOSPHO1 0.85 0.943 0.003 0.032 HSPC1590.823 PDE3B 0.85 0.966 0.001 0.008 HSPC159 0.823 SULF2 0.819 0.929 0.0050.032 HSPC159 0.823 C15orf54 0.821 0.923 0.041 0.001 HSPC159 0.823 CCR40.784 0.925 0.008 0.002 HSPC159 0.823 FAM118A 0.759 0.89 0.019 0.02HSPC159 0.823 PYHIN1 0.807 0.911 0.011 0.02 HSPC159 0.823 CLC 0.81 0.9140.039 0.014 HSPC159 0.823 TSHZ2 0.801 0.929 0.001 0.014 HSPC159 0.823CAMK1D 0.702 0.884 0.037 0.003 OLAH 0.885 CHI3L1 0.909 0.968 0.047 0.018OLAH 0.885 RUNX2 0.848 0.968 0.012 0.003 OLAH 0.885 PHOSPHO1 0.85 0.960.01 0.011 OLAH 0.885 PDE3B 0.85 0.977 0.009 0.002 OLAH 0.885 IRS2 0.6480.98 0.003 0 OLAH 0.885 ABCG1 0.789 0.96 0.006 0.003 OLAH 0.885 LASS40.794 0.967 0.002 0.003 PPP2R5A_SNORA16 0.775 KLRD1 0.784 0.899 0.033 0PPP2R5A_SNORA16 0.775 GIMAP7 0.755 0.913 0.003 0.001 PPP2R5A_SNORA160.775 ANAPC11 0.818 0.915 0.003 0.014 PPP2R5A_SNORA16 0.775 RUNX2 0.8480.945 0 0.02 PPP2R5A_SNORA16 0.775 HLA-DRA 0.768 0.87 0.014 0.032PPP2R5A_SNORA16 0.775 DNAJC9_FAM149B1 0.811 0.92 0.027 0.001PPP2R5A_SNORA16 0.775 PLA2G7 0.834 0.898 0.023 0.015 PPP2R5A_SNORA160.775 PMS2CL_PMS2 0.685 0.887 0.014 0 PPP2R5A_SNORA16 0.775 PDE3B 0.850.966 0 0.003 PPP2R5A_SNORA16 0.775 SULF2 0.819 0.908 0.004 0.034PPP2R5A_SNORA16 0.775 IRF4 0.781 0.897 0.012 0.012 PPP2R5A_SNORA16 0.775HSP90AB1_HSP90A 0.799 0.904 0.003 0.015 PPP2R5A_SNORA16 0.775ITGA4_CERKL 0.694 0.885 0.03 0.001 PPP2R5A_SNORA16 0.775 NPCDR1 0.860.929 0.001 0.016 PPP2R5A_SNORA16 0.775 NA 0.763 0.883 0.028 0.003PPP2R5A_SNORA16 0.775 C15orf54 0.821 0.888 0.031 0.005 PPP2R5A_SNORA160.775 LY6G5B_CSNK2B 0.661 0.887 0.008 0 PPP2R5A_SNORA16 0.775 CCR4 0.7840.938 0.001 0.001 PPP2R5A_SNORA16 0.775 FAM118A 0.759 0.875 0.015 0.018PPP2R5A_SNORA16 0.775 PYHIN1 0.807 0.933 0.004 0.001 PPP2R5A_SNORA160.775 CLC 0.81 0.905 0.013 0.016 PPP2R5A_SNORA16 0.775 SYNE2 0.678 0.8840.035 0 PPP2R5A_SNORA16 0.775 TSHZ2 0.801 0.925 0 0.008 PPP2R5A_SNORA160.775 RASA4_RASA4P_R 0.779 0.885 0.007 0.01 PPP2R5A_SNORA16 0.775 CAMK1D0.702 0.887 0.01 0.001 PPP2R5A_SNORA16 0.775 IL5RA 0.832 0.893 0.0190.034 TMTC1 0.826 ANAPC11 0.818 0.905 0.011 0.047 TMTC1 0.826 PHOSPHO10.85 0.937 0.006 0.046 TMTC1 0.826 C15orf54 0.821 0.925 0.006 0.013TMTC1 0.826 CCR4 0.784 0.893 0.023 0.021 TMTC1 0.826 CFD 0.767 0.9010.027 0.008 EAF2_HCG11_LOC 0.917 GIMAP7 0.755 0.975 0.04 0EAF2_HCG11_LOC 0.917 RUNX2 0.848 0.952 0.043 0.012 EAF2_HCG11_LOC 0.917PDE3B 0.85 0.97 0.05 0.004 EAF2_HCG11_LOC 0.917 ITGA4_CERKL 0.694 0.9890.035 0 EAF2_HCG11_LOC 0.917 TSHZ2 0.801 0.974 0.028 0 RCBTB2_LOC100130.905 CHI3L1 0.909 0.966 0.048 0.029 RCBTB2_LOC10013 0.905 GIMAP7 0.7550.97 0.008 0 RCBTB2_LOC10013 0.905 RUNX2 0.848 0.98 0.007 0.002RCBTB2_LOC10013 0.905 CCR4 0.784 0.962 0.05 0 SEC24A_SAR1B 0.761 GIMAP70.755 0.915 0.001 0.001 SEC24A_SAR1B 0.761 ANAPC11 0.818 0.895 0.0040.043 SEC24A_SAR1B 0.761 HLA-DRA 0.768 0.897 0.003 0.005 SEC24A_SAR1B0.761 DNAJC9_FAM149B1 0.811 0.912 0.022 0.001 SEC24A_SAR1B 0.761 PLA2G70.834 0.903 0.014 0.006 SEC24A_SAR1B 0.761 PDE3B 0.85 0.935 0.002 0.017SEC24A_SAR1B 0.761 SULF2 0.819 0.893 0.007 0.026 SEC24A_SAR1B 0.761 IRF40.781 0.88 0.022 0.024 SEC24A_SAR1B 0.761 HSP90AB1_HSP90A 0.799 0.9270.004 0.001 SEC24A_SAR1B 0.761 ITGA4_CERKL 0.694 0.881 0.024 0.001SEC24A_SAR1B 0.761 NPCDR1 0.86 0.922 0.001 0.012 SEC24A_SAR1B 0.761 NA0.763 0.875 0.031 0.001 SEC24A_SAR1B 0.761 C15orf54 0.821 0.886 0.0230.011 SEC24A_SAR1B 0.761 LY6G5B_CSNK2B 0.661 0.874 0.024 0 SEC24A_SAR1B0.761 CCR4 0.784 0.903 0.004 0.004 SEC24A_SAR1B 0.761 FAM118A 0.7590.872 0.039 0.004 SEC24A_SAR1B 0.761 PYHIN1 0.807 0.912 0.006 0.004SEC24A_SAR1B 0.761 CLC 0.81 0.901 0.013 0.008 SEC24A_SAR1B 0.761 SON0.604 0.87 0.037 0 SEC24A_SAR1B 0.761 TSHZ2 0.801 0.909 0.002 0.01SEC24A_SAR1B 0.761 RASA4_RASA4P_R 0.779 0.893 0.005 0.003 SEC24A_SAR1B0.761 IL5RA 0.832 0.889 0.02 0.016 SH3PXD2B 0.734 NA 0.696 0.817 0.0320.02 SH3PXD2B 0.734 NA 0.746 0.825 0.047 0.017 SH3PXD2B 0.734 CFD 0.7670.857 0.029 0.035 HMGB2 0.849 GIMAP7 0.755 0.934 0.011 0.001 HMGB2 0.849ANAPC11 0.818 0.963 0.008 0.001 HMGB2 0.849 RUNX2 0.848 0.969 0.0040.004 HMGB2 0.849 DNAJC9_FAM149B1 0.811 0.974 0.011 0 HMGB2 0.849PMS2CL_PMS2 0.685 0.93 0.008 0 HMGB2 0.849 PDE3B 0.85 0.973 0.003 0.007HMGB2 0.849 IRF4 0.781 0.932 0.005 0.012 HMGB2 0.849 NPCDR1 0.86 0.9330.017 0.035 HMGB2 0.849 C15orf54 0.821 0.93 0.039 0.003 HMGB2 0.849LY6G5B_CSNK2B 0.661 0.935 0.004 0 HMGB2 0.849 CCR4 0.784 0.958 0.007 0HMGB2 0.849 FAM118A 0.759 0.91 0.038 0.007 HMGB2 0.849 PYHIN1 0.8070.937 0.033 0.003 HMGB2 0.849 LASS4 0.794 0.915 0.049 0.038 HMGB2 0.849TSHZ2 0.801 0.957 0.004 0.002 HMGB2 0.849 CAMK1D 0.702 0.924 0.03 0KLRD1 0.784 AMFR 0.69 0.841 0.013 0.038 KLRD1 0.784 HDHD1A 0.63 0.8370.048 0.004 KLRD1 0.784 ZRANB1 0.724 0.872 0.004 0.016 KLRD1 0.784UBE2F_C20orf194 0.762 0.882 0.002 0.017 KLRD1 0.784 HIST1H2BJ 0.6970.858 0.035 0.005 KLRD1 0.784 CEP97 0.695 0.871 0.019 0.003 KLRD1 0.784DYNLL1 0.776 0.897 0.016 0.002 KLRD1 0.784 FAM118B 0.737 0.868 0.0240.024 KLRD1 0.784 SPARC 0.703 0.868 0.024 0.004 KLRD1 0.784 PLEKHA30.658 0.839 0.049 0.008 KLRD1 0.784 TMEM62_SPCS2_L 0.645 0.863 0.0140.002 KLRD1 0.784 CMTM5 0.694 0.843 0.045 0.012 KLRD1 0.784HIST2H2BF_HIST2 0.754 0.854 0.031 0.048 KLRD1 0.784 CALM2_C2orf61 0.7330.86 0.008 0.018 CHI3L1 0.909 PRR13_PCBP2 0.77 0.962 0.045 0 CHI3L10.909 FFAR2 0.868 0.949 0.045 0.013 CHI3L1 0.909 SIAE 0.814 0.981 0.0370 CHI3L1 0.909 ABCA13 0.868 0.98 0.028 0.004 CHI3L1 0.909 SAP30 0.7280.944 0.016 0.001 CHI3L1 0.909 AGTRAP 0.856 0.957 0.023 0.02 CHI3L10.909 SUCNR1 0.922 0.996 0.02 0.006 CHI3L1 0.909 AIG1 0.842 0.969 0.0460.003 CHI3L1 0.909 ACTA2 0.783 0.97 0.016 0.001 CHI3L1 0.909 TRIM210.874 0.984 0.018 0.01 CHI3L1 0.909 ICAM1 0.821 0.937 0.039 0.026 CHI3L10.909 ZRANB1 0.724 0.967 0.042 0 CHI3L1 0.909 UBE2F_C20orf194 0.7620.968 0.033 0 CHI3L1 0.909 MYL9 0.771 0.97 0.045 0 CHI3L1 0.909CYP4F3_CYP4F2 0.593 0.979 0.046 0 CHI3L1 0.909 FAM118B 0.737 0.98 0.0470 CHI3L1 0.909 NP 0.633 0.965 0.047 0 CHI3L1 0.909 ATP6V0D1_LOC100 0.8560.958 0.011 0.049 SLC39A9 0.551 DNAJC9_FAM149B1 0.811 0.882 0 0.001SLC39A9 0.551 P4HA1_RPL17 0.715 0.792 0.001 0.028 SLC39A9 0.551 FAM118B0.737 0.833 0 0.019 GIMAP7 0.755 NA 0.866 0.933 0.001 0.013 GIMAP7 0.755CCR1 0.897 0.963 0 0.005 GIMAP7 0.755 MTHFS 0.757 0.87 0.005 0.021GIMAP7 0.755 EIF2AK2 0.857 0.955 0 0.002 GIMAP7 0.755 SIAE 0.814 0.8970.001 0.039 GIMAP7 0.755 MTRR 0.703 0.923 0 0 GIMAP7 0.755 AIG1 0.8420.939 0 0.009 GIMAP7 0.755 GAB2 0.729 0.858 0.025 0.014 GIMAP7 0.755HS2ST1_UBA2 0.758 0.865 0.009 0.026 GIMAP7 0.755 TREML1 0.793 0.8630.045 0.033 GIMAP7 0.755 GSTO1 0.793 0.902 0.001 0.03 GIMAP7 0.755CLEC4A 0.87 0.957 0 0.012 GIMAP7 0.755 GPR65 0.886 0.972 0 0.018 GIMAP70.755 MACF1 0.742 0.877 0.03 0.001 GIMAP7 0.755 HDHD1A 0.63 0.859 0.0120 GIMAP7 0.755 LRRFIP1 0.673 0.887 0.025 0 GIMAP7 0.755 TRIM21 0.8740.944 0 0.023 GIMAP7 0.755 TAF13 0.854 0.925 0 0.039 GIMAP7 0.755P4HA1_RPL17 0.715 0.923 0.003 0 GIMAP7 0.755 KLHL5 0.826 0.954 0 0.002GIMAP7 0.755 ANKRD28 0.8 0.924 0.001 0.004 GIMAP7 0.755 MGST3 0.602 0.840.03 0 GIMAP7 0.755 LAIR1_LAIR2 0.749 0.857 0.034 0.032 GIMAP7 0.755ZRANB1 0.724 0.87 0.019 0.003 GIMAP7 0.755 UBE2F_C20orf194 0.762 0.8520.044 0.012 GIMAP7 0.755 CCRL2 0.786 0.868 0.029 0.034 GIMAP7 0.755ZNF587_ZNF417 0.648 0.865 0.049 0 GIMAP7 0.755 CEP97 0.695 0.891 0.013 0GIMAP7 0.755 DYNLL1 0.776 0.915 0.004 0 GIMAP7 0.755 PLIN2 0.671 0.8870.003 0.001 GIMAP7 0.755 FAM118B 0.737 0.966 0 0 GIMAP7 0.755CTSL1_CTSLL3 0.715 0.862 0.024 0.005 GIMAP7 0.755 TMEM62_SPCS2_L 0.6450.886 0.011 0 GIMAP7 0.755 PLEKHF2 0.822 0.914 0.002 0.014 GIMAP7 0.755AIF1 0.816 0.953 0 0.002 GIMAP7 0.755 HIST2H2BF_HIST2 0.754 0.875 0.0360.001 GIMAP7 0.755 CALM2_C2orf61 0.733 0.898 0.003 0.001 ANAPC11 0.818NA 0.866 0.924 0.014 0.024 ANAPC11 0.818 FOLR3_FOLR2 0.848 0.93 0.0080.007 ANAPC11 0.818 LGALS1 0.736 0.915 0.005 0.003 ANAPC11 0.818 MTHFS0.757 0.911 0.004 0.003 ANAPC11 0.818 SIAE 0.814 0.917 0.004 0.016ANAPC11 0.818 ABCA13 0.868 0.94 0.005 0.006 ANAPC11 0.818 CDA 0.8040.912 0.006 0.016 ANAPC11 0.818 SAP30 0.728 0.86 0.046 0.025 ANAPC110.818 AIG1 0.842 0.937 0.006 0.006 ANAPC11 0.818 HS2ST1_UBA2 0.758 0.8790.035 0.022 ANAPC11 0.818 VOPP1_LOC100128 0.618 0.88 0.034 0 ANAPC110.818 SLC11A1 0.785 0.903 0.008 0.031 ANAPC11 0.818 GSTO1 0.793 0.910.022 0.008 ANAPC11 0.818 CLEC4A 0.87 0.939 0.003 0.024 ANAPC11 0.818NEK6_LOC1001290 0.765 0.895 0.005 0.017 ANAPC11 0.818 OR9A2 0.813 0.9180.009 0.005 ANAPC11 0.818 DPH3 0.86 0.949 0.001 0.009 ANAPC11 0.818TAF13 0.854 0.94 0.017 0.004 ANAPC11 0.818 KLHL5 0.826 0.903 0.028 0.034ANAPC11 0.818 DLEU2_DLEU2L 0.874 0.95 0.001 0.014 ANAPC11 0.818 ANKRD280.8 0.928 0.005 0.006 ANAPC11 0.818 LHFP 0.759 0.866 0.048 0.02 ANAPC110.818 MYL9 0.771 0.895 0.036 0.009 ANAPC11 0.818 FAM118B 0.737 0.9070.034 0.001 ANAPC11 0.818 AIF1 0.816 0.917 0.007 0.022 ANAPC11 0.818CALM2_C2orf61 0.733 0.915 0.015 0 EXOSC4 0.731 DNAJC9_FAM149B1 0.8110.864 0.043 0.032 EXOSC4 0.731 JUP 0.804 0.905 0.002 0.025 EXOSC4 0.731C15orf54 0.821 0.878 0.013 0.017 EXOSC4 0.731 CFD 0.767 0.869 0.021 0.02NA 0.866 RUNX2 0.848 0.943 0.001 0.047 NA 0.866 HLA-DRA 0.768 0.9250.022 0.002 NA 0.866 NA 0.696 0.939 0.032 0 NA 0.866 PLA2G7 0.834 0.9520.016 0.003 NA 0.866 PMS2CL_PMS2 0.685 0.92 0.049 0 NA 0.866 PDE3B 0.850.972 0.001 0.006 NA 0.866 SULF2 0.819 0.933 0.017 0.02 NA 0.866ITGA4_CERKL 0.694 0.931 0.035 0 NA 0.866 NPCDR1 0.86 0.957 0.006 0.005NA 0.866 NA 0.763 0.927 0.035 0.001 NA 0.866 LY6G5B_CSNK2B 0.661 0.9340.017 0 NA 0.866 CCR4 0.784 0.949 0.009 0.001 NA 0.866 ABCG1 0.789 0.9150.038 0.015 NA 0.866 FAM118A 0.759 0.921 0.026 0.002 NA 0.866 PYHIN10.807 0.949 0.024 0.001 NA 0.866 SYNE2 0.678 0.945 0.011 0 NA 0.866TSHZ2 0.801 0.942 0.005 0.003 NA 0.866 RASA4_RASA4P_R 0.779 0.93 0.0240.001 NA 0.866 CAMK1D 0.702 0.933 0.009 0 INSIG1 0.509 TAF13 0.854 0.9040 0.029 INSIG1 0.509 CALM2_C2orf61 0.733 0.8 0 0.049 FOLR3_FOLR2 0.848RUNX2 0.848 0.933 0.005 0.039 FOLR3_FOLR2 0.848 PHOSPHO1 0.85 0.9440.003 0.024 FOLR3_FOLR2 0.848 PPIF 0.614 0.908 0.016 0 FOLR3_FOLR2 0.848PDE3B 0.85 0.926 0.035 0.04 FOLR3_FOLR2 0.848 RRP12_LOC644215 0.6320.905 0.038 0 FOLR3_FOLR2 0.848 LASS4 0.794 0.946 0 0.013 RUNX2 0.848CCR1 0.897 0.94 0.019 0.025 RUNX2 0.848 FFAR2 0.868 0.935 0.014 0.014RUNX2 0.848 MTHFS 0.757 0.943 0.022 0 RUNX2 0.848 SIAE 0.814 0.965 0.0030 RUNX2 0.848 ABCA13 0.868 0.951 0.018 0.003 RUNX2 0.848 CDA 0.804 0.9530.013 0 RUNX2 0.848 SAP30 0.728 0.95 0.008 0 RUNX2 0.848 AGTRAP 0.8560.938 0.005 0.022 RUNX2 0.848 SUCNR1 0.922 0.97 0.003 0.009 RUNX2 0.848AIG1 0.842 0.948 0.009 0.005 RUNX2 0.848 HS2ST1_UBA2 0.758 0.953 0.004 0RUNX2 0.848 SLC11A1 0.785 0.959 0.013 0.001 RUNX2 0.848 CLEC4A 0.870.944 0.028 0.002 RUNX2 0.848 NEK6_LOC1001290 0.765 0.943 0.006 0.001RUNX2 0.848 GPR65 0.886 0.933 0.027 0.018 RUNX2 0.848 DPH3 0.86 0.9490.017 0.001 RUNX2 0.848 TRIM21 0.874 0.941 0.016 0.029 RUNX2 0.848 TAF130.854 0.943 0.029 0.002 RUNX2 0.848 KLHL5 0.826 0.941 0.024 0.001 RUNX20.848 DLEU2_DLEU2L 0.874 0.944 0.012 0.006 RUNX2 0.848 ANKRD28 0.8 0.9790.002 0 RUNX2 0.848 MYL9 0.771 0.939 0.048 0 RUNX2 0.848 FAM118B 0.7370.939 0.037 0 PRR13_PCBP2 0.77 PLA2G7 0.834 0.888 0.039 0.029PRR13_PCBP2 0.77 C15orf54 0.821 0.879 0.041 0.04 PRR13_PCBP2 0.77LY6G5B_CSNK2B 0.661 0.871 0.046 0 PRR13_PCBP2 0.77 CCR4 0.784 0.8840.017 0.02 PRR13_PCBP2 0.77 RASA4_RASA4P_R 0.779 0.886 0.012 0.008LGALS1 0.736 CCR4 0.784 0.865 0.036 0.005 LGALS1 0.736 CLC 0.81 0.8840.03 0.026 LGALS1 0.736 LASS4 0.794 0.891 0.002 0.049 LGALS1 0.736 TSHZ20.801 0.872 0.022 0.027 CCR1 0.897 HLA-DRA 0.768 0.965 0.017 0 CCR10.897 NPCDR1 0.86 0.971 0.019 0.001 CCR1 0.897 CCR4 0.784 0.961 0.012 0HLA-DRA 0.768 FFAR2 0.868 0.949 0.001 0.002 HLA-DRA 0.768 EIF2AK2 0.8570.942 0.003 0.006 HLA-DRA 0.768 AIG1 0.842 0.91 0.008 0.032 HLA-DRA0.768 GSTO1 0.793 0.893 0.016 0.018 HLA-DRA 0.768 CLEC4A 0.87 0.967 00.011 HLA-DRA 0.768 GPR65 0.886 0.959 0 0.034 HLA-DRA 0.768 ACTA2 0.7830.878 0.043 0.017 HLA-DRA 0.768 TRIM21 0.874 0.985 0 0.002 HLA-DRA 0.768ICAM1 0.821 0.933 0.002 0.005 HLA-DRA 0.768 P4HA1_RPL17 0.715 0.8830.032 0 HLA-DRA 0.768 KLHL5 0.826 0.952 0 0.002 HLA-DRA 0.768HSPB1_HSPBL2 0.778 0.867 0.021 0.048 HLA-DRA 0.768 IL1B 0.871 0.9450.001 0.023 HLA-DRA 0.768 CCRL2 0.786 0.892 0.029 0.007 HLA-DRA 0.768PLIN2 0.671 0.874 0.045 0 HLA-DRA 0.768 CTSL1_CTSLL3 0.715 0.887 0.0180.001 HLA-DRA 0.768 TMEM62_SPCS2_L 0.645 0.874 0.017 0 HLA-DRA 0.768PLEKHF2 0.822 0.916 0.002 0.007 HLA-DRA 0.768 AIF1 0.816 0.952 0 0.004CD163 0.735 NA 0.696 0.834 0.014 0.044 CD163 0.735 PLA2G7 0.834 0.9180.004 0.018 CD163 0.735 PMS2CL_PMS2 0.685 0.818 0.03 0.034 CD163 0.735SULF2 0.819 0.933 0 0.034 CD163 0.735 NA 0.718 0.857 0.017 0.022 CD1630.735 LY6G5B_CSNK2B 0.661 0.835 0.007 0.023 CD163 0.735 NA 0.746 0.8810.002 0.007 CD163 0.735 CAMK1D 0.702 0.866 0.004 0.013 CD163 0.735 CFD0.767 0.874 0.01 0.031 FFAR2 0.868 NPCDR1 0.86 0.958 0.013 0.001 FFAR20.868 CCR4 0.784 0.934 0.034 0 FFAR2 0.868 ABCG1 0.789 0.937 0.017 0.006PHOSPHO1 0.85 SIAE 0.814 0.949 0.003 0.006 PHOSPHO1 0.85 ABCA13 0.8680.981 0.003 0.001 PHOSPHO1 0.85 CDA 0.804 0.919 0.021 0.023 PHOSPHO10.85 SAP30 0.728 0.933 0.004 0.001 PHOSPHO1 0.85 SUCNR1 0.922 0.99 0.0010.009 PHOSPHO1 0.85 NEK6_LOC1001290 0.765 0.904 0.017 0.02 PHOSPHO1 0.85AMFR 0.69 0.93 0.015 0 PHOSPHO1 0.85 DPH3 0.86 0.951 0.004 0.01 PHOSPHO10.85 ICAM1 0.821 0.919 0.011 0.033 PHOSPHO1 0.85 TAF13 0.854 0.931 0.0190.01 PHOSPHO1 0.85 DLEU2_DLEU2L 0.874 0.947 0.007 0.019 PHOSPHO1 0.85ANKRD28 0.8 0.932 0.044 0.005 PHOSPHO1 0.85 HSPB1_HSPBL2 0.778 0.9330.013 0.003 PHOSPHO1 0.85 LHFP 0.759 0.92 0.036 0.001 PHOSPHO1 0.85ZRANB1 0.724 0.94 0.029 0 PHOSPHO1 0.85 PTGS1 0.68 0.965 0.007 0PHOSPHO1 0.85 UBE2F_C20orf194 0.762 0.949 0.015 0 PHOSPHO1 0.85 MYL90.771 0.98 0.005 0 PHOSPHO1 0.85 CMTM5 0.694 0.969 0.012 0 PHOSPHO1 0.85AIF1 0.816 0.922 0.03 0.008 PPIF 0.614 C22orf37 0.582 0.774 0.027 0.004PPIF 0.614 OR9A2 0.813 0.881 0 0.02 PPIF 0.614 ICAM1 0.821 0.898 0 0.042PPIF 0.614 IL1B 0.871 0.935 0 0.035 PPIF 0.614 MYL9 0.771 0.83 0.0030.04 PPIF 0.614 CALM2_C2orf61 0.733 0.801 0.011 0.039 MTHFS 0.757DNAJC9_FAM149B1 0.811 0.904 0.024 0.002 MTHFS 0.757 PLA2G7 0.834 0.8910.014 0.03 MTHFS 0.757 PMS2CL_PMS2 0.685 0.863 0.035 0.001 MTHFS 0.757PDE3B 0.85 0.985 0 0.002 MTHFS 0.757 C15orf54 0.821 0.884 0.019 0.014MTHFS 0.757 CCR4 0.784 0.911 0.003 0.001 MTHFS 0.757 FAM118A 0.759 0.8630.021 0.023 MTHFS 0.757 PYHIN1 0.807 0.887 0.016 0.011 MTHFS 0.757 CLC0.81 0.89 0.025 0.018 MTHFS 0.757 SYNE2 0.678 0.861 0.042 0 MTHFS 0.757TSHZ2 0.801 0.899 0.003 0.013 MTHFS 0.757 RASA4_RASA4P_R 0.779 0.8590.014 0.036 MTHFS 0.757 CAMK1D 0.702 0.889 0.008 0 MTHFS 0.757 CFD 0.7670.878 0.025 0.008 MTHFS 0.757 IL5RA 0.832 0.883 0.02 0.024DNAJC9_FAM149B1 0.811 ABCA13 0.868 0.932 0.005 0.049 DNAJC9_FAM149B10.811 MTRR 0.703 0.916 0 0.004 DNAJC9_FAM149B1 0.811 AIG1 0.842 0.953 00.021 DNAJC9_FAM149B1 0.811 HS2ST1_UBA2 0.758 0.887 0.005 0.05DNAJC9_FAM149B1 0.811 GSTO1 0.793 0.912 0.004 0.048 DNAJC9_FAM149B10.811 MACF1 0.742 0.927 0.002 0.003 DNAJC9_FAM149B1 0.811 AMFR 0.690.853 0.022 0.045 DNAJC9_FAM149B1 0.811 GALNT2 0.651 0.86 0.039 0.01DNAJC9_FAM149B1 0.811 OR9A2 0.813 0.897 0.018 0.037 DNAJC9_FAM149B10.811 HDHD1A 0.63 0.884 0.011 0.002 DNAJC9_FAM149B1 0.811 LRRFIP1 0.6730.919 0.007 0 DNAJC9_FAM149B1 0.811 P4HA1_RPL17 0.715 0.933 0.001 0.001DNAJC9_FAM149B1 0.811 MGST3 0.602 0.877 0.02 0 DNAJC9_FAM149B1 0.811CCDC125 0.632 0.886 0.019 0 DNAJC9_FAM149B1 0.811 PDK4 0.71 0.922 0.0080.002 DNAJC9_FAM149B1 0.811 LAIR1_LAIR2 0.749 0.887 0.007 0.05DNAJC9_FAM149B1 0.811 FSD1L_GARNL1 0.66 0.889 0.004 0.003DNAJC9_FAM149B1 0.811 UBE2F_C20orf194 0.762 0.88 0.026 0.037DNAJC9_FAM149B1 0.811 CEP97 0.695 0.906 0.006 0.002 DNAJC9_FAM149B10.811 DYNLL1 0.776 0.959 0.001 0 DNAJC9_FAM149B1 0.811 PLIN2 0.671 0.8720.022 0.007 DNAJC9_FAM149B1 0.811 FAM118B 0.737 0.927 0.001 0.006DNAJC9_FAM149B1 0.811 CTSL1_CTSLL3 0.715 0.897 0.039 0.002DNAJC9_FAM149B1 0.811 NP 0.633 0.876 0.013 0.001 DNAJC9_FAM149B1 0.811TMEM62_SPCS2_L 0.645 0.895 0.004 0.001 DNAJC9_FAM149B1 0.811CALM2_C2orf61 0.733 0.907 0.002 0.007 LCN2 0.752 HIST1H3J 0.722 0.8740.016 0.002 LCN2 0.752 HIST1H3A 0.715 0.876 0.005 0.005 LCN2 0.752RRP12_LOC644215 0.632 0.794 0.03 0.047 LCN2 0.752 B4GALT3 0.659 0.8550.001 0.014 LCN2 0.752 C4orf3 0.629 0.818 0.023 0.012 LCN2 0.752 RPIA0.713 0.843 0.039 0.027 LCN2 0.752 C1orf128 0.751 0.864 0.013 0.049EIF2AK2 0.857 PLA2G7 0.834 0.957 0.011 0.002 EIF2AK2 0.857 PMS2CL_PMS20.685 0.922 0.037 0 EIF2AK2 0.857 PDE3B 0.85 0.956 0.008 0.008 EIF2AK20.857 SULF2 0.819 0.944 0.022 0.002 EIF2AK2 0.857 HSP90AB1_HSP90A 0.7990.964 0.007 0.001 EIF2AK2 0.857 ITGA4_CERKL 0.694 0.953 0.002 0 EIF2AK20.857 NPCDR1 0.86 0.959 0.002 0.006 EIF2AK2 0.857 NA 0.763 0.954 0.008 0EIF2AK2 0.857 CCR4 0.784 0.961 0.002 0 EIF2AK2 0.857 FAM118A 0.759 0.9070.036 0.005 EIF2AK2 0.857 PYHIN1 0.807 0.939 0.015 0.004 EIF2AK2 0.857SYNE2 0.678 0.932 0.015 0 EIF2AK2 0.857 NA 0.746 0.95 0.007 0 EIF2AK20.857 TSHZ2 0.801 0.951 0.003 0.002 EIF2AK2 0.857 RASA4_RASA4P_R 0.7790.925 0.021 0.001 EIF2AK2 0.857 MPZL2 0.612 0.914 0.044 0 EIF2AK2 0.857IL5RA 0.832 0.943 0.035 0.002 SIAE 0.814 PDE3B 0.85 0.95 0.011 0.002SIAE 0.814 SULF2 0.819 0.926 0.005 0.011 SIAE 0.814 NPCDR1 0.86 0.9160.011 0.033 SIAE 0.814 CCR4 0.784 0.919 0.019 0 SIAE 0.814 FAM118A 0.7590.918 0.013 0.001 SIAE 0.814 PYHIN1 0.807 0.911 0.036 0.004 SIAE 0.814LASS4 0.794 0.945 0.001 0.007 SIAE 0.814 TSHZ2 0.801 0.931 0.004 0.002SIAE 0.814 RASA4_RASA4P_R 0.779 0.906 0.029 0.001 ABCA13 0.868 PDE3B0.85 0.947 0.005 0.016 ABCA13 0.868 NPCDR1 0.86 0.924 0.035 0.033 ABCA130.868 CCR4 0.784 0.925 0.03 0.002 ABCA13 0.868 CLC 0.81 0.939 0.02 0.009ABCA13 0.868 LASS4 0.794 0.953 0.001 0.009 ABCA13 0.868 B4GALT3 0.6590.945 0.017 0 ABCA13 0.868 IL5RA 0.832 0.925 0.042 0.014 NA 0.696 MTRR0.703 0.826 0.032 0.006 NA 0.696 MACF1 0.742 0.866 0.004 0.003 NA 0.696GALNT2 0.651 0.805 0.03 0.012 NA 0.696 P4HA1_RPL17 0.715 0.825 0.0240.008 NA 0.696 ZRANB1 0.724 0.81 0.023 0.043 NA 0.696 CCRL2 0.786 0.8920 0.012 NA 0.696 IRF1 0.651 0.776 0.049 0.05 NA 0.696 DYNLL1 0.776 0.8390.008 0.028 NA 0.696 FAM118B 0.737 0.826 0.015 0.045 EFCAB2 0.96PMS2CL_PMS2 0.685 0.988 0.047 0 EFCAB2 0.96 PDE3B 0.85 0.988 0.022 0.001EFCAB2 0.96 CFD 0.767 0.988 0.05 0 HINT1 0.658 DYNLL1 0.776 0.894 00.004 HINT1 0.658 CALM2_C2orf61 0.733 0.856 0 0.041 HIST1H3J 0.722C22orf37 0.582 0.758 0.037 0.032 HIST1H3J 0.722 AREG 0.598 0.76 0.0330.046 HIST1H3J 0.722 DAAM2_LOC100131 0.664 0.799 0.021 0.016 HIST1H3J0.722 CEACAM8 0.748 0.844 0.015 0.029 HIST1H3J 0.722 MINPP1 0.497 0.8160.018 0 HIST1H3J 0.722 HIST1H2BM 0.504 0.794 0.04 0.001 HIST1H3J 0.722ITGA2B 0.699 0.83 0.002 0.039 HIST1H3J 0.722 NA 0.705 0.82 0.007 0.045HIST1H3J 0.722 HIST1H2BJ 0.697 0.865 0 0.015 HIST1H3J 0.722 CMTM5 0.6940.863 0 0.021 HIST1H3J 0.722 IFI44 0.762 0.842 0.014 0.046 HIST1H3J0.722 KIAA0101_CSNK1G 0.581 0.858 0.015 0 CDA 0.804 PDE3B 0.85 0.9290.009 0.023 CDA 0.804 JUP 0.804 0.896 0.014 0.04 CDA 0.804 NPCDR1 0.860.914 0.009 0.049 CDA 0.804 LY6G5B_CSNK2B 0.661 0.892 0.038 0 CDA 0.804CCR4 0.784 0.925 0.006 0.001 CDA 0.804 PYHIN1 0.807 0.901 0.03 0.01 CDA0.804 CLC 0.81 0.92 0.023 0.008 CDA 0.804 LASS4 0.794 0.902 0.018 0.042CDA 0.804 TSHZ2 0.801 0.894 0.023 0.016 CDA 0.804 RASA4_RASA4P_R 0.7790.895 0.026 0.004 CDA 0.804 IL5RA 0.832 0.903 0.027 0.016 SAP30 0.728PLA2G7 0.834 0.859 0.043 0.031 SAP30 0.728 PDE3B 0.85 0.942 0 0.002SAP30 0.728 SULF2 0.819 0.864 0.034 0.033 SAP30 0.728 C15orf54 0.8210.857 0.038 0.03 SAP30 0.728 IL5RA 0.832 0.862 0.049 0.02 AGTRAP 0.856LASS4 0.794 0.944 0.028 0.001 SUCNR1 0.922 PDE3B 0.85 0.976 0.038 0.001SUCNR1 0.922 B4GALT3 0.659 0.977 0.018 0 MTRR 0.703 PLA2G7 0.834 0.8970.004 0.007 MTRR 0.703 ITGA4_CERKL 0.694 0.839 0.012 0.012 MTRR 0.703NPCDR1 0.86 0.92 0 0.039 MTRR 0.703 NA 0.763 0.868 0.005 0.002 MTRR0.703 LY6G5B_CSNK2B 0.661 0.839 0.006 0.006 MTRR 0.703 CCR4 0.784 0.89 00.016 MTRR 0.703 PYHIN1 0.807 0.904 0.001 0.027 MTRR 0.703 CLC 0.810.881 0.003 0.034 MTRR 0.703 NA 0.746 0.832 0.029 0.02 MTRR 0.703 TSHZ20.801 0.904 0 0.039 MTRR 0.703 CAMK1D 0.702 0.821 0.025 0.018 PLA2G70.834 CLEC4A 0.87 0.956 0.001 0.036 PLA2G7 0.834 TRAF3 0.594 0.888 0.0130 PLA2G7 0.834 OR9A2 0.813 0.928 0.005 0.017 PLA2G7 0.834 ACTA2 0.7830.901 0.023 0.031 PLA2G7 0.834 TAF13 0.854 0.947 0.002 0.028 PLA2G70.834 P4HA1_RPL17 0.715 0.923 0.005 0 PLA2G7 0.834 KLHL5 0.826 0.9320.001 0.033 PLA2G7 0.834 LHFP 0.759 0.863 0.043 0.039 PLA2G7 0.834 CCRL20.786 0.907 0.038 0.014 PLA2G7 0.834 DYNLL1 0.776 0.92 0.023 0.001PLA2G7 0.834 PLIN2 0.671 0.89 0.01 0.004 PLA2G7 0.834 FAM118B 0.7370.929 0.005 0.002 PLA2G7 0.834 CTSL1_CTSLL3 0.715 0.901 0.035 0.002PLA2G7 0.834 TMEM62_SPCS2_L 0.645 0.894 0.039 0 PLA2G7 0.834 PLEKHF20.822 0.929 0.003 0.026 PLA2G7 0.834 AIF1 0.816 0.939 0.002 0.022 PLA2G70.834 PPP1R2_PPP1R2P3 0.569 0.893 0.048 0 PLA2G7 0.834 HIST2H2BF_HIST20.754 0.905 0.036 0.004 PLA2G7 0.834 CALM2_C2orf61 0.733 0.918 0.0060.001 AIG1 0.842 PMS2CL_PMS2 0.685 0.937 0.031 0 AIG1 0.842 PDE3B 0.850.955 0.014 0.006 AIG1 0.842 IRF4 0.781 0.923 0.017 0.005 AIG1 0.842HSP90AB1_HSP90A 0.799 0.94 0.023 0.003 AIG1 0.842 ITGA4_CERKL 0.694 0.920.04 0 AIG1 0.842 NPCDR1 0.86 0.941 0.009 0.012 AIG1 0.842 LY6G5B_CSNK2B0.661 0.913 0.034 0 AIG1 0.842 CCR4 0.784 0.946 0.007 0 AIG1 0.842 CLC0.81 0.929 0.038 0.01 AIG1 0.842 TSHZ2 0.801 0.924 0.024 0.005 AIG10.842 RASA4_RASA4P_R 0.779 0.921 0.019 0.002 AIG1 0.842 IL5RA 0.8320.921 0.039 0.008 PCOLCE2 0.709 NA 0.763 0.817 0.046 0.017 PCOLCE2 0.709CFD 0.767 0.84 0.019 0.044 GAB2 0.729 SULF2 0.819 0.932 0 0.011 GAB20.729 HSP90AB1_HSP90A 0.799 0.878 0.015 0.03 GAB2 0.729 NA 0.718 0.8720.033 0 GAB2 0.729 LY6G5B_CSNK2B 0.661 0.866 0.026 0 GAB2 0.729 CCR40.784 0.883 0.006 0.018 GAB2 0.729 CLC 0.81 0.859 0.03 0.047 GAB2 0.729NA 0.746 0.872 0.03 0 GAB2 0.729 RASA4_RASA4P_R 0.779 0.887 0.003 0.003GAB2 0.729 CAMK1D 0.702 0.876 0.014 0.002 HS2ST1_UBA2 0.758 PDE3B 0.850.963 0 0.008 HS2ST1_UBA2 0.758 NPCDR1 0.86 0.908 0.003 0.041HS2ST1_UBA2 0.758 C15orf54 0.821 0.882 0.037 0.006 HS2ST1_UBA2 0.758CCR4 0.784 0.892 0.013 0.002 HS2ST1_UBA2 0.758 ABCG1 0.789 0.89 0.0110.049 HS2ST1_UBA2 0.758 TSHZ2 0.801 0.907 0.005 0.007 HS2ST1_UBA2 0.758RASA4_RASA4P_R 0.779 0.869 0.024 0.012 HS2ST1_UBA2 0.758 IL5RA 0.8320.885 0.021 0.017 HIST1H3A 0.715 C22orf37 0.582 0.77 0.015 0.024HIST1H3A 0.715 DAAM2_LOC100131 0.664 0.801 0.032 0.018 HIST1H3A 0.715CEACAM8 0.748 0.841 0.029 0.019 HIST1H3A 0.715 HIST1H2BM 0.504 0.790.046 0.001 HIST1H3A 0.715 ITGA2B 0.699 0.82 0.012 0.05 HIST1H3A 0.715HIST1H2BJ 0.697 0.854 0.001 0.027 HIST1H3A 0.715 CMTM5 0.694 0.856 00.03 HIST1H3A 0.715 SDHC 0.627 0.821 0.041 0.003 C22orf37 0.582PMS2CL_PMS2 0.685 0.775 0.011 0.027 HLA-DPA1 0.65 TRAF3 0.594 0.7670.036 0.015 HLA-DPA1 0.65 P4HA1_RPL17 0.715 0.823 0.006 0.015 HLA-DPA10.65 PDK4 0.71 0.808 0.027 0.016 HLA-DPA1 0.65 CCRL2 0.786 0.888 0 0.031HLA-DPA1 0.65 IRF1 0.651 0.779 0.021 0.043 HLA-DPA1 0.65 FAM118B 0.7370.832 0.005 0.028 HLA-DPA1 0.65 TMEM62_SPCS2_L 0.645 0.772 0.026 0.032VOPP1_LOC100128 0.618 PMS2CL_PMS2 0.685 0.766 0.037 0.05 SLC11A1 0.785PDE3B 0.85 0.937 0.005 0.016 SLC11A1 0.785 CCR4 0.784 0.896 0.028 0.003SLC11A1 0.785 RRP12_LOC644215 0.632 0.867 0.036 0.001 SLC11A1 0.785ABCG1 0.789 0.913 0.014 0.023 SLC11A1 0.785 LASS4 0.794 0.915 0.0050.033 ABCA1 0.866 CCR4 0.784 0.916 0.029 0.015 ABCA1 0.866 ABCG1 0.7890.966 0.005 0.007 ABCA1 0.866 TSHZ2 0.801 0.921 0.034 0.032 ABCA1 0.866CAMK1D 0.702 0.914 0.035 0.001 DAAM2_LOC100131 0.664 IRS2 0.648 0.825 00.05 LTF 0.732 B4GALT3 0.659 0.814 0.014 0.037 TREML1 0.793 IRS2 0.6480.861 0.036 0.011 TREML1 0.793 C15orf54 0.821 0.929 0.006 0.004 TREML10.793 CCR4 0.784 0.901 0.004 0.025 TREML1 0.793 CLC 0.81 0.897 0.0460.028 TREML1 0.793 B4GALT3 0.659 0.871 0.028 0.005 TREML1 0.793 CFD0.767 0.886 0.046 0.022 TREML1 0.793 IL5RA 0.832 0.907 0.017 0.048 GSTO10.793 HSP90AB1_HSP90A 0.799 0.896 0.028 0.021 GSTO1 0.793 NPCDR1 0.860.93 0.002 0.029 GSTO1 0.793 NA 0.763 0.911 0.044 0 GSTO1 0.793 C15orf540.821 0.904 0.048 0.001 GSTO1 0.793 CCR4 0.784 0.933 0.006 0 GSTO1 0.793ABCG1 0.789 0.893 0.011 0.033 GSTO1 0.793 PYHIN1 0.807 0.908 0.035 0.003GSTO1 0.793 CLC 0.81 0.937 0.013 0.003 GSTO1 0.793 TSHZ2 0.801 0.9230.005 0.006 GSTO1 0.793 RASA4_RASA4P_R 0.779 0.89 0.013 0.016 GSTO10.793 IL5RA 0.832 0.923 0.026 0.005 CEACAM8 0.748 B4GALT3 0.659 0.84 00.03 CLEC4A 0.87 PDE3B 0.85 0.952 0.015 0.018 CLEC4A 0.87 ITGA4_CERKL0.694 0.952 0.031 0 CLEC4A 0.87 NPCDR1 0.86 0.938 0.048 0.006 CLEC4A0.87 LY6G5B_CSNK2B 0.661 0.933 0.024 0 CLEC4A 0.87 CCR4 0.784 0.9520.017 0 CLEC4A 0.87 ABCG1 0.789 0.955 0.007 0.001 CLEC4A 0.87 TSHZ20.801 0.954 0.009 0.001 CLEC4A 0.87 CAMK1D 0.702 0.938 0.028 0PMS2CL_PMS2 0.685 MACF1 0.742 0.852 0.007 0.007 PMS2CL_PMS2 0.685LRRFIP1 0.673 0.821 0.024 0.003 PMS2CL_PMS2 0.685 DPH3 0.86 0.928 00.033 PMS2CL_PMS2 0.685 TAF13 0.854 0.913 0 0.036 PMS2CL_PMS2 0.685P4HA1_RPL17 0.715 0.848 0.011 0.002 PMS2CL_PMS2 0.685 ZRANB1 0.724 0.8230.009 0.035 PMS2CL_PMS2 0.685 NA 0.705 0.833 0.032 0.002 PMS2CL_PMS20.685 UBE2F_C20orf194 0.762 0.899 0 0.006 PMS2CL_PMS2 0.685 CEP97 0.6950.832 0.011 0.016 PMS2CL_PMS2 0.685 DYNLL1 0.776 0.87 0.003 0.006PMS2CL_PMS2 0.685 FAM118B 0.737 0.841 0.005 0.043 PMS2CL_PMS2 0.685PLEKHA3 0.658 0.861 0.001 0.001 PMS2CL_PMS2 0.685 TMEM62_SPCS2_L 0.6450.79 0.04 0.023 PMS2CL_PMS2 0.685 PLEKHF2 0.822 0.912 0 0.012PMS2CL_PMS2 0.685 AIF1 0.816 0.916 0 0.02 PMS2CL_PMS2 0.685CALM2_C2orf61 0.733 0.897 0 0.001 PDE3B 0.85 NEK6_LOC1001290 0.765 0.9060.026 0.016 PDE3B 0.85 OR9A2 0.813 0.943 0.042 0 PDE3B 0.85 DPH3 0.860.962 0.012 0.001 PDE3B 0.85 TRIM21 0.874 0.962 0.001 0.036 PDE3B 0.85ICAM1 0.821 0.915 0.014 0.023 PDE3B 0.85 TAF13 0.854 0.959 0.017 0.004PDE3B 0.85 KLHL5 0.826 0.944 0.019 0.01 PDE3B 0.85 DLEU2_DLEU2L 0.8740.986 0.001 0.001 PDE3B 0.85 ANKRD28 0.8 0.995 0.001 0 PDE3B 0.85UBE2F_C20orf194 0.762 0.929 0.045 0 PDE3B 0.85 CEP97 0.695 0.929 0.04 0PDE3B 0.85 FAM118B 0.737 0.941 0.016 0.001 PDE3B 0.85 PLEKHF2 0.8220.961 0.021 0 PDE3B 0.85 AIF1 0.816 0.934 0.042 0.008 PDE3B 0.85CALM2_C2orf61 0.733 0.978 0.002 0 SULF2 0.819 ACTA2 0.783 0.926 0.0130.005 SULF2 0.819 ICAM1 0.821 0.929 0.002 0.038 SULF2 0.819 ANKRD28 0.80.904 0.024 0.036 SULF2 0.819 HSPB1_HSPBL2 0.778 0.895 0.038 0.017 SULF20.819 ZRANB1 0.724 0.908 0.031 0.001 SULF2 0.819 PLIN2 0.671 0.906 0.0080.001 SULF2 0.819 FAM118B 0.737 0.928 0.008 0.001 SULF2 0.819CALM2_C2orf61 0.733 0.89 0.043 0.003 NEK6_LOC1001290 0.765 CCR4 0.7840.872 0.045 0.008 NEK6_LOC1001290 0.765 ABCG1 0.789 0.89 0.037 0.024NEK6_LOC1001290 0.765 LASS4 0.794 0.887 0.028 0.014 CENPK 0.688 NA 0.7050.811 0.011 0.039 CENPK 0.688 DYNLL1 0.776 0.864 0.001 0.05 TRAF3 0.594ITGA4_CERKL 0.694 0.807 0.002 0.039 TRAF3 0.594 NPCDR1 0.86 0.901 00.048 TRAF3 0.594 NA 0.718 0.788 0.016 0.04 TRAF3 0.594 SYNE2 0.6780.775 0.01 0.034 TRAF3 0.594 NA 0.746 0.827 0.003 0.004 TRAF3 0.594CAMK1D 0.702 0.82 0.001 0.013 GPR65 0.886 ITGA4_CERKL 0.694 0.969 0.0470 MACF1 0.742 HSP90AB1_HSP90A 0.799 0.913 0 0.016 MACF1 0.742ITGA4_CERKL 0.694 0.85 0.012 0.008 MACF1 0.742 NPCDR1 0.86 0.925 0 0.025MACF1 0.742 NA 0.718 0.834 0.025 0.031 MACF1 0.742 NA 0.763 0.86 0.0060.019 MACF1 0.742 LY6G5B_CSNK2B 0.661 0.874 0.001 0.002 MACF1 0.742 CCR40.784 0.904 0 0.015 MACF1 0.742 RRP12_LOC644215 0.632 0.803 0.04 0.007MACF1 0.742 PYHIN1 0.807 0.902 0.001 0.042 MACF1 0.742 SON 0.604 0.8060.043 0.005 MACF1 0.742 SYNE2 0.678 0.881 0.001 0.001 MACF1 0.742 NA0.746 0.884 0.002 0.003 MACF1 0.742 TSHZ2 0.801 0.918 0 0.024 MACF10.742 CAMK1D 0.702 0.881 0.001 0.003 MACF1 0.742 LOC100128751 0.6510.822 0.021 0.016 AMFR 0.69 CCR4 0.784 0.873 0.008 0.008 AMFR 0.69B4GALT3 0.659 0.869 0.012 0 RPL17_SNORD58B 0.694 HDHD1A 0.63 0.786 0.0110.031 RPL17_SNORD58B 0.694 MGST3 0.602 0.772 0.02 0.033 RPL17_SNORD58B0.694 FSD1L_GARNL1 0.66 0.812 0.006 0.028 RPL17_SNORD58B 0.694 NA 0.7050.842 0.006 0.008 RPL17_SNORD58B 0.694 UBE2F_C20orf194 0.762 0.866 00.048 RPL17_SNORD58B 0.694 CEP97 0.695 0.838 0.001 0.025 RPL17_SNORD58B0.694 DYNLL1 0.776 0.925 0 0 RPL17_SNORD58B 0.694 PLEKHA3 0.658 0.834 00.021 RPL17_SNORD58B 0.694 TMEM62_SPCS2_L 0.645 0.797 0.003 0.048RPL17_SNORD58B 0.694 CALM2_C2orf61 0.733 0.909 0 0.001 IRS2 0.648 ITGA2B0.699 0.831 0.038 0.001 IRS2 0.648 LHFP 0.759 0.879 0 0.032 IRS2 0.648PTGS1 0.68 0.817 0.04 0.008 IRS2 0.648 MYL9 0.771 0.879 0.002 0.024 IRS20.648 CMTM5 0.694 0.814 0.047 0.005 GALNT2 0.651 HSP90AB1_HSP90A 0.7990.861 0.005 0.024 GALNT2 0.651 NPCDR1 0.86 0.904 0 0.047 GALNT2 0.651PYHIN1 0.807 0.852 0.005 0.045 GALNT2 0.651 NA 0.746 0.805 0.029 0.011GALNT2 0.651 RASA4_RASA4P_R 0.779 0.85 0.001 0.049 HSP90AB1_HSP90A 0.799ACTA2 0.783 0.931 0.001 0.012 HSP90AB1_HSP90A 0.799 TRIM21 0.874 0.977 00.014 HSP90AB1_HSP90A 0.799 P4HA1_RPL17 0.715 0.898 0.035 0HSP90AB1_HSP90A 0.799 HSPB1_HSPBL2 0.778 0.903 0.005 0.029HSP90AB1_HSP90A 0.799 LAIR1_LAIR2 0.749 0.883 0.037 0.008HSP90AB1_HSP90A 0.799 UBE2F_C20orf194 0.762 0.91 0.033 0.001HSP90AB1_HSP90A 0.799 CCRL2 0.786 0.904 0.044 0.008 HSP90AB1_HSP90A0.799 DYNLL1 0.776 0.922 0.025 0 HSP90AB1_HSP90A 0.799 PLIN2 0.671 0.8950.027 0.001 HSP90AB1_HSP90A 0.799 FAM118B 0.737 0.91 0.017 0.001HSP90AB1_HSP90A 0.799 NP 0.633 0.911 0.031 0 HSP90AB1_HSP90A 0.799TMEM62_SPCS2_L 0.645 0.886 0.01 0 OR9A2 0.813 C15orf54 0.821 0.895 0.0340.033 OR9A2 0.813 CCR4 0.784 0.908 0.004 0.007 OR9A2 0.813 FAM118A 0.7590.871 0.031 0.028 OR9A2 0.813 TSHZ2 0.801 0.914 0.003 0.016 OR9A2 0.813RASA4_RASA4P_R 0.779 0.885 0.015 0.018 OR9A2 0.813 CAMK1D 0.702 0.8990.011 0.001 OR9A2 0.813 CFD 0.767 0.924 0.016 0.001 OR9A2 0.813 IL5RA0.832 0.914 0.018 0.03 HDHD1A 0.63 ITGA4_CERKL 0.694 0.799 0.01 0.029HDHD1A 0.63 NA 0.763 0.825 0.004 0.047 HDHD1A 0.63 CCR4 0.784 0.879 00.018 HDHD1A 0.63 S100B 0.72 0.795 0.033 0.02 HDHD1A 0.63 SYNE2 0.6780.797 0.013 0.015 ACTA2 0.783 C15orf54 0.821 0.889 0.029 0.022 ACTA20.783 CCR4 0.784 0.882 0.011 0.027 ACTA2 0.783 PYHIN1 0.807 0.892 0.0320.03 ACTA2 0.783 RASA4_RASA4P_R 0.779 0.892 0.023 0.004 ACTA2 0.783IL5RA 0.832 0.896 0.021 0.021 ACPL2 0.651 TAS2R31 0.685 0.778 0.039 0.05LRRFIP1 0.673 SFRS9 0.527 0.794 0.004 0.002 LRRFIP1 0.673 NPCDR1 0.860.916 0 0.047 LRRFIP1 0.673 LY6G5B_CSNK2B 0.661 0.877 0 0.004 LRRFIP10.673 CCR4 0.784 0.906 0 0.012 LRRFIP1 0.673 S100B 0.72 0.804 0.05 0.022LRRFIP1 0.673 SON 0.604 0.754 0.031 0.04 LRRFIP1 0.673 SYNE2 0.678 0.8460.001 0.005 LRRFIP1 0.673 NA 0.746 0.861 0.001 0.008 LRRFIP1 0.673 TSHZ20.801 0.93 0 0.01 LRRFIP1 0.673 CAMK1D 0.702 0.903 0 0.002 OCR1 0.647NF-E4 0.628 0.823 0.015 0.001 OCR1 0.647 PDK4 0.71 0.819 0.011 0.041OCR1 0.647 CYP4F3_CYP4F2 0.593 0.754 0.044 0.046 OCR1 0.647 DYNLL1 0.7760.859 0 0.041 OCR1 0.647 SPARC 0.703 0.839 0.001 0.026 OCR1 0.647 FBXL130.614 0.807 0.03 0.002 ITGA4_CERKL 0.694 TRIM21 0.874 0.953 0 0.014ITGA4_CERKL 0.694 TAF13 0.854 0.922 0 0.035 ITGA4_CERKL 0.694P4HA1_RPL17 0.715 0.889 0.003 0 ITGA4_CERKL 0.694 KLHL5 0.826 0.923 00.043 ITGA4_CERKL 0.694 DLEU2_DLEU2L 0.874 0.943 0 0.036 ITGA4_CERKL0.694 MGST3 0.602 0.798 0.027 0.005 ITGA4_CERKL 0.694 CCRL2 0.786 0.8670.003 0.027 ITGA4_CERKL 0.694 ZNF587_ZNF417 0.648 0.816 0.036 0.004ITGA4_CERKL 0.694 CEP97 0.695 0.832 0.029 0.005 ITGA4_CERKL 0.694 DYNLL10.776 0.884 0.002 0.002 ITGA4_CERKL 0.694 PLIN2 0.671 0.821 0.026 0.013ITGA4_CERKL 0.694 FAM118B 0.737 0.895 0.003 0.001 ITGA4_CERKL 0.694CTSL1_CTSLL3 0.715 0.845 0.009 0.014 ITGA4_CERKL 0.694 PLEKHA3 0.6580.822 0.022 0.005 ITGA4_CERKL 0.694 TMEM62_SPCS2_L 0.645 0.887 0 0ITGA4_CERKL 0.694 PLEKHF2 0.822 0.935 0 0.004 ITGA4_CERKL 0.694HIST2H2BF_HIST2 0.754 0.842 0.013 0.033 ITGA4_CERKL 0.694 CALM2_C2orf610.733 0.863 0.002 0.007 DPH3 0.86 NA 0.763 0.938 0.038 0 DPH3 0.86 CCR40.784 0.944 0.019 0 DPH3 0.86 CLC 0.81 0.944 0.029 0.003 DPH3 0.86 LASS40.794 0.917 0.021 0.02 DPH3 0.86 TSHZ2 0.801 0.92 0.037 0.005 DPH3 0.86C4orf3 0.629 0.927 0.048 0 DPH3 0.86 CAMK1D 0.702 0.917 0.043 0 DPH30.86 IL5RA 0.832 0.94 0.05 0.002 ERGIC1 0.628 LY6G5B_CSNK2B 0.661 0.7840.024 0.019 ERGIC1 0.628 CCR4 0.784 0.859 0 0.039 ERGIC1 0.628 CAMK1D0.702 0.838 0.002 0.012 CD300A 0.623 CAMK1D 0.702 0.792 0.016 0.045NF-E4 0.628 KIAA1324 0.666 0.778 0.015 0.045 TRIM21 0.874 NPCDR1 0.860.956 0.032 0.001 TRIM21 0.874 LY6G5B_CSNK2B 0.661 0.952 0.037 0 TRIM210.874 CCR4 0.784 0.957 0.019 0 NPCDR1 0.86 ICAM1 0.821 0.937 0.003 0.017NPCDR1 0.86 TAF13 0.854 0.935 0.021 0.014 NPCDR1 0.86 KLHL5 0.826 0.9430.004 0.008 NPCDR1 0.86 ANKRD28 0.8 0.917 0.033 0.006 NPCDR1 0.86HSPB1_HSPBL2 0.778 0.91 0.029 0.009 NPCDR1 0.86 IL1B 0.871 0.951 0.0040.017 NPCDR1 0.86 CCRL2 0.786 0.935 0.016 0.001 NPCDR1 0.86 PLEKHF20.822 0.919 0.046 0.012 NPCDR1 0.86 AIF1 0.816 0.932 0.008 0.01 NA 0.718P4HA1_RPL17 0.715 0.849 0.005 0.007 NA 0.763 P4HA1_RPL17 0.715 0.8790.004 0.002 NA 0.763 DLEU2_DLEU2L 0.874 0.942 0 0.035 NA 0.763 ZRANB10.724 0.834 0.05 0.029 NA 0.763 UBE2F_C20orf194 0.762 0.878 0.001 0.02NA 0.763 CEP97 0.695 0.874 0.005 0.003 NA 0.763 DYNLL1 0.776 0.898 0.010.001 NA 0.763 PLIN2 0.671 0.845 0.009 0.009 NA 0.763 FAM118B 0.7370.873 0.003 0.014 NA 0.763 CTSL1_CTSLL3 0.715 0.862 0.002 0.018 NA 0.763HIST2H2BF_HIST2 0.754 0.854 0.03 0.023 NA 0.763 CALM2_C2orf61 0.7330.869 0.004 0.011 ICAM1 0.821 CCR4 0.784 0.9 0.045 0.004 ICAM1 0.821ABCG1 0.789 0.916 0.012 0.018 ICAM1 0.821 RASA4_RASA4P_R 0.779 0.9140.045 0.001 TAF13 0.854 CCR4 0.784 0.935 0.009 0.002 TAF13 0.854 ABCG10.789 0.922 0.019 0.005 TAF13 0.854 PYHIN1 0.807 0.929 0.038 0.009 TAF130.854 CLC 0.81 0.946 0.027 0.003 TAF13 0.854 LASS4 0.794 0.913 0.0110.017 TAF13 0.854 TSHZ2 0.801 0.924 0.01 0.016 TAF13 0.854RASA4_RASA4P_R 0.779 0.91 0.034 0.007 P4HA1_RPL17 0.715 LY6G5B_CSNK2B0.661 0.857 0.001 0.004 P4HA1_RPL17 0.715 CCR4 0.784 0.893 0 0.032P4HA1_RPL17 0.715 PYHIN1 0.807 0.917 0 0.015 P4HA1_RPL17 0.715 CLC 0.810.905 0 0.022 P4HA1_RPL17 0.715 SON 0.604 0.847 0.002 0.001 P4HA1_RPL170.715 SYNE2 0.678 0.875 0 0.002 P4HA1_RPL17 0.715 NA 0.746 0.87 0.0020.005 P4HA1_RPL17 0.715 TSHZ2 0.801 0.911 0 0.035 P4HA1_RPL17 0.715CAMK1D 0.702 0.884 0 0.002 P4HA1_RPL17 0.715 LOC100128751 0.651 0.8170.02 0.01 P4HA1_RPL17 0.715 IL5RA 0.832 0.894 0.001 0.047 P4HA1_RPL170.715 TAS2R31 0.685 0.833 0.035 0.001 P4HA1_RPL17 0.715 C1orf128 0.7510.813 0.028 0.022 C15orf54 0.821 ANKRD28 0.8 0.929 0 0.013 C15orf540.821 ITGA2B 0.699 0.881 0.05 0.002 C15orf54 0.821 LHFP 0.759 0.8940.001 0.024 C15orf54 0.821 ZRANB1 0.724 0.898 0.022 0.001 C15orf54 0.821PTGS1 0.68 0.886 0.014 0.002 C15orf54 0.821 UBE2F_C20orf194 0.762 0.9120.003 0.004 C15orf54 0.821 MYL9 0.771 0.915 0.003 0.008 C15orf54 0.821HIST1H2BJ 0.697 0.91 0.018 0.001 C15orf54 0.821 CTSL1_CTSLL3 0.715 0.8750.049 0.004 C15orf54 0.821 SPARC 0.703 0.905 0.01 0.001 C15orf54 0.821PLEKHA3 0.658 0.897 0.012 0 C15orf54 0.821 CMTM5 0.694 0.888 0.031 0.001C15orf54 0.821 HIST2H2BF_HIST2 0.754 0.884 0.03 0.013 C15orf54 0.821CALM2_C2orf61 0.733 0.905 0.008 0.002 KLHL5 0.826 LY6G5B_CSNK2B 0.6610.931 0.002 0 KLHL5 0.826 CCR4 0.784 0.958 0.002 0 KLHL5 0.826 ABCG10.789 0.932 0.002 0.003 KLHL5 0.826 TSHZ2 0.801 0.928 0.01 0.004 KLHL50.826 RASA4_RASA4P_R 0.779 0.905 0.02 0.008 KLHL5 0.826 CAMK1D 0.7020.902 0.044 0 KLHL5 0.826 IL5RA 0.832 0.919 0.048 0.004 DLEU2_DLEU2L0.874 CCR4 0.784 0.947 0.009 0 DLEU2_DLEU2L 0.874 ABCG1 0.789 0.9390.042 0.001 DLEU2_DLEU2L 0.874 IL5RA 0.832 0.936 0.049 0.005 ANKRD28 0.8LY6G5B_CSNK2B 0.661 0.904 0.006 0 ANKRD28 0.8 CCR4 0.784 0.946 0.005 0ANKRD28 0.8 ABCG1 0.789 0.897 0.024 0.015 ANKRD28 0.8 FAM118A 0.7590.906 0.006 0.005 ANKRD28 0.8 PYHIN1 0.807 0.926 0.01 0.003 ANKRD28 0.8SYNE2 0.678 0.891 0.045 0 ANKRD28 0.8 TSHZ2 0.801 0.933 0.001 0.007ANKRD28 0.8 RASA4_RASA4P_R 0.779 0.9 0.023 0.004 ANKRD28 0.8 CAMK1D0.702 0.907 0.017 0 LY6G5B_CSNK2B 0.661 LAIR1_LAIR2 0.749 0.886 0 0.008LY6G5B_CSNK2B 0.661 ZRANB1 0.724 0.811 0.01 0.032 LY6G5B_CSNK2B 0.661UBE2F_C20orf194 0.762 0.84 0.003 0.029 LY6G5B_CSNK2B 0.661 FSD1L 0.70.783 0.043 0.035 LY6G5B_CSNK2B 0.661 ZNF587_ZNF417 0.648 0.833 0.013 0LY6G5B_CSNK2B 0.661 KDM6B_TMEM88 0.711 0.839 0 0.047 LY6G5B_CSNK2B 0.661CEP97 0.695 0.85 0.005 0.001 LY6G5B_CSNK2B 0.661 IRF1 0.651 0.774 0.0240.044 LY6G5B_CSNK2B 0.661 DYNLL1 0.776 0.856 0.005 0.006 LY6G5B_CSNK2B0.661 PLIN2 0.671 0.801 0.023 0.018 LY6G5B_CSNK2B 0.661 FAM118B 0.7370.885 0.001 0.001 LY6G5B_CSNK2B 0.661 PLEKHA3 0.658 0.773 0.04 0.021LY6G5B_CSNK2B 0.661 AIF1 0.816 0.902 0 0.019 LY6G5B_CSNK2B 0.661HIST2H2BF_HIST2 0.754 0.826 0.007 0.05 LY6G5B_CSNK2B 0.661 CALM2_C2orf610.733 0.826 0.008 0.017 MGST3 0.602 CCR4 0.784 0.868 0 0.024HSPB1_HSPBL2 0.778 CCR4 0.784 0.874 0.047 0.009 HSPB1_HSPBL2 0.778PYHIN1 0.807 0.884 0.033 0.021 HSPB1_HSPBL2 0.778 RASA4_RASA4P_R 0.7790.883 0.023 0.005 HSPB1_HSPBL2 0.778 IL5RA 0.832 0.89 0.048 0.019 CCR40.784 LHFP 0.759 0.85 0.013 0.032 CCR4 0.784 LAIR1_LAIR2 0.749 0.8850.03 0.008 CCR4 0.784 ZRANB1 0.724 0.878 0.022 0.001 CCR4 0.784UBE2F_C20orf194 0.762 0.923 0.002 0.001 CCR4 0.784 ZNF587_ZNF417 0.6480.882 0.05 0 CCR4 0.784 MYL9 0.771 0.903 0.006 0.003 CCR4 0.784 CEP970.695 0.93 0.003 0 CCR4 0.784 DYNLL1 0.776 0.91 0.013 0 CCR4 0.784 PLIN20.671 0.872 0.021 0.001 CCR4 0.784 FAM118B 0.737 0.94 0.001 0 CCR4 0.784NP 0.633 0.874 0.018 0 CCR4 0.784 PLEKHA3 0.658 0.869 0.046 0 CCR4 0.784TMEM62_SPCS2_L 0.645 0.872 0.038 0 CCR4 0.784 PLEKHF2 0.822 0.923 0.0050.002 CCR4 0.784 AIF1 0.816 0.946 0 0.006 CCR4 0.784 HIST2H2BF_HIST20.754 0.887 0.049 0.001 CCR4 0.784 CALM2_C2orf61 0.733 0.923 0.002 0CCDC125 0.632 SYNE2 0.678 0.804 0.002 0.036 ABCG1 0.789 PLEKHF2 0.8220.908 0.012 0.008 ABCG1 0.789 AIF1 0.816 0.905 0.003 0.05 ITGA2B 0.699B4GALT3 0.659 0.801 0.019 0.05 LHFP 0.759 LASS4 0.794 0.91 0.001 0.016LHFP 0.759 TSHZ2 0.801 0.861 0.021 0.049 LAIR1_LAIR2 0.749 PYHIN1 0.8070.888 0.024 0.028 LAIR1_LAIR2 0.749 TSHZ2 0.801 0.896 0.002 0.045 ZRANB10.724 FAM118A 0.759 0.867 0.002 0.033 ZRANB1 0.724 PYHIN1 0.807 0.8840.003 0.031 ZRANB1 0.724 CLC 0.81 0.88 0.006 0.021 ZRANB1 0.724 NA 0.7460.855 0.012 0.004 ZRANB1 0.724 TSHZ2 0.801 0.899 0 0.047 ZRANB1 0.724CAMK1D 0.702 0.855 0.004 0.006 ZRANB1 0.724 IL5RA 0.832 0.886 0.0030.047 ZRANB1 0.724 C1orf128 0.751 0.866 0.015 0.006 TIMM10 0.554 IFI440.762 0.82 0.004 0.024 FSD1L_GARNL1 0.66 TAS2R31 0.685 0.811 0.026 0.002HIST1H2AJ_HIST1 0.631 POLE2 0.539 0.689 0.007 0.007 PTGS1 0.68 CLC 0.810.852 0.011 0.05 PTGS1 0.68 B4GALT3 0.659 0.825 0.008 0.01 PTGS1 0.68CFD 0.767 0.843 0.012 0.047 PTGS1 0.68 C1orf128 0.751 0.849 0.01 0.047UBE2F_C20orf194 0.762 FAM118A 0.759 0.87 0.012 0.018 UBE2F_C20orf1940.762 PYHIN1 0.807 0.895 0.005 0.008 UBE2F_C20orf194 0.762 CLC 0.810.906 0.007 0.019 UBE2F_C20orf194 0.762 B4GALT3 0.659 0.922 0 0UBE2F_C20orf194 0.762 RASA4_RASA4P_R 0.779 0.878 0.001 0.038UBE2F_C20orf194 0.762 C4orf3 0.629 0.851 0.025 0 UBE2F_C20orf194 0.762RPIA 0.713 0.884 0.035 0 UBE2F_C20orf194 0.762 IL5RA 0.832 0.906 0.0030.025 UBE2F_C20orf194 0.762 C1orf128 0.751 0.92 0.007 0 FAM118A 0.759DYNLL1 0.776 0.878 0.043 0.001 FAM118A 0.759 FAM118B 0.737 0.88 0.0270.002 FAM118A 0.759 CALM2_C2orf61 0.733 0.862 0.036 0.004 CCRL2 0.786CLC 0.81 0.908 0.016 0.029 CCRL2 0.786 NA 0.746 0.887 0.014 0.003 CCRL20.786 TSHZ2 0.801 0.905 0.003 0.024 CCRL2 0.786 IL5RA 0.832 0.912 0.0070.029 SRXN1 0.612 RPIA 0.713 0.799 0.017 0.025 SRXN1 0.612 C1orf1280.751 0.848 0.002 0.022 ZNF587_ZNF417 0.648 SYNE2 0.678 0.849 0.0010.008 ZNF587_ZNF417 0.648 CAMK1D 0.702 0.857 0 0.018 PYHIN1 0.807 MYL90.771 0.876 0.046 0.03 PYHIN1 0.807 CEP97 0.695 0.91 0.018 0 PYHIN10.807 DYNLL1 0.776 0.91 0.047 0 PYHIN1 0.807 PLIN2 0.671 0.879 0.040.002 PYHIN1 0.807 FAM118B 0.737 0.927 0.004 0.001 PYHIN1 0.807TMEM62_SPCS2_L 0.645 0.904 0.009 0 PYHIN1 0.807 DCTN5 0.557 0.879 0.0460 KIAA1324 0.666 CYP4F3_CYP4F2 0.593 0.765 0.039 0.033 KDM6B_TMEM880.711 RASA4_RASA4P_R 0.779 0.852 0.012 0.022 KDM6B_TMEM88 0.711 CAMK1D0.702 0.835 0.041 0.004 MYL9 0.771 CLC 0.81 0.886 0.048 0.013 MYL9 0.771LASS4 0.794 0.926 0 0.048 MYL9 0.771 B4GALT3 0.659 0.881 0.022 0 MYL90.771 CFD 0.767 0.882 0.04 0.006 MYL9 0.771 IL5RA 0.832 0.903 0.0120.025 MYL9 0.771 C1orf128 0.751 0.879 0.037 0.014 TAAR1 0.657 TAS2R310.685 0.763 0.016 0.049 CLC 0.81 CEP97 0.695 0.908 0.016 0.001 CLC 0.81DYNLL1 0.776 0.914 0.033 0.001 CLC 0.81 PLIN2 0.671 0.893 0.02 0.002 CLC0.81 FAM118B 0.737 0.914 0.008 0.002 CLC 0.81 CTSL1_CTSLL3 0.715 0.9030.034 0.001 CLC 0.81 PLEKHF2 0.822 0.923 0.014 0.021 CLC 0.81CALM2_C2orf61 0.733 0.908 0.018 0.002 CEP97 0.695 SYNE2 0.678 0.8450.011 0.002 CEP97 0.695 B4GALT3 0.659 0.814 0.01 0.019 CEP97 0.695CAMK1D 0.702 0.825 0.014 0.032 CEP97 0.695 IL5RA 0.832 0.902 0 0.025 SON0.604 DYNLL1 0.776 0.837 0.002 0.027 SON 0.604 FAM118B 0.737 0.835 0.0010.027 SON 0.604 TMEM62_SPCS2_L 0.645 0.768 0.02 0.019 SON 0.604CALM2_C2orf61 0.733 0.816 0.002 0.036 IRF1 0.651 NA 0.746 0.818 0.0150.01 IRF1 0.651 CAMK1D 0.702 0.797 0.024 0.027 IRF1 0.651 IL5RA 0.8320.884 0 0.041 IRF1 0.651 C1orf128 0.751 0.803 0.042 0.038 SYNE2 0.678DYNLL1 0.776 0.882 0.001 0.005 SYNE2 0.678 FAM118B 0.737 0.887 0 0.004SYNE2 0.678 NP 0.633 0.778 0.027 0.035 SYNE2 0.678 TMEM62_SPCS2_L 0.6450.814 0.007 0.011 SYNE2 0.678 CALM2_C2orf61 0.733 0.843 0.001 0.025SYNE2 0.678 DCTN5 0.557 0.78 0.026 0.003 DYNLL1 0.776 NA 0.746 0.8620.014 0.012 DYNLL1 0.776 B4GALT3 0.659 0.857 0.007 0.006 DYNLL1 0.776CAMK1D 0.702 0.883 0.001 0.004 DYNLL1 0.776 IL5RA 0.832 0.91 0.002 0.038DYNLL1 0.776 C1orf128 0.751 0.885 0.013 0.006 NA 0.746 PLIN2 0.671 0.8210.024 0.025 NA 0.746 FAM118B 0.737 0.85 0.009 0.023 NA 0.746HIST2H2BF_HIST2 0.754 0.875 0.002 0.018 TSHZ2 0.801 PLIN2 0.671 0.9190.009 0 TSHZ2 0.801 FAM118B 0.737 0.935 0.002 0 TSHZ2 0.801 PLEKHF20.822 0.902 0.04 0.009 TSHZ2 0.801 AIF1 0.816 0.92 0.007 0.013 PLIN20.671 CAMK1D 0.702 0.805 0.02 0.034 FAM118B 0.737 RASA4_RASA4P_R 0.7790.874 0.002 0.042 FAM118B 0.737 CAMK1D 0.702 0.881 0.002 0.002 FAM118B0.737 CFD 0.767 0.855 0.045 0.01 FAM118B 0.737 IL5RA 0.832 0.895 0.0030.038 B4GALT3 0.659 NP 0.633 0.84 0.007 0.001 B4GALT3 0.659 PLEKHA30.658 0.761 0.036 0.049 B4GALT3 0.659 TMEM62_SPCS2_L 0.645 0.752 0.0440.044 B4GALT3 0.659 CMTM5 0.694 0.816 0.019 0.015 B4GALT3 0.659CALM2_C2orf61 0.733 0.84 0.001 0.024 RASA4_RASA4P_R 0.779 PLEKHF2 0.8220.877 0.037 0.045 RASA4_RASA4P_R 0.779 AIF1 0.816 0.898 0.01 0.013 NP0.633 C1orf128 0.751 0.849 0.003 0.014 PLEKHF2 0.822 IL5RA 0.832 0.9150.027 0.017 CAMK1D 0.702 AIF1 0.816 0.906 0 0.049 CAMK1D 0.702HIST2H2BF_HIST2 0.754 0.839 0.011 0.049 CAMK1D 0.702 CALM2_C2orf61 0.7330.856 0.006 0.006 CAMK1D 0.702 SPATA6 0.642 0.832 0.035 0.001 AIF1 0.816IL5RA 0.832 0.926 0.034 0.005 CFD 0.767 HIST2H2BF_HIST2 0.754 0.8610.036 0.025 CFD 0.767 CALM2_C2orf61 0.733 0.879 0.01 0.007 MPZL2 0.612IFI44 0.762 0.809 0.016 0.009 IL5RA 0.832 HIST2H2BF_HIST2 0.754 0.9050.021 0.008 IL5RA 0.832 CALM2_C2orf61 0.733 0.901 0.033 0.002CALM2_C2orf61 0.733 C1orf128 0.751 0.855 0.025 0.007

TABLE 18 Ratios inSIRS Versus ipSIRS Gene 1 Name Gene 1 AUC Gene 2 NameGene 2 AUC Ratio AUC Ratio Signif to Gene 1 Ratio Signif to Gene 2 TLR50.725 CLEC4D 0.732 0.868 0.016 0.015 TLR5 0.725 SLC37A3 0.668 0.9070.001 0 TLR5 0.725 BMX_HNRPDL 0.716 0.877 0.027 0.001 TLR5 0.725FKBP5_LOC285847 0.79 0.901 0.003 0.026 TLR5 0.725 MMP9_LOC1001280 0.7290.861 0.01 0.02 TLR5 0.725 PFKFB2 0.777 0.888 0.011 0.007 TLR5 0.725ODZ1 0.777 0.891 0.015 0.002 TLR5 0.725 SH3PXD2B 0.751 0.873 0.032 0.009TLR5 0.725 PRR13_PCBP2 0.758 0.898 0 0.048 TLR5 0.725 CD163 0.808 0.8870.022 0.019 TLR5 0.725 MTHFS 0.733 0.909 0 0.013 TLR5 0.725 PLA2G7 0.7380.868 0.019 0.005 TLR5 0.725 KDM6B_TMEM88 0.672 0.842 0 0.049 TLR5 0.725HIST2H2BF_HIST2 0.62 0.82 0.035 0.007 CD177 0.611 ARG1 0.715 0.816 0.010.014 VNN1 0.523 ARG1 0.715 0.842 0 0.012 UBE2J1 0.814 SLC37A3 0.6680.943 0.011 0 UBE2J1 0.814 CLEC4E 0.849 0.918 0.031 0.022 UBE2J1 0.814PPP2R5A_SNORA16 0.716 0.935 0.015 0 UBE2J1 0.814 PRR13_PCBP2 0.758 0.9180.029 0.003 UBE2J1 0.814 MTHFS 0.733 0.96 0.005 0 UBE2J1 0.814 CDA 0.6940.902 0.043 0.001 UBE2J1 0.814 HAL 0.846 0.916 0.021 0.045 UBE2J1 0.814CCDC125 0.79 0.906 0.043 0.011 UBE2J1 0.814 RGS2 0.789 0.935 0.006 0.005IMP3 0.908 RUNX2 0.868 0.98 0.018 0.016 IMP3 0.908 SYNE2 0.886 0.990.049 0.003 RNASE2_LOC64333 0.718 CLEC4D 0.732 0.836 0.045 0.016RNASE2_LOC64333 0.718 SLC37A3 0.668 0.858 0.007 0.004 RNASE2_LOC643330.718 MMP9_LOC1001280 0.729 0.857 0.006 0.037 RNASE2_LOC64333 0.718PFKFB2 0.777 0.855 0.031 0.026 RNASE2_LOC64333 0.718 CD163 0.808 0.8810.017 0.004 RNASE2_LOC64333 0.718 MTHFS 0.733 0.862 0.006 0.027RNASE2_LOC64333 0.718 PLA2G7 0.738 0.874 0.022 0.003 CLEC4D 0.732 C3AR10.777 0.875 0.008 0.038 CLEC4D 0.732 FAR2 0.706 0.842 0.035 0.019 CLEC4D0.732 OMG 0.769 0.901 0.004 0.009 CLEC4D 0.732 TDRD9 0.752 0.904 0.014 0CLEC4D 0.732 ACER3 0.842 0.926 0 0.048 CLEC4D 0.732 GPR84 0.71 0.8740.043 0 CLEC4D 0.732 PLB1 0.722 0.904 0.005 0.001 CLEC4D 0.732 DSE 0.7840.907 0.001 0.026 CLEC4D 0.732 GSR 0.605 0.822 0.019 0.008 CLEC4D 0.732SMPDL3A 0.736 0.911 0.003 0.001 CLEC4D 0.732 ATP13A3 0.796 0.894 0.0070.042 CLEC4D 0.732 PDGFC 0.822 0.943 0.001 0.009 CLEC4D 0.732SEC24A_SAR1B 0.739 0.86 0.004 0.046 CLEC4D 0.732 EXOSC4 0.742 0.957 00.001 CLEC4D 0.732 CCR1 0.72 0.848 0.017 0.039 CLEC4D 0.732 AP3B2 0.6970.843 0.046 0.015 CLEC4D 0.732 PCOLCE2 0.667 0.889 0.003 0.002 CLEC4D0.732 GALNT2 0.673 0.892 0.001 0.002 CLEC4D 0.732 HDHD1A 0.7 0.823 0.0260.039 CLEC4D 0.732 KIAA0746 0.713 0.854 0.038 0.007 CLEC4D 0.732 PLEKHF20.737 0.868 0.005 0.039 CLEC4D 0.732 IGLV6-57 0.757 0.849 0.025 0.034C3AR1 0.777 SLC37A3 0.668 0.863 0.037 0.001 C3AR1 0.777 ERLIN1 0.7560.868 0.048 0.033 C3AR1 0.777 FKBP5_LOC285847 0.79 0.898 0.009 0.046C3AR1 0.777 MMP9_LOC1001280 0.729 0.884 0.011 0.02 C3AR1 0.777 PFKFB20.777 0.887 0.035 0.026 C3AR1 0.777 CDA 0.694 0.86 0.022 0.02 C3AR10.777 SLC11A1 0.705 0.842 0.044 0.04 C3AR1 0.777 ACPL2 0.756 0.868 0.0350.024 C3AR1 0.777 CPM 0.812 0.89 0.036 0.046 ARG1 0.715 TDRD9 0.7520.906 0 0.008 ARG1 0.715 GPR84 0.71 0.828 0.018 0.044 ARG1 0.715 HPGD0.655 0.864 0.008 0.003 ARG1 0.715 HSPC159 0.577 0.792 0.04 0.012 ARG10.715 FOLR3_FOLR2 0.585 0.795 0.026 0.02 ARG1 0.715 LCN2 0.639 0.8510.008 0.003 ARG1 0.715 ABCA13 0.699 0.868 0.001 0.026 ARG1 0.715 MKI670.674 0.835 0.009 0.043 ARG1 0.715 LTF 0.642 0.809 0.036 0.022 ARG10.715 RETN 0.473 0.792 0.033 0 ARG1 0.715 ANKRD28 0.71 0.858 0.002 0.04ARG1 0.715 LHFP 0.561 0.783 0.026 0.017 ARG1 0.715 TAAR1 0.589 0.810.029 0.005 ARG1 0.715 DEFA4_DEFA8P 0.663 0.829 0.022 0.013 ARG1 0.715SPARC 0.661 0.802 0.044 0.033 ARG1 0.715 IGJ 0.683 0.833 0.028 0.011FCGR1A_FCGR1B_(—) 0.797 IFI16 0.721 0.902 0.006 0.008 FCGR1A_FCGR1B_(—)0.797 PRR13_PCBP2 0.758 0.895 0.005 0.025 FCGR1A_FCGR1B_(—) 0.797 MTHFS0.733 0.914 0.003 0.006 FCGR1A_FCGR1B_(—) 0.797 KDM6B_TMEM88 0.672 0.8690.022 0.007 C11orf82 0.927 MMP9_LOC1001280 0.729 0.976 0.025 0 C11orf820.927 PPP2R5A_SNORA16 0.716 0.974 0.049 0 C11orf82 0.927 PRR13_PCBP20.758 0.974 0.016 0 C11orf82 0.927 HIST1H2AA 0.825 0.973 0.033 0.002C11orf82 0.927 CDA 0.694 0.965 0.022 0 C11orf82 0.927 SYNE2 0.886 0.9710.043 0.023 FAR2 0.706 BMX_HNRPDL 0.716 0.85 0.037 0.003 FAR2 0.706CLEC4E 0.849 0.954 0 0.013 FAR2 0.706 ERLIN1 0.756 0.897 0.006 0.001FAR2 0.706 FKBP5_LOC285847 0.79 0.907 0.001 0.022 FAR2 0.706 PFKFB20.777 0.904 0.004 0.003 FAR2 0.706 ECHDC3 0.823 0.941 0.001 0.004 FAR20.706 PPP2R5A_SNORA16 0.716 0.869 0.002 0.023 FAR2 0.706 HMGB2 0.6730.868 0.009 0.003 FAR2 0.706 TPST1 0.754 0.874 0.024 0.001 FAR2 0.706CD163 0.808 0.873 0.036 0.023 FAR2 0.706 SAP30 0.789 0.913 0 0.044 FAR20.706 DAAM2_LOC100131 0.778 0.89 0.024 0.001 FAR2 0.706 ACPL2 0.7560.892 0.004 0.006 FAR2 0.706 CCDC125 0.79 0.913 0 0.049 FAR2 0.706 THBS10.698 0.851 0.039 0.001 FAR2 0.706 CPM 0.812 0.908 0.003 0.022 FAR20.706 CAMK1D 0.735 0.882 0.002 0.016 GALNT3 0.859 CLEC4E 0.849 0.9440.026 0.018 GALNT3 0.859 IFI16 0.721 0.923 0.041 0.002 GALNT3 0.859ECHDC3 0.823 0.929 0.043 0.01 GALNT3 0.859 PPP2R5A_SNORA16 0.716 0.9620.003 0 GALNT3 0.859 PRR13_PCBP2 0.758 0.93 0.02 0.007 GALNT3 0.859MTHFS 0.733 0.946 0.022 0.001 GALNT3 0.859 SAP30 0.789 0.917 0.019 0.022GALNT3 0.859 AREG 0.814 0.916 0.028 0.032 GALNT3 0.859 ERGIC1 0.758 0.920.022 0.003 GALNT3 0.859 NA 0.884 0.959 0.012 0.028 GALNT3 0.859 HAL0.846 0.933 0.011 0.037 GALNT3 0.859 KIAA1257_ACAD9/ 0.823 0.926 0.0220.02 GALNT3 0.859 CCDC125 0.79 0.938 0.016 0.01 GALNT3 0.859 RGS2 0.7890.945 0.002 0.018 OMG 0.769 SLC37A3 0.668 0.902 0.01 0 OMG 0.769 CLEC4E0.849 0.947 0 0.036 OMG 0.769 FKBP5_LOC285847 0.79 0.915 0.007 0.013 OMG0.769 MMP9_LOC1001280 0.729 0.888 0.014 0.004 OMG 0.769 PFKFB2 0.7770.906 0.016 0.003 OMG 0.769 IFI16 0.721 0.845 0.033 0.047 OMG 0.769 ODZ10.777 0.906 0.036 0.001 OMG 0.769 ECHDC3 0.823 0.934 0.001 0.024 OMG0.769 PPP2R5A_SNORA16 0.716 0.916 0.001 0.005 OMG 0.769 HMGB2 0.6730.917 0.011 0 OMG 0.769 PRR13_PCBP2 0.758 0.89 0.002 0.041 OMG 0.769TPST1 0.754 0.926 0.019 0 OMG 0.769 MTHFS 0.733 0.893 0.012 0.012 OMG0.769 CDA 0.694 0.873 0.011 0.012 OMG 0.769 SLC11A1 0.705 0.898 0.0030.008 OMG 0.769 DAAM2_LOC100131 0.778 0.899 0.035 0.004 OMG 0.769 ACPL20.756 0.935 0.003 0.002 OMG 0.769 ERGIC1 0.758 0.903 0.003 0.03 OMG0.769 HAL 0.846 0.947 0 0.039 OMG 0.769 CCDC125 0.79 0.913 0.001 0.039OMG 0.769 ZRANB1 0.718 0.85 0.028 0.038 OMG 0.769 CYP4F3_CYP4F2 0.7550.868 0.035 0.029 OMG 0.769 MME 0.847 0.94 0.001 0.027 OMG 0.769 CPM0.812 0.908 0.009 0.031 OMG 0.769 RBP7 0.803 0.939 0.001 0.014 OMG 0.769RGS2 0.789 0.94 0 0.023 OMG 0.769 CAMK1D 0.735 0.864 0.007 0.048 SLC37A30.668 TDRD9 0.752 0.894 0.007 0 SLC37A3 0.668 ACER3 0.842 0.934 0 0.02SLC37A3 0.668 C7orf53 0.711 0.847 0.006 0.012 SLC37A3 0.668 PLB1 0.7220.922 0 0 SLC37A3 0.668 DSE 0.784 0.924 0 0.005 SLC37A3 0.668 GSR 0.6050.773 0.042 0.026 SLC37A3 0.668 SMPDL3A 0.736 0.861 0.004 0.019 SLC37A30.668 ATP13A3 0.796 0.919 0.001 0.004 SLC37A3 0.668 PDGFC 0.822 0.941 00.014 SLC37A3 0.668 EXOSC4 0.742 0.924 0 0.003 SLC37A3 0.668 CCR1 0.720.826 0.015 0.027 SLC37A3 0.668 ABCA13 0.699 0.8 0.046 0.03 SLC37A30.668 PCOLCE2 0.667 0.832 0.001 0.026 SLC37A3 0.668 MKI67 0.674 0.790.028 0.026 SLC37A3 0.668 MACF1 0.699 0.817 0.025 0.019 SLC37A3 0.668GALNT2 0.673 0.866 0 0.008 SLC37A3 0.668 HDHD1A 0.7 0.829 0.004 0.024SLC37A3 0.668 KIAA0746 0.713 0.847 0.007 0.008 SLC37A3 0.668 LAIR1_LAIR20.777 0.874 0.001 0.03 SLC37A3 0.668 CD151 0.767 0.892 0 0.018 SLC37A30.668 IGK@_IGKC_IGKV 0.774 0.848 0.017 0.04 SLC37A3 0.668 MYL9 0.6950.816 0.019 0.028 SLC37A3 0.668 HIST1H2BJ 0.797 0.874 0.001 0.047SLC37A3 0.668 IGLV6-57 0.757 0.851 0.007 0.025 SLC37A3 0.668 SDHC 0.850.907 0.001 0.042 BMX_HNRPDL 0.716 TDRD9 0.752 0.938 0.002 0 BMX_HNRPDL0.716 GPR84 0.71 0.904 0.006 0 BMX_HNRPDL 0.716 PLB1 0.722 0.884 0 0.021BMX_HNRPDL 0.716 GSR 0.605 0.805 0.012 0.035 BMX_HNRPDL 0.716 SMPDL3A0.736 0.9 0.001 0.008 BMX_HNRPDL 0.716 PDGFC 0.822 0.936 0 0.033BMX_HNRPDL 0.716 EXOSC4 0.742 0.918 0 0.015 BMX_HNRPDL 0.716DNAJC9_FAM149B1 0.742 0.835 0.033 0.036 BMX_HNRPDL 0.716 ABCA13 0.6990.839 0.014 0.026 BMX_HNRPDL 0.716 PCOLCE2 0.667 0.857 0.002 0.024BMX_HNRPDL 0.716 MKI67 0.674 0.839 0.007 0.032 BMX_HNRPDL 0.716 RETN0.473 0.828 0.019 0 BMX_HNRPDL 0.716 MACF1 0.699 0.836 0.018 0.033BMX_HNRPDL 0.716 GALNT2 0.673 0.864 0 0.024 BMX_HNRPDL 0.716 KIAA07460.713 0.857 0.012 0.018 BMX_HNRPDL 0.716 LHFP 0.561 0.798 0.02 0.009BMX_HNRPDL 0.716 IGK@_IGKC_IGKV 0.774 0.87 0.007 0.026 BMX_HNRPDL 0.716TAAR1 0.589 0.806 0.047 0.006 BMX_HNRPDL 0.716 IGLV6-57 0.757 0.8670.004 0.043 STOM 0.792 CLEC4E 0.849 0.922 0.033 0.005 STOM 0.792LOC284757 0.921 0.958 0.003 0.03 STOM 0.792 PPP2R5A_SNORA16 0.716 0.9080.044 0 STOM 0.792 PRR13_PCBP2 0.758 0.926 0.016 0.001 STOM 0.792 GAB20.842 0.919 0.012 0.02 STOM 0.792 AREG 0.814 0.92 0.01 0.008 STOM 0.792IRS2 0.851 0.906 0.045 0.044 STOM 0.792 CCDC125 0.79 0.912 0.038 0.005STOM 0.792 MME 0.847 0.887 0.047 0.04 TDRD9 0.752 IL18R1 0.748 0.8950.01 0.008 TDRD9 0.752 MMP9_LOC1001280 0.729 0.906 0 0.026 TDRD9 0.752GK3P_GK 0.654 0.874 0.015 0.001 TDRD9 0.752 PFKFB2 0.777 0.942 0 0.007TDRD9 0.752 ODZ1 0.777 0.914 0.002 0.007 TDRD9 0.752 SH3PXD2B 0.7510.894 0.004 0.017 TDRD9 0.752 HMGB2 0.673 0.835 0.03 0.025 TDRD9 0.752TPST1 0.754 0.86 0.026 0.032 TDRD9 0.752 THBS1 0.698 0.837 0.041 0.029KREMEN1 0.835 PRR13_PCBP2 0.758 0.926 0.013 0.012 KREMEN1 0.835 SLC11A10.705 0.9 0.018 0.011 KREMEN1 0.835 KDM6B_TMEM88 0.672 0.919 0.017 0.002CLEC4E 0.849 DNAJC13 0.772 0.921 0.03 0.005 CLEC4E 0.849 FOXD4L3_FOXD4L60.861 0.951 0.012 0.015 CLEC4E 0.849 SLC15A2 0.817 0.913 0.043 0.039CLEC4E 0.849 VAMP2 0.595 0.911 0.012 0 CLEC4E 0.849 CLU 0.784 0.9210.017 0.009 CLEC4E 0.849 CD63 0.813 0.956 0.001 0.011 CLEC4E 0.849 DDAH20.809 0.942 0.003 0.029 CLEC4E 0.849 PDGFC 0.822 0.958 0.005 0.006CLEC4E 0.849 LRRC70_IPO11 0.886 0.952 0.012 0.033 CLEC4E 0.849 EXOSC40.742 0.934 0.012 0.002 CLEC4E 0.849 HIST1H3J 0.829 0.955 0.006 0.009CLEC4E 0.849 SUCNR1 0.861 0.942 0.024 0.008 CLEC4E 0.849 AIG1 0.8730.962 0.001 0.039 CLEC4E 0.849 PCOLCE2 0.667 0.901 0.037 0.001 CLEC4E0.849 HS2ST1_UBA2 0.837 0.942 0.005 0.032 CLEC4E 0.849 HIST1H3A 0.8220.947 0.009 0.008 CLEC4E 0.849 GSTO1 0.83 0.939 0.005 0.026 CLEC4E 0.849ACTA2 0.818 0.946 0.006 0.015 CLEC4E 0.849 DPH3 0.706 0.932 0.038 0CLEC4E 0.849 TYMS 0.838 0.944 0.004 0.026 CLEC4E 0.849 ITGA2B 0.7520.924 0.038 0.001 CLEC4E 0.849 HIST1H3B 0.829 0.936 0.038 0.01 CLEC4E0.849 PTGS1 0.794 0.94 0.01 0.003 CLEC4E 0.849 HIST1H3C 0.854 0.9510.023 0.004 CLEC4E 0.849 CD151 0.767 0.921 0.046 0.003 CLEC4E 0.849HIST1H3H 0.836 0.932 0.035 0.02 CLEC4E 0.849 FSD1L 0.834 0.937 0.0150.01 CLEC4E 0.849 TPX2 0.745 0.928 0.021 0.002 CLEC4E 0.849 APOLD1 0.7770.911 0.03 0.014 CLEC4E 0.849 HIST1H2BJ 0.797 0.941 0.031 0.004 CLEC4E0.849 SON 0.794 0.921 0.024 0.02 CLEC4E 0.849 LASS4 0.669 0.902 0.0350.002 CLEC4E 0.849 B4GALT3 0.785 0.917 0.029 0.015 CLEC4E 0.849 TNFRSF170.827 0.932 0.028 0.008 CLEC4E 0.849 CMTM5 0.814 0.957 0.008 0.002CLEC4E 0.849 IGL@_IGLV1-44_(—) 0.77 0.922 0.022 0.005 CLEC4E 0.849 GLDC0.775 0.939 0.002 0.005 CLEC4E 0.849 KIAA0101_CSNK1G 0.87 0.948 0.0140.025 IL18R1 0.748 HPGD 0.655 0.874 0.027 0.001 IL18R1 0.748 FOLR3_FOLR20.585 0.81 0.024 0.014 IL18R1 0.748 PCOLCE2 0.667 0.842 0.014 0.04IL18R1 0.748 LHFP 0.561 0.8 0.045 0.01 IL18R1 0.748 TAAR1 0.589 0.8340.024 0.004 ACER3 0.842 PRR13_PCBP2 0.758 0.911 0.034 0.009 ACER3 0.842MTHFS 0.733 0.939 0.009 0.001 ACER3 0.842 AREG 0.814 0.906 0.023 0.04ACER3 0.842 KDM6B_TMEM88 0.672 0.9 0.039 0.001 ERLIN1 0.756 GSR 0.6050.819 0.043 0.013 ERLIN1 0.756 SMPDL3A 0.736 0.859 0.036 0.01 ERLIN10.756 EXOSC4 0.742 0.876 0.004 0.039 ERLIN1 0.756 EFCAB2 0.784 0.870.049 0.016 ERLIN1 0.756 PCOLCE2 0.667 0.855 0.017 0.005 ERLIN1 0.756GALNT2 0.673 0.86 0.008 0.012 ERLIN1 0.756 HDHD1A 0.7 0.841 0.022 0.035ERLIN1 0.756 DPH3 0.706 0.845 0.035 0.03 ERLIN1 0.756 ANKRD28 0.71 0.8510.03 0.017 TGFBR1 0.874 LOC284757 0.921 0.977 0.025 0.02 TGFBR1 0.874RUNX2 0.868 0.952 0.024 0.029 TGFBR1 0.874 MPZL3 0.889 0.969 0.016 0.011TGFBR1 0.874 SYNE2 0.886 0.974 0.029 0.005 TGFBR1 0.874 RGS2 0.789 0.9650.028 0 FKBP5_LOC285847 0.79 C7orf53 0.711 0.882 0.041 0.004FKBP5_LOC285847 0.79 PLB1 0.722 0.908 0.015 0.002 FKBP5_LOC285847 0.79DNAJC13 0.772 0.913 0.004 0.017 FKBP5_LOC285847 0.79 GSR 0.605 0.8660.034 0.002 FKBP5_LOC285847 0.79 METTL7B 0.749 0.874 0.042 0.018FKBP5_LOC285847 0.79 VAMP2 0.595 0.853 0.048 0.002 FKBP5_LOC285847 0.79CD63 0.813 0.935 0 0.05 FKBP5_LOC285847 0.79 PDGFC 0.822 0.948 0.0010.013 FKBP5_LOC285847 0.79 SEC24A_SAR1B 0.739 0.87 0.032 0.031FKBP5_LOC285847 0.79 EXOSC4 0.742 0.906 0.005 0.009 FKBP5_LOC285847 0.79PCOLCE2 0.667 0.888 0.007 0.002 FKBP5_LOC285847 0.79 GALNT2 0.673 0.8870.014 0.004 FKBP5_LOC285847 0.79 DPH3 0.706 0.882 0.033 0.006FKBP5_LOC285847 0.79 ANKRD28 0.71 0.882 0.045 0.003 FKBP5_LOC285847 0.79ITGA2B 0.752 0.878 0.039 0.017 FKBP5_LOC285847 0.79 CD151 0.767 0.8810.029 0.043 FKBP5_LOC285847 0.79 FSD1L 0.834 0.919 0.005 0.043FKBP5_LOC285847 0.79 HIST1H2BJ 0.797 0.897 0.029 0.034 FKBP5_LOC2858470.79 FAM118B 0.74 0.875 0.04 0.02 FKBP5_LOC285847 0.79 PLEKHF2 0.7370.868 0.041 0.038 GPR84 0.71 GK3P_GK 0.654 0.831 0.037 0.004 GPR84 0.71SH3PXD2B 0.751 0.858 0.009 0.029 C7orf53 0.711 PFKFB2 0.777 0.857 0.0320.015 C7orf53 0.711 ODZ1 0.777 0.871 0.023 0.006 C7orf53 0.711PPP2R5A_SNORA16 0.716 0.869 0.002 0.029 C7orf53 0.711 CHI3L1 0.798 0.8610.02 0.049 C7orf53 0.711 TPST1 0.754 0.869 0.034 0.001 C7orf53 0.711MTHFS 0.733 0.856 0.007 0.036 C7orf53 0.711 HAL 0.846 0.945 0 0.047C7orf53 0.711 CPM 0.812 0.905 0.001 0.031 C7orf53 0.711 PPP1R2_PPP1R2P30.637 0.791 0.038 0.043 PLB1 0.722 MMP9_LOC1001280 0.729 0.88 0.0040.012 PLB1 0.722 PFKFB2 0.777 0.927 0.001 0.001 PLB1 0.722 ODZ1 0.7770.902 0.015 0 PLB1 0.722 SH3PXD2B 0.751 0.877 0.018 0.005 PLB1 0.722CD163 0.808 0.894 0.011 0.032 PLB1 0.722 MTHFS 0.733 0.906 0 0.014 PLB10.722 SLC11A1 0.705 0.864 0 0.045 DSE 0.784 MMP9_LOC1001280 0.729 0.8810.043 0.005 DSE 0.784 PPP2R5A_SNORA16 0.716 0.894 0.021 0.002 DSE 0.784PRR13_PCBP2 0.758 0.878 0.017 0.038 DSE 0.784 MTHFS 0.733 0.934 0.0030.001 DSE 0.784 CDA 0.694 0.879 0.026 0.006 DSE 0.784 SLC11A1 0.7050.875 0.025 0.004 DSE 0.784 CCDC125 0.79 0.894 0.012 0.044 DSE 0.784KDM6B_TMEM88 0.672 0.86 0.047 0.004 DSE 0.784 RGS2 0.789 0.915 0.0010.037 PTGDR 0.616 DNAJC9_FAM149B1 0.742 0.835 0.002 0.049 DNAJC13 0.772PFKFB2 0.777 0.903 0.031 0.002 DNAJC13 0.772 IFI16 0.721 0.892 0.0180.006 DNAJC13 0.772 PPP2R5A_SNORA16 0.716 0.913 0.005 0.002 DNAJC130.772 PRR13_PCBP2 0.758 0.891 0.01 0.014 DNAJC13 0.772 SLC11A1 0.7050.869 0.033 0.003 DNAJC13 0.772 ERGIC1 0.758 0.894 0.014 0.003 DNAJC130.772 CCDC125 0.79 0.932 0.002 0.007 DNAJC13 0.772 CPM 0.812 0.907 0.0210.007 DNAJC13 0.772 MPZL2 0.775 0.879 0.032 0.011 TNFAIP6 0.676 EIF2AK20.646 0.824 0.025 0.006 TNFAIP6 0.676 HIST2H2BF_HIST2 0.62 0.773 0.0460.041 FOXD4L3_FOXD4L6 0.861 PPP2R5A_SNORA16 0.716 0.93 0.022 0.001FOXD4L3_FOXD4L6 0.861 MTHFS 0.733 0.919 0.049 0.003 FOXD4L3_FOXD4L60.861 SAP30 0.789 0.926 0.008 0.017 FOXD4L3_FOXD4L6 0.861 AREG 0.8140.914 0.041 0.034 FOXD4L3_FOXD4L6 0.861 HAL 0.846 0.945 0.006 0.044FOXD4L3_FOXD4L6 0.861 CCDC125 0.79 0.921 0.032 0.021 FOXD4L3_FOXD4L60.861 ZRANB1 0.718 0.91 0.049 0.003 FOXD4L3_FOXD4L6 0.861 RGS2 0.7890.926 0.003 0.035 FOXD4L3_FOXD4L6 0.861 CAMK1D 0.735 0.923 0.02 0.003MMP9_LOC1001280 0.729 METTL7B 0.749 0.875 0.016 0.011 MMP9_LOC10012800.729 SLC15A2 0.817 0.914 0.001 0.042 MMP9_LOC1001280 0.729 SMPDL3A0.736 0.89 0.012 0.003 MMP9_LOC1001280 0.729 CD63 0.813 0.949 0 0.016MMP9_LOC1001280 0.729 DDAH2 0.809 0.933 0 0.025 MMP9_LOC1001280 0.729ATP13A3 0.796 0.898 0.01 0.017 MMP9_LOC1001280 0.729 PDGFC 0.822 0.94 00.017 MMP9_LOC1001280 0.729 SEC24A_SAR1B 0.739 0.882 0.006 0.013MMP9_LOC1001280 0.729 EXOSC4 0.742 0.911 0.002 0.003 MMP9_LOC10012800.729 AP3B2 0.697 0.843 0.046 0.011 MMP9_LOC1001280 0.729 SUCNR1 0.8610.918 0.003 0.021 MMP9_LOC1001280 0.729 AIG1 0.873 0.955 0 0.039MMP9_LOC1001280 0.729 PCOLCE2 0.667 0.886 0.001 0.004 MMP9_LOC10012800.729 GALNT2 0.673 0.906 0 0.002 MMP9_LOC1001280 0.729 ITGA2B 0.7520.863 0.029 0.015 MMP9_LOC1001280 0.729 LHFP 0.561 0.832 0.046 0MMP9_LOC1001280 0.729 LAIR1_LAIR2 0.777 0.887 0.011 0.016MMP9_LOC1001280 0.729 HIST1H3B 0.829 0.912 0.002 0.047 MMP9_LOC10012800.729 PTGS1 0.794 0.881 0.005 0.049 MMP9_LOC1001280 0.729 CD151 0.7670.899 0.002 0.011 MMP9_LOC1001280 0.729 FSD1L 0.834 0.914 0.003 0.03MMP9_LOC1001280 0.729 TPX2 0.745 0.855 0.019 0.027 MMP9_LOC1001280 0.729IGK@_IGKC_IGKV 0.774 0.873 0.036 0.004 MMP9_LOC1001280 0.729 HIST1H2BJ0.797 0.874 0.013 0.047 MMP9_LOC1001280 0.729 TNFRSF17 0.827 0.921 0.0020.01 MMP9_LOC1001280 0.729 IGLV6-57 0.757 0.881 0.019 0.002MMP9_LOC1001280 0.729 IGL@_IGLV1-44_(—) 0.77 0.883 0.006 0.021 GSR 0.605PFKFB2 0.777 0.861 0.003 0.005 GSR 0.605 ODZ1 0.777 0.819 0.021 0.027GSR 0.605 CD163 0.808 0.849 0.01 0.015 GSR 0.605 THBS1 0.698 0.771 0.0460.033 KLRF1 0.635 IGJ 0.683 0.81 0.01 0.015 GK3P_GK 0.654 C1orf161 0.5770.754 0.031 0.042 GK3P_GK 0.654 HPGD 0.655 0.797 0.039 0.01 GK3P_GK0.654 TAAR1 0.589 0.763 0.028 0.026 PFKFB2 0.777 METTL7B 0.749 0.8750.009 0.03 PFKFB2 0.777 VAMP2 0.595 0.833 0.019 0.009 PFKFB2 0.777SMPDL3A 0.736 0.894 0.018 0.004 PFKFB2 0.777 PDGFC 0.822 0.958 0.0010.01 PFKFB2 0.777 LRRC70_IPO11 0.886 0.965 0 0.048 PFKFB2 0.777SEC24A_SAR1B 0.739 0.881 0.003 0.031 PFKFB2 0.777 EXOSC4 0.742 0.940.001 0.003 PFKFB2 0.777 FOLR3_FOLR2 0.585 0.855 0.034 0.001 PFKFB20.777 AP3B2 0.697 0.859 0.037 0.019 PFKFB2 0.777 ABCA13 0.699 0.8670.043 0.009 PFKFB2 0.777 EFCAB2 0.784 0.887 0.041 0.012 PFKFB2 0.777PCOLCE2 0.667 0.913 0.002 0.001 PFKFB2 0.777 MKI67 0.674 0.861 0.030.005 PFKFB2 0.777 RETN 0.473 0.868 0.026 0 PFKFB2 0.777 IRF4 0.74 0.8440.012 0.034 PFKFB2 0.777 MACF1 0.699 0.879 0.015 0.007 PFKFB2 0.777GALNT2 0.673 0.911 0.002 0.002 PFKFB2 0.777 HDHD1A 0.7 0.855 0.025 0.016PFKFB2 0.777 DPH3 0.706 0.874 0.013 0.015 PFKFB2 0.777 KIAA0746 0.7130.876 0.024 0.005 PFKFB2 0.777 LHFP 0.561 0.848 0.034 0 PFKFB2 0.777LAIR1_LAIR2 0.777 0.9 0.005 0.044 PFKFB2 0.777 FSD1L 0.834 0.932 0.0030.019 PFKFB2 0.777 TPX2 0.745 0.873 0.009 0.046 PFKFB2 0.777IGK@_IGKC_IGKV 0.774 0.871 0.015 0.047 PFKFB2 0.777 LASS4 0.669 0.8350.015 0.027 PFKFB2 0.777 IGLV6-57 0.757 0.881 0.015 0.015 PICALM 0.758ECHDC3 0.823 0.894 0.037 0.005 PICALM 0.758 PPP2R5A_SNORA16 0.716 0.8820.041 0.001 PICALM 0.758 PRR13_PCBP2 0.758 0.862 0.046 0.03 PICALM 0.758SLC11A1 0.705 0.861 0.038 0.01 PICALM 0.758 PDE3B 0.861 0.95 0.001 0.017PICALM 0.758 ERGIC1 0.758 0.87 0.026 0.021 PICALM 0.758 NA 0.884 0.9430.002 0.035 PICALM 0.758 HAL 0.846 0.958 0.001 0.004 PICALM 0.758KIAA1257_ACAD9/ 0.823 0.906 0.005 0.038 PICALM 0.758 SYNE2 0.886 0.9580.001 0.033 PICALM 0.758 MME 0.847 0.93 0.013 0.003 PICALM 0.758 RBP70.803 0.913 0.023 0.006 PICALM 0.758 RGS2 0.789 0.973 0 0.001 PICALM0.758 CAMK1D 0.735 0.859 0.039 0.027 METTL7B 0.749 PPP2R5A_SNORA16 0.7160.86 0.006 0.018 METTL7B 0.749 MTHFS 0.733 0.861 0.023 0.016 METTL7B0.749 CDA 0.694 0.861 0.007 0.015 METTL7B 0.749 SLC11A1 0.705 0.8480.026 0.011 METTL7B 0.749 ERGIC1 0.758 0.853 0.017 0.038 METTL7B 0.749CAMK1D 0.735 0.835 0.007 0.036 HIST1H4C 0.881 RUNX2 0.868 0.969 0.0040.027 HIST1H4C 0.881 AREG 0.814 0.936 0.038 0.01 HIST1H4C 0.881 PDE3B0.861 0.973 0.012 0.006 HIST1H4C 0.881 OCR1 0.934 0.979 0.014 0.049HIST1H4C 0.881 NA 0.884 0.984 0.008 0.003 HIST1H4C 0.881 HAL 0.846 0.9450.042 0.016 HIST1H4C 0.881 CCDC125 0.79 0.945 0.044 0.004 HIST1H4C 0.881SYNE2 0.886 0.971 0.011 0.013 HIST1H4C 0.881 RGS2 0.789 0.944 0.0210.008 C9orf72 0.843 NA 0.884 0.951 0.009 0.042 C9orf72 0.843 HAL 0.8460.946 0.024 0.007 C9orf72 0.843 KIAA1257_ACAD9/ 0.823 0.939 0.02 0.006C9orf72 0.843 RGS2 0.789 0.97 0.005 0.001 HIST1H3I 0.895 PPP2R5A_SNORA160.716 0.951 0.05 0 HIST1H3I 0.895 RUNX2 0.868 0.955 0.023 0.039 HIST1H3I0.895 OCR1 0.934 0.984 0.015 0.042 HIST1H3I 0.895 NA 0.884 0.995 0.0080.003 HIST1H3I 0.895 SYNE2 0.886 0.977 0.014 0.014 SLC15A2 0.817PPP2R5A_SNORA16 0.716 0.906 0.033 0.001 SLC15A2 0.817 PRR13_PCBP2 0.7580.894 0.043 0.013 SLC15A2 0.817 AREG 0.814 0.897 0.041 0.029 SLC15A20.817 CCDC125 0.79 0.93 0.015 0.009 SLC15A2 0.817 SYNE2 0.886 0.9590.002 0.03 SLC15A2 0.817 RGS2 0.789 0.895 0.013 0.035 SLC15A2 0.817LOC100128751 0.809 0.934 0.017 0.01 TLR10 0.884 CASS4 0.732 0.936 0.0350.001 TLR10 0.884 PPP2R5A_SNORA16 0.716 0.951 0.039 0 TLR10 0.884HIST1H2AA 0.825 0.932 0.031 0.032 TLR10 0.884 PDE3B 0.861 0.965 0.0080.03 TLR10 0.884 ERGIC1 0.758 0.945 0.033 0.002 TLR10 0.884 NA 0.8840.96 0.008 0.05 TLR10 0.884 HAL 0.846 0.974 0.013 0.006 TLR10 0.884KIAA1257_ACAD9/ 0.823 0.958 0.018 0.009 TLR10 0.884 ZRANB1 0.718 0.940.036 0 TLR10 0.884 SYNE2 0.886 0.962 0.013 0.047 TLR10 0.884 MME 0.8470.963 0.039 0.004 TLR10 0.884 RBP7 0.803 0.958 0.048 0.002 TLR10 0.884RGS2 0.789 0.971 0.003 0.004 TLR10 0.884 CAMK1D 0.735 0.936 0.039 0.001ADM 0.888 LOC284757 0.921 0.968 0.031 0.032 ADM 0.888 PRR13_PCBP2 0.7580.963 0.037 0 ADM 0.888 MTHFS 0.733 0.978 0.016 0 ADM 0.888 GAB2 0.8420.959 0.013 0.012 ADM 0.888 AREG 0.814 0.959 0.032 0.003 ADM 0.888 MPZL30.889 0.975 0.006 0.022 ADM 0.888 KDM6B_TMEM88 0.672 0.953 0.045 0 CD2740.926 IFI16 0.721 0.961 0.022 0 CD274 0.926 NA 0.884 0.968 0.018 0.031CRIP1 0.833 CASS4 0.732 0.881 0.035 0.023 CRIP1 0.833 PPP2R5A_SNORA160.716 0.888 0.027 0.018 CRIP1 0.833 ZRANB1 0.718 0.888 0.037 0.014 CRIP10.833 RASA4_RASA4P_R 0.713 0.881 0.033 0.027 CRIP1 0.833 CAMK1D 0.7350.928 0.006 0.005 VAMP2 0.595 TPST1 0.754 0.804 0.022 0.044 VAMP2 0.595SAP30 0.789 0.871 0 0.023 VAMP2 0.595 ACPL2 0.756 0.822 0.01 0.03 VAMP20.595 CCDC125 0.79 0.863 0.001 0.036 SMPDL3A 0.736 SLC1A3 0.777 0.880.007 0.04 SMPDL3A 0.736 PPP2R5A_SNORA16 0.716 0.868 0.002 0.024 SMPDL3A0.736 MTHFS 0.733 0.882 0.003 0.024 SMPDL3A 0.736 CDA 0.694 0.87 0.0010.025 SMPDL3A 0.736 SLC11A1 0.705 0.835 0.009 0.027 SMPDL3A 0.736 ACPL20.756 0.844 0.02 0.048 IFI16 0.721 SEC24A_SAR1B 0.739 0.862 0.007 0.035IFI16 0.721 CCR1 0.72 0.874 0.026 0.003 IFI16 0.721 FFAR2 0.744 0.8950.006 0.004 IFI16 0.721 TRIM21 0.857 0.95 0 0.045 IFI16 0.721UBE2F_C20orf194 0.758 0.857 0.042 0.017 IFI16 0.721 DYNLL1 0.787 0.8640.024 0.038 IFI16 0.721 CTSL1_CTSLL3 0.819 0.899 0.009 0.029 MRPL410.845 CASS4 0.732 0.906 0.034 0.003 MRPL41 0.845 PPP2R5A_SNORA16 0.7160.932 0.016 0.001 MRPL41 0.845 AREG 0.814 0.896 0.043 0.048 MRPL41 0.845SFRS9 0.523 0.895 0.013 0 MRPL41 0.845 HAL 0.846 0.934 0.012 0.029MRPL41 0.845 KIAA1257_ACAD9/ 0.823 0.923 0.021 0.036 MRPL41 0.845CCDC125 0.79 0.936 0.003 0.017 MRPL41 0.845 SYNE2 0.886 0.98 0.002 0.012MRPL41 0.845 MME 0.847 0.946 0.027 0.006 MRPL41 0.845 RBP7 0.803 0.9740.005 0.001 MRPL41 0.845 RGS2 0.789 0.923 0.007 0.039 MRPL41 0.845CAMK1D 0.735 0.919 0.014 0.004 SLC1A3 0.777 PDGFC 0.822 0.926 0.0070.004 SLC1A3 0.777 EXOSC4 0.742 0.894 0.002 0.029 SLC1A3 0.777 PCOLCE20.667 0.923 0.005 0 SLC1A3 0.777 GALNT2 0.673 0.898 0.002 0.003 CASS40.732 CLU 0.784 0.863 0.012 0.041 CASS4 0.732 KPNA5 0.793 0.862 0.0370.031 CASS4 0.732 FFAR2 0.744 0.846 0.015 0.017 CASS4 0.732 LGALS2 0.770.881 0.008 0.005 CASS4 0.732 EFCAB2 0.784 0.865 0.022 0.012 CASS4 0.732HINT1 0.819 0.882 0.015 0.015 CASS4 0.732 HIST1H3A 0.822 0.891 0.0050.031 CASS4 0.732 PMS2CL_PMS2 0.857 0.932 0 0.045 CASS4 0.732NEK6_LOC1001290 0.844 0.928 0 0.047 CASS4 0.732 RPL17_SNORD58B 0.8420.908 0.004 0.028 CASS4 0.732 DLEU2_DLEU2L 0.758 0.876 0.007 0.011 CASS40.732 IL1B 0.769 0.867 0.015 0.009 CASS4 0.732 ITGA2B 0.752 0.844 0.050.016 CASS4 0.732 PTGS1 0.794 0.887 0.004 0.014 CASS4 0.732 HIST1H3C0.854 0.897 0.009 0.047 CASS4 0.732 E2F6 0.798 0.882 0.019 0.018 CASS40.732 CD151 0.767 0.85 0.038 0.043 CASS4 0.732 HIST1H3H 0.836 0.8950.009 0.019 CASS4 0.732 TPX2 0.745 0.852 0.024 0.033 CASS4 0.732 APOLD10.777 0.9 0.003 0.012 CASS4 0.732 HIST1H2BJ 0.797 0.876 0.024 0.011CASS4 0.732 C7orf58 0.787 0.879 0.012 0.006 CASS4 0.732 DYNLL1 0.7870.888 0.008 0.006 CASS4 0.732 B4GALT3 0.785 0.89 0.006 0.018 CASS4 0.732NP 0.787 0.883 0.008 0.015 CASS4 0.732 CMTM5 0.814 0.882 0.008 0.042CASS4 0.732 AIF1 0.745 0.87 0.012 0.011 CASS4 0.732 NFXL1 0.808 0.9070.002 0.013 CLU 0.784 PPP2R5A_SNORA16 0.716 0.903 0.015 0.002 CLU 0.784PRR13_PCBP2 0.758 0.905 0.014 0.003 CLU 0.784 SULF2 0.775 0.91 0.0120.007 CLU 0.784 OCR1 0.934 0.966 0.001 0.043 CLU 0.784 ERGIC1 0.7580.882 0.033 0.017 CLU 0.784 HAL 0.846 0.946 0.001 0.01 CLU 0.784KIAA1257_ACAD9/ 0.823 0.92 0.004 0.021 CLU 0.784 CCDC125 0.79 0.9190.008 0.007 CLU 0.784 ZRANB1 0.718 0.913 0.006 0.001 CLU 0.784 MME 0.8470.922 0.009 0.025 CLU 0.784 CPM 0.812 0.912 0.034 0.002 CLU 0.784 RBP70.803 0.91 0.017 0.007 CLU 0.784 RGS2 0.789 0.903 0.006 0.033 CLU 0.784CAMK1D 0.735 0.863 0.048 0.012 CLU 0.784 MPZL2 0.775 0.899 0.02 0.006CLU 0.784 LOC100128751 0.809 0.895 0.014 0.045 ODZ1 0.777 ANAPC11 0.7050.837 0.05 0.045 ODZ1 0.777 DNAJC9_FAM149B1 0.742 0.868 0.035 0.027 ODZ10.777 TREML1 0.704 0.868 0.038 0.01 ODZ1 0.777 MACF1 0.699 0.861 0.0350.011 ODZ1 0.777 GALNT2 0.673 0.837 0.011 0.048 ODZ1 0.777 ANKRD28 0.710.87 0.02 0.007 ODZ1 0.777 KIAA0746 0.713 0.861 0.012 0.023 ODZ1 0.777ITGA2B 0.752 0.892 0.002 0.031 ODZ1 0.777 MYL9 0.695 0.872 0.007 0.015ODZ1 0.777 PLB1 0.609 0.841 0.036 0.003 KPNA5 0.793 PPP2R5A_SNORA160.716 0.853 0.047 0.044 KPNA5 0.793 ZRANB1 0.718 0.882 0.016 0.011 KPNA50.793 PYHIN1 0.647 0.919 0.026 0 KPNA5 0.793 PPP1R2_PPP1R2P3 0.637 0.8710.02 0.003 CD63 0.813 LOC284757 0.921 0.984 0.001 0.015 CD63 0.813PPP2R5A_SNORA16 0.716 0.924 0.028 0 CD63 0.813 RUNX2 0.868 0.953 0.0030.019 CD63 0.813 MTHFS 0.733 0.936 0.034 0 CD63 0.813 HIST1H2AA 0.8250.917 0.016 0.013 CD63 0.813 CDA 0.694 0.936 0.02 0 CD63 0.813 SAP300.789 0.919 0.032 0.002 CD63 0.813 GAB2 0.842 0.942 0.003 0.033 CD630.813 SLC11A1 0.705 0.965 0.003 0 CD63 0.813 AREG 0.814 0.952 0.0020.003 CD63 0.813 PDE3B 0.861 0.945 0.018 0.009 CD63 0.813 IRS2 0.8510.962 0.007 0.002 CD63 0.813 ERGIC1 0.758 0.947 0.013 0 CD63 0.813 NA0.884 0.924 0.019 0.039 CD63 0.813 HAL 0.846 0.945 0.012 0.006 CD630.813 KIAA1257_ACAD9/ 0.823 0.927 0.032 0.005 CD63 0.813 CCDC125 0.790.93 0.026 0.004 CD63 0.813 SYNE2 0.886 0.94 0.01 0.036 CD63 0.813 RGS20.789 0.929 0.014 0.004 HPSE 0.894 PPP2R5A_SNORA16 0.716 0.966 0.026 0HPSE 0.894 RUNX2 0.868 0.95 0.04 0.02 HPSE 0.894 GAB2 0.842 0.965 0.0220.003 HPSE 0.894 OCR1 0.934 0.977 0.02 0.038 HPSE 0.894 NA 0.884 0.9750.016 0.007 HPSE 0.894 MPZL3 0.889 0.963 0.011 0.037 HPSE 0.894 SYNE20.886 0.969 0.02 0.01 HPSE 0.894 RGS2 0.789 0.96 0.018 0.001 C1orf1610.577 OLAH 0.706 0.778 0.05 0.004 C1orf161 0.577 CD163 0.808 0.875 0.0010.03 DDAH2 0.809 PRR13_PCBP2 0.758 0.935 0.018 0 DDAH2 0.809 CDA 0.6940.95 0.011 0 DDAH2 0.809 GAB2 0.842 0.933 0.008 0.022 DDAH2 0.809SLC11A1 0.705 0.932 0.026 0 DDAH2 0.809 AREG 0.814 0.936 0.006 0.005DDAH2 0.809 IRS2 0.851 0.921 0.046 0.019 DDAH2 0.809 RGS2 0.789 0.9070.044 0.007 ATP13A3 0.796 PPP2R5A_SNORA16 0.716 0.921 0.001 0.004ATP13A3 0.796 MTHFS 0.733 0.915 0.002 0.01 ATP13A3 0.796 CDA 0.694 0.880.014 0.015 ATP13A3 0.796 CCDC125 0.79 0.915 0.004 0.039 PMAIP1 0.945RUNX2 0.868 0.974 0.029 0.018 LOC284757 0.921 PDGFC 0.822 0.98 0.0360.002 LOC284757 0.921 B3GAT3 0.857 0.977 0.013 0.013 LOC284757 0.921RCBTB2_LOC10013 0.882 0.966 0.01 0.046 LOC284757 0.921 SLC39A9 0.8370.968 0.008 0.014 LOC284757 0.921 LGALS1 0.855 0.965 0.03 0.016LOC284757 0.921 AIG1 0.873 0.975 0.034 0.012 LOC284757 0.921 PCOLCE20.667 0.964 0.039 0 LOC284757 0.921 SLC39A8 0.867 0.984 0.032 0.01LOC284757 0.921 GSTO1 0.83 0.971 0.041 0.004 LOC284757 0.921 PTGER20.842 0.979 0.026 0.007 LOC284757 0.921 PMS2CL_PMS2 0.857 0.957 0.0240.016 LOC284757 0.921 NEK6_LOC1001290 0.844 0.976 0.01 0.009 LOC2847570.921 GLT25D1 0.808 0.977 0.016 0.001 LOC284757 0.921 ICAM1 0.895 0.9750.019 0.032 LOC284757 0.921 P4HA1_RPL17 0.88 0.961 0.037 0.04 LOC2847570.921 RRP12_LOC644215 0.84 0.973 0.019 0.007 LOC284757 0.921 LAIR1_LAIR20.777 0.966 0.034 0.001 LOC284757 0.921 FSD1L_GARNL1 0.844 0.981 0.0230.008 LOC284757 0.921 FSD1L 0.834 0.977 0.033 0.001 LOC284757 0.921 MPO0.684 0.954 0.043 0 LOC284757 0.921 ATP6V0D1_LOC100 0.828 0.955 0.0270.025 PDGFC 0.822 ECHDC3 0.823 0.926 0.031 0.011 PDGFC 0.822PPP2R5A_SNORA16 0.716 0.939 0.006 0.001 PDGFC 0.822 HMGB2 0.673 0.9420.033 0 PDGFC 0.822 RUNX2 0.868 0.962 0.001 0.049 PDGFC 0.822PRR13_PCBP2 0.758 0.906 0.028 0.007 PDGFC 0.822 CD163 0.808 0.938 0.0190.008 PDGFC 0.822 MTHFS 0.733 0.914 0.029 0.002 PDGFC 0.822 CDA 0.6940.927 0.015 0.001 PDGFC 0.822 SAP30 0.789 0.92 0.008 0.013 PDGFC 0.822SLC11A1 0.705 0.93 0.017 0 PDGFC 0.822 AREG 0.814 0.922 0.01 0.014 PDGFC0.822 IRS2 0.851 0.948 0.01 0.018 PDGFC 0.822 ACPL2 0.756 0.943 0.023 0PDGFC 0.822 ERGIC1 0.758 0.933 0.017 0.001 PDGFC 0.822 HAL 0.846 0.9430.01 0.022 PDGFC 0.822 KIAA1257_ACAD9/ 0.823 0.929 0.025 0.015 PDGFC0.822 CCDC125 0.79 0.952 0.005 0.006 PDGFC 0.822 MME 0.847 0.94 0.0360.003 PDGFC 0.822 CPM 0.812 0.915 0.047 0.011 PDGFC 0.822 RBP7 0.8030.937 0.017 0.007 PDGFC 0.822 RGS2 0.789 0.944 0.005 0.007 B3GAT3 0.857RUNX2 0.868 0.945 0.022 0.022 B3GAT3 0.857 PDE3B 0.861 0.957 0.014 0.009B3GAT3 0.857 NA 0.884 0.962 0.025 0.004 B3GAT3 0.857 HAL 0.846 0.9340.048 0.009 B3GAT3 0.857 KIAA1257_ACAD9/ 0.823 0.932 0.045 0.018 B3GAT30.857 CCDC125 0.79 0.946 0.034 0.004 B3GAT3 0.857 SYNE2 0.886 0.9530.016 0.041 HPGD 0.655 OLAH 0.706 0.834 0.01 0.03 HPGD 0.655 IL1RL10.655 0.812 0.008 0.026 LRRC70_IPO11 0.886 ECHDC3 0.823 0.958 0.0320.004 LRRC70_IPO11 0.886 MTHFS 0.733 0.938 0.04 0.001 LRRC70_IPO11 0.886HIST1H2AA 0.825 0.943 0.014 0.021 LRRC70_IPO11 0.886 SAP30 0.789 0.9390.017 0.009 LRRC70_IPO11 0.886 SLC11A1 0.705 0.942 0.012 0.001LRRC70_IPO11 0.886 AREG 0.814 0.96 0.01 0.004 LRRC70_IPO11 0.886 IRS20.851 0.946 0.021 0.033 LRRC70_IPO11 0.886 ACPL2 0.756 0.955 0.035 0LRRC70_IPO11 0.886 ERGIC1 0.758 0.938 0.017 0.004 LRRC70_IPO11 0.886 NA0.884 0.95 0.032 0.042 LRRC70_IPO11 0.886 KIAA1257_ACAD9/ 0.823 0.9460.018 0.012 LRRC70_IPO11 0.886 RGS2 0.789 0.937 0.008 0.009TMEM144_LOC2855 0.653 PLA2G7 0.738 0.857 0.003 0.023 TMEM144_LOC28550.653 PDK4 0.598 0.782 0.05 0.009 CDS2 0.944 RUNX2 0.868 0.987 0.050.004 CDS2 0.944 MPZL3 0.889 0.995 0.023 0.005 ECHDC3 0.823 EXOSC4 0.7420.889 0.048 0.017 ECHDC3 0.823 HIST1H3J 0.829 0.933 0.003 0.039 ECHDC30.823 HIST1H3A 0.822 0.929 0.005 0.028 ECHDC3 0.823 DPH3 0.706 0.9220.008 0.001 ECHDC3 0.823 DLEU2_DLEU2L 0.758 0.902 0.029 0.015 ECHDC30.823 ANKRD28 0.71 0.914 0.05 0 ECHDC3 0.823 HIST1H3B 0.829 0.926 0.0180.037 ECHDC3 0.823 PTGS1 0.794 0.915 0.022 0.015 ECHDC3 0.823 HIST1H3C0.854 0.948 0.007 0.015 ECHDC3 0.823 HIST1H3H 0.836 0.926 0.022 0.024ECHDC3 0.823 TPX2 0.745 0.884 0.031 0.041 ECHDC3 0.823 APOLD1 0.7770.901 0.01 0.036 ECHDC3 0.823 HIST1H2BJ 0.797 0.941 0.019 0.002 ECHDC30.823 FAM118B 0.74 0.89 0.033 0.011 ECHDC3 0.823 CMTM5 0.814 0.939 0.0080.012 ECHDC3 0.823 SDHC 0.85 0.928 0.01 0.036 ECHDC3 0.823 GLDC 0.7750.902 0.003 0.048 OLAH 0.706 TAAR1 0.589 0.777 0.02 0.03 PPP2R5A_SNORA160.716 EAF2_HCG11_LOC 0.869 0.955 0 0.042 PPP2R5A_SNORA16 0.716SEC24A_SAR1B 0.739 0.906 0.003 0.003 PPP2R5A_SNORA16 0.716 EXOSC4 0.7420.905 0.002 0.003 PPP2R5A_SNORA16 0.716 HIST1H4L 0.929 0.978 0 0.046PPP2R5A_SNORA16 0.716 CCR1 0.72 0.823 0.047 0.022 PPP2R5A_SNORA16 0.716SIAE 0.894 0.975 0 0.024 PPP2R5A_SNORA16 0.716 HINT1 0.819 0.876 0.0180.032 PPP2R5A_SNORA16 0.716 HIST1H3J 0.829 0.906 0.004 0.014PPP2R5A_SNORA16 0.716 SUCNR1 0.861 0.939 0.001 0.007 PPP2R5A_SNORA160.716 MTRR 0.832 0.913 0.002 0.036 PPP2R5A_SNORA16 0.716 AIG1 0.8730.975 0 0.003 PPP2R5A_SNORA16 0.716 PCOLCE2 0.667 0.835 0.011 0.012PPP2R5A_SNORA16 0.716 HS2ST1_UBA2 0.837 0.954 0 0.013 PPP2R5A_SNORA160.716 HIST1H3A 0.822 0.914 0.002 0.011 PPP2R5A_SNORA16 0.716 GSTO1 0.830.937 0 0.014 PPP2R5A_SNORA16 0.716 IRF4 0.74 0.841 0.021 0.05PPP2R5A_SNORA16 0.716 GALNT2 0.673 0.839 0.017 0.014 PPP2R5A_SNORA160.716 HDHD1A 0.7 0.887 0.006 0.002 PPP2R5A_SNORA16 0.716 EIF1AX_SCARNA9L0.814 0.895 0.008 0.01 PPP2R5A_SNORA16 0.716 DPH3 0.706 0.888 0.012 0PPP2R5A_SNORA16 0.716 TAF13 0.908 0.971 0 0.021 PPP2R5A_SNORA16 0.716HIST1H2BM 0.862 0.939 0 0.029 PPP2R5A_SNORA16 0.716 IL1B 0.769 0.8390.031 0.032 PPP2R5A_SNORA16 0.716 ITGA2B 0.752 0.874 0.019 0.005PPP2R5A_SNORA16 0.716 HIST1H3B 0.829 0.893 0.01 0.035 PPP2R5A_SNORA160.716 FSD1L_GARNL1 0.844 0.943 0 0.038 PPP2R5A_SNORA16 0.716 PTGS1 0.7940.901 0.002 0.016 PPP2R5A_SNORA16 0.716 UBE2F_C20orf194 0.758 0.8860.018 0.002 PPP2R5A_SNORA16 0.716 HIST1H3C 0.854 0.924 0.004 0.007PPP2R5A_SNORA16 0.716 CD151 0.767 0.919 0.001 0.004 PPP2R5A_SNORA160.716 HIST1H3H 0.836 0.909 0.005 0.013 PPP2R5A_SNORA16 0.716 FSD1L 0.8340.913 0.002 0.013 PPP2R5A_SNORA16 0.716 TPX2 0.745 0.901 0.004 0.003PPP2R5A_SNORA16 0.716 MYL9 0.695 0.866 0.027 0.001 PPP2R5A_SNORA16 0.716HIST1H2BJ 0.797 0.913 0.008 0.001 PPP2R5A_SNORA16 0.716 C7orf58 0.7870.861 0.03 0.019 PPP2R5A_SNORA16 0.716 DYNLL1 0.787 0.896 0.012 0.006PPP2R5A_SNORA16 0.716 FAM118B 0.74 0.867 0.023 0.009 PPP2R5A_SNORA160.716 B4GALT3 0.785 0.913 0.001 0.025 PPP2R5A_SNORA16 0.716 NP 0.7870.919 0.002 0.005 PPP2R5A_SNORA16 0.716 TNFRSF17 0.827 0.901 0.003 0.023PPP2R5A_SNORA16 0.716 PLEKHF2 0.737 0.897 0.004 0.005 PPP2R5A_SNORA160.716 CMTM5 0.814 0.924 0.001 0.013 PPP2R5A_SNORA16 0.716 AIF1 0.7450.853 0.017 0.019 PPP2R5A_SNORA16 0.716 IGLV6-57 0.757 0.874 0.017 0.005PPP2R5A_SNORA16 0.716 IGL@_IGLV1-44_(—) 0.77 0.873 0.003 0.05PPP2R5A_SNORA16 0.716 SDHC 0.85 0.925 0.006 0.011 PPP2R5A_SNORA16 0.716KIAA0101_CSNK1G 0.87 0.926 0.003 0.03 EAF2_HCG11_LOC 0.869 NA 0.8840.956 0.036 0.027 EAF2_HCG11_LOC 0.869 CCDC125 0.79 0.946 0.041 0.005RCBTB2_LOC10013 0.882 RUNX2 0.868 0.951 0.014 0.047 RCBTB2_LOC100130.882 GAB2 0.842 0.952 0.029 0.007 RCBTB2_LOC10013 0.882 SYNE2 0.8860.961 0.026 0.015 SEC24A_SAR1B 0.739 PRR13_PCBP2 0.758 0.869 0.012 0.033SEC24A_SAR1B 0.739 MTHFS 0.733 0.873 0.024 0.007 SEC24A_SAR1B 0.739 CDA0.694 0.861 0.016 0.014 SEC24A_SAR1B 0.739 SLC11A1 0.705 0.823 0.0420.026 SEC24A_SAR1B 0.739 ERGIC1 0.758 0.84 0.042 0.044 SEC24A_SAR1B0.739 CCDC125 0.79 0.912 0.003 0.014 SEC24A_SAR1B 0.739 MPZL2 0.7750.872 0.027 0.014 SH3PXD2B 0.751 PCOLCE2 0.667 0.846 0.009 0.026SH3PXD2B 0.751 MACF1 0.699 0.861 0.005 0.027 SH3PXD2B 0.751 GALNT2 0.6730.868 0 0.03 SH3PXD2B 0.751 KIAA0746 0.713 0.846 0.013 0.05 HMGB2 0.673DNAJC9_FAM149B1 0.742 0.823 0.027 0.05 HMGB2 0.673 ABCA13 0.699 0.8610.004 0.006 HMGB2 0.673 MKI67 0.674 0.819 0.013 0.036 HMGB2 0.673 TREML10.704 0.829 0.018 0.024 HMGB2 0.673 DPH3 0.706 0.856 0.002 0.036 HMGB20.673 ANKRD28 0.71 0.845 0.006 0.022 HMGB2 0.673 LHFP 0.561 0.76 0.0340.016 HMGB2 0.673 HIST1H3C 0.854 0.929 0 0.025 HMGB2 0.673 MYL9 0.6950.825 0.005 0.048 HMGB2 0.673 HIST1H2BJ 0.797 0.914 0 0.018 HMGB2 0.673TAAR1 0.589 0.794 0.045 0.002 KLRD1 0.594 IGJ 0.683 0.776 0.028 0.018CHI3L1 0.798 LGALS2 0.77 0.9 0.002 0.028 CHI3L1 0.798 SUCNR1 0.861 0.9460.001 0.042 CHI3L1 0.798 MKI67 0.674 0.881 0.017 0.005 CHI3L1 0.798MINPP1 0.718 0.896 0.02 0.005 CHI3L1 0.798 ITGA2B 0.752 0.885 0.0130.025 CHI3L1 0.798 UBE2F_C20orf194 0.758 0.887 0.006 0.046 CHI3L1 0.798CD151 0.767 0.889 0.007 0.04 CHI3L1 0.798 TPX2 0.745 0.889 0.01 0.026CHI3L1 0.798 MYL9 0.695 0.874 0.02 0.008 CHI3L1 0.798 HIST1H2BJ 0.7970.932 0.002 0.017 CHI3L1 0.798 C7orf58 0.787 0.906 0.005 0.022 CHI3L10.798 DYNLL1 0.787 0.898 0.008 0.023 CHI3L1 0.798 TNFRSF17 0.827 0.9260.004 0.039 CHI3L1 0.798 IGLV6-57 0.757 0.919 0.006 0.005 FRMD3 0.884RUNX2 0.868 0.977 0.011 0.01 FRMD3 0.884 GAB2 0.842 0.958 0.033 0.006FRMD3 0.884 OCR1 0.934 0.967 0.041 0.035 FRMD3 0.884 MPZL3 0.889 0.9550.018 0.043 SLC39A9 0.837 RUNX2 0.868 0.972 0.006 0.003 SLC39A9 0.837GAB2 0.842 0.933 0.024 0.008 SLC39A9 0.837 PDE3B 0.861 0.956 0.033 0.003SLC39A9 0.837 NA 0.884 0.954 0.024 0.004 SLC39A9 0.837 CCDC125 0.790.953 0.032 0.001 SLC39A9 0.837 MPZL3 0.889 0.961 0.004 0.031 SLC39A90.837 SYNE2 0.886 0.975 0.008 0.003 SLC39A9 0.837 RGS2 0.789 0.939 0.0360.001 EXOSC4 0.742 PRR13_PCBP2 0.758 0.893 0.003 0.012 EXOSC4 0.742CD163 0.808 0.887 0.04 0.01 EXOSC4 0.742 MTHFS 0.733 0.95 0 0 EXOSC40.742 CDA 0.694 0.939 0 0 EXOSC4 0.742 SLC11A1 0.705 0.875 0.011 0.006EXOSC4 0.742 AREG 0.814 0.907 0.001 0.041 EXOSC4 0.742 ACPL2 0.756 0.8710.048 0.006 EXOSC4 0.742 ERGIC1 0.758 0.876 0.018 0.008 EXOSC4 0.742CCDC125 0.79 0.898 0.005 0.031 NA 0.601 MACF1 0.699 0.804 0.005 0.035 NA0.601 C7orf58 0.787 0.85 0.002 0.043 RUNX2 0.868 HIST1H4L 0.929 0.9780.019 0.017 RUNX2 0.868 LGALS1 0.855 0.962 0.015 0.006 RUNX2 0.868 SIAE0.894 0.968 0.024 0.008 RUNX2 0.868 AIG1 0.873 0.952 0.028 0.015 RUNX20.868 PTGER2 0.842 0.967 0.02 0.003 RUNX2 0.868 PMS2CL_PMS2 0.857 0.9560.046 0.003 RUNX2 0.868 NEK6_LOC1001290 0.844 0.962 0.008 0.006 RUNX20.868 AMFR 0.874 0.983 0.011 0.005 RUNX2 0.868 CD300A 0.888 0.957 0.0190.03 RUNX2 0.868 ZNF28 0.891 0.977 0.017 0.007 RUNX2 0.868 TAF13 0.9080.96 0.045 0.022 RUNX2 0.868 KLHL5 0.913 0.954 0.044 0.047 RUNX2 0.868MGST3 0.897 0.962 0.022 0.028 RUNX2 0.868 HSPB1_HSPBL2 0.886 0.953 0.0350.022 RUNX2 0.868 TYMS 0.838 0.941 0.047 0.009 RUNX2 0.868 HIST1H2BM0.862 0.952 0.038 0.008 RUNX2 0.868 CDC26 0.868 0.978 0.012 0.003PRR13_PCBP2 0.758 FFAR2 0.744 0.888 0.028 0.002 PRR13_PCBP2 0.758 AIG10.873 0.953 0 0.034 PRR13_PCBP2 0.758 PCOLCE2 0.667 0.868 0.019 0.001PRR13_PCBP2 0.758 HS2ST1_UBA2 0.837 0.924 0.002 0.031 PRR13_PCBP2 0.758GSTO1 0.83 0.924 0.001 0.022 PRR13_PCBP2 0.758 GALNT2 0.673 0.861 0.0430.002 PRR13_PCBP2 0.758 GLT25D1 0.808 0.898 0.006 0.037 PRR13_PCBP20.758 ACTA2 0.818 0.944 0.001 0.006 PRR13_PCBP2 0.758 LAIR1_LAIR2 0.7770.859 0.048 0.031 PRR13_PCBP2 0.758 PTGS1 0.794 0.885 0.011 0.017PRR13_PCBP2 0.758 UBE2F_C20orf194 0.758 0.888 0.033 0.004 PRR13_PCBP20.758 CD151 0.767 0.894 0.016 0.008 PRR13_PCBP2 0.758 FSD1L 0.834 0.9040.006 0.029 PRR13_PCBP2 0.758 TPX2 0.745 0.868 0.034 0.007 PRR13_PCBP20.758 APOLD1 0.777 0.886 0.009 0.027 PRR13_PCBP2 0.758 HIST1H2BJ 0.7970.901 0.012 0.015 PRR13_PCBP2 0.758 LASS4 0.669 0.823 0.047 0.009PRR13_PCBP2 0.758 CTSL1_CTSLL3 0.819 0.874 0.041 0.038 PRR13_PCBP2 0.758NP 0.787 0.878 0.031 0.026 PRR13_PCBP2 0.758 SDHC 0.85 0.915 0.014 0.024PRR13_PCBP2 0.758 NFXL1 0.808 0.888 0.026 0.04 HIST1H4L 0.929 PDE3B0.861 0.98 0.023 0.013 HIST1H4L 0.929 OCR1 0.934 0.993 0.028 0.042HIST1H4L 0.929 NA 0.884 0.992 0.022 0.005 HIST1H4L 0.929 HAL 0.846 0.9770.046 0.007 HIST1H4L 0.929 CCDC125 0.79 0.972 0.04 0.002 HIST1H4L 0.929SYNE2 0.886 0.991 0.021 0.008 HIST1H4L 0.929 MME 0.847 0.985 0.045 0.002LGALS1 0.855 NA 0.884 0.946 0.044 0.007 LGALS1 0.855 MPZL3 0.889 0.9770.002 0.024 LGALS1 0.855 SYNE2 0.886 0.959 0.026 0.006 LGALS1 0.855 RGS20.789 0.969 0.008 0.001 CCR1 0.72 MTHFS 0.733 0.858 0.004 0.049 CCR10.72 CDA 0.694 0.822 0.013 0.044 CCR1 0.72 PLA2G7 0.738 0.874 0.0270.001 CCR1 0.72 KDM6B_TMEM88 0.672 0.829 0.013 0.024 TPST1 0.754 ABCA130.699 0.866 0.01 0.015 TPST1 0.754 MKI67 0.674 0.843 0.014 0.02 TPST10.754 TREML1 0.704 0.867 0.013 0.014 TPST1 0.754 HDHD1A 0.7 0.844 0.0110.047 TPST1 0.754 DPH3 0.706 0.871 0.003 0.031 TPST1 0.754 ANKRD28 0.710.878 0.006 0.017 TPST1 0.754 ITGA2B 0.752 0.884 0.001 0.041 TPST1 0.754MYL9 0.695 0.878 0.002 0.015 TPST1 0.754 HIST1H2BJ 0.797 0.919 0.0010.035 TPST1 0.754 SPARC 0.661 0.848 0.029 0.007 CD163 0.808 GALNT2 0.6730.883 0.008 0.01 CD163 0.808 HDHD1A 0.7 0.87 0.017 0.018 CD163 0.808FAM118B 0.74 0.883 0.003 0.048 FFAR2 0.744 MTHFS 0.733 0.891 0.005 0.01FFAR2 0.744 CDA 0.694 0.829 0.034 0.026 FFAR2 0.744 KDM6B_TMEM88 0.6720.852 0.009 0.017 PHOSPHO1 0.63 HIST1H3H 0.836 0.927 0 0.021 PHOSPHO10.63 POLE2 0.704 0.838 0.01 0.006 PPIF 0.879 GAB2 0.842 0.937 0.0310.036 PPIF 0.879 KIAA1257_ACAD9/ 0.823 0.943 0.048 0.009 PPIF 0.879MPZL3 0.889 0.965 0.006 0.05 MTHFS 0.733 MTRR 0.832 0.922 0.002 0.033MTHFS 0.733 AIG1 0.873 0.958 0 0.03 MTHFS 0.733 PCOLCE2 0.667 0.8730.005 0.002 MTHFS 0.733 HS2ST1_UBA2 0.837 0.939 0 0.032 MTHFS 0.733GALNT2 0.673 0.901 0.001 0.001 MTHFS 0.733 GLT25D1 0.808 0.904 0.0020.041 MTHFS 0.733 HDHD1A 0.7 0.855 0.022 0.006 MTHFS 0.733 DPH3 0.7060.855 0.047 0.01 MTHFS 0.733 DLEU2_DLEU2L 0.758 0.848 0.029 0.049 MTHFS0.733 IL1B 0.769 0.874 0.044 0.007 MTHFS 0.733 LAIR1_LAIR2 0.777 0.880.013 0.018 MTHFS 0.733 NA 0.87 0.933 0.001 0.022 MTHFS 0.733 FSD1L0.834 0.906 0.003 0.026 MTHFS 0.733 DYNLL1 0.787 0.886 0.011 0.01 MTHFS0.733 FAM118B 0.74 0.861 0.014 0.026 MTHFS 0.733 PLEKHF2 0.737 0.86 0.040.027 MTHFS 0.733 AIF1 0.745 0.865 0.029 0.028 MTHFS 0.733 SDHC 0.850.927 0.006 0.01 DNAJC9_FAM149B1 0.742 PYHIN1 0.647 0.851 0.008 0.01DNAJC9_FAM149B1 0.742 PPP1R2_PPP1R2P3 0.637 0.811 0.026 0.033 LGALS20.77 SULF2 0.775 0.911 0.001 0.029 LGALS2 0.77 RASA4_RASA4P_R 0.7130.872 0.034 0.005 LGALS2 0.77 RBP7 0.803 0.902 0.005 0.024 LGALS2 0.77CAMK1D 0.735 0.873 0.011 0.009 LGALS2 0.77 MPZL2 0.775 0.877 0.025 0.034SIAE 0.894 GAB2 0.842 0.945 0.04 0.027 SIAE 0.894 IRS2 0.851 0.958 0.0320.012 SIAE 0.894 OCR1 0.934 0.975 0.036 0.026 SIAE 0.894 NA 0.884 0.9670.033 0.008 SIAE 0.894 HAL 0.846 0.958 0.037 0.006 SIAE 0.894 CCDC1250.79 0.969 0.026 0.001 SIAE 0.894 SYNE2 0.886 0.965 0.031 0.013 SIAE0.894 RGS2 0.789 0.953 0.03 0.002 ABCA13 0.699 CDA 0.694 0.857 0.0020.04 ABCA13 0.699 DAAM2_LOC100131 0.778 0.866 0.029 0.002 ABCA13 0.699ACPL2 0.756 0.873 0.006 0.017 ABCA13 0.699 THBS1 0.698 0.832 0.032 0.01EFCAB2 0.784 KDM6B_TMEM88 0.672 0.845 0.016 0.03 EFCAB2 0.784 CAMK1D0.735 0.863 0.011 0.04 EFCAB2 0.784 HIST2H2BF_HIST2 0.62 0.856 0.0480.003 HIST1H2AA 0.825 AIG1 0.873 0.93 0.013 0.049 HIST1H2AA 0.825PCOLCE2 0.667 0.905 0.033 0.001 HIST1H2AA 0.825 TYMS 0.838 0.912 0.0260.044 HIST1H2AA 0.825 HIST1H2BM 0.862 0.925 0.019 0.028 HIST1H2AA 0.825NA 0.87 0.926 0.037 0.037 HIST1H2AA 0.825 TNFRSF17 0.827 0.928 0.0380.004 HINT1 0.819 NA 0.884 0.966 0.001 0.038 HINT1 0.819 LY6G5B_CSNK2B0.63 0.879 0.01 0.002 HINT1 0.819 CCDC125 0.79 0.915 0.002 0.043 HINT10.819 ZRANB1 0.718 0.891 0.031 0.005 HINT1 0.819 PYHIN1 0.647 0.9130.015 0 HINT1 0.819 CYP4F3_CYP4F2 0.755 0.897 0.044 0.009 HINT1 0.819MME 0.847 0.93 0.008 0.05 HINT1 0.819 RASA4_RASA4P_R 0.713 0.879 0.0390.014 HINT1 0.819 RBP7 0.803 0.919 0.005 0.042 HINT1 0.819 CAMK1D 0.7350.887 0.004 0.029 HINT1 0.819 PPP1R2_PPP1R2P3 0.637 0.889 0.024 0.001HIST1H3J 0.829 CDA 0.694 0.888 0.038 0.004 HIST1H3J 0.829 SAP30 0.7890.932 0.003 0.015 HIST1H3J 0.829 AREG 0.814 0.917 0.009 0.047 HIST1H3J0.829 NA 0.884 0.963 0.005 0.013 HIST1H3J 0.829 CCDC125 0.79 0.942 0.0010.015 HIST1H3J 0.829 ZRANB1 0.718 0.922 0.033 0 HIST1H3J 0.829CYP4F3_CYP4F2 0.755 0.925 0.034 0.002 HIST1H3J 0.829 MME 0.847 0.9490.012 0.013 HIST1H3J 0.829 RBP7 0.803 0.952 0.006 0.004 CDA 0.694 SUCNR10.861 0.912 0.001 0.047 CDA 0.694 AIG1 0.873 0.961 0 0.014 CDA 0.694PCOLCE2 0.667 0.857 0.004 0.006 CDA 0.694 HIST1H3A 0.822 0.908 0.0010.018 CDA 0.694 GALNT2 0.673 0.832 0.015 0.021 CDA 0.694 HDHD1A 0.70.819 0.044 0.024 CDA 0.694 DPH3 0.706 0.85 0.027 0.004 CDA 0.694 ITGA2B0.752 0.827 0.036 0.048 CDA 0.694 HIST1H3B 0.829 0.893 0.005 0.038 CDA0.694 UBE2F_C20orf194 0.758 0.874 0.016 0.005 CDA 0.694 HIST1H3C 0.8540.9 0.004 0.027 CDA 0.694 CD151 0.767 0.875 0.003 0.034 CDA 0.694 FSD1L0.834 0.894 0.002 0.043 CDA 0.694 TPX2 0.745 0.862 0.011 0.011 CDA 0.694IGK@_IGKC_IGKV 0.774 0.848 0.045 0.016 CDA 0.694 HIST1H2BJ 0.797 0.8890.007 0.015 CDA 0.694 DYNLL1 0.787 0.858 0.017 0.039 CDA 0.694 PLEKHF20.737 0.851 0.02 0.042 CDA 0.694 AIF1 0.745 0.837 0.018 0.036 CDA 0.694IGLV6-57 0.757 0.843 0.035 0.012 CDA 0.694 SDHC 0.85 0.926 0.003 0.005SAP30 0.789 SUCNR1 0.861 0.923 0.012 0.02 SAP30 0.789 HS2ST1_UBA2 0.8370.913 0.021 0.039 SAP30 0.789 HIST1H3A 0.822 0.923 0.013 0.004 SAP300.789 ACTA2 0.818 0.913 0.014 0.019 SAP30 0.789 EIF1AX_SCARNA9L 0.8140.891 0.048 0.008 SAP30 0.789 TYMS 0.838 0.932 0.002 0.028 SAP30 0.789HIST1H3B 0.829 0.906 0.043 0.011 SAP30 0.789 FSD1L_GARNL1 0.844 0.9390.004 0.014 SAP30 0.789 PTGS1 0.794 0.911 0.023 0.004 SAP30 0.789HIST1H3C 0.854 0.937 0.019 0.001 SAP30 0.789 HIST1H3H 0.836 0.931 0.020.003 SAP30 0.789 FSD1L 0.834 0.919 0.016 0.013 SAP30 0.789 TPX2 0.7450.881 0.046 0.013 SAP30 0.789 APOLD1 0.777 0.89 0.038 0.016 SAP30 0.789HIST1H2BJ 0.797 0.914 0.038 0.003 SAP30 0.789 LASS4 0.669 0.878 0.0120.003 SAP30 0.789 B4GALT3 0.785 0.89 0.033 0.024 SAP30 0.789 TNFRSF170.827 0.902 0.018 0.014 SAP30 0.789 PLEKHA3 0.777 0.876 0.049 0.037SAP30 0.789 CMTM5 0.814 0.935 0.012 0.002 SAP30 0.789 IGL@_IGLV1-44_(—)0.77 0.883 0.021 0.019 SAP30 0.789 GLDC 0.775 0.921 0.003 0.007 SAP300.789 KIAA0101_CSNK1G 0.87 0.929 0.009 0.03 AGTRAP 0.928 MPZL3 0.8890.991 0.034 0.003 SUCNR1 0.861 SLC11A1 0.705 0.905 0.031 0.003 SUCNR10.861 AREG 0.814 0.935 0.01 0.019 SUCNR1 0.861 PDE3B 0.861 0.948 0.0110.037 SUCNR1 0.861 ERGIC1 0.758 0.913 0.027 0.007 SUCNR1 0.861 NA 0.8840.965 0.004 0.028 SUCNR1 0.861 HAL 0.846 0.94 0.004 0.044 SUCNR1 0.861KIAA1257_ACAD9/ 0.823 0.939 0.007 0.028 SUCNR1 0.861 CCDC125 0.79 0.9530.004 0.006 SUCNR1 0.861 ZRANB1 0.718 0.939 0.008 0.001 SUCNR1 0.861CYP4F3_CYP4F2 0.755 0.95 0.005 0.001 SUCNR1 0.861 MME 0.847 0.965 0.0050.007 SUCNR1 0.861 RBP7 0.803 0.954 0.014 0.003 SUCNR1 0.861 RGS2 0.7890.925 0.006 0.036 MTRR 0.832 AREG 0.814 0.896 0.047 0.034 MTRR 0.832 NA0.884 0.954 0.007 0.019 MTRR 0.832 CCDC125 0.79 0.929 0.012 0.01 MTRR0.832 RGS2 0.789 0.907 0.024 0.033 PLA2G7 0.738 MACF1 0.699 0.826 0.0430.021 PLA2G7 0.738 HSP90AB1_HSP90A 0.65 0.84 0.027 0.008 PLA2G7 0.738ITGA4_CERKL 0.721 0.854 0.008 0.035 PLA2G7 0.738 IL1B 0.769 0.888 0.0020.042 PLA2G7 0.738 C7orf58 0.787 0.937 0 0.004 PLA2G7 0.738 DYNLL1 0.7870.901 0.001 0.037 AIG1 0.873 GAB2 0.842 0.949 0.019 0.011 AIG1 0.873AREG 0.814 0.956 0.015 0.003 AIG1 0.873 NA 0.884 0.964 0.013 0.011 AIG10.873 KIAA1257_ACAD9/ 0.823 0.952 0.041 0.002 AIG1 0.873 CCDC125 0.790.965 0.016 0.002 AIG1 0.873 SYNE2 0.886 0.954 0.017 0.039 AIG1 0.873RGS2 0.789 0.946 0.018 0.003 PCOLCE2 0.667 SLC11A1 0.705 0.845 0.0160.003 PCOLCE2 0.667 AREG 0.814 0.907 0 0.016 PCOLCE2 0.667DAAM2_LOC100131 0.778 0.848 0.023 0.017 PCOLCE2 0.667 ACPL2 0.756 0.8480.02 0.002 PCOLCE2 0.667 ERGIC1 0.758 0.831 0.019 0.031 PCOLCE2 0.667CYP4F3_CYP4F2 0.755 0.823 0.04 0.048 GAB2 0.842 GSTO1 0.83 0.915 0.050.017 GAB2 0.842 PMS2CL_PMS2 0.857 0.926 0.043 0.027 GAB2 0.842NEK6_LOC1001290 0.844 0.927 0.035 0.015 GAB2 0.842 ACTA2 0.818 0.9650.012 0.001 GAB2 0.842 CD300A 0.888 0.974 0.004 0.01 GAB2 0.842 TRIM210.857 0.972 0.006 0.008 GAB2 0.842 ICAM1 0.895 0.964 0.008 0.02 GAB20.842 P4HA1_RPL17 0.88 0.945 0.01 0.044 GAB2 0.842 RRP12_LOC644215 0.840.958 0.009 0.004 GAB2 0.842 TIMM10 0.868 0.933 0.049 0.017 GAB2 0.842IRF1 0.894 0.979 0.001 0.015 GAB2 0.842 ATP6V0D1_LOC100 0.828 0.9540.002 0.023 GAB2 0.842 CDC26 0.868 0.941 0.012 0.021 HS2ST1_UBA2 0.837PDE3B 0.861 0.943 0.012 0.032 HS2ST1_UBA2 0.837 NA 0.884 0.943 0.0240.026 HS2ST1_UBA2 0.837 HAL 0.846 0.949 0.013 0.01 HS2ST1_UBA2 0.837KIAA1257_ACAD9/ 0.823 0.926 0.037 0.012 HS2ST1_UBA2 0.837 SYNE2 0.8860.953 0.009 0.024 HS2ST1_UBA2 0.837 RGS2 0.789 0.967 0.003 0.001HIST1H3A 0.822 SLC11A1 0.705 0.897 0.028 0.007 HIST1H3A 0.822 AREG 0.8140.927 0.003 0.031 HIST1H3A 0.822 ERGIC1 0.758 0.917 0.01 0.008 HIST1H3A0.822 NA 0.884 0.96 0.002 0.016 HIST1H3A 0.822 KIAA1257_ACAD9/ 0.8230.937 0.002 0.027 HIST1H3A 0.822 CCDC125 0.79 0.945 0.002 0.01 HIST1H3A0.822 CYP4F3_CYP4F2 0.755 0.91 0.028 0.004 HIST1H3A 0.822 MME 0.8470.945 0.006 0.018 HIST1H3A 0.822 RBP7 0.803 0.939 0.019 0.002 HIST1H3A0.822 CAMK1D 0.735 0.887 0.023 0.015 SLC39A8 0.867 NA 0.884 0.951 0.0190.045 SLC39A8 0.867 CCDC125 0.79 0.946 0.019 0.006 SLC39A8 0.867 RGS20.789 0.922 0.021 0.034 MKI67 0.674 CCDC125 0.79 0.925 0 0.034 MKI670.674 CYP4F3_CYP4F2 0.755 0.855 0.009 0.028 MKI67 0.674 RBP7 0.803 0.8980.001 0.027 SLC11A1 0.705 GALNT2 0.673 0.831 0.009 0.022 SLC11A1 0.705GLT25D1 0.808 0.902 0.001 0.038 SLC11A1 0.705 DPH3 0.706 0.85 0.0280.002 SLC11A1 0.705 DLEU2_DLEU2L 0.758 0.845 0.044 0.024 SLC11A1 0.705ITGA2B 0.752 0.84 0.05 0.012 SLC11A1 0.705 HIST1H3B 0.829 0.889 0.0110.049 SLC11A1 0.705 PTGS1 0.794 0.875 0.007 0.033 SLC11A1 0.705 CD1510.767 0.874 0.007 0.019 SLC11A1 0.705 APOLD1 0.777 0.874 0.009 0.039SLC11A1 0.705 HIST1H2BJ 0.797 0.88 0.017 0.019 SLC11A1 0.705 LASS4 0.6690.822 0.032 0.019 SLC11A1 0.705 PLEKHF2 0.737 0.851 0.025 0.013 SLC11A10.705 CMTM5 0.814 0.892 0.007 0.025 SLC11A1 0.705 AIF1 0.745 0.841 0.0270.026 SLC11A1 0.705 KIAA0101_CSNK1G 0.87 0.906 0.005 0.048 AREG 0.814GSTO1 0.83 0.918 0.018 0.011 AREG 0.814 PTGER2 0.842 0.923 0.007 0.029AREG 0.814 RPL17_SNORD58B 0.842 0.909 0.02 0.045 AREG 0.814 GLT25D10.808 0.92 0.011 0.012 AREG 0.814 ACTA2 0.818 0.905 0.049 0.021 AREG0.814 EIF1AX_SCARNA9L 0.814 0.905 0.049 0.007 AREG 0.814 TAF13 0.9080.958 0.005 0.036 AREG 0.814 TYMS 0.838 0.92 0.022 0.019 AREG 0.814HIST1H2BM 0.862 0.939 0.009 0.019 AREG 0.814 LAIR1_LAIR2 0.777 0.9010.036 0.017 AREG 0.814 HIST1H3B 0.829 0.926 0.048 0.004 AREG 0.814FSD1L_GARNL1 0.844 0.942 0.006 0.011 AREG 0.814 NA 0.87 0.932 0.02 0.029AREG 0.814 HIST1H3C 0.854 0.923 0.038 0.011 AREG 0.814 FSD1L 0.834 0.9330.022 0.004 AREG 0.814 TNFRSF17 0.827 0.914 0.015 0.02 AREG 0.814PLEKHA3 0.777 0.904 0.03 0.005 AREG 0.814 CDC26 0.868 0.944 0.005 0.035AREG 0.814 GLDC 0.775 0.919 0.018 0.004 AREG 0.814 KIAA0101_CSNK1G 0.870.927 0.031 0.03 DAAM2_LOC100131 0.778 DPH3 0.706 0.858 0.007 0.037DAAM2_LOC100131 0.778 ANKRD28 0.71 0.859 0.014 0.032 DAAM2_LOC1001310.778 MYL9 0.695 0.842 0.041 0.03 LTF 0.642 THBS1 0.698 0.823 0.0020.031 TREML1 0.704 NF-E4 0.674 0.864 0.023 0.002 TREML1 0.704 THBS10.698 0.858 0.008 0.008 TREML1 0.704 MME 0.847 0.94 0 0.031 GSTO1 0.83PDE3B 0.861 0.929 0.025 0.05 GSTO1 0.83 NA 0.884 0.972 0.004 0.008 GSTO10.83 KIAA1257_ACAD9/ 0.823 0.923 0.026 0.012 GSTO1 0.83 CCDC125 0.790.948 0.012 0.003 GSTO1 0.83 CYP4F3_CYP4F2 0.755 0.912 0.049 0.004 GSTO10.83 SYNE2 0.886 0.953 0.008 0.028 GSTO1 0.83 RGS2 0.789 0.926 0.010.013 PTGER2 0.842 PDE3B 0.861 0.953 0.018 0.009 PTGER2 0.842 IRS2 0.8510.932 0.035 0.019 PTGER2 0.842 NA 0.884 0.957 0.021 0.008 PTGER2 0.842HAL 0.846 0.934 0.048 0.005 PTGER2 0.842 CCDC125 0.79 0.937 0.042 0.005PTGER2 0.842 SYNE2 0.886 0.971 0.004 0.02 PTGER2 0.842 RGS2 0.789 0.9520.015 0.001 PMS2CL_PMS2 0.857 PDE3B 0.861 0.961 0.009 0.015 PMS2CL_PMS20.857 NA 0.884 0.977 0.005 0.01 PMS2CL_PMS2 0.857 HAL 0.846 0.938 0.020.029 PMS2CL_PMS2 0.857 KIAA1257_ACAD9/ 0.823 0.942 0.018 0.011PMS2CL_PMS2 0.857 CCDC125 0.79 0.96 0.012 0.002 PMS2CL_PMS2 0.857 SYNE20.886 0.993 0.002 0.006 PMS2CL_PMS2 0.857 RBP7 0.803 0.952 0.022 0.002PMS2CL_PMS2 0.857 RGS2 0.789 0.93 0.017 0.011 PMS2CL_PMS2 0.857 CAMK1D0.735 0.92 0.02 0.002 PDE3B 0.861 NEK6_LOC1001290 0.844 0.95 0.004 0.035PDE3B 0.861 AMFR 0.874 0.961 0.01 0.039 PDE3B 0.861 RPL17_SNORD58B 0.8420.961 0.05 0.001 PDE3B 0.861 GLT25D1 0.808 0.916 0.034 0.031 PDE3B 0.861EIF1AX_SCARNA9L 0.814 0.956 0.039 0 PDE3B 0.861 ZNF28 0.891 0.973 0.0030.05 PDE3B 0.861 TYMS 0.838 0.939 0.034 0.038 PDE3B 0.861 HIST1H2BM0.862 0.945 0.032 0.034 PDE3B 0.861 FSD1L_GARNL1 0.844 0.959 0.009 0.019PDE3B 0.861 PTGS1 0.794 0.943 0.038 0.001 PDE3B 0.861 FSD1L 0.834 0.9480.015 0.005 PDE3B 0.861 APOLD1 0.777 0.95 0.023 0.001 PDE3B 0.861 SON0.794 0.946 0.012 0.007 PDE3B 0.861 PLEKHA3 0.777 0.946 0.018 0.001PDE3B 0.861 CDC26 0.868 0.958 0.006 0.039 PDE3B 0.861 GLDC 0.775 0.9220.028 0.008 PDE3B 0.861 KIAA0101_CSNK1G 0.87 0.953 0.05 0.008 SULF20.775 IRF4 0.74 0.868 0.015 0.046 SULF2 0.775 RPL17_SNORD58B 0.842 0.9040.017 0.034 SULF2 0.775 ACTA2 0.818 0.924 0.003 0.033 SULF2 0.775 PTGS10.794 0.909 0.009 0.015 SULF2 0.775 E2F6 0.798 0.906 0.018 0.01 SULF20.775 CD151 0.767 0.896 0.02 0.01 SULF2 0.775 TPX2 0.745 0.874 0.0170.026 SULF2 0.775 C7orf58 0.787 0.9 0.028 0.002 SULF2 0.775 DYNLL1 0.7870.893 0.03 0.013 SULF2 0.775 NP 0.787 0.895 0.015 0.024 SULF2 0.775NFXL1 0.808 0.889 0.044 0.044 SULF2 0.775 DCTN5 0.773 0.892 0.01 0.042NEK6_LOC1001290 0.844 NA 0.884 0.931 0.045 0.038 NEK6_LOC1001290 0.844SYNE2 0.886 0.946 0.027 0.026 NEK6_LOC1001290 0.844 RGS2 0.789 0.9360.038 0.001 CENPK 0.739 PYHIN1 0.647 0.854 0.026 0.007 CENPK 0.739PPP1R2_PPP1R2P3 0.637 0.812 0.032 0.043 TRAF3 0.889 SYNE2 0.886 0.9620.032 0.017 IRF4 0.74 NA 0.884 0.935 0.002 0.034 IRF4 0.74 CCDC125 0.790.89 0.003 0.044 IRF4 0.74 CYP4F3_CYP4F2 0.755 0.874 0.04 0.004 IRF40.74 SYNE2 0.886 0.954 0 0.017 IRF4 0.74 MME 0.847 0.906 0.008 0.022IRF4 0.74 RBP7 0.803 0.873 0.032 0.04 MACF1 0.699 ACPL2 0.756 0.8580.008 0.041 MACF1 0.699 CAMK1D 0.735 0.854 0.003 0.05 MACF1 0.699PPP1R2_PPP1R2P3 0.637 0.797 0.026 0.034 AMFR 0.874 IRS2 0.851 0.9520.031 0.011 AMFR 0.874 OCR1 0.934 0.977 0.033 0.021 AMFR 0.874 NA 0.8840.965 0.042 0.005 AMFR 0.874 HAL 0.846 0.971 0.028 0.003 AMFR 0.874ZRANB1 0.718 0.965 0.044 0 AMFR 0.874 SYNE2 0.886 0.973 0.023 0.01 AMFR0.874 RGS2 0.789 0.954 0.019 0.004 RPL17_SNORD58B 0.842 NA 0.884 0.980.004 0.006 RPL17_SNORD58B 0.842 LY6G5B_CSNK2B 0.63 0.892 0.044 0RPL17_SNORD58B 0.842 KIAA1257_ACAD9/ 0.823 0.922 0.011 0.049RPL17_SNORD58B 0.842 CCDC125 0.79 0.939 0.005 0.015 RPL17_SNORD58B 0.842ZRANB1 0.718 0.921 0.039 0.001 RPL17_SNORD58B 0.842 MME 0.847 0.9470.011 0.017 RPL17_SNORD58B 0.842 RBP7 0.803 0.944 0.005 0.011RPL17_SNORD58B 0.842 CAMK1D 0.735 0.894 0.023 0.014 IRS2 0.851 GLT25D10.808 0.926 0.023 0.016 IRS2 0.851 RRP12_LOC644215 0.84 0.938 0.0080.038 IRS2 0.851 PTGS1 0.794 0.953 0.021 0.001 IRS2 0.851 CMTM5 0.8140.949 0.031 0.002 IRS2 0.851 GLDC 0.775 0.946 0.016 0.001 GALNT2 0.673ACPL2 0.756 0.832 0.033 0.019 GALNT2 0.673 ERGIC1 0.758 0.845 0.0110.018 GLT25D1 0.808 ERGIC1 0.758 0.905 0.046 0.001 GLT25D1 0.808 HAL0.846 0.916 0.024 0.019 GLT25D1 0.808 RGS2 0.789 0.887 0.038 0.016GLT25D1 0.808 CAMK1D 0.735 0.925 0.023 0 HDHD1A 0.7 ACPL2 0.756 0.8550.01 0.018 HDHD1A 0.7 LY6G5B_CSNK2B 0.63 0.811 0.028 0.009 HDHD1A 0.7CCDC125 0.79 0.927 0 0.021 HDHD1A 0.7 ZRANB1 0.718 0.84 0.018 0.02HDHD1A 0.7 CYP4F3_CYP4F2 0.755 0.844 0.028 0.018 HDHD1A 0.7 SYNE2 0.8860.952 0 0.047 HDHD1A 0.7 CPM 0.812 0.906 0.002 0.009 HDHD1A 0.7 CAMK1D0.735 0.871 0.001 0.021 ACTA2 0.818 ERGIC1 0.758 0.906 0.03 0.008 ACTA20.818 HAL 0.846 0.944 0.006 0.028 ACTA2 0.818 KIAA1257_ACAD9/ 0.8230.932 0.006 0.018 ACTA2 0.818 CCDC125 0.79 0.914 0.03 0.012 ACTA2 0.818ZRANB1 0.718 0.93 0.021 0 ACTA2 0.818 MPZL2 0.775 0.919 0.034 0.004ACPL2 0.756 DPH3 0.706 0.882 0.009 0.008 ACPL2 0.756 ANKRD28 0.71 0.9060.005 0.001 ACPL2 0.756 ITGA2B 0.752 0.878 0.009 0.016 ACPL2 0.756HIST1H3C 0.854 0.935 0.002 0.016 ACPL2 0.756 MYL9 0.695 0.861 0.0220.006 ACPL2 0.756 HIST1H2BJ 0.797 0.92 0.004 0.01 ACPL2 0.756 MPO 0.6840.832 0.025 0.043 ACPL2 0.756 FAM118B 0.74 0.869 0.008 0.033 ACPL2 0.756SDHC 0.85 0.93 0.002 0.038 OCR1 0.934 ZNF28 0.891 0.976 0.038 0.043 OCR10.934 HSPB1_HSPBL2 0.886 0.977 0.018 0.033 OCR1 0.934 PTGS1 0.794 0.9740.023 0.001 OCR1 0.934 MYL9 0.695 0.977 0.028 0 OCR1 0.934 CMTM5 0.8140.979 0.024 0.002 OCR1 0.934 CDC26 0.868 0.965 0.044 0.033EIF1AX_SCARNA9L 0.814 LY6G5B_CSNK2B 0.63 0.88 0.024 0.001EIF1AX_SCARNA9L 0.814 CCDC125 0.79 0.929 0.001 0.028 EIF1AX_SCARNA9L0.814 ZRANB1 0.718 0.901 0.009 0.004 EIF1AX_SCARNA9L 0.814 MME 0.8470.94 0.008 0.012 EIF1AX_SCARNA9L 0.814 CPM 0.812 0.9 0.029 0.048EIF1AX_SCARNA9L 0.814 RASA4_RASA4P_R 0.713 0.881 0.041 0.008EIF1AX_SCARNA9L 0.814 RBP7 0.803 0.937 0.005 0.013 EIF1AX_SCARNA9L 0.814CAMK1D 0.735 0.898 0.003 0.013 DPH3 0.706 ERGIC1 0.758 0.883 0 0.035DPH3 0.706 HAL 0.846 0.938 0 0.05 DPH3 0.706 RBP7 0.803 0.905 0.0010.048 ERGIC1 0.758 HIST1H3B 0.829 0.89 0.031 0.035 ERGIC1 0.758 PTGS10.794 0.91 0.008 0.004 ERGIC1 0.758 HIST1H3C 0.854 0.901 0.03 0.013ERGIC1 0.758 CD151 0.767 0.885 0.018 0.014 ERGIC1 0.758 HIST1H3H 0.8360.898 0.032 0.019 ERGIC1 0.758 FSD1L 0.834 0.901 0.005 0.042 ERGIC10.758 TPX2 0.745 0.861 0.037 0.023 ERGIC1 0.758 APOLD1 0.777 0.917 0.0040.004 ERGIC1 0.758 HIST1H2BJ 0.797 0.901 0.032 0.003 ERGIC1 0.758 LASS40.669 0.85 0.017 0.012 ERGIC1 0.758 PLEKHF2 0.737 0.867 0.043 0.011ERGIC1 0.758 CMTM5 0.814 0.927 0.005 0.006 ERGIC1 0.758 AIF1 0.745 0.870.028 0.007 ERGIC1 0.758 CDC26 0.868 0.955 0 0.05 ERGIC1 0.758 SDHC 0.850.919 0.006 0.015 ERGIC1 0.758 GLDC 0.775 0.893 0.004 0.023 CD300A 0.888MPZL3 0.889 0.974 0.014 0.01 NF-E4 0.674 MYL9 0.695 0.868 0 0.023 NF-E40.674 HIST1H2BJ 0.797 0.926 0 0.027 NF-E4 0.674 SPARC 0.661 0.834 0.0070.02 MINPP1 0.718 ZRANB1 0.718 0.895 0 0.009 MINPP1 0.718 RPIA 0.6550.887 0.011 0 MINPP1 0.718 C1orf128 0.662 0.86 0.033 0.001 TRIM21 0.857NA 0.884 0.945 0.029 0.048 TRIM21 0.857 SYNE2 0.886 0.956 0.024 0.033ZNF28 0.891 NA 0.884 0.977 0.019 0.008 ZNF28 0.891 SYNE2 0.886 0.9820.012 0.008 ZNF28 0.891 RGS2 0.789 0.953 0.044 0.004 NA 0.884 TAF130.908 0.984 0.005 0.026 NA 0.884 P4HA1_RPL17 0.88 0.969 0.018 0.018 NA0.884 TYMS 0.838 0.953 0.018 0.012 NA 0.884 RRP12_LOC644215 0.84 0.9390.019 0.048 NA 0.884 HIST1H2BM 0.862 0.977 0.006 0.007 NA 0.884 HIST1H3B0.829 0.961 0.034 0.003 NA 0.884 TIMM10 0.868 0.958 0.01 0.034 NA 0.884FSD1L_GARNL1 0.844 0.951 0.02 0.024 NA 0.884 PTGS1 0.794 0.949 0.0330.002 NA 0.884 NA 0.87 0.963 0.025 0.004 NA 0.884 HIST1H3C 0.854 0.9710.023 0.003 NA 0.884 HIST1H3H 0.836 0.972 0.018 0.002 NA 0.884 FSD1L0.834 0.956 0.032 0.003 NA 0.884 TPX2 0.745 0.955 0.015 0.001 NA 0.884APOLD1 0.777 0.943 0.013 0.004 NA 0.884 MPO 0.684 0.94 0.04 0 NA 0.884B4GALT3 0.785 0.948 0.03 0.002 NA 0.884 CTSL1_CTSLL3 0.819 0.945 0.0330.009 NA 0.884 TNFRSF17 0.827 0.962 0.029 0.002 NA 0.884 PLEKHA3 0.7770.951 0.033 0.001 NA 0.884 CMTM5 0.814 0.944 0.032 0.009 NA 0.884IGL@_IGLV1-44_(—) 0.77 0.939 0.028 0.002 NA 0.884 DCTN5 0.773 0.9390.034 0.003 NA 0.884 KIAA0101_CSNK1G 0.87 0.985 0.006 0.008 TAF13 0.908CCDC125 0.79 0.965 0.031 0.003 TAF13 0.908 SYNE2 0.886 0.965 0.036 0.043TAF13 0.908 RGS2 0.789 0.953 0.048 0.008 P4HA1_RPL17 0.88 CCDC125 0.790.961 0.032 0.002 P4HA1_RPL17 0.88 SYNE2 0.886 0.984 0.005 0.016C15orf54 0.672 POLE2 0.704 0.824 0.039 0.01 KLHL5 0.913 SYNE2 0.8860.976 0.03 0.016 KLHL5 0.913 RGS2 0.789 0.963 0.011 0.005 HAL 0.846 TYMS0.838 0.932 0.02 0.031 HAL 0.846 RRP12_LOC644215 0.84 0.936 0.011 0.031HAL 0.846 TIMM10 0.868 0.931 0.034 0.041 HAL 0.846 FSD1L_GARNL1 0.8440.937 0.015 0.046 HAL 0.846 PTGS1 0.794 0.955 0.016 0.001 HAL 0.846CD151 0.767 0.926 0.047 0.002 HAL 0.846 FSD1L 0.834 0.919 0.041 0.019HAL 0.846 APOLD1 0.777 0.962 0.006 0.001 HAL 0.846 SON 0.794 0.918 0.0430.011 HAL 0.846 LASS4 0.669 0.925 0.015 0 HAL 0.846 B4GALT3 0.785 0.9450.015 0.002 HAL 0.846 PLEKHA3 0.777 0.912 0.045 0.01 HAL 0.846 CMTM50.814 0.97 0.013 0.001 HAL 0.846 AIF1 0.745 0.936 0.018 0.001 HAL 0.846CDC26 0.868 0.957 0.004 0.036 HAL 0.846 GLDC 0.775 0.946 0.01 0.002 HAL0.846 DCTN5 0.773 0.905 0.023 0.012 DLEU2_DLEU2L 0.758 KIAA1257_ACAD9/0.823 0.918 0.002 0.033 DLEU2_DLEU2L 0.758 MME 0.847 0.916 0.004 0.045DLEU2_DLEU2L 0.758 CAMK1D 0.735 0.87 0.008 0.022 ANKRD28 0.71LY6G5B_CSNK2B 0.63 0.791 0.024 0.048 ANKRD28 0.71 THBS1 0.698 0.8360.039 0.005 ANKRD28 0.71 ZRANB1 0.718 0.874 0.001 0.016 ANKRD28 0.71 CPM0.812 0.9 0.002 0.032 ANKRD28 0.71 CAMK1D 0.735 0.867 0.001 0.036LY6G5B_CSNK2B 0.63 KIAA0746 0.713 0.792 0.048 0.015 KIAA1257_ACAD9/0.823 TYMS 0.838 0.929 0.012 0.039 KIAA1257_ACAD9/ 0.823 RRP12_LOC6442150.84 0.939 0.004 0.038 KIAA1257_ACAD9/ 0.823 TIMM10 0.868 0.937 0.0190.023 KIAA1257_ACAD9/ 0.823 PTGS1 0.794 0.935 0.016 0.002KIAA1257_ACAD9/ 0.823 NA 0.87 0.928 0.018 0.036 KIAA1257_ACAD9/ 0.823CD151 0.767 0.909 0.05 0.004 KIAA1257_ACAD9/ 0.823 HIST1H3H 0.836 0.9330.045 0.002 KIAA1257_ACAD9/ 0.823 FSD1L 0.834 0.911 0.036 0.035KIAA1257_ACAD9/ 0.823 APOLD1 0.777 0.941 0.007 0.003 KIAA1257_ACAD9/0.823 B4GALT3 0.785 0.938 0.009 0.007 KIAA1257_ACAD9/ 0.823 CMTM5 0.8140.952 0.008 0.002 KIAA1257_ACAD9/ 0.823 SDHC 0.85 0.926 0.039 0.011KIAA1257_ACAD9/ 0.823 GLDC 0.775 0.904 0.033 0.014 KIAA1257_ACAD9/ 0.823KIAA0101_CSNK1G 0.87 0.939 0.044 0.015 MGST3 0.897 MPZL3 0.889 0.9830.005 0.022 MGST3 0.897 RGS2 0.789 0.948 0.036 0.005 HSPB1_HSPBL2 0.886MPZL3 0.889 0.976 0.005 0.024 TYMS 0.838 CCDC125 0.79 0.956 0.007 0.003TYMS 0.838 SYNE2 0.886 0.965 0.004 0.025 CCDC125 0.79 HIST1H2BM 0.8620.965 0.002 0.009 CCDC125 0.79 HIST1H3B 0.829 0.921 0.03 0.014 CCDC1250.79 FSD1L_GARNL1 0.844 0.964 0.001 0.013 CCDC125 0.79 PTGS1 0.794 0.9150.009 0.016 CCDC125 0.79 UBE2F_C20orf194 0.758 0.91 0.048 0.001 CCDC1250.79 HIST1H3C 0.854 0.943 0.021 0.001 CCDC125 0.79 CD151 0.767 0.8890.05 0.016 CCDC125 0.79 HIST1H3H 0.836 0.931 0.02 0.007 CCDC125 0.79FSD1L 0.834 0.935 0.009 0.005 CCDC125 0.79 TPX2 0.745 0.969 0.003 0CCDC125 0.79 APOLD1 0.777 0.886 0.014 0.039 CCDC125 0.79 HIST1H2BJ 0.7970.932 0.032 0 CCDC125 0.79 SON 0.794 0.913 0.017 0.02 CCDC125 0.79 LASS40.669 0.846 0.032 0.015 CCDC125 0.79 DYNLL1 0.787 0.917 0.041 0.001CCDC125 0.79 FAM118B 0.74 0.921 0.033 0 CCDC125 0.79 B4GALT3 0.785 0.9230.014 0.005 CCDC125 0.79 CTSL1_CTSLL3 0.819 0.897 0.048 0.049 CCDC1250.79 NP 0.787 0.927 0.012 0.003 CCDC125 0.79 TNFRSF17 0.827 0.927 0.0090.012 CCDC125 0.79 PLEKHA3 0.777 0.901 0.022 0.014 CCDC125 0.79TMEM62_SPCS2_L 0.849 0.94 0.012 0.018 CCDC125 0.79 CMTM5 0.814 0.9220.013 0.017 CCDC125 0.79 IGL@_IGLV1-44_(—) 0.77 0.899 0.021 0.02 CCDC1250.79 SDHC 0.85 0.932 0.031 0.007 CCDC125 0.79 GLDC 0.775 0.899 0.010.026 CCDC125 0.79 DCTN5 0.773 0.91 0.008 0.02 CCDC125 0.79KIAA0101_CSNK1G 0.87 0.956 0.01 0.005 HIST1H2BM 0.862 SYNE2 0.886 0.9820.006 0.011 HIST1H2BM 0.862 MME 0.847 0.947 0.047 0.004 HIST1H2BM 0.862RGS2 0.789 0.932 0.028 0.011 IL1B 0.769 KDM6B_TMEM88 0.672 0.842 0.0140.031 THBS1 0.698 ITGA2B 0.752 0.919 0 0.007 THBS1 0.698 MYL9 0.6950.858 0.001 0.021 THBS1 0.698 SPARC 0.661 0.835 0.016 0.007 ITGA2B 0.752ZRANB1 0.718 0.906 0 0.006 ITGA2B 0.752 CYP4F3_CYP4F2 0.755 0.894 0.0110.008 ITGA2B 0.752 MME 0.847 0.941 0.001 0.014 ITGA2B 0.752 RBP7 0.8030.913 0.003 0.015 ITGA2B 0.752 MPZL2 0.775 0.885 0.007 0.019 LAIR1_LAIR20.777 MPZL2 0.775 0.883 0.044 0.01 HIST1H3B 0.829 CYP4F3_CYP4F2 0.7550.909 0.038 0.008 ZRANB1 0.718 PTGS1 0.794 0.945 0 0.002 ZRANB1 0.718UBE2F_C20orf194 0.758 0.87 0.009 0.016 ZRANB1 0.718 HIST1H3C 0.854 0.9140.003 0.038 ZRANB1 0.718 E2F6 0.798 0.899 0.01 0.011 ZRANB1 0.718 CD1510.767 0.881 0.005 0.014 ZRANB1 0.718 HIST1H3H 0.836 0.946 0 0.006 ZRANB10.718 TPX2 0.745 0.861 0.004 0.049 ZRANB1 0.718 MYL9 0.695 0.866 0.0310.001 ZRANB1 0.718 HIST1H2BJ 0.797 0.929 0.002 0.001 ZRANB1 0.718C7orf58 0.787 0.886 0.01 0.003 ZRANB1 0.718 DYNLL1 0.787 0.887 0.0130.009 ZRANB1 0.718 FAM118B 0.74 0.833 0.041 0.024 ZRANB1 0.718 B4GALT30.785 0.926 0 0.018 ZRANB1 0.718 NP 0.787 0.913 0.001 0.014 ZRANB1 0.718TNFRSF17 0.827 0.891 0.003 0.031 ZRANB1 0.718 CMTM5 0.814 0.946 0 0.005ZRANB1 0.718 IGLV6-57 0.757 0.846 0.026 0.047 TIMM10 0.868 SYNE2 0.8860.971 0.017 0.007 FSD1L_GARNL1 0.844 SYNE2 0.886 0.965 0.007 0.02FSD1L_GARNL1 0.844 RGS2 0.789 0.94 0.036 0.002 PTGS1 0.794 CYP4F3_CYP4F20.755 0.902 0.049 0.001 PTGS1 0.794 MME 0.847 0.951 0.005 0.004 PTGS10.794 CPM 0.812 0.906 0.031 0.006 PTGS1 0.794 RBP7 0.803 0.952 0.0030.001 PTGS1 0.794 RGS2 0.789 0.91 0.004 0.027 PTGS1 0.794 CAMK1D 0.7350.874 0.041 0.014 PTGS1 0.794 MPZL2 0.775 0.901 0.036 0.002UBE2F_C20orf194 0.758 CYP4F3_CYP4F2 0.755 0.861 0.05 0.026UBE2F_C20orf194 0.758 RBP7 0.803 0.906 0.008 0.012 HIST1H3C 0.854 RBP70.803 0.949 0.007 0.008 HIST1H3C 0.854 CAMK1D 0.735 0.9 0.021 0.016FAM118A 0.717 SYNE2 0.886 0.961 0 0.018 FAM118A 0.717 RBP7 0.803 0.8940.009 0.035 E2F6 0.798 RASA4_RASA4P_R 0.713 0.894 0.008 0.013 E2F6 0.798RBP7 0.803 0.93 0.002 0.023 E2F6 0.798 CAMK1D 0.735 0.883 0.01 0.023MPZL3 0.889 IRF1 0.894 0.971 0.011 0.026 MPZL3 0.889 ATP6V0D1_LOC1000.828 0.965 0.027 0.004 MPZL3 0.889 CDC26 0.868 0.972 0.015 0.004 CD1510.767 KDM6B_TMEM88 0.672 0.856 0.024 0.008 CD151 0.767 CYP4F3_CYP4F20.755 0.894 0.015 0.005 CD151 0.767 RBP7 0.803 0.919 0.009 0.004 CD1510.767 RGS2 0.789 0.909 0.002 0.042 CD151 0.767 MPZL2 0.775 0.87 0.0260.02 HIST1H3H 0.836 CYP4F3_CYP4F2 0.755 0.948 0.01 0 HIST1H3H 0.836 MME0.847 0.973 0.004 0.003 HIST1H3H 0.836 RBP7 0.803 0.958 0.006 0.002HIST1H3H 0.836 RGS2 0.789 0.923 0.001 0.046 FSD1L 0.834 RGS2 0.789 0.90.022 0.02 FSD1L 0.834 CAMK1D 0.735 0.912 0.028 0.001 TPX2 0.745CYP4F3_CYP4F2 0.755 0.893 0.02 0.003 TPX2 0.745 SYNE2 0.886 0.965 00.017 TPX2 0.745 MME 0.847 0.913 0.009 0.022 TPX2 0.745 RBP7 0.803 0.9080.02 0.006 TPX2 0.745 MPZL2 0.775 0.85 0.04 0.034 PYHIN1 0.647IGK@_IGKC_IGKV 0.774 0.855 0.006 0.032 APOLD1 0.777 SYNE2 0.886 0.9450.001 0.048 APOLD1 0.777 MME 0.847 0.917 0.013 0.011 APOLD1 0.777 RGS20.789 0.918 0.004 0.01 APOLD1 0.777 CAMK1D 0.735 0.887 0.031 0.003KDM6B_TMEM88 0.672 AIF1 0.745 0.833 0.017 0.039 MYL9 0.695 CYP4F3_CYP4F20.755 0.886 0.004 0.009 MYL9 0.695 MME 0.847 0.949 0 0.007 MYL9 0.695RBP7 0.803 0.948 0 0.004 HIST1H2BJ 0.797 CYP4F3_CYP4F2 0.755 0.929 0.0030.004 HIST1H2BJ 0.797 MME 0.847 0.96 0.001 0.012 HIST1H2BJ 0.797 RBP70.803 0.957 0.001 0.005 CYP4F3_CYP4F2 0.755 LASS4 0.669 0.837 0.0070.043 CYP4F3_CYP4F2 0.755 DYNLL1 0.787 0.89 0.007 0.021 CYP4F3_CYP4F20.755 MPO 0.684 0.861 0.039 0.005 CYP4F3_CYP4F2 0.755 FAM118B 0.74 0.850.039 0.041 CYP4F3_CYP4F2 0.755 TNFRSF17 0.827 0.927 0.002 0.013CYP4F3_CYP4F2 0.755 CMTM5 0.814 0.927 0.001 0.035 CYP4F3_CYP4F2 0.755IGLV6-57 0.757 0.933 0.001 0.002 CYP4F3_CYP4F2 0.755 IGL@_IGLV1-44_(—)0.77 0.903 0.001 0.024 SON 0.794 SYNE2 0.886 0.962 0 0.047 SON 0.794LOC100128751 0.809 0.926 0.005 0.008 SYNE2 0.886 B4GALT3 0.785 0.960.018 0.002 SYNE2 0.886 NP 0.787 0.965 0.013 0.001 SYNE2 0.886 PLEKHA30.777 0.955 0.042 0.001 SYNE2 0.886 CDC26 0.868 0.967 0.008 0.013 SYNE20.886 KIAA0101_CSNK1G 0.87 0.971 0.036 0.003 MME 0.847 LASS4 0.669 0.9060.003 0.003 MME 0.847 DYNLL1 0.787 0.919 0.043 0.006 MME 0.847 B4GALT30.785 0.926 0.009 0.014 MME 0.847 NP 0.787 0.912 0.03 0.021 MME 0.847SPARC 0.661 0.929 0.043 0 MME 0.847 TNFRSF17 0.827 0.953 0.006 0.003 MME0.847 PLEKHA3 0.777 0.919 0.02 0.017 MME 0.847 CMTM5 0.814 0.968 0.0020.005 MME 0.847 IGLV6-57 0.757 0.92 0.047 0.002 MME 0.847IGL@_IGLV1-44_(—) 0.77 0.919 0.006 0.013 MME 0.847 GLDC 0.775 0.9 0.0080.033 MME 0.847 KIAA0101_CSNK1G 0.87 0.947 0.016 0.026 LASS4 0.669 RBP70.803 0.883 0.009 0.004 C7orf58 0.787 CAMK1D 0.735 0.881 0.004 0.022DYNLL1 0.787 RBP7 0.803 0.921 0.003 0.02 DYNLL1 0.787 CAMK1D 0.735 0.8870.005 0.021 DYNLL1 0.787 PPP1R2_PPP1R2P3 0.637 0.869 0.018 0.004 CPM0.812 FAM118B 0.74 0.919 0.011 0.002 CPM 0.812 AIF1 0.745 0.897 0.040.009 FAM118B 0.74 CAMK1D 0.735 0.874 0.002 0.027 B4GALT3 0.785 RBP70.803 0.921 0.024 0.001 NP 0.787 RBP7 0.803 0.912 0.026 0.003 NP 0.787MPZL2 0.775 0.879 0.039 0.013 POLE2 0.704 RPIA 0.655 0.854 0.001 0.017POLE2 0.704 C1orf128 0.662 0.864 0.003 0.008 TNFRSF17 0.827 RGS2 0.7890.913 0.007 0.039 PLEKHA3 0.777 RBP7 0.803 0.906 0.026 0.015 PLEKHA30.777 RGS2 0.789 0.913 0.005 0.02 PLEKHA3 0.777 CAMK1D 0.735 0.866 0.0390.02 RBP7 0.803 CMTM5 0.814 0.976 0.001 0.001 RBP7 0.803 IGLV6-57 0.7570.899 0.03 0.01 RBP7 0.803 IGL@_IGLV1-44_(—) 0.77 0.894 0.013 0.035 RBP70.803 SDHC 0.85 0.919 0.038 0.036 RBP7 0.803 GLDC 0.775 0.89 0.005 0.046RBP7 0.803 KIAA0101_CSNK1G 0.87 0.958 0.004 0.01 RGS2 0.789 CMTM5 0.8140.941 0.017 0.001 RGS2 0.789 CDC26 0.868 0.956 0.001 0.016 RGS2 0.789IGL@_IGLV1-44_(—) 0.77 0.888 0.033 0.013 RGS2 0.789 KIAA0101_CSNK1G 0.870.932 0.032 0.008 CAMK1D 0.735 AIF1 0.745 0.876 0.011 0.009 CAMK1D 0.735NFXL1 0.808 0.893 0.009 0.029 CAMK1D 0.735 DCTN5 0.773 0.885 0.004 0.022CAMK1D 0.735 KIAA0101_CSNK1G 0.87 0.919 0.007 0.029 LOC100128751 0.809DCTN5 0.773 0.899 0.033 0.031 IFI44 0.712 NA 0.623 0.83 0.007 0.01

TABLE 19 Ratios Mild ipSIRS Versus Severe ipSIRS Gene 1 Gene 2 RatioSignif Ratio Signif Gene 1 Name AUC Gene 2 Name AUC Ratio AUC to Gene 1to Gene 2 CD177 0.668 ACER3 0.649 0.815 0.046 0.049 CD177 0.668NEK6_LOC1001290 0.471 0.748 0.043 0.008 CD177 0.668 GLT25D1 0.454 0.7770.018 0.001 VNN1 0.649 UBE2J1 0.468 0.713 0.021 0.001 UBE2J1 0.468SEC24A_SAR1B 0.679 0.795 0 0.04 IMP3 0.611 DNAJC9_FAM149B1 0.759 0.8370.03 0.028 CLEC4D 0.522 FKBP5_LOC285847 0.423 0.654 0.035 0.027 GPR560.686 NA 0.629 0.797 0.045 0.016 C11orf82 0.619 DPH3 0.648 0.799 0.0160.046 GNLY 0.691 GOT2 0.702 0.86 0.015 0.035 GNLY 0.691 HSPC159 0.6120.789 0.018 0.047 TGFBR1 0.6 SEC24A_SAR1B 0.679 0.803 0.031 0.035 TGFBR10.6 MTRR 0.66 0.786 0.049 0.03 TGFBR1 0.6 KIAA0746 0.727 0.812 0.0350.013 FKBP5_LOC285847 0.423 B3GNT5_MCF2L2 0.566 0.735 0.006 0.018FKBP5_LOC285847 0.423 GLT25D1 0.454 0.698 0.042 0.03 C7orf53 0.75DLEU2_DLEU2L 0.785 0.913 0.007 0.027 CAMK4 0.595 KPNA5 0.831 0.967 00.033 CAMK4 0.595 ITGA4_CERKL 0.659 0.842 0.002 0.034 GSR 0.795 VAMP20.811 0.92 0.004 0.042 GSR 0.795 JKAMP 0.752 0.94 0.005 0.004 GSR 0.795SON 0.722 0.909 0.046 0.003 GSR 0.795 ATP6V0D1_LOC100 0.754 0.903 0.0040.027 GSR 0.795 AIF1 0.826 0.918 0.034 0.03 KLRF1 0.702 MME 0.68 0.8480.046 0.035 PICALM 0.595 DLEU2_DLEU2L 0.785 0.899 0.001 0.022 HIST1H4C0.571 HIST1H3B 0.712 0.81 0.034 0.041 C9orf72 0.603 PPP2R5A_SNORA160.649 0.81 0.01 0.025 SLC15A2 0.629 EAF2_HCG11_LOC 0.682 0.844 0.0120.025 ADM 0.649 CD63 0.645 0.818 0.022 0.025 LRRN3 0.724 EIF1AX_SCARNA9L0.767 0.89 0.006 0.048 LRRN3 0.724 DPH3 0.648 0.845 0.039 0.008 LRRN30.724 E2F6 0.8 0.897 0.016 0.023 LRRN3 0.724 RFESD_SPATA9 0.815 0.8950.014 0.043 HLA-DPB1 0.694 GOT2 0.702 0.859 0.032 0.017 VAMP2 0.811SFRS9 0.841 0.97 0.003 0.018 JKAMP 0.752 LOC284757 0.834 0.916 0.0310.011 JKAMP 0.752 SEC24A_SAR1B 0.679 0.898 0.038 0.002 JKAMP 0.752SLC39A9 0.731 0.909 0.013 0.013 JKAMP 0.752 SFRS9 0.841 0.969 0 0.022TCN1 0.755 AIG1 0.588 0.829 0.03 0.02 KPNA5 0.831 IRF4 0.759 0.941 0.0410.017 CD63 0.645 SLC11A1 0.624 0.789 0.044 0.047 KLRK1_KLRC4 0.608 CCR40.44 0.758 0.011 0.012 ITK 0.646 ITGA4_CERKL 0.659 0.859 0.006 0.025GOT2 0.702 HINT1 0.649 0.838 0.049 0.026 GOT2 0.702 ITGA4_CERKL 0.6590.856 0.027 0.013 B3GAT3 0.605 EFCAB2 0.801 0.85 0.018 0.036 HIST1H4E0.69 NF-E4 0.78 0.859 0.023 0.033 FGFBP2 0.698 PYHIN1 0.548 0.796 0.0450.034 BPI 0.78 PPIF 0.683 0.833 0.033 0.05 BPI 0.78 AIG1 0.588 0.8820.013 0.001 BPI 0.78 DPH3 0.648 0.865 0.036 0.012 BPI 0.78 S100B 0.7030.906 0.011 0.008 BPI 0.78 CDC26 0.657 0.834 0.05 0.037 PPP2R5A_SNORA160.649 EAF2_HCG11_LOC 0.682 0.844 0.016 0.023 PPP2R5A_SNORA16 0.649 NA0.682 0.818 0.048 0.018 PPP2R5A_SNORA16 0.649 EIF1AX_SCARNA9L 0.7670.868 0.009 0.025 PPP2R5A_SNORA16 0.649 DPH3 0.648 0.812 0.047 0.014PPP2R5A_SNORA16 0.649 TAF13 0.743 0.883 0.005 0.012 PPP2R5A_SNORA160.649 FSD1L_GARNL1 0.665 0.846 0.02 0.006 EAF2_HCG11_LOC 0.682SEC24A_SAR1B 0.679 0.872 0.012 0.011 EAF2_HCG11_LOC 0.682 MTRR 0.660.845 0.046 0.007 EAF2_HCG11_LOC 0.682 KIAA0746 0.727 0.869 0.049 0.001RCBTB2_LOC10013 0.578 NA 0.838 0.897 0.002 0.038 RCBTB2_LOC10013 0.578PLEKHF2 0.85 0.924 0 0.044 SEC24A_SAR1B 0.679 TAF13 0.743 0.859 0.0440.013 KLRD1 0.687 CCR4 0.44 0.799 0.029 0.003 KLRD1 0.687 PYHIN1 0.5480.815 0.026 0.014 KLRD1 0.687 IGK@_IGKC_IGKV 0.664 0.818 0.018 0.037SLC39A9 0.731 ZNF28 0.837 0.903 0.039 0.027 GIMAP7 0.618 DNAJC9_FAM149B10.759 0.89 0.003 0.013 HLA-DRA 0.669 HSP90AB1_HSP90A 0.735 0.865 0.0060.047 DNAJC9_FAM149B1 0.759 HINT1 0.649 0.869 0.029 0.008DNAJC9_FAM149B1 0.759 CENPK 0.781 0.922 0.003 0.045 DNAJC9_FAM149B10.759 ITGA4_CERKL 0.659 0.887 0.007 0.009 DNAJC9_FAM149B1 0.759CTSL1_CTSLL3 0.697 0.856 0.03 0.028 NA 0.709 TRIM21 0.739 0.85 0.0320.04 NA 0.709 NA 0.838 0.917 0.01 0.04 MTRR 0.66 TAF13 0.743 0.876 0.0140.01 MTRR 0.66 FSD1L_GARNL1 0.665 0.859 0.014 0.007 MTRR 0.66 PLEKHF20.85 0.916 0.004 0.047 HIST1H3A 0.593 TYMS 0.761 0.899 0.001 0.015HIST1H3A 0.593 HIST1H2BM 0.693 0.875 0.001 0.011 HIST1H3A 0.593 HIST1H3B0.712 0.891 0.005 0.001 HIST1H3A 0.593 IGK@_IGKC_IGKV 0.664 0.777 0.040.046 TREML1 0.581 MYL9 0.472 0.717 0.028 0.006 TREML1 0.581 CMTMS 0.4940.679 0.039 0.03 PDE3B 0.622 EIF1AX_SCARNA9L 0.767 0.844 0.025 0.026PDE3B 0.622 TAF13 0.743 0.844 0.01 0.037 PDE3B 0.622 DLEU2_DLEU2L 0.7850.867 0.005 0.043 PDE3B 0.622 E2F6 0.8 0.856 0.025 0.037 PDE3B 0.622ATP5L_ATP5L2 0.797 0.878 0.006 0.033 PDE3B 0.622 CALM2_C2orf61 0.7760.905 0.001 0.024 CENPK 0.781 IRF4 0.759 0.95 0.003 0.02 AMFR 0.582 E2F60.8 0.857 0.003 0.042 HSP90AB1_HSP90A 0.735 RFESD_SPATA9 0.815 0.8870.026 0.041 HSP90AB1_HSP90A 0.735 SON 0.722 0.865 0.005 0.049EIF1AX_SCARNA9L 0.767 CEP97 0.702 0.91 0.005 0.007 SFRS9 0.841 PLEKHA30.875 0.974 0.018 0.014 DPH3 0.648 KIAA0746 0.727 0.852 0.01 0.04 NF-E40.78 E2F6 0.8 0.906 0.022 0.041 NPCDR1 0.752 KLHL5 0.739 0.861 0.0430.044 NPCDR1 0.752 SON 0.722 0.861 0.032 0.047 TAF13 0.743 CEP97 0.7020.852 0.041 0.049 KIAA0746 0.727 FSD1L_GARNL1 0.665 0.848 0.046 0.017ABCG1 0.669 RFESD_SPATA9 0.815 0.879 0.016 0.046 FAM118A 0.644 E2F6 0.80.876 0.017 0.02 E2F6 0.8 RASA4_RASA4P_R 0.645 0.861 0.031 0.023 S100B0.703 MPO 0.705 0.856 0.029 0.018 CEP97 0.702 CALM2_C2orf61 0.776 0.8950.003 0.043

TABLE 20 Ratios Mild ipSIRS Versus Shock ipSIRS Gene 1 Name Gene 1 AUCGene 2 Name Gene 2 AUC Ratio AUC Ratio Signif to Gene 1 Ratio Signif toGene 2 TLR5 0.769 NA 0.808 0.893 0.021 0.05 TLR5 0.769 DLEU2_DLEU2L0.782 0.874 0.03 0.029 TLR5 0.769 NA 0.838 0.908 0.022 0.012 TLR5 0.769ATP6V0D1_LOC100 0.701 0.859 0.018 0.017 VNN1 0.71 HIST1H4E 0.678 0.8260.01 0.017 VNN1 0.71 SLC11A1 0.556 0.768 0.047 0.023 VNN1 0.71 CENPK0.752 0.851 0.017 0.021 VNN1 0.71 ERGIC1 0.6 0.769 0.044 0.044 VNN1 0.71SON 0.632 0.781 0.044 0.047 VNN1 0.71 PLEKHF2 0.692 0.864 0.002 0.011VNN1 0.71 CALM2_C2orf61 0.687 0.848 0.003 0.016 UBE2J1 0.645 PLEKHF20.692 0.81 0.046 0.001 IMP3 0.742 GSR 0.723 0.864 0.027 0.013 IMP3 0.742SLC39A9 0.736 0.873 0.012 0.025 ARG1 0.683 HMGB2 0.556 0.749 0.034 0.002FAR2 0.746 VAMP2 0.834 0.923 0 0.046 FAR2 0.746 TRIM21 0.779 0.869 0.0350.023 FAR2 0.746 ZNF28 0.797 0.883 0.018 0.022 FAR2 0.746PPP1R2_PPP1R2P3 0.739 0.857 0.03 0.021 FAR2 0.746 ATP5L_ATP5L2 0.7860.904 0.007 0.006 GNLY 0.792 GSR 0.723 0.851 0.05 0.041 OMG 0.709C9orf72 0.573 0.784 0.028 0.022 OMG 0.709 JKAMP 0.554 0.793 0.023 0.007OMG 0.709 HIST1H4E 0.678 0.801 0.047 0.037 OMG 0.709 CDS2 0.562 0.7760.01 0.02 OMG 0.709 PLEKHF2 0.692 0.836 0.011 0.025 OMG 0.709 AIF1 0.7190.83 0.021 0.031 OMG 0.709 CALM2_C2orf61 0.687 0.824 0.014 0.037 SLC37A30.653 HIST1H4E 0.678 0.802 0.024 0.02 BMX_HNRPDL 0.749 PLEKHF2 0.6920.833 0.018 0.046 BMX_HNRPDL 0.749 CALM2_C2orf61 0.687 0.822 0.029 0.05STOM 0.684 VAMP2 0.834 0.923 0 0.022 STOM 0.684 MINPP1 0.78 0.848 0.0240.016 STOM 0.684 ATP5L_ATP5L2 0.786 0.865 0.005 0.034 TDRD9 0.735 AGTRAP0.569 0.768 0.046 0.044 FAIM3 0.749 SLC15A2 0.733 0.861 0.01 0.026 FAIM30.749 SRXN1 0.7 0.834 0.015 0.049 CLEC4E 0.681 HIST1H4E 0.678 0.8 0.0470.021 CLEC4E 0.681 ERGIC1 0.6 0.792 0.007 0.027 CLEC4E 0.681 PLEKHF20.692 0.819 0.011 0.038 CLEC4E 0.681 CALM2_C2orf61 0.687 0.823 0.0070.033 IL18R1 0.715 SLC11A1 0.556 0.763 0.025 0.034 IL18R1 0.715RRP12_LOC644215 0.569 0.76 0.014 0.035 TGFBR1 0.663 NA 0.838 0.909 0.0010.024 FKBP5_LOC285847 0.685 HIST1H4E 0.678 0.804 0.022 0.016FKBP5_LOC285847 0.685 PLEKHF2 0.692 0.823 0.008 0.024 FKBP5_LOC2858470.685 CALM2_C2orf61 0.687 0.815 0.012 0.029 PLB1 0.651 EFCAB2 0.7720.851 0.01 0.022 DSE 0.623 PLEKHF2 0.692 0.827 0.006 0.01 DSE 0.623ARL17P1_ARL17 0.745 0.805 0.024 0.041 CAMK4 0.726 HDHD1A 0.647 0.8040.048 0.035 DNAJC13 0.661 ARL17P1_ARL17 0.745 0.819 0.019 0.048 GSR0.723 MINPP1 0.78 0.845 0.034 0.026 GSR 0.723 TRIM21 0.779 0.866 0.0130.035 GSR 0.723 ZNF28 0.797 0.887 0.005 0.024 GSR 0.723 LY6G5B_CSNK2B0.737 0.897 0.003 0.003 GSR 0.723 ZNF587_ZNF417 0.842 0.927 0.001 0.025GSR 0.723 KDM6B_TMEM88 0.695 0.827 0.028 0.038 GSR 0.723 PLEKHF2 0.6920.833 0.049 0.002 GSR 0.723 ATP6V0D1_LOC100 0.701 0.85 0.002 0.042 GSR0.723 PPP1R2_PPP1R2P3 0.739 0.84 0.026 0.044 GSR 0.723 ATP5L_ATP5L20.786 0.878 0.004 0.035 SGMS2 0.752 ERGIC1 0.6 0.838 0.042 0.004 SGMS20.752 ATP5L_ATP5L2 0.786 0.878 0.005 0.046 B3GNT5_MCF2L2 0.692 EFCAB20.772 0.898 0.005 0.003 B3GNT5_MCF2L2 0.692 PLEKHF2 0.692 0.838 0.0080.038 B3GNT5_MCF2L2 0.692 CALM2_C2orf61 0.687 0.829 0.012 0.033 GK3P_GK0.729 DPH3 0.536 0.806 0.048 0.003 GK3P_GK 0.729 CALM2_C2orf61 0.6870.842 0.009 0.038 PICALM 0.749 GIMAP7 0.827 0.888 0.019 0.04 PICALM0.749 NA 0.808 0.887 0.012 0.035 PICALM 0.749 DLEU2_DLEU2L 0.782 0.9110.009 0.002 HIST1H4C 0.638 ANAPC11 0.58 0.744 0.031 0.03 SLC15A2 0.733ITK 0.736 0.856 0.049 0.004 SLC15A2 0.733 TRIM21 0.779 0.864 0.032 0.047SLC15A2 0.733 PPP1R2_PPP1R2P3 0.739 0.86 0.012 0.025 SLC15A2 0.733ATP5L_ATP5L2 0.786 0.873 0.014 0.029 VAMP2 0.834 CD63 0.722 0.945 0.0260 VAMP2 0.834 SLC39A9 0.736 0.931 0.025 0 VAMP2 0.834 AREG 0.668 0.9090.045 0 VAMP2 0.834 SFRS9 0.798 0.933 0.047 0.005 VAMP2 0.834 SRXN1 0.70.922 0.023 0 VAMP2 0.834 C4orf3 0.776 0.962 0.001 0.001 SMPDL3A 0.733EFCAB2 0.772 0.883 0.008 0.042 SMPDL3A 0.733 TAF13 0.585 0.834 0.040.003 SMPDL3A 0.733 SON 0.632 0.809 0.007 0.04 SMPDL3A 0.733TMEM62_SPCS2_L 0.629 0.81 0.035 0.024 SMPDL3A 0.733 PLEKHF2 0.692 0.8570.014 0.021 JKAMP 0.554 PTGER2 0.616 0.731 0.047 0.032 SLC1A3 0.807EFCAB2 0.772 0.902 0.046 0.008 SLC1A3 0.807 PPP1R2_PPP1R2P3 0.739 0.8690.04 0.026 TCN1 0.726 FGFBP2 0.696 0.809 0.04 0.049 TCN1 0.726PMS2CL_PMS2 0.581 0.79 0.024 0.006 TCN1 0.726 MYL9 0.6 0.777 0.05 0.033ODZ1 0.733 HIST1H4E 0.678 0.825 0.02 0.025 KPNA5 0.845 SLC39A9 0.7360.898 0.03 0.012 KPNA5 0.845 SFRS9 0.798 0.917 0.003 0.044 KPNA5 0.845C4orf3 0.776 0.947 0.006 0.002 CD63 0.722 AGTRAP 0.569 0.82 0.025 0.004CD63 0.722 TRIM21 0.779 0.863 0.022 0.044 CD63 0.722 ZNF28 0.797 0.8730.007 0.034 CD63 0.722 LY6G5B_CSNK2B 0.737 0.856 0.015 0.048 CD63 0.722NA 0.838 0.917 0.002 0.029 CD63 0.722 KDM6B_TMEM88 0.695 0.851 0.010.014 DDAH2 0.681 HIST1H4E 0.678 0.832 0.016 0.012 DDAH2 0.681 EFCAB20.772 0.851 0.028 0.017 DDAH2 0.681 AGTRAP 0.569 0.793 0.008 0.023 DDAH20.681 KDM6B_TMEM88 0.695 0.833 0.003 0.05 DDAH2 0.681 PLEKHF2 0.6920.837 0.018 0.01 DDAH2 0.681 AIF1 0.719 0.822 0.021 0.044 ATP13A3 0.664PLEKHF2 0.692 0.833 0.004 0.021 ITK 0.736 HDHD1A 0.647 0.812 0.037 0.022ITK 0.736 TSHZ2 0.529 0.842 0.037 0 HIST1H4E 0.678 PPP2R5A_SNORA16 0.6730.811 0.017 0.036 HIST1H4E 0.678 FOLR3_FOLR2 0.691 0.806 0.044 0.013HIST1H4E 0.678 LGALS1 0.643 0.816 0.005 0.03 HIST1H4E 0.678 MTHFS 0.6490.788 0.036 0.043 HIST1H4E 0.678 AP3B2 0.722 0.822 0.027 0.026 HIST1H4E0.678 GSTO1 0.604 0.811 0.043 0.003 HIST1H4E 0.678 REIN 0.756 0.8570.008 0.046 HIST1H4E 0.678 CD151 0.582 0.786 0.047 0.004 HIST1H4E 0.678C4orf3 0.776 0.905 0 0.048 HIST1H4E 0.678 CDC26 0.519 0.792 0.018 0.001FGFBP2 0.696 MKI67 0.667 0.793 0.032 0.045 ECHDC3 0.702 PLEKHF2 0.6920.818 0.046 0.025 ECHDC3 0.702 CALM2_C2orf61 0.687 0.834 0.023 0.017HSPC159 0.612 MINPP1 0.78 0.842 0.002 0.026 OLAH 0.723 DPH3 0.536 0.7670.046 0.015 PPP2R5A_SNORA16 0.673 CENPK 0.752 0.851 0.025 0.004PPP2R5A_SNORA16 0.673 MINPP1 0.78 0.846 0.014 0.03 PPP2R5A_SNORA16 0.673PLEKHF2 0.692 0.849 0.012 0.003 PPP2R5A_SNORA16 0.673 CALM2_C2orf610.687 0.845 0.011 0.005 SEC24A_SAR1B 0.716 PLEKHF2 0.692 0.834 0.040.006 SLC39A9 0.736 NA 0.808 0.882 0.019 0.044 SLC39A9 0.736 ZNF28 0.7970.896 0.019 0.003 SLC39A9 0.736 NA 0.838 0.91 0.006 0.016 SLC39A9 0.736ZNF587_ZNF417 0.842 0.933 0.003 0.01 SLC39A9 0.736 ATP6V0D1_LOC100 0.7010.846 0.017 0.031 SLC39A9 0.736 ATP5L_ATP5L2 0.786 0.882 0.03 0.006EXOSC4 0.723 EFCAB2 0.772 0.856 0.043 0.04 EXOSC4 0.723 AGTRAP 0.5690.791 0.035 0.023 EXOSC4 0.723 PLEKHF2 0.692 0.849 0.03 0.008 NA 0.808C4orf3 0.776 0.899 0.026 0.029 HIST1H4L 0.596 CD24 0.721 0.807 0.010.032 LGALS1 0.643 CENPK 0.752 0.811 0.044 0.032 LGALS1 0.643 ZNF280.797 0.875 0.002 0.022 LGALS1 0.643 AIF1 0.719 0.844 0.012 0.002 PPIF0.704 SRXN1 0.7 0.813 0.033 0.048 MTHFS 0.649 EFCAB2 0.772 0.825 0.0340.047 MTHFS 0.649 PLEKHF2 0.692 0.813 0.026 0.025 MTHFS 0.649CALM2_C2orf61 0.687 0.816 0.015 0.017 LCN2 0.679 PMS2CL_PMS2 0.581 0.7450.032 0.047 AP3B2 0.722 AGTRAP 0.569 0.788 0.035 0.019 AP3B2 0.722RRP12_LOC644215 0.569 0.781 0.047 0.023 AP3B2 0.722 AIF1 0.719 0.8430.013 0.04 EFCAB2 0.772 REIN 0.756 0.867 0.029 0.044 EFCAB2 0.772 GALNT20.674 0.848 0.023 0.017 HIST1H2AA 0.769 DLEU2_DLEU2L 0.782 0.908 0.0130.002 HIST1H3A 0.642 CD24 0.721 0.82 0.028 0.01 C22orf37 0.725 C4orf30.776 0.864 0.027 0.042 SLC39A8 0.646 PLEKHF2 0.692 0.832 0.005 0.022SLC39A8 0.646 CALM2_C2orf61 0.687 0.794 0.019 0.047 AREG 0.668 CENPK0.752 0.815 0.05 0.042 PTGER2 0.616 PLEKHF2 0.692 0.808 0.005 0.044PMS2CL_PMS2 0.581 FSD1L_GARNL1 0.595 0.728 0.048 0.025 RETN 0.756KDM6B_TMEM88 0.695 0.852 0.026 0.022 RETN 0.756 AIF1 0.719 0.856 0.0260.019 PDE3B 0.582 CENPK 0.752 0.82 0.006 0.025 PDE3B 0.582 CALM2_C2orf610.687 0.81 0.003 0.041 CENPK 0.752 HDHD1A 0.647 0.816 0.037 0.036 CD240.721 HIST1H3C 0.558 0.82 0.036 0.001 CD24 0.721 MYL9 0.6 0.777 0.050.042 HDHD1A 0.647 MGST3 0.647 0.802 0.016 0.023 LRRFIP1 0.744ZNF587_ZNF417 0.842 0.926 0.002 0.049 LRRFIP1 0.744 PPP1R2_PPP1R2P30.739 0.869 0.015 0.022 LRRFIP1 0.744 CALM2_C2orf61 0.687 0.881 0.0110.001 SFRS9 0.798 NA 0.838 0.92 0.028 0.007 SFRS9 0.798 ZNF587_ZNF4170.842 0.93 0.034 0.009 SFRS9 0.798 PLEKHA3 0.794 0.896 0.047 0.03 MINPP10.78 C4orf3 0.776 0.914 0.001 0.033 ZNF28 0.797 C4orf3 0.776 0.915 0.0050.011 TAF13 0.585 FSD1L_GARNL1 0.595 0.776 0.016 0.012 THBS1 0.619 POLE20.708 0.773 0.026 0.039 HIST1H3B 0.488 HIST1H3C 0.558 0.732 0.008 0.015ZRANB1 0.521 RFESD_SPATA9 0.697 0.761 0.003 0.043 FSD1L_GARNL1 0.595RFESD_SPATA9 0.697 0.793 0.011 0.047 NA 0.838 C4orf3 0.776 0.915 0.0120.013 UBE2F_C20orf194 0.622 POLE2 0.708 0.804 0.039 0.009 ZNF587_ZNF4170.842 C4orf3 0.776 0.916 0.038 0.018 C4orf3 0.776 PLEKHA3 0.794 0.9240.003 0.009 C4orf3 0.776 PLEKHF2 0.692 0.911 0.029 0 C4orf3 0.776ATP6V0D1_LOC100 0.701 0.854 0.049 0.032 C4orf3 0.776 ATP5L_ATP5L2 0.7860.905 0.019 0.004

TABLE 21 Ratios Severe ipSIRS Versus Shock ipSIRS Gene 1 Name Gene 1 AUCGene 2 Name Gene 2 AUC Ratio AUC Ratio Signif to Gene 1 Ratio Signif toGene 2 ACER3 0.724 GSR 0.554 0.804 0.014 0.027 ACER3 0.724 MTRR 0.5520.842 0.017 0.001 CAMK4 0.777 PTGER2 0.653 0.841 0.036 0.014 GSR 0.554SH3PXD2B 0.676 0.77 0.013 0.032 PICALM 0.612 SYNE2 0.678 0.799 0.0290.05 SLC15A2 0.619 CCR4 0.693 0.797 0.041 0.038 TMEM144_LOC2855 0.578PLIN2 0.434 0.652 0.028 0.048 MKI67 0.671 RETN 0.664 0.82 0.022 0.047MME 0.671 CFD 0.554 0.767 0.022 0.036

Throughout this specification and claims which follow, unless thecontext requires otherwise, the word “comprise”, and variations such as“comprises” or “comprising”, will be understood to imply the inclusionof a stated integer or group of integers or steps but not the exclusionof any other integer or group of integers.

Persons skilled in the art will appreciate that numerous variations andmodifications will become apparent. All such variations andmodifications, which become apparent to persons skilled in the art,should be considered to fall within the spirit and scope that theinvention broadly appearing before described.

The claims defining the invention are as follows: 1) Apparatus foridentifying biomarkers, the apparatus including an electronic processingdevice that: a) uses reference data from a plurality of individuals todefine a number of groups of individuals, the reference data includingmeasurements of the activity of a plurality of reference biomarkers; b)uses a plurality of analysis techniques to identify a number ofpotential biomarkers from the plurality of reference biomarkers that arepotentially useful for distinguishing the groups of individuals,allowing the potential biomarkers to be used in generating signaturesfor use in clinical assessments. 2) Apparatus according to claim 1,wherein the electronic processing device, for each analysis technique:a) using the analysis technique, identifies a number of referencebiomarkers that best distinguish the groups of individuals; b)determines if the predictive performance of the identified referencebiomarkers exceeds a predetermined threshold; and, c) in response to asuccessful determination, determines the identified reference biomarkersto be potential biomarkers. 3) Apparatus according to claim 2, whereinthe number of reference biomarkers is at least one of: a) less than 10;b) more than 1; c) between 2 and 8; and, d)
 5. 4) Apparatus according toclaim 2 or claim 3, wherein the predetermined threshold is at least oneof: a) at least 90%; b) at least 85%; and, c) at least 80%. 5) Apparatusaccording to any one of the claims 1 to 4, wherein the electronicprocessing device: a) adds potential biomarkers to a potential biomarkercollection; and, b) removes the potential biomarkers from a referencebiomarker collection. 6) Apparatus according to any one of the claims 1to 5, wherein for each of a plurality of analysis techniques theelectronic processing device repeatedly identifies reference biomarkersas potential biomarkers until the predictive performance of theidentified reference biomarkers falls below the predetermined threshold.7) Apparatus according to any of the claims 1 to 6, wherein theelectronic processing device iteratively identifies potentialbiomarkers. 8) Apparatus according to any one of the claims 1 to 7,wherein the electronic processing device uses a number of iterationsincluding at least one of: a) at least 100; b) at least 500; c) at least1000; d) at least 2000; and, e) at least
 5000. 9) Apparatus according toany one of the claims 1 to 8, wherein the electronic processing devicerepeatedly determines potential biomarkers until a predetermined numberof potential biomarkers are identified. 10) Apparatus according to claim9, wherein the predetermined number of potential biomarkers includes atleast one of: a) at least 100; b) less than 500; c) about
 200. 11)Apparatus according to any one of the claims 1 to 10, wherein theanalysis techniques include at least one of: a) regression techniques;b) correlation analysis; and, c) a combination of regression andcorrelation techniques. 12) Apparatus according to any one of the claims1 to 12, wherein the analysis techniques include: a) sparse PLS; b)random forest; and, c) support vector machines. 13) Apparatus accordingto any one of the claims 1 to 12, wherein the electronic processingdevice: a) removes a validation subgroup from the reference data priorto determining the potential biomarkers; b) determines the potentialbiomarkers using the reference data without the validation subgroup;and, c) uses the validation subgroup to validate at least one of: i) thepotential biomarkers; and, ii) signatures including a number of thepotential biomarkers. 14) Apparatus according to any one of the claims 1to 13, wherein the processing system determines the number of groups byclassifying the individuals using at least one of: a) an indication of apresence, absence, degree, stage or progression of a condition; b)phenotypic traits associated with the individuals; c) geneticinformation associated with the individuals; d) biomarkers associatedwith the individuals. 15) Apparatus according to any one of the claims 1to 14, wherein the processing system determines groups at least in partusing input commands from a user. 16) Apparatus according to any one ofthe claims 1 to 15, wherein the reference data includes time series dataindicative of the progression of a condition. 17) Apparatus according toclaim 16, wherein the time series data is indicative of whether acondition that is at least one of: a) improving; b) worsening; and, c)static. 18) Apparatus according to any one of the claims 1 to 17,wherein the reference data includes for each of the individuals anindication of at least one of: a) an activity of each of the referencebiomarkers; b) a degree of a condition; c) a stage of a condition d) apresence of a condition; e) an absence of a condition; f) an indicationof a condition progression; g) phenotypic information; h) geneticinformation; and, i) a SOFA score. 19) Apparatus according to any one ofthe claims 1 to 18, wherein the electronic processing device identifiesa number of potential biomarkers for use as signature biomarkers, thesignature biomarkers being used in generating the signatures. 20)Apparatus according to claim 19, wherein the electronic processingdevice: a) determines a clinical assessment; and, b) identifies thesignature biomarkers for the clinical assessment. 21) Apparatusaccording to any one of the claims 1 to 20, wherein the electronicprocessing device: a) determines second groups of individuals relevantto the clinical assessment; b) using a second analysis technique,identifies a number of the potential biomarkers that best distinguishthe second groups of individuals; c) determines if the predictiveperformance of the identified potential biomarkers exceeds apredetermined threshold; and, d) in response to a successfuldetermination, determines the identified potential biomarkers to besignature biomarkers. 22) Apparatus according to claim 21, wherein theelectronic processing device, in response to an unsuccessfuldetermination: a) modifies parameters of the second analysis technique;and, b) uses the second analysis technique to identify alternativepotential biomarkers. 23) Apparatus according to claim 21 or claim 22,wherein the electronic processing device: a) determines if theidentified potential biomarkers are to be excluded; and, b) in responseto a successful determination: i) removes the potential biomarkers froma potential biomarker database; and, ii) uses the second analysistechnique to identify alternative potential biomarkers for use assignature biomarkers. 24) Apparatus according to any one of the claims21 to 23, wherein the second analysis technique includes at least oneof: a) ordinal regression and, b) support vector machines. 25) Apparatusaccording to any one of the claims 1 to 24, wherein the signatures areindicative of: a) activities of each of a number of signaturebiomarkers; and, b) at least one of: i) a SOFA score; and, ii) apresence, absence, degree, stage or progression of a condition. 26)Apparatus according to any one of the claims 1 to 25, wherein thesignatures are indicative of a presence, absence, degree, stage orprogression of at least one of: a) infection-negative SIRS; and, b)infection-positive SIRS. 27) Apparatus according to any one of theclaims 1 to 26, wherein activities of at least some of the potentialbiomarkers are indicative of at least one of: a) a presence, absence,degree, stage or progression of SIRS; b) a healthy diagnosis; c) apresence, absence, degree, stage, or progression of infection positiveSIRS; and, d) a presence, absence, degree, stage or progression ofinfection negative SIRS. 28) Apparatus according to any one of theclaims 1 to 27, wherein an activity of biomarkers are indicative of alevel or abundance of a molecule selected from one or more of: a) Anucleic acid molecule; b) A proteinaceous molecule; c) An amino acid d)A carbohydrate; e) A lipid; f) A steroid; g) An inorganic molecule; h)An ion; i) A drug; j) A chemical; k) A metabolite; l) A toxin; m) Anutrient; n) A gas; o) A cell; p) A pathogenic organism; and, q) Anon-pathogenic organism. 29) A method for determining the likelihood ofthe presence or absence of a condition selected from a healthy condition(e.g., a normal condition or one in which inSIRS and inSIRS are absent),SIRS generally (i.e., not distinguishing between inSIRS or ipSIRS),inSIRS or ipSIRS, or to assess the likelihood of the presence, absenceor risk of development of a stage of ipSIRS (e.g., a stage of ipSIRSwith a particular severity), the method comprising: (1) correlating areference IRS biomarker profile with the presence or absence, or degreeof a condition selected from a healthy condition, SIRS, inSIRS, ipSIRS,or a particular stage of ipSIRS, wherein the reference IRS biomarkerprofile evaluates at least one IRS biomarker; (2) obtaining an IRSbiomarker profile of a sample from a subject, wherein the sample IRSbiomarker profile evaluates for an individual IRS biomarker in thereference IRS biomarker profile a corresponding IRS biomarker; and (3)determining a likelihood of the subject having or not having thecondition based on the sample IRS biomarker profile and the referenceIRS biomarker profile, wherein an individual IRS biomarker is anexpression product of an IRS biomarker gene selected from the groupconsisting of: TLR5; CD177; VNN1; UBE2J1; IMP3; RNASE2//LOC643332;CLEC4D; C3AR1; GPR56; ARG1; FCGR1A//FCGR1B//FCGR1C; C11orf82; FAR2;GNLY; GALNT3; OMG; SLC37A3; BMX//HNRPDL; STOM; TDRD9; KREMEN1; FAIM3;CLEC4E; IL18R1; ACER3; ERLIN1; TGFBR1; FKBP5//LOC285847; GPR84; C7orf53;PLB1; DSE; PTGDR; CAMK4; DNAJC13; TNFAIP6;FOXD4L3//FOXD4L6//FOXD4//FOXD4L1//FOXD4L2//FOXD4L4//FOXD4L5;MMP9//LOC100128028; GSR; KLRF1; SH2D1B; ANKRD34B; SGMS2; B3GNT5//MCF2L2;GK3P//GK; PFKFB2; PICALM; METTL7B; HIST1H4C; C9orf72; HIST1H3I; SLC15A2;TLR10; ADM; CD274; CRIP1; LRRN3; HLA-DPB1; VAMP2; SMPDL3A; IF116; JKAMP;MRPL41; SLC1A3; OLFM4; CASS4; TCN1; WSB2; CLU; ODZ1; KPNA5; PLAC8; CD63;HPSE; C1orf161; DDAH2; KLRK1//KLRC4; ATP13A3; ITK; PMAIP1; LOC284757;GOT2; PDGFC; B3GAT3; HIST1H4E; HPGD; FGFBP2; LRRC70//IPO11;TMEM144//LOC285505; CDS2; BPI; ECHDC3; CCR3; HSPC159; OLAH;PPP2R5A//SNORA16B; TMTC1; EAF2//HCG11//LOC647979; RCBTB2//LOC100131993;SEC24A//SAR1B; SH3PXD2B; HMGB2; KLRD1; CHI3L1; FRMD3; SLC39A9; GIMAP7;ANAPC11; EXOSC4; gene for IL-1beta-regulated neutrophil survival proteinas set forth in GenBank Accession No. AF234262; INSIG1; FOLR3//FOLR2;RUNX2; PRR13//PCBP2; HIST1H4L; LGALS1; CCR1; TPST1; HLA-DRA; CD163;FFAR2; PHOSPHO1; PPIF; MTHFS; DNAJC9//FAM149B1//RPL26; LCN2; EIF2AK2;LGALS2; SIAE; AP3B2; ABCA13; gene for transcript set forth in GenBankAccession No. AK098012; EFCAB2; HIST1H2AA; HINT1; HIST1H3J; CDA; SAP30;AGTRAP; SUCNR1; MTRR; PLA2G7; AIG1; PCOLCE2; GAB2; HS2ST1//UBA2;HIST1H3A; C22orf37; HLA-DPA1; VOPP1//LOC100128019; SLC39A8; MKI67;SLC11A1; AREG; ABCA1; DAAM2//LOC100131657; LTF; TREML1; GSTO1; PTGER2;CEACAM8; CLEC4A; PMS2CL//PMS2; RETN; PDE3B; SULF2; NEK6//LOC100129034;CENPK; TRAF3; GPR65; IRF4; MACF1; AMFR; RPL17//SNORD58B; IRS2; JUP;CD24; GALNT2; HSP90AB1//HSP90AB3P//HSP90AB2P; GLT25D1; OR9A2; HDHD1A;ACTA2; ACPL2; LRRFIP1; KCNMA1; OCR1; ITGA4//CERKL;EIF1AX//SCARNA9L//EIF1AP1; SFRS9; DPH3; ERGIC1; CD300A; NF-E4; MINPP1;TRIM21; ZNF28; NPCDR1; gene for protein FLJ21394 as set forth in GenBankAccession No. BC013935; gene for transcript set forth in GenBankAccession No. AK000992; ICAM1; TAF13; P4HA1//RPL17; C15orf54; KLHL5;HAL; DLEU2//DLEU2L; ANKRD28; LY6G5B//CSNK2B;KIAA1257//ACAD9//LOC100132731; MGST3; KIAA0746; HSPB1//HSPBL2; CCR4;TYMS; RRP12//LOC644215; CCDC125; HIST1H2BM; PDK4; ABCG1; IL1B; THBS1;ITGA2B; LHFP; LAIR1//LAIR2; HIST1H3B; ZRANB1; TIMM10; FSD1L//GARNL1;HIST1H2AJ//HIST1H2AI; PTGS1; gene for transcript set forth in GenBankAccession No. BC008667; UBE2F//C20orf194//SCLY; HIST1H3C; FAM118A;CCRL2; E2F6; MPZL3; SRXN1; CD151; HIST1H3H; FSD1L; RFESD//SPATA9; TPX2;S100B; ZNF587//ZNF417; PYHIN1; KIAA1324; CEACAM6//CEACAM5; APOLD1;FABP2; KDM6B//TMEM88;IGK@//IGKC//IGKV1-5//IGKV3D-11//IGKV3-20//IGKV3D-15//LOC440871//LOC652493//LOC100291464//LOC652694//IGKV3-15//LOC650405//LOC100291682;MYL9; HIST1H2BJ; TAAR1; CLC; CYP4F3//CYP4F2; CEP97; SON; IRF1; SYNE2;MME; LASS4; DEFA4//DEFA8P; C7orf58; DYNLL1; gene for transcript setforth in GenBank Accession No. AY461701; MPO; CPM; TSHZ2; PLIN2;FAM118B; B4GALT3; RASA4//RASA4P//RASA4B//POLR2J4//LOC100132214;CTSL1//CTSLL3; NP; ATF7; SPARC; PLB1; C4orf3; POLE2; TNFRSF17; FBXL13;PLEKHA3; TMEM62//SPCS2//LOC653566; RBP7; PLEKHF2; RGS2;ATP6V0D1//LOC100132855; RPIA; CAMK1D; IL1RL1; CMTM5; AIF1; CFD; MPZL2;LOC100128751; IGJ; CDC26; PPP1R2//PPP1R2P3; IL5RA; ARL17P1//ARL17;ATP5L//ATP5L2; TAS2R31; HIST2H2BF//HIST2H3D; CALM2//C2orf61; SPATA6;IGLV6-57; C1orf128; KRTAP15-1; IF144;IGL@//IGLV1-44//LOC96610//IGLV2-23//IGLC1//IGLV2-18//IGLV5-45//IGLV3-25//IGLV3-12//IGLV1-36//IGLV3-27//IGLV7-46//IGLV4-3//IGLV3-16//IGLV3-19//IGLV7-43//IGLV3-22//IGLV5-37//IGLV10-54//IGLV8-61//LOC651536;gene for transcript set forth in GenBank Accession No. BC034024; SDHC;NFXL1; GLDC; DCTN5; and KIAA0101//CSNK1G1 30) A method according toclaim 29, wherein the method determines the likelihood that SIRS or ahealthy condition is present or absent in the subject, and wherein themethod comprises: 1) providing a correlation of a reference IRSbiomarker profile with the presence or absence of SIRS or the healthycondition, wherein the reference biomarker profile evaluates at leastone IRS biomarker selected from CD177, CLEC4D, BMX, VNN1, GPR84, ARG1,IL18R1, ERLIN1, IMP3, TLR5, UBE2J1, GPR56, FCGR1A, SLC1A3, SLC37A3,FAIM3, C3AR1, RNASE2, TNFAIP6, GNLY, OMG, FAR2, OLAH, CAMK4, METTL7B,B3GNT5, CLEC4E, MMP9, KREMEN1, GALNT3, PTGDR, TDRD9, GK3P, FKBP5, STOM,SMPDL3A, PFKFB2, ANKRD34B, SGMS2, DNAJC13, LRRN3, SH2D1B, C1orf161,HIST1H4C, IFI16, ACER3, PLB1, C9orf72, HMGB2, KLRK1, C7orf53, GOT2,TCN1, DSE, CCR3, CRIP1, ITK, KLRF1, TGFBR1, GSR, HIST1H4E, HPGD, FRMD3,ABCA13, C11orf82, PPP2R5A, BPI, CASS4, AP3B2, ODZ1, TMTC1, ADM, FGFBP2,HSPC159, HLA-DRA, HIST1H3I, TMEM144, MRPL41, FOLR3, PICALM, SH3PXD2B,DDAH2, HLA-DPB1, KPNA5, PHOSPHO1, TPST1, EIF2AK2, OR9A2, OLFM4, CD163,CDA, CHI3L1, MTHFS, CLU, ANAPC11, JUP, PMAIP1, GIMAP7, KLRD1, CCR1,CD274, EFCAB2, SUCNR1, KCNMA1, LGALS2, SLC11A1, FOXD4L3, VAMP2, ITGA4,LHFP, PRR13, FFAR2, B3GAT3, EAF2, HPSE, CLC, TLR10, CCR4, HIST1H3A,CENPK, DPH3, HLA-DPA1, ATP13A3, DNAJC9, S100B, HIST1H3J, 110, RPL17,C15orf54, LRRC70, IL5RA, PLA2G7, ECHDC3, HINT1, LCN2, PPIF, SLC15A2,PMS2CL, HIST1H2AA, CEACAM8, HSP90AB1, ABCG1, PDGFC, NPCDR1, PDK4, GAB2,WSB2, FAM118A, JKAMP, TREML1, PYHIN1, IRF4, ABCA1, DAAM2, ACPL2, RCBTB2,SAP30, THBS1, PCOLCE2, GPR65, NF-E4, LTF, LASS4, B4GALT3, RETN, TIMM10,IL1B, CLEC4A, SEC24A, RUNX2, LRRFIP1, CFD, EIF1AX, ZRANB1, SULF2,EXOSC4, CCDC125, LOC284757, ANKRD28, HIST1H2AJ, CD63, PLIN2, SON,HIST1H4L, KRTAP15-1, DLEU2, MYL9, FABP2, CD24, MACF1, GSTO1, RRP12,AIG1, RASA4, FBXL13, PDE3B, CCRL2, C1orf128, E2F6, IL1RL1, CEACAM6,CYP4F3, 199, TAAR1, TSHZ2, PLB1, UBE2F; (2) obtaining a sample IRSbiomarker profile from the subject, which evaluates for an individualIRS biomarker in the reference IRS biomarker profile a corresponding IRSbiomarker, and (3) determining a likelihood of the subject having or nothaving the healthy condition or SIRS based on the sample IRS biomarkerprofile and the reference IRS biomarker profile. 31) A method accordingto claim 29, wherein the method determines the likelihood that inSIRS,ipSIRS or a healthy condition is present or absent in the subject, andwherein the method comprises: 1) providing a correlation of a referenceIRS biomarker profile with the likelihood of having or not havinginSIRS, ipSIRS or the healthy condition, wherein the reference biomarkerprofile evaluates at least one IRS biomarker selected from PLAC8, 132,INSIG1, CDS2, VOPP1, SLC39A9, B3GAT3, CD300A, OCR1, PTGER2, LGALS1,HIST1H4L, AMFR, SIAE, SLC39A8, TGFBR1, GAB2, MRPL41, TYMS, HIST1H3B,MPZL3, KIAA1257, OMG, HIST1H2BM, TDRD9, C22orf37, GALNT3, SYNE2, MGST3,HIST1H3I, LOC284757, TRAF3, HIST1H3C, STOM, C3AR1, KIAA0101, TNFRSF17,HAL, UBE2J1, GLT25D1, CD151, HSPB1, IMP3, PICALM, ACER3, IGL@,HIST1H2BJ, CASS4, KREMEN1, IRS2, APOLD1, RBP7, DNAJC13, ERGIC1, FSD1L,TLR5, TMEM62, SDHC, C9orf72, NP, KIAA0746, PMAIP1, DSE, SMPDL3A, DNAJC9,HIST1H3H, CDC26, CRIP1, FAR2, FRMD3, RGS2, METTL7B, CLEC4E, MME, ABCA13,PRR13, HIST1H4C, RRP12, GLDC, ECHDC3, IRF1, C7orf53, IGK@, RNASE2,FCGR1A, SAP30, PMS2CL, SLC11A1, AREG, PLB1, PPIF, GSR, NFXL1, AP3B2,DCTN5, RPL17, IGLV6-57, KLRF1, CHI3L1, ANKRD34B, OLFM4, CPM, CCDC125,GPR56, PPP1R2, 110, ACPL2, HIST1H3A, C7orf58, IRF4, ANAPC11, HIST1H33,KLRD1, GPR84, ZRANB1, KDM6B, TPST1, HINT1, DAAM2, PTGDR, FKBP5,HSP90AB1, HPGD, IFI16, CD177, TAS2R31, CD163, B4GALT3, EIF1AX, CYP4F3,HIST1H2AA, LASS4 (where if a gene name is not provided then a SEQ ID NO.is provided); (2) obtaining a sample IRS biomarker profile from thesubject, which evaluates for an individual IRS biomarker in thereference IRS biomarker profile a corresponding IRS biomarker; and (3)determining a likelihood of the subject having or not having inSIRS,ipSIRS or a healthy condition the condition based on the sample IRSbiomarker profile and the reference IRS biomarker profile. 32) A methodaccording to claim 29, wherein the method determines the likelihood thatinSIRS or ipSIRS is present or absent in the subject, and wherein themethod comprises: 1) providing a correlation of a reference IRSbiomarker profile with the likelihood of having or not having inSIRS oripSIRS, wherein the reference biomarker profile evaluates at least oneIRS biomarker selected from C11orf82, PLACE, 132, INSIG1, CDS2, VOPP1,SLC39A9, FOXD4L3, WSB2, CD63, CD274, B3GAT3, CD300A, OCR1, JKAMP, TLR10,PTGER2, PDGFC, LGALS1, HIST1H4L, AGTRAP, AMFR, SIAE, 200, SLC15A2,SLC39A8, TGFBR1, DDAH2, HPSE, SUCNR1, MTRR, GAB2, P4HA1, HS2ST1, MRPL41,TYMS, RUNX2, GSTO1, LRRC70, HIST1H3B, RCBTB2, MPZL3, KIAA1257, AIG1,NEK6, OMG, HIST1H2BM, TDRD9, GALNT3, ATP13A3, C22orf37, SYNE2, ADM,MGST3, PDE3B, HIST1H3I, LOC284757, TRAF3, HIST1H3C, STOM, KLHL5, EXOSC4,C3AR1, KIAA0101, TNFRSF17, HAL, UBE2J1, GLT25D1, CD151, TPX2, PCOLCE2,HSPB1, EAF2, IMP3, PICALM, ACER3, IGL@, HIST1H2BJ, CASS4, ACTA2, PTGS1,KREMEN1, IRS2, TAF13, FSD1L, APOLD1, RBP7, DNAJC13, SEC24A, ERGIC1,FSD1L, TLR5, MKI67, TMEM62, CLEC4A, SDHC, C9orf72, NP, CLU, ABCA1,KIAA0746, PMAIP1, DSE, CMTM5, SMPDL3A, DNAJC9, HDHD1A, HIST1H3H, CDC26,ICAM1, LOC100128751, FAR2, CRIP1, MPZL2, FRMD3, CTSL1, METTL7B, RGS2,CLEC4E, MME, ABCA13, PRR13, HIST1H4C, RRP12, GLDC, ECHDC3, ITGA2B,C7orf53, IRF1, 268, IGK@, RNASE2, FCGR1A, UBE2F, SAP30, LAIR1, PMS2CL,SLC11A1, PLB1, AREG, PPIF, GSR, NFXL1, AP3B2, DCTN5, RPL17, PLA2G7,GALNT2, IGLV6-57, KLRF1, CHI3L1, ANKRD34B, OLFM4, 199, CPM, CCDC125,SULF2, LTF, GPR56, MACF1, PPP1R2, DYNLL1, LCN2, FFAR2, SFRS9, IGJ,FAM118B, 110, ACPL2, HIST1H3A, C7orf58, ANAPC11, HIST1H3J, IRF4, MPO,TREML1, KLRD1, GPR84, CCRL2, CAMK1D, CCR1, ZRANB1, KDM6B, TPST1, HINT1,DAAM2, PTGDR, FKBP5, CD24, HSP90AB1, HPGD, CEACAM8, DEFA4, IL1B, IFI16,CD177, KIAA1324, SRXN1, TAS2R31, CEACAM6, CD163, B4GALT3, ANKRD28,TAAR1, EIF1AX, CYP4F3, 314, HIST1H2AA, LY6G5B, LASS4 (where if a genename is not provided then a SEQ ID NO. is provided); (2) obtaining asample IRS biomarker profile from the subject, which evaluates for anindividual IRS biomarker in the reference IRS biomarker profile acorresponding IRS biomarker; and (3) determining a likelihood of thesubject having or not having inSIRS or ipSIRS based on the sample IRSbiomarker profile and the reference IRS biomarker profile. 33) A methodaccording to claim 29, wherein the method determines the likelihood thata stage of ipSIRS selected from mild sepsis, severe sepsis and septicshock is present or absent the subject, and wherein the methodcomprises: 1) providing a correlation of a reference IRS biomarkerprofile with the likelihood of having or not having the stage of ipSIRS,wherein the reference biomarker IRS biomarker profile evaluates at leastone IRS biomarker selected from PLEKHA3, PLEKHF2, 232, SFRS9, ZNF587,KPNA5, LOC284757, GPR65, VAMP2, SLC1A3, ITK, ATF7, ZNF28, AIF1, MINPP1,GIMAP7, MKI67, IRF4, TSHZ2, HLA-DPB1, EFCAB2, POLE2, FAIM3, 110, CAMK4,TRIM21, IF144, CENPK, ATP5L, GPR56, HLA-DPA1, C4orf3, GSR, GNLY, RFESD,BPI, HIST1H2AA, NF-E4, CALM2, EIF1AX, E2F6, ARL17P1, TLR5, SH3PXD2B,FAM118A, RETN, PMAIP1, DNAJC9, PCOLCE2, TPX2, BMX, LRRFIP1, DLEU2,JKAMP, JUP, ABCG1, SLC39A9, B3GNT5, ACER3, LRRC70, NPCDR1, TYMS,HLA-DRA, TDRD9, FSD1L, FAR2, C7orf53, PPP1R2, SGMS2, EXOSC4, TGFBR1,CD24, TCN1, TAF13, AP3B2, CD63, SLC15A2, IL18R1, ATP6V0D1, SON,HSP90AB1, CEACAM8, SMPDL3A, IMP3, SEC24A, PICALM, 199, CEACAM6, CYP4F3,OLAH, ECHDC3, ODZ1, KIAA0746, KIAA1324, HINT1, VNN1, C22orf37, FSD1L,FOLR3, IL1RL1, OMG, MTHFS, OLFM4, S100B, ITGA4, KLRD1, SLC39A8, KLHL5,KLRK1, MPO, PPIF, GOT2, LRRN3, HIST1H2AJ, CLU, LCN2, 132, CEP97, KLRF1,FBXL13, HIST1H3B, ANKRD34B, RPIA, HPGD, HIST2H2BF, GK3P (where if a genename is not provided then a SEQ ID NO. is provided); (2) obtaining asample IRS biomarker profile from the subject, which evaluates for anindividual IRS biomarker in the reference IRS biomarker profile acorresponding IRS biomarker; and (3) determining a likelihood of thesubject having or not having the stage of ipSIRS based on the sample IRSbiomarker profile and the reference IRS biomarker profile. 34) A methodaccording to any one of claims 29 to 33, wherein an individual IRSbiomarker is selected from the group consisting of: (a) a polynucleotideexpression product comprising a nucleotide sequence that shares at least70% (or at least 71% to at least 99% and all integer percentages inbetween) sequence identity with the sequence set forth in any one of SEQID NO: 1-319, or a complement thereof; (b) a polynucleotide expressionproduct comprising a nucleotide sequence that encodes a polypeptidecomprising the amino acid sequence set forth in any one of SEQ ID NO:320-619; (c) a polynucleotide expression product comprising a nucleotidesequence that encodes a polypeptide that shares at least 70% (or atleast 71% to at least 99% and all integer percentages in between)sequence similarity or identity with at least a portion of the sequenceset forth in SEQ ID NO: 320-619; (d) a polynucleotide expression productcomprising a nucleotide sequence that hybridizes to the sequence of (a),(b), (c) or a complement thereof, under medium or high stringencyconditions; (e) a polypeptide expression product comprising the aminoacid sequence set forth in any one of SEQ ID NO: 320-619; and (f) apolypeptide expression product comprising an amino acid sequence thatshares at least 70% (or at least 71% to at least 99% and all integerpercentages in between) sequence similarity or identity with thesequence set forth in any one of SEQ ID NO: 320-619. 35) A methodaccording to any one of claims 29 to 34, wherein evaluation of the IRSmarkers includes determining the levels of individual IRS markers. 36) Amethod according to claim 35, comprising comparing the level of a firstIRS biomarker in the sample IRS biomarker profile with the level of asecond IRS biomarker in the sample IRS biomarker profile to provide aratio and determining a likelihood of the presence or absence of thecondition based on that ratio. 37) A method according to claim 36,wherein the determination is carried out in the absence of comparing thelevel of the first or second IRS biomarkers in the sample IRS biomarkerprofile to the level of a corresponding IRS biomarker in the referenceIRS biomarker profile. 38) A method according to claim 36 or claim 37,wherein the first and second IRS biomarkers are selected from the IRSbiomarkers listed in Example 6 and Tables 16-21. 39) A kit comprisingone or more reagents and/or devices for use in performing the method ofany one of claims 29 to
 38. 40) A method for treating, preventing orinhibiting the development of inSIRS, ipSIRS or a particular stage ofipSIRS in a subject, the method comprising: (1) correlating a referenceIRS biomarker profile with the presence or absence of a conditionselected from a healthy condition, SIRS, inSIRS, ipSIRS, or a particularstage of ipSIRS, wherein the reference IRS biomarker profile evaluatesat least one IRS biomarker; (2) obtaining an IRS biomarker profile of asample from a subject, wherein the sample IRS biomarker profileevaluates for an individual IRS biomarker in the reference IRS biomarkerprofile a corresponding IRS biomarker; (3) determining a likelihood ofthe subject having or not having the condition based on the sample IRSbiomarker profile and the reference IRS biomarker profile, andadministering to the subject, on the basis that the subject has anincreased likelihood of having inSIRS, an effective amount of an agentthat treats or ameliorates the symptoms or reverses or inhibits thedevelopment of inSIRS, or administering to the subject, on the basisthat the subject has an increased likelihood of having ipSIRS or aparticular stage of ipSIRS, an effective amount of an agent that treatsor ameliorates the symptoms or reverses or inhibits the development ofipSIRS or the particular stage of ipSIRS. 41) A method of monitoring theefficacy of a particular treatment regimen in a subject towards adesired health state (e.g., healthy condition), the method comprising:(1) providing a correlation of a reference IRS biomarker profile withthe likelihood of having a healthy condition; (2) obtaining acorresponding IRS biomarker profile of a subject having inSIRS, ipSIRSor a particular stage of ipSIRS after treatment with a treatmentregimen, wherein a similarity of the subject's IRS biomarker profileafter treatment to the reference IRS biomarker profile indicates thelikelihood that the treatment regimen is effective for changing thehealth status of the subject to the desired health state. 42) A methodof correlating a reference IRS biomarker profile with an effectivetreatment regimen for a condition selected from inSIRS, ipSIRS or aparticular stage of ipSIRS, wherein the reference IRS biomarker profileevaluates at least one IRS biomarker, the method comprising: (a)determining a sample IRS biomarker profile from a subject with thecondition prior to treatment, wherein the sample IRS biomarker profileevaluates for an individual IRS biomarker in the reference IRS biomarkerprofile a corresponding IRS biomarker; and correlating the sample IRSbiomarker profile with a treatment regimen that is effective fortreating the condition. 43) A method of determining whether a treatmentregimen is effective for treating a subject with a condition selectedfrom inSIRS, ipSIRS or a particular stage of ipSIRS, the methodcomprising: (a) correlating a reference biomarker profile prior totreatment with an effective treatment regimen for the condition, whereinthe reference IRS biomarker profile evaluates at least one IRSbiomarker; and (b) obtaining a sample IRS biomarker profile from thesubject after treatment, wherein the sample IRS biomarker profileevaluates for an individual IRS biomarker in the reference IRS biomarkerprofile a corresponding IRS biomarker, and wherein the sample IRSbiomarker profile after treatment indicates whether the treatmentregimen is effective for treating the condition in the subject. 44) Amethod of correlating an IRS biomarker profile with a positive ornegative response to a treatment regimen, the method comprising: (a)obtaining an IRS biomarker profile from a subject with a conditionselected from inSIRS, ipSIRS or a particular stage of ipSIRS followingcommencement of the treatment regimen, wherein the IRS biomarker profileevaluates at least one IRS biomarker; and (b) correlating the IRSbiomarker profile from the subject with a positive or negative responseto the treatment regimen. 45) A method of determining a positive ornegative response to a treatment regimen by a subject with a conditionselected from inSIRS, ipSIRS or a particular stage of ipSIRS, the methodcomprising: (a) correlating a reference IRS biomarker profile with apositive or negative response to the treatment regimen, wherein thereference IRS biomarker profile evaluates at least one (e.g., 1, 2, 3,4, 5, 6, 7, 8, 9, 10, etc.) IRS biomarker; and (b) determining a sampleIRS biomarker profile from the subject, wherein the subject's sample IRSbiomarker profile evaluates for an individual IRS biomarker in thereference IRS biomarker profile a corresponding IRS biomarker andindicates whether the subject is responding to the treatment regimen.46) A method according to claim 45, further comprising: determining afirst sample IRS biomarker profile from the subject prior to commencingthe treatment regimen, wherein the first sample IRS biomarker profileevaluates at least one IRS biomarker; and comparing the first sample IRSbiomarker profile with a second sample IRS biomarker profile from thesubject after commencement of the treatment regimen, wherein the secondsample IRS biomarker profile evaluates for an individual IRS biomarkerin the first sample IRS biomarker profile a corresponding IRS biomarker.47) A method according to any one of claims 1 to 38, wherein the methodis performed at least at 2-hour intervals. 48) A method according to anyone of claims 1 to 38, wherein the method is performed at least at4-hour intervals. 49) A kit according to claim 39, which is used atleast at 2-hour intervals. 50) A kit according to claim 39, which isused at least at 4-hour intervals.